0001193125-18-187299.txt : 20180608 0001193125-18-187299.hdr.sgml : 20180608 20180608061613 ACCESSION NUMBER: 0001193125-18-187299 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 42 FILED AS OF DATE: 20180608 DATE AS OF CHANGE: 20180608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-225235 FILM NUMBER: 18888031 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 S-1/A 1 d544598ds1a.htm S-1/A S-1/A
Table of Contents

As filed with the Securities and Exchange Commission on June 8, 2018.

Registration No. 333-225235

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Amendment No. 1 to

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

EIDOS THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   2834   46-3733671

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification No.)

101 Montgomery Street, Suite 2550

San Francisco, CA 94104

(415) 887-1471

(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)

 

 

Neil Kumar

Chief Executive Officer

Eidos Therapeutics, Inc.

101 Montgomery Street, Suite 2550

San Francisco, CA 94104

(415) 887-1471

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Maggie L. Wong

Mitchell S. Bloom

Goodwin Procter LLP

Three Embarcadero Center, 28th Floor

San Francisco, CA 94111

(415) 733-6000

 

Neil Kumar

Chief Executive Officer

Eidos Therapeutics, Inc.

101 Montgomery Street, Suite 2550

San Francisco, CA 94104

(415) 887-1471

 

David Peinsipp

Divakar Gupta

Charles S. Kim

Cooley LLP

101 California Street, 5th Floor

San Francisco, CA 94111

(415) 693-2000

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.  

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer     (Do not check if a smaller reporting company)    Smaller reporting company  
     Emerging growth company  

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

 

Amount

to be

Registered(1)

 

Proposed Maximum
Offering Price

per Share(2)

 

Proposed Maximum

Aggregate

Offering Price(1)(2)

 

Amount of

Registration Fee(3)

Common Stock, par value $0.001 per share

  7,187,500   $17.00   $122,187,500   $15,213

 

 

(1)   Includes 937,500 additional shares that the underwriters have the option to purchase.
(2)   Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act.
(3)   $14,317.50 of this registration fee was previously paid.

 

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 


Table of Contents

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where such offer or sale is not permitted.

 

Subject to Completion, dated June 8, 2018.

Preliminary prospectus

6,250,000 shares

 

LOGO

Common stock

This is an initial public offering of 6,250,000 shares of common stock by Eidos Therapeutics, Inc. We are offering shares of our common stock to be sold in the offering. The initial public offering price is expected to be between $15.00 and $17.00 per share.

Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on The Nasdaq Global Market under the symbol “EIDX.”

We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements.

 

      Per share      Total  

Initial public offering price

   $                   $               

Underwriting discounts and commissions(1)

   $      $  

Proceeds to Eidos Therapeutics, Inc., before expenses

   $      $  

 

(1)   See “Underwriting” for a description of the compensation payable to the underwriters.

We have granted the underwriters an option for a period of 30 days to purchase up to 937,500 additional shares of common stock.

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The underwriters will receive the same discount from any shares sold to such entities as they will from any other shares sold to the public in this offering.

Investing in our common stock involves a high degree of risk. See “Risk factors” beginning on page 11.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the shares to purchasers on or about                , 2018.

 

J.P. Morgan   BofA Merrill Lynch

Barclays

                , 2018


Table of Contents

Table of contents

     Page No.  

Prospectus summary

     1  

The offering

     7  

Risk factors

     11  

Cautionary note regarding forward-looking statements

     59  

Use of proceeds

     61  

Dividend policy

     63  

Capitalization

     64  

Dilution

     66  

Selected financial data

     69  

Market and industry data and forecasts

     71  

Management’s discussion and analysis of financial condition and results of operations

     72  

Business

     84  

Management

     131  

Executive and director compensation

     139  

Certain relationships and related party transactions

     151  

Principal stockholders

     156  

Description of capital stock

     158  

Shares eligible for future sale

     164  

Material U.S. federal income tax considerations to non-U.S. holders

     167  

Underwriting

     172  

Legal matters

     184  

Experts

     184  

Where you can find more information

     184  

Index to financial statements

     F-1  

We and the underwriters have not authorized anyone to provide any information other than that contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

Through and including                 , 2018 (the 25th day after the date of this prospectus) all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States.


Table of Contents

Prospectus summary

This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes included elsewhere in this prospectus. You should also consider, among other things, the matters described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in each case appearing elsewhere in this prospectus. Unless otherwise stated, all references to “us,” “our,” “Eidos” “we,” the “Company” and similar designations refer to Eidos Therapeutics, Inc.

Overview

We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR, a therapeutic approach that is supported by genetic evidence as well as previous clinical trials. Our product candidate, AG10, is an orally-administered small molecule designed to potently stabilize TTR, with the potential to halt the progression of ATTR and be a promising treatment for this family of diseases. The development of AG10 is led by our proven management team who are responsible for developing over 30 molecules through Investigational New Drug, or IND, applications, and more than ten approved drugs. Together with patients and physicians, we aim to bring a well-tolerated, effective and disease-modifying treatment for ATTR to market as quickly as possible.

Disease background

ATTR represents a significant unmet need, with a comparatively large patient population in the context of rare genetic diseases and an inadequate current standard of care. There are three distinct diseases that comprise the ATTR family: wild-type ATTR cardiomyopathy, or ATTRwt-CM, mutant ATTR cardiomyopathy, or ATTRm-CM, and ATTR polyneuropathy, or ATTR-PN. The worldwide prevalence of each disease is approximately 200,000, 40,000, and 10,000, respectively, although we believe the cardiomyopathic forms of the disease are significantly underdiagnosed due to non-specific symptoms and a historical reliance on an invasive heart biopsy diagnostic method. We believe that improvements in disease awareness and the introduction of a non-invasive, imaging-based diagnostic algorithm are significantly increasing rates of diagnosis for ATTRwt-CM and ATTRm-CM.

All three forms of ATTR are progressive and fatal and no disease-modifying therapies have been approved by the FDA. For patients with ATTRwt-CM and ATTRm-CM, symptoms usually begin to manifest later in life (age 50+) with median survival of between three to five years from diagnosis. ATTR-PN presents either in a patient’s early 30s or later (age 50+) with a median life expectancy of five to ten years from diagnosis. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care.

Mechanism of disease and therapeutic approach

Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, a molecular structure consisting of four identical subunits, or monomers, stemming from either specific gene mutations or aging. Destabilized TTR drives an irreversible dissociation of the TTR tetramer into monomers, which subsequently aggregate and deposit throughout the body, leading to organ damage, loss of organ function and eventual death if left untreated.

 

1


Table of Contents

We are building upon our significant mechanistic understanding of ATTR to develop a potentially disease-modifying treatment for this family of diseases. Previous clinical trials of small molecule TTR stabilizers have demonstrated that increasing levels of TTR stabilization may lead to increasing levels of clinical benefit. In March 2018, Pfizer announced that its Phase 3 trial of tafamidis in ATTRwt-CM and ATTRm-CM patients (ATTR-ACT) reportedly met its primary endpoint: a reduction in the combination of all-cause mortality and cumulative incidence of cardiovascular-related hospitalizations in patients treated with either 20 mg or 80 mg of tafamidis relative to placebo. The 20 mg dose of tafamidis, which in preclinical studies resulted in a lower rate of TTR stabilization than the 80 mg dose, resulted in a non-statistically significant improvement relative to placebo in a Phase 3 clinical trial in ATTR-PN. The generic NSAID, diflunisal, which in preclinical studies has been shown to result in greater TTR stabilization at a 250 mg twice-daily dose than tafamidis at either 20 mg or 80 mg dose, showed statistically significant improvements on clinical endpoints in a separate NIH-funded Phase 3 trial in ATTR-PN. Diflunisal has not been approved for the treatment of ATTR and its usage is limited by non-TTR-related toxicities. We believe that the relative clinical data for tafamidis at the 20 mg dose, tafamidis at the 80 mg dose and diflunisal support the hypothesis that maximally stabilizing TTR may lead to optimal clinical benefit. We aim to provide a compelling treatment for ATTR by developing a well-tolerated small molecule that completely stabilizes TTR.

Our product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a “rescue mutation” because it has been shown to prevent ATTR in individuals carrying pathogenic, or disease-causing, mutations in the TTR gene. We have observed through X-ray crystallography that the binding of AG10 to TTR creates strong molecular bonds at the same locations as seen in T119M. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the “super-stabilizing” properties of this rescue mutation.

We believe the clinical and preclinical data generated to date by AG10 strongly support its development as a preferred therapeutic to treat ATTR, as outlined below:

 

 

In our Phase 1 clinical trial, the primary objective of evaluating safety and tolerability of single and multiple doses of AG10 administered to healthy adult volunteers was achieved. AG10 was well tolerated and was not associated with any clinically important adverse events in our Phase 1 clinical trial. This is consistent with our preclinical studies in which AG10 was demonstrated to have a greater than 50-fold therapeutic window between our target therapeutic blood levels and concentrations associated with toxicity in nonhuman mammals.

 

 

The secondary objectives of evaluating pharmacokinetics (PK), pharmacodynamics (PD) and the PK-PD relationship were also achieved in our Phase 1 clinical trial. PD properties were assessed by established assays of TTR stabilization. In these assays in our Phase 1 clinical trial, AG10 demonstrated 100% TTR stabilization at peak concentrations and over 95% TTR stabilization on average at the highest tested dose in healthy adult volunteers at steady state. These data are consistent with our preclinical studies.

 

 

In our preclinical studies at clinically relevant concentrations, AG10 demonstrated near-complete stabilization of wild-type TTR and all TTR variants tested, which represent greater than 70% of all patients with mutation-driven ATTR.

In April 2018, we initiated a randomized, placebo-controlled, double-blind Phase 2 clinical trial of AG10 in ATTR-CM patients. In this trial, we are evaluating safety and tolerability and TTR stabilization as clinical proof of concept in the target patient population. We expect to report topline data from this Phase 2 clinical trial by the end of 2018. In addition, we intend to initiate a Phase 3 clinical trial of AG10 in ATTR-PN patients in early 2019.

 

2


Table of Contents

We are developing AG10 to treat three distinct forms of ATTR in the clinical trials shown in the table below.

 

Indication   Worldwide
prevalence
   Stage    Endpoint and biomarkers    Next anticipated
milestone

ATTR-CM

(both ATTRwt-CM and

ATTRm-CM)

  200,000
ATTRwt-CM

40,000
ATTRm-CM

   Phase 2    Safety and tolerability; pharmacokinetics; TTR stabilization    Phase 2 topline data readout (End of 2018)
     Open label extension (OLE) to be initiated    Safety and tolerability; TTR stabilization; Biomarkers: NTpro-BNP, troponin, wall thickness, strain    OLE initiation (2018)

ATTR-PN

  10,000   

Phase 3 to be initiated

   Neuropathy impairment score (mNIS +7); Safety and tolerability; Norfolk quality of life score; pharmacokinetics; TTR stabilization   

Phase 3 initiation (Early 2019)

Our leadership team

We are led by a management team that has worked together previously and has a successful track record in drug development, contributing to over 30 molecules through IND and more than ten approved drugs. More importantly, our team has a rich set of experiences at the intersection of genetic disease and cardiovascular medicine owing from experiences at companies including Global Blood Therapeutics, Inc., MyoKardia, Inc. and Portola Pharmaceuticals, Inc. We are a majority-owned subsidiary of BridgeBio Pharma, LLC, or BridgeBio, a biotechnology company dedicated to identifying and developing novel therapies for genetic diseases.

Led by experienced scientists, drug developers and investors, BridgeBio employs a distributed corporate structure that enables focus at the level of each disease while providing centralized resources to scale across many opportunities. BridgeBio currently has a portfolio of more than 15 product candidates spanning preclinical development to late-stage clinical trials across multiple therapeutic areas. Eidos is a leading example of BridgeBio’s approach to building lean organizations dedicated to targeting well-defined genetic conditions at their source.

Our strategy

Our goal is to be a leader in developing and commercializing disease-modifying therapeutics to address ATTR. The key components of our strategy are to:

 

 

Rapidly develop AG10 for the treatment of ATTR-CM;

 

 

Advance AG10 for the treatment of ATTR-PN;

 

 

Expand our leadership role in the ATTR community;

 

 

Retain development and commercialization rights to AG10 in core strategic markets; and

 

 

Evaluate opportunities to expand the scope of our development candidate portfolio.

 

3


Table of Contents

Risks associated with our business

Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section entitled “Risk factors” in this prospectus. These risks include, among others:

 

 

We are a clinical development-stage company with a limited operating history, have incurred and anticipate that we will continue to incur significant losses for the foreseeable future, and have only one product candidate in development;

 

 

Even if this offering is successful, we will require substantial additional funding to achieve our business goals;

 

 

We are heavily dependent upon the success of our only product candidate, AG10, which is in the early stages of clinical development, and we have not identified any other development candidates;

 

 

The results observed to date in our clinical development of AG10, including our Phase 1 clinical trial in which 56 subjects were enrolled, are based on a limited sample size and may not be observed in later-stage clinical trials involving larger numbers of patients;

 

 

We may fail to complete the clinical development of AG10 in a timely manner, or at all, for a variety of reasons, and if we are unable to obtain regulatory approval for AG10, our business will be substantially harmed;

 

 

If we are unable to maintain sufficient intellectual property protection for AG10, including under our exclusive license agreement with Stanford University, our ability to successfully commercialize AG10 will be impaired;

 

 

We rely on third parties to conduct our clinical trials and other research and development activities, and to manufacture and supply AG10 for clinical development and potential commercialization;

 

 

Our success depends on our ability to retain and recruit key employees, consultants and advisors; and certain of our current executive officers, including our Chief Executive Officer, devote a portion of their business time to services to our controlling stockholder, BridgeBio, and its other subsidiaries;

 

 

BridgeBio will continue to be our controlling stockholder, owning approximately 52.0% of the voting power of our common stock upon the completion of this offering, and will be able to exert significant control over matters subject to stockholder approval;

 

 

Certain of our directors and officers may have actual or potential conflicts of interest with us because of their positions or affiliations with BridgeBio and its other subsidiaries; and

 

 

We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.

 

4


Table of Contents

Implications of being an emerging growth company

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:

 

 

Two years of audited financial statements in addition to any required unaudited condensed interim financial statements with correspondingly reduced “Management’s discussion and analysis of financial condition and results of operations” disclosure prior to our first filing of our Annual Report on Form 10-K;

 

 

Reduced disclosure about our executive compensation arrangements;

 

 

No non-binding advisory votes on executive compensation or golden parachute arrangements; and

 

 

Exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.

We may take advantage of these exemptions for up to five years from the date of effectiveness of this registration statement or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the last day of the fiscal year in which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Also, we have irrevocably elected to “opt out” of the exemption for the delayed adoption of certain accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Indications of interest

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The underwriters will receive the same discount from any shares sold to such entities as they will from any other shares sold to the public in this offering.

Corporate history and information

We were incorporated under the laws of the State of Delaware in August 2013. Our principal executive office is located at 101 Montgomery Street, Suite 2550, San Francisco, CA, and our telephone number is (415) 887-1471. Our website address is www.eidostx.com. We do not incorporate the information on or accessible through our

 

5


Table of Contents

website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus.

We use various trademarks and trade names in our business, including without limitation our corporate name and logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

 

6


Table of Contents

The offering

 

Common stock offered by us

6,250,000 shares

 

Common stock to be outstanding immediately after this offering

35,799,821 shares (or 36,737,321 shares if the underwriters exercise their option to purchase additional shares in full).

 

Option to purchase additional shares

We have granted the underwriters an option to purchase up to 937,500 additional shares of common stock from us. The underwriters can exercise this option at any time within 30 days from the date of this prospectus.

 

Use of proceeds

We estimate that we will receive net proceeds from the sale of our common stock in this offering of approximately $90.2 million, or $104.2 million if the underwriters fully exercise their option to purchase additional shares, assuming an initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering to fund our clinical development of AG10 for the treatment of ATTR-CM and ATTR-PN, including our ongoing Phase 2 ATTR-CM and planned Phase 3 ATTR-PN clinical trials, as well as future clinical trials, additional research and development activities, and for working capital and general corporate purposes. See “Use of proceeds” for additional information.

 

Directed shares

At our request, the underwriters have reserved for sale, at the initial public offering price, up to 2.0% of the shares offered hereby for employees and other persons associated with us who have expressed an interest in purchasing common stock in the offering. See “Underwriting” for more information.

 

Risk factors

You should read carefully “Risk factors” beginning on page 11 and other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock.

 

Proposed Nasdaq Global Market symbol

“EIDX”

The number of shares of common stock to be outstanding after this offering is based on 5,333,010 shares of common stock outstanding as of March 31, 2018 and 24,216,811 additional shares of our common stock issuable upon the conversion of all outstanding shares of our redeemable convertible preferred stock upon the

 

7


Table of Contents

completion of this offering, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and excludes:

 

 

560,128 shares of common stock issuable upon exercise of outstanding options as of March 31, 2018 at a weighted-average exercise price of $0.91 per share;

 

 

213,842 shares of common stock issuable upon exercise of options granted after March 31, 2018 at a weighted-average exercise price of $7.24 per share;

 

 

807,682 shares of common stock reserved for future issuance under our 2016 Equity Incentive Plan, or the 2016 Plan, as of March 31, 2018;

 

 

No shares of common stock issued after March 31, 2018;

 

 

598,000 shares of our common stock reserved for future issuance under our 2018 Stock Option and Incentive Plan, or the 2018 Plan, which will become available for issuance upon the effectiveness of the registration statement of which this prospectus is a part; and

 

 

143,520 shares of our common stock reserved for future issuance under our 2018 Employee Stock Purchase Plan, or the 2018 ESPP, which will become available for issuance upon the effectiveness of the registration statement of which this prospectus is a part.

Except as otherwise indicated, all information in this prospectus assumes or gives effect to:

 

 

the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 24,025,270 shares of our common stock immediately prior to the completion of this offering;

 

 

no exercise of the outstanding options described above;

 

 

no exercise by the underwriters of their option to purchase up to 937,500 additional shares of our common stock in this offering;

 

 

a 1.196 for 1 split of our outstanding shares of common stock effected on June 7, 2018;

 

 

the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, which will occur immediately prior to the completion of this offering; and

 

 

the automatic net exercise immediately prior to the completion of this offering of warrants issued in February 2018 for an aggregate of 191,541 shares of our redeemable convertible preferred stock and the subsequent conversion of such shares into an aggregate of 191,541 shares of common stock immediately prior to the completion of this offering, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus.

 

8


Table of Contents

Summary financial data

The following tables present summary financial data for our business. We have derived the statements of operations data for the years ended December 31, 2016 and 2017 from our audited financial statements appearing elsewhere in this prospectus. We have derived the statements of operations data for the three months ended March 31, 2017 and 2018 and the balance sheet data as of March 31, 2018 from our unaudited interim condensed financial statements appearing elsewhere in this prospectus. We have prepared the unaudited interim condensed financial statements on the same basis as our audited financial statements and, in the opinion of management, these financial statements reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair statement of our unaudited interim condensed financial statements. Our historical results are not necessarily indicative of the results that may be expected in the future and our interim results for the three months ended March 31, 2018 are not necessarily indicative of results to be expected for the full year ending December 31, 2018, or any other period. You should read this data together with our financial statements and related notes appearing elsewhere in this prospectus and the information under the captions “Selected financial data” and “Management’s discussion and analysis of financial condition and results of operations.”

 

      Year ended December 31,     Three months ended March 31,  
(in thousands, except share and per share data)    2016     2017                   2017                   2018  

Statements of Operations Data:

        

Operating expenses:

        

Research and development

   $ 1,734     $ 9,286     $ 2,039     $ 6,034  

General and administrative

     651       2,730       378       2,143  
  

 

 

 

Total operating expenses

     2,385       12,016       2,417       8,177  
  

 

 

 

Loss from operations

     (2,385     (12,016     (2,417     (8,177

Other income (expense), net

     (157     75       75       (725

Loss on extinguishment of debt

     —         —         —         (6,677
  

 

 

 

Net loss

   $ (2,542   $ (11,941   $ (2,342   $ (15,579
  

 

 

 

Net loss per share:(1)

        

Basic and diluted

   $ (0.98   $ (3.32   $ (0.72   $ (3.89
  

 

 

 

Weighted-average shares used in computing net loss per share:(1)

        

Basic and diluted

     2,599,641       3,596,673       3,241,138       4,006,085  
  

 

 

 

Pro forma net loss per share:(1)

        

Basic and diluted

     $ (0.93     $ (0.80
    

 

 

     

 

 

 

Weighted-average shares used in computing pro forma net loss per share:(1)

        

Basic and diluted

       12,777,063         19,574,812  

 

 

 

(1)   See Notes 2, 14, and 15 to our audited financial statements and Notes 11 and 12 to our unaudited interim condensed financial statements included elsewhere in this prospectus for an explanation of the calculations of our basic and diluted net loss per share, basic and diluted pro forma net loss per share, and the weighted-average number of shares used in the computation of these per share amounts.

 

9


Table of Contents
                                                                          
      As of March 31, 2018  
(In thousands)    Actual    

Pro

forma(1)

   

Pro forma as

adjusted(2)(3)

 

Balance Sheet Data:

      

Cash

   $ 25,269     $ 73,269     $ 163,469  

Working capital

     21,231       69,231       159,431  

Redeemable convertible preferred stock put option asset

     1,527       —         —    

Total assets

     28,823       75,296       165,496  

Redeemable convertible preferred stock tranche liability

     2,028       —         —    

Redeemable convertible preferred stock warrant liability

     841       —         —    

Redeemable convertible preferred stock

     46,603       —         —    

Accumulated deficit

     (30,111     (30,111     (30,111

Total stockholders’ (deficit) equity

     (25,826     70,119       160,319  

 

 

 

(1)   The pro forma column reflects (i) the sale and issuance in May 2018 of 4,430,162 shares of our Series B redeemable convertible preferred stock at $10.8348 per share, for net proceeds of $48.0 million and the related settlement of the redeemable convertible preferred stock put option asset and the redeemable convertible preferred stock tranche liability, (ii) the conversion of all of the outstanding shares of our redeemable convertible preferred stock into an aggregate of 24,025,270 shares of common stock immediately prior to the completion of this offering; (iii) the automatic net exercise immediately prior to the completion of this offering of warrants issued in February 2018 for an aggregate of 191,541 shares of our redeemable convertible preferred stock, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, the subsequent conversion of such shares into an aggregate of 191,541 shares of common stock immediately prior to the completion of this offering and the resultant reclassification of our preferred stock warrant liability to additional paid-in capital, a component of stockholders’ (deficit) equity, all of which will occur in connection with the completion of this offering; and (iv) the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, which will occur immediately prior to the completion of this offering.

 

(2)   The pro forma as adjusted column reflects (i) the pro forma adjustments set forth above and (ii) the receipt of $90.2 million in net proceeds from our sale of shares of common stock in this offering based on an assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

(3)   Each $1.00 increase or decrease in the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, respectively, the amount of cash, working capital, total assets and total stockholders’ (deficit) equity by approximately $5.8 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease, respectively, the amount of each of cash, working capital, total assets and total stockholders’ (deficit) equity by approximately $14.9 million, based on the assumed initial public offering price per share, the midpoint of the price range as set forth on the cover page of this prospectus, remains the same. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing.

 

10


Table of Contents

Risk factors

Investing in our common stock involves a high degree of risk. You should consider carefully the following risks, together with all the other information in this prospectus, including our financial statements and notes thereto, before you invest in our common stock. If any of the following risks actually materializes, our operating results, financial condition and liquidity could be materially adversely affected. As a result, the trading price of our common stock could decline and you could lose part or all of your investment.

Risk related to our financial position and need for additional capital

Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have only one product candidate in development and have not generated any revenue since our inception, which, together with our limited operating history, may make it difficult for you to assess our future viability.

We are a clinical development-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale and have not generated any revenue from product sales. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused principally on developing our only product candidate, AG10, which is in clinical development and will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales.

We are not profitable and have incurred losses in each year since our inception in August 2013. Our net losses for the years ended December 31, 2016 and 2017 and three months ended March 31, 2018 were $2.5 million, $11.9 million and $15.6 million, respectively. As of March 31, 2018, we had an accumulated deficit of $30.1 million. We have not generated any revenue since our inception, and have financed our operations solely through the sale of equity securities and convertible debt. We continue to incur significant research and development and other expenses related to our ongoing operations and expect to incur losses for the foreseeable future. We anticipate these losses will increase significantly following the completion of this offering and we will not generate any revenue from product sales until after we have successfully completed clinical development and received regulatory approval for the commercial sale of AG10 or any other product candidate that we may identify and pursue.

Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory authorities, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators’ clinical trials or the development of AG10 or other product candidates that we may identify. Even if AG10 or any future product candidate that we may identify is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate and ongoing compliance efforts.

We may never be able to develop or commercialize a marketable drug or achieve profitability. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain reimbursement at any price and whether we own the commercial rights for that territory. If the number of addressable patients is not as significant as we anticipate, the indication approved by regulatory

 

11


Table of Contents

authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our research and development pipeline, market AG10 or any other product candidates we may identify and pursue, if approved, or continue our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital. In any particular quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.

We will require substantial additional funding to achieve our business goals. If we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts.

We are currently advancing AG10, our only clinical development candidate, in a Phase 2 clinical trial. Developing biopharmaceutical products is expensive and time-consuming, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance AG10 in planned and future clinical trials. We are also responsible for license maintenance fees, milestone payments and royalties to Stanford University, or Stanford. As of March 31, 2018, we had working capital of $21.2 million and cash of $25.3 million. Because the outcome of any clinical development and regulatory approval process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of AG10 and any future product candidates we may identify.

We estimate that the net proceeds from this offering will be approximately $90.2 million (or approximately $104.2 million if the underwriters exercise in full their option to purchase additional shares), based on the midpoint of the price range set forth on the cover of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We expect that the net proceeds from this offering, together with our existing cash will be sufficient to fund our operations for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or license and development agreements. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize AG10 and other product candidates that we may identify and pursue. Moreover, such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our future funding requirements will depend on many factors, including, but not limited to:

 

 

the time and cost necessary to complete our ongoing Phase 2 clinical trial of AG10 in ATTR-CM, to initiate and complete any pivotal clinical trials of AG10 and to pursue regulatory approvals for AG10, and the costs of post-marketing studies that could be required by regulatory authorities;

 

 

the progress and results of our ongoing Phase 2 and planned Phase 3 clinical trials of AG10;

 

12


Table of Contents
 

the progress, timing, scope and costs of our nonclinical studies, clinical trials and other related activities, including the ability to enroll patients in a timely manner for our Phase 2 clinical trial of AG10 and potential future clinical trials;

 

 

the costs of obtaining clinical and commercial supplies of AG10 and any other product candidates we may identify and develop;

 

 

our ability to successfully commercialize AG10 and any other product candidates we may identify and develop;

 

 

the manufacturing, selling and marketing costs associated with AG10 and any other product candidates we may identify and develop, including the cost and timing of expanding our sales and marketing capabilities;

 

 

the amount and timing of sales and other revenues from AG10 and any other product candidates we may identify and develop, including the sales price and the availability of adequate third-party reimbursement;

 

 

the cash requirements of any future acquisitions or discovery of product candidates;

 

 

the time and cost necessary to respond to technological and market developments;

 

 

the costs of acquiring, licensing or investing in intellectual property rights, products, product candidates and businesses;

 

 

our ability to attract, hire and retain qualified personnel; and

 

 

the costs of maintaining, expanding and protecting our intellectual property portfolio.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit or terminate one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, prospects, financial condition and results of operations.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to AG10 or any future product candidates which we develop on unfavorable terms to us.

We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.

 

13


Table of Contents

Risk related to our business and the clinical development, regulatory review and approval of our product candidates

We are heavily dependent on the success of our only product candidate, AG10, and we have not identified any other clinical development candidates through our research activities. If we are unable to successfully complete clinical development, obtain regulatory approval for, or commercialize AG10, or experience delays in doing so, our business will be materially harmed.

To date, we have invested all of our efforts and financial resources to the development of AG10, including conducting preclinical studies and clinical trials and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize AG10. Before we can generate any revenues from sales of AG10, we will be required to conduct additional clinical development, including, among other things, additional toxicology studies that may be required before we can conduct longer-term clinical trials and a larger pivotal clinical trial if our ongoing clinical trial of AG10 is successful, seek and obtain regulatory approval, secure adequate manufacturing supply to support larger clinical trials and commercial sales and build a commercial organization. Further, the success of AG10 will depend on patent and trade secret protection, obtaining and maintaining regulatory exclusivity, acceptance of AG10 by patients, the medical community and third-party payors, its ability to compete with other therapies, healthcare coverage and reimbursement, and maintenance of an acceptable safety profile following approval, among other factors. If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize AG10, which would materially harm our business.

Currently, AG10 is our only product candidate, and it may be years before we can advance AG10 into a pivotal trial, if at all. We have not yet identified any other product candidates for studies that would enable the filing of an investigational new drug application, or IND, or for clinical evaluation. We cannot be certain that AG10 will be successful in clinical trials or receive regulatory approval. If we do not receive regulatory approval for, or otherwise fail to successfully commercialize, AG10, we may need to discontinue our operations as currently contemplated unless we identify other product candidates, advance them through preclinical and clinical development and apply for regulatory approvals, which could be time-consuming and costly, and may adversely affect our business, prospects, financial condition and results of operations.

If we are unable to obtain regulatory approval in one or more jurisdictions for AG10 or any other product candidates that we may identify and develop, our business will be substantially harmed.

We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Approval by the FDA and comparable foreign regulatory authorities is lengthy and unpredictable, and depends upon numerous factors. Approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for AG10, and it is possible that neither AG10 nor any other product candidates which we may seek to develop in the future will ever obtain regulatory approval.

Applications for AG10 or any other product candidates we may develop could fail to receive regulatory approval for many reasons, including but not limited to:

 

 

our inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that AG10 or any other product candidate we may develop is safe and effective;

 

 

the FDA or comparable foreign regulatory authorities may disagree with the design, endpoints or implementation of our clinical trials, including those of our planned Phase 3 clinical trial;

 

14


Table of Contents
 

the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;

 

 

the FDA’s or comparable foreign regulatory authorities’ requirement for additional preclinical studies or clinical trials beyond those that we currently anticipate;

 

 

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;

 

 

the data collected from clinical trials of AG10 and other product candidates that we may identify and pursue may not be sufficient to support the submission of a new drug application, or NDA, or other submission for regulatory approval in the United States or elsewhere;

 

 

we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate’s risk-benefit ratio for its proposed indication is acceptable;

 

 

the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

 

 

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may change in a manner that renders our clinical trial design or data insufficient for approval.

The lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failure to obtain regulatory approval to market AG10 or any other product candidates that we may pursue in the United States or elsewhere, which would significantly harm our business, prospects, financial condition and results of operations.

We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.

Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any of our ongoing and planned clinical trials will be conducted as planned or completed on schedule, if at all. Moreover, even if these trials are initiated or conducted on a timely basis, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:

 

 

inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;

 

 

delays in confirming target engagement, patient selection or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;

 

 

delays in reaching a consensus with regulatory agencies on study design;

 

 

delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;

 

 

delays in identifying, recruiting and training suitable clinical investigators;

 

 

delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site;

 

15


Table of Contents
 

imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, clinical trial application, or CTA, or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or study sites;

 

 

developments in trials for other drug candidates targeting ATTR conducted by competitors that raise regulatory or safety concerns about risk to patients of the treatment, including the approach of TTR stabilization; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;

 

 

delays in identifying, recruiting and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials or failing to return for post-treatment follow-up;

 

 

difficulty collaborating with patient groups and investigators;

 

 

failure by our CROs, other third parties, or us to adhere to clinical trial requirements;

 

 

failure to perform in accordance with the FDA’s or any other regulatory authority’s current good clinical practices, or cGCP, requirements, or regulatory guidelines in other countries;

 

 

occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;

 

 

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;

 

 

changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;

 

 

the cost of clinical trials of AG10 or any our product candidates that we may identify and pursue being greater than we anticipate;

 

 

clinical trials of AG10 or any other product candidates that we may identify and pursue producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs;

 

 

transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and

 

 

delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of AG10 or other product candidates that we may identify for use in clinical trials or the inability to do any of the foregoing.

Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to AG10 or other product candidates that we may identify, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize AG10 or other product candidates that we may identify and may harm our business and results of operations.

We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board, or DSMB, for such trial or by the FDA or other regulatory authority, or if the IRBs of the institutions in

 

16


Table of Contents

which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Delays in the initiation, conduct or completion of any clinical trial of AG10 or other product candidates that we may develop will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of AG10 or any future product candidates which we may develop. In the event we identify any additional product candidates to pursue, we cannot be sure that submission of an IND or a CTA will result in the FDA or comparable foreign regulatory authority allowing clinical trials to begin in a timely manner, if at all. Any of these events could have a material adverse effect on our business, prospects, financial condition and results of operations.

Our clinical trials may fail to demonstrate substantial evidence of the safety and effectiveness of AG10 or any other product candidates that we may identify and pursue, which would prevent, delay or limit the scope of regulatory approval and commercialization.

Before obtaining regulatory approvals for the commercial sale of AG10 or any other product candidate that we may identify and pursue, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for AG10 or any other product candidate we may identify and pursue, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential.

Results of earlier studies or clinical trials may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for AG10 and other product candidates that we may pursue to justify proceeding to advanced clinical trials or an application for regulatory approval.

The results of nonclinical and preclinical studies and Phase 1 or Phase 2 clinical trials of AG10 or any other product candidates that we may pursue may not be predictive of the results of later-stage clinical trials, and

 

17


Table of Contents

interim results of a clinical trial do not necessarily predict final results. For example, our preclinical and preliminary clinical observations that AG10 potently stabilizes TTR in human serum may not be replicated in later stage clinical trials. Additionally, some of our preclinical studies in which AG10 demonstrated greater TTR stabilization and inhibition of amyloid fibril formation than tafamidis were conducted using synthesized, research-grade tafamidis and therefore may not be indicative of the comparative efficacy of AG10 to commercially available tafamidis. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and we cannot be certain that we will not face similar setbacks. Even if early stage clinical trials are successful, we may need to conduct additional clinical trials of AG10 or other product candidates that we may pursue in additional patient populations or under different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure obtain marketing approval for AG10 or any other product candidate we may choose to develop in our ongoing and any future clinical trials would substantially harm our business, prospects, financial condition and results of operations.

We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:

 

 

the size and nature of the patient population;

 

 

the patient eligibility criteria defined in the applicable clinical trial protocols, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication;

 

 

the size of the study population required for analysis of the trial’s primary endpoints;

 

 

the proximity of patients to a trial site;

 

 

the design of the trial;

 

 

our ability to recruit clinical trial investigators with the appropriate competencies and experience;

 

 

the approval of competing product candidates currently under development for ATTR, or competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria;

 

 

clinicians’ and patients’ perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;

 

 

our ability to obtain and maintain patient consents; and

 

18


Table of Contents
 

the risk that patients enrolled in clinical trials will not complete such trials, for any reason.

If we have difficulty enrolling sufficient numbers of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have an adverse effect on our business.

If serious adverse events or unacceptable side effects are identified during the development of AG10 or other product candidates that we may develop, we may need to delay, limit or terminate our clinical development activities.

Clinical trials by their nature utilize a sample of the potential patient population. Our Phase 2 clinical trial of AG10 for ATTR-CM is designed to enroll approximately 45 subjects. Subject to the successful completion of our Phase 2 clinical trial of AG10 in ATTR-CM and authorization from applicable regulatory authorities, we also plan to initiate a Phase 3 clinical trial of AG10 in up to 130 symptomatic ATTR-PN subjects in early 2019. To date, we have only begun to evaluate AG10 in a limited number of subjects at a limited duration of exposure in our Phase 1 clinical trial and the duration of exposure in our Phase 2 and 3 clinical trials is expected to be significantly longer. Accordingly, any rare and severe side effects of AG10 may be uncovered in later stages of our Phase 2 clinical trial or in any larger, subsequent trials that we may conduct, such as our planned Phase 3 clinical trial of AG10 for ATTR-PN. Additionally, although our animal safety pharmacology studies of AG10 demonstrated a wide safety margin between anticipated therapeutic exposures and doses associated with toxicity and no dose limiting toxicities were established in the 90 day GLP toxicology dog study, in prior toxicology studies of shorter duration, at doses above the no adverse effect level, dogs experienced dose limiting toxicities of gastrointestinal effects including vomiting, dehydration and weight loss. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented their further development. If AG10 or any product candidates that we may develop are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which could adversely affect our business, prospects, financial condition and results of operations.

We may in the future conduct clinical trials for AG10 or other product candidates that we may identify outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.

We may in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe. For instance, subject to the successful completion of our Phase 2 clinical trial of AG10 in ATTR-CM and authorization from applicable regulatory authorities, we plan to initiate a Phase 3 clinical trial of AG10 in up to 130 symptomatic ATTR-PN subjects in early 2019. We do not intend to file an IND with the FDA in connection with this clinical trial as it will be conducted outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the

 

19


Table of Contents

applicable jurisdiction, including our planned Phase 3 clinical trial of AG10 in ATTR-PN. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in AG10 or other product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction.

Even if we obtain FDA approval for AG10 or any other product candidates that we may identify and pursue in the United States, we may never obtain approval to commercialize AG10 or other product candidates that we may develop outside of the United States, which would limit our ability to realize their full market potential.

In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of AG10 or any other product candidates that we may identify and pursue in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.

Even though we may apply for orphan drug designation for AG10, we may not be able to obtain orphan drug marketing exclusivity for this product candidate or any of our other product candidates.

Our business strategy focuses on the development of product candidates for the treatment of transthyretin amyloidosis that may be eligible for FDA or European Union, or EU, orphan drug designation. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the Committee for Orphan Medicinal Products of the European Medicines Agency, or EMA, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU (or where it is unlikely that the development of the medicine would generate sufficient return to justify the investment) and for which no satisfactory method of diagnosis, prevention, or treatment is authorized or, if a method exists, the product would be of significant benefit to those affected by the condition. Although the diagnosed ATTR patient population in the United States is currently below 200,000, if the size of the population is shown to be greater as a result of increased rates of diagnosis or otherwise, ATTR may not in the future qualify as an orphan indication.

Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or comparable foreign regulatory authority from approving another marketing application for the same drug for that time period. The applicable period is seven years in the United States and 10 years in

 

20


Table of Contents

the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or comparable foreign regulatory authority determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

Although we may apply for orphan drug designation for AG10 or other product candidates we may develop, applicable regulatory authorities may not grant us this designation. In addition, even if we obtain orphan drug exclusivity for AG10 or any other product candidate that we may develop, that exclusivity may not effectively protect the candidate from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior, in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Orphan drug designation neither shortens the development or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for AG10 and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations. Any inability to secure orphan drug designation or the exclusivity benefits of this designation would have an adverse impact on our ability to develop and commercialize our product candidates.

We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to product candidates granted breakthrough therapy or fast track designation by the FDA.

We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies to rapidly advance the development of AG10. For example, potential expedited development pathways include breakthrough therapy or fast track designation. The breakthrough therapy program is designed for product candidates intended to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. The fast track program is designed for product candidates that treat a serious or life-threatening condition, and nonclinical or clinical data demonstrate the potential to address an unmet medical need. Although we believe AG10 could potentially qualify under either or both of the breakthrough therapy and fast track programs, we may elect not to pursue either of these programs, and the FDA has broad discretion whether or not to grant these designations. Accordingly, even if we believe a particular product candidate is eligible for breakthrough therapy or fast track designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive breakthrough therapy or fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw breakthrough therapy or fast track designation if it believes that the product no longer meets the qualifying criteria. Our business may be harmed if we are unable to avail ourselves of these or any other expedited development and regulatory pathways.

Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny.

If AG10 or other product candidates that we may develop are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market

 

21


Table of Contents

information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities are required to comply with extensive requirements imposed by the FDA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to current good manufacturing practices, or cGMP, regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or marketing authorization application, or MAA. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.

Any regulatory approvals that we receive for AG10 or other product candidates that we may develop will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval, or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA or MAA must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

 

 

issue warning letters that would result in adverse publicity;

 

 

impose civil or criminal penalties;

 

 

suspend or withdraw regulatory approvals;

 

 

suspend any of our ongoing clinical trials;

 

 

refuse to approve pending applications or supplements to approved applications submitted by us;

 

 

impose restrictions on our operations, including closing our contract manufacturers’ facilities;

 

 

seize or detain products; or

 

 

require a product recall.

 

22


Table of Contents

Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

If AG10 or other product candidates that we may identify are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as AG10 if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

If we engage in acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition or strategic partnership may entail numerous risks, including:

 

 

increased operating expenses and cash requirements;

 

 

the assumption of indebtedness or contingent liabilities;

 

 

the issuance of our equity securities which would result in dilution to our stockholders;

 

 

assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;

 

 

the diversion of our management’s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership;

 

 

retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;

 

 

risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and

 

 

our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.

In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.

 

23


Table of Contents

Risks related to our reliance on third parties

We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.

We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. If we need to enter into alternative arrangements, it would delay our product development activities.

Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. Our failure or the failure of these third parties to comply applicable regulatory requirements or our stated protocols could also subject us to enforcement action.

We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.

We rely entirely on third parties for the manufacturing of AG10 or other product candidates that we may develop for preclinical studies and clinical trials and expect to continue to do so for commercialization. Our business could be harmed if those third parties fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.

We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture drug supplies for our ongoing Phase 2 clinical trial of AG10 or any future clinical trials that we may conduct, and we lack the resources to manufacture any product candidates on a commercial scale. We rely, and expect to continue to rely, on third-party manufacturers to produce AG10 or other product candidates that we may identify for our clinical trials, as well as for commercial manufacture if any of our product candidates receives marketing approval. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the trial, any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to

 

24


Table of Contents

replace a third-party manufacturer could considerably delay the clinical development and potential regulatory approval of our product candidates, which could harm our business and results of operations. We also expect to rely on third parties for the manufacturing of commercial supply of AG10 or any other product candidates, if approved.

We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

 

 

reliance on the third party for regulatory compliance and quality assurance;

 

 

the possible breach of the manufacturing agreement by the third party;

 

 

the possible misappropriation of our proprietary information, including our trade secrets and know-how; and

 

 

the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.

Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers’ facilities generally. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the manufacture of our product candidates or if any agency withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

AG10 and any future product candidates that we may develop may compete with other product candidates and marketed drugs for access to manufacturing facilities. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We are currently manufacturing AG10 through a third party and have adequate supplies to conduct our ongoing Phase 2 clinical trial. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If we are unable to enter into relationships with additional contract manufacturers, or our current or future contract manufacturers cannot perform as agreed, we may experience delays and incur additional costs in our clinical development and commercialization activities. Our current and anticipated future dependence upon others for the manufacturing of AG10 or other product candidates that we may identify or marketed drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.

If the contract manufacturing facilities on which we rely do not continue to meet regulatory requirements or are unable to meet our supply demands, our business will be harmed.

All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for AG10, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP, or similar regulatory requirements outside the United States. These regulations govern manufacturing processes and procedures, including recordkeeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of AG10. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions,

 

25


Table of Contents

civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, seizures or recalls of product candidates or marketed drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect clinical or commercial supplies of AG10.

We or our contract manufacturers must supply all necessary documentation in support of an NDA or MAA on a timely basis and must adhere to regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our contract manufacturers have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of AG10 or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of AG10 or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.

The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.

Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of AG10 or other product candidates that we may identify. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.

Risks related to our intellectual property

If we are unable to obtain and maintain sufficient intellectual property protection for AG10 or other product candidates that we may identify, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to ours, and our ability to successfully commercialize AG10 and other product candidates that we may pursue may be impaired.

As is the case with other biopharmaceutical companies, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others,

 

26


Table of Contents

particularly patents, in the United States and other countries with respect to our product candidates and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to AG10 or other product candidates that we may identify.

Obtaining and enforcing biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner.

Moreover, we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.

 

27


Table of Contents

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or these agreements are terminated or we otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.

We are a party to an exclusive license agreement with Stanford and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of AG10 or any other product candidates we may identify and pursue. Our license agreement with Stanford imposes, and we expect that future license agreements will impose, various development, diligence, commercialization, and other obligations on us. For example, under our license agreement with Stanford we are required to use commercially reasonable efforts to engage in various development and commercialization activities with respect to licensed products, and must satisfy specified milestone and royalty payment obligations. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If our license agreement with Stanford is terminated, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to AG10 and we may be required to cease our development and commercialization of AG10. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:

 

 

the scope of rights granted under the license agreement and other interpretation-related issues;

 

 

the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

 

 

the sublicensing of patent and other rights under our collaborative development relationships;

 

 

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

 

 

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

 

 

the priority of invention of patented technology.

In addition, certain provisions in our license agreement with Stanford may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent

 

28


Table of Contents

and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that AG10 or other product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of AG10 or other product candidates that we may identify. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that AG10 or other product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of AG10 or other product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all, or it may be non-exclusive, which could result in our competitors gaining access to the same intellectual property.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize AG10 or other product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from

 

29


Table of Contents

competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If we are not able to obtain patent term extension or non-patent exclusivity in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for AG10 or other product candidates that we may identify, our business may be materially harmed.

Depending upon the timing, duration and specifics of FDA marketing approval of AG10 or other product candidates that we may identify, one of the U.S. patents covering each of such product candidates or the use thereof may be eligible for up to five years of patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request.

If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration sooner, and our revenue could be reduced, possibly materially.

It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering AG10 or other product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought. Further, for our licensed patents, we do not have the right to control prosecution, including filing with the USPTO, a petition for patent term extension under the Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTO.

Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.

 

30


Table of Contents

If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.

We seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.

Although we are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to enforce a patent covering AG10 or other product candidates that we may identify, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring AG10 or other product candidates that we may identify to market. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

 

31


Table of Contents

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.

If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of AG10 or other product candidates that we may identify, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover AG10 or other product candidates that we may identify. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

 

32


Table of Contents

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United

 

33


Table of Contents

States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor’s patents or patent applications.

The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.

Risks related to commercialization

Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.

The commercial success of AG10 or other product candidates that we may identify will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:

 

 

the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals;

 

34


Table of Contents
 

the potential and perceived advantages compared to alternative treatments;

 

 

the ability to offer our products for sale at competitive prices;

 

 

the ability to offer appropriate patient access programs, such as co-pay assistance;

 

 

the extent to which physicians recommend our products to their patients;

 

 

convenience and ease of dosing and administration compared to alternative treatments;

 

 

the clinical indications for which the product candidate is approved by FDA or comparable regulatory agencies;

 

 

product labeling or product insert requirements of the FDA or other comparable foreign regulatory authorities, including any limitations, contraindications or warnings contained in a product’s approved labeling;

 

 

restrictions on how the product is distributed;

 

 

the timing of market introduction of competitive products;

 

 

publicity concerning our products or competing products and treatments;

 

 

the strength of marketing and distribution support;

 

 

favorable third-party coverage and sufficient reimbursement; and

 

 

the prevalence and severity of any side effects.

If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.

If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.

We do not have a sales or marketing infrastructure and have little experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to market and sell AG10 and any other product candidates we may identify, if and when they are approved. We may also elect to enter into collaborations or strategic partnerships with third parties to engage in commercialization activities, although there is no guarantee we will be able to enter into these arrangements even if we intend to do so.

There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.

Factors that may inhibit our efforts to commercialize any approved product on our own include:

 

 

our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;

 

35


Table of Contents
 

the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products;

 

 

the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;

 

 

the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;

 

 

restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;

 

 

the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and

 

 

unforeseen costs and expenses associated with creating an independent commercialization organization.

If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize AG10 or other product candidates that we may identify or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved.

The insurance coverage and reimbursement status of newly-approved products is uncertain. AG10 and any other product candidates that we may develop may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.

Our ability to successfully commercialize AG10 or any other products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as AG10. Sales of AG10 or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize AG10 or any other product candidates we may identify. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.

A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. In many countries, the prices of medical products are subject to varying price control

 

36


Table of Contents

mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for AG10 or other product candidates that we may identify. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.

There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement in certain European countries. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition.

Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs, or VA, hospitals, and may seek to increase such discounts at any time. Future regulation both domestically and abroad may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to obtain reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

 

37


Table of Contents

The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.

If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.

Our ongoing and planned operations, including clinical research, sales, marketing and promotion of AG10 or other product candidates that we may identify and begin commercializing in the United States, may subject us to various federal and state fraud and abuse laws and other healthcare laws. The laws that may impact our operations include:

 

 

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;

 

 

federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which impose criminal and civil penalties, including through civil “qui tam” or “whistleblower” actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;

 

 

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

 

 

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered

 

38


Table of Contents
 

healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;

 

 

the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

 

 

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and

 

 

analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

 

39


Table of Contents

Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.

Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010 the ACA was enacted, which, among other things increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government’s comparative effectiveness research.

There have been a number of significant changes to the ACA and its implementation. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing effective January 1, 2019 the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October 13, 2017, President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. Moreover, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, also amends the ACA, effective January 1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. Similarly, on April 9, 2018, CMS issued a final rule that will give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces by relaxing certain requirements for essential health benefits required under the ACA for plans sold through such marketplaces. Congress will likely consider additional legislation to repeal, replace, or modify other elements of the ACA. The implications of the ACA, its possible repeal, replacement, or modification, and the political uncertainty surrounding these matters for our business and financial condition, if any, are not yet clear.

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

 

40


Table of Contents

There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

 

 

the demand for AG10 or other product candidates that we may identify, if we obtain regulatory approval;

 

 

our ability to receive or set a price that we believe is fair for our products;

 

 

our ability to generate revenue and achieve or maintain profitability;

 

 

the level of taxes that we are required to pay; and

 

 

the availability of capital.

We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize AG10 or other product candidates that we may identify, if approved.

We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.

The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.

There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of ATTR. Companies that we are aware are developing therapeutics for ATTR include large companies with significant financial resources, such as Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc./Akcea Therapeutics, Inc., Corino Therapeutics Inc./SOM Innovation Biotech, S.L., GlaxoSmithKline plc, Intellia Therapeutics Inc., Arcturus Therapeutics Inc., Neurimmune Holding AG and Prothena Therapeutics plc. In particular, in March 2018, Pfizer announced that its Phase 3 clinical trial of tafamidis in ATTRwt-CM and ATTRm-CM patients (ATTR-ACT) reportedly met its primary endpoint of a reduction in the combination of all-cause mortality and cumulative incidence of cardiovascular-related hospitalizations. If tafamidis receives FDA approval for one or both forms of ATTR-CM, AG10 would not be the first treatment on the market for ATTR, and its market share may be limited. In addition to competition from other companies targeting ATTR, any products we may develop may also face competition from other types of therapies.

Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do.

 

41


Table of Contents

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of TTR, which could give such products significant regulatory and market timing advantages over AG10 or other product candidates that we may identify. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that AG10 or other product candidates that we may identify are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors.

In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors’ products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. See “Risks related to our intellectual property.”

If the market opportunities for AG10 are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Our ability to successfully identify patients and acquire a significant market share will be necessary for us to achieve profitability and growth.

We focus our research and product development on treatments for ATTR. Our projections of both the number of individuals who have a form of ATTR, as well as the subset of individuals with a form of ATTR who have the potential to benefit from treatment with AG10 or other product candidates that we may identify, are based on our beliefs and estimates, including our belief that the availability of minimally invasive diagnostics will result in increased rates of diagnosis for ATTR. These estimates have been derived from a variety of sources, including the scientific literature, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for AG10 or other product candidates that we may identify may be limited or may not be amenable to treatment with AG10 or other product candidates that we may identify, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for AG10 or other product candidates that we may identify, because the potential target populations are small, we may never achieve profitability despite obtaining such significant market share. In addition, our market share could be limited by the availability of other treatments for ATTR, such as tafamidis, that could receive regulatory approval or otherwise be commercially launched before AG10.

 

42


Table of Contents

Risks related to our business and industry

Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.

We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, as well as the other members of our scientific and clinical teams. However, some of these executive officers and other personnel are not our full-time employees. For example, Neil Kumar, our Chief Executive Officer, is employed by BridgeBio and spends a portion of his time on other BridgeBio matters, including involvement with other BridgeBio subsidiaries. Christine Siu, our Chief Financial Officer, also serves as the Chief Operating Officer for other BridgeBio subsidiaries. Uma Sinha, our Chief Scientific Officer, also serves as the Chief Scientific Officer of BridgeBio and other BridgeBio subsidiaries. Jonathan Fox, our Chief Medical Officer, also serves as the Therapeutic Area Lead of Cardiovascular and Renal Diseases for BridgeBio. As a result, these executive officers may not be able to devote their full attention to our Company, which could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Since joining us, all of our executives, including Dr. Kumar, have each spent the majority of their time devoted to us. While none of the executives has a minimum time commitment to us, each retains flexibility to ensure that he or she can re-allocate his or her time based on the needs of each business. The particulars of these executives’ time-allocation strategy may change over time. The risks related to our dependence upon Dr. Kumar are compounded by BridgeBio’s significant ownership percentage and Dr. Kumar’s role in our company. If we were to lose Dr. Kumar or any of our other executives or key personnel, we may not be able to find appropriate replacements on a timely basis and our financial condition and results of operations could be materially adversely affected. Furthermore, although we have employment offer letters with each of our executive officers other than Dr. Kumar, each of them may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our executives or employees. Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our drug pipeline toward scaling up for commercialization, sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize AG10 or other product candidates that we may identify. Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Furthermore, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with BridgeBio.

Following this offering, Neil Kumar, founder and Chief Executive Officer of BridgeBio, Ali Satvat, a member of the Board of Managers of BridgeBio, and Hoyoung Huh, a member of BridgeBio, will serve on our board

 

43


Table of Contents

of directors and retain their positions and affiliations with BridgeBio. Similarly, Christine Siu, our Chief Financial Officer, will also serve as the Chief Operating Officer for other BridgeBio subsidiaries. In addition, certain of these individuals own equity interests in BridgeBio, which represent a significant portion of these individuals’ net worth. Their position at BridgeBio and the ownership of any BridgeBio equity or equity awards creates, or may create the appearance of, conflicts of interest when we ask these individuals to make decisions that could have different implications for BridgeBio than the decisions have for us.

We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.

As of March 31, 2018, we had 14 full-time employees. As we mature, we expect to expand our full-time employee base and to hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time toward managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

We may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and personnel resources, we are placing significant focus on the development of our product candidate, AG10. As a result, we may forgo or delay pursuit of opportunities with other future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to that future product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.

We face an inherent risk of product liability exposure related to the testing of AG10 or other product candidates that we may identify in human clinical trials and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

 

 

decreased demand for any product candidates or medicines that we may develop;

 

 

injury to our reputation and significant negative media attention;

 

 

withdrawal of clinical trial participants;

 

44


Table of Contents
 

significant costs to defend the related litigation;

 

 

substantial monetary awards to trial participants or patients;

 

 

loss of revenue; and

 

 

the inability to commercialize AG10 or any other product candidates that we may develop.

Although we maintain product liability insurance, including coverage for clinical trials that we sponsor, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we commence additional clinical trials and if we successfully commercialize any product candidates. The market for insurance coverage is increasingly expensive, and the costs of insurance coverage will increase as our clinical programs increase in size. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, political influences and inflationary pressures. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the ACA, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization

 

45


Table of Contents

of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected.

In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for AG10 or other product candidates that we may identify. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches.

Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of AG10 and other third parties for the manufacture of AG10 and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of AG10 could be delayed.

Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive, and financial penalties may also apply.

Our insurance policies may not be adequate to compensate us for the potential losses arising from breaches, failures or disruptions of our infrastructure, catastrophic events and disasters or otherwise. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly and divert management’s attention.

Furthermore, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on other third parties for the manufacture of AG10 and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business.

We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power

 

46


Table of Contents

outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Our anticipated international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement and economic risks associated with doing business outside of the United States.

We currently have no international operations, but our business strategy incorporates potential international expansion to target ATTR patient populations outside the United States. If we receive regulatory approval for and commercialize AG10 in patient populations outside the United States, we may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:

 

 

multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;

 

 

failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;

 

 

additional potentially relevant third-party patent rights;

 

 

complexities and difficulties in obtaining protection and enforcing our intellectual property;

 

 

difficulties in staffing and managing foreign operations;

 

 

complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;

 

 

limits in our ability to penetrate international markets;

 

 

financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;

 

 

natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;

 

 

certain expenses including, among others, expenses for travel, translation, and insurance; and

 

 

regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.

Any of these factors could significantly harm our potential international expansion and operations and, consequently, our results of operations.

 

47


Table of Contents

If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.

As a public company, we will be required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following this offering, provide a management report on internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.

Any failure to develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our results of operations, cause us to fail to meet our reporting obligations, result in a restatement of our financial statements for prior periods, or adversely affect the results of management evaluations and independent registered public accounting firm audits of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal controls over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our common stock.

We are in the process of designing and implementing the internal control over financial reporting required to comply with Section 404 of the Sarbanes-Oxley Act. This process will be time consuming, costly, and complicated. If we are unable to assert that our internal control over financial reporting is effective or when required in the future, if our independent registered public accounting firm issues an adverse opinion on the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.

The report of our independent registered public accounting firm on our 2017 financial statements contains an explanatory paragraph regarding our ability to continue as a going concern, and we will need additional financing to execute our business plan, to fund our operations and to continue as a going concern.

Since inception, we have experienced recurring operating losses and negative cash flows and we expect to continue to generate operating losses and consume significant cash resources for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern without additional financing. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our 2017 financial statements with respect to this uncertainty. Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock and we may have a more difficult time obtaining financing.

 

48


Table of Contents

Risks related to our equity securities and this offering

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

 

 

being permitted to provide only two years of audited financial statements prior to our first filing of our Annual Report on Form 10-K, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s discussion and analysis of financial condition and results of operations” disclosure;

 

 

not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;

 

 

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

 

 

reduced disclosure obligations regarding executive compensation; and

 

 

not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved.

We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the initial public offering price.

The market price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

 

 

adverse results or delays in our preclinical studies or clinical trials, including our ongoing Phase 2 and planned Phase 3 clinical trials of AG10;

 

 

reports of adverse events or other negative results in clinical trials of third parties’ product candidates for ATTR or similar indications, including the Phase 3 ATTR-ACT clinical trial of tafamidis;

 

49


Table of Contents
 

inability to obtain additional funding;

 

 

any delay in filing an IND or NDA for AG10 or other product candidates that we may identify and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;

 

 

failure to develop successfully and commercialize AG10 or other product candidates that we may identify;

 

 

failure to maintain our existing license arrangements or enter into new licensing and collaboration agreements;

 

 

failure by us or our licensors to prosecute, maintain or enforce our intellectual property rights;

 

 

changes in laws or regulations applicable to future products;

 

 

inability to obtain adequate clinical or commercial supply for our product candidates or the inability to do so at acceptable prices;

 

 

adverse regulatory decisions, including failure to reach agreement with applicable regulatory authorities on the design or scope of our planned clinical trials;

 

 

failure to obtain and maintain regulatory exclusivity for our product candidates;

 

 

regulatory approval or commercialization of new products or other methods of treating our target disease indications by our competitors;

 

 

failure to meet or exceed financial projections we may provide to the public or to the investment community;

 

 

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

 

 

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors;

 

 

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

 

 

additions or departures of key scientific or management personnel;

 

 

significant lawsuits, including patent or stockholder litigation;

 

 

changes in the market valuations of similar companies;

 

 

sales of our common stock by us or our stockholders in the future; and

 

 

trading volume of our common stock.

In addition, companies trading in the stock market in general, and Nasdaq, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.

Investors purchasing shares of common stock in this offering will pay a price per share that substantially exceeds the pro forma as adjusted book value per share of our tangible assets after subtracting our liabilities.

 

50


Table of Contents

As a result, investors purchasing shares of common stock in this offering will incur immediate dilution of $11.52 per share, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and our pro forma adjusted net tangible book value as of March 31, 2018. Further, based on these assumptions, investors purchasing shares of common stock in this offering will contribute approximately 52.3% of the total amount invested by stockholders since our inception, but will own only approximately 17.5% of the shares of common stock outstanding. For information on how the foregoing amounts were calculated, see “Dilution” located elsewhere in this prospectus.

This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this offering as compared to the price offered to the public in this offering, and the exercise of stock options granted to our employees. In addition, as of March 31, 2018, options to purchase 560,128 shares of our common stock at a weighted-average exercise price of $0.91 per share were outstanding. The exercise of any of these options or any outstanding options granted subsequently would result in additional dilution. As a result of the dilution to investors purchasing shares in this offering, as well as other factors, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

Pursuant to our 2018 Stock Option and Incentive Plan, or the 2018 Plan, which will become effective upon the effectiveness of the registration statement of which this prospectus is a part, we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. If our board of directors elects to increase the number of shares available for future grant and our stockholders approve of such an increase at our annual meeting, our stockholders may experience additional dilution, and our stock price may fall.

A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, upon the expiration of the market standoff and lock-up agreements, the early release of these agreements, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering and after giving effect to the conversion immediately prior to the completion of this offering of all outstanding shares of our redeemable convertible preferred stock into 24,025,270 shares of our common stock, the automatic net exercise of warrants for 191,541 shares of our redeemable convertible preferred stock, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover of this prospectus, and the subsequent conversion of such shares into an aggregate of 191,541 shares of common stock immediately prior to the completion of this offering, upon the completion of this offering, we will have 35,799,821 shares of common stock outstanding based on 5,333,010 shares of our common stock outstanding as of March 31, 2018. Of these shares, the 6,250,000 shares we are selling in this offering may be resold in the public market immediately, unless purchased by our affiliates. The remaining 29,549,821 shares, or 82.5% of our outstanding shares after this offering, are currently prohibited or otherwise restricted under securities

 

51


Table of Contents

laws, market standoff agreements entered into by our stockholders with us or lock-up agreements entered into by our stockholders with the underwriters; however, subject to applicable securities law restrictions and excluding shares of restricted stock that will remain unvested, these shares will be able to be sold in the public market beginning 180 days after the date of this prospectus. The representatives may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements at any time and for any reason. In addition, the 1,285,778 shares of unvested restricted stock and common stock issued and outstanding as of March 31, 2018 will become available for sale immediately upon the vesting of such shares, as applicable, and the expiration of any applicable market standoff or lock-up agreements. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. See the section titled “Shares eligible for future sale” for additional information.

Moreover, after the completion of this offering, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, holders of an aggregate of 24,216,811 shares of our common stock will have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described in the section titled “Underwriting” in this prospectus. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

Participation in this offering by certain of our existing owners would reduce the available public float for our shares.

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing up to an aggregate of approximately $50.0 million of our common stock in this offering, at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell more, less or no shares to any of these potential investors and any of these potential investors could determine to purchase more, less or no shares in this offering. To the extent existing stockholders affiliated with certain of our directors are allocated all or a portion of the shares in which they have indicated an interest in purchasing in this offering and purchase any such shares, such purchase would reduce the available public float for our shares because such entities would be restricted from selling the shares by restrictions under applicable securities laws. As a result, any purchase of shares by such entities in this offering may reduce the liquidity of our common stock relative to what it would have been had these shares been purchased by investors that were not existing stockholders.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.

 

52


Table of Contents

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors, five percent stockholders and their affiliates beneficially own approximately 91.9% of our voting stock as of March 31, 2018 and, upon the completion of this offering, that same group will beneficially own approximately 68.7% of our outstanding voting stock. Therefore, even after this offering, these stockholders, and in particular, our controlling stockholder, BridgeBio, will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The foregoing discussion does not reflect any potential purchases by these potential purchasers.

BridgeBio will continue to own a significant percentage of our common stock, will be able to exert significant control over matters subject to stockholder approval and may have interests that conflict with those of our other stockholders.

BridgeBio is currently our majority stockholder, and after this offering is completed, we will continue to be controlled by BridgeBio. Upon the completion of this offering, BridgeBio will beneficially own approximately 52.0% of the voting power of our outstanding common stock, or approximately 50.6% if the underwriters exercise their option to purchase additional shares of common stock in full. Therefore, even after this offering, BridgeBio will have the ability to substantially influence us and exert significant control through this ownership position. For example, BridgeBio will be able to control elections of directors, amendments of our organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction.

Furthermore, certain of our directors and officers may have actual or potential conflicts of interest with us because of their positions or affiliations with BridgeBio. For example, following this offering, Neil Kumar, founder and Chief Executive Officer of BridgeBio, and Hoyoung Huh, a member of BridgeBio, will continue to serve on our board of directors and retain their positions and affiliations with BridgeBio. Christine Siu, our Chief Financial Officer, also serves as the Chief Operating Officer for other BridgeBio subsidiaries. Uma Sinha, our Chief Scientific Officer, also serves as the Chief Scientific Officer of BridgeBio and other BridgeBio subsidiaries. Jonathan Fox, our Chief Medical Officer, also serves as the Therapeutic Area Lead of Cardiovascular and Renal Diseases for BridgeBio. BridgeBio’s interests may not always coincide with our corporate interests or the interests of other stockholders, and it may exercise its voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other stockholders. So long as it continues to own a significant amount of our equity, BridgeBio will continue to be able to strongly influence and significantly control our decisions.

 

53


Table of Contents

Although we do not expect to rely on the “controlled company” exemption under the rules and regulations of Nasdaq, we expect to have the right to use such exemption and therefore we could in the future avail ourselves of certain reduced corporate governance requirements.

BridgeBio will hold a majority of the voting power of our outstanding capital stock following the completion of this offering, and therefore we will be considered a “controlled company” as that term is set forth in the rules and regulations of Nasdaq. Under these rules, a company of which more than 50% of the voting power is held by a person or group of persons acting together is a “controlled company” and may elect not to comply with certain rules and regulations of Nasdaq regarding corporate governance, including:

 

 

the requirement that a majority of its board of directors consist of independent directors;

 

 

the requirement that its director nominees be selected or recommended for the board’s selection by a majority of the board’s independent directors in a vote in which only independent directors participate or by a nominating committee comprised solely of independent directors, in either case, with board resolutions or a written charter, as applicable, addressing the nominations process and related matters as required under the federal securities laws; and

 

 

the requirement that its compensation committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities.

These requirements would not apply to us if, in the future, we choose to avail ourselves of the “controlled company” exemption. Although we qualify as a “controlled company,” we do not currently expect to rely on these exemptions and intend to fully comply with all corporate governance requirements under the rules and regulations of Nasdaq. However, if we were to utilize some or all of these exemptions, we would not comply with certain of the corporate governance standards of Nasdaq, which could adversely affect the protections for our other stockholders.

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled “Use of Proceeds” located elsewhere in this prospectus, and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Our restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our restated certificate of incorporation and amended and restated bylaws, which will become effective upon the completion of this offering, include provisions that:

 

 

authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;

 

 

specify that special meetings of our stockholders can be called only by our board of directors or stockholders holding at least 25% of our outstanding voting stock;

 

54


Table of Contents
 

establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;

 

 

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum, or by the holders of a majority of the outstanding shares of capital stock then entitled to vote at an election of directors;

 

 

specify that no stockholder is permitted to cumulate votes at any election of directors;

 

 

expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and

 

 

require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Any provision of our restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.

Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. Our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:

 

 

the timing, results and cost of, and level of investment in, our clinical development activities for AG10 and any other product candidates we may identify and pursue, which may change from time to time;

 

 

the cost of manufacturing AG10 or other product candidates that we may identify, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;

 

 

our ability to conduct clinical trials of AG10 in accordance with our plans and to obtain regulatory approval for AG10 or other product candidates that we may identify, and the timing and scope of any such approvals we may receive;

 

 

the timing and success or failure of clinical trials for competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;

 

 

expenditures that we will or may incur to acquire or develop additional product candidates and technologies;

 

 

our ability to attract, hire and retain qualified personnel;

 

 

the level of demand for AG10 or other product candidates that we may identify, should they receive approval, which may vary significantly;

 

 

future accounting pronouncements or changes in our accounting policies;

 

55


Table of Contents
 

the risk/benefit profile, cost and reimbursement policies with respect to AG10 or other product candidates that we may identify, if approved, and existing and potential future drugs that compete with our product candidates; and

 

 

the changing and volatile U.S., European and global economic environments.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially.

Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset a portion of future taxable income, if any, subject to expiration of such carryforwards in the case of carryforwards generated prior to 2018. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. Our prior equity offerings and other changes in our stock ownership may have resulted in ownership changes. In addition, we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. At the state level, there may also be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. In addition, under the Tax Cuts and Jobs Act of 2017, or the Tax Act, the amount of post 2017 NOLs that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. The Tax Act generally eliminates the ability to carry back any NOL to prior taxable years, while allowing post 2017 unused NOLs to be carried forward indefinitely. There is a risk that due to changes under the Tax Act, regulatory changes, or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs, whether or not we attain profitability.

Comprehensive tax reform legislation could adversely affect our business and financial condition.

On December 22, 2017, the Tax Act was signed into law. The Tax Act, among other things, contains significant changes to corporate taxation, including (i) reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, (ii) limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), (iii) limitation of the deduction for net operating losses to 80% of current year taxable income in respect of net operating losses generated during or after 2018 and elimination of net operating loss carrybacks, (iv) one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, (v) immediate deductions for certain new investments instead of deductions for depreciation expense over time, and (vi) modifying or repealing many business deductions and credits. Any

 

56


Table of Contents

federal net operating loss incurred in 2018 and in future years may now be carried forward indefinitely pursuant to the Tax Act. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. We will continue to examine the impact the Tax Act may have on our business.

We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock.

We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.

An active trading market for our common stock may not develop.

Prior to this offering, there has been no public market for shares of our common stock. Although our common stock will be approved for listing on The Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. The initial public offering price of our common stock was determined through negotiations between us and the underwriters. This initial public offering price may not be indicative of the market price of our common stock after this offering. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the initial public offering price or at the time that they would like to sell.

Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the laws of the FDA and comparable foreign regulatory authorities; provide true, complete and accurate information to the FDA and comparable foreign regulatory authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of AG10 or other product candidates that we may identify and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

 

57


Table of Contents

We will incur significant costs as a result of operating as a new public company, and our management will devote substantial time to new compliance initiatives.

As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering. We intend to take advantage of this new legislation, but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

 

58


Table of Contents

Cautionary note regarding forward-looking statements

This prospectus, including the sections entitled “Prospectus summary,” “Risk factors,” “Management’s discussion and analysis of financial condition and results of operations” and “Business,” contains forward-looking statement, within the meaning of the Private Securities Litigation Reform Act of 1995, concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about:

 

 

the success, cost and timing of our clinical development of AG10 for the treatment of ATTR-CM and ATTR-PN, including the progress of, and results from, our ongoing Phase 2 clinical trial of AG10 in ATTR-CM and our planned Phase 3 clinical trial of AG10 in ATTR-PN;

 

 

our ability to initiate, recruit and enroll patients in, and conduct our clinical trials at the pace that we project;

 

 

our ability to obtain and maintain regulatory approval of our only current product candidate, AG10, and any related restrictions, limitations or warnings in the label of AG10, if approved;

 

 

our ability to compete with companies currently marketing or engaged in the development of treatments for ATTR;

 

 

our reliance on third parties to conduct our clinical trials and to manufacture drug substance for use in our clinical trials;

 

 

the size and growth potential of the markets for AG10 and any additional product candidates we may identify and pursue, and our ability to serve those markets;

 

 

our ability to identify and advance through clinical development any additional product candidates;

 

 

the commercialization of AG10 and any other product candidates we may identify and pursue, if approved, including our ability to successfully build a specialty sales force and commercial infrastructure to market AG10 and any other product candidates we may identify and pursue;

 

 

our ability to retain and recruit key personnel;

 

 

our ability to obtain and maintain adequate intellectual property rights, including under our exclusive license with Stanford University, to develop and commercialize AG10;

 

 

our expectations regarding government and third-party payor coverage and reimbursement;

 

 

our estimates of our expenses, ongoing losses, capital requirements and our needs for or ability to obtain additional financing;

 

 

our expected uses of the net proceeds to us from this offering;

 

 

our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;

 

59


Table of Contents
 

our financial performance; and

 

 

developments and projections relating to our competitors or our industry.

In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk factors” and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we assume no obligation to update or revise any forward-looking statements except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon these statements.

 

60


Table of Contents

Use of proceeds

We estimate that our net proceeds from the sale of 6,250,000 shares of our common stock in this offering will be approximately $90.2 million, or $104.2 million if the underwriters exercise in full their option to purchase 937,500 additional shares, assuming an initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

A $1.00 increase (decrease) in the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $5.8 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from this offering by $14.9 million, assuming no change in the assumed initial public offering price per share and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We intend to use the net proceeds from this offering as follows:

 

 

Approximately 80% of the net proceeds will be used to fund our clinical development of AG10 for the treatment of ATTR-CM and ATTR-PN, including our ongoing Phase 2 ATTR-CM and planned Phase 3 ATTR-PN clinical trials, as well as future clinical trials and additional research and development activities; and

 

The remaining proceeds will be used for working capital and general corporate purposes.

We may also use a portion of the net proceeds to in-license, acquire or invest in new businesses, technology or assets. Although we have no current agreements, commitments or understandings with respect to any such in-license or acquisition, we evaluate such opportunities and engage in related discussions with third parties from time to time.

We estimate that our current cash, along with the net proceeds from this offering, will be sufficient for us to fund our operating expenses and capital expenditure requirements through at least the next 12 months, including through the completion of our ongoing Phase 2 and planned Phase 3 clinical trials of AG10. However, the net proceeds from this offering, together with our current cash, will not be sufficient for us to fund the development of AG10 through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of AG10. At this time, we cannot predict with certainty the amount of capital needed to complete the development and commercialization of AG10, but we anticipate seeking additional capital in the future to fund such capital needs through further equity offerings and/or debt borrowings, or through collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements. We cannot guarantee that we will be able to raise additional capital on reasonable terms or at all.

This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above.

The amounts and timing of our actual expenditures and the extent of our research and development activities may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from any preclinical or clinical trials we may commence in the future, our ability to take advantage of expedited programs or to obtain regulatory approval for any other product candidates we may identify and pursue, the timing and costs associated with the manufacture and supply of any other product

 

61


Table of Contents

candidates we may identify and pursue for clinical development or commercialization, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.

We intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities.

 

62


Table of Contents

Dividend policy

We have never declared or paid any cash dividends on our capital stock. We do not anticipate paying any dividends on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. Any future determination to declare dividends will be subject to the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.

 

63


Table of Contents

Capitalization

The following table sets forth our cash and capitalization as of March 31, 2018:

 

 

on an actual basis;

 

 

on a pro forma basis to give effect to (i) the sale and issuance in May 2018 of 4,430,162 shares of our Series B redeemable convertible preferred stock at $10.8348 per share, for net proceeds of $48.0 million and the related settlement of the redeemable convertible preferred stock put option asset and the redeemable convertible preferred stock tranche liability, (ii) the filing and effectiveness of our restated certificate of incorporation as of immediately prior to the completion of this offering; (iii) the automatic net exercise of warrants issued in February 2018 for an aggregate of 191,541 shares of our redeemable convertible preferred stock, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, the subsequent conversion of such shares into an aggregate of 191,541 shares of common stock immediately prior to the completion of this offering and the resultant reclassification of our preferred stock warrant liabilities to additional paid-in capital, a component of stockholders’ deficit, all of which will occur in connection with the completion of this offering; and (iv) the conversion of all of the outstanding shares of our redeemable convertible preferred stock into an aggregate of 24,025,270 shares of common stock immediately prior to the completion of this offering; and

 

 

on a pro forma as adjusted basis to give further effect to the sale of 6,250,000 shares of common stock in this offering at an assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions, and estimated offering expenses payable by us.

You should read this information together with our financial statements and related notes appearing elsewhere in this prospectus and the information set forth under the heading “Selected financial data” and “Management’s discussion and analysis of financial condition and results of operations.”

 

      As of March 31, 2018  
(In thousands, except share and per share amounts)    Actual     Pro forma    

Pro forma

as adjusted(1)

 

Cash

   $ 25,269     $ 73,269     $ 163,469  
  

 

 

 

Redeemable convertible preferred stock put option asset

   $ 1,527     $     $  

Redeemable convertible preferred stock tranche liability

     2,028              

Redeemable convertible preferred stock warrant liability

     841              

Redeemable convertible preferred stock, $0.001 par value, 20,457,205 shares authorized; 15,657,863 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted

     46,603              

Stockholders’ (deficit) equity:

      

Preferred stock, $0.001 par value, no shares authorized, issued and outstanding, actual; 5,000,000 shares authorized, no shares issued and outstanding pro forma and pro forma as adjusted

                  

Common stock, $0.001 par value, 27,000,000 shares authorized; 5,333,010 shares issued and outstanding, actual; 150,000,000 shares authorized, pro forma and pro forma as adjusted; 29,549,821 shares issued and outstanding, pro forma; 35,799,821 shares issued and outstanding, pro forma as adjusted

     4       30       36  

Additional paid-in capital

     4,281       100,200       190,394  

Accumulated deficit

     (30,111     (30,111     (30,111
  

 

 

 

Total stockholders’ (deficit) equity

     (25,826     70,119       160,319  
  

 

 

 

Total capitalization

   $ 22,119     $ 70,119     $ 160,319  

 

 

 

64


Table of Contents
(1)   A $1.00 increase (decrease) in the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash, additional paid-in capital, total stockholders’ (deficit) equity and total capitalization by approximately $5.8 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered would increase (decrease) each of cash, additional paid-in capital, total stockholders’ (deficit) equity and total capitalization by approximately $14.9 million, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

The number of shares of common stock issued and outstanding actual, pro forma and pro forma as adjusted in the table above is based on 5,333,010 shares of common stock outstanding as of March 31, 2018 and 24,216,811 additional shares of our common stock issuable upon the conversion of all outstanding shares of our redeemable convertible preferred stock upon the completion of this offering based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and excludes:

 

 

560,128 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were outstanding as of March 31, 2018, with a weighted-average exercise price of $0.91 per share;

 

 

213,842 shares of common stock issuable upon exercise of options granted after March 31, 2018 at a weighted-average exercise price of $7.24 per share;

 

 

807,682 shares of our common stock reserved for issuance pursuant under our 2016 Plan as of March 31, 2018;

 

 

No shares of common stock issued after March 31, 2018;

 

 

598,000 shares of common stock reserved for future issuance under our 2018 Plan, which will become available for issuance upon the effectiveness of the registration statement of which this prospectus is a part; and

 

 

143,520 shares of our common stock reserved for future issuance under our 2018 ESPP, which will become available for issuance upon the effectiveness of the registration statement of which this prospectus is a part.

 

65


Table of Contents

Dilution

If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering.

Net tangible book value (deficit) per share is determined by dividing our total tangible assets (which excludes deferred offering costs) less our total liabilities by the number of shares of common stock outstanding. Our historical net tangible book value (deficit) as of March 31, 2018 was ($26.8) million, or ($5.02) per share. Our pro forma net tangible book value as of March 31, 2018 was $69.2 million, or $2.34 per share. Our pro forma net tangible book value per share represents the amount of our total tangible assets (which excludes deferred offering costs) reduced by the amount of our total liabilities and divided by the total number of shares of our common stock outstanding as of March 31, 2018, assuming (i) the sale and issuance in May 2018 of 4,430,162 shares of our Series B redeemable convertible preferred stock at $10.8348 per share, for net proceeds of $48.0 million, (ii) the automatic net exercise of warrants issued in February 2018 for an aggregate of 191,541 shares of our redeemable convertible preferred stock, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover of this prospectus, the subsequent conversion of such shares into an aggregate of 191,541 shares of common stock immediately prior to the completion of this offering and the resultant reclassification of our preferred stock warrant liabilities to additional paid-in capital, a component of stockholders’ deficit, all of which will occur in connection with the completion of this offering and (iii) the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 24,025,270 shares of common stock, which conversion will occur immediately prior to the completion of this offering.

Net tangible book value dilution per share to new investors represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the pro forma as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving effect to our sale of shares of common stock in this offering at an assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March 31, 2018 would have been $160.3 million, or $4.48 per share. This represents an immediate increase in net tangible book value of $2.14 per share to existing stockholders and an immediate dilution in net tangible book value of $11.52 per share to purchasers of common stock in this offering, as illustrated in the following table:

 

Assumed initial public offering price per share

           $ 16.00  

Historical net tangible book value (deficit) per share as of March 31, 2018

   ($ 5.02  

Pro forma increase in net tangible book value (deficit) per share as of March 31, 2018

     7.36    
  

 

 

   

Pro forma net tangible book value per share as of March 31, 2018

     2.34    

Increase in pro forma net tangible book value per share attributable to new investors participating in this offering

     2.14    
  

 

 

   

Pro forma as adjusted net tangible book value per share after this offering

       4.48  
    

 

 

 

Dilution per share to new investors participating in this offering

     $ 11.52  

 

 

If the underwriters’ option to purchase additional shares from us is exercised in full, the pro forma as adjusted net tangible book value per share after this offering would be $4.74 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $2.40 per share and the dilution to new investors purchasing shares in this offering would be $11.26 per share.

 

66


Table of Contents

Each $1.00 increase (decrease) in the assumed public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value by $5.8 million, or $0.16 per share, and dilution per share to investors in this offering by $0.84 per share, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting underwriting discounts and commissions, and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of shares we are offering would increase (decrease) our pro forma as adjusted net tangible book value by approximately $14.9 million, or approximately $0.28 and $(0.30) per share, and would increase (decrease) dilution per share to investors in this offering by approximately $(0.28) and $0.30 per share, assuming the assumed initial public offering price per share remains the same and after deducting underwriting discounts and commissions, and estimated offering expenses payable by us. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing.

The following table shows, as of March 31, 2018, on a pro forma as adjusted basis described above, the differences between the existing stockholders and the purchasers of shares in this offering with respect to the number of shares purchased from us, the total consideration paid, which includes net proceeds received from the issuance of common and redeemable convertible preferred stock, cash received from the exercise of stock options, and the value of any stock issued for services and the average price paid per share (in thousands, except per share amounts and percentages):

 

      Shares purchased      Total consideration      Average price
per  share
 
      Number      Percent      Amount      Percent     

Existing stockholders before this offering

     29,549,821        82.5%      $ 91,073,422        47.7%      $ 3.08  

New investors participating in this offering

     6,250,000        17.5            100,000,000        52.3            16.00  
  

 

 

 

Totals

     35,799,821        100%      $ 191,073,422        100%     

 

 

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The table above does not reflect any potential purchases by these potential purchasers.

The foregoing calculations are based on 5,333,010 shares of common stock outstanding as of March 31, 2018 and 24,216,811 additional shares of our common stock issuable upon the conversion of all outstanding shares of our redeemable convertible preferred stock upon the completion of this offering based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and excludes:

 

 

560,128 shares of common stock issuable upon exercise of outstanding options as of March 31, 2018 at a weighted-average exercise price of $0.91 per share;

 

 

213,842 shares of common stock issuable upon exercise of options granted after March 31, 2018 at a weighted-average exercise price of $7.24 per share;

 

 

807,682 shares of common stock reserved for future issuance under our 2016 Plan as of March 31, 2018;

 

67


Table of Contents
 

No shares of common stock issued after March 31, 2018;

 

 

598,000 shares of common stock reserved for future issuance under our 2018 Plan, which will become available for issuance upon the effectiveness of the registration statement of which this prospectus is a part; and

 

 

143,520 shares of our common stock reserved for future issuance under our 2018 ESPP, which will become available for issuance upon the effectiveness of the registration statement of which this prospectus is a part.

To the extent that any outstanding options are exercised, new options are issued under our stock-based compensation plans or we issue additional shares of common stock or convertible debt in the future, there will be further dilution to investors participating in this offering.

 

68


Table of Contents

Selected financial data

We have derived the statements of operations data for the years ended December 31, 2016 and 2017 and the balance sheet data as of December 31, 2016 and 2017 from our audited financial statements appearing elsewhere in this prospectus. We have derived the statements of operations data for the three months ended March 31, 2017 and 2018 and the balance sheet data as of March 31, 2018 from our unaudited interim condensed financial statements appearing elsewhere in this prospectus. We have prepared the unaudited interim condensed financial statements on the same basis as our audited financial statements and, in the opinion of management, these financial statements reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair statement of our unaudited interim condensed financial statements. Our historical results are not necessarily indicative of the results that may be expected in the future and our interim results for the three months ended March 31, 2018 are not necessarily indicative of results to be expected for the full year ending December 31, 2018, or any other period. You should read this data together with our financial statements and related notes appearing elsewhere in this prospectus and the information under the caption “Management discussion and analysis of financial condition and results of operations.”

 

      Year ended December 31,     Three months ended March 31,  
(in thousands, except share and per share data)    2016     2017     2017     2018  

Summary of Operations Data:

        

Operating expenses:

        

Research and development

   $ 1,734     $ 9,286     $ 2,039     $ 6,034  

General and administrative

     651       2,730       378       2,143  
  

 

 

 

Total operating expenses

     2,385       12,016       2,417       8,177  
  

 

 

 

Loss from operations

     (2,385     (12,016     (2,417     (8,177

Other income (expense), net

     (157     75       75       (725

Loss on extinguishment of debt

         —         (6,677
  

 

 

 

Net loss

   $ (2,542   $ (11,941   $ (2,342   $ (15,579
  

 

 

 

Net loss per share:(1)

        

Basic and diluted

   $ (0.98   $ (3.32   $ (0.72   $ (3.89
  

 

 

 

Weighted-average shares outstanding used in computing net loss per share:(1)

        

Basic and diluted

     2,599,641       3,596,673       3,241,138       4,006,085  
  

 

 

 

Pro forma net loss per share:(1)

        

Basic and diluted

     $ (0.93     $ (0.80
    

 

 

     

 

 

 

Weighted-average shares outstanding used in computing pro forma net loss per share:(1)

        

Basic and diluted

       12,777,063         19,574,812  

 

 

 

(1)   See Notes 2, 14, and 15 to our audited financial statements and Notes 11 and 12 to our unaudited interim condensed financial statements included elsewhere in this prospectus for an explanation of the calculations of our basic and diluted net loss per share, basic and diluted pro forma net loss per share, and the weighted-average number of shares used in the computation of these per share amounts.

 

69


Table of Contents
      As of December 31,     As of March 31,  
(in thousands)    2016     2017     2018  

Balance Sheet Data:

      

Cash

   $ 1,956     $ 5,497     $ 25,269  

Working capital

     1,675       3,810       21,231  

Redeemable convertible preferred stock put option asset

                 1,527  

Total assets

     1,975       6,343       28,823  

Redeemable convertible preferred tranche liability

     315             2,028  

Redeemable convertible preferred stock warrant liability

                 841  

Redeemable convertible preferred stock

     3,795       17,028       46,603  

Accumulated deficit

     (2,591     (14,532     (30,111

Total stockholders’ (deficit) equity

     (2,473     (13,196     (25,826

 

 

 

70


Table of Contents

Market and industry data and forecasts

We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in “Risk Factors.” These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.

 

71


Table of Contents

Management’s discussion and analysis of financial condition and results of operations

You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled “Selected Financial Data” and our financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled “Risk factors” included elsewhere in this prospectus.

Overview

We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin, or TTR, amyloidosis, or ATTR. We are advancing our product candidate, AG10, to treat ATTR, a progressive and fatal family of diseases. We were founded in 2013 and are led by a management team that has a successful track record in drug development.

We are a majority-owned subsidiary of BridgeBio Pharma LLC, or BridgeBio, a biotechnology company dedicated to identifying and developing novel therapies for genetic diseases. Led by experienced scientists, drug developers and investors, BridgeBio employs a distributed corporate structure that enables focus at the level of each disease while providing centralized resources to scale across many opportunities.

Our financial information includes allocations of expenses attributable to certain corporate functions that were provided to us by BridgeBio and its affiliates, including expenses attributable to certain executive personnel, facility-related costs, advisory services, insurance costs and other general corporate expenses. These allocations were made based on direct usage or estimates which are considered to be reasonable by our management and in accordance with our services agreement with BridgeBio. We have moved into our own leased facility and expect to reduce the services provided by BridgeBio as we hire additional personnel.

Since the commencement of our operations, we have devoted substantially all of our resources to research and development activities in support of our product development efforts, hiring personnel, raising capital to support and expand such activities and general and administrative support for these operations. We have funded our operations to date primarily from the issuance and sale of shares of redeemable convertible preferred stock and notes convertible into shares of redeemable convertible preferred stock.

In April 2016, we entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University, or Stanford, for rights relating to novel transthyretin aggregation inhibitors. Under the license agreement, Stanford has granted us an exclusive worldwide license to make, use and sell products that are covered by the licensed patent rights. In connection with the execution of the license agreement, we paid an upfront license fee in April 2016 and issued Stanford shares of common stock, which were recorded as research and development expense during the year ended December 31, 2016. In March 2017, we paid an annual maintenance fee under the license agreement, which was recorded as research and development expense during the year ended December 31, 2017. We are obligated to make future payments to Stanford upon the achievement of specific intellectual property, clinical and regulatory milestone events, as well as pay royalties in the low single digits on future net sales, if any.

We have not generated any revenue to date. Since inception, we have incurred significant operating losses. We have incurred net losses of $2.5 million and $11.9 million during the years ended December 31, 2016 and 2017,

 

72


Table of Contents

and $2.3 million and $15.6 million during the three months ended March 31, 2017 and 2018, respectively, and we expect to continue to incur significant losses for the foreseeable future. As of March 31, 2018, we had an accumulated deficit of $30.1 million. We expect these losses to increase as we continue our development of, and seek regulatory approvals for our product candidate, AG10, begin to commercialize AG10, if approved, and engage in any other research and development activities. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.

As of March 31, 2018, we had $25.3 million in cash. In May 2018, we issued 4,430,162 shares of our Series B redeemable convertible preferred stock for net proceeds of $48.0 million. The Company believes that its cash as of March 31, 2018, without any future financing, will not be sufficient for the Company to continue as a going concern for at least one year from the issuance date of its unaudited condensed financial statements for the three months ended March 31, 2018.

We will need substantial additional funding in addition to the net proceeds of this offering to support our continuing operations and pursue our long-term development strategy. We will need to obtain additional financing in the future, and may seek financing through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts for AG10 and other research and development activities. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed would compromise our ability to execute on our business plan and we may have to significantly delay, scale back, or discontinue the development of AG10 or curtail any efforts to expand our product pipeline. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Financial operations overview

Research and development expense

Research and development expense consist primarily of costs incurred for the development of AG10, which include:

 

 

employee-related expenses, including salaries, benefits and stock-based compensation;

 

 

laboratory, manufacturing and other vendor expenses related to the execution of preclinical studies and clinical trials;

 

 

the costs related to the production of clinical supplies and the engagement of consultants that conduct research and development activities on our behalf;

 

 

fees paid under our license agreement with Stanford; and

 

 

facilities and other allocated expenses, expenses for rent, depreciation and amortization, maintenance of facilities and other supplies.

We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Nonrefundable payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized. The capitalized amounts are recognized as expense as the goods are delivered or the related services are performed.

 

73


Table of Contents

The following table summarizes our research and development expenses incurred during the respective periods:

 

      Year ended
December  31,
     Three months  ended
March 31,
 
(in thousands)              2016                2017                2017                2018  

Clinical development

   $      $ 1,272      $      $ 1,376  

Contract manufacturing

            1,888        21        1,024  

Preclinical, discovery and other research and development costs

     1,429        3,919        1,874        1,216  

Compensation and related personnel costs

     305        2,032        133        2,311  

Facility and other costs

            175        11        107  
  

 

 

 

Total research and development expenses

   $ 1,734      $ 9,286      $ 2,039      $ 6,034  

 

 

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to AG10 as we advance AG10 into later stages of clinical development, including our ongoing Phase 2 clinical trial of AG10 in ATTR-CM and our planned Phase 3 clinical trial of AG10 in ATTR-PN and any subsequent clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of AG10 is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization of our product candidate, if at all.

General and administrative expense

Our general and administrative expenses consist primarily of personnel costs, allocated facility costs and other expenses for outside professional services, including legal, human resource, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation. We expect to incur additional expenses as a result of this offering and operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase the size of our administrative function to support the growth of our business.

Other income (expense), net

Other income (expense), net primarily includes gains and losses from the remeasurement of our liabilities related to our redeemable convertible preferred stock tranche liability and our redeemable convertible preferred stock warrant liability. We will continue to adjust the liabilities for changes in estimated fair value until the settlement of the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant liability. At such time, the redeemable convertible preferred stock tranche liability will be reclassified to redeemable convertible preferred stock and we will no longer record any related periodic fair value adjustments. We will continue to record adjustments to the estimated fair value of the redeemable convertible preferred stock warrants until such time as these instruments are exercised, expire or are net exercised upon the completion of an IPO.

Loss on extinguishment of debt

Loss on extinguishment of debt resulted from the conversion of our convertible promissory notes into Series B redeemable convertible preferred stock prior to its maturity date, resulting in the immediate recognition of unamortized debt discount amounts and related settlement of the embedded derivative liability.

 

74


Table of Contents

Comparison of the three months ended March 31, 2017 and 2018

      Three months ended
March 31,
               
(dollars in thousands)    2017     2018     $ Change     % Change  

Operating expenses:

        

Research and development

   $ 2,039     $ 6,034     $ 3,995       196%  

General and administrative

     378       2,143       1,765       467  
  

 

 

 

Total operating expenses

     2,417       8,177       5,760       238  
  

 

 

 

Loss from operations

     (2,417     (8,177     (5,760     238  

Other income (expense), net

     75       (725     (800     (1,067

Loss on extinguishment of debt

           (6,677     (6,677     N/A  
  

 

 

 

Net loss

   $ (2,342   $ (15,579   $ (13,237     565%  

 

 

Research and development expense

Research and development expense increased by $4.0 million, or 196%, during the three months ended March 31, 2018, compared to the three months ended March 31, 2017. The increase was primarily attributable to increased personnel costs of $1.7 million due to a higher headcount, an increase of $1.6 million in clinical trial related activities and contract manufacturing activities for our clinical trials and their product supply and an increase in stock-based compensation of $0.5 million.

General and administrative expense

General and administrative expense increased by $1.8 million, or 467%, during the three months ended March 31, 2018, compared to the three months ended March 31, 2017. The increase was primarily attributable to an increase of $1.3 million in professional service fees and consulting services, primarily for financial, legal and accounting fees and an increase of $0.3 million in personnel-related expenses due to an increase in headcount to support the growth of our operations.

Other income (expense), net

Other income (expense), net was an expense of $0.7 million during the three months ended March 31, 2018, compared to income of $75,000 during the three months ended March 31, 2017. The expense during the three months ended March 31, 2018 is primarily from the amortization of the debt discount of $0.7 million related to the convertible promissory note payable which was converted into Series B redeemable convertible preferred stock in March 2018. The other income during the three months ended March 31, 2017 was due to the settlement of the redeemable convertible preferred stock tranche liability in March 2017.

Loss on extinguishment of debt

Loss on extinguishment of debt was due to our convertible promissory notes converting into Series B redeemable convertible preferred stock. The convertible promissory notes had a contractual term of one year, however, they were converted in March 2018, as such the remaining debt discounts were recognized immediately upon the conversion of the notes. There was no similar activity during the three months ended March 31, 2017.

 

75


Table of Contents

Comparison of the years ended December 31, 2016 and 2017

 

      Year ended
December 31,
        
(dollars in thousands)    2016     2017     $ Change     % Change  

Operating expenses:

        

Research and development

   $ 1,734     $ 9,286     $ 7,552       436%  

General and administrative

     651       2,730       2,079       319  
  

 

 

 

Total operating expenses

     2,385       12,016       9,631       404  
  

 

 

 

Loss from operations

     (2,385     (12,016     (9,631     404  

Other income (expense), net

     (157     75       232       (148
  

 

 

 

Net loss

   $ (2,542   $ (11,941   $ (9,399     370%  

 

 

Research and development expense

Research and development expense increased by $7.6 million, or 436%, during the year ended December 31, 2017, compared to the year ended December 31, 2016. The increase was related to an increase of $2.5 million primarily in preclinical activities for AG10, an increase of $1.9 million in contract manufacturing activities for AG10 to supply our Phase 1 clinical trial, an increase of $1.7 million in salaries and employee-related expenses due to an increase in headcount, an increase of $1.3 million in clinical research organization and related costs for the Phase 1 clinical trial, which were incurred primarily in the second half of 2017, and an increase in $0.2 million in facility-related costs due to increased costs for our office and lab facilities.

General and administrative expense

General and administrative expense increased by $2.1 million, or 319%, during the year ended December 31, 2017, compared to the year ended December 31, 2016. The increase was attributable to an increase of $1.2 million in professional service fees, primarily for financial and accounting consulting fees and an increase of $0.9 million in personnel-related expenses due to an increase in headcount to support the growth of our operations.

Other income (expense), net

Other income (expense), net was $0.2 million expense during the year ended December 31, 2016, compared to $75,000 income the year ended December 31, 2017. The change resulted from the final settlement of the redeemable convertible preferred stock tranche liability in March 2017. We will no longer record any related periodic fair value adjustments for the liability.

Critical accounting policies and estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other

 

76


Table of Contents

sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

While our significant accounting policies are described in the notes to our financial statements included elsewhere in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.

Accrued research and development

We record accrued expenses for estimated costs of our research and development activities conducted by third-party service providers, which include preclinical studies and clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and include these costs in accrued expenses and other current liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of our research and development expenses.

We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers. We record advance payments to service providers as prepaid assets, which are expensed as the contracted services are performed. To date, there have been no material differences from our accrued expenses to actual expenses.

Redeemable convertible preferred stock tranche liability and put option asset

In connection with our Series Seed and Series B redeemable convertible preferred stock financings we were obligated to sell additional shares of Series Seed and Series B redeemable convertible preferred stock in subsequent closings, in each case, contingent upon the achievement of certain specified milestones. We recorded this redeemable convertible preferred stock tranche liability incurred as a derivative financial instrument liability at the fair value on the date of issuance, and we remeasure the liability on each subsequent balance sheet date.

The subsequent closings were deemed to be freestanding financial instruments that were outside of our control. The changes in fair value are recognized as a gain or loss within other income (expense), net in the statements of operations and the liability is remeasured at each reporting period and settlement of the related tranche closing. We estimated the fair value of this liability using the Black-Scholes option pricing model that includes assumptions of probability of achievement of the development milestones, stock price per share, expected life, dividend yield and risk-free interest rate. The preferred stock tranche liability will be remeasured at the end of each reporting period until the obligation is settled or expires upon the earlier of (i) a deemed liquidation event, (ii) conversion of the redeemable convertible preferred stock into common stock or (iii) until the holders of the redeemable convertible preferred stock can no longer trigger a deemed liquidation event.

In connection with our Series B redeemable convertible preferred stock financing in March 2018, we determined that our right to request investors purchase additional shares of our redeemable convertible preferred stock

 

77


Table of Contents

represents a freestanding financial instrument. The freestanding redeemable convertible preferred stock the purchase put option asset was recorded at fair value, based on its relative fair value to the redeemable convertible preferred stock. The put option asset will remain outstanding until the settlement of the redeemable convertible preferred stock additional closing. At such time, the value of the redeemable convertible preferred stock tranche liability and the put option asset will be reclassified to redeemable convertible preferred stock with no further remeasurement required.

Redeemable convertible preferred stock warrant liability

We issued freestanding warrants to purchase shares of redeemable convertible preferred stock in connection with the issuance of our convertible promissory note that was converted into Series B redeemable convertible preferred stock. We account for these warrants as a liability in our financial statements because the underlying instrument, Series B redeemable convertible preferred stock, into which the warrants are exercisable contains redemption provisions that are outside our control.

The fair value of the warrants at the issuance date and at March 31, 2018 was determined using a probability-weighted expected return model in combination with the option pricing model. The warrants are remeasured at each financial reporting period with any changes in fair value being recognized in the statements of operations. We will continue to adjust the liability for changes in fair value until the earlier of (i) exercise of the warrants, (ii) net exercise of the warrants into Series B redeemable convertible preferred stock upon the completion of an IPO, or (iii) expiration of the warrants.

Stock-based compensation

We recognize compensation costs related to stock options granted to employees and non-employees based on the estimated fair value of the awards on the date of grant. Prior to January 1, 2017, the fair value of the portion of the award that is ultimately expected to vest was recognized as expense over the requisite service periods in our statements of operations. Upon the adoption of ASU 2016-09 on January 1, 2017, we elected to recognize the actual forfeitures by reducing the employee stock-based compensation expense in the same period as the forfeitures occur. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.

The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. These assumptions include:

 

 

Expected term—The expected term represents the period that the stock-based awards are expected to be outstanding. We used the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options. For non-employees we use the contractual term.

 

 

Expected volatility—Since we are not yet a public company and do not have any trading history for our common stock, the expected volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their size, stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.

 

 

Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards.

 

78


Table of Contents
 

Expected Dividend—We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.

We will continue to use judgment in evaluating the expected volatility, and expected terms utilized for our stock-based compensation calculations on a prospective basis.

Historically, for all periods prior to this offering, the fair value of the shares of common stock underlying our share-based awards were estimated on each grant date by our board of directors. In order to determine the fair value of our common stock underlying option grants, our board of directors considered, among other things, timely valuations of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provide by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Given the absence of a public trading market for our common stock, our board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including our stage of development; progress of our research and development efforts; the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common stock; equity market conditions affecting comparable public companies and the lack of marketability of our common stock.

After the completion of this offering, our board of directors will determine the fair value of each share of underlying common stock based on the closing price of our common stock on The Nasdaq Global Market as reported on the date of grant.

The intrinsic value of all outstanding options as of March 31, 2018 was $8.5 million based on an assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover of this prospectus.

Income taxes

We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the net losses incurred and the uncertainty of realizing the deferred tax assets, for all the periods presented, we have a full valuation allowance against our deferred tax assets.

As of December 31, 2017, we had federal net operating loss carryforwards of $12.8 million and research and development credits totaling $331,000, as well as state net operating loss carryforwards of $12.9 million and state research and development credits of $223,000. If not utilized, the federal credits will expire at various dates beginning in 2037. The federal net operating loss carries forward indefinitely, subject to potential limitations as noted below.

Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Code, and similar state provisions. These ownership change limitations may limit the amount of net operating loss carryforwards and other tax attributes that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points (by value) of the outstanding stock of a company by certain stockholders. The annual limitation may result in the expiration of net operating losses and credits before utilization.

 

79


Table of Contents

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. It is our policy to recognize both accrued interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

Liquidity and capital resources

Since inception, we have funded our operations primarily through net proceeds from the sale of our redeemable convertible preferred stock and notes convertible into shares of redeemable convertible preferred stock. Our expenditures are primarily related to research and development activities. As of March 31, 2018, we had available cash of $25.3 million and no outstanding borrowings. In May 2018, we issued 4,430,162 shares of our Series B redeemable convertible preferred stock for net proceeds of $48.0 million.

We have not generated any revenue to date. Since inception, we have incurred significant operating losses and expect to incur significant and increasing losses in the foreseeable future. Our net loss was $11.9 million and $15.6 million for the year ended December 31, 2017 and, as of March 31, 2018, we had an accumulated deficit of $30.1 million.

Our recurring operating losses and our need for additional sources of capital to fund our ongoing operations raise substantial doubt about our ability to continue as a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended December 31, 2017 with respect to this uncertainty. Our ability to continue as a going concern will require us to obtain additional financing to fund our operations and there can be no assurance that additional financing will be available to us or that such financing, if available, will be available on terms acceptable to us.

Cash flows

The following table summarizes our cash flows for the periods indicated (in thousands):

 

      Year ended December 31,     Three months ended
March 31,
 
                2016               2017               2017               2018  

Cash used in operating activities

   $ (2,059   $ (9,717   $ (1,819   $ (5,891

Cash used in investing activities

           (53     (3     (114

Cash provided by financing activities

     3,990       13,311       4,006       25,777  
  

 

 

 

Net increase in cash

   $ 1,931     $ 3,541     $ 2,184     $ 19,772  

 

 

Cash flows from operating activities

During the three months ended March 31, 2018, cash used in operating activities was $5.9 million and consisted primarily of a net loss of $15.6 million, which was partially offset by non-cash charges of $8.0 million and a change in net operating assets of $1.5 million. Our non-cash charges primary consisted of $6.7 million on extinguishment of debt and $0.5 million for stock-based compensation expense. The change in our net operating assets of $1.5 million was primarily due to an increase in accounts payable of $1.1 million and accrued expenses of $1.5 million as a result of an increase in operating expenses and timing of payments, which was

 

80


Table of Contents

partially offset by an increase in other assets of $0.7 million pertaining to costs we have incurred in connection with our proposed initial public offering.

During the three months ended March 31, 2017, cash used in operating activities was $1.8 million and consisted primarily of a net loss of $2.3 million, which was partially offset by a decrease in net operating assets of $0.6 million. The change in our net operating assets of $0.6 million was primarily due to an increase in accounts payable of $0.4 million and accrued expenses of $0.3 million as a result of an increase in operating expenses and timing of payments.

During 2017, cash used in operating activities was $9.7 million, which consisted of a net loss of $11.9 million, adjusted by non-cash charges of $1.1 million and a net change of $1.1 million in our net operating assets and liabilities. The non-cash charges are primarily comprised of $1.1 million for stock-based compensation, offset by a gain of $0.1 million for the remeasurement of the redeemable convertible preferred stock tranche liability. The change in our net operating assets and liabilities was primarily due to an increase in accounts payable, accrued expenses and other liabilities and related party payable of $1.9 million as a result of an increase in operating expenses and timing of payments, offset by $0.5 million increase in cash used for prepaid and other current assets related to payments associated with clinical trials and studies and $0.2 million increase in cash used for other assets related to the security deposit for our facility leases.

During 2016, cash used in operating activities was $2.1 million, which consisted of a net loss of $2.5 million, adjusted by non-cash charges of $0.2 million and a net change of $0.2 million in our net operating assets and liabilities. The non-cash charges are primarily comprised of $0.2 million for the remeasurement of the redeemable convertible preferred stock tranche liability. The change in our net operating assets and liabilities was primarily due to an increase in accounts payable, accrued expenses and other liabilities of $0.2 million as a result of an increase in operating expenses and timing of payments.

Cash flows from investing activities

During the three months ended March 31, 2018, cash used in investing activities was $0.1 million, which consisted of our purchase of property and equipment for our office and lab facilities.

During 2017, cash used in investing activities was $0.1 million, which consisted of our purchase of property and equipment for our office and lab facilities.

Cash flows from financing activities

During the three months ended March 31, 2018, cash provided by financing activities was $25.8 million, which consisted of net proceeds from the issuance of Series B redeemable convertible preferred stock of $15.9 million and proceeds from the issuance of convertible promissory notes of $10.0 million.

During the three months ended March 31, 2017, cash provided by financing activities was $4.0 million, which consisted of net proceeds from the issuance of Series Seed redeemable convertible preferred stock.

During 2017, cash provided by financing activities was $13.3 million, which consisted of net proceeds of $13.0 million from the issuance of Series Seed redeemable convertible preferred stock and $0.3 million of proceeds from the issuance of common stock upon the exercise of stock options.

During 2016, cash provided by financing activities was $4.0 million, which consisted of net proceeds of $3.9 million from the issuance of Series Seed redeemable convertible preferred stock and $0.1 million of proceeds from the issuance of common stock upon the exercise of stock options.

 

81


Table of Contents

Funding requirements

We do not believe that our existing capital resources will be sufficient to meet our projected operating requirements for at least the next 12 months. We will require additional financing to fund working capital and pay our obligations. We may pursue financing opportunities through the issuance of debt or equity to private investors. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. Our future funding requirements will depend on many factors, including the following:

 

 

the progress, timing, scope, results and costs of our ongoing and planned clinical trials and other research and development activities related to AG10 and any other product candidates we may identify and pursue, including the ability to enroll patients in a timely manner in our clinical trials;

 

 

the costs of obtaining AG10 in amounts sufficient for our ongoing and planned clinical trials and, if approved, for commercialization;

 

 

the cost, timing and outcomes of any regulatory approvals for AG10;

 

 

our ability to successfully commercialize AG10, if approved;

 

 

the extent to which we may acquire or in-license other product candidates and technologies;

 

 

our ability to attract, hire and retain qualified personnel;

 

 

the size and success of this offering; and

 

 

the cost of obtaining, maintaining, preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights related to AG10 and any other product candidates we may identify and pursue.

If we need to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, research and development programs or commercialization efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements.

To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

82


Table of Contents

Contractual obligations and other commitments

The following table summarizes our contractual obligations as of December 31, 2017:

 

      Payments due by period  
(in thousands)    Less than
1 year
     1 to 3
years
     3 to 5
years
     More than
5 years
     Total  

Contractual obligations:

              

Operating lease obligations

   $ 325      $ 664      $ 674      $      $ 1,663  
  

 

 

 

Total contractual obligations

   $ 325      $ 664      $ 674      $      $ 1,663  

 

 

In addition to the amounts set forth in the table above, we have certain payment obligations under our license agreement with Stanford of up to approximately $1.0 million, which are contingent upon achieving specific intellectual property, clinical and regulatory milestone events and are obligated to pay royalties on future net sales, if any. As the achievement and timing of these future milestone payments are not probable and estimable, such amounts have not been included on our balance sheets or in the contractual obligations table above. See the section titled “Business—Our material agreements—License agreement with the Board of Trustees of the Leland Stanford Junior University.”

In addition, we enter into agreements in the normal course of business with contract research organizations for clinical trials and with vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. These payments are not included in this table of contractual obligations.

Off-balance sheet arrangements

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

Quantitative and qualitative disclosures about market risk

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We had cash of $5.5 million and $25.3 million as of December 31, 2017 and March 31, 2018, respectively, which consists of bank deposits. Historical fluctuations in interest rates have not been material for us. Due to the nature of our cash, a hypothetical 100 basis point change in interest rates would not have a material effect on the fair value of our cash.

JOBS Act accounting election

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.

We have elected to “opt out” of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This election to opt out of the extended transition period under the JOBS Act is irrevocable.

Recent accounting pronouncements

See Note 2, “Summary of significant accounting policies—Recent accounting pronouncements” to our audited financial statements included elsewhere in this prospectus for more information.

 

83


Table of Contents

Business

Overview

We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins. Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, stemming from either specific gene mutations or aging. TTR destabilization drives an irreversible dissociation of the tetramer into monomers, which subsequently aggregate and deposit predominantly in the heart and peripheral nervous system, leading to organ damage, loss of organ function, and eventual death if left untreated. There are currently no therapies approved by the U.S. Food and Drug Administration, or FDA, for the treatment of ATTR. We are building upon our significant mechanistic understanding of ATTR to develop a potentially disease-modifying treatment for this family of diseases.

Our product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. Our approach to the treatment of ATTR is designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a “rescue mutation” because it has been shown to prevent ATTR in individuals carrying pathogenic, or disease-causing, mutations in the TTR gene. We measure stabilization of TTR using three well-established ex vivo assays: immunoblotting (Western blot), fluorescent probe exclusion (FPE) and fibril formation. We have observed through X-ray crystallography that the binding of AG10 to tetrameric TTR creates strong molecular bonds at the same locations as the bonds created by the T119M variant, which “super-stabilizes” TTR and has been shown to prevent ATTR in individuals carrying pathogenic TTR mutations. We believe this specific binding mode underlies the results of our Phase 1 clinical trial of AG10, in which AG10 was observed in the highest dose cohort to stabilize tetrameric TTR completely at peak blood concentrations, suggesting that AG10 may prevent the dissociation into disease-causing TTR monomers in the bloodstream. Based on our clinical data and data from previous third-party clinical trials in ATTR demonstrating that either stabilizing tetrameric TTR or reducing the circulating levels of tetrameric TTR by interfering with its production by the liver, may lead to improved clinical outcomes, we believe that AG10 could be a promising therapy. We are currently evaluating the safety, tolerability and stabilization effects of AG10 in wild-type and mutant ATTR cardiomyopathy patients in a Phase 2 clinical trial, and we expect to report topline data from this trial by the end of 2018.

The ATTR family of diseases

ATTR represents a significant unmet need, with a comparatively large patient population in the context of rare genetic diseases and an inadequate current standard of care. There are three distinct diseases that comprise the ATTR family: wild-type ATTR cardiomyopathy, or ATTRwt-CM, which results from an age-related process; mutant ATTR cardiomyopathy, or ATTRm-CM; and ATTR polyneuropathy, or ATTR-PN. The worldwide prevalence of each disease is approximately 200,000, 40,000, and 10,000, respectively, although we believe the cardiomyopathic forms of the disease are significantly underdiagnosed. Of note, wild-type patients predominantly exhibit cardiomyopathy and do not demonstrate prominent signs of polyneuropathy.

All three forms of disease are progressive and fatal. ATTRwt-CM and ATTRm-CM patients generally present with symptoms later in life (age 50+) and have median life expectancies of three to five years from diagnosis. ATTR-PN either presents in a patient’s early 30s or later (age 50+), and results in a median life expectancy of five to ten years from diagnosis. Progression of all forms of the disease causes significant morbidity, impacts

 

84


Table of Contents

productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care. As the disease progresses, ATTRwt-CM and ATTRm-CM patients become increasingly difficult to medically manage and may require frequent hospitalizations and repeated interventions. ATTR-PN patients experience gradual loss of the ability to walk without assistance, and autonomic nervous system function affecting digestion and blood pressure over time, requiring increasing levels of supportive care.

The population of diagnosed ATTRwt-CM and ATTRm-CM patients is growing due to increasing disease awareness and a shift to an accurate and reliable non-invasive diagnostic approach, which allows cardiologists to use a well-established medical imaging modality and readily available blood tests to diagnose ATTR instead of using the previously required, invasive diagnostic method of heart biopsy. We believe this enables both earlier diagnosis and the identification of previously misdiagnosed patients. Specifically, recent literature suggests that a sizeable proportion (>10%) of patients diagnosed with heart failure with preserved ejection fraction, or HFpEF, which represents about half of the 7 million estimated people with heart failure in the United States alone, may in fact have ATTRwt-CM or ATTRm-CM but in the past have not been diagnosed as such.

AG10 and our therapeutic hypothesis

We are developing AG10, an orally-administered, small molecule stabilizer of tetrameric TTR, to treat ATTR at its source. Over the past decade, research has suggested that agents that bind and stabilize TTR, as measured by established ex vivo assays, can lead to improved clinical outcomes. The data supporting this hypothesis include genetic validation and clinical data in both ATTR-PN and ATTR-CM. The concept of tetrameric TTR stabilization as a potentially viable therapeutic approach originated from our understanding of the molecular pathogenesis of ATTR and the mechanistic details of a naturally occurring rescue mutation in the TTR gene, known as the T119M mutation, that “super-stabilizes” the tetramer. T119M has been observed to prevent the dissociation of TTR tetramers into monomers; T119M tetramers dissociate 40-fold more slowly than wild-type tetramers in biochemical assays. The increased stability of the T119M variant confers protection against ATTR such that, in individuals who carry a highly penetrant, TTR-destabilizing mutation, co-inheritance of T119M protects them against the development of ATTR. This stabilization hypothesis is further supported by clinical trials performed with Pfizer’s TTR stabilizer, tafamidis, in ATTR-CM as well as diflunisal, a non-steroidal anti-inflammatory drug, or NSAID, in ATTR-PN.

Summary of our preclinical and clinical results

We believe the clinical and preclinical data generated to date by AG10 strongly support its development as a preferred therapeutic to treat ATTR, as outlined below.

 

 

The therapeutic potential of previously studied small molecule TTR stabilizers has been illustrated by the evaluation of tafamidis in ATTRwt-CM and ATTRm-CM and diflunisal in ATTR-PN. The clinical data support the hypothesis that increasing levels of TTR stabilization lead to increasing clinical benefit. Preclinical studies have shown that AG10 provided a higher degree of ex vivo stabilization than tafamidis or diflunisal using multiple well-established assays.

 

 

In our Phase 1 clinical trial, healthy volunteers were administered AG10 and at the highest tested dose we observed greater than 95% stabilization of TTR, on average, across the entire dosing interval and 100% stabilization at peak blood levels. In contrast, tafamidis at 20 mg and 80mg provided approximately 45% and 60% stabilization at peak blood levels, respectively, in our preclinical studies. We believe these observations of AG10’s comparatively higher stabilization are attributable to advantages in AG10’s binding mode and specificity for binding to TTR and not other plasma proteins.

 

85


Table of Contents
 

In particular, X-ray crystallography demonstrates that AG10 uniquely drives hydrogen bonding at the bottom of the thyroxine binding pocket of the TTR molecule to help hold tetrameric TTR together, mimicking the binding mode of the naturally-occurring T119M rescue mutation. To our knowledge, AG10 is the only TTR stabilizer in clinical development or clinical use that has been observed to mimic this “super-stabilizing” mechanism of the naturally-occurring rescue mutation.

 

 

Further, our preclinical studies support that AG10’s binding to TTR may be highly specific and not significantly affected by the presence of additional plasma proteins. In contrast, published regulatory documents support that tafamidis also binds to the highly abundant plasma protein albumin, which competes with tafamidis’ ability to bind and stabilize TTR. This is reflected in the free fraction observed for tafamidis (<0.5%) from the reported literature versus AG10 (3.6%) in our preclinical studies, suggesting that the percentage of total drug available for TTR binding may be greater for AG10 than for tafamidis.

 

 

In our preclinical studies, 10µM AG10 also resulted in greater than 85% TTR stabilization across a range of mutations that lead to ATTRm-CM or ATTR-PN, which represent over 70% of all patients with mutation-driven ATTR.

 

 

We observed no clinically important adverse events or laboratory-based signals of potential clinical concern associated with AG10 in healthy adult volunteers participating in or Phase 1 clinical trial of AG10. In our preclinical studies, AG10 exhibited a greater than 50-fold therapeutic window between its target therapeutic blood level and those concentrations associated with observed, dose-limiting animal toxicity. We achieved or exceeded that targeted therapeutic blood level in healthy volunteers at doses that were well tolerated in the Phase 1 clinical trial.

Based on these data, in April 2018, we initiated a randomized, placebo-controlled, double-blind Phase 2 clinical trial of AG10 in ATTR-CM patients. In this trial, we are evaluating safety and tolerability, as well as TTR stabilization as clinical proof-of-concept in the target patient population. We expect to report topline data from this Phase 2 clinical trial by the end of 2018 and to initiate a Phase 3 clinical trial of AG10 in ATTR-PN patients in early 2019.

Prior to initiating the Phase 1 clinical trial, and in advance of our ongoing Phase 2 clinical trial we developed a tablet formulation for AG10 and have produced over 100 kg of AG10 conforming with the FDA’s current Good Manufacturing Practice, or cGMP, manufacturing requirements, which we believe will be sufficient to complete our ongoing Phase 2 clinical trial.

We are developing AG10 to treat three distinct forms of ATTR in the clinical trials shown in the table below.

 

Indication   Worldwide
prevalence
   Stage    Endpoint and biomarkers    Next anticipated
milestone

ATTR-CM

(both ATTRwt-CM and

ATTRm-CM)

  200,000
ATTRwt-CM

40,000
ATTRm-CM

   Phase 2    Safety and tolerability; pharmacokinetics; TTR stabilization    Phase 2 topline data readout (End of 2018)
     Open label extension (OLE) to be initiated    Safety and tolerability; TTR stabilization; Biomarkers: NTpro-BNP, troponin, wall thickness, strain    OLE initiation (2018)

ATTR-PN

  10,000   

Phase 3 to be initiated

  

Neuropathy impairment score (mNIS +7); Safety and tolerability; Norfolk quality of life score; pharmacokinetics; TTR stabilization

  

Phase 3 initiation (Early 2019)

 

86


Table of Contents

Our leadership team

We are led by a management team that has worked together previously and has a successful track record in drug development, contributing to over 30 molecules through Initial New Drug, or IND, application and more than ten approved drugs. More importantly, our team has a rich set of experiences at the intersection of genetic disease and cardiovascular medicine owing from experiences at companies including Global Blood Therapeutics, Inc., MyoKardia, Inc. and Portola Pharmaceuticals, Inc. We are a majority-owned subsidiary of BridgeBio Pharma LLC, or BridgeBio, a biotechnology company dedicated to identifying and developing novel therapies for genetic diseases.

Led by experienced scientists, drug developers and investors, BridgeBio employs a distributed corporate structure that enables focus at the level of each disease while providing centralized resources to scale across many opportunities. BridgeBio currently has a portfolio of more than 15 product candidates spanning preclinical development to late-stage clinical trials across multiple therapeutic areas. Eidos is a leading example of BridgeBio’s approach to building lean organizations dedicated to targeting well-defined genetic conditions at their source.

Our strategy

Our goal is to be a leader in developing and commercializing disease-modifying therapeutics to treat ATTR. The key components of our strategy are to:

 

 

Rapidly develop AG10 for the treatment of ATTR-CM.    We have completed a first-in-human, Phase 1 single and multiple ascending dose, safety, tolerability, PK and pharmacodynamic, or PD, trial in healthy adult volunteers. AG10 was well tolerated in the Phase 1 trial and at the highest tested dose achieved complete stabilization of TTR at peak blood concentrations. Based on these data, we have initiated a randomized, placebo-controlled, double-blind Phase 2 clinical trial of AG10 in ATTR-CM patients. In this trial, we are evaluating safety, tolerability, and ex vivo TTR stabilization effects of AG10 to demonstrate clinical proof of concept in the target patient population. We expect to report topline data from this Phase 2 clinical trial by the end of 2018. We intend to evaluate regulatory strategies and conduct ongoing discussions with the FDA and other regulatory bodies to rapidly advance the development of AG10 for this indication. Subject to the successful completion of our Phase 2 clinical trial and our discussions with regulatory authorities, we intend to advance AG10 into a Phase 3 clinical trial for the treatment of ATTR-CM in early 2019.

 

 

Advance AG10 for the treatment of ATTR-PN.    ATTR-PN is caused by the destabilization of tetrameric TTR and deposition of TTR amyloid in the peripheral nervous system. Based on our preclinical and preliminary clinical observations that AG10 potently stabilizes TTR in human serum (at blood levels roughly equal to the level of available TTR binding sites), we also plan to develop AG10 for ATTR-PN. Subject to the successful completion of our Phase 2 clinical trial of AG10 in ATTR-CM and authorization from applicable regulatory authorities, we plan to initiate a Phase 3 clinical development program for AG10 in ATTR-PN in early 2019.

 

 

Expand our leadership role in the ATTR community.    We have established strong relationships with academics, clinical investigators, and patient advocacy groups in the ATTR field. Working closely with these key stakeholders, we aim to advance the understanding of ATTR in terms of its epidemiology, diagnosis, natural history, and treatment. Further, we plan to support clinical scientific conferences, diagnostic method and other training programs, patient and family advocacy and support organizations, and community-wide advances to increase awareness of this family of diseases among physicians and patients.

 

 

Retain development and commercialization rights to AG10 in core strategic markets.    We plan to develop and commercialize AG10 in major markets. We believe we can devise time- and cost-efficient strategies to

 

87


Table of Contents
 

develop, and to obtain regulatory approvals for, novel product candidates such as AG10. We have assembled an experienced team with a successful track record in pharmaceutical development, regulatory strategy and execution of global clinical trials. Given the concentrated market and increasing levels of disease awareness, we intend to establish a small and focused sales force targeting key cardiology and neurology specialists in major markets, and we may evaluate opportunities to establish strategic partnerships in additional markets.

 

 

Evaluate opportunities to expand the scope of our development candidate portfolio.    We may also form collaborative alliances to expand our capabilities and development opportunities into new therapeutic areas and potentially accelerate commercialization in select geographic markets. Consistent with our strategy and that of our parent company, BridgeBio, we may in-license or acquire additional assets targeting well-defined inherited diseases at their source that complement our primary focus on ATTR. While complementary approaches to the treatment of ATTR are the most synergistic opportunity, building on our deep understanding of ATTR, we may also pursue additional research and development opportunities as well as the acquisition or in-licensing of adjacent precision cardiovascular medicine assets.

ATTR background and disease pathology

ATTR is a rare, progressive, fatal disease caused by the accumulation of amyloid fibrils in vital organs as a result of the destabilization of TTR. TTR is named for its role in the transport of thyroxine (thyroid hormone) and retinol (vitamin A). Beyond its activity as a transport protein, multiple lines of evidence point to a larger role of TTR in human physiology. First, TTR is highly conserved evolutionarily and is present in all vertebrates and many invertebrates. In humans, no mutations resulting in reduced or complete elimination of TTR have been described. In a 2013 study of over 68,000 participants in Denmark over an average 32 years of clinical follow-up, the naturally-occurring T119M mutation led to higher circulating TTR concentrations, protection against a range of cerebrovascular events, especially fatal or debilitating stroke, and a 5-10 year increase in life expectancy relative to the general population. In contrast to these beneficial effects, the destabilization of TTR can lead to ATTR. With an estimated prevalence of over 250,000 patients worldwide, ATTR is one of the most prevalent rare genetic diseases, although each of its clinical forms is currently considered to be an orphan disease indication.

TTR circulates as a tetramer containing two thyroxine binding sites; TTR monomers do not bind these ligands by themselves. ATTR can result from either defects in protein handling associated with aging (driving wild-type ATTR) or genetic mutations (mutant ATTR), which destabilize TTR and drive its dissociation into TTR monomers. The monomers subsequently aggregate into complexes that are deposited in tissues, including the heart and peripheral nerves. Left untreated, these deposits can cause severe organ damage, loss of organ function and eventual death. Clinically, ATTR primarily presents as either a cardiomyopathy, or ATTR-CM, a form of heart failure, or as a peripheral polyneuropathy, or ATTR-PN, a neurodegenerative disease.

ATTR-CM is an infiltrative, restrictive cardiomyopathy characterized by progressive right and left heart failure, initially with preserved ejection fraction. Patients suffering from ATTR-CM generally become symptomatic at age 50 or older. Patients with ATTR-CM experience typical symptoms of heart failure, which may include persistent fatigue, dizziness, shortness of breath, edema (swelling of the legs), and a disproportionate age-related incidence of atrial fibrillation with its associated risk of stroke. As the disease progresses, patients often require frequent hospitalization due to decompensated congestive heart failure. ATTR-CM patients are challenging to medically manage, as commonly used treatments for other forms of heart failure, like ACE inhibitors and beta blockers, can be ineffective or harmful due to the specific effects of ATTR-CM on the ability of the heart to relax and fill with fresh blood between heartbeats, and the frequent involvement of the heart’s electrical conduction system and autonomic control of blood pressure, all affecting patients’ ability to maintain cardiac output. As a result, ATTR-CM patients also have a high associated risk of developing both heart block

 

88


Table of Contents

and atrial fibrillation, requiring permanent pacemaker and anticoagulant therapy to prevent stroke, respectively.

ATTR-CM can develop in older patients in whom TTR is destabilized as part of the natural aging process, a condition known as ATTRwt-CM. ATTR-CM can also be caused by genetic mutations that destabilize TTR, known as ATTRm-CM. ATTRm-CM may have an earlier age of onset and progress more rapidly than ATTRwt-CM. The Transthyretin Cardiac Amyloidosis Study published in 2012 found that the median survival from diagnosis for ATTRwt-CM and ATTRm-CM patients was 43 months and 26 months, respectively.

The numbers of diagnosed ATTRwt-CM and ATTRm-CM patients are estimated to be 200,000 and 40,000 worldwide, respectively. We believe both forms of ATTR-CM are under-diagnosed due to limited disease awareness and historical reliance on invasive diagnostic techniques. Until recently, a cardiac biopsy was required to make the definitive diagnosis of ATTR-CM. However, non-invasive nuclear medicine imaging agents (technetium-labelled pyrophosphate or bis-phosphonates), coupled with blood tests, have demonstrated the ability to detect ATTR-CM with 99% sensitivity and specificity. These imaging agents allow physicians suspecting ATTR-CM to readily diagnose it in patients without the need for a heart biopsy. In addition, we believe the development of new potential treatments for ATTR has also raised awareness of ATTR amongst physicians, prompting them to consider the diagnosis when evaluating patients with an initial recognition of heart failure, especially HFpEF. These two factors have the potential to lead to broader adoption of a noninvasive diagnostic algorithm and earlier identification of the disease. We are actively supporting efforts to establish training and certification in the use of the noninvasive algorithm with key opinion leaders. Recent clinical reports have suggested significant prevalence of ATTR-CM in multiple cardiac disease and other populations. For example, ATTR-CM has been detected in an important proportion of patients suffering from associated conditions such as carpal tunnel syndrome, and as a comorbid condition in patients with aortic stenosis or those presenting for hip and knee replacement surgery.

There are over 140 known pathogenic mutations in the TTR gene that can lead to destabilization of the tetramer, driving ATTRm-CM. The most prevalent TTR mutation in the United States, V122I, is associated with an increased risk of developing ATTRm-CM. The V122I mutation is present in approximately 3.4% of African Americans, and may be even higher in related Afro-Caribbean populations living in the Americas and Europe.

Clinically, ATTR also presents as ATTR-PN, a neurodegenerative disease, in individuals carrying pathogenic TTR mutation. Patients suffering from ATTR-PN generally become symptomatic between ages 30 and 50. While the median survival for patients diagnosed with ATTR-PN is only five to ten years, the various disease complications from initial onset create a substantial economic and social burden on patients, caregivers and the entire healthcare system. In ATTR-PN patients, symptoms generally begin with pain in the extremities from nerve damage, loss of sensation, limb weakness, and GI dysfunction leading to malnutrition. Patients generally lose motor control (muscle strength, tone and bulk) and sensation in their extremities, starting with the feet and ascending to involve the lower and upper legs followed by the hands and arms. As the disease progresses up the legs to the body, patients lose the ability to walk without assistance, and eventually lose the ability to control basic motor and sensory functions. Loss of sensation exposes patients to the risk of so-called insensate trauma, or the inability to notice that they have sustained injuries to their hands and feet, which may become complicated by infection and require hospitalization for intravenous therapy or amputation.

 

89


Table of Contents

ATTR-PN is caused by pathogenic, destabilizing mutations in the TTR gene and affects approximately 10,000 patients worldwide. The V30M mutation is the most prevalent mutation associated with ATTR-PN and is endemic in certain areas of Portugal, Sweden and Japan, where it has arisen independently as a founder mutation, as illustrated in the figure below.

Distribution of ATTR mutations in the United States and the rest of world in the THAOS Registry

 

 

LOGO

Source: (Maurer, Hanna, Grogan, Dispenzieri, Witteles, Drachman, Judge, Lenihan, Gottlieb, Shah, Steidley, Ventura, Murali, Silver, Jacoby, Fedson, Hummel, Kristen, Damy, Planté-Bordeneuve, et al., 2016)

Mutant ATTR (ATTRm) spans a spectrum of phenotypic expression from predominantly cardiomyopathic (as in the case of the prevalent mutation V122I) to predominantly polyneuropathic (as in the case of V30M, especially the early onset subset), with many mutations driving a mixed clinical phenotype, as illustrated in the figure below. The symptoms associated with wild-type ATTR (ATTRwt) are predominantly cardiovascular, but may include connective tissue disease such as carpal tunnel syndrome.

Spectrum of Mutations (non-exhaustive) and Phenotypes in ATTR

 

 

LOGO

Source: adapted from (Semigran, 2016)

 

90


Table of Contents

Unmet medical need in ATTR

There are currently no therapies approved by the FDA for the treatment of any form of ATTR. In ATTR-PN, treatment options had historically been limited to symptomatic relief, with liver transplantation being the only definitive treatment to arrest the progression of disease. This therapy, however, is complicated by limited organ availability, the need for lifelong immunosuppression, surgical risk (especially in patients with substantial cardiac involvement) and limited efficacy, as wild-type TTR amyloid continues to contribute to disease progression in many patients after transplant.

Some advancements have been made in the development of disease-modifying therapies for ATTR-PN. For example, regulatory authorities outside of the United States, including the European Medicines Agency, or EMA, have approved tafamidis for the treatment of ATTR-PN, although its single Phase 3 clinical trial in ATTR-PN patients did not meet its primary endpoint. Tafamidis was approved by the European Union in 2011 and Japan in 2013. The FDA, in contrast, requested additional trials to be completed as a prerequisite for any resubmission for U.S. approval. Additionally, diflunisal, a generic, non-steroidal anti-inflammatory drug, or NSAID, approved by the FDA to treat pain and inflammation, may be prescribed by physicians for ATTR patients, despite not having been approved for the treatment of ATTR. Diflunisal exhibits some biochemical properties as a TTR stabilizer and has been studied in a randomized study in ATTR-PN patients funded by the National Institutes of Health. The use of diflunisal is limited, however, by its Boxed Warning in the U.S. Product Insert (label) listing increased risks of gastrointestinal bleeding, thromboembolic events (clotting and blood vessel blockage), and kidney failure. These are all “on-target” complications related to diflunisal’s intended inhibition of the cyclooxygenase, or COX, enzyme. While diflunisal is commercially available as a generic, prescription-only medical product in the United States, it is generally unavailable in the European Union and elsewhere. Finally, recent Phase 3 clinical trials of TTR gene-silencing, or “knockdown” agents (patisiran and inotersen) have shown clinically important and statistically significant results in the treatment of ATTR-PN.

More limited progress has been made in the development of a safe and effective, disease-modifying treatment of ATTRwt-CM and ATTRm-CM. In March 2018, Pfizer Inc. announced that tafamidis had met its primary endpoint, a reduction in the combination of all-cause mortality and cumulative incidence of cardiovascular-related hospitalizations in its Phase 3 clinical trial (ATTR-ACT) that enrolled both ATTRwt-CM and ATTRm-CM patients. Diflunisal is also prescribed for some ATTR-CM patients, although it is not approved for ATTR-CM and its usage is limited given the overlap between its labeled risk of serious adverse effects and the prominent cardiovascular and renal manifestations in these patients. The only Phase 3 clinical trial of a TTR knockdown agent in patients with diagnosed cardiomyopathy, the ENDEAVOUR study of revusiran sponsored by Alnylam Pharmaceuticals, Inc., was halted due to an imbalance of deaths in the active treatment arms. Given the significant and growing prevalence of ATTRwt-CM and ATTRm-CM, the limitations of product candidates currently under development for ATTR and the absence of products approved by the FDA for ATTR, we believe there is a significant unmet need for an efficacious therapeutic agent that targets the disease at its source.

 

91


Table of Contents

AG10—our differentiated solution for the treatment of ATTR

AG10 is an orally-administered small molecule designed to treat ATTR at its source by stabilizing tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The following graphic illustrates the disease mechanism of ATTR and our therapeutic hypothesis.

 

 

LOGO

Although there are currently no FDA approved therapies to treat ATTR, multiple therapeutic approaches are in clinical and preclinical development. These therapeutic approaches are referred to as stabilization, knockdown and clearance.

 

 

Stabilization.    Small molecule stabilizers, including AG10, target the disease at its source by stabilizing TTR and inhibiting the disease-initiating step of amyloid formation (i.e., the dissociation of tetrameric TTR into monomers).

 

 

Knockdown.    Knockdown approaches inhibit the synthesis of TTR by the liver, thereby reducing the amount of circulating tetrameric TTR and presumably the amount of TTR monomers available to form amyloid deposits.

 

 

Clearance.    Agents target the amyloid formation process further downstream and/or established amyloid deposits. The goal of these agents is to disrupt the formation of circulating TTR amyloid precursors (aggregates of misfolded monomers) and/or clear amyloid fibrils that have already been deposited.

We believe that the TTR stabilization approach targets ATTR at its source and represents a validated therapeutic approach to prevent or slow disease progression. In addition, we believe our therapeutic approach has the potential to complement other approaches to treating ATTR.

The therapeutic approach of AG10 leverages over 25 years of research understanding the molecular mechanism of ATTR and the rational design using structural biology by our founders at Stanford University. We believe the therapeutic hypothesis underlying TTR stabilization is validated by human genetic and clinical data, as follows:

 

 

Genetic data demonstrate not only how the disease is caused (through mutations that destabilize the TTR tetramer) but also how the disease is ameliorated (through mutations that super-stabilize tetrameric TTR). Furthermore, beneficial effects of the naturally-occurring, stabilizing mutation T119M have been demonstrated in both a diseased and healthy population;

 

92


Table of Contents
 

Tafamidis, a TTR stabilizer, reportedly met its primary endpoint in the reduction in the combination of all-cause mortality and cumulative incidence of cardiovascular-related hospitalizations in ATTR-CM patients in Pfizer’s global, Phase 3 ATTR-ACT clinical trial.

Genetic validation

The concept of TTR tetramer stabilization as a viable therapeutic approach originated from our understanding of the molecular pathogenesis of ATTR, as well as a naturally-occurring rescue mutation. The molecular pathogenesis of ATTR has been described in over 25 years of scientific publications. Specifically, ATTR results from the dissociation of native, tetrameric TTR into monomeric subunits that misfold and aggregate as TTR amyloid. There are over 140 known pathogenic, missense mutations that destabilize TTR. On the other hand, there exist naturally occurring mutations that protect against disease, and have been shown to stabilize TTR. A naturally-occurring, gain-of-function rescue mutation, T119M, results in the “super-stabilization” of TTR and prevents ATTR in compound heterozygotes carrying the V30M disease-causing mutation, as reported by Coelho et al. in 1996 and Hammarstrom et. al in Science in 2001. The T119M mutation, when carried in otherwise healthy individuals, is also associated with both a lower risk of cerebrovascular events and an increased life expectancy of five to ten years compared to healthy non-carriers, and is correlated with 17% higher circulating levels of TTR. This result was identified by Hornstrup et. al. in a 2013 study of over 68,000 individuals in Denmark over an average 32 years of clinical follow-up. AG10’s mode of binding is designed to mimic the stabilizing mechanism of this rescue mutation, which we believe provides a mechanistic advantage to slow or halt the progression of ATTR. In addition, the scientific literature suggests that this mode of binding may be unique to AG10.

Clinical data

In March 2018, Pfizer announced that tafamidis, a TTR stabilizer, met its primary endpoint of a reduction in the combination of all-cause mortality and cumulative incidence of cardiovascular-related hospitalizations in both types of ATTR-CM patients in the Phase 3 ATTR-ACT study. The trial was designed to enroll a minimum of 30% ATTRm-CM patients and 30% ATTRwt-CM patients. 441 patients were randomized to placebo, 20 mg tafamidis, or 80 mg tafamidis in a 2:1:2 ratio. We believe tafamidis is the first therapeutic to reportedly show a benefit in an ATTR-CM clinical trial and validates the hypothesis that TTR stabilization can lead to a meaningful clinical benefit in this population. Further, we believe that the reported reduction in mortality and cardiovascular hospitalizations observed in a randomized clinical trial of a TTR stabilizer, combined with the convenience of oral dosing, supports potential first line usage of oral TTR stabilizers in ATTR-CM.

The reported outcomes from previous clinical trials with TTR stabilizers, including those from the ATTR-ACT study, further support the TTR stabilization approach and suggest that increasing levels of TTR stabilization may lead to increasing levels of clinical benefit. To support this hypothesis, we evaluated each of three small molecule stabilizers (tafamidis, diflunisal and AG10) in head-to-head, established in vitro TTR stabilization assays (Western blot and FPE) and compared these results to the reported clinical outcomes, leading to the following observations:

 

 

Tafamidis, at the reported mean peak plasma concentration achieved at steady state on a 20 mg daily oral dose in healthy volunteers, was observed to stabilize approximately 45% of TTR in our preclinical studies. At this dose, tafamidis demonstrated a non-statistically significant improvement relative to placebo in ATTR-PN patients in a Phase 3 clinical trial conducted by FoldRx Pharmaceuticals Inc. (acquired by Pfizer Inc.).

 

 

When tested at the mean reported peak plasma concentration achieved following an 80 mg dose of tafamidis, we observed approximately 60% TTR stabilization in our preclinical studies. Pfizer has reported that its Phase 3 ATTR-ACT trial met its primary endpoint in the combined active treatment group of patients treated with either 20 mg or 80 mg tafamidis.

 

 

Diflunisal, a generic NSAID, stabilized TTR by approximately 75% in our preclinical studies and showed a statistically significant improvement relative to placebo in ATTR-PN patients in a randomized, controlled study.

 

93


Table of Contents

We believe that these comparative data of tafamidis at the 20 mg dose, tafamidis at the 80 mg dose and diflunisal support the hypothesis that maximally stabilizing TTR may lead to optimal clinical benefit. In our Phase 1 clinical trial in healthy volunteers, we achieved 100% TTR stabilization at peak concentrations and 95% or greater on average over the entire dosing interval in the 800 mg twice daily cohort, which we believe represent best-in-class TTR stabilization. The following table summarizes the levels of TTR stabilization observed to date in our preclinical stabilization assays of tafamidis, diflunisal and AG10, as compared to their reported clinical outcomes:

 

LOGO

In the table above, the figures for percent stabilization at peak concentration represent values averaged between Western blot and FPE assays, except for diflunisal, which only includes data from FPE assays. We used commercially available tafamidis in the Western blot assays and synthesized tafamidis in the FPE assays. Although we believe our preclinical observations described above are consistent with the reported clinical literature, the use of synthesized tafamidis in our preclinical studies may not be indicative of results that would be obtained using commercially-available tafamidis.

AG10

There are multiple lines of evidence that we believe support the potential for AG10 to be a disease-modifying TTR stabilizer and lead to meaningful clinical benefit.

 

 

We believe AG10 is the only TTR stabilizer that mimics the binding mode of the naturally-occurring, super-stabilizing T119M mutation.

 

 

In preclinical testing, AG10 has been observed to exhibit greater specificity for TTR than tafamidis. Compared to tafamidis, AG10’s binding to TTR is less affected by the presence of other plasma proteins, allowing a greater fraction of AG10 to bind TTR.

 

94


Table of Contents
 

In established preclinical assays, AG10 has demonstrated the highest levels of TTR stabilization compared to other TTR stabilizers at clinically-relevant concentrations; and

 

 

In our Phase 1 clinical trial, AG10 was well-tolerated and the highest tested dose achieved 100% TTR stabilization at peak concentrations and over 95% TTR stabilization on average in healthy adult volunteers at steady state.

Unique binding mode

AG10’s mode of binding is designed to mimic the naturally-occurring, super-stabilizing T119M rescue mutation, which we believe provides a mechanistic advantage in potentially slowing or halting the progression of ATTR. To our knowledge, this mode of binding is unique to AG10 among product candidates under clinical development for ATTR. The binding modes of the T119M variant and AG10 are further described below.

The T119M mutation “super-stabilizes” the tetramer by bringing the TTR monomers closer together, allowing for strong electrostatic interactions (hydrogen bonds and salt bridges) between adjacent monomers that stabilize the tetramer. In the thyroxine binding pocket of wild-type TTR, the serine 117 residues on each of the adjacent monomeric subunits are too far apart to form hydrogen bonds, as illustrated in the ribbon diagram below.

 

 

LOGO

The T119M variant, depicted below, results in structural changes in the tetramer such that the serine residues are now close enough to each other (under 3 angstroms) to permit hydrogen bonds to form between serine residues in adjacent monomers, holding the tetramer more tightly together than in the wild-type tetramer.

 

 

LOGO

 

95


Table of Contents

By similarly facilitating the formation of hydrogen bonds with the serines at position 117, we believe AG10 structurally mimics the disease-suppressing mechanism of the T119M rescue mutation. As illustrated in the diagram below, AG10 has been observed to bind to TTR and participate in hydrogen bonding interactions with the serine 117 residues on adjacent monomers, stabilizing the tetramer in a manner similar to that observed in the T119M mutant protein. We also believe AG10’s binding mode, which mimics that of the naturally occurring, disease-suppressing T119M rescue mutation, may lead to a slowing or halting of the dissociation of tetrameric TTR into monomers, the disease-initiating step in ATTR. To our knowledge, AG10 is the only compound in clinical development that mimics the structural effect of the T119M mutation with interactions at the bottom of the thyroxine binding pocket to confer TTR stabilization.

 

 

LOGO

Published isothermal titration calorimetry studies demonstrate that the binding mode of AG10 to TTR is almost entirely driven by enthalpy, or the strength of the chemical bonds. In contrast, the binding of tafamidis to TTR is driven approximately only 50% by enthalpy. We believe that the relative enthalpic binding mode of AG10 as compared to tafamidis confers additional stability to the tetramer, thereby preventing the dissociation of tetrameric TTR into monomers.

TTR binding affinity and selectivity

In addition to its unique binding mode, AG10 has been observed in preclinical studies to bind to TTR with high affinity and specificity. TTR has two binding sites for its native ligand, thyroxine, or the small molecule stabilizers that bind into the same pocket. Binding to these sites is non-cooperative, meaning that binding to the second site becomes less likely after a molecule is bound to the first. However, we believe binding to both sites may be required for complete TTR stabilization. AG10 has been shown to exhibit high binding affinity, as represented by its single-digit nanomolar dissociation constant, to TTR at its first site, and additionally an approximately 140-300 nanomolar dissociation constant at its second site. A dissociation constant measures the proportion of a compound that is bound to its target, with a lower dissociation constant implying stronger binding affinity. Based on ex vivo data from our Phase 1 clinical trial, we believe AG10 may bind TTR and potentially occupy more than one binding site per tetramer molecule.

AG10 binding to TTR has been observed to be also highly specific. In vitro assays demonstrate that AG10 has the potential to stabilize TTR while not being affected by the presence of other plasma proteins. In pre-clinical studies, approximately 3.6% of non-protein bound AG10 was observed to circulate in human plasma at relevant clinical concentrations, suggesting an available pool of compound to bind to newly synthesized TTR. In contrast, we believe the ability of synthesized tafamidis to bind and stabilize TTR is reduced in the presence of other proteins (particularly albumin, which is present at high concentrations in human plasma). Specifically, in published regulatory documents, the free fraction of tafamidis is less than 0.5% in human peripheral blood,

 

96


Table of Contents

suggesting that the majority of non-TTR bound tafamidis is bound to other plasma proteins. We believe data from our preclinical studies suggesting AG10’s ability to bind TTR with high affinity and specificity support its potential to be a preferred TTR stabilizer.

TTR stabilization in preclinical data

In established preclinical assays, AG10 demonstrated near-complete levels of TTR stabilization at clinically-relevant concentrations, further supporting our belief that AG10 could be a compelling therapeutic for ATTR.

In vitro studies demonstrated that AG10 potently stabilizes TTR at doses tested in our Phase 1 clinical trial, as evaluated in three separate, established assays. In the first assay, immunoblotting, or Western blots, were used to measure TTR stabilization as demonstrated by the percentage of tetrameric TTR remaining under accelerated destabilizing conditions (acidic pH). Shown below is the dose response effect of AG10 and commercially available tafamidis on stabilizing TTR at different compound concentrations. AG10 was observed to completely stabilize TTR at doses tested in our Phase 1 clinical trial and demonstrated greater TTR stabilization than tafamidis in this assay. The following graphs show the amount of TTR stabilization, as measured by the Western blot assay, using the solvent, dimethyl sulfoxide, or DMSO, and at different concentrations of AG10 and commercially available tafamidis:

 

LOGO

 

97


Table of Contents

The fluorescent probe exclusion (FPE) assay is a competitive binding assay that measures the ability of a stabilizer to block the binding of a small molecule probe to the thyroxine binding site of TTR. A fluorescent signal is emitted only when the probe is bound to TTR. In the plots below, AG10 and tafamidis, as synthesized for use in our preclinical studies, were compared head-to-head under identical assay conditions. At the clinical concentrations achieved by AG10 in our Phase 1 clinical trial (approximately 10-40 µM), AG10 was observed to occupy >90% of TTR tetramers. For tafamidis, clinical concentrations reported in regulatory documents predict plasma concentrations of approximately 15-20 µM from an 80 mg daily dose. These concentrations were observed to result in approximately 55-65% TTR occupancy. The following graphs show the amount of TTR stabilization, as measured by the FPE assay, using DMSO and at different concentrations of AG10 and synthesized tafamidis:

 

LOGO

Fibril formation measures the amount of amyloid that is formed in vitro after purified TTR, in the absence of serum proteins, is incubated under denaturing conditions. As shown below, AG10 potently inhibits the formation of amyloid fibrils in vitro from either wild-type or V122I TTR, the most prevalent destabilizing TTR mutation associated with ATTRm-CM. In addition, AG10 resulted in significantly greater inhibition of amyloid fibril formation at a 2:1 ratio of TTR to compound than tafamidis, as synthesized for use in our preclinical studies. The following graphs show the amount of TTR stabilization, as measured by the percentage of fibril formation, for synthesized tafamidis and AG10:

 

LOGO

 

98


Table of Contents

Clinical data

AG10 was shown to be well-tolerated in our Phase 1 clinical trial and at the highest tested dose achieved 100% ex vivo TTR stabilization at peak concentrations and over 95% TTR stabilization on average at steady state at the highest dose cohort. AG10 is designed to treat ATTR at its source by stabilizing tetrameric TTR in order to prevent the initiating event in the disease (dissociation of tetrameric TTR). X-ray crystallography indicates that AG10 may uniquely drive hydrogen bonding at the bottom of the thyroxine binding pocket to help hold TTR together, mimicking the naturally-occurring T119M rescue mutation. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the “super-stabilizing” properties of the naturally-occurring rescue mutation. In preclinical studies, AG10 has also shown high levels of stabilization across a wide range of mutations that lead to ATTR-CM or ATTR-PN.

We have observed no clinically significant adverse events in our Phase 1 clinical trial and a greater than 50x therapeutic window between the achieved therapeutic AG10 drug levels and those associated with observed animal toxicity. We believe these data support that AG10 could be a preferred TTR stabilizer and support its continued clinical development.

Phase 1 clinical trial of AG10

In September 2017, following acceptance of our IND application for AG10 in ATTR-CM, we initiated our first clinical trial of AG10. The study was designed as a randomized, placebo-controlled, single and multiple ascending dose study in healthy adult volunteers. The primary objective of the study was to evaluate the safety and tolerability of single and multiple doses of AG10. The secondary objectives were to characterize the PK of AG10 and to describe the PD properties of AG10, as well as the PK-PD relationship of AG10 in healthy adult subjects.

 

99


Table of Contents

The trial design is depicted below. Part A consists of a single ascending dose, or SAD, design, where four cohorts of eight healthy individuals were randomized to receive AG10 or placebo in a 3:1 overall ratio. Part B consists of a multiple ascending dose, or MAD, design, where three cohorts of eight healthy individuals were randomized to receive AG10 or placebo in a 3:1 ratio. A total of 32 subjects, 24 dosed with AG10 and eight with placebo to match, completed Part A with doses of 50 mg, 150 mg, 300 mg or 800 mg of AG10. The intermediate dose group of 300 mg was selected for the food effect portion of the study. In Part B, a total of 24 subjects, 18 dosed with AG10 and six with placebo to match, were dosed with 100 mg, 300 mg or 800 mg AG10 every 12 hours for 12 days. The results observed to date in our clinical development of AG10, including our Phase 1 clinical trial in which 32 subjects were enrolled, are based on a limited sample size and may not be observed in later-stage clinical trials involving larger numbers of patients:

 

LOGO

The safety evaluations in this study include vital signs (blood pressure, heart rate), physical examination, clinical laboratory tests (hematology, clinical chemistry, urinalysis, including microscopic evaluation), electrocardiography, and Holter monitoring.

Below is a summary of our observations of treatment emergent serious adverse events (SAEs) and adverse events (AEs) observed in the Phase 1 study.

Number of patients experiencing adverse events (%)

 

      Single ascending dose    Multiple ascending dose (q12h)
      Placebo
(n=8)
   50 mg
(n=6)
   150 mg
(n=6)
   300 mg1
(n=6)
   800 mg
(n=6)
   Placebo
(n=6)
   100 mg
(n=6)
   300 mg
(n=6)
   800 mg
(n=6)

SAEs

   0 (0%)    0 (0%)    0 (0%)    0 (0%)    0 (0%)    0 (0%)    0 (0%)    0 (0%)    0 (0%)

AEs

   2 (25%)    3 (50%)    2 (33%)    1 (17%)    1 (17%)    3 (50%)    2 (33%)    5 (83%)    1 (17%)

1: Adverse events in the fed component; no subjects in the fasted component experienced treatment emergent SAEs or AEs

 

100


Table of Contents

Results from both the SAD and MAD parts of the study indicate that AG10 was well-tolerated. No deaths or SAEs were reported during the study and no subject discontinued study drug or the study due to an AE. Most AEs were reported by single subjects in both the SAD and MAD parts, and all were mild to moderate in intensity. The only AEs that occurred in more than one subject were dry mouth, generalized headache, upper respiratory infection, and dizziness, all of which occurred in two separate subjects. No AEs were reported as “probable” with regards to their relationship to AG10.

PK properties of AG10 were evaluated in both parts of the trial. The data indicate that AG10 is rapidly absorbed (peak concentrations achieved within 1 hour of dosing), and the terminal half-life of the compound is approximately 25 hours. Plasma concentrations achieved in these studies reached our expected steady-state target concentrations. The PK of AG10 in the MAD portion of the study is shown below.

 

 

LOGO

 

101


Table of Contents

We evaluated the PD properties of AG10 with the fluorescent probe exclusion, or FPE, and Western blot assays, both previously reported assays of TTR stabilization. The percentage target engagement with TTR by AG10 as measured by the FPE assay in the SAD portion of the study is shown below. AG10 demonstrated rapid and near-complete TTR stabilization, reflecting rapid absorption and achievement of therapeutic blood levels, even at the lowest dose tested. A progressively longer duration of TTR stabilization was observed with escalating AG10 doses, reflecting dose-related increases in blood levels of AG10.

 

 

LOGO

The percentage of TTR stabilization as measured by the FPE assay at peak, trough and on average over the dosing interval at steady-state (Day 12) in the MAD portion of the study is shown below. The data from the highest tested daily dose demonstrated 100% steady-state TTR stabilization in all subjects at peak drug concentration measured shortly after oral dosing. At the same 800 mg dose administered every 12 hours, TTR stabilization on average over the dosing interval and at trough (pre-dose at steady state) was 96% and 92%, respectively. We believe these are the highest levels of ex vivo TTR stabilization demonstrated in any clinical trial of a TTR stabilizer and support AG10’s potential to slow or halt the progression of ATTR.

 

 

LOGO

 

102


Table of Contents

TTR stabilization was also measured using the Western blot assay. A characteristic blot and summarized quantification (mean +/- standard deviation) of all MAD data is shown below. These data similarly showed high levels of TTR stabilization in all MAD cohorts at peak and trough concentrations. Further, the blots demonstrate that near-complete TTR stabilization was achieved at 60 hours following final dose in the cohort dosed with 800 mg every 12 hours.

 

 

LOGO

The aggregate PK-PD data from subjects administered any dose of AG10 in the MAD portion shown below demonstrate a predictable and dose-responsive PD effect of AG10 in both FPE and Western blot assays.

 

 

LOGO

 

103


Table of Contents

 

LOGO

The correlation between FPE and Western blot (WB) data was also examined in a post-hoc analysis. The data shown below from the MAD portion of the Phase 1 trial demonstrate a high level of correlation between assays.

 

LOGO

Phase 2 and 3 clinical trials of AG10

Based on the safety and tolerability profile and the TTR stabilization data for AG10 in our Phase 1 clinical trial, we initiated a randomized, placebo-controlled, double-blind Phase 2 clinical trial of AG10 in ATTR-CM patients in April 2018. The primary objective of this study is to evaluate the safety and tolerability of AG10 administered to symptomatic ATTR-CM patients. The secondary objectives are to characterize the PK of AG10 administered orally daily for 28 days and to describe the PD properties of AG10, as assessed by established assays of TTR stabilization including the FPE assay and Western blot. The study will also describe the PK-PD relationship of AG10 in adult patients with symptomatic ATTR-CM. The trial is enrolling both wild-type and mutant ATTR-CM patients. As shown below, patients will be randomized 1:1:1 to AG10 400 mg twice daily, 800 mg twice daily, or placebo for 28 days.

 

104


Table of Contents

We also plan to invite patients in this Phase 2 clinical trial to participate in an open label extension in which patients will receive 800 mg AG10 twice daily. The purpose of this extension study is to evaluate the long-term safety and tolerability of AG10, as well as track measures of cardiac health and function including NT-proBNP, troponin I, left ventricular wall thickness, and global longitudinal strain. We expect topline data from the randomized, placebo-controlled, double-blind portion of the Phase 2 clinical trial in ATTR-CM by the end of 2018.

Randomized, double-blind, placebo controlled, multi-center study of AG10 in ATTR-CM patients

 

LOGO

 

105


Table of Contents

Anticipated clinical and regulatory path for AG10

Our Phase 3 clinical development plan in ATTR-CM will be based on the results of our Phase 2 clinical trial in ATTR-CM patients, the existing and forecasted treatment landscape, and further discussions with U.S. and European regulatory authorities. Of particular importance in the design our of Phase 3 study in ATTR-CM are the full data from Pfizer’s Phase 3 clinical trial of tafamidis (ATTR-ACT). We believe the ATTR-ACT study, as it reportedly met its primary endpoint, validates the stabilization hypothesis and, based on incomplete levels of TTR stabilization in our in vitro assays, is likely to highlight remaining unmet medical need that could be addressed with a more potent stabilizer. In particular, we believe the following ATTR-ACT study parameters, results for which have not yet been reported to date, as well as future results from our Phase 2 clinical trial of AG10 in ATTR-CM and our potential end of Phase 2 meeting with the FDA, will have direct implications for our Phase 3 clinical trial design:

LOGO

We believe that a Phase 3 registration trial for AG10 will be possible regardless of the outcome of the ATTR-ACT trial. Supporting this belief are our pre-clinical and Phase 1 data which indicate that AG10 may achieve best-in-class TTR stabilization at a well-tolerated dose. Further, we believe the large and growing prevalence of ATTR-CM provides sufficient patient numbers to facilitate rapid trial enrollment. We are examining multiple potential trial designs that will be informed by the detailed results of the ATTR-ACT trial when they are reported. Current trial size estimates are preliminary and difficult to calculate but we believe potential pivotal trial designs may include a placebo-controlled trial with approximately 300-400 patients or an active comparator trial with approximately 500-1,000 patients. Our assumptions will be refined based on the full ATTR-ACT data, our Phase 2 data in ATTR-CM, and interactions with regulatory authorities. Subject to the successful completion of the Phase 2 ATTR-CM trial and our discussions with regulatory authorities, we intend to advance AG10 into a Phase 3 clinical trial for the treatment of ATTR-CM (both mutant and wild-type) in the first half of 2019.

While AG10 is not likely to become the first-to-market targeted therapy for ATTR-CM, we believe that, if approved, it has the potential to demonstrate improved clinical results relative to previous trials. Systematic reviews of recent commercial drug launches demonstrate that best-in-class compounds can achieve significant, and in some instances the leading market share even if they are not the first approved product for a particular indication. Further, we believe certain qualities of the ATTR-CM market could yield additional benefits to a best-in-class therapeutic. Specifically, the ATTR-CM market is sufficiently large and heterogenous that subsets of

 

106


Table of Contents

patients may be unresponsive to any particular therapy, causing physicians to cycle between available therapies. In addition, the potential growth of the market may lead to a large number of newly diagnosed cases which would not require switching from an established therapy to a novel, best-in-class agent.

Subject to the successful completion of our Phase 2 clinical trial of AG10 in ATTR-CM and authorization from applicable regulatory authorities, we also plan to initiate a Phase 3 clinical development program for AG10 in ATTR-PN in early 2019. We plan to enroll up to 130 symptomatic ATTR-PN patients in a randomized, placebo-controlled, double-blinded clinical trial of 12 months’ duration. The planned primary endpoint is the modified Neurologic Impairment Score +7 (mNIS+7), with secondary endpoints of overall safety and tolerability, Norfolk Quality of Life (QoL) score, assessments of autonomic function, and cardiac function (which may be important in patients with mixed phenotype). Other endpoints may include population PK of AG10 in ATTR-PN patients and assessments of TTR stabilization as measured by FPE and Western blot assays. We do not intend to file an IND with the FDA for this indication, and we plan to conduct this study outside of the United States.

Preclinical data for AG10 in ATTR

In 2016 through 2018, we conducted in vitro pharmacology and predictive safety screens, and evaluated in vivo (nonclinical) safety, PK and PD of AG10 in several mammalian species, including in single and repeat dose non-GLP and repeat dose (up to 90 days) GLP toxicology studies in rat and dog. These studies suggest that AG10 is a potent, highly selective, orally-available TTR stabilizer. We are also conducting chronic toxicology studies to examine the long-term safety profile of AG10 in rats and dogs.

Animal safety pharmacology studies of AG10 demonstrated a wide margin between anticipated therapeutic exposures and doses associated with toxicity. The respiratory and central nervous system animal safety studies did not demonstrate any adverse effects. GLP toxicology studies (28 day repeat dosing and 90 day repeat dosing) identified a no adverse effect level, or NOAEL, in both rats and dogs that provided safety margins over 50 fold higher than the target human drug concentration for clinical investigation. No dose limiting toxicities were established in the 90 day GLP toxicology dog study. However, in prior toxicology studies of shorter duration, at doses above the NOAEL, dogs experienced dose limiting toxicities of gastrointestinal effects including vomiting, dehydration and weight loss.

 

107


Table of Contents

In vivo studies have also demonstrated AG10’s stabilization effects on TTR. Upon oral administration to dogs, AG10 stabilized serum TTR in a dose dependent manner, as measured by the FPE assay as shown below.

 

 

LOGO

Similarly, orally-administered AG10 resulted in stabilization of TTR in a dose dependent manner in monkeys, as measured by the FPE assay as shown below.

 

 

LOGO

 

108


Table of Contents

In addition, ex vivo studies in patient blood samples have supported AG10’s stabilization effects on TTR across several pathogenic mutations. Over 140 mutations leading to ATTR-CM and ATTR-PN have been described. We selected mutations that occur at different amino acid positions in the protein, as shown below, to test the hypothesis that AG10 could stabilize multiple TTR variants as well as wild-type protein.

 

 

LOGO

Blood samples were obtained from patients carrying a series of mutations that are distributed throughout the primary amino acid sequence of the protein and are manifest across a spectrum of clinical phenotypes. In in vitro experiments, AG10 was added to patient sera and then evaluated for AG10’s ability to stabilize TTR. AG10 was observed to potently stabilize all the tested TTR mutations, as measured by FPE assay and Western blots. Shown below are the Western blot results illustrating the effects of AG10 on variant TTR.

 

 

LOGO

We believe the results for our nonclinical studies and GLP toxicology studies strongly support the continued clinical development of AG10 for ATTR.

 

109


Table of Contents

TTR stabilization assays

Multiple assays have been developed to biochemically measure TTR stabilization. AG10 has consistently demonstrated the highest levels of TTR stabilization across all four assays explained below. These assays were powered for statistical significance. Importantly, data from these assays may correlate with clinical outcome for naturally occurring TTR variants and small molecule drug candidates. In the absence of validated and reliable biomarkers of disease progression or TTR stabilization in vivo, we believe these in vitro/ex vivo assays are our best tool to predict the clinical efficacy of drug candidates. Specifically, the ability of small molecules to stabilize TTR can be estimated based on in vitro studies in which study drug is added to buffer, plasma, or serum containing TTR. These assays can be performed using plasma or serum samples taken from animals or humans who have been treated with the study drug. In either case, these assays aim to measure distinct components of the ATTR disease cascade, as illustrated below:

 

1.   Ligand binding and dissociation

 

2.   Tetramer dissociation into monomers

 

3.   Fibril aggregation

 

 

LOGO

Each assay presents its own technical limitations and yields a differing absolute measure of “TTR stabilization” depending on specific conditions. Importantly, however, stabilization values have been highly correlated between assays in multiple studies. Further, the relative affinity and potency of stabilization by small molecules is consistent across assay conditions. In aggregate, the experimental measures allow for rank ordering of TTR stabilization between various small molecules at relevant clinical concentrations. We believe that no single assay should be viewed as a gold standard, but instead a consensus view should be drawn from collated results obtained across modalities. For this reason, we have examined AG10 and other small molecule TTR stabilizers in head-to-head experiments using each of the assays listed below.

For our clinical studies, we have selected Western blot and fluorescent probe exclusion assays as our primary measures of TTR stabilization. These assays were selected because they provide consistent data across multiple laboratories, appear to correlate with clinical benefit observed in previous studies, and can be conducted at high throughput in a non-academic laboratory setting.

 

110


Table of Contents

Further details regarding the four assays most commonly used in recent literature are detailed in the table below:

 

     Fibril formation   Western blot   Fluorescent probe
exclusion (FPE)
  Subunit exchange
ATTR step measured   Fibril aggregation   Tetramer dissociation into monomers   Ligand dissociation   Tetramer dissociation into monomers
Solution   Buffer   Plasma/serum   Serum   Plasma/serum
pH   Acidic (4.4)   Acidic (< 4.0) or Neutral (Urea)   Neutral (7.4)   Neutral (7.4)
Time   24 hours   72 hours   6 hours   2-7 days
Temperature   25°C   25°C   25°C   25°C /37°C
Covalent probe  

-

  -   +   +
Exogenous protein  

-

  -   -   +
Read out method   UV–vis turbidity measurements of light transmission reduced by the formation of TTR amyloid fibrils.   Plasma or serum samples, post tetramer dissociation, are subjected to cross-linking and immunoblotting. The intensity of residual TTR tetramer is then quantified. Absent any stabilizer, tetrameric TTR dissociates to 10-20% its original amount. In the presence of stabilizer, measured ex vivo post dosing or added in vitro, samples retain up to 100% of tetrameric TTR despite acidic conditions.   Fluorescence of covalent probe binding to TTR tetramer (i.e. the lower the fluorescence signal, the higher the extent of target engagement and TTR stabilization). Initial binding of probe can be competed out completely by therapeutic concentrations of stabilizer dosed in vivo or added in vitro.  

Recombinant (E. coli) FLAG-tagged TTR is added to plasma. The subunit exchange between TTR and FLAG-tagged TTR is monitored by anion exchange chromatography via intrinsic protein fluorescence (buffer) or covalent probe (plasma).

 

NOTE: covalent probe cannot displace AG10 bound to TTR so plasma stabilization measurements cannot be made using the method reported.

The four assays described above have been used to various extents across the number of non-clinical and clinical studies in the ATTR field. Specifically, the fibril formation and Western blot assays have been used broadly across numerous studies, whereas the FPE assay has been utilized more recently in a smaller number of labs. The subunit exchange assay has only been used in research studies by the Kelly lab at Scripps, which also originated the FPE assay.

Additional opportunities

We may evaluate opportunities to expand our capabilities and product pipeline. Consistent with our strategy and that of our parent company, BridgeBio, we may look for assets that target well-defined genetic diseases at their source. Complementary approaches in ATTR are the most synergistic opportunity. We may also pursue acquisition or in-licensing of adjacent precision cardiovascular medicine assets.

 

111


Table of Contents

Manufacturing

Given the small molecule and oral formulation of AG10, we believe the synthesis of the drug substance for AG10 is reliable and reproducible from readily available starting materials, and the synthetic routes are amenable to large-scale production and do not require unusual equipment or handling in the manufacturing process. We have already established the synthetic process and scaled up to large kilogram quantities similar to the campaigns that will be required to provide drug product for our anticipated Phase 3 clinical trial. We have obtained an adequate supply of the drug substance for AG10 from our first North American contract manufacturing organization, or CMO, to satisfy our clinical and preclinical requirements in 2018. We are engaging secondary raw material suppliers and North American and European CMOs to mitigate supply chain risk and ensure continuity of supply of drug substance. To maximize flexibility, we have established relationships with non-overlapping vendors for supply of both starting materials as well as drug substance.

Drug product formulation for AG10 has been developed as a film coated tablet and continues to be optimized. We have contracted with a North American third-party manufacturer capable of both formulation development and drug product manufacturing through commercialization. We have identified a second drug product manufacturer adding additional capacity and redundancy to our supply chain. The current formulation used in the Phase 1 and Phase 2 studies of AG10 is an immediate release tablet. We have already manufactured over 60,000 tablets, sufficient to dose our ongoing Phase 2 clinical trial in ATTR-CM. For future development and commercialization, we intend to optimize the tablet formulation to reduce pill burden and facilitate compliance.

We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently depend on third-party CMOs for all of our requirements of raw materials, drug substance and drug product for our preclinical research and our ongoing clinical trial of AG10. We have not entered into long-term agreements with our current CMOs. We intend to continue to rely on CMOs for later-stage development and commercialization of AG10, as well as the development and commercialization of any other product candidates that we may identify. Although we rely on CMOs, we have personnel and third-party consultants with extensive manufacturing experience to oversee the relationships with our contract manufacturers.

Sales and marketing

We intend to begin building a commercial infrastructure in the United States and selected other territories to support the commercialization of AG10 when we believe a regulatory approval in a particular territory is likely. Because ATTR-CM and ATTR-PN are rare diseases with a concentrated prescribing audience and a small number of key opinion leaders who influence the treatments prescribed for the relevant patient population, we believe that we can effectively address the market using our own targeted, specialty sales and marketing organization supported by internal sales personnel, an internal marketing group and distribution support.

In any core markets outside of the United States that we may identify, where appropriate, we may utilize strategic partners, distributors or contract sales forces to expand the commercial availability of AG10. We currently do not expect that we will require large pharmaceutical partners for the commercialization of AG10 or any other product candidates we may identify and pursue, although we may consider partnering in certain territories or indications or for other strategic purposes. We intend to evaluate our commercialization strategy as we advance AG10 through clinical development.

Intellectual property

We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents and patent applications intended to cover our product candidates and compositions,

 

112


Table of Contents

their methods of use and processes for their manufacture, and any other aspects of inventions that are commercially important to the development of our business. We have entered into an exclusive license agreement with The Board of Trustees of the Leland Stanford Junior University, or Stanford, to obtain the rights to use certain patents for the development and commercialization of our product candidates. See “—Our material agreements—License agreement with the Board of Trustees of the Leland Stanford Junior University.” We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

Our success will depend on our ability to obtain and maintain patent and other proprietary rights protecting our commercially important technology, inventions and know-how related to our business, defend and enforce our current and future issued patents, if any, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our intellectual property portfolio. We seek to obtain domestic and international patent protection, and endeavor to promptly file patent applications for new commercially valuable inventions.

The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any patents, if issued, will provide sufficient protection from competitors.

Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings or derivation proceedings declared by the United States Patent and Trademark Office, or USPTO, to determine priority of invention.

Patents and patent applications

Our patent portfolio includes five issued U.S. patents, one allowed U.S. patent application, three pending U.S. patent applications, patent applications in Europe and Japan in various stages of prosecution and one pending international application filed under the Patent Cooperation Treaty (PCT).

Specifically, our patent portfolio includes five issued U.S. patents and one allowed U.S. patent application, exclusively licensed from Stanford, which are directed to AG10’s composition of matter and methods of use.

These patents are currently expected to expire in 2031 or 2033, absent any applicable patent term extensions. Our patent portfolio licensed from Stanford also includes one pending U.S. patent application, two pending European patent applications, and one pending Japanese patent application directed to AG10 and methods of its use, which, if issued, are expected to expire between 2031 and 2033, absent any applicable patent term extensions.

In addition, we are the sole assignee of two patent families directed to particular salt forms of AG10, particular polymorphic forms of AG10, methods of manufacturing AG10, and formulations of AG10. One of the families consists of a pending U.S. provisional patent application, and the other family includes one pending U.S. patent

 

113


Table of Contents

application, a pending PCT patent application and one related pending patent application in Taiwan. If issued, these patent applications are expected to expire in 2038, absent any applicable patent term adjustments or extensions.

Patent term

The base term of a U.S. patent is 20 years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority assuming that all maintenance fees are paid. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the USPTO the extent of which is offset by delays by the patent owner before the USPTO in obtaining the patent. In some cases, the term of a U.S. patent is shortened by a terminal disclaimer that reduces its term to that of an earlier-expiring patent. The term of a U.S. patent may be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of an FDA-approved drug, an FDA-approved method of treatment using the drug and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. In the future, if our product candidates receive FDA approval, we expect to apply for patent term extension on patents, if issued, covering those products, their methods of use and/or methods of manufacture.

Trade secrets

In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors and contractors. These agreements generally provide that all confidential information developed or made known during the course of an individual or entities’ relationship with us must be kept confidential during and after the relationship. These agreements also typically provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.

Our material agreements

License agreement with the Board of Trustees of the Leland Stanford Junior University

In April 2016, we entered into an exclusive license agreement with Stanford for rights relating to novel transthyretin aggregation inhibitors. Under our agreement, Stanford has granted us an exclusive worldwide license to make, use and sell products that are covered by the licensed patent rights. This license grant expires when the last licensed patent expires. The patent rights exclusively licensed to us under the license are described in more detail above under the heading “—Intellectual property.”

 

114


Table of Contents

Stanford retains the right, on behalf of itself and all other non-profit academic research institutions, to practice under the patent rights for any non-profit purpose, including sponsored research and collaborations. We may grant sublicenses to third parties so long as we are actively pursuing the development or commercialization of products covered by the patent rights. We may also be required to sublicense our rights under the agreement at Stanford’s request under certain conditions, including if we are unwilling or unable to serve a potential market or territory and there is a third party willing to be a sublicensee in such market or territory.

We are obligated to pay to Stanford a yearly license maintenance fee during the term of the agreement, but we may offset the maintenance fee against earned royalty payments due on net sales occurring in that year. Stanford is entitled to receive a royalty as a percentage of net sales of licensed products, in the low single digits. We have agreed to pay Stanford a percentage of non-royalty revenue we receive from our sublicensees, with the amount owed decreasing annually for three years based on when we enter into the applicable sublicense agreement. We also issued to Stanford 56,809 shares of our common stock with a price of $0.15 per share, the fair market value at the time of issuance, a portion of which were issued directly to Drs. Graef and Alhamadsheh. In addition, we are obligated to pay Stanford up to approximately $1.0 million upon the achievement of specific intellectual property, clinical and regulatory milestone events. In the event of a change of control transaction, we are obligated to pay Stanford a change of control fee of $250,000 in connection with the assignment of the license agreement to our acquirer.

Under the license agreement with Stanford, we are obligated to use commercially reasonable efforts to develop, manufacture, and commercialize at least one licensed product; to develop markets for such licensed products; and to meet certain development milestones as agreed upon between us and Stanford.

Subject to the expiration of the license grant described above, the agreement does not have a specified term. We may terminate the agreement by providing prior written notice to Stanford, and Stanford has the right to terminate the agreement if we fail to achieve certain milestones or make payments under the agreement, or are not actively pursuing development of a licensed product, or if we otherwise materially breach the agreement and fail to cure such breach within a specified grace period.

Competition

The biopharmaceutical industry is highly competitive. There are many public and private biopharmaceutical companies, universities, governmental agencies and other research organizations actively engaged in the research and development of products that may be similar to our product candidates or address similar markets. In addition, the number of companies seeking to develop and commercialize products and therapies similar to our product candidates is likely to increase. In the area of ATTR, we expect to face competition from competitors targeting three distinct mechanisms of action: TTR stabilization, TTR knockdown, and TTR clearance.

Among TTR stabilizers, we expect to face competition from tafamidis (marketed as Vyndaqel by Pfizer Inc., or Pfizer, in the EU). Tafamidis is an oral TTR stabilizer that is approved in the EU for Stage 1 (early stage) ATTR-PN. In March 2018, tafamidis reportedly met its primary endpoint, a reduction in combined all-cause mortality and cumulative incidence of cardiovascular-related hospitalizations, in the Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study. Corino Therapeutics Inc./SOM Innovation Biotech, S.L. is developing SOM0226 (tolcapone, CRX-1008), an oral, small molecule TTR stabilizer for ATTR. Tolcapone is a generic drug that is FDA-approved for the treatment of Parkinson’s disease. The drug has demonstrated significant liver toxicity and consequently, had been previously removed from the US market. The marketing authorization in the US was renewed in August 2009, but it remains off the market in a number of other countries, including Australia, Bulgaria, and Iceland. Corino Therapeutics/SOM Biotech completed a Phase 2a trial of tolcapone in ATTR-PN. Diflunisal, a generic, non-steroidal anti-inflammatory drug (NSAID) indicated for mild to moderate

 

115


Table of Contents

pain and arthritis, may also be considered a competitor, having been shown to significantly slow development of ATTR-PN in a randomized Phase 3 trial. Diflunisal’s label contains a boxed warning for cardiovascular, renal and gastrointestinal risks.

Potentially competitive TTR knockdown approaches are being pursued by multiple companies. Alnylam Pharmaceuticals Inc., or Alnylam, is developing patisiran, an intravenously administered RNAi therapeutic for the treatment of hereditary ATTR with polyneuropathy and initiated a rolling submission of an NDA with the FDA in November 2017. Alnylam is also developing ALN-TTRsc02, a subcutaneously administered RNAi therapeutic for ATTR. Alnylam has reportedly completed a Phase 1 clinical trial of ALN-TTRsc02 in healthy volunteers. Ionis Pharmaceuticals Inc./Akcea Therapeutics, Inc. is developing inotersen, an antisense oligonucleotide (ASO) drug, for hereditary ATTR with polyneuropathy and filed an NDA with the FDA in November 2017. Intellia’s program is currently in preclinical development. Arcturus Therapeutics Ltd. is developing LUNAR-TTR, a lipid-based RNA medicine currently in preclinical development.

Therapeutics targeting TTR clearance may also be competitive to AG10. GlaxoSmithKline plc is developing a combination of GSK2315698 and GSK2398852 to target serum amyloid P component, or SAP, that deposits with TTR amyloid. This combination has been evaluated in a Phase 1 clinical trial. Prothena Therapeutics plc is developing PRX004, a monoclonal antibody, for ATTR that is currently in a Phase 1 clinical trial. Neurimmune Holding AG is also developing a recombinant human antibody for ATTR that is in preclinical development.

Government regulation

The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.

U.S. government regulation of drug products

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

 

 

Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice, or GLP, regulations;

 

 

Submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;

 

116


Table of Contents
 

Approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;

 

 

Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication;

 

 

Submission to the FDA of an NDA;

 

 

Satisfactory completion of an FDA advisory committee review, if applicable;

 

 

Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;

 

 

Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;

 

 

Payment of user fees and securing FDA approval of the NDA; and

 

 

Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.

Preclinical studies

Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.

Clinical trials

Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.

 

117


Table of Contents

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

 

 

Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.

 

 

Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

 

 

Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.

Marketing approval

Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of “filing” of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a “filing” decision.

In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. An Agreed Initial Pediatric Study Plan requesting a waiver from the requirement to conduct clinical studies has been submitted to the FDA.

The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.

The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be

 

118


Table of Contents

resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product’s continued safety, quality and purity.

The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.

After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.

Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Special FDA expedited review and approval programs

The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.

To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy

 

119


Table of Contents

based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the new PDUFA agreement, these six and ten month review periods are measured from the “filing” date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Many products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.

In addition, products tested for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures if, for example, the sponsor fails to confirm clinical benefit.

Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.

Accelerated approval pathway

The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

 

120


Table of Contents

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.

The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.

The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.

Orphan drug designation and exclusivity

Under the Orphan Drug Act, the FDA may designate a drug product as an “orphan drug” if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.

 

121


Table of Contents

U.S. marketing exclusivity

Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for the original non-modified version of the drug. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued “Written Request” for such a trial.

Post-approval requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products and the establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical data.

The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.

Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the

 

122


Table of Contents

market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

 

 

Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

 

 

Fines, warning letters or holds on post-approval clinical trials;

 

 

Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;

 

 

Product seizure or detention, or refusal to permit the import or export of products; and

 

 

Injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

Other healthcare laws

Healthcare providers, physicians, and third party payors play a primary role in the recommendation and prescription of drug products for which we obtain marketing approval. Arrangements with third party payors, healthcare providers and physicians, in connection with the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below:

 

 

the federal Anti-Kickback Statute, or AKS, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;

 

 

the federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which impose criminal and civil penalties, including through civil “qui tam” or “whistleblower” actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Similar to the federal Anti-Kickback Statute, a person or entity

 

123


Table of Contents
 

does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;

 

 

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

 

 

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;

 

 

the federal Physician Payments Sunshine Act, created under Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, or HHS, under the Open Payments Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and

 

 

analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of a pharmaceutical manufacturer’s business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that a pharmaceutical manufacturer’s business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against a pharmaceutical manufacturer, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on its business, including

 

124


Table of Contents

the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, integrity and oversight agreements to resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, any of which could adversely affect a pharmaceutical manufacturer’s ability to operate its business and the results of operations. In addition, commercialization of any drug product outside the United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

Current and future healthcare reform legislation

In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system. In particular, in 2010 the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government’s comparative effectiveness research.

There have been a number of significant changes to the ACA and its implementation. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing effective January 1, 2019 the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October 13, 2017, President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. Moreover, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, also amends the ACA, effective January 1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole”. Similarly, on April 9, 2018, the Centers for Medicare and Medicaid Services, or CMS, issued a final rule that will give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces by relaxing certain requirements for essential health benefits required under the ACA for plans sold through such marketplaces.

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to

 

125


Table of Contents

several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Legislative and regulatory proposals, and enactment of laws, at the foreign, federal and state levels, directed at containing or lowering the cost of healthcare, will continue into the future.

Regulation outside the United States

To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.

European Union Drug Development

In the European Union, or EU, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained.

Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics Committees, or ECs. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.

The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will be identical.

European Union Drug Review and Approval

To market our future products in the EEA (which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein) and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:

 

 

The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency, or EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and

 

126


Table of Contents
 

National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

Data and marketing exclusivity

In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

Pediatric investigation plan

In the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA’s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and trial results are included in the product information, even when negative, the product is eligible for six months’ supplementary protection certificate extension.

Orphan drug designation and exclusivity

In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in development. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis,

 

127


Table of Contents

prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP.

This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of “clinical superiority” by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs.

Rest of World Regulation

For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Coverage and reimbursement

Successful commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors.

A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are

 

128


Table of Contents

substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States.

In the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.

For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of the law these newly eligible entities (with the exception of children’s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs. As 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our drug candidates, if any such drug or the condition that they are intended to treat are the subject of a trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor’s drug could adversely affect the sales of our drug candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis.

 

129


Table of Contents

These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures.

Employees

As of March 31, 2018, we had 14 full-time employees, including ten in research and development and four in general and administrative in the United States. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.

Facilities

We lease our office space, which consists of approximately 4,659 square feet located in San Francisco, California. Our lease expires on October 31, 2022. We lease our laboratory space, which consists of two benches and two desks in a shared facility, in San Francisco, California. We believe our current office and laboratory space is sufficient to meet our needs until the expiration of our lease.

Legal proceedings

As of the date of this prospectus, we were not party to any legal matters or claims. In the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.

 

130


Table of Contents

Management

Executive officers and directors

The following table sets forth certain information about our executive officers and directors, including their ages as of June 5, 2018.

 

Name    Age      Position(s)
Executive Officers:      
Neil Kumar, Ph.D.      39      Chief Executive Officer and Director
Jonathan C. Fox, M.D., Ph.D.      61      President and Chief Medical Officer
Uma Sinha, Ph.D.      61      Chief Scientific Officer
Christine Siu      41      Chief Financial Officer
Other Directors:      

Eric Aguiar, M.D.(1)(2)(3)

     56      Director
Rajeev Shah(1)(2)(3)      41      Director
Hoyoung Huh, M.D., Ph.D.(1)      48      Director
Ali Satvat(2)      40      Director

 

 

(1)   Member of the Audit Committee.

 

(2)   Member of the Compensation Committee.

 

(3)   Member of the Nominating and Corporate Governance Committee.

Neil Kumar, Ph.D. has served as our Chief Executive Officer and a member of our board of directors since March 2016. Dr. Kumar founded BridgeBio Pharma, LLC and has served as its chief executive officer since September 2014. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures from 2011 to 2014. Before joining Third Rock, he served as an associate principal at McKinsey & Company from 2007 to 2011. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

Jonathan C. Fox, M.D., Ph.D., FACC, has served as our President and Chief Medical Officer since October 2016. Dr. Fox has served as the TA lead of cardiovascular and renal diseases at BridgeBio Pharma, LLC since October 2016. Prior to that, from March 2013 to September 2016, Dr. Fox served as the chief medical officer of MyoKardia, Inc. and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology.

Uma Sinha, Ph.D. has served as our Chief Scientific Officer since June 2016. Dr. Sinha has served as the chief scientific officer at BridgeBio Pharma, LLC since April 2016 and serves as the chief scientific officer of other BridgeBio subsidiaries. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. from 2014 to 2015 and as senior vice president of research from 2013 to 2014. She was vice president, head

 

131


Table of Contents

of biology at Portola Pharmaceuticals, Inc. from 2010 to 2012 and was the vice president of translational biology from 2004 to 2010 and had held senior research positions at Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B Sc. with honors in chemistry from Presidency College.

Christine Siu has served as our Chief Financial Officer since December 2017. From 2016 to 2017, she served as the chief operating officer of Eidos. She also serves as the chief operating officer of other BridgeBio subsidiaries. Prior to that, Ms. Siu served as the chief business officer of the Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017. Prior to that, she served as senior director of corporate development of Global Blood Therapeutics, Inc. from 2012 to 2014. She served as venture principal at Third Rock Ventures from 2011 to 2012. Previously, she held roles of increasing responsibility at private equity and venture capital firms, Warburg Pincus and Thomas, McNerney & Partners, where she invested in life sciences companies. She received her B.S. in cellular molecular biology and economics from the University of Michigan and her MBA from Harvard Business School.

Hoyoung Huh, M.D., Ph.D. has served as a member of our board of directors since March 2016. He is the founder of pH Pharma and Healthcare & Humanity Foundation. He currently also serves as the chairman of the board of directors of Geron Corporation since 2010, and CytomX Therapeutics since 2011, and a member of the board of directors of Rezolute since 2012. Previously, Dr. Huh was the chief executive officer and chairman of the board of directors of BiPar Sciences, the chairman of the board of directors of Epizyme, a member of the board of directors of Facet Biotech, Nektar Therapeutics, Addex Therapeutics and EOS, S.p.A (Milano, Italy). Earlier in his career, Dr. Huh was a partner at McKinsey & Company. Dr. Huh holds A.B. in Biochemistry from Dartmouth College, and his M.D./Ph.D. in Cell Biology and Genetics from Cornell University Medical College.

Eric Aguiar, M.D. has served as a member of our board of directors since March 2018. Dr. Aguiar has been a partner at Aisling Capital since January 2016 and prior to that was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund, since 2007. Prior to joining that firm, he was a Managing Director of HealthCare Ventures, a healthcare focused venture capital firm, from 2001 to 2007. Dr. Aguiar currently serves on the board of directors of Invitae Corporation (NYSE: NVTA) since September 2010 and Biohaven Corporation (NYSE: BHVN) since October 2016. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Dr. Aguiar received his medical degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst. We believe that Dr. Aguiar’s medical and finance background and experience as an investor in life science companies qualifies him to serve as a member of our board of directors.

Rajeev Shah has served as a member of our board of directors since March 2018. Mr. Shah has been a portfolio manager and managing director at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, since 2004. Mr. Shah is also a member of the board of directors of Ra Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc., and Solid Biosciences Inc. Mr. Shah was previously a member of the board of directors of KalVista Pharmaceuticals from 2015 through April 2018. Mr. Shah received a B.A. in Chemistry from Cornell University. We believe Mr. Shah is qualified to serve on our board of directors because of his leadership and financial experience at RA Capital Management, his experience in the biopharmaceutical industry, and his experience with venture capital investments.

Ali Satvat has served as a member of our board of directors since June 2018. Mr. Satvat joined Kohlberg Kravis Roberts & Co. L.P. (“KKR”) in January 2012 and is a Member of KKR Management LLC, the general partner of KKR, on the Health Care industry team within KKR’s Americas Private Equity platform. Mr. Satvat leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment

 

132


Table of Contents

Committee and the Health Care Strategic Growth Portfolio Management Committee. Mr. Satvat has served as a member of the board of directors of Coherus BioSciences, Inc. (Nasdaq: CHRS) since May 2014 and multiple privately held organizations. Mr. Satvat served as a member of the board of directors of PRA Health Sciences, Inc. (Nasdaq: PRAH) from September 2013 through April 2018. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat also serves on the board of directors of the Healthcare Private Equity Association. We believe that Mr. Satvat is qualified to serve on our board of directors based on his extensive investment experience in the health care industry

Composition of our board of directors

Our board of directors consists of five members, each of whom are members pursuant to the board composition provisions of our certificate of incorporation and our voting agreement, which agreement is described under “Certain relationships and related party transactions” in this prospectus. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors.

Effective upon the completion of this offering, we intend to form a nominating and corporate governance committee. Our nominating and corporate governance committee and our board of directors may consider a broad range of factors relating to the qualifications and background of director nominees, which may include diversity, which is not only limited to race, gender or national origin, although we currently have no formal policy regarding board diversity. Our nominating and corporate governance committee’s and our board of directors’ priority in selecting board members is to identify persons who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion of this offering also provide that our directors may be removed by the affirmative vote of the holders of a majority of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled by vote of a majority of our directors then in office or by the holders of a majority of the outstanding shares of capital stock entitled to vote at an election of directors.

Director independence

Upon the completion of this offering, we expect that our common stock will be listed on the Nasdaq Global Market. Applicable rules of the Nasdaq Stock Market LLC, or Nasdaq, require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq rules require that, (1) on the date of the completion of the offering, at least one member of each of a listed company’s audit, compensation and nominating and corporate governance committees be independent, (2) within 90 days of the date of the completion of the offering, a majority of the members of such committees be independent and (3) within one year of the date of the completion of the offering, all the members of such committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an “independent director” if, in the opinion of the listed company’s board of directors, that person does not have a

 

133


Table of Contents

relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.

Our board of directors has determined that Dr. Aguiar and Messrs. Shah and Satvat are independent directors for purposes of the rules of Nasdaq and the SEC. In making such determination, our board of directors considered the relationships that each director has with us, and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each director. Our board of directors also considered the association of our directors with the holders of more than 5% of our common stock, including our controlling stockholder, BridgeBio. Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of our committees will comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC, subject to the transition rules described above for newly listed companies. There are no family relationships among any of our directors or executive officers.

We will have a single class of directors who are each elected for one-year terms and until their successors are duly elected and qualified.

Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion of this offering provide that the number of directors may be changed only by resolution of our board of directors.

Committees of our board of directors

Our board of directors plans on establishing an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate pursuant to a charter to be adopted by our board of directors and which will be effective upon completion of the offering. Following the completion of this offering, copies of each committee’s charter will be posted on the Corporate Governance section of our website, at www.eidostx.com. The inclusion of our website address in this prospectus does not incorporate by reference the information on or accessible through our website into this prospectus.

Audit committee.     Effective upon completion of this offering, Drs. Aguiar and Huh and Mr. Shah will serve on the audit committee, which will be chaired by Dr. Aguiar. Our board of directors has determined that Dr. Aguiar and Mr. Shah are “independent” for audit committee purposes as that term is defined in the rules of the SEC and the applicable Nasdaq rules, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has designated Dr. Aguiar as an “audit committee financial expert,” as defined under the applicable rules of the SEC. We intend to rely on the phase-in provisions of Rule 10A-3 of the Exchange Act and the Nasdaq transition rules applicable to companies completing an initial public offering, and we plan to have an audit committee comprised solely of directors that are independent for purposes of serving on an audit committee within one year after our listing. The audit committee’s responsibilities include:

 

 

appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;

 

 

pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;

 

134


Table of Contents
 

reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;

 

 

reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;

 

 

coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;

 

 

establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;

 

 

recommending based upon the audit committee’s review and discussions with management and our independent registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form 10-K;

 

 

monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;

 

 

preparing the audit committee report required by SEC rules to be included in our annual proxy statement;

 

 

reviewing all related person transactions for potential conflict of interest situations and approving all such transactions; and

 

 

reviewing quarterly earnings releases and scripts.

Compensation committee.     Effective upon completion of this offering, Dr. Aguiar and Messrs. Shah and Satvat will serve on the compensation committee, which will be chaired by Dr. Aguiar. Our board of directors has determined that each of Dr. Aguiar and Messrs. Shah and Satvat is “independent” under the applicable rules and regulations of Nasdaq, and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. We intend to rely on the Nasdaq transition rules applicable to companies completing an initial public offering, and we plan to have a compensation committee comprised solely of directors that are independent for purposes of serving on a compensation committee within one year after our listing. The compensation committee’s responsibilities include:

 

 

annually reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer;

 

 

evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and determining the compensation of our Chief Executive Officer;

 

 

reviewing and approving the compensation of our other executive officers;

 

 

reviewing and establishing our overall management compensation, philosophy and policy;

 

 

overseeing and administering our compensation and similar plans;

 

 

evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;

 

 

retaining and approving the compensation of any compensation advisors;

 

 

reviewing and approving our policies and procedures for the grant of equity-based awards;

 

 

reviewing and making recommendations to the board of directors with respect to director compensation;

 

135


Table of Contents
 

reviewing and discussing with management the compensation disclosure to be included in our annual proxy statement or Annual Report on Form 10-K; and

 

 

reviewing and discussing with the board of directors the corporate succession plans for the Chief Executive Officer and other key officers.

Nominating and corporate governance committee.     Effective upon completion of this offering,                 , Dr. Aguiar and Mr. Shah will serve on the nominating and corporate governance committee, which will be chaired by Mr. Shah. Our board of directors has determined that each of Dr. Aguiar and Mr. Shah is “independent” as defined in the applicable Nasdaq rules. We intend to rely on the Nasdaq transition rules applicable to companies completing an initial public offering, and we plan to have a nominating and corporate governance committee comprised solely of directors that are independent for purposes of serving on a nominating and corporate governance committee within one year after our listing. The nominating and corporate governance committee’s responsibilities include:

 

 

developing and recommending to the board of directors criteria for board and committee membership;

 

 

establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by stockholders;

 

 

reviewing the size and composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;

 

 

identifying individuals qualified to become members of the board of directors;

 

 

recommending to the board of directors the persons to be nominated for election as directors and to each of the board’s committees;

 

 

developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate governance guidelines;

 

 

developing a mechanism by which violations of the code of business conduct and ethics can be reported in a confidential manner; and

 

 

overseeing the evaluation of the board of directors and management.

Our board of directors may from time to time establish other committees.

Compensation committee interlocks and insider participation

None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee.

Code of business conduct and ethics

We plan to adopt a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting, which will be effective upon completion of this offering. Upon the completion of this offering, our code of business conduct and ethics will be available on our website at www.eidostx.com. We intend to disclose any substantive amendments to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K.

 

136


Table of Contents

Board leadership structure and board’s role in risk oversight

We do not currently have a chairman of the board, however, once we are a public company, we may establish a role of chairman of the board that is separate from the role of Chief Executive Officer. We believe that separating these positions would allow our Chief Executive Officer to focus on our day-to-day business, while allowing the chairman of the board to lead the board of directors in its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our chairman, particularly as the board of directors’ oversight responsibilities continue to grow. While our amended and restated bylaws and corporate governance guidelines will not require that our chairman and Chief Executive Officer positions be separate, our board of directors believes that having separate positions may provide the appropriate leadership structure for us and would demonstrate our commitment to good corporate governance.

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property as more fully discussed in the section titled “Risk Factors” appearing elsewhere in this prospectus. Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed.

The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed in the descriptions of each of the committees above and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.

Limitation on liability and indemnification matters

Our amended and restated certificate of incorporation, which will become effective immediately prior to the consummation of this offering, will contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:

 

 

any breach of the director’s duty of loyalty to us or our stockholders;

 

 

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

 

unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

 

 

any transaction from which the director derived an improper personal benefit.

Each of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to the consummation of this offering, will provide that we are required to

 

137


Table of Contents

indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws will also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors’ and officers’ liability insurance.

The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage.

 

138


Table of Contents

Executive and director compensation

Executive Compensation

Overview

The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion.

The compensation provided to our named executive officers for the fiscal year ended December 31, 2017 is detailed in the Summary Compensation Table and accompanying footnotes and narrative that follow this section.

Our named executive officers for the fiscal year ended December 31, 2017, which consists of our Chief Executive Officer and our two most highly compensated executive officers other than our Chief Executive Officer, are:

 

 

Neil Kumar, our Chief Executive Officer;

 

 

Jonathan Fox, our President and Chief Medical Officer; and

 

 

Uma Sinha, our Chief Scientific Officer.

Summary compensation table

The following table presents information regarding the total compensation, for services rendered in all capacities, that was earned by, paid to or awarded to each of our named executive officers during the fiscal year ended December 31, 2017.

 

Name and principal position   Year    

Salary

($)

   

Bonus(1)

($)

   

Stock
awards(2)

($)

   

Option
awards(2)

($)

   

Non-equity
incentive plan
compensation

($)

   

All other
compensation

($)

   

Total

($)

 

Neil Kumar, M.D.

    2017       140,353 (3)                                    140,353  

Chief Executive Officer

               

Jonathan C. Fox, M.D., Ph.D.

    2017       350,000       100,000             1,256,078             1,500 (4)      1,707,578  

President and Chief

Medical Officer

               

Uma Sinha, Ph.D

    2017       337,500 (5)      100,000       131,670                   4,179 (6)      573,349  

Chief Scientific Officer

               

 

 

 

(1)   The amounts reported reflect the discretionary cash bonuses earned by the named executive officers, and determined by our board of directors, for the fiscal year ended December 31, 2017, based on the named executive officers’ performance during such fiscal year.

 

(2)   In accordance with SEC rules, these columns reflect the aggregate grant date fair values of the stock awards and option awards, as applicable, granted during the fiscal year ended December 31, 2017, computed in accordance with Financial Accounting Standard Board ASC Topic 718 for stock-based compensation transactions, or ASC 718. Such aggregate grant date fair values do not take into account any estimated forfeitures related to service-vesting conditions. Assumptions used in the calculation of these amounts are included in Note 12 to our audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive officers upon the exercise of the options, the lapse of our repurchase right on any shares of restricted stock or the sale of shares of our common stock underlying such awards.

 

(3)   Dr. Kumar did not receive any cash compensation from us for his services as our Chief Executive Officer, as his services were provided to us through an agreement with BridgeBio Services Inc., or the BridgeBio Agreement. As described below under “Narrative to summary compensation table—Employment arrangements with our named executive officers—Arrangements in place during the fiscal year ended December 31, 2017 for named executive officers—Neil Kumar” and “Certain relationships and related party transactions,” we incurred management fees totaling $769,972 during the fiscal year ended December 31, 2017 for the services provided by BridgeBio Services Inc., which includes, among other things, the services of Dr. Kumar. Of the total fees we incurred with BridgeBio Services Inc. in the year ended December 31, 2017, $140,353 was related to the services provided by Dr. Kumar.

 

139


Table of Contents
(4)   We provided Dr. Fox with reimbursements for his healthcare costs from January 1, 2017 through March 31, 2017.

 

(5)   From January 1, 2017 through March 31, 2017, Dr. Sinha worked for us part time, devoting 60% of her work time to us and her annual base salary rate was $300,000. Since April 1, 2017, Dr. Sinha has devoted 100% of her work time to us and her annual base salary rate was increased to $350,000.

 

(6)   We provided Dr. Sinha with reimbursements for her healthcare costs from January 1, 2017 through March 31, 2017, along with tax gross-ups for such reimbursements.

Narrative to summary compensation table

Base salaries

Dr. Kumar did not receive any cash compensation from us for his services as our Chief Executive Officer, as his services were provided to us through the BridgeBio Agreement, as described further below under “Narrative to summary compensation table—Employment arrangements with our named executive officers—Arrangements in place during the fiscal year ended December 31, 2017 for named executive officers—Neil Kumar” and “Certain relationships and related party transactions.” For the fiscal year ended December 31, 2017, the annual base salary for Dr. Fox was $350,000. From January 1, 2017 through March 31, 2017, Dr. Sinha worked for us part time, devoting 60% of her work time to us. Since April 1, 2017, Dr. Sinha has devoted 100% of her work time to us. From January 1, 2017 through March 31, 2017, Dr. Sinha’s annual base salary rate was $300,000, which was increased to $350,000 effective as of April 1, 2017.

Bonus Arrangements

Annual discretionary cash bonuses

During the fiscal year ended December 31, 2017, Drs. Fox and Sinha each earned a discretionary cash bonus equal to $100,000 based on his or her performance during the year, as determined by our board of directors in its sole discretion.

Bonus agreement with Dr. Kumar

On April 26, 2018, we entered into a bonus agreement with Dr. Kumar (the “Bonus Agreement”). In June 2018, however, Dr. Kumar and the Company agreed to terminate the Bonus Agreement. Under the Bonus Agreement, in the event that following our initial public offering (or the date on which our common stock otherwise becomes publicly-traded), either (i) our market capitalization is, following the expiration of any applicable lock-up period for such common stock, equal to or greater than certain valuation thresholds for any 30 consecutive trading days or (ii) a “Change in Control” (as defined in the Bonus Agreement) occurs and the “Transaction Proceeds” (as defined in the Bonus Agreement) from such Change in Control equal or exceed certain valuation thresholds (each such event, a “Trigger Event”), Dr. Kumar would have been entitled to a lump sum cash bonus equal to the following, subject to his continuous service relationship with the Company as its Chief Executive Officer through the date of such applicable Trigger Event: $11.25 million if the valuation threshold is at least $750 million; an additional bonus equal to $3.75 million if the valuation threshold is at least $1 billion; and an additional bonus equal to $3.75 million if the valuation threshold is at least $1.25 billion. The bonus would have been paid to Dr. Kumar in a single lump sum cash payment on, or as soon as reasonably practicable following, the date of the applicable Trigger Event, but in no event later than 30 days following the date of a Trigger Event.

The Bonus Agreement also provided that in the event that any payments by us to Dr. Kumar pursuant to the terms of the Bonus Agreement would be subject to the excise tax imposed under Section 4999 of the Code, Dr. Kumar would have been entitled to an additional payment such that the amount retained by Dr. Kumar equals the amount Dr. Kumar would have retained had the excise tax not been imposed.

 

140


Table of Contents

The Bonus Agreement was effective as of April 26, 2018 and would have terminated upon the earliest of (a) a Change in Control resulting in Transaction Proceeds less than $750 million; (b) the date of payment to Dr. Kumar of a bonus pursuant to clause (ii) above; (c) 12 months following the date of payment to Dr. Kumar of an aggregate of $18.75 million, pursuant to clause (i) above; (d) the termination of Dr. Kumar’s service relationship with us as our Chief Executive Officer; and (e) April 26, 2028.

Equity compensation

During the fiscal year ended December 31, 2017, we granted an option to purchase shares of our common stock to Dr. Fox and shares of our common stock to Dr. Sinha, as shown in more detail in the “Outstanding equity awards at fiscal year end” table. Dr. Kumar has not received any grants of equity awards due to his association with BridgeBio Pharma LLC.

Employment arrangements with our named executive officers

We entered into offer letters with each of the named executive officers, except for Dr. Kumar, in connection with his or her employment with us, which set forth the terms and conditions of employment of each individual, including initial base salary, initial target annual bonus opportunity and eligibility to participate in our standard employee benefit plans. In addition, certain of these offer letters provided for certain payments and benefits in the event of qualifying terminations of employment in connection with a change in control of the Company.

Arrangements in place during the fiscal year ended December 31, 2017 for named executive officers

Neil Kumar

Dr. Kumar did not enter into an offer letter or employment agreement with the Company prior to the offering. Since 2016, we have received management services from BridgeBio Services, Inc., an affiliate of BridgeBio Pharma LLC, pursuant to the BridgeBio Agreement. Dr. Kumar provided services to the Company as our Chief Executive Officer through BridgeBio Services, Inc. pursuant to the BridgeBio Agreement. Of the $769,972 in total fees we incurred to BridgeBio Services, Inc. in the fiscal year ended December 31, 2017, $140,353 was related to the services provided by Dr. Kumar. There are no other agreements or arrangements between us and Dr. Kumar with respect to his services as our Chief Executive Officer.

See “Certain relationships and related party transactions” for additional information regarding our relationship with BridgeBio Pharma, LLC and the BridgeBio Agreement.

Jonathan Fox

On October 25, 2016, we entered into an offer letter with Dr. Fox, who currently serves as our Chief Medical Officer. The offer letter provided for Dr. Fox’s at-will employment and set forth his initial annual base salary, initial target annual bonus opportunity and an initial option grant for 300,512 shares of our common stock, or the Initial Option, as well as his eligibility to participate in our employee benefit plans generally. Dr. Fox’s Initial Option vests with respect to 25% of the shares subject thereto on the first anniversary of the vesting commencement date and 1/48th of the shares subject thereto each month thereafter, subject to Dr. Fox’s continued service to the Company on each applicable vesting date. In the event of a termination of his service relationship by the Company without “cause” (as defined in Dr. Fox’s offer letter) or Dr. Fox’s resignation from the Company for “good reason” (as defined in Dr. Fox’s offer letter), in either case subject to Dr. Fox’s execution of an effective release of claims in favor of the Company, Dr. Fox will be entitled to the following severance benefits: (i) a lump sum payment equal to nine months of his then-base salary; (ii) a pro-rated bonus based on Company and individual performance for the year of termination; (iii) up to nine months of COBRA reimbursements for Dr. Fox and his dependents; and (iv) accelerated vesting of the number of shares subject to

 

141


Table of Contents

the Initial Option equal to the lesser of (A) the remaining unvested shares underlying the Initial Option on the date of such termination or (B) 1/48th of the shares underlying the Initial Option multiplied by the number of completed months of service provided by Dr. Fox to the Company following the grant date and prior to such termination date. Notwithstanding the foregoing, in the event of a termination of Dr. Fox’s service relationship by the Company without cause or Dr. Fox’s resignation from the Company for good reason, in either case during the period commencing one month prior to a “change of control” (as defined in Dr. Fox’s offer letter) and ending 12 months following the change in control, subject to Dr. Fox’s execution of an effective release of claims in favor the Company, the lesser of (1) 150,256 of the unvested shares underlying the Initial Option or (2) the remaining unvested shares underlying the Initial Option, will vest and become exercisable as of the date of such termination. Dr. Fox is subject to our standard proprietary information and inventions agreement.

Uma Sinha

On June 1, 2016, we entered into an offer letter with Dr. Sinha, who currently serves as our Chief Scientific Officer. The offer letter provided for Dr. Sinha’s at-will employment and set forth her initial annual base salary and an initial stock grant, or the Initial Shares, as well as her eligibility to participate in our employee benefit plans generally. Dr. Sinha’s Initial Shares covered 114,194 shares of our common stock and were fully vested on the date of grant; however, the Company has a right of repurchase, at fair market value, any vested shares upon her termination of service relationship with the Company, which repurchase right lapses with respect to 25% of the shares on the first anniversary of the vesting commencement date and 1/48th of the shares each month thereafter, subject to Dr. Sinha’s continued service to the Company on each applicable vesting date. Dr. Sinha is subject to our standard proprietary information and inventions agreement.

In May 2018, we entered into an amendment to Dr. Sinha’s offer letter to provide her with certain severance benefits. This amendment provides that, in the event of a termination of her service relationship by the Company without “cause” (as defined in Dr. Sinha’s offer letter) or Dr. Sinha’s resignation from the Company for “good reason” (as defined in Dr. Sinha’s offer letter), within one (1) month before or twelve (12) months after a Change in Control (as defined in the 2016 Plan) in either case subject to Dr. Sinha’s execution of an effective release of claims in favor of the Company, Dr. Sinha will be entitled to the following severance benefits: (i) a lump sum payment equal to nine months of her then-base salary; (ii) an amount equal to her target bonus for the year in which her employment was terminated (pro-rated in the case of any partial year during which she was employed by the Company) and (iii) up to nine months of COBRA reimbursements for Dr. Sinha and her dependents. In the event of a termination of her service relationship by the Company without cause or Dr. Sinha’s resignation from the Company for good reason, other than in connection with a Change in Control in either case subject to Dr. Sinha’s execution of an effective release of claims in favor of the Company, Dr. Sinha will be entitled to the following severance benefits: (i) a lump sum payment equal to six months of her then-base salary; (ii) an amount equal to her target bonus for the year in which her employment was terminated (pro-rated in the case of any partial year during which she was employed by the Company) and (iii) up to six months of COBRA reimbursements for Dr. Sinha and her dependents.

 

142


Table of Contents

Outstanding equity awards at fiscal year end

The following table presents the outstanding equity awards held by each of our named executive officers as of December 31, 2017:

 

      Stock Awards(1)  
Name    Number of shares
or units of stock
that have not
vested (#)
    Market value
of shares or
units of stock
that have not
vested ($)(2)
 

Neil Kumar, Ph.D.

            

Jonathan C. Fox, M.D., Ph.D.

     219,125 (3)      1,264,184  
     221,264 (4)      1,276,528  

Uma Sinha, Ph.D.

            

 

 

 

(1)   Each equity award was granted pursuant to our 2016 Plan.

 

(2)   There was no public market for our common stock as of December 31, 2017. This column represents the value of the shares of restricted stock as of December 31, 2017, based on the fair value of our common stock as of December 31, 2017, which was $5.7692 per share.

 

(3)  

Dr. Fox was granted an option to purchase 300,512 shares of our common stock on November 2, 2016. The option was immediately exercisable on the date of grant. Dr. Fox has early exercised the entire option and the shares of restricted stock acquired by Dr. Fox from the early exercise of the option are subject to the Company’s right of repurchase upon his termination of service relationship with the Company, which lapses with respect to 25% of the shares on November 1, 2017 and 1/48th of the shares on each month thereafter, subject to Dr. Fox’s continuous service with the Company through each applicable date. The shares of restricted stock are subject to certain acceleration of vesting provisions, as set forth in Dr. Fox’s offer letter, as described in “Narrative to summary compensation table—Employment arrangements with our named executive officers—Arrangements in place during the fiscal year ended December 31, 2017 for named executive officers—Jonathan Fox.”

 

(4)  

Dr. Fox was granted an option to purchase 236,015 shares of our common stock on December 22, 2017. The option was immediately exercisable on the date of grant. Dr. Fox has early exercised the entire option and the shares of restricted stock acquired by Dr. Fox from the early exercise of the option are subject to the Company’s right of repurchase upon his termination of service relationship with the Company, which lapses with respect to 1/48th of the shares on the 7th of each month following September 7, 2017, subject to Dr. Fox’s continuous service with the Company through each applicable date.

Employee benefits and stock plans

2016 Equity incentive plan

The 2016 Plan was approved by our board of directors and our stockholders on March 31, 2016, amended in September 2017, December 2017, and amended and restated in May 2018. The 2016 Plan allowed for the grant of incentive stock options to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards to our employees, directors, and consultants, including employees and consultants of our affiliates, subject in each case to compliance with applicable tax laws.

Our 2018 Plan will become effective the day before the date that the registration statement of which this prospectus is part is declared effective by the SEC. As a result, we do not expect to grant any additional awards under the 2016 Plan following that date. Any awards granted under the 2016 Plan will remain subject to the terms of our 2016 Plan and applicable award agreements. As of December 31, 2017, options to purchase 846,166 shares of common stock and restricted stock grants for 203,880 shares of common stock were outstanding under the 2016 Plan.

Authorized shares.    The maximum number of shares of our common stock that may have been issued under our 2016 Plan was 2,583,696. The maximum number of shares of stock that may have been issued pursuant to the exercise of incentive stock options was three times such maximum number of shares. Shares subject to stock awards granted under our 2016 Plan that expire, are forfeited, are repurchased or otherwise terminate without all the shares covered by such stock awards having been issued, or are settled in cash, do not reduce

 

143


Table of Contents

the number of shares available for issuance under our 2018 Plan. Additionally, shares used to pay the exercise price or purchase price of a stock award or shares reacquired by us to satisfy the tax withholding obligations related to a stock award will return to the share reserve under our 2018 Plan. The shares issuable pursuant to stock awards granted under the 2016 Plan were authorized but unissued or reacquired shares, including shares repurchased by us on the open market or otherwise.

Plan administration.    Our board of directors or a duly authorized committee of our board of directors administers our 2016 Plan and the stock awards granted under it, and has the power to interpret and administer our 2016 Plan and any agreement thereunder and to determine the terms of awards, including the recipients, the number of shares subject to each award, the exercise, purchase or strike price, if any, the vesting schedule applicable to the awards together with any vesting acceleration and the terms of the award agreement for use under our 2016 Plan. Under the 2016 Plan, the board of directors also generally has the authority to effect, with the consent of any adversely affected participant, the reduction of the exercise price of any outstanding option or stock appreciation right, the cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of other awards, cash, or other consideration, or any other action that is treated as a repricing under generally accepted accounting principles.

Pursuant to the 2016 Plan and subject to applicable law, the plan administrator may have, in its discretion, delegated to one of more of our officers, the power to designate non-officer employees as recipients of options and/or stock appreciation rights and to determine the number of shares subject to such stock awards to be granted to such employees; provided, however, the plan administrator must have specified the total number of shares that may be subject to the stock awards granted by such officer and such officer may not have granted options to himself or herself. The board of directors could not delegate the authority to determine the fair market value of our common stock.

Corporate transactions.    Our 2016 Plan provides that in the event of and subject to the consummation of certain specified significant corporate transactions, generally including: (i) a sale of all or substantially all of our assets, (ii) the sale or disposition of at least 90% of our outstanding securities, (iii) the consummation of a merger or consolidation where we do not survive the transaction, and (iv) the consummation of a merger or consolidation where we do survive the transaction but the shares of common stock outstanding before such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award agreement all awards with time-based vesting, conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of such transaction shall automatically accelerate as of the effective time of the transaction, and all awards with performance-based conditions and restrictions may accelerate in connection with such transaction in the discretion of our board of directors or as specified in an award agreement. In the event of such transaction, the Company in its sole discretion may take one or more of the following actions with respect to such awards: (i) make a payment to the holder of options or stock appreciation rights, in exchange for the cancellation thereof, equal to the difference between the value, as determined by the board of directors, of the consideration payable per share of our common stock pursuant to such transaction, or the “sale price,” multiplied by the number of shares of common stock subject to such award, and the aggregate exercise price of such award; (ii) provide each grantee with an opportunity to exercise such option or stock appreciation right within a specified period of time prior to the consummation of the transaction; (iii) make a payment to holders of other awards equal to the sale price multiplied by the number of shares of common stock subject to such award; or (iv) arrange for the assumption, continuation, or substitution of such awards by the successor entity or parent thereof (taking into account the acceleration of such awards pursuant to the 2016 Plan). The plan administrator is not obligated to treat all stock awards, even those that are of the same type, or all participants, in the same manner. In the event of a change in control, awards granted under the 2016 Plan will not receive automatic acceleration of vesting and exercisability, although the board of directors may provide for this treatment in an award agreement. Under the 2016 Plan, a

 

144


Table of Contents

change in control is defined to include (1) the acquisition by any person of more than 50% of the combined voting power of our then outstanding stock, (2) a merger, consolidation, or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity), or (3) a sale, lease, exclusive license, or other disposition of all or substantially all of the assets to an entity that did not previously hold more than 50% of the voting power of our stock.

Transferability.    Under our 2016 Plan, the board of directors may have provided for limitations on the transferability of awards, in its sole discretion. Option awards are generally not transferable other than by will or the laws of descent and distribution, except as otherwise provided under our 2016 Plan.

Plan amendment or termination.    Our board of directors has the authority to amend, suspend, or terminate our 2016 Plan, although certain material amendments require the approval of our stockholders, and amendments that would impair the rights of any participant require the consent of that participant.

Our board of directors has determined not to make any further awards under the 2016 Plan following the completion of this offering.

2018 stock option and incentive plan

Our 2018 Plan, has been adopted by our board of directors and is approved by our stockholders and will become effective the day before the date that the registration statement of which this prospectus is part is declared effective by the SEC. The 2018 Plan will replace the 2016 Plan, as our board of directors is expected to determine not to make additional awards under the 2016 Plan following the completion of our initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The 2018 Plan will allow the compensation committee to make equity-based incentive awards to our officers, employees, directors and other key persons, including consultants.

Authorized shares.    We have initially reserved 598,000 shares of our common stock for the issuance of awards under the 2018 Plan. This number will be subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The shares we issue under the 2018 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated, other than by exercise, under the 2018 Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Plan. The maximum number of shares that may be issued as incentive stock options may not exceed 598,000. This number will be subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The value of all awards issued under the 2018 Plan and all other cash compensation paid by us to any non-employee director in any calendar year cannot exceed $1,250,000.

Administration.    The 2018 Plan will be administered by our compensation committee. Our compensation committee will have full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2018 Plan.

Eligibility.    Persons eligible to participate in the 2018 Plan will be those full or part-time employees, non-employee directors and consultants, as selected from time to time by our compensation committee in its discretion.

Options.    The 2018 Plan will permit the granting of both options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and options that do not so qualify. The option exercise

 

145


Table of Contents

price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of grant. The term of each option will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised.

Stock appreciation rights.    Our compensation committee will be able to award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price may not be less than 100% of the fair market value of our common stock on the date of grant. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised.

Restricted stock and restricted stock units.    Our compensation committee will be able to award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment or service relationship with us through a specified vesting period.

Unrestricted stock awards.    Our compensation committee will also be able to grant shares of common stock that are free from any restrictions under the 2018 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant.

Dividend equivalent rights.    Our compensation committee will be able to grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock.

Cash-based awards.    Our compensation committee will be able to grant cash bonuses under the 2018 Plan to participants, subject to the achievement of certain performance goals.

Sale event.    The 2018 Plan will provide that in the event of and subject to the consummation of a “sale event,” as defined in the 2018 Plan, except as may be otherwise provided in the relevant award agreement, all options and stock appreciation rights with time-based vesting, conditions or restrictions that are not exercisable immediately prior to the sale event will become fully exercisable as of the sale event, all other awards with time-based vesting, conditions or restrictions will become fully vested and nonforfeitable as of the sale event, and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with the sale event in the plan administrator’s discretion or to the extent specified in the relevant award agreement. In the event of such sale event, individuals holding options and stock appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent exercisable) prior to the sale event. In addition, in connection with the termination of the 2018 Plan upon a sale event, we may make or provide for a cash payment to participants holding vested and exercisable options and stock appreciation rights equal to the difference between the per share cash consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights. We may also make or provide for a payment, in cash or in kind, to grantees holding other awards in an amount equal to the per share cash consideration payable to stockholders in the sale event multiplied by the number of vested shares subject to such awards. Finally, an acquirer or successor entity may assume, continue or substitute for the outstanding awards under the 2018 Plan (taking into account the acceleration of such awards under the 2018 Plan).

Amendment.    Our board of directors will be able to amend or discontinue the 2018 Plan and our compensation committee will be able to amend or cancel outstanding awards for purposes of satisfying changes in law or any

 

146


Table of Contents

other lawful purpose, but no such action may adversely affect rights under an award without the holder’s consent. The compensation committee is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options or stock appreciation rights or effect the repricing of such awards through cancellation and re-grants. Certain amendments to the 2018 Plan will require the approval of our stockholders.

No awards may be granted under the 2018 Plan after the date that is 10 years from the date of stockholder approval of the 2018 Plan. No awards under the 2018 Plan have been made prior to the date hereof, however, in May 2018, we granted an option to purchase 83,720 shares of our common stock to Dr. Huh pursuant to our 2018 Plan, which grant will become effective upon completion of this offering. For more information, see “Certain relationships and related party transactions—Executive officer and director compensation—Option award to Dr. Huh.”

2018 employee stock purchase plan

Our 2018 Employee Stock Purchase Plan, or the 2018 ESPP, has been adopted by our board of directors and approved by our stockholders and will become effective the day before the date that the registration statement of which this prospectus is part is declared effective by the SEC. The 2018 ESPP initially reserves and authorizes the issuance of up to a total of 143,520 shares of common stock to participating employees. This number will be subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.

All employees whose customary employment is for more than 20 hours per week will be eligible to participate in the 2018 ESPP. Any employee who owns 5% or more of the total combined voting power or value of all classes of stock will not be eligible to purchase shares under the 2018 ESPP.

We will make one or more offerings, consisting of one or more purchase periods, each year to our employees to purchase shares under the 2018 ESPP. The first offering will begin on the effective date of the registration statement of which this prospectus is part and, unless otherwise determined by the administrator of the ESPP, will end on the following November 30th. Each eligible employee as of the effective date of the registration statement for the offering will be deemed to be a participant in the 2018 ESPP at that time and must authorize payroll deductions or other contributions by submitting an enrollment form by the deadline specified by the plan administrator. Subsequent offerings will usually begin every six months and will continue for six-month periods, referred to as offering periods. Each eligible employee may elect to participate in any subsequent offering by submitting an enrollment form at least 15 days before the relevant offering date.

Each employee who is a participant in the 2018 ESPP may purchase shares by authorizing contributions of up to 20% of his or her compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated contributions will be used to purchase shares on the last business day of the purchase period at a price equal to 85% of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period, whichever is lower, provided that no more than 2,392 shares of common stock (or a lesser number as established by the plan administrator in advance of the purchase period) may be purchased by any one employee during each purchase period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of common stock, valued at the start of the offering period, under the 2018 ESPP for each calendar year in which a purchase right is outstanding.

The accumulated contributions of any employee who is not a participant on the last day of a purchase period will be refunded. An employee’s rights under the 2018 ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason.

The 2018 ESPP may be terminated or amended by our board of directors at any time, but shall automatically terminate on the 10 year anniversary of this offering. An amendment that increases the number of shares of

 

147


Table of Contents

common stock that are authorized under the 2018 ESPP and certain other amendments will require the approval of our stockholders. The plan administrator may adopt subplans under the 2018 ESPP for employees of our non-U.S. subsidiaries who may participate in the 2018 ESPP and may permit such employees to participate in the 2018 ESPP on different terms, to the extent permitted by applicable law.

Senior executive cash incentive bonus plan

In May 2018, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan, which will govern the cash incentive bonuses for certain of our eligible executives, including our named executive officers. The Bonus Plan provides for bonus payments based upon the attainment of performance targets, or the Performance Goals, established by the compensation committee and related to operational and financial measures or objectives with respect to the company, as well as individual performance objectives.

The Performance Goals from which the compensation committee may select include the following: achievement of specified research and development, publication, clinical and/or regulatory milestones, total shareholder return, earnings before interest, taxes, depreciation and amortization, net income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of our common stock, economic value-added, funds from operations or similar measure, sales or revenue, acquisitions or strategic transactions, operating income (loss), cash flow (including, but not limited to, operating cash flow and free cash flow), return on capital, assets, equity, or investment, return on sales, gross or net profit levels, productivity, expense, margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per share of our common stock; bookings, new bookings or renewals; sales or market shares; number of customers, number of new customers or customer references; operating income and/or net annual recurring revenue, any of which may be (A) measured in absolute terms or compared to any incremental increase, (B) measured in terms of growth, (C) compared to another company or companies or to results of a peer group, (D) measured against the market as a whole and/or as compared to applicable market indices and/or (E) measured on a pre-tax or post-tax basis (if applicable).

Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The Performance Goals will be measured at the end of each performance period or such other appropriate time as the compensation committee determines; provided, that if the Performance Goal is dependent on financial metrics as reported in our financial reports for any particular period, such Performance Goals shall be measured after our financial reports have been published. No bonuses shall be paid under the Bonus Plan unless and until the compensation committee makes a determination with respect to the attainment of the performance targets relating to the Performance Goals for the applicable performance period. If the Performance Goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period but not later than 74 days after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion and to adjust bonuses (by increasing or decreasing the amount payable) based on an executive officer’s attainment of individual performance objectives.

401(k) plan and other benefits

BridgeBio Pharma, LLC maintains a tax-qualified retirement plan that provides our eligible U.S. employees with an opportunity to save for retirement on a tax-advantaged basis. Plan participants are able to defer eligible

 

148


Table of Contents

compensation subject to applicable annual Code limits. BridgeBio Pharma, LLC has the ability to make discretionary contributions to the 401(k) plan but has not done so to date. The 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan’s related trust intended to be tax exempt under Section 501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the participants until distributed from the 401(k) plan.

Director compensation

We did not pay any compensation or make any equity awards or non-equity awards to any of our non-employee directors during the fiscal year ended December 31, 2017. Directors may be reimbursed for travel, food, lodging and other expenses directly related to their activities as directors. Directors who also serve as employees receive no additional compensation for their service as directors. During the fiscal year ended December 31, 2017, Dr. Kumar received no additional compensation for his service as a director. See the section titled “Executive and director compensation” for more information about Dr. Kumar’s compensation for the fiscal year ended December 31, 2017. See the section titled “Certain relationships and related party transactions” for more information about Drs. Huh’s and Graef’s compensation for the fiscal year ended December 31, 2017.

Prior to this offering, we did not have a formal policy or plan to compensate our non-employee directors. Immediately prior to the completion of this offering, we intend to implement a formal policy, effective upon effectiveness of the registration statement of which this prospectus forms a part, pursuant to which our non-employee directors will be eligible to receive the following cash retainers and equity awards:

 

Annual Retainer for Board Membership

        

Annual service on the board of directors

   $ 35,000  

Additional Annual Retainer for Non-Executive Chairman of the Board of Directors

   $ 25,000  

Additional Annual Retainer for Committee Membership

  

Annual service as member of the audit committee (other than chair)

   $ 15,000  

Annual service as chair of the audit committee

   $ 7,500  

Annual service as member of the compensation committee (other than chair)

   $ 15,000  

Annual service as chair of the compensation committee

   $ 7,500  

Annual service as member of the nominating and corporate governance committee (other than chair)

   $ 15,000  

Annual service as chair of the nominating and corporate governance committee

   $ 7,500  

 

 

Our policy provides that, upon initial election to our board of directors, each non-employee director will be granted an option to purchase 43,056 shares of the Company’s common stock with an exercise price per share equal to the closing price of a share of the Company’s common stock on the date of grant and a term of ten years (the “Initial Grant”). In addition, on the date of each of our annual meetings of stockholders following the completion of this offering, each non-employee director who will continue as a member of our board of directors following such annual meeting will be granted an annual award of an option to purchase 21,528 shares of the Company’s common stock with an exercise price equal to the closing price of a share of the Company’s common stock on the date of grant and a term of ten years (the “Annual Grant”). The Initial Grant will vest in equal annual installments over three years, subject to continued service as a director through the applicable vesting dates. The Annual Grant will vest in full on the earlier of (i) the anniversary of the grant date or (ii) our next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Such awards are subject to full accelerated vesting upon a “sale event,” as defined in the 2018 Plan. The policy also provides that, pursuant to the 2018 Plan, the aggregate amount of compensation, including both equity compensation and cash compensation, paid to any non-employee director in a calendar year will not exceed $1,250,000 (or such other limit as may be set forth in the 2018 Plan or any similar provision of a successor plan).

Employee directors will receive no additional compensation for their service as a director.

 

149


Table of Contents

We will reimburse all reasonable out-of-pocket expenses incurred by our non-employee directors for their attendance at meetings of our board of directors or any committee thereof.

The following table provides certain information concerning compensation earned by our non-employee directors during the year ended December 31, 2017.

 

Name(1)    Fees earned
or paid in
cash ($)
    Stock
awards
($)(2)
     Option
awards
($)(2)
     All other
compensation
($)
   

Total

($)

 

Isabella Graef, M.D.

           (3)            $ 150,000 (3)(4)    $ 150,000  

Hoyoung Huh, M.D., Ph.D.

     (5)                           

 

 

 

(1)   Drs. Graef and Huh did not have any equity awards outstanding as of December 31, 2017.

 

(2)   In accordance with SEC rules, these columns reflect the aggregate grant date fair values of the stock awards and option awards, as applicable, granted during fiscal year ended December 31, 2017 computed in accordance with ASC 718. Such aggregate grant date fair values do not take into account any estimated forfeitures related to service-vesting conditions. Assumptions used in the calculation of these amounts are included in Note 12 to our audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the directors upon the exercise of the options, the lapse of our repurchase right on any shares of restricted stock or the sale of shares of our common stock underlying such awards.

 

(3)   Dr. Graef received a grant of 195,273 shares of common stock on December 22, 2017, as well as certain tax-gross up payments for such shares, in connection with her role as the Company’s founder and not for her service as a member of our board of directors, as discussed further in “Certain relationships and related party transactions.” Dr. Graef was a member of our board of directors from August 2013 to March 2018.

 

(4)   Pursuant to a consulting agreement by and between Dr. Graef and the Company, dated April 1, 2016, which has a term of four years, the Company will pay Dr. Graef an annual consulting fee up to $150,000 in exchange for consulting services provided by Dr. Graef in the field relating to novel stabilizers, mutant characterization, assay development, drug discovery and the use of relevant in vitro and in vivo models.

 

(5)   Dr. Huh did not receive any cash compensation from the Company for his services as a member of our board of directors.

 

150


Table of Contents

Certain relationships and related party transactions

In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers, including those discussed in the sections titled “Management” and “Executive and director compensation,” and the registration rights described in the section titled “Description of capital stock—Registration rights,” the following is a description of each transaction since January 1, 2015 and each currently proposed transaction in which:

 

 

we have been or are to be a participant;

 

 

the amounts involved exceeded or will exceed $120,000; and

 

 

any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.

Private placements of securities

Series Seed financing

From April 2016 through September 2017, we sold an aggregate of 12,856,325 shares of our Series Seed redeemable convertible preferred stock at a purchase price of $1.3248 per share for an aggregate purchase price of approximately $17.0 million.

All purchasers of our Series Seed redeemable convertible preferred stock are entitled to specified registration rights. See the section titled “Description of capital stock—Registration rights” for more information regarding these registration rights.

The following table summarizes the Series Seed redeemable convertible preferred stock purchased by members of our board of directors or their affiliates and holders of more than 5% of our outstanding capital stock.

 

Name of stockholder  

Shares of Series Seed

redeemable
convertible preferred
stock

    

Total

purchase price

 

BridgeBio Pharma LLC(1)

    12,832,123      $ 16,999,996.55  

 

 

 

(1)   Ali Satvat, a member of our board of directors, is a member of the board of managers of BridgeBio Pharma LLC and Neil Kumar, a member of our board of directors and our Chief Executive Officer, is the chief executive officer and a managing member of BridgeBio Pharma LLC and, therefore, each may be deemed to hold voting and dispositive power over the shares held by BridgeBio Pharma LLC.

Series B financing

In March 2018 and May 2018, we sold an aggregate of 5,906,877 shares of our Series B redeemable convertible preferred stock at a purchase price of $10.8348 per share for an aggregate purchase price of approximately $64.0 million.

All purchasers of our Series B redeemable convertible preferred stock are entitled to specified registration rights. See the section titled “Description of capital stock—Registration rights” for more information regarding these registration rights.

 

151


Table of Contents

The following table summarizes the Series B redeemable convertible preferred stock purchased by members of our board of directors or their affiliates and holders of more than 5% of our outstanding capital stock.

 

Name of stockholder    Shares of Series B redeemable
convertible preferred stock
     Total purchase price  

Aisling Capital IV, LP (1)

     553,770      $ 5,999,987.21  

BridgeBio Pharma LLC(2)

     1,384,426      $ 14,999,978.83  

Entities affiliated with RA Capital Healthcare Fund, L.P.(3)

    
922,950
 
   $ 9,999,979.68  

 

 

 

(1)   Eric Aguiar, a member of our board of directors, is a partner at Aisling Capital IV, LP. Dr. Aguiar does not hold voting or dispositive power over the shares held by Aisling Capital IV, LP.

 

(2)   Ali Satvat, a member of our board of directors, is a member of the board of managers of BridgeBio Pharma LLC and Neil Kumar, a member of our board of directors and our Chief Executive Officer, is the chief executive officer and a managing member of BridgeBio Pharma LLC and, therefore, each may be deemed to hold voting and dispositive power over the shares held by BridgeBio Pharma LLC.

 

(3)   Rajeev Shah, a member of our board of directors, is a portfolio manager and managing director of RA Capital Healthcare Fund, L.P.

Convertible note and warrant financing

In February 2018, we entered into a Note and Warrant Purchase Agreement with BridgeBio, pursuant to which we issued a convertible note in the principal amount of $10.0 million and a warrant to purchase a number of shares of preferred stock equal to $4.0 million at the price paid by investors in such next equity financing. In March 2018, BridgeBio transferred 10% of its interests in the convertible note and the warrant to another stockholder that currently holds less than 1% of our outstanding voting stock. Upon the initial closing of the Series B redeemable convertible preferred stock financing described above, the note then held by BridgeBio was converted into 1,192,341 shares of Series B redeemable convertible preferred stock at a price per share of $7.5844 representing a 30% discount to the price paid by other investors in the financing. The warrant held by BridgeBio has a term of three years and is exercisable for 332,262 shares of Series B redeemable convertible preferred stock at an exercise price of $10.8348 per share. If the warrant remains outstanding upon the consummation of this offering, the warrant will automatically be deemed net-exercised in full immediately prior to the completion of this offering based on the initial public offering price.

Agreements with stockholders

Investors’ rights agreement

On March 29, 2018, we entered into an Amended and Restated Investors’ Rights Agreement, which we refer to as our investors’ rights agreement, with certain holders of our outstanding redeemable convertible preferred stock, including entities with which certain of our directors are affiliated. After the completion of this offering, the holders of 24,216,811 shares of our common stock issuable in connection with the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into common stock, are entitled to rights with respect to the registration of their shares following this offering under the Securities Act. See the section titled “Description of capital stock—Registration rights” for more information regarding these registration rights.

Right of first refusal and co-sale agreement

We are a party to a right of first refusal and co-sale agreement, which imposes restrictions on the transfer of our capital stock. Upon the completion of this offering, the right of first refusal and co-sale agreement will terminate and the restrictions on the transfer of our capital stock set forth in this agreement will no longer apply.

 

152


Table of Contents

Voting agreement

We are party to a voting agreement under which certain holders of our capital stock, including persons who hold more than 5% of our outstanding capital stock and entities with which certain of our directors are affiliated, have agreed to vote their shares on certain matters, including with respect to the election of directors. Upon the completion of this offering, the voting agreement will terminate and none of our stockholders will have any special rights regarding the election or designation of members of our board of directors or the voting of our capital stock of the company.

Intercompany services agreements with BridgeBio Services Inc.

We have received consulting and management services pursuant to two Intercompany Services Agreements with BridgeBio Services Inc., or, collectively, the BridgeBio Agreements. BridgeBio Services Inc. is affiliated with BridgeBio Pharma LLC, which has a controlling interest in us. The initial BridgeBio Agreement was entered into on March 1, 2016 and was superseded by the subsequent BridgeBio Agreement, effective as of May 1, 2017. During the years ended December 31, 2016 and December 31, 2017, we incurred an aggregate of $160,843 and $769,972 for these services, respectively, which included, among other things, the services of Dr. Kumar, as well as other personnel, and the supervision of our strategic, financial, legal, personnel and executive recruitment activities. Dr. Kumar is the chief executive officer of BridgeBio Pharma LLC.

Indication of interest to participate in this offering

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The underwriters will receive the same discount from any shares sold to such entities as they will from any other shares sold to the public in this offering.

Executive officer and director compensation

See the section titled ‘‘Executive and director compensation’’ for information regarding compensation of our executive officers and directors.

Agreements with Dr. Graef

Consulting agreement

In April 2016, we entered into a consulting agreement with Dr. Graef, one of our founders and a holder of more than 5% of our outstanding capital stock. Dr. Graef also served as a member of our board of directors from August 2013 to March 2018. Pursuant to the consulting agreement, Dr. Graef agreed to provide consulting services with respect to discovery and development of novel TTR stabilizers. As compensation for these services, Dr. Graef is entitled to an annual fee in the amount of up to $150,000 and reimbursement by us for pre-approved expenses. The consulting agreement has a term of four years but may be terminated by either us or Dr. Graef for any reason with thirty days’ prior notice. During the years ended December 31, 2016 and December 31, 2017, we incurred $112,500 and $150,000, respectively, for her services under the consulting agreement.

 

153


Table of Contents

Issuance of antidilution shares

In December 2017, we issued to Dr. Graef 195,273 shares of our common stock in order to offset dilution to her ownership in connection with our issuance of additional shares of Series Seed Preferred Stock in financing transactions. In addition, we agreed to make a “gross-up” payment of $83,073 to Dr. Graef for the taxes owed by Dr. Graef as a result of such issuance of common stock, which payment was made in January 2018.

Agreements with Dr. Alhamadsheh

Consulting agreement

In August 2016, we entered into a consulting agreement with Dr. Alhamadsheh and his employer, the University of the Pacific, one of our founders and a holder of more than 5% of our outstanding capital stock. Pursuant to the consulting agreement, Dr. Alhamadsheh and the University of the Pacific agreed that Dr. Alhamadsheh would provide consulting services with respect to discovery and development of novel TTR stabilizers. As compensation for these services, Dr. Alhamadsheh is entitled to an annual fee in the amount of up to $115,000. The consulting agreement has a term of two years but may be terminated by either us or Dr. Alhamadsheh for any reason with thirty days’ prior notice. During the years ended December 31, 2016 and December 31, 2017, we incurred $83,748 and $115,000, respectively, for Dr. Alhamadsheh’s services under the consulting agreement.

Issuance of antidilution shares

In December 2017, we issued to Dr. Alhamadsheh 195,273 shares of our common stock in order to offset dilution to his ownership in connection with our issuance of additional shares of Series Seed Preferred Stock in financing transactions. In addition, we agreed to make a “gross-up” payment of $83,073 to Dr. Alhamadsheh for the taxes owed by Dr. Alhamadsheh as a result of such issuance of common stock, which payment was made in January 2018.

Option award to Dr. Huh

In May 2018, our board of directors approved a grant to Dr. Huh of an option to purchase 83,720 shares of our common stock pursuant to the 2018 Plan, to be effective upon the completion of this offering at an exercise price per share equal to our initial public offering price. The option will vest in equal annual installments over three years from the grant date, subject to Dr. Huh’s continued service as a director through the applicable vesting dates. The award is subject to full accelerated vesting upon a “sale event,” as defined in the 2018 Plan.

Indemnification agreements

We have entered into or plan to enter into indemnification agreements with each of our directors and executive officers, the form of which is attached as an exhibit to the registration statement of which this prospectus is a part. The indemnification agreements and our amended and restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.

Policies and procedures for related party transactions

Our audit committee will have the primary responsibility for reviewing and approving or disapproving “related party transactions,” which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. The written charter of our audit committee will provide that our audit committee shall review and approve in advance any related party transaction.

 

154


Table of Contents

Prior to the completion of this offering, we intend to adopt a formal written policy providing that we are not permitted to enter into any transaction that exceeds $120,000 and in which any related person has a direct or indirect material interest without the consent of our audit committee. In approving or rejecting any such transaction, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

 

155


Table of Contents

Principal stockholders

The following table presents information concerning the beneficial ownership of the shares of our common stock as of June 5, 2018 by:

 

 

each person we know to be the beneficial owner of 5% or more of our outstanding shares of our capital stock;

 

each of our directors;

 

each of our named executive officers; and

 

all of our current executive officers and directors as a group.

We have determined beneficial ownership in accordance with SEC rules. The information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, a person is deemed to be a beneficial owner of our common stock if that person has a right to acquire ownership within 60 days by the exercise of options or the conversion of our redeemable convertible preferred stock. A person is also deemed to be a beneficial owner of our common stock if that person has or shares voting power, which includes the power to vote or direct the voting of our common stock, or investment power, which includes the power to dispose of or to direct the disposition of such capital stock. Except in cases where community property laws apply or as indicated in the footnotes to this table, we believe that each stockholder identified in the table possesses sole voting and investment power over all shares of common stock shown as beneficially owned by the stockholder.

Percentage of beneficial ownership in the table below is based on 29,549,821 shares of common stock deemed to be outstanding as of June 5, 2018, assuming the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into common stock, immediately prior to the completion of this offering, the automatic net exercise immediately prior to the completion of this offering of warrants issued in February 2018 for an aggregate of 191,541 shares of redeemable convertible preferred stock at the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus and the subsequent conversion of such shares into an aggregate of 191,541 shares of common stock immediately prior to the completion of this offering. The table below assumes that the underwriters do not exercise their option to purchase additional shares. Shares of common stock subject to options that are currently exercisable or exercisable within 60 days of June 5, 2018 are considered outstanding and beneficially owned by the person holding the options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated below, the address of each individual listed below is c/o Eidos Therapeutics, Inc., 101 Montgomery Street, Suite 2550, San Francisco, CA 94104.

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The following table does not reflect any potential purchases by these potential purchasers. If any shares are purchased by our existing principal stockholders, directors or their affiliated entities, the number and percentage of shares of our common stock beneficially owned by them after this offering will differ from those set forth in the following table.

 

156


Table of Contents
Name and address of beneficial owner    Number of
shares
beneficially
owned before
offering
     Number of
shares
beneficially
owned after
offering
     Percentage
of shares
beneficially
owned before
offering
     Percentage of
shares
beneficially
owned  after
offering
 

5% or Greater Stockholders:

           

BridgeBio Pharma LLC(1)

     18,429,032        18,601,420        62.8%        52.0%  

Mamoun Alhamadsheh, Ph.D.(2)

     1,997,323        1,997,323        6.8        5.6  

Isabella Graef, M.D.(3)

     1,997,323        1,997,323        6.8        5.6  

Named Executive Officers and Directors:

           

Jonathan C. Fox, M.D., Ph.D.(4)

     536,527        536,527        1.8        1.5  

Neil Kumar, Ph.D.(1)(5)

     18,429,032        18,601,420        62.8        52.0  

Christine Siu(6)

     57,347        57,347        *        *  

Uma Sinha, Ph.D.(7)

     353,231        353,231        1.2        *  

Hoyoung Huh, M.D., Ph.D.(8)

                           

Rajeev Shah(9)

     1,103,847        1,103,847        3.8        3.1  

Eric Aguiar, M.D.(10)

                           

Ali Satvat(11)

     18,429,032        18,601,420        62.8        52.0  

All executive officers and directors as a group (8 persons)

     20,479,984        20,652,372        69.6%        57.6%  

 

 

 

*   Represents beneficial ownership of less than one percent.

 

(1)   Consists of (a) 15,347,219 shares of common stock issuable upon the conversion of Series Seed redeemable convertible preferred stock, (b) 3,081,813 shares of common stock issuable upon the conversion of Series B redeemable convertible preferred stock held directly by BridgeBio Pharma LLC, and (c) shares issued pursuant to the automatic net exercise immediately prior to the completion of this offering of warrants issued in February 2018 for an aggregate of 191,544 shares of our redeemable convertible preferred stock and the subsequent conversion of such shares into an aggregate of 191,544 shares of common stock immediately prior to the completion of this offering, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. Dr. Kumar, Ali Satvat, James Momtazee and Richard Scheller, the members of the board of managers of BridgeBio Pharma LLC, may be deemed to have shared voting and investment power over the shares held of record by BridgeBio Pharma LLC. Such persons disclaim beneficial ownership of all shares held by BridgeBio Pharma LLC except to the extent of any indirect pecuniary interests therein. The address of BridgeBio Pharma LLC is 421 Kipling St., Palo Alto, California 94301.

 

(2)   Consists of 1,997,323 shares of common stock, of which 195,273 shares are subject to our right of repurchase as of June 5, 2018, held by Dr. Alhamadsheh.

 

(3)   Consists of 1,997,323 shares of common stock, of which 195,273 shares are subject to our right of repurchase as of June 5, 2018, held by Dr. Graef.

 

(4)   Consists of 536,527 shares of common stock, of which 378,238 shares are subject to our right of repurchase as of June 5, 2018 held by the Fox Family Trust Dated 17 Dec. 2014, for which Jonathan C. Fox and Suzanne Markel-Fox serve as co-Trustees.

 

(5)   Dr. Kumar is the Chief Executive Officer of BridgeBio Pharma LLC. These shares are owned directly by BridgeBio Pharma LLC. Dr. Kumar, Ali Satvat, James Momtazee and Richard Scheller, the members of the board of managers of BridgeBio Pharma LLC, may be deemed to have shared voting and investment power over the shares held of record by BridgeBio Pharma LLC. Such persons disclaim beneficial ownership of all shares held by BridgeBio Pharma LLC except to the extent of any indirect pecuniary interests therein. The address of BridgeBio Pharma LLC is 421 Kipling St., Palo Alto, California 94301.

 

(6)   Consists of options to purchase 57,347 shares of common stock that are exercisable within 60 days of June 5, 2018, held by Ms. Siu.

 

(7)   Consists of 353,231 shares of common stock, of which 239,570 shares are subject to our right of repurchase as of June 5, 2018, held by Dr. Sinha.

 

(8)   Dr. Huh does not beneficially own any shares of common stock or hold any options to purchase shares of common stock that are exercisable within 60 days of June 5, 2018.

 

(9)   Consists of (a) 898,533 shares of common stock issuable upon conversion of preferred stock held by RA Capital Healthcare Fund, L.P. (“RA Capital”) and (b) 205,314 shares of common stock issuable upon conversion of preferred stock held by Blackwell Partners LLC — Series A (“Blackwell”). RA Capital Management, LLC (“RA Capital Management”) is the general partner of RA Capital and the investment manager to Blackwell. Investment decisions with respect to the shares held by RA Capital and Blackwell are made by a portfolio management team at RA Capital Management of which Rajeev Shah, a member of our board of directors, is a member. Mr. Shah disclaims beneficial ownership of all shares held by RA Capital and Blackwell, except to the extent of his pecuniary interest therein. The address for each of RA Capital, Blackwell, and RA Capital Management is c/o 20 Park Plaza, Suite 1200, Boston, MA 02116.

 

(10)   Dr. Aguiar does not beneficially own any shares of common stock or hold any options to purchase shares of common stock that are exercisable within 60 days of June 5, 2018.

 

(11)   Mr. Satvat is a member of the Board of Managers of BridgeBio Pharma LLC. These shares are owned directly by BridgeBio Pharma LLC. Dr. Kumar, Ali Satvat, James Momtazee and Richard Scheller, the members of the board of managers of BridgeBio Pharma LLC, may be deemed to have shared voting and investment power over the shares held of record by BridgeBio Pharma LLC. Such persons disclaim beneficial ownership of all shares held by BridgeBio Pharma LLC except to the extent of any indirect pecuniary interests therein. The address of BridgeBio Pharma LLC is 421 Kipling St., Palo Alto, California 94301.

 

157


Table of Contents

Description of capital stock

Upon the completion of this offering, our authorized capital stock will consist of 150,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share, all of which will be undesignated, and there will be 35,799,821 shares of common stock outstanding and no shares of preferred stock outstanding. As of March 31, 2018, we had approximately 26 record holders of our capital stock. All of our outstanding shares of redeemable convertible preferred stock will convert into shares of our common stock immediately prior to the completion of this offering. In addition, upon the completion of this offering, 857,690 options to purchase shares of our common stock will be outstanding and 514,280 shares of our common stock will be reserved for future grants under our equity incentive plans after taking into account an option to purchase 83,720 shares of our common stock pursuant to the 2018 Plan which was granted to Dr. Huh in May 2018 and which will become effective upon completion of this offering. See “Certain relationships and related party transactions—Executive officer and director compensation—Option award to Dr. Huh” for more information.

The following description of our capital stock and provisions of our amended and restated certificate of incorporation and bylaws are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of incorporation and bylaws, copies of which have been filed with the SEC as exhibits to the registration statement of which this prospectus is a part. The descriptions of our common stock and preferred stock reflect amendments to our amended and restated certificate of incorporation and bylaws that will become effective immediately prior to the completion of this offering.

Common stock

Upon the completion of this offering, we will be authorized to issue one class of common stock. Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote of stockholders. Except as described under “Anti-takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Bylaws” below, a majority vote of the holders of common stock is generally required to take action under our amended and restated certificate of incorporation and bylaws. Holders of our common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available funds, subject to any preferential dividend rights of any preferred stock then outstanding. Upon our dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in our net assets legally available after the payment of all our debts and other liabilities, subject to the preferential rights of any preferred stock then outstanding. Holders of our common stock have no preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to our common stock. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Preferred stock

Upon the completion of this offering, our board of directors will be authorized, without action by the stockholders, to designate and issue up to an aggregate of 5,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting the voting power of our common stock,

 

158


Table of Contents

impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of our company, which might harm the market price of our common stock. See also “—Anti-takeover effects of Delaware Law and provisions of our amended and restated certificate of incorporation and bylaws—Provisions of our amended and restated certificate of incorporation and bylaws—Undesignated preferred stock” below.

Our board of directors will make any determination to issue such shares based on its judgment as to our company’s best interests and the best interests of our stockholders. Upon the completion of this offering, we will have no shares of preferred stock outstanding and we have no current plans to issue any shares of preferred stock following completion of this offering.

Options

As of March 31, 2018, we had outstanding options to purchase 560,128 shares of our common stock, with a per share weighted-average exercise price of $0.91 under our 2016 Plan.

Registration rights

Upon the completion of this offering, the holders of 24,216,811 shares of our common stock, including shares issuable upon the automatic net exercise of warrants issued in February 2018 for shares of our redeemable convertible preferred stock, based on the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and the subsequent conversion of such shares into common stock, and shares issuable upon the conversion of our outstanding redeemable convertible preferred stock, or their permitted transferees, which we refer to as our registrable securities, are entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the investor rights agreement. The investor rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses incurred in connection with registrations under the investor rights agreement will be borne by us, and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.

Demand registration rights

Upon the completion of this offering, the holders of our registrable securities are entitled to demand registration rights. Under the terms of our investor rights agreement, we will be required, upon the request of holders of at least a majority of our outstanding registrable securities, to file a registration statement with an anticipated offering amount of at least $10.0 million and use commercially reasonable efforts to effect the registration of these shares for public resale. We are required to effect up to two registrations pursuant to this provision of the investor rights agreement. A demand for registration may not be made until six months after the effective date of the registration statement for this offering.

Short form registration rights

Upon the completion of this offering, the holders of our registrable securities are also entitled to short form registration rights. Pursuant to our investor rights agreement, if we are eligible to file a registration statement on Form S-3, upon the request of holders of at least 30% of our outstanding registrable securities to sell registrable securities with an anticipated aggregate offering amount of at least $1.0 million net of certain expenses related to the offering, we will be required to use our commercially reasonable efforts to effect a registration of such shares. We are required to effect up to two registrations in any twelve month period pursuant to this provision of the investor rights agreement.

 

159


Table of Contents

Piggyback registration rights

The holders of our registrable securities are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of our outstanding registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the investor rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering if the underwriters determine that marketing factors require a limitation of the number of shares to be underwritten.

Indemnification

Our investor rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.

Expenses of registration

We will pay the registration expenses, subject to certain limited exceptions contained in the investor rights agreement, of the holders of the shares registered pursuant to the demand, short form and piggyback registration rights described above, including the expenses of one counsel for the selling holders.

Expiration of registration rights

The registration rights granted under the investor rights agreement will terminate upon the earlier of (i) a deemed liquidation event, as defined in our amended and restated certificate of incorporation (as in effect prior to the completion of this offering) or certain other events constituting a sale of the company, (ii) the consummation of a transaction or series of transactions in which a person, or a group of persons, acquires from our stockholders, shares representing more than 50% of our outstanding voting stock, (iii) at such time after our initial public offering when all registrable securities could be sold under Rule 144 of the Securities Act or a similar exemption without limitation during a three-month period without registration or (iv) the fifth anniversary of our initial public offering.

Anti-takeover effects of Delaware Law and provisions of our amended and restated certificate of incorporation and bylaws

Certain provisions of the Delaware General Corporation Law and of our amended and restated certificate of incorporation and bylaws that will become effective upon the completion of this offering could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms.

 

160


Table of Contents

Delaware takeover statute

Upon completion of this offering, we will be subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:

 

 

before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 

 

upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or

 

 

at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

Section 203 defines a business combination to include:

 

 

any merger or consolidation involving the corporation and the interested stockholder;

 

 

any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

 

 

subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

 

subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

 

 

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

Provisions of our amended and restated certificate of incorporation and bylaws

Our amended and restated certificate of incorporation and bylaws to be in effect upon completion of this offering will include a number of provisions that may have the effect of delaying, deferring or discouraging another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.

 

161


Table of Contents

Board composition and filling vacancies.    Our amended and restated certificate of incorporation provides that directors may be removed only by the affirmative vote of the holders of a majority of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum or by the holders of a majority of the outstanding shares of capital stock then entitled to vote at an election of directors.

Meetings of stockholders.    Our bylaws provide that either a majority of the members of our board of directors then in office or the holders of at least 25% of the voting power of our common stock may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.

Advance notice requirements.    Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days or more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. The notice must contain certain information specified in our bylaws.

Amendment to certificate of incorporation and bylaws.    As required by the Delaware General Corporation Law, any amendment of our amended and restated certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority vote of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class.

Undesignated preferred stock.    Our amended and restated certificate of incorporation provides for authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors’ broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.

Transfer agent and registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent and registrar’s address is 6201 15th Avenue, Brooklyn, New York 11219.

 

162


Table of Contents

Listing

We have applied to list our common stock on The Nasdaq Global Market under the symbol “EIDX.”

Limitations of liability and indemnification matters

For a discussion of liability and indemnification, see “Management—Limitation on liability and indemnification matters.”

 

163


Table of Contents

Shares eligible for future sale

Prior to this offering, there has been no public market for our common stock. Future sales of our common stock in the public market, or the availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to raise equity capital in the future.

Sale of restricted shares

Based on the number of shares of common stock outstanding as of March 31, 2018, upon completion of this offering, 35,799,821 shares of common stock will be outstanding, assuming no exercise by the underwriters of their option to purchase additional shares and no exercise of options. All of the shares sold in this offering will be freely tradable, except for shares purchased in this offering by certain of our principal stockholders, including stockholders affiliated with certain of our directors, and shares purchased in this offering by participants in our directed share program, who have signed lock-up agreements or are otherwise restricted from reselling such shares by Rule 144 of the Securities Act. The remaining shares of common stock outstanding after this offering will be restricted as a result of securities laws or lock-up agreements as described below. Following the expiration of the lock-up period, all shares will be eligible for resale in compliance with Rule 144 or Rule 701 under the Securities Act. “Restricted securities” as defined under Rule 144 of the Securities Act were issued and sold by us in reliance on exemptions from the registration requirements of the Securities Act. These shares may be sold in the public market only if registered or qualified for an exemption from registration, such as under Rule 144 or Rule 701 under the Securities Act.

Rule 144

In general, a person who has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following:

 

 

1% of the number of shares then outstanding, which will equal approximately 357,998 shares immediately after this offering assuming no exercise of the underwriters’ option to purchase additional shares, based on the number of shares outstanding as of March 31, 2018; or

 

 

the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale;

provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by non-affiliates must also comply with the manner of sale, current public information and notice provisions of Rule 144.

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers

 

164


Table of Contents

in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities.

Rule 701

Rule 701 under the Securities Act, or Rule 701, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to lock-up agreements as described below and under “Underwriting” included elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements.

Lock-up agreements

In connection with this offering, we, each of our directors and executive officers, and holders of approximately 29,358,280 shares of our outstanding stock have agreed with the underwriters that for a period of 180 days following the date of this prospectus, subject to certain exceptions, we will not offer, sell, assign, transfer, pledge, contract to sell or otherwise dispose of or hedge any shares of our common stock or any securities convertible into or exchangeable for shares of our common stock. J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated may, in their sole discretion, at any time, release all or any portion of the shares from the restrictions in this agreement.

Rule 10b5-1 trading plans

Following the completion of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as Rule 10b5-1 trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these 10b5-1 trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director or stockholder. Such sales would not commence until the expiration of the applicable lock-up agreements entered into by such officer, director or stockholder in connection with this offering.

Registration rights

We are party to an investor rights agreement which provides that holders holding 24,216,811 shares of our common stock, including shares issuable upon the exercise of warrants issued in February 2018 for shares of our redeemable convertible preferred stock and shares issuable upon the conversion of our redeemable convertible preferred stock, have the right to demand that we file a registration statement or request that their shares of our common stock be covered by a registration statement that we are otherwise filing. See “Description of capital stock—Registration rights” in this prospectus. Except for shares purchased by affiliates, registration of their shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon effectiveness of the registration, subject to the expiration of the lock-up period described above and under “Underwriting” in this prospectus, and to the extent such shares have been released from any repurchase option that we may hold.

 

165


Table of Contents

Equity incentive plans

As soon as practicable after the completion of this offering, we intend to file a Form S-8 registration statement under the Securities Act to register shares of our common stock subject to options and other equity awards outstanding or reserved for issuance under our equity incentive plans. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will thereupon be eligible for sale in the public markets, subject to Rule 144 limitations applicable to affiliates and any lock-up agreements. For a more complete discussion of our equity incentive plans, see “Executive and director compensation—Employee benefits and stock plans.”

 

166


Table of Contents

Material U.S. federal income tax considerations to non-U.S. holders

The following is a general discussion of certain material U.S. federal income tax considerations relating to ownership and disposition of our common stock by a non-U.S. holder. For purposes of this discussion, the term “non-U.S. holder” means a beneficial owner of our common stock that is not, for U.S. federal income tax purposes:

 

 

an individual who is a citizen or resident of the United States;

 

 

a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or of any political subdivision of the United States;

 

 

an estate the income of which is subject to U.S. federal income taxation regardless of its source; or

 

 

a trust, if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (as defined in the Code) have authority to control all substantial decisions of the trust or if the trust has a valid election in effect to be treated as a U.S. person under applicable U.S. Treasury Regulations.

A modified definition of “non-U.S. holder” applies for U.S. federal estate tax purposes (as discussed below).

This discussion is based on current provisions of the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change could alter the tax consequences to non-U.S. holders described in this prospectus. In addition, the Internal Revenue Service, or the IRS, could challenge one or more of the tax consequences described in this prospectus.

We assume in this discussion that each non-U.S. holder holds shares of our common stock as a capital asset (generally, property held for investment) within the meaning of Section 1221 of the Code. This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder’s individual circumstances nor does it address any aspects of state, local or non-U.S. taxes, alternative minimum tax, or U.S. federal gift or estate taxes (except to the limited extent set forth below) or any other U.S. federal tax laws. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:

 

 

banks;

 

 

financial institutions;

 

 

insurance companies;

 

 

brokers, dealers or traders in securities, commodities or currencies;

 

 

persons who have elected to mark securities to market;

 

 

tax-qualified retirement plans;

 

 

tax-exempt organizations;

 

 

government entities;

 

 

controlled foreign corporations;

 

167


Table of Contents
 

passive foreign investment companies;

 

 

corporations that accumulate earnings to avoid U.S. federal income tax;

 

 

certain former U.S. citizens or long-term residents;

 

 

holders who hold or receive our common stock pursuant to the exercise of employee stock options or otherwise as compensation;

 

 

holders holding our common stock as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment; or

 

 

holders deemed to sell our common stock under the constructive sale provisions of the Code.

In addition, this discussion does not address the tax treatment of partnerships (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) or other entities that are transparent for U.S. federal income tax purposes or persons who hold their common stock through partnerships or other entities that are transparent for U.S. federal income tax purposes. In the case of a holder that is classified as a partnership for U.S. federal income tax purposes, the tax treatment of a person treated as a partner in such partnership for U.S. federal income tax purposes generally will depend on the status of the partner and the activities of the partner and the partnership. A person treated as a partner in a partnership or who holds their stock through another transparent entity should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other transparent entity, as applicable.

Prospective investors should consult their own tax advisors regarding the U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding and disposing of our common stock.

Distributions on our common stock

We do not currently expect to pay dividends. See “Dividend policy” above in this prospectus. However, in the event that we do pay distributions of cash or property on our common stock, those distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder’s investment, up to such holder’s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below under the heading “Gain on sale, exchange or other taxable disposition of common stock.”

Subject also to the discussions below under the headings “Information reporting and backup withholding tax” and “Foreign Account Tax Compliance Act,” dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder’s country of residence. If we determine, at a time reasonably close to the date of payment of a distribution on our common stock, that the distribution will not constitute a dividend because we do not anticipate having current or accumulated earnings and profits, we intend not to withhold any U.S. federal income tax on the distribution as permitted by U.S. Treasury Regulations. If we or another withholding agent apply over-withholding, a non-U.S. holder may be entitled to a refund or credit of any excess tax withheld by timely filing an appropriate claim with the IRS.

Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States, and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are

 

168


Table of Contents

generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. To obtain this exemption, a non-U.S. holder must generally provide us with a properly executed original and unexpired IRS Form W-8ECI properly certifying such exemption. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional “branch profits tax” at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder’s country of residence.

A non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder’s country of residence generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or applicable successor form) and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their own tax advisors regarding their entitlement to benefits under a relevant income tax treaty.

A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS.

Any documentation provided to an applicable withholding agent may need to be updated in certain circumstances. The certification requirements described above also may require a non-U.S. holder to provide its U.S. taxpayer identification number.

Gain on sale, exchange or other taxable disposition of common stock

Subject to the discussions below under the headings “Information reporting and backup withholding tax” and “Foreign Account Tax Compliance Act,” a non-U.S. holder generally will not be subject to U.S. federal income tax or withholding tax on gain recognized on a sale, exchange or other taxable disposition of our common stock unless:

 

 

the gain is effectively connected with the non-U.S. holder’s conduct of a trade or business in the United States, and, if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and, if the non-U.S. holder is a foreign corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income tax treaty, may also apply;

 

 

the non-U.S. holder is an individual present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the amount by which the non-U.S. holder’s capital gains allocable to U.S. sources exceed capital losses allocable to U.S. sources during the taxable year of the disposition (without taking into account any capital loss carryovers); or

 

 

we are or were a “U.S. real property holding corporation” during a certain look-back period, unless our common stock is regularly traded on an established securities market and the non-U.S. holder held no more than five percent of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. Generally, a corporation is a “U.S. real property holding corporation” if the fair market value of its “U.S. real property interests” equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we have not been and are not currently, and we do not anticipate becoming, a “U.S. real property holding corporation” for U.S. federal income tax purposes.

 

169


Table of Contents

Information reporting and backup withholding tax

We (or the applicable paying agent) must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN or W-8BEN-E or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or otherwise establishes an exemption.

Information reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a foreign broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.

Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is formed under the provisions of a specific treaty or agreement. Any documentation provided to an applicable withholding agent may need to be updated in certain circumstances.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder may be refunded or credited against the non-U.S. holder’s U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.

Foreign Account Tax Compliance Act

Legislation commonly referred to as the Foreign Account Tax Compliance Act and associated guidance, or collectively, FATCA, will generally impose a 30% withholding tax on any “withholdable payment” (as defined below) to a “foreign financial institution,” unless such institution enters into an agreement with the U.S. government to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which would include certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with United States owners) or another applicable exception applies or such institution is compliant with applicable foreign law enacted in connection with an applicable intergovernmental agreement between the United States and a foreign jurisdiction. FATCA will also generally impose a 30% withholding tax on any “withholdable payment” (as defined below) to a foreign entity that is not a financial institution, unless such entity provides the withholding agent with a certification identifying the substantial U.S. owners of the entity (which generally includes any U.S. person who directly or indirectly owns more than 10% of the entity), if any, or another applicable exception applies or such entity is compliant with applicable foreign law enacted in connection with an applicable intergovernmental agreement between the United States and such foreign jurisdiction. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes.

Under final regulations and other current guidance, “withholdable payments” currently include dividends on our common stock and will include the gross proceeds of a disposition of our common stock on or after January 1, 2019. The FATCA withholding tax will apply regardless of whether a payment would otherwise be exempt from or not subject to U.S. nonresident withholding tax (e.g., as capital gain).

 

170


Table of Contents

Federal estate tax

Common stock owned or treated as owned by an individual who is a non-U.S. holder (as specially defined for U.S. federal estate tax purposes) at the time of death will be included in the individual’s gross estate for U.S. federal estate tax purposes and, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise.

The preceding discussion of material U.S. federal tax considerations is for general information only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed changes in applicable laws.

 

171


Table of Contents

Underwriting

We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as representatives of the underwriters in the offering. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:

 

Name    Number
of shares
 

J.P. Morgan Securities LLC

  

Merrill Lynch, Pierce, Fenner & Smith

                     Incorporated

  

Barclays Capital Inc.

  
  

 

 

 

Total

     6,250,000  

 

 

The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated.

The underwriters propose to offer the common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $         per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $         per share from the initial public offering price. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of shares made outside of the United States may be made by affiliates of the underwriters.

Certain of our principal stockholders, including stockholders affiliated with certain of our directors, have indicated an interest in purchasing an aggregate of up to approximately $50.0 million in shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. However, because these indications of interest are not binding agreements or commitments to purchase, such entities may elect to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. In addition, the underwriters may elect to sell fewer shares or not to sell any shares in this offering to such entities. The underwriters will receive the same discount from any shares sold to such entities as they will from any other shares sold to the public in this offering.

The underwriters have an option to buy up to 937,500 additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.

At our request, the underwriters have reserved for sale, at the initial public offering price, up to 2.0% of the shares offered hereby for employees, directors and other persons associated with us who have expressed an interest in purchasing common stock in the offering. Our officers and directors who are participating in this

 

172


Table of Contents

program have agreed that any shares purchased through this program will be subject to a 180-day lock-up restriction. The number of shares available for sale to the general public in the offering will be reduced to the extent these persons purchase the reserved shares. Any reserved shares not so purchased will be offered by the underwriters to the general public on the same terms as the other shares.

The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $         per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares.

 

      Without
option to
purchase
additional
shares
exercise
     With full
option to
purchase
additional
shares
exercise
 

Per Share

   $                       $                   

Total

   $      $  

 

 

We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $2.8 million. We have agreed to reimburse the underwriters for expenses relating to the clearance of this offering with the Financial Industry Regulatory Authority, Inc. in an amount up to $40,000.

A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations.

We have agreed that we will not (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii) enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated for a period of 180 days after the date of this prospectus, subject to certain exceptions.

Our directors and executive officers, and substantially all of our securityholders have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 180 days after the date of this prospectus, or the restricted period, may not, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such directors,

 

173


Table of Contents

executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of common stock or such other securities, in cash or otherwise, or (3) make any demand for or exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock.

The restrictions described in the immediately preceding paragraph do not apply to, among other items:

 

  (i)   the sale of shares to the underwriters;

 

  (ii)   transfers of shares of common stock as a bona fide gift or gifts or through will or intestacy, or to an immediate family member or trust or entity beneficially owned and controlled by the securityholder or for the benefit of the securityholder or any immediate family member of the securityholder for bona fide estate planning purposes in a transaction not involving a disposition for value;

 

  (iii)   if the securityholder is (i) an entity, transfers of shares of Common Stock or any security directly or indirectly convertible into Common Stock to its members, stockholders, limited partners, subsidiaries or affiliates of the securityholder or to any investment fund or other entity that controls or manages the securityholder in a transaction not involving a disposition for value or (ii) a trust, distributions of shares of Common Stock or any security directly or indirectly convertible into Common Stock to its beneficiaries in a transaction not involving a disposition for value;

 

  (iv)   transfers of the securities following the consummation of this offering pursuant to a bona fide third-party tender offer, merger, consolidation, spin-off or other similar transaction that is approved by our board of directors and made to all holders of our capital stock involving a Change of Control (as defined in the lockup agreement) of the Company; the exercise of options granted or the vesting of any restricted securities pursuant to any of our equity incentive or benefit plans or agreements described in this prospectus, or the Incentive Arrangements, and the delivery of securities to us for cancellation (or the withholding and cancellation of securities by us) as payment for (i) the exercise price of any options granted under the Incentive Arrangements or (ii) the withholding taxes due upon the exercise of any such option or the vesting of any restricted securities granted under any Incentive Arrangements, with any securities received as contemplated by any transaction described in this clause remaining subject to the terms of the lock-up agreement; provided that, no filing under the Exchange Act shall be made in connection with such transfer or distribution unless such filing or report includes a statement to the effect that such transfer is being made in connection with a “net” or “cashless” exercise or settlement of stock options, restricted stock units or other equity awards;

 

  (v)   dispositions to us in exercise of our right to purchase or acquire the securities pursuant to the our equity incentive plans, restricted stock agreements and option agreements described in this prospectus that grant us the right to purchase or acquire such securities;

 

  (vi)   transfers of any securities acquired on the open market after the completion of this offering;

 

  (vii)   the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of securities, provided that (i) such plan does not provide for the transfer of securities during the restricted period and (ii) no public announcement or filing under the Exchange Act is required of or voluntarily made by or on behalf of the securityholder regarding the establishment of such plan;

 

174


Table of Contents
  (viii)   pursuant to a domestic order or divorce settlement in a transaction not involving a disposition for value, provided that any filing made pursuant to the Exchange Act shall include a footnote noting the circumstances described in this clause;

 

  (ix)   the exercise (whether for cash, cashless or net exercise) of warrants to purchase shares of common stock (or any security convertible into or exercisable for common stock) outstanding as of the date of this prospectus or described in this prospectus excluding any manner of exercise that would involve a sale in the open market of any securities relating to such warrants, whether to cover the aggregate exercise price, withholding tax obligations or otherwise; provided, that the underlying shares shall continue to be subject to the lock up agreement; or

 

  (x)   the conversion of our outstanding redeemable convertible preferred stock into shares of common stock, that the common stock received upon such conversion shall be subject to the lock-up agreement.

provided that, in the case of any transfer or distribution pursuant to clause (ii), (iii) or (viii), each donee or distributee shall execute a lock-up agreement and in the case of any transfer or distribution pursuant to clause (ii), (iii), (v), (vi) and (ix), no filing by any party under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the restricted period).

J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in their sole discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time with or without notice, provided that, when and as required by FINRA Rule 5131, at least two business days before the release or waiver of any applicable lock-up, J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated will notify us of the impending release or waiver and announce the impending release or waiver through a major news service, except where the release or waiver is effected solely to permit a transfer of securities that is not for consideration and where the transferee has agreed in writing to be bound by the same lock-up agreement terms in place for the transferor.

J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, in their sole discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time.

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act.

We have applied to have our common stock approved for listing/quotation on The Nasdaq Global Market under the symbol “EIDX.”

In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be “covered” shorts, which are short positions in an amount not greater than the underwriters’ option to purchase additional shares referred to above, or may be “naked” shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in

 

175


Table of Contents

the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position.

The underwriters have advised us that, pursuant to Regulation M of the Securities Act they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them.

These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on The Nasdaq Global Market, in the over-the-counter market or otherwise.

Prior to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including:

 

 

the information set forth in this prospectus and otherwise available to the representatives;

 

 

our prospects and the history and prospects for the industry in which we compete;

 

 

an assessment of our management;

 

 

our prospects for future earnings;

 

 

the general condition of the securities markets at the time of this offering;

 

 

the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and

 

 

other factors deemed relevant by the underwriters and us.

Neither we nor the underwriters can assure investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the initial public offering price.

Other relationships

Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.

 

176


Table of Contents

Selling restrictions

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

Notice to prospective investors in the European economic area

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, or a Relevant Member State, with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, no offer of shares may be made to the public in that Relevant Member State other than:

 

  a)   to any legal entity which is a qualified investor as defined in the Prospectus Directive;

 

  b)   to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or

 

  c)   in any other circumstances falling within Article 3(2) of the Prospectus Directive,

provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that it is a “qualified investor” within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive.

In the case of any shares being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale.

For the purposes of this provision, the expression an “offer of shares to the public” in relation to any shares in any Relevant Member State means the communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression “Prospectus Directive” means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State.

 

177


Table of Contents

Notice to prospective investors in the United Kingdom

In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are “qualified investors” (as defined in the Prospectus Directive) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000.

Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.

Notice to prospective investors in Canada

The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

Notice to prospective investors in Switzerland

The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this document nor any other offering or marketing material relating to the offering, the Company or the shares has been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss

 

178


Table of Contents

Federal Act on Collective Investment Schemes (“CISA”). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.

Notice to prospective investors in the Dubai International Financial Centre (“DIFC”)

This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai Financial Services Authority (“DFSA”). This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document. The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document you should consult an authorized financial advisor.

In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.

Notice to prospective investors in the United Arab Emirates

The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority.

Notice to prospective investors in Australia

This prospectus:

 

 

does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the “Corporations Act”);

 

 

has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document under Chapter 6D.2 of the Corporations Act;

 

 

does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or invitation to arrange the issue or sale, or an issue or sale, of interests to a “retail client” (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and

 

 

may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, or Exempt Investors, available under section 708 of the Corporations Act.

The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to

 

179


Table of Contents

investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor.

As any offer of shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.

Notice to prospective investors in Japan

The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any “resident” of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time.

Notice to prospective investors in Hong Kong

The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the Securities and Futures Ordinance and any rules made under that Ordinance.

Notice to prospective investors in Singapore

This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

 

180


Table of Contents

Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

 

  a)   a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

 

  b)   a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except:

 

  a)   to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;

 

  b)   where no consideration is or will be given for the transfer;

 

  c)   where the transfer is by operation of law;

 

  d)   as specified in Section 276(7) of the SFA; or

 

  e)   as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

Notice to prospective investors in Bermuda

Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.

Notice to prospective investors in Saudi Arabia

This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number 2-11-2004 dated 4 October 2004 as amended by resolution number 1-28-2008, as amended, or the CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorised financial adviser.

Notice to prospective investors in the British Virgin Islands

The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of the Company. The Company may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. This prospectus has not been, and will not be, registered with the Financial Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the shares for the purposes of the Securities and Investment Business Act, 2010, or SIBA, or the Public Issuers Code of the British Virgin Islands.

 

181


Table of Contents

Notice to prospective investors in China

This prospectus does not constitute a public offer of shares, whether by sale or subscription, in the People’s Republic of China, or the PRC. The shares are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC.

Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the shares or any beneficial interest therein without obtaining all prior PRC’s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

Notice to prospective investors in Korea

The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or the FETL. Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea.

Notice to prospective investors in Malaysia

No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with the Securities Commission of Malaysia, or the Commission, for the Commission’s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i) a closed end fund approved by the Commission; (ii) a holder of a Capital Markets Services Licence; (iii) a person who acquires the shares, as principal, if the offer is on terms that the shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv) an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3 million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v) an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi) an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii) a corporation with total net assets exceeding RM10 million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii) a partnership with total net assets exceeding RM10 million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi) any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i) to (xi), the distribution of the shares is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the

 

182


Table of Contents

purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007.

Notice to prospective investors in Taiwan

The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan.

Notice to prospective investors in South Africa

Due to restrictions under the securities laws of South Africa, the shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies:

 

a)   the offer, transfer, sale, renunciation or delivery is to:

 

  i)   persons whose ordinary business is to deal in securities, as principal or agent;

 

  ii)   the South African Public Investment Corporation;

 

  iii)   persons or entities regulated by the Reserve Bank of South Africa;

 

  iv)   authorised financial service providers under South African law;

 

  v)   financial institutions recognised as such under South African law;

 

  vi)   a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund or collective investment scheme (in each case duly registered as such under South African law); or

 

  vii)   any combination of the person in (a) to (f); or

 

b)   the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000.

No “offer to the public” (as such term is defined in the South African Companies Act, No. 71 of 2008 (as amended or re-enacted), or the South African Companies Act) in South Africa is being made in connection with the issue of the shares. Accordingly, this document does not, nor is it intended to, constitute a “registered prospectus” (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. Any issue or offering of the shares in South Africa constitutes an offer of the shares in South Africa for subscription or sale in South Africa only to persons who fall within the exemption from “offers to the public” set out in section 96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by persons in South Africa who do not fall within section 96(1)(a) of the South African Companies Act (such persons being referred to as “SA Relevant Persons”). Any investment or investment activity to which this document relates is available in South Africa only to SA Relevant Persons and will be engaged in South Africa only with SA relevant persons.

 

183


Table of Contents

Legal matters

The validity of the common stock offered hereby will be passed upon for us by Goodwin Procter LLP, San Francisco, California and for the underwriters by Cooley LLP, San Francisco, California.

Experts

The financial statements as of December 31, 2016 and December 31, 2017 and for each of the two years in the period ended December 31, 2017 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company’s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

Where you can find more information

We have filed with the SEC a registration statement on Form S-1 under the Securities Act that registers the shares of our common stock to be sold in this offering. This prospectus does not contain all of the information set forth in the registration statement and the exhibits and schedules filed as part of the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The reports and other information we file with the SEC can be read and copied at the SEC’s Public Reference Room at 100 F Street, NE, Washington D.C. 20549. Copies of these materials can be obtained at prescribed rates from the Public Reference Section of the SEC at the principal offices of the SEC, 100 F Street, NE, Washington D.C. 20549. You may obtain information regarding the operation of the public reference room by calling 1(800) SEC-0330. The SEC also maintains a web site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers like us that file electronically with the SEC.

Upon completion of this offering, we will become subject to the reporting and information requirements of the Exchange Act and, as a result, will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available for inspection and copying at the SEC’s public reference room and the web site of the SEC referred to above. We maintain a website at www.eidostx.com. Upon consummation of this offering, you may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock.

 

184


Table of Contents

Eidos Therapeutics, Inc.

Index to financial statements

 

     Page  

Audited Financial statements

  

Report of independent registered public accounting firm

     F-2  

Balance sheets

     F-3  

Statements of operations

     F-4  

Statements of redeemable convertible preferred stock and stockholders’ deficit

     F-5  

Statements of cash flows

     F-6  

Notes to financial statements

     F-7  

Unaudited Interim Condensed Financial Statements

  

Condensed balance sheets

     F-29  

Condensed statements of operations

     F-30  

Condensed statements of redeemable convertible preferred stock and stockholders’ deficit

     F-31  

Condensed statements of cash flows

     F-32  

Notes to unaudited condensed financial statements

     F-33  

 

F-1


Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders

of Eidos Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Eidos Therapeutics, Inc. as of December 31, 2017 and 2016, and the related statements of operations, of redeemable convertible preferred stock and stockholders’ deficit and of cash flows for the years then ended, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt About the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net stockholders’ deficit that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ PricewaterhouseCoopers LLP

San Jose, California

March 22, 2018, except for the effects of the stock split discussed in Note 1 to the financial statements, as to which the date is June 7, 2018.

We have served as the Company’s auditor since 2017.

 

F-2


Table of Contents

Eidos Therapeutics, Inc.

Balance sheets

(in thousands, except for share and per share amounts)

 

      December 31,  
      2016     2017  
              

ASSETS

    

CURRENT ASSETS:

    

Cash

   $ 1,956     $ 5,497  

Related party receivable

     5       67  

Prepaid expenses and other current assets

     7       484  
  

 

 

 

Total current assets

     1,968       6,048  

Property and equipment, net

           114  

Other assets

     7       181  
  

 

 

 

TOTAL ASSETS

   $ 1,975     $ 6,343  
  

 

 

 

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY

    

CURRENT LIABILITIES:

    

Accounts payable

   $ 94     $ 566  

Related party payable

     59       372

Accrued expenses and other current liabilities

     140       1,300  
  

 

 

 

Total current liabilities

     293       2,238  

Redeemable convertible preferred stock tranche liability

     315        

Other liabilities

     45       273  
  

 

 

 

TOTAL LIABILITIES

     653       2,511  
  

 

 

 

Commitments and contingencies (Note 6)

    

Series Seed redeemable convertible preferred stock, $0.001 par value; 8,000,000 and 14,000,000 shares authorized as of December 31, 2016 and 2017, respectively; 3,043,525 and 12,856,325 shares issued and outstanding as of December 31, 2016 and 2017, respectively; aggregate liquidation preference of $4,032 and $17,032 as of December 31, 2016 and 2017, respectively;

     3,795       17,028  

STOCKHOLDERS’ (DEFICIT) EQUITY:

    

Common stock, $0.001 par value; 20,000,000 shares authorized as of December 31, 2016 and 2017, 4,059,515 and 5,137,771 shares issued and outstanding as of December 31, 2016 and 2017, respectively;

     3       4  

Additional paid-in capital

     115       1,332  

Accumulated deficit

     (2,591     (14,532
  

 

 

 

TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY

     (2,473     (13,196
  

 

 

 

TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY

   $ 1,975     $ 6,343  

 

 

The accompanying notes are an integral part of these financial statements.

 

F-3


Table of Contents

Eidos Therapeutics, Inc.

Statements of operations

(in thousands, except for share and per share amounts)

 

      Year ended December 31,  
      2016     2017  

Operating expenses:

    

Research and development (includes related party expense of zero and $92, respectively)

   $ 1,734     $ 9,286  

General and administrative (includes related party expense of $161 and $705, respectively)

     651       2,730  
  

 

 

 

Total operating expenses

     2,385       12,016  
  

 

 

 

Loss from operations

     (2,385     (12,016

Other income (expense), net

     (157     75  
  

 

 

 

Net loss

   $ (2,542   $ (11,941
  

 

 

 

Net loss per share:

    

Basic and diluted

   $ (0.98   $ (3.32
  

 

 

 

Weighted-average shares used in computing net loss per share:

    

Basic and diluted

     2,599,641       3,596,673  
  

 

 

 

Pro forma net loss per share, basic and diluted (unaudited)

     $ (0.93
    

 

 

 

Weighted-average shares used in computing pro forma net loss per share, basic and diluted (unaudited)

       12,777,063  

 

 

The accompanying notes are an integral part of these financial statements.

 

F-4


Table of Contents

Eidos Therapeutics, Inc.

Statements of redeemable convertible preferred stock and stockholders’ deficit

(in thousands, except for share amounts)

 

     Redeemable  convertible
preferred stock
    Common stock     Additional
paid in

capital
    Accumulated
deficit
    Total
stockholders’
deficit
 
     Shares     Amount     Shares     Amount        

Balance—December 31, 2015

        $       3,588,000     $ 2     $     $ (49   $ (47

Issuance of Series Seed redeemable convertible preferred stock, net of issuance costs of $73 and redeemable convertible preferred stock tranche liability of $287

    3,019,323       3,640                                

Issuance of Series Seed redeemable convertible preferred stock upon conversion of redeemable convertible notes payable and accrued interest

    24,202       32                                

Settlement of fair value of redeemable convertible preferred stock tranche liability

          123                                

Issuance of common stock to founders and Stanford University in exchange for services and technology

                56,809       1       8             9  

Issuance of common stock upon early exercise of stock options

                414,706                          

Stock-based compensation expense

                            107             107  

Net loss

                                  (2,542     (2,542
 

 

 

 

Balance—December 31, 2016

    3,043,525       3,795       4,059,515       3       115       (2,591     (2,473

Issuance of Series Seed redeemable convertible preferred stock, net of issuance costs of $7

    9,812,800       12,993                                

Settlement of fair value of redeemable convertible preferred stock tranche liability

          240                                

Issuance of common stock to Stanford University in exchange for services and technology

                35,880             5             5  

Issuance of restricted common stock to founders in connection with anti-dilution rights

          390,546                          

Issuance of common stock upon exercise of stock options and restricted stock

                651,830       1       26             27  

Vesting of restricted stock and early exercised options

                            38             38  

Stock-based compensation expense

                            1,148             1,148  

Net loss

                                  (11,941     (11,941
 

 

 

 

Balance—December 31, 2017

    12,856,325     $ 17,028       5,137,771     $ 4     $ 1,332     $ (14,532   $ (13,196

 

 

The accompanying notes are an integral part of these financial statements.

 

F-5


Table of Contents

Eidos Therapeutics, Inc.

Statements of cash flows

(in thousands)

 

      Year ended
December 31,
 
      2016     2017  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net loss

   $ (2,542   $ (11,941

Adjustments to reconcile net loss to net cash used in operating activities:

    

Depreciation and amortization

           4  

Stock-based compensation

     107       1,148  

Accrued interest on convertible note

     1        

Change in fair value of convertible note payable derivative liability

     6        

Change in fair value of redeemable convertible preferred stock tranche liability

     151       (75

Issuance of common stock in exchange for services and technology

     9       5  

Changes in operating assets and liabilities:

    

Related party receivable

     (5     (62

Prepaid expenses and other current assets

     (7     (477

Other assets

     (7     (174

Accounts payable

     52       472  

Accrued expenses and other liabilities

     117       1,070  

Related party payable

     59       313  
  

 

 

 

Net cash used in operating activities

     (2,059     (9,717
  

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Purchase of property and equipment

           (53
  

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

     3,927       12,993  

Proceeds from issuance of common stock upon exercise of stock options and restricted stock

     63       318  
  

 

 

 

Net cash provided by financing activities

     3,990       13,311  
  

 

 

 

Net increase in cash

     1,931       3,541  

Cash—Beginning of period

     25       1,956  
  

 

 

 

Cash—End of period

   $ 1,956     $ 5,497  
  

 

 

 

SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ITEMS:

    

Settlement of fair value of redeemable convertible preferred stock tranche liability

   $ 123     $ 240  
  

 

 

 

Tenant improvement allowance provide by landlord

   $     $ 65  
  

 

 

 

Vesting of restricted stock and early exercised options

   $     $ 38  
  

 

 

 

Conversion of convertible note payable and accrued interest into redeemable convertible preferred stock

   $ 32     $  

 

 

The accompanying notes are an integral part of these financial statements.

 

F-6


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

1. The company

Eidos Therapeutics, Inc., or the Company, was incorporated as an S corporation in the state of Delaware on August 6, 2013. The Company was converted into a C corporation on April 4, 2016 in conjunction with its Series Seed redeemable convertible preferred stock financing. The Company is advancing a drug candidate to treat multiple forms of transthyretin amyloidosis, which leads to organ damage, loss of organ function and eventual death from abnormal buildup of protein deposits predominantly in the heart and peripheral nervous system. Through December 31, 2017, the Company has been primarily engaged in business planning, research, recruiting personnel and raising capital. The Company is headquartered in San Francisco, California and it operates as one operating segment.

Liquidity and going concern

The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $14.5 million as of December 31, 2017. The Company has a cash balance of $5.5 million as of December 31, 2017. In February 2018, the Company entered into a Note and Warrant Purchase Agreement with BridgeBio Pharma LLC, or BBP LLC, an existing significant investor in the Company, and issued a convertible note in the principal amount of $10.0 million (see Note 16). The Company has historically financed its operations primarily through the sale of redeemable convertible preferred stock. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses to continue for the foreseeable future. The Company believes that its cash as of December 31, 2017 and the $10.0 million from the convertible note in February 2018, without any future financing, will not be sufficient for the Company to continue as a going concern for at least one year from the issuance date of its financial statements for the year ended December 31, 2017. The Company believes that this raises substantial doubt about its ability to continue as a going concern. As a result, the Company will be required to raise additional capital. If sufficient funds on acceptable terms are not available when needed, the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. Failure to manage discretionary spending or raise additional financing, as needed, may adversely impact the Company’s ability to achieve its intended business objectives. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

On June 6, 2018, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a split of the Company’s issued and outstanding common stock at a 1.196 for 1 ratio, which was effected on June 7, 2018. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect the stock split for all periods presented. The financial statements have also been retroactively adjusted to reflect a proportional adjustment to the conversion ratio for each series of preferred stock that will be effected in connection with the stock split.

 

F-7


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

2. Summary of significant accounting policies

Basis of preparation

These financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. These financial statements include transactions with BridgeBio Pharma LLC, a controlling investor in the Company. For the periods presented, BridgeBio Pharma LLC has provided consulting and management services to the Company in the ordinary course of business, including certain executive personnel, facility related costs, advisory services, insurance costs and other general corporate expenses. These allocations were made based on direct usage, when identifiable, with the remainder allocated primarily based on a proportional share of headcount. The Company’s historical financial statements do not purport to reflect what the Company’s results of operations, financial position, or cash flows would have been if the Company had operated as an independent entity during the periods presented. Management believes the basis on which the expenses have been allocated to be a reasonable reflection of the utilization of services provided to or the benefit received by the Company during the periods presented. For more information on the allocated costs and related party transactions, see Note 7—Related party transactions.

The Company converted to a C corporation in April 2016. As the amount in members’ equity prior to April 4, 2016 was not material, the Company has presented the Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit as if it was a C corporation since January 1, 2016.

Use of estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the fair value of the redeemable convertible preferred stock tranche liability, the fair value of the Company’s common stock, stock-based compensation, the useful lives of fixed assets, accruals for research and development activities and income taxes. Management bases its estimates on historical experience and on other relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Concentration of credit risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company’s cash is held in a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.

Fair value of financial instruments

Carrying amounts of certain of the Company’s financial instruments including related party receivables and payables, accounts payable and accrued expenses and other current liabilities approximate fair value due to their relatively short maturities.

 

F-8


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Property and equipment, net

Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization begin at the time the asset is placed in service. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and accumulated depreciation and amortization are removed from the balance sheet and any resulting gain or loss is reflected in the statement of operations in the period realized.

Impairment of long-lived assets

The Company reviews long-lived assets, primarily comprised of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the estimated undiscounted future cash flows which the assets or asset groups are expected to generate. If such assets are considered to be impaired, the impairment to be recognized as the amount by which the carrying amount of the assets or asset groups exceeds the estimated discounted future cash flows arising from the assets or asset groups. There have been no such impairments of long-lived assets for any of the periods presented.

Research and development expense

Research and development costs are expensed as incurred and consist of payroll and related expenses, consulting expenses, laboratory and manufacturing supplies, certain allocated expenses, amounts incurred under license agreements, as well as fees paid to others that conduct certain research and development activities on the Company’s behalf.

Accrued research and development

The Company records accrued expenses for estimated costs of research and development activities conducted by third-party service providers, which include preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and include these costs in accrued expenses and other current liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company’s research and development expenses.

The Company estimates the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, the Company adjusts its accrued estimates. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may vary from its estimates and could result in its reporting amounts that are too high or too low in any particular period. The Company’s accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers. The Company records advance payments to service providers as prepaid assets, which are expensed as the contracted services are performed. To date, there have been no material differences from the Company’s accrued expenses to actual expenses.

 

F-9


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Accrued repurchase liability for common stock

The Company records as a liability, within accrued expenses and other current liabilities, the purchase price of unvested common stock that the Company has a right to repurchase if and when the stockholder ceases to be a service provider to the Company before the end of the requisite service period. The proceeds are recorded as a liability and the proceeds related to the vested common stock is reclassified to additional paid-in capital as the Company’s repurchase right lapses.

Redeemable convertible preferred stock tranche liability

The Company has determined that its obligation to issue additional shares of redeemable convertible preferred stock upon the achievement of certain milestones or at the option of the holder represents a freestanding financial instrument. The instrument is classified as a liability on the balance sheets and is subject to remeasurement at each balance sheet date and any change in fair value is recognized through other income (expense), net in the statements of operations.

Stock-based compensation

The Company maintains performance incentive plans under which incentive stock options and nonqualified stock options are granted to employees and non-employee consultants.

The Company recognizes stock-based compensation expense based on the estimated fair value of stock-based payment awards on the date of grant using the Black-Scholes option-pricing model. The Company uses the straight-line attribution method for recognizing compensation expense. The Company has elected to recognize the actual forfeitures by reducing the employee stock-based compensation expense in the same period as the forfeitures occur.

The Company recognizes the fair value of stock options granted to non-employees as stock-based compensation expense over the period in which the related services are received. Stock-based compensation expense related to stock options granted to non-employees is recognized based on the vesting date fair value of awards as the stock options are earned. The Company believes that the estimated fair value of stock options is more readily measurable than the fair value of the services rendered. In addition, the Company estimates the service period for the awards based on the time that would be required to satisfy the service condition, assuming the service condition will be satisfied. Stock-based compensation expense is recognized over the estimated service period but is accelerated if the performance condition is achieved earlier than estimated.

Income taxes

The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are currently in effect. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Financial statement effects of uncertain tax positions are recognized when it is more-likely-than-not, based on the technical merits of the position, that it will be sustained upon examination. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax. To date, there have been no interest or penalties recorded in relation to the unrecognized tax benefits.

 

F-10


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Comprehensive loss

Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.

Net loss per share

Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share since the effects of potentially dilutive securities are antidilutive given the net loss of the Company.

Unaudited pro forma net loss per share

Pro forma basic and diluted net loss per share has been computed to give effect to the conversion of the Company’s redeemable convertible preferred stock into common stock as if such conversion had occurred at the beginning of the period or the date of issuance, if later. The unaudited pro forma net loss per share does not include the shares expected to be sold and related proceeds to be received from the Company’s proposed initial public offering.

Recent accounting pronouncements

In November 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred income taxes by requiring deferred tax liabilities and assets to be classified as noncurrent in the Balance Sheet. The standard will be effective for financial statements issued for annual periods beginning after December 15, 2016 for public entities. Early adoption is permitted for financial statements that have not been previously issued. The ASU may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company has early adopted this ASU as of December 31, 2016, on a retrospective basis. The adoption had no impact on the Company’s financial statements due to a full valuation allowance on its deferred tax assets.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which for operating leases requires the lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The guidance also requires a lessee to recognize single lease costs, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not determined the potential effects of this ASU on its financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718)—Improvements to Employee Share-Based Payment Accounting, which simplifies the accounting for employee share-based transactions. The amendments in this update cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the statements of cash flows, an

 

F-11


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification, and the classification of those taxes paid on the statements of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016 for all public entities with early adoption permitted. As part of the amendment, the Company has elected to recognize the actual forfeitures by reducing the employee share-based compensation expense in the same period as the forfeitures occur. The adoption had no material impact on its financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The areas affected by ASU 2016-15 are debt prepayment and debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies), distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. Specifically, under this guidance, cash payments for debt prepayment or debt extinguishment costs will be classified as cash outflows for financing activities. The amendments in ASU 2016-15 are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in ASU 2016-15 will be applied using a retrospective transition method to each period presented. The adoption of ASU 2016-15 is not expected to materially impact the Company’s financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 provides clarity and reduces the complexity of applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. This standard is effective for annual periods beginning after December 15, 2017. The Company has adopted this ASU as of December 31, 2017, on a retrospective basis, and the adoption had no material impact on its financial statements.

3. Fair value measurement

Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

F-12


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

Financial liabilities measured and recognized at fair value are as follows (in thousands):

 

      December 31, 2016  
      Level 1      Level 2      Level 3      Total  

Liabilities:

           

Redeemable convertible preferred stock tranche liability

   $      $      $ 315      $ 315  
  

 

 

 

Total financial liabilities

   $      —      $      —      $  315      $  315  

 

 

There were no financial assets outside of cash in an operating account as of December 31, 2016 and 2017. There were no transfers between Level 1, Level 2 and Level 3 categories during the periods presented. There were no financial liabilities measured at fair value as of December 31, 2017.

The fair value of the redeemable convertible preferred stock tranche liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. The Company estimates the fair value of the redeemable convertible preferred stock tranche liability using the Black-Scholes option pricing model (See Note 10). The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instrument as follows (in thousands):

 

      Year ended
December 31,
 
      2016     2017  

Redeemable convertible preferred stock tranche liability:

    

Balance—beginning of period

   $     $ 315  

Issuance of Seed Series redeemable convertible preferred stock tranche liability

     287        

Loss (gain) on the change in fair value upon revaluation

     151       (75

Settlement of the redeemable convertible preferred stock tranche liability

     (123     (240
  

 

 

 

Balance—end of period

   $ 315     $  

 

 

4. Balance sheet components

Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

      December 31,  
      2016      2017  

Prepaid clinical and research related expenses

   $      $ 432  

Other current assets

     7        52  
  

 

 

 

Total prepaid expenses and other current assets

   $      7      $  484  

 

 

 

F-13


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Property and equipment, net

Property and equipment, net consisted of the following (in thousands):

 

      December 31,  
      2016      2017  

Furniture and computer equipment

   $      $ 41  

Leasehold improvements

            77  
  

 

 

 

Total property and equipment

            118  

Less: accumulated depreciation and amortization

            (4
  

 

 

 

Total property and equipment, net

   $      $ 114  

 

 

Depreciation and amortization expense for the years ended December 31, 2016 and 2017 was zero and $4,000, respectively.

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

      December 31,  
      2016      2017  

Accrued research and development costs

   $ 82      $ 564  

Accrued employee related expenses

     12        606  

Liability for unvested stock, short-term

     18        109  

Accrued other current liabilities

     28        21  
  

 

 

 

Total accrued expenses and other current liabilities

   $ 140      $ 1,300  

 

 

As of December 31, 2016 and 2017, the balances of $45,000 and $208,000, respectively, in other liabilities related to the long-term liability for unvested stock.

5. Convertible note

In September 2015, the Company entered into a convertible note with a related party, a stockholder of the Company. The principal amount of the convertible note was $25,000 with a fixed interest rate of 5% per annum. The note was convertible at the option of the holder at the next equity financing of at least $1.5 million at a price of 80% of the new equity price. The conversion feature was deemed to be a freestanding derivative with an initial fair value of $6,000. In April 2016, the entire amount due, including accrued interest of $1,000, was converted into 24,202 shares of Series Seed redeemable convertible preferred stock (see Note 9). The derivative liability related to the convertible note of $6,000 was recorded in other income (expense), net in the statement of operations at the date of conversion in April 2016.

6. Commitments and contingencies

Lease arrangements

In September 2017, the Company entered into a one-year operating lease for laboratory facilities in San Francisco, California. In November 2017, the Company entered into an operating lease for a facility in San

 

F-14


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Francisco, California, which expires in November 2022. The Company has provided a security deposit of $158,000 as collateral for the lease, which is included in other assets on the balance sheet.

Future minimum lease payments as of December 31, 2017 are as follows (in thousands):

 

Year ending December 31:    Amount  

2018

   $ 325  

2019

     327  

2020

     337  

2021

     347  

2022

     327  
  

 

 

 

Total future minimum lease payments

   $ 1,663  

 

 

The Company’s rent expense was $23,000 and $131,000 for the years ended December 31, 2016 and 2017, respectively, of which $23,000 and $76,000 was incurred pursuant to the service agreement with BridgeBio Services, Inc., an affiliate of BridgeBio Pharma LLC, for the years ended December 31, 2016 and 2017, respectively (see Note 7). Rent expense is recognized on a straight-line basis over the terms of the Company’s leases and accordingly, the Company recorded the difference between rent expense and amount paid under the leases as deferred rent liability within other liabilities in the balance sheets. Incentives granted under the Company’s facility lease, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the lease.

Indemnification

In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s balance sheets, statements of operations, or statements of cash flows.

7. Related party transactions

BridgeBio Pharma LLC and its affiliates, or BBP LLC, is a controlling investor in the Company, as it owned 47% and 75% of the Company’s total outstanding shares as of December 31, 2016 and 2017. In April 2016, the Company began receiving consulting, management, facility and infrastructure services pursuant to a services agreement with BBP LLC. The initial agreement was entered into on March 1, 2016 and was superseded by the subsequent agreement effective as of May 1, 2017. The Company incurred the following expenses: rent of $23,000 and $76,000, facility related costs of $15,000 and $65,000 and consulting expenses of $123,000 and $656,000 for the years ended December 31, 2016 and 2017, respectively. As of December 31, 2016 and 2017, the Company had an outstanding receivable from BBP LLC of $5,000 and $67,000, respectively, related to

 

F-15


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

providing services to other subsidiaries of BBP LLC. As of December 31, 2016 and 2017, the Company had an outstanding liability due to BBP LLC of $59,000 and $372,000, respectively.

In April 2016, the Company entered into a consulting agreement with Dr. Graef, one of the Company’s founders. Pursuant to the consulting agreement, Dr. Graef agreed to provide consulting services in connection with the discovery and development of novel TTR stabilizers. As compensation for these services, Dr. Graef is entitled to an annual fee in the amount of up to $150,000 and reimbursement by the Company for pre-approved expenses. The consulting agreement has a term of four years but may be terminated by either party for any reason with thirty days’ prior notice. During the years ended December 31, 2016 and December 31, 2017, the Company incurred $112,500 and $150,000, respectively, for services under the consulting agreement.

In August 2016, the Company entered into a consulting agreement with Dr. Alhamadsheh, one of the Company’s founders. Pursuant to the consulting agreement, Dr. Alhamadsheh agreed to provide consulting services in connection with the discovery and development of novel TTR stabilizers. As compensation for these services, Dr. Alhamadsheh is entitled to an annual fee in the amount of up to $115,000 and reimbursement by the Company for pre-approved expenses. The consulting agreement has a term of two years but may be terminated by either party for any reason with thirty days’ prior notice. During the years ended December 31, 2016 and December 31, 2017, the Company incurred $84,000 and $115,000, respectively, for services under the consulting agreement.

In December 2017, the Company issued 195,273 shares of common stock to each of Dr. Alhamadsheh and Dr. Graef in order to offset dilution to their ownership in connection with the Company’s issuance of additional shares of Series Seed redeemable convertible preferred stock in financing transactions (See Note 12). In addition, the Company accrued a “gross-up” amount of $83,000 to each of Dr. Alhamadsheh and Dr. Graef for the taxes owed by Dr. Alhamadsheh and Dr. Graef as a result of such issuance of common stock.

8. Income taxes

No provision for income taxes was recorded for the years ended December 31, 2016 and 2017. The Company has incurred net operating losses since its inception. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.

In December 2017, the SEC staff issued SAB 118, which provides guidance for the tax effect of the Tax Cuts and Jobs Act of 2017, or the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act’s enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes, or ASC 740. In accordance with SAB 118, the Company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that the Company’s accounting for certain income tax effects of the Tax Act is incomplete, but it is able to determine a reasonable estimate, the Company must record a provisional estimate in its financial statements. If the Company cannot determine a provisional estimate to be included in its financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. The $1.6 million decrease in deferred tax assets and corresponding adjustment to the valuation allowance represent the Company’s reasonable estimates based on the corporate tax rate reduction to 21% from 35% for tax years beginning after December 31, 2017 and are provisional amounts within the meaning of SAB 118. Also, it is expected that the U.S. Treasury will issue

 

F-16


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

regulations and other guidance on the application of certain provisions of the Tax Act. In subsequent periods, but within the measurement period, the Company will analyze that guidance and other necessary information to refine its estimates and complete its accounting for the tax effects of the Tax Act as necessary.

The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:

 

      Year ended
December 31,
 
      2016     2017  

Federal statutory income tax rate

     34.0%       34.0%  

State taxes

            

Federal rate change impact due to Tax Act

           (13.4

Research and development credits

     2.1       1.5  

Stock-based compensation

           (1.5

Change in fair value of convertible note

     (2.1      

Other permanent differences

     (1.3     (0.5

Change in valuation allowance

     (32.7     (20.1
  

 

 

 
     0.0%       0.0%  

 

 

The income tax effect of temporary differences that give rise to significant portions of the Company’s deferred tax assets is presented below (in thousands):

 

      December 31,  
      2016     2017  

Deferred tax assets:

    

Net operating loss carryforward

   $ 873     $ 3,596  

Research and development credits

     66       355  

Stock-based compensation

     43       208  

Other

           32  
  

 

 

 

Total deferred tax assets

     982       4,191  

Less: valuation allowance

     (982     (4,191
  

 

 

 

Total deferred tax assets, net

   $     $  

 

 

As of December 31, 2017, the Company has net operating loss carryforwards of approximately $12.8 million and $12.9 million, respectively, available to reduce future taxable income, if any, for federal and California state income tax purposes. The net operating losses will begin to expire in 2037.

As of December 31, 2017, the Company has federal research and development credit carryforwards of $331,000, which will expire beginning in 2037 if not utilized. As of December 31, 2017, the Company has California research and development credit carryforwards of $223,000. The California research and development credits have no expiration date.

The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. The net increase in the valuation allowance for the years ended December 31, 2016 and 2017 was $1.0 million and $3.2 million, respectively. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the

 

F-17


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

deferred income tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, and projected future taxable income in making this assessment. Based on these factors, management has provided a full valuation allowance for its deferred tax assets.

Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purchases, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company’s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):

 

      December 31,  
      2016      2017  

Balance at beginning of year

   $      $ 31  

Additions based on tax positions related to current year

     31        135  
  

 

 

 

Balance at end of year

   $ 31      $ 166  

 

 

The Company’s unrecognized gross tax benefits would not reduce the annual effective tax rate if recognized because it has recorded a full valuation allowance on its deferred tax assets. The Company does not foresee any material changes to the gross unrecognized tax benefit within the next twelve months. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense.

The Company files income tax returns in the United States and California. The Company currently has no federal or state tax examinations in progress. The Company did not recognize any accrued interest and penalties related to gross unrecognized tax benefits related to the year ended December 31, 2017. All years are open for examination by federal and state authorities.

9. Redeemable convertible preferred stock

In April 2016, the Company completed a Series Seed redeemable convertible preferred stock financing. The initial total committed amount was $8.0 million to be received in three tranches. The first tranche of $1.0 million was received and 754,831 shares were issued in April 2016 and the second tranche of $3.0 million was received and 2,264,492 shares were issued in September 2016. The third tranche of $4.0 million was received and 3,019,323 shares were issued in March 2017. In September 2017, the Company completed an extension of its Series Seed redeemable convertible preferred stock financing for a total of $9.0 million and 6,793,477 shares were issued. The Company also converted notes payable, derivative liability and accrued interest of $32,000 (see Note 5) into 24,202 shares of Series Seed redeemable convertible preferred stock concurrently with the first tranche of this financing in April 2016.

Redeemable convertible preferred stock as of December 31, 2016 consists of the following:

 

Series    Shares
authorized
     Shares
outstanding
     Price
per share
     Proceeds, net of
issuance cost
(in thousands)
     Liquidation
amount
(in thousands)
 

Seed

     8,000,000        3,043,525      $ 1.3248      $ 3,927      $ 4,032  

 

 

 

F-18


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Redeemable convertible preferred stock as of December 31, 2017 consists of the following:

 

Series    Shares
authorized
     Shares
outstanding
     Price
per share
     Proceeds, net of
issuance cost
(in thousands)
     Liquidation
amount
(in thousands)
 

Seed

     14,000,000        12,856,325      $ 1.3248      $ 16,920      $ 17,032  

 

 

The holders of the redeemable convertible preferred stock have various rights and preferences as follows:

Voting rights

The holders of redeemable convertible preferred stock are entitled to vote on all matters on which the common stockholders are entitled to vote. Holders of redeemable convertible preferred and common stock generally vote together as a single class, not as separate classes. Each holder of redeemable convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of redeemable convertible preferred stock held by such holder are convertible.

As long as at least 250,000 shares of redeemable convertible preferred stock remain outstanding, the Company must obtain approval from a majority of the holders of the then outstanding shares of redeemable convertible preferred stock in order to alter or change the rights, preferences and privileges of preferred stock, change the authorized number of preferred and common stock, create a new class or series of shares having any rights, preferences or privileges superior to or on parity with any outstanding shares of redeemable convertible preferred stock, purchase or redeem or declare or pay any dividend or distribution on shares of capital stock (subject to certain exceptions), merge, consolidate with or implement a reorganization that would result in the transfer of 50% of the voting power of the Company, sell all or substantially all of the Company’s assets, liquidate, dissolve or wind up the business and affairs of the Company, or change the authorized number of directors.

Dividends

The holders of shares of Series Seed redeemable convertible preferred stock are entitled to receive noncumulative cash dividends at a rate of 8% per share, only when, as and if declared by the board of directors. In the event dividends are paid on any share of common stock, the Company will pay an additional dividend on all outstanding shares of preferred stock in a per share amount equal (on an as-converted to common stock basis) to the amount paid or set aside for each share of common stock. No dividends were declared as of December 31, 2016 and 2017.

Liquidation preference

A liquidation, dissolution or winding up of the Company, a merger or consolidation after which the shares of capital stock of the Company immediately prior to such transaction do not represent or are not exchanged for shares representing a majority in voting power of the surviving or resulting entity, or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets would trigger a redemption event. Accordingly, the redemption event is outside the control of the Company, and all shares of preferred stock have been presented outside of permanent equity. Further, the Company has elected not to adjust the carrying values of the Series Seed redeemable convertible preferred stock to the liquidation

 

F-19


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

preference of such shares, since it is uncertain whether or when a redemption event will occur. Subsequent adjustments to increase the carrying value to the redemption values will be made when it becomes probable that such redemption will occur.

In the event of any liquidation, dissolution or winding up of the Company, a merger or consolidation after which the shares of capital stock of the Company immediately prior to such transaction do not represent or are not exchanged for shares representing a majority in voting power of the surviving or resulting entity, or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets, the holders of Series Seed redeemable convertible preferred stock are entitled to receive prior to and in preference to any distribution to holders of common stock, an amount equal to $1.3248 per share plus any declared but unpaid dividends on such shares. The remaining assets, if any, shall be distributed to the holders of common stock. Should the Company’s legally available assets be insufficient to satisfy the liquidation preferences, the funds will be distributed ratably among the holders of Series Seed redeemable convertible preferred stock in proportion to the preferential amount each holder is otherwise entitled to receive.

Conversion

Each share of Series Seed redeemable convertible preferred stock is convertible, at the option of the holder, into the number of shares of common stock into which such shares are convertible at the then effective conversion ratio. The initial conversion price per share for Series Seed redeemable convertible preferred stock is $1.3248 per share. The initial conversion price is subject to adjustment from time to time for events such as future stock splits, combinations and dividends. Additionally, the conversion price is subject to adjustment from time to time in the event of dilutive issuances based on a broad-based weighted-average anti-dilution formula. As of December 31, 2016 and 2017, the redeemable convertible preferred stock is convertible into common stock on a one for 1.196 basis.

Each share of Series Seed redeemable convertible preferred stock is convertible into common stock automatically upon the earlier of (i) immediately prior to the completion of the sale of shares of common stock at a price of at least $6.624 per share in a firm commitment underwritten public offering in which the public offering aggregate gross proceeds raised equals or exceeds $30.0 million, or (ii) the Company’s receipt of a written request for such conversion from the holders of a majority of the then outstanding shares of redeemable convertible preferred stock.

Redemption and classification

The Company has classified the redeemable convertible preferred stock as mezzanine equity on the balance sheets as the stock is contingently redeemable. Upon the occurrence of certain change in control events that are outside the Company’s control, including liquidation, sale or transfer of the Company, holders of the redeemable convertible preferred stock can cause redemption for cash to the extent permitted by applicable law.

10. Redeemable convertible preferred stock tranche liability

In April 2016, the Company entered into a Series Seed Preferred Stock Purchase Agreement, or the Agreement, for the issuance of up to 6,062,848 shares of Series Seed redeemable convertible preferred stock at a price of $1.3248 per share in three closings. Upon the initial closing on April 4, 2016, 754,831 shares of Series Seed

 

F-20


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

redeemable convertible preferred stock were issued for gross proceeds of $1.0 million and 24,202 shares were issued upon conversion of outstanding convertible note principal balance and accrued interest of $26,000. According to the initial terms of the Agreement, the Company can issue 5,283,815 shares under the same terms as the initial closing, in two subsequent closings contingent upon the achievement of certain scientific milestones. The second tranche of $3.0 million was received and 2,264,492 shares were issued in September 2016. The third tranche of $4.0 million was received and 3,019,323 shares were issued in March 2017.

The Company has determined that the Company’s obligation to issue additional shares of its redeemable convertible preferred stock represents a freestanding financial instrument. The freestanding redeemable convertible preferred stock tranche liability is initially recorded at fair value, with fair value changes recognized as increases or reductions in other income (expense), net in the statements of operations. The Company continued to adjust the liability for changes in the estimated fair value until the settlement of the redeemable convertible preferred stock tranche liability. At such time, any remaining value of the redeemable convertible preferred stock tranche liability was reclassified to redeemable convertible preferred stock with no further remeasurement required. The Company had recorded a redeemable convertible preferred stock tranche liability in April 2016 of $287,000 related to the Series Seed redeemable convertible preferred stock financing.

The Company estimated the fair value of the preferred stock liability using a Black-Scholes option pricing model using the following assumptions to determine the fair value of the redeemable convertible preferred stock tranche liability:

Expected term—The expected term represents the period for which the redeemable convertible preferred stock tranche liabilities are expected to be outstanding, which is estimated to be the remaining contractual term.

Expected volatility—The volatility data was estimated based on a study of publicly traded industry peer companies, as there is no trading history for our redeemable convertible preferred stock. For purposes of identifying these comparable peer companies, the Company considered the industry, stage of development, size and financial leverage. The Company has measured historical volatility over a period equivalent to the expected term and believes that historical volatility provides a reasonable estimate of future expected volatility.

Expected dividends—The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company currently has no history or expectation of paying cash dividends on its preferred stock.

Risk-free interest rate—The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the redeemable convertible preferred stock tranche liability.

The Black-Scholes option pricing model resulted in a tranche liability of $123,000 for the second milestone closing and $164,000 for the third milestone closing using the following assumptions: estimated equity value of $2.1 million, a term of three years, a risk-free rate of 0.87%, a volatility of 75%, and a dividend yield of 0.0%.

The second milestone closing redeemable convertible preferred stock tranche liability was revalued at the time of settlement (September 7, 2016) and therefore, $123,000 was reclassified to redeemable convertible preferred stock at that date. The third milestone closing fair value was remeasured as of December 31, 2016 with the following assumptions: estimated equity value was $4.0 million, a term of 2.5 years, a risk-free rate of 1.34%, a volatility of 76% and a dividend yield of 0.0% resulting in a fair value of $315,000. The Company recorded the change in fair value of $151,000 as other income (expense), net in the statements of operations for the year ended December 31, 2016.

 

F-21


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

The redeemable convertible preferred stock tranche liability for the third milestone was settled in March 2017 at the time of the final tranche closing of the Series Seed redeemable convertible preferred stock and the remeasured liability balance of $240,000 was reclassified to redeemable convertible preferred stock. The final closing fair value was remeasured with the following assumptions: estimated equity value was $4.0 million, a term of 2.3 years, a risk-free rate of 1.40%, a volatility of 70% and a dividend yield of 0.0%. The Company recorded the change in fair value of $75,000 in other income (expense), net in the statements of operations for the year ended December 31, 2017.

11. Common stock

Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of the preferred stockholders.

The Company has reserved common stock, on an as-converted basis, for issuance as follows:

 

      December 31,  
      2016      2017  

Redeemable convertible preferred stock outstanding, as-converted

     3,640,055        15,376,164  

Options issued and outstanding

     30,068        846,166  

Options available for future grants

     643,922        670,994  
  

 

 

 

Total

     4,324,045        16,893,324  

 

 

12. Stock option plan

In April 2016, the Company established its 2016 Equity Incentive Plan, or the 2016 Plan, which provides for the granting of stock options to employees and consultants of the Company. Options granted under the 2016 Plan may be either incentive stock options, or ISOs, nonqualified stock options, or NSOs or restricted stock awards. ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. As of December 31, 2016 and 2017, the Company has reserved 1,088,696 and 2,583,696 shares of common stock for issuance under the 2016 Plan, respectively.

The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. The exercise price of an ISO granted to an employee who at the time of grant is a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. To date, options have a term of ten years and generally vest over a four-year period with annual cliff vesting and the balance monthly over 36 months.

 

F-22


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

2016 Plan award activity is as follows (in thousands, except per share and per share data and years):

 

      Number of
options
available for
grant
    Options
outstanding
    Weighted-
average
exercise
price per
option
     Weighted-
average
remaining
contractual
life (years)
    

Aggregate

intrinsic

value

 

Outstanding—December 31, 2015

               $        

Additional authorized

     1,088,696                    

Granted

     (444,774     444,774       0.15        

Exercised

           (414,706     0.15        
  

 

 

 

Outstanding—December 31, 2016

     643,922       30,068     $ 0.15        9.62      $  

Additional authorized

     1,495,000                    

Granted

     (1,467,928     1,467,928       0.55        

Exercised

           (651,830     0.48        
  

 

 

 

Outstanding—December 31, 2017

     670,994       846,166     $ 0.59        9.97      $ 4,384  
  

 

 

 

Vested and expected to vest—December 31, 2017

       846,166     $ 0.59        9.97      $ 4,384  
  

 

 

 

Exercisable—December 31, 2017

       47,725     $ 0.49        9.80      $ 252  

 

 

Aggregate intrinsic value represents the difference between the Company’s estimated fair value of its common stock and the exercise price of outstanding in–the–money options. The total intrinsic value of options exercised was zero and $2.9 million for the years ended December 31, 2016 and 2017.

The total fair value of shares vested during the year ended December 31, 2016 and 2017 was $4,000 and $534,000, respectively.

Stock options valuation

The fair value of the Company’s shares of common stock underlying its stock options has historically been determined by the Company’s Board of Directors. Because there has been no public market for the Company’s common stock, the Company’s Board of Directors has determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including important developments in the Company’s operations, valuations performed by an independent third party, sales of redeemable convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company’s common stock, among other factors.

The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee/consultant stock option exercise behaviors, risk-free interest rates, and expected dividends. Estimating the fair value of equity-settled awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of complex variables. These inputs include:

Fair value of common stock—Given the absence of a public trading market, the Company’s board of directors considered numerous objective and subjective factors to determine the fair value of common

 

F-23


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

stock at each meeting at which awards were approved. The factors included, but were not limited to: (i) third-party valuations of common stock; (ii) the prices, rights, preferences and privileges of the redeemable convertible preferred stock relative to those of common stock; (iii) the lack of marketability of common stock; (iv) actual operating and financial results; (v) current business conditions and projections; and (vi) the likelihood of achieving a liquidity event, such as an initial public offering or sale of the Company, given prevailing market conditions.

Expected term—The Company has opted to use the “simplified method” for estimating the expected term of the options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. For non-employees, the term is the remaining contractual term of the option.

Expected volatility—For all stock options granted to date, the volatility data was estimated based on a study of publicly traded industry peer companies, as there is no trading history for the Company’s common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.

Risk-free interest rate—The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award.

Expected dividend—The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company currently has no history or expectation of paying cash dividends on its common stock.

The estimated grant-date fair values of the employee and non-employee stock options for the year ended December 31, 2016 were calculated using the Black-Scholes valuation model, based on the following weighted-average assumptions:

 

      Year ended
December 31, 2016
 
      Employee      Non-employee  

Expected term (in years)

     6.08        10.00  

Expected volatility

     76.23%        79.62%  

Risk-free interest rate

     1.34%        1.57%  

Expected dividend

             

 

 

The estimated grant-date fair values of the employee and non-employee stock options for the year ended December 31, 2017 were calculated using the Black-Scholes valuation model, based on the following weighted-average assumptions:

 

      Year ended
December 31, 2017
 
      Employee      Non-employee  

Expected term (in years)

     5.83        9.66  

Expected volatility

     68.40%        80.08%  

Risk-free interest rate

     2.27%        2.41%  

Expected dividend

             

 

 

 

F-24


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Accrued repurchase liability for common stock early exercises

During the years of December 31, 2016 and 2017, there were 300,512 shares and 496,215 shares, respectively, of common stock issued upon the early exercise of stock options prior to the vesting of the underlying shares. These shares are subject to repurchase by the Company at the original issuance price upon termination of the services received from the holder of the option. The right to repurchase these shares generally lapses with respect to 25% of the shares underlying the option after one year of service to the Company and 1/48 of the shares underlying the original grant per month over 36 months thereafter. The shares purchased by the employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the balance sheets. As of December 31, 2016 and 2017, the Company recorded $46,000 and $287,000, respectively, associated with shares issued upon the early exercise of stock options that are subject to repurchase rights as a liability.

Restricted stock

In August 2013, the Company issued 3,588,000 shares of common stock to founders at a price of $0.001 per share in exchange for intellectual property and for ongoing consulting services. Under the related stock purchase agreements, the Company has the right to repurchase the common stock at $0.001 per share, which right lapses as the shares vest, which is 25% cliff after one year and monthly thereafter over 36 months. As of December 31, 2016 and 2017, 598,000 and zero shares remained subject to purchase under the related stock purchase agreements, which were valued at less than $1,000 and zero, respectively.

In December 2017, the Company issued 390,546 shares of common stock for no consideration to the founders pursuant to the Series Seed Preferred Stock Purchase Agreement and license agreement (see Note 13) in connection with certain anti-dilution rights held by these parties. If the shares issued under the license agreement represent less than 1% of the shares issued and outstanding of common stock on an as-converted basis, the Company will issue additional common stock to the founders and Stanford University. The Company has the right to repurchase the common stock at the fair value per share on the date of repurchase, which right lapses as the shares vest, which is 25% cliff after one year and monthly thereafter over 36 months. In order to vest, the holders are required to provide continued service to the Company. As of December 31, 2017, 390,546 shares remained subject to repurchase.

The Company recognizes stock-based compensation expense over the period in which the related services from the founders are received. Stock-based compensation expense related to the restricted stock is recognized based on the vesting date fair value of stock using Black-Scholes pricing model. During the years of December 31, 2016 and 2017, $103,000 and $273,000, respectively, was recognized as stock-based compensation expense related to the restricted stock.

During the years of December 31, 2016 and 2017, the Company issued 114,194 shares and 89,687 shares of common stock to an employee at a purchase price ranging from $0.15 to $0.59 per share. These shares are subject to repurchase by the Company at the fair value per share on the date of repurchase. The right to repurchase these shares lapses with respect to 25% of the underlying shares after one year of service to the Company and 1/48th of the shares per month over 36 months thereafter or 1/48th of the share per month over 48 months. The cash received for the purchase of these shares was recorded as a liability on the balance sheets. As of December 31, 2016 and 2017, the Company recorded $17,000 and $30,000, respectively, associated with 114,194, and 134,789 shares, respectively, remained subject to repurchase rights as a liability.

 

F-25


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

Stock-based compensation expense

During the year ended December 31, 2016, the Company granted stock options and restricted stock awards to employees and non-employees to purchase 414,706 and 30,048 shares of common stock, respectively, with a weighted-average grant date fair value of $0.10 and $0.12 per share, respectively. During the year ended December 31, 2017, the Company granted stock options and restricted stock awards to employees and non-employees to purchase 1,278,368 and 189,577 shares of common stock, respectively, with a weighted-average grant date fair value of $4.91 and $5.17 per share, respectively.

Total stock-based compensation recognized for both employees and non-employees was as follows (in thousands):

 

      Year ended
December 31,
 
      2016      2017  

Research and development

   $ 103      $ 519  

General and administrative

     4        629  
  

 

 

 

Total stock-based compensation expense

   $ 107      $ 1,148  

 

 

As of December 31, 2017, there was $8.2 million of total unrecognized compensation cost related to unvested stock-based compensation arrangements under the 2016 Plan. The unrecognized stock-based compensation cost is expected to be recognized over a weighted-average period of 3.7 years.

13. License agreement

In April 2016, the Company entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University, or Stanford University relating to the Company’s drug discovery and development initiatives. Under this agreement, the Company has been granted certain worldwide exclusive licenses to use the licensed compounds. The Company paid an upfront license payment of $25,000 in April 2016, which was recorded as research and development expense and issued 56,809 shares of common stock. The value of this equity was recorded, at fair value of $0.15 per share, as research and development expense of $8,000 during the year ended December 31, 2016. In March 2017, the Company paid a license fee of $10,000, which was recorded as research and development expense during the year ended December 31, 2017. Under the agreement, the Company will issue additional shares of common stock without further consideration to ensure the number of shares issued to the founders, as the license inventors, and Stanford University does not represent less than 1% of the Company’s total outstanding shares through the completion of $8.0 million in Series Seed financing. Stanford University retains participation rights to purchase up to 10% of equity in future private financings at the then fair value of the equity. The Company may also be required to make future payments of up to approximately $1.0 million to Stanford University upon achievement of specific intellectual property, clinical and regulatory milestone events, as well as pay royalties in the low single digits on future net sales, if any. In addition, the Company is obligated to pay Stanford University a percentage of non-royalty revenue received by the Company from its sublicensees, with the amount owed decreasing annually for three years based on when the applicable sublicense agreement is executed.

 

F-26


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

14. Net loss per share

The following table sets forth the calculation of basic and diluted net loss per common share during the periods presented (in thousands, except share and per share data), which excludes shares which are legally outstanding, but subject to repurchase by the Company:

 

      Year ended
December 31,
 
      2016     2017  

Numerator:

    

Net loss—basic and diluted

   $ (2,542   $ (11,941
  

 

 

 

Denominator:

    

Weighted-average shares outstanding used in computing net loss per share – basic and diluted

     2,599,641       3,596,673  
  

 

 

 

Net loss per share—basic and diluted

   $ (0.98   $ (3.32

 

 

The following outstanding shares were excluded from the computation of the diluted net loss per common share for the periods presented because their effect would have been anti-dilutive.

 

      Year ended
December 31,
 
      2016      2017  

Redeemable convertible preferred stock on an as-converted basis

     3,640,055        15,376,164  

Options to purchase common stock

     30,048        846,163  

Common stock subject to vesting or repurchase

     1,012,707        1,216,308  
  

 

 

 

Total

     4,682,810        17,438,635  

 

 

15. Pro forma net loss per share (unaudited)

The following table sets forth (in thousands, except share and per share amounts) the computation of the Company’s unaudited pro forma basic and diluted net loss per common share after giving effect to the conversion of the redeemable convertible preferred stock using the as-converted method into common stock as though the conversion had occurred at the beginning of the period presented or date of issuance, if later.

 

      Year ended
December 31,
2017
 

Net loss used in computing pro forma net loss per share, basic and diluted

   $ (11,941
  

 

 

 

Weighted-average shares used to compute net loss per share, basic and diluted

     3,596,673  

Pro forma adjustment to reflect assumed conversion of redeemable convertible preferred stock

     9,180,390  
  

 

 

 

Shares used to compute pro forma net loss per share, basic and diluted

     12,777,063  
  

 

 

 

Pro forma net loss per share, basic and diluted

   $ (0.93

 

 

 

F-27


Table of Contents

Eidos Therapeutics, Inc.

Notes to financial statements

 

16. Subsequent events

In February 2018, the Company entered into a Note and Warrant Purchase Agreement with BBP LLC and issued a convertible note in the principal amount of $10.0 million. The note has a maturity date in February 2019 and an annual interest rate of 5.0%. The note is convertible into future preferred stock at a 30% discount to the price paid by investors in the Company’s next preferred equity financing of at least $10.0 million or convertible into common stock at the price per share in an IPO with aggregate proceeds of at least $30.0 million. In connection with the convertible note, the Company issued warrants for the purchase of $4.0 million in shares of the Company’s Series Seed redeemable convertible preferred stock or the Company’s preferred stock in the next equity financing. The exercise period commences upon the earlier of the closing of the next qualified financing and the consummation of a deemed liquidation event. The exercise price of the warrant is the price lesser of the per share in the next equity financing or the purchase price of Series Seed redeemable convertible preferred stock of $1.3248 per share. If the warrant remains outstanding upon the consummation of this offering, the warrant will automatically be deemed net-exercised in full immediately prior to the completion of this offering at the initial public offering price.

The Company has reviewed and evaluated subsequent events through March 22, 2018 the date the financial statements were available for issuance. In connection with the reissuance of the audited financial statements to reflect the 1.196 for 1 stock split as described in Note 1, the Company has evaluated subsequent events through June 7, 2018, the date of the audited financial statements were available to be reissued.

17. Subsequent events – Unaudited

On March 29, 2018, the Company sold an aggregate of 1,476,715 shares of Series B redeemable convertible preferred stock at a purchase price of $10.8348 per share for a total purchase price of $16.0 million and converted $10.0 million of notes payable plus interest into 1,324,823 shares of Series B redeemable convertible preferred stock at a conversion price of $7.5844 per share.

In May 2018, the Company issued 4,430,162 shares of Series B redeemable convertible preferred stock at a purchase price of $10.8348 per share, for total proceeds of $48.0 million. The issuance of the shares is in connection with the additional shares related to the put option asset pertaining to the Series B redeemable convertible preferred stock financing in March 2018. The tranche liability will be remeasured at the closing date of the additional shares to the then fair value and the tranche liability and put option asset balances will be reclassified to redeemable convertible preferred stock.

On May 22, 2018, the Board of Directors approved the amendment to the certificate of incorporation to increase the number of redeemable convertible preferred stock authorized and available for issuance by 369,180 shares.

On June 6, 2018, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a split of the Company’s issued and outstanding common stock at a 1.196 for 1 ratio. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect the stock split for all periods presented. The financial statements have also been retroactively adjusted to reflect a proportional adjustment to the conversion ratio for each series of preferred stock that will be effected in connection with the stock split.

On June 6, 2018 the board of directors increased the authorized number of shares of common stock to 32,292,000 with a par value of $0.001.

 

F-28


Table of Contents

Eidos Therapeutics, Inc.

Unaudited Condensed Balance sheets

(in thousands, except for share and per share amounts)

 

      December 31,     March 31,    

Pro forma

March 31,

 
      2017     2018     2018  

ASSETS

      

CURRENT ASSETS:

      

Cash

   $ 5,497     $ 25,269    

Related party receivable

     67       76    

Prepaid expenses and other current assets

     484       624    
  

 

 

   

Total current assets

     6,048       25,969    

Property and equipment, net

     114       218    

Redeemable convertible preferred stock put option asset

           1,527     $  

Other assets

     181       1,109    
  

 

 

   

TOTAL ASSETS

   $ 6,343     $ 28,823    
  

 

 

   

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY

      

CURRENT LIABILITIES:

      

Accounts payable

   $ 566     $ 1,667    

Related party payable

     372       327    

Accrued expenses and other current liabilities

     1,300       2,744    
  

 

 

   

Total current liabilities

     2,238       4,738    

Redeemable convertible preferred stock tranche liability

           2,028        

Redeemable convertible preferred stock warrant liability

           841        

Other liabilities

     273       439    
  

 

 

   

TOTAL LIABILITIES

     2,511       8,046    
  

 

 

   

Commitments and contingencies (Note 14)

      

Redeemable convertible preferred stock, $0.001 par value; 14,000,000 and 20,088,025 shares authorized as of December 31, 2017 and March 31, 2018, respectively; 12,856,325 and 15,657,863 shares issued and outstanding as of December 31, 2017 and March 31, 2018, respectively; aggregate liquidation preference of $17,032 and $30,354 as of December 31, 2017 and March 31, 2018, respectively; no shares authorized, issued and outstanding, pro forma

     17,028       46,603        

STOCKHOLDERS’ (DEFICIT) EQUITY:

      

Common stock, $0.001 par value; 20,000,000 and 27,000,000 shares authorized as of December 31, 2017 and March 31, 2018, respectively; 5,137,771 and 5,333,010 shares issued and outstanding as of December 31, 2017 and March 31, 2018, respectively; 150,000,000 shares authorized, 24,251,347 issued or outstanding, pro forma

     4       4       24  

Additional paid-in capital

     1,332       4,281       52,206  

Accumulated deficit

     (14,532     (30,111     (30,111
  

 

 

 

TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY

     (13,196     (25,826     22,119  
  

 

 

 

TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY

   $ 6,343     $ 28,823    

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-29


Table of Contents

Eidos Therapeutics, Inc.

Unaudited Condensed Statements of operations

(in thousands, except for share and per share amounts)

 

      Three months ended March 31,  
      2017     2018  

Operating expenses:

    

Research and development (includes related party expense of $5 and $18, respectively)

   $ 2,039     $ 6,034  

General and administrative (includes related party expense of $66 and $318, respectively)

     378       2,143  
  

 

 

 

Total operating expenses

     2,417       8,177  
  

 

 

 

Loss from operations

     (2,417     (8,177

Other income (expense), net

     75       (725

Loss on extinguishment of debt

     —         (6,677
  

 

 

 

Net loss

   $ (2,342   $ (15,579
  

 

 

 

Net loss per share:

    

Basic and diluted

   $ (0.72   $ (3.89
  

 

 

 

Weighted-average shares used in computing net loss per share:

    

Basic and diluted

     3,241,138       4,006,085  
  

 

 

 

Pro forma net loss per share, basic and diluted

     $ (0.80
    

 

 

 

Weighted-average shares used in computing pro forma net loss per share, basic and diluted

       19,574,812  

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-30


Table of Contents

Eidos Therapeutics, Inc.

Unaudited Condensed Statements of redeemable convertible preferred stock and stockholders’ deficit

(in thousands, except for share amounts)

 

      Redeemable  convertible
preferred stock
     Common stock      Additional
paid in
capital
     Accumulated
deficit
    Total
stockholders’
deficit
 
      Shares     Amount      Shares      Amount          

Balance—December 31, 2017

     12,856,325     $ 17,028        5,137,771      $ 4      $ 1,332      $ (14,532   $ (13,196

Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $125 and redeemable convertible preferred stock tranche liability and put option asset of $501

     1,476,715       15,374                                    

Issuance of Series B redeemable convertible preferred stock upon conversion of convertible promissory notes and accrued interest

     1,324,823       10,048                                    

Settlement of embedded derivative liability

           4,153                                    

Beneficial conversion feature related to convertible promissory notes

                                2,360              2,360  

Issuance of common stock to Stanford University in exchange for services and technology

                45,889               7              7  

Issuance of common stock upon exercise of stock options and restricted stock

                  149,350                             

Vesting of restricted stock and early exercised options

                                18              18  

Stock-based compensation expense

                                564              564  

Net loss

                                       (15,579     (15,579
  

 

 

 

Balance—March 31, 2018

     15,657,863     $ 46,603        5,333,010      $ 4      $ 4,281      $ (30,111   $ (25,826

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-31


Table of Contents

Eidos Therapeutics, Inc.

Unaudited Condensed Statements of cash flows

(in thousands)

 

      Three months ended
March 31,
 
      2017     2018  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net loss

   $ (2,342   $ (15,579

Adjustments to reconcile net loss to net cash used in operating activities:

    

Depreciation and amortization

           10  

Stock-based compensation

     38       564  

Accrued interest on convertible promissory notes

           48  

Change in fair value of redeemable convertible preferred stock tranche liability

     (75      

Change in fair value of redeemable convertible preferred stock warrant liability

           (37

Amortization of debt discount

           713  

Loss on extinguishment of debt

           6,677  

Changes in operating assets and liabilities:

    

Related party receivable

           (9

Prepaid expenses and other current assets

     (3     (140

Other assets

           (741

Accounts payable

     364       1,102  

Accrued expenses and other liabilities

     258       1,546  

Related party payable

     (59     (45
  

 

 

 

Net cash used in operating activities

     (1,819     (5,891
  

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Purchase of property and equipment

     (3     (114
  

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Proceeds from issuance of redeemable convertible preferred stock, net of issuance
costs

     4,000       15,875  

Proceeds from issuance of convertible promissory notes

           10,000  

Payment of deferred offering costs

           (187

Proceeds from issuance of common stock upon exercise of stock options and restricted stock

     6       89  
  

 

 

 

Net cash provided by financing activities

     4,006       25,777  
  

 

 

 

Net increase in cash

     2,184       19,772  

Cash—Beginning of period

     1,956       5,497  
  

 

 

 

Cash—End of period

   $ 4,140     $ 25,269  
  

 

 

 

SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ITEMS:

    

Deferred offering costs in accounts payable and accrued liabilities

   $     $ 760  
  

 

 

 

Vesting of restricted stock and early exercised options

   $     $ 18  
  

 

 

 

Conversion of convertible promissory notes and accrued interest into redeemable convertible preferred stock

   $     $ 10,048  

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

F-32


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

1. The company

Eidos Therapeutics, Inc., or the Company, was incorporated as an S corporation in the state of Delaware on August 6, 2013. The Company was converted into a C corporation on April 4, 2016 in conjunction with its Series Seed redeemable convertible preferred stock financing. The Company is advancing a drug candidate to treat multiple forms of transthyretin amyloidosis, which leads to organ damage, loss of organ function and eventual death from abnormal buildup of protein deposits predominantly in the heart and peripheral nervous system. Through March 31, 2018, the Company has been primarily engaged in business planning, research, recruiting personnel and raising capital. The Company is headquartered in San Francisco, California and it operates as one operating segment.

Liquidity and going concern

The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of $30.1 million as of March 31, 2018. The Company has a cash balance of $25.3 million as of March 31, 2018 and in May 2018, the Company issued 4,430,162 shares of Series B redeemable convertible preferred stock for total net proceeds of $48.0 million. The Company has historically financed its operations primarily through the sale of redeemable convertible preferred stock. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses to continue for the foreseeable future. The Company believes that its cash as of March 31, 2018, without any future financing, will not be sufficient for the Company to continue as a going concern for at least one year from the issuance date of its unaudited condensed financial statements for the three months ended March 31, 2018. The Company believes that this raises substantial doubt about its ability to continue as a going concern. As a result, the Company will be required to raise additional capital. If sufficient funds on acceptable terms are not available when needed, the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. Failure to manage discretionary spending or raise additional financing, as needed, may adversely impact the Company’s ability to achieve its intended business objectives. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.

On June 6, 2018, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a split of the Company’s issued and outstanding common stock at a 1.196 for 1 ratio, which was effected on June 7, 2018. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect the stock split for all periods presented. The financial statements have also been retroactively adjusted to reflect a proportional adjustment to the conversion ratio for each series of preferred stock that will be effected in connection with the stock split.

 

F-33


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

2. Summary of significant accounting policies

Basis of preparation

These financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. These financial statements include transactions with BridgeBio Pharma LLC, a controlling investor in the Company. For the periods presented, BridgeBio Pharma LLC has provided consulting and management services to the Company in the ordinary course of business, including certain executive personnel, facility related costs, advisory services, insurance costs and other general corporate expenses. These allocations were made based on direct usage, when identifiable, with the remainder allocated primarily based on a proportional share of headcount. The Company’s historical financial statements do not purport to reflect what the Company’s results of operations, financial position, or cash flows would have been if the Company had operated as an independent entity during the periods presented. Management believes the basis on which the expenses have been allocated to be a reasonable reflection of the utilization of services provided to or the benefit received by the Company during the periods presented. For more information on the allocated costs and related party transactions, see Note 6—Related party transactions.

Unaudited Interim Condensed Financial Statements

The interim condensed balance sheet as of March 31, 2018, and the condensed statements of operations, and cash flows for the three months ended March 31, 2017 and 2018 are unaudited. The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of March 31, 2018 and its results of operations and cash flows for the three months ended March 31, 2017 and 2018. The financial data and the other financial information disclosed in these notes to the financial statements related to the three-month periods are also unaudited. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018, or for any other future annual or interim period. The condensed balance sheet as of December 31, 2017, included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included elsewhere in this prospectus.

Use of estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the fair value of the redeemable convertible preferred stock tranche liability, the preferred stock put asset, the fair value of the redeemable convertible preferred stock warrant liability, the fair value of the Company’s common stock, stock-based compensation, the useful lives of fixed assets, accruals for research and development activities and income taxes. Management bases its estimates on historical experience and on other relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

 

F-34


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Pro forma balance sheet

The pro forma balance sheet as of March 31, 2018 presents the Company’s stockholders’ equity as though all of the Company’s outstanding redeemable convertible preferred stock had converted into 18,726,796 shares of common stock, the redeemable convertible preferred stock warrants have been net exercised into shares of common stock immediately prior to the completion of a firm commitment underwritten public offering in which the public offering proceeds raised equals or exceeds $75.0 million (IPO), the settlement of the redeemable convertible preferred stock put option asset, and the settlement of the redeemable convertible preferred stock tranche liability. The pro forma balance sheet does not assume any proceeds from the offering.

Deferred offering costs

Deferred offering costs, which include legal, accounting, printer and filing fees, related to the IPO are capitalized. The deferred offering costs will be offset against proceeds from the IPO upon the effectiveness of the offering. In the event that the offering is terminated, all capitalized deferred offering costs will be immediately expensed. As of March 31, 2018, $947,000 of deferred offering costs were capitalized, which are included in other assets on the condensed balance sheet. There were no such costs capitalized as of December 31, 2017.

Accrued research and development

The Company records accrued expenses for estimated costs of research and development activities conducted by third-party service providers, which include preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and include these costs in accrued expenses and other current liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company’s research and development expenses.

The Company estimates the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, the Company adjusts its accrued estimates. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may vary from its estimates and could result in its reporting amounts that are too high or too low in any particular period. The Company’s accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers. The Company records advance payments to service providers as prepaid assets, which are expensed as the contracted services are performed. To date, there have been no material differences from the Company’s accrued expenses to actual expenses.

Accrued repurchase liability for common stock

The Company records as a liability, within accrued expenses and other current liabilities, the purchase price of unvested common stock that the Company has a right to repurchase if and when the stockholder ceases to be a service provider to the Company before the end of the requisite service period. The proceeds are recorded as a

 

F-35


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

liability and the proceeds related to the vested common stock is reclassified to additional paid-in capital as the Company’s repurchase right lapses.

Redeemable convertible preferred stock put option asset

The Company has determined that its right to cause the Series B shareholders to purchase additional shares of redeemable convertible preferred stock upon the achievement of the specified milestone represented a freestanding financial instrument. The instrument is classified as an asset on the balance sheets based on its relative fair value. The put option asset balance will be reclassified to redeemable convertible preferred stock upon the settlement of the additional shares.

Redeemable convertible preferred stock tranche liability

The Company has determined that its obligation to issue additional shares of redeemable convertible preferred stock upon the achievement of certain milestones or at the option of the holder represents a freestanding financial instrument. The instrument is classified as a liability on the balance sheets and is subject to remeasurement at each balance sheet date and any change in fair value is recognized through other income (expense), net in the condensed statements of operations.

Redeemable convertible preferred stock warrant liability

The Company’s redeemable convertible preferred stock warrants require liability classification and accounting as the underlying preferred stock is considered redeemable. At initial recognition, the warrants are recorded at their estimated fair value. The warrants are subject to remeasurement at each balance sheet date, with changes in fair value recognized as a component of other income (expense), net.

The Company will continue to adjust the liability for changes in fair value until the earlier of (i) exercise or expiration of the warrants, (ii) conversion of the redeemable convertible preferred stock warrants into equity classified common stock warrants or (iii) the completion of an IPO, at which time all redeemable convertible preferred stock warrants will be net exercised into shares of common stock and the related redeemable convertible preferred stock warrant liability will be reclassified to common stock and additional paid-in capital.

Comprehensive loss

Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.

Net loss per share

Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share since the effects of potentially dilutive securities are antidilutive given the net loss of the Company.

 

F-36


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Pro forma net loss per share

Pro forma basic and diluted net loss per share has been computed to give effect to the conversion of the Company’s redeemable convertible preferred stock into common stock as if such conversion had occurred at the beginning of the period or the date of issuance, if later. In addition, the numerator in the pro forma basic and diluted net loss per common share calculation has been adjusted to remove gains or losses resulting from the remeasurement of the redeemable convertible preferred stock warrant liability as the warrants will be net exercised into common stock and the related redeemable convertible preferred stock warrant liability will be reclassified to common stock and additional paid-in capital upon the completion of an IPO of the Company’s common stock. The pro forma net loss per share does not include the shares expected to be sold and related proceeds to be received from the Company’s proposed initial public offering.

Recent accounting pronouncements

In February 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-02, Leases (Topic 842), which for operating leases requires the lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The guidance also requires a lessee to recognize single lease costs, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company has not determined the potential effects of this ASU on its financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The areas affected by ASU 2016-15 are debt prepayment and debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies), distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. Specifically, under this guidance, cash payments for debt prepayment or debt extinguishment costs will be classified as cash outflows for financing activities. On January 1, 2018, the Company adopted this guidance and applied this amendment using a retrospective transition method to each period presented in the Company’s condensed statements of cash flows. The condensed statement of cash flows for the periods ended March 31, 2017 and 2018 have been presented in accordance with this amendment. The adoption of this amendment did not have a material impact on the Company’s condensed financial statements and disclosures.

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815) (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. This update simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are

 

F-37


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

common in warrants, preferred shares and convertible debt instruments issued by private companies and development-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. The provisions of this update related to down rounds are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact the adoption of this standard will have on our financial statements and related disclosures.

3. Fair value measurement

Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

Financial liabilities measured and recognized at fair value are as follows (in thousands):

 

      March 31, 2018  
      Level 1      Level 2      Level 3      Total  

Assets:

           

Redeemable convertible preferred stock put option asset

   $      —      $      —      $ 1,527      $ 1,527  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total financial assets

   $      $      $ 1,527      $ 1,527  

Liabilities:

           

Redeemable convertible preferred stock tranche liability

   $      $      $ 2,028      $ 2,028  

Redeemable convertible preferred stock warrant liability

                   841        841  
  

 

 

 

Total financial liabilities

   $      $      $ 2,869      $ 2,869  

 

 

 

F-38


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

There were no financial assets outside of cash in an operating account as of December 31, 2017. There were no transfers between Level 1, Level 2 and Level 3 categories during the periods presented. There were no financial liabilities measured at fair value as of December 31, 2017. Following are the Company’s Level 3 financial liabilities as of March 31, 2018:

Redeemable convertible preferred stock tranche liability

The fair value of the redeemable convertible preferred stock tranche liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. The Company estimates the fair value of the redeemable convertible preferred stock tranche liability using the Black-Scholes option pricing model (See Note 8). The following table sets forth a summary of the changes in the fair value of the Company’s redeemable convertible preferred stock tranche liability (in thousands):

 

     

Three months
ended
March 31,

2018

 

Redeemable convertible preferred stock tranche liability:

  

Balance—beginning of period

   $  

Issuance of Series B redeemable convertible preferred stock tranche liability

     2,028  

Loss (gain) on the change in fair value upon revaluation

      
  

 

 

 

Balance—end of period

   $ 2,028  

 

 

Redeemable convertible preferred stock warrant liability

The fair value of the redeemable convertible preferred stock warrant liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. The Company estimates the fair value of the redeemable convertible preferred stock warrant liability using the Black-Scholes option pricing model (See Note 5). The following table sets forth a summary of the changes in the fair value of the Company’s redeemable convertible preferred stock warrant liability (in thousands):

 

     

Three months
ended
March 31,

2018

 

Redeemable convertible preferred stock warrant liability:

  

Balance—beginning of period

   $  

Issuance of redeemable convertible preferred stock warrant liability

     878  

Loss (gain) on the change in fair value upon revaluation

     (37
  

 

 

 

Balance—end of period

   $ 841  

 

 

Embedded derivative in convertible note

The convertible note issued in February 2018 had a redemption feature which was determined to be an embedded derivative requiring bifurcation and separate accounting (See Note 5). The fair value of the derivative was determined based on an income approach that identified the cash flows using a

 

F-39


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

“with-and-without” valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based largely on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event. The following table sets forth a summary of the changes in the fair value of the Company’s embedded derivative in convertible note (in thousands):

 

     

Three months ended
March 31,

2018

 

Derivative instrument:

  

Balance—beginning of period

   $  

Initial fair value of the embedded derivative issued with the convertible note

     4,153  

Loss (gain) on the change in fair value upon revaluation

     0  

Extinguishment of the embedded derivative

     (4,153
  

 

 

 

Balance—end of period

   $         —  

 

 

4. Condensed balance sheet components

Prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

      December 31,
2017
     March 31,
2018
 

Prepaid clinical and research related expenses

   $ 432      $ 525  

Other current assets

     52        99  
  

 

 

 

Total prepaid expenses and other current assets

   $ 484      $ 624  

 

 

Property and equipment, net

Property and equipment, net consisted of the following (in thousands):

 

      December 31,
2017
    March 31,
2018
 

Furniture and computer equipment

   $ 41     $ 147  

Leasehold improvements

     77       85  
  

 

 

 

Total property and equipment

     118       232  

Less: accumulated depreciation and amortization

     (4     (14
  

 

 

 

Total property and equipment, net

   $ 114     $ 218  

 

 

Depreciation and amortization expense for the three months ended March 31, 2018 was $10,000. No depreciation and amortization expense recognized for the three months ended March 31, 2017.

 

F-40


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

      December 31,
2017
     March 31,
2018
 

Accrued research and development costs

   $ 564      $ 1,006  

Accrued employee related expenses

     606        978  

Liability for unvested stock, short-term

     109        179  

Accrued other current liabilities

     21        581  
  

 

 

 

Total accrued expenses and other current liabilities

   $ 1,300      $ 2,744  

 

 

As of December 31, 2017 and March 31, 2018, the balances of $208,000 and $372,000, respectively, in other liabilities related to the long-term liability for unvested stock.

5. Convertible promissory notes

In February 2018, the Company entered into a Note and Warrant Purchase Agreement with BBP LLC and Stanford University. The Company issued two convertible promissory notes in an aggregate principal amount of $10.0 million. The notes had a maturity date of the earliest of a qualified financing, a deemed liquidation event, a qualified initial public offering or February 2019. The convertible promissory notes had an annual interest rate of 5.0%. The convertible promissory notes were convertible into future preferred stock at a 30% discount to the price paid by investors in the Company’s next preferred equity financing of at least $10.0 million or convertible into common stock at the price per share in an IPO with aggregate proceeds of at least $30.0 million. In connection with the convertible promissory notes, the Company issued warrants for the purchase of $4.0 million in shares of the Company’s Series Seed redeemable convertible preferred stock or the Company’s preferred stock in the next equity financing. The exercise period commences upon the earlier of the closing of the next qualified financing and the consummation of a deemed liquidation event. The exercise price of the warrant is the price per share in the next equity financing if the warrant is exercisable for the Company’s redeemable convertible preferred stock in the next qualified financing, or $1.3248 per share if the warrant is exercisable for shares of Series Seed redeemable convertible preferred stock. If the warrant remains outstanding upon the consummation of this offering, the warrant will automatically be deemed net-exercised in full immediately prior to the completion of this offering at the initial public offering price.

Upon issuance of the convertible promissory notes, the Company recorded the fair value of the warrants of $877,000 as a debt discount and redeemable convertible preferred stock warrant liability. The convertible promissory notes also contained a redemption feature which was determined to be an embedded derivative requiring bifurcation and separate accounting. The fair value of the embedded derivative liability at issuance was determined to be $4.2 million and was recorded as an additional debt discount. The debt discount was accreted using the effective interest method as additional interest expense over the term of the convertible note. Changes in the fair value of the embedded derivative and redeemable convertible preferred stock warrant liability have also been recorded within other income (expense), net, in the condensed statement of operations for the three months ended March 31, 2018.

During the three months ended March 31, 2018, the Company recognized interest expense of $761,000 related to the accrued interest and amortization of debt discount.

 

F-41


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

As the convertible notes payable contained an embedded conversion feature that does not qualify for derivative treatment, the Company evaluated if there was beneficial conversion feature (BCF). The Company determined there was a BCF of $2.4 million as the effective conversion rate of the convertible note was below market value. The Company accounted for the value of the BCF as a debt discount, which was being accreted to interest expense over the life of the related debt using the effective interest method. The value of the BCF was recorded to additional paid-in capital with the offset to discount on convertible notes payable. The debt discount was to be accreted to other income (expense), net over the one-year original term of the convertible notes payable. The Company recorded $228,000 as an expense related to this debt discount during the three months ended March 31, 2018. On March 29, 2018 the Company converted the convertible notes payable into Series B redeemable convertible preferred stock, and the remaining amount of unamortized debt discount was recorded as an extinguishment of debt.

In March 2018, as a result of the Series B redeemable convertible preferred stock financing event (see Note 7), the outstanding principal and accrued interest of $10.0 million related to the convertible promissory notes automatically converted into 1,324,823 shares of Series B redeemable convertible preferred stock using a conversion price of $7.5844. Consequently, the Company recorded $6.7 million related to the loss on the extinguishment of the convertible promissory notes. In the addition, the warrants associated with the convertible note became warrants to purchase 369,180 shares of the Company’s Series B redeemable convertible preferred stock at an exercise price of $10.8348 per share.

6. Related party transactions

BridgeBio Pharma LLC and its affiliates, or BBP LLC, is a controlling investor in the Company, as it owned 75% and 71% of the Company’s total outstanding shares as of December 31, 2017 and March 31, 2018. In April 2016, the Company began receiving consulting, management, facility and infrastructure services pursuant to a services agreement with BBP LLC. The initial agreement was entered into on March 1, 2016 and was superseded by the subsequent agreement effective as of May 1, 2017. The Company incurred the following expenses: rent of $5,400 and $8,400, facility related costs of $1,700 and $45,800 and consulting expenses of $64,700 and $282,500 for the three months ended March 31, 2017 and 2018, respectively. As of March 31, 2018, the Company had an outstanding receivable from BBP LLC of $76,000 related to providing services to other subsidiaries of BBP LLC. As of March 31, 2018, the Company had an outstanding liability due to BBP LLC of $327,000.

In April 2016, the Company entered into a consulting agreement with Dr. Graef, one of the Company’s founders. Pursuant to the consulting agreement, Dr. Graef agreed to provide consulting services in connection with the discovery and development of novel TTR stablizers. As compensation for these services, Dr. Graef is entitled to an annual fee in the amount of up to $150,000 and reimbursement by the Company for pre-approved expenses. The consulting agreement has a term of four years but may be terminated by either party for any reason with thirty days’ prior notice. During the three months ended March 31, 2017 and 2018, the Company incurred $37,500 and $83,000, respectively, for services under the consulting agreement.

In August 2016, the Company entered into a consulting agreement with Dr. Alhamadsheh, one of the Company’s founders. Pursuant to the consulting agreement, Dr. Alhamadsheh agreed to provide consulting services in connection with the discovery and development of novel TTR stablizers. As compensation for these services, Dr. Alhamadsheh is entitled to an annual fee in the amount of up to $115,000 and reimbursement by the Company for pre-approved expenses. The consulting agreement has a term of two years but may be terminated

 

F-42


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

by either party for any reason with thirty days’ prior notice. During the three months ended March 31, 2017 and 2018, the Company incurred $28,700 and $111,800, respectively, for services under the consulting agreement.

7. Redeemable convertible preferred stock

In March 2018, the Company sold an aggregate of 1,476,715 shares of Series B redeemable convertible preferred stock financing in an initial closing for total gross proceeds of $16.0 million. An additional 4,430,162 shares of Series B redeemable convertible preferred stock may be issued in an additional closing contingent upon the release of specified data study either upon the request of the Company for investors to purchase the shares (purchased put option) or the investors may call for the purchase of such shares (tranche liability or call option). The Company has determined that its right to cause the Series B shareholders to purchase additional shares of redeemable convertible preferred stock upon the achievement of the specified milestone represented a freestanding financial instrument. In addition, the Company determined it was obligated to sell additional shares of Series B redeemable convertible preferred stock contingent upon the achievement of the specified milestone. This additional closing was also deemed to be freestanding financial instrument.

Upon issuance of the Series B redeemable convertible preferred stock, the Company recorded the redeemable convertible preferred stock tranche liability incurred in connection with its Series B redeemable convertible preferred stock as a derivative financial instrument liability at the fair value of $2.0 million on the date of issuance, and will remeasure the liability on each subsequent balance sheet date. The changes in fair value are recognized as a gain or loss within other income (expense), net in the statements of operations and the liability is remeasured at each reporting period and settlement of the related tranche closing. Additionally, the Company recorded the redeemable convertible preferred stock put option asset, based on its relative fair value of $1.5 million as an asset on the balance sheets at March 31, 2018.

The Company also converted outstanding promissory notes and accrued interest of $10.0 million (see Note 5) into 1,324,823 shares of Series B redeemable convertible preferred stock concurrently with the initial closing of the Series B redeemable convertible preferred stock financing.

Redeemable convertible preferred stock as of December 31, 2017 consists of the following:

 

Series    Shares
authorized
     Shares
outstanding
     Price
per share
     Proceeds, net of
issuance cost
(in thousands)
     Liquidation
amount
(in thousands)
 

Seed

     14,000,000        12,856,325      $ 1.3248      $ 16,920      $ 17,032  

 

 

Redeemable convertible preferred stock as of March 31, 2018 consists of the following:

 

Series    Shares
authorized
     Shares
outstanding
     Price
per share
     Proceeds, net of
issuance cost
(in thousands)
     Liquidation
amount
(in thousands)
 

Seed

     12,856,325        12,856,325      $ 1.3248      $ 16,920      $ 17,032  

Series B

     7,231,700        2,801,538      $ 10.8348        25,923        30,354  
  

 

 

 

Total

     20,088,025        15,657,863         $ 42,843      $ 47,386  

 

 

 

F-43


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

The holders of the redeemable convertible preferred stock have various rights and preferences as follows:

Voting rights

The holders of redeemable convertible preferred stock are entitled to vote on all matters on which the common stockholders are entitled to vote. Holders of redeemable convertible preferred and common stock generally vote together as a single class, not as separate classes. Each holder of redeemable convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of redeemable convertible preferred stock held by such holder are convertible.

As long as at least 250,000 shares of each class of redeemable convertible preferred stock remain outstanding, the Company must obtain approval from a majority of the holders of the then outstanding shares of Series B or Series Seed redeemable convertible preferred stock in order to alter or change the rights, preferences and privileges of preferred stock, change the authorized number of preferred and common stock, create a new class or series of shares having any rights, preferences or privileges superior to or on parity with any outstanding shares of redeemable convertible preferred stock, purchase or redeem or declare or pay any dividend or distribution on shares of capital stock (subject to certain exceptions), merge, consolidate with or implement a reorganization that would result in the transfer of 50% of the voting power of the Company, sell all or substantially all of the Company’s assets, liquidate, dissolve or wind up the business and affairs of the Company, or change the authorized number of directors.

Dividends

The holders of shares of Series B redeemable convertible preferred stock, in preference to both the holders of Series Seed redeemable convertible preferred stock and common stock, are entitled to receive noncumulative cash dividends at a rate of 8% per share, only when, as and if declared by the board of directors. The holders of shares of Series Seed redeemable convertible preferred stock, in preference to the holders of common stock, are entitled to receive noncumulative cash dividends at a rate of 8% per share, only when, as and if declared by the board of directors. In the event dividends are paid on any share of common stock, the Company will pay an additional dividend on all outstanding shares of preferred stock in a per share amount equal (on an as-converted to common stock basis) to the amount paid or set aside for each share of common stock. No dividends were declared as of December 31, 2017 and March 31, 2018.

Liquidation preference

A liquidation, dissolution or winding up of the Company, a merger or consolidation after which the shares of capital stock of the Company immediately prior to such transaction do not represent or are not exchanged for shares representing a majority in voting power of the surviving or resulting entity, or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets would trigger a redemption event. Accordingly, the redemption event is outside the control of the Company, and all shares of preferred stock have been presented outside of permanent equity. Further, the Company has elected not to adjust the carrying values of the redeemable convertible preferred stock to the liquidation preference of such shares, since it is uncertain whether or when a redemption event will occur. Subsequent adjustments to increase the carrying value to the redemption values will be made when it becomes probable that such redemption will occur.

 

F-44


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

In the event of any liquidation, dissolution or winding up of the Company, a merger or consolidation after which the shares of capital stock of the Company immediately prior to such transaction do not represent or are not exchanged for shares representing a majority in voting power of the surviving or resulting entity, or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets, the holders of Series B redeemable convertible preferred stock are entitled to receive prior to and in preference to any distribution to holders of Series Seed redeemable convertible preferred stock and common stock, an amount equal to the greater of (i) $10.8348 per share plus any declared but unpaid dividends on such shares, or (ii) such amount per share as would have been payable had all Series B redeemable convertible preferred stock been converted into common stock prior to such event. After payment of all preferential amounts required to be paid to the holders of Series B redeemable convertible preferred stock, the holders of Series Seed redeemable convertible preferred stock are entitled to receive prior to and in preference to any distribution to holders of common stock, an amount equal to the greater of (i) $1.3248 per share plus any declared but unpaid dividends on such shares, or (ii) such amount per share as would have been payable had all Series Seed redeemable convertible preferred stock been converted into common stock prior to such event. The remaining assets, if any, shall be distributed to the holders of common stock. Should the Company’s legally available assets be insufficient to satisfy the liquidation preferences, the funds will be distributed ratably among the holders of redeemable convertible preferred stock in proportion to the preferential amount each holder is otherwise entitled to receive.

Conversion

Each share of Series Seed redeemable convertible preferred stock is convertible, at the option of the holder, into the number of shares of common stock into which such shares are convertible at the then effective conversion ratio. The initial conversion price per share for Series B redeemable convertible preferred stock is $10.8348 per share. The initial conversion price per share for Series Seed redeemable convertible preferred stock is $1.3248 per share. The initial conversion price is subject to adjustment from time to time for events such as future stock splits, combinations and dividends. Additionally, the conversion price is subject to adjustment from time to time in the event of dilutive issuances based on a broad-based weighted-average anti-dilution formula. As of December 31, 2017 and March 31, 2018, the redeemable convertible preferred stock is convertible into common stock on a one for 1.196 basis.

Each share of redeemable convertible preferred stock is convertible into common stock automatically upon the closing of the sale of shares of common stock in a firm commitment underwritten public offering in which the public offering aggregate gross proceeds raised exceeds $75.0 million. In addition, all outstanding shares of Series B redeemable convertible preferred stock is convertible into common stock automatically upon the Company’s receipt of a written request for such conversion from the holders of a majority of the then outstanding shares of Series B redeemable convertible preferred stock. Similarly, all outstanding shares of Series Seed redeemable convertible preferred stock is convertible into common stock automatically upon the Company’s receipt of a written request for such conversion from the holders of a majority of the then outstanding shares of Series Seed redeemable convertible preferred stock.

In the event that any holder of Series B redeemable convertible preferred stock is a defaulting purchaser with respect to the additional closing described in the Series B Preferred Stock Purchase Agreement, or the Agreement, then each two shares of Series B redeemable convertible preferred stock held by such holder will automatically be converted into one share of common stock, (a) effective upon the consummation of the additional closing, or (b) if such additional closing does not occur as a result of such holder’s failure to purchase

 

F-45


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

additional shares of Series B redeemable convertible preferred stock, effective upon the date on which the holder became a defaulting purchaser pursuant to the Agreement.

Redemption and classification

The Company has classified the redeemable convertible preferred stock as mezzanine equity on the condensed balance sheets as the stock is contingently redeemable. Upon the occurrence of certain change in control events that are outside the Company’s control, including liquidation, sale or transfer of the Company, holders of the redeemable convertible preferred stock can cause redemption for cash to the extent permitted by applicable law.

8. Redeemable convertible preferred stock tranche liability and put option asset

In March 2018, the Company entered into a Series B Preferred Stock Purchase Agreement, or the Agreement, for the issuance of up to 7,231,700 shares of Series B redeemable convertible preferred stock at a price of $10.8348 per share in two closings. Upon the initial closing on March 29, 2018, 1,476,715 shares of Series B redeemable convertible preferred stock were issued for gross proceeds of $16.0 million and 1,324,823 shares were issued upon conversion of the outstanding convertible promissory note principal balance and accrued interest of $10.0 million.

According to the terms of the Agreement, the Company may issue 4,430,162 shares under the same terms as the initial closing, in an additional closing contingent upon the achievement of certain milestone. Either the investors or the Company may provide written notice for the additional closing to occur.

The Company has determined that the its obligation to issue additional shares of its redeemable convertible preferred stock and the Company’s right to request investors purchase additional shares of its redeemable convertible preferred stock represent freestanding financial instruments. The freestanding redeemable convertible preferred stock tranche liability was initially recorded at fair value, with fair value changes recorded within other income (expense), net in the condensed statement of operations. The purchased put option was recorded at fair value without subsequent remeasurement. The Company will continue to adjust the tranche liability for changes in the fair value until the settlement of the redeemable convertible preferred stock additional closing. At such time, any remaining value of the redeemable convertible preferred stock tranche liability and the put option asset will be reclassified to redeemable convertible preferred stock with no further remeasurement required. The Company has recorded a redeemable convertible preferred stock tranche liability and a put option asset in March 2018 of $2.0 million and $1.5 million, respectively, related to the Series B redeemable convertible preferred stock financing.

The Company estimated the fair value of the preferred stock liability and the put option asset using a Black-Scholes option pricing model using the following assumptions:

Expected term—The expected term represents the period for which the redeemable convertible preferred stock tranche liability and put option asset are expected to be outstanding, which is estimated to be the remaining contractual term.

Expected volatility—The volatility data was estimated based on a study of publicly traded industry peer companies, as there is no trading history for our redeemable convertible preferred stock. For purposes of identifying these comparable peer companies, the Company considered the industry, stage of development, size

 

F-46


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

and financial leverage. The Company has measured historical volatility over a period equivalent to the expected term and believes that historical volatility provides a reasonable estimate of future expected volatility.

Expected dividends—The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company currently has no history or expectation of paying cash dividends on its redeemable convertible preferred stock.

Risk-free interest rate—The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the redeemable convertible preferred stock tranche liability and put option asset.

The Company used the following assumptions: a term of 0.08 years, a risk-free rate of 1.63%, a volatility of 36.4%, and a dividend yield of 0.0%.

9. Common stock

Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of the preferred stockholders.

The Company has reserved common stock, on an as-converted basis, for issuance as follows:

 

      December 31,
2017
     March 31,
2018
 

Redeemable convertible preferred stock outstanding, as-converted

     15,376,164        18,726,796  

Options issued and outstanding

     846,166        560,128  

Options available for future grants

     670,994        807,682  

Series B convertible stock warrant, as-converted

            441,538  
  

 

 

 

Total

     16,893,324        20,536,144  

 

 

10. Stock option plan

The 2016 Equity Incentive Plan, or the 2016 Plan, award activity is as follows (in thousands, except for share and per share data and years):

 

      Number of
options
available for
grant
    Options
outstanding
    Weighted-
average
exercise
price per
option
     Weighted-
average
remaining
contractual
life (years)
    

Aggregate

intrinsic

value

 

Outstanding—December 31, 2017

     670,994       846,166     $ 0.59        9.97      $ 4,384  

Granted

     (185,228     185,228       2.49        

Exercised

           (149,350     1.70        

Cancelled

     321,916       (321,916     0.59        
  

 

 

 

Outstanding—March 31, 2018

     807,682       560,128     $ 0.91        9.73      $ 3,541  
  

 

 

 

Vested and expected to vest—March 31, 2018

       560,128     $ 0.91        9.73      $ 3,541  
  

 

 

 

Exercisable—March 31, 2018

       73,325     $ 1.01        9.63      $ 349  

 

 

 

F-47


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Aggregate intrinsic value represents the difference between the Company’s estimated fair value of its common stock and the exercise price of outstanding in–the–money options. The total intrinsic value of options exercised was zero and $828,000 for the three months ended March 31, 2017 and March 31, 2018, respectively.

The total fair value of shares vested during the three months ended March 31, 2017 and March 31, 2018 was $38,000 and $564,000, respectively.

Stock options valuation

The estimated grant-date fair values of the employee and non-employee stock options for the three months ended March 31, 2017 were calculated using the Black-Scholes valuation model, based on the following weighted-average assumptions:

 

      Three months ended
March 31, 2017
 
      Employee      Non-employee  

Expected term (in years)

     5.04        10  

Expected volatility

     75.69%        75.69%  

Risk-free interest rate

     2.02%        2.49%  

Expected dividend

             

 

 

The estimated grant-date fair values of the employee and non-employee stock options for the three months ended March 31, 2018 were calculated using the Black-Scholes valuation model, based on the following weighted-average assumptions:

 

      Three months ended
March 31, 2018
 
      Employee      Non-employee  

Expected term (in years)

     6.08        9.95  

Expected volatility

     69.08%        69.08%  

Risk-free interest rate

     2.69%        2.73%  

Expected dividend

             

 

 

Accrued repurchase liability for common stock early exercises

During the three months ended March 31, 2017 and 2018, there were 854,570 and 1,285,770 shares, respectively, of common stock issued upon the early exercise of stock options prior to the vesting of the underlying shares. These shares are subject to repurchase by the Company at the original issuance price upon termination of the services received from the holder of the option. The right to repurchase these shares generally lapses with respect to 25% of the shares underlying the option after one year of service to the Company and 1/48 of the shares underlying the original grant per month over 36 months thereafter. The shares purchased by the employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the balance sheets. As of December 31, 2017 and March 31, 2018, the Company recorded $287,000 and $551,000, respectively, associated with shares issued upon the early exercise of stock options that are subject to repurchase rights as a liability.

 

F-48


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Restricted stock

In December 2017, the Company issued 390,546 shares of common stock for no consideration to the founders pursuant to the Series Seed Preferred Stock Purchase Agreement and license agreement in connection with certain anti-dilution rights held by these parties. If the shares issued under the license agreement represent less than 1% of the shares issued and outstanding common stock on an as-converted basis, the Company will issue additional common stock to the founders and Stanford University. The Company has the right to repurchase the common stock at the fair value per share on the date of repurchase, which right lapses as the shares vest, which is 25% cliff after one year and monthly thereafter over 36 months. In order to vest, the holders are required to provide continued service to the Company. As of December 31, 2017 and March 31, 2018, 390,546 and 390,546 shares remained subject to repurchase.

The Company recognizes stock-based compensation expense over the period in which the related services from the founders are received. Stock-based compensation expense related to the restricted stock is recognized based on the vesting date fair value of stock using Black-Scholes pricing model. During the three months ended March 31, 2017 and March 31, 2018 the Company recognized zero and $212,000 stock-based compensation expense related to the restricted stock.

During the three months ended March 31, 2017 and 2018, the Company issued 66,113 shares and 149,350 shares of common stock to an employee at a purchase price ranging from $0.15 to $5.77 per share. These shares are subject to repurchase by the Company at the fair value per share on the date of repurchase. The right to repurchase these shares lapses with respect to 25% of the underlying shares after one year of service to the Company and 1/48th of the shares per month over 36 months thereafter or 1/48th of the share per month over 48 months. The cash received for the purchase of these shares was recorded as a liability on the balance sheets. As of December 31, 2017 and March 31, 2018, the Company recorded $30,000 and $272,000, respectively, associated with 134,789 shares and 256,713 shares, respectively, remained subject to repurchase rights as a liability.

Stock-based compensation expense

During the three months ended March 31, 2017, the Company granted stock options and restricted stock awards to employees and non-employees to purchase 66,113 and 10,871 shares of common stock, respectively, with a weighted-average grant date fair value of $0.12 and $0.09 per share, During the three months ended March 31, 2018, the Company granted stock options and restricted stock awards to employees and non-employees to purchase 149,349 and 35,880 shares of common stock, respectively, with a weighted-average grant date fair value of $6.40 and $5.71 per share, respectively.

Total stock-based compensation recognized for both employees and non-employees was as follows (in thousands):

 

      Three months ended
March 31,
 
      2017      2018  

Research and development

   $ 37      $ 556  

General and administrative

     1        8  
  

 

 

 

Total stock-based compensation expense

   $ 38      $ 564  

 

 

 

F-49


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

As of March 31, 2018, there was $7.8 million of total unrecognized compensation cost related to unvested stock-based compensation arrangements under the 2016 Plan. The unrecognized stock-based compensation cost is expected to be recognized over a weighted-average period of 3.48 years.

11. Net loss per share

The following table sets forth the calculation of basic and diluted net loss per common share during the periods presented (in thousands, except for share and per share data), which excludes shares which are legally outstanding, but subject to repurchase by the Company:

 

      Three months ended
March 31,
 
      2017     2018  

Numerator:

    

Net loss—basic and diluted

   $ (2,342   $ (15,579
  

 

 

 

Denominator:

    

Weighted-average shares outstanding used in computing net loss per share – basic and diluted

     3,241,138       4,006,085  
  

 

 

 

Net loss per share—basic and diluted

   $ (0.72   $ (3.89

 

 

The following outstanding shares were excluded from the computation of the diluted net loss per common share for the periods presented because their effect would have been anti-dilutive.

 

      Three months ended
March 31,
 
      2017      2018  

Redeemable convertible preferred stock on an as-converted basis

     7,251,165        18,726,796  

Options to purchase common stock

     40,921        560,128  

Common stock subject to vesting or repurchase

     854,570        1,285,770  

Redeemable convertible preferred stock warrants on an as-converted basis

            441,538  
  

 

 

 

Total

     8,146,656        21,014,234  

 

 

 

F-50


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

12. Pro forma net loss per share

The following table sets forth (in thousands, except for share and per share amounts) the computation of the Company’s pro forma basic and diluted net loss per common share after giving effect to the conversion of the redeemable convertible preferred stock using the as-converted method into common stock as though the conversion had occurred at the beginning of the period presented or date of issuance, if later.

 

      Three months ended
March 31,
2018
 

Net loss

   $ (15,579

Change in fair value of redeemable convertible preferred stock warrant liability

     (37
  

 

 

 

Net loss used in computing pro forma net loss per share, basic and diluted

   $ (15,616

Weighted-average shares used to compute net loss per share, basic and diluted

     4,006,085  

Pro forma adjustment to reflect assumed cashless exercise of redeemable convertible preferred stock warrants

     80,874  

Pro forma adjustment to reflect assumed conversion of redeemable convertible preferred stock

     15,487,853  
  

 

 

 

Shares used to compute pro forma net loss per share, basic and diluted

     19,574,812  
  

 

 

 

Pro forma net loss per share, basic and diluted

   $ (0.80

 

 

13. License agreement

In April 2016, the Company entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University, or Stanford University relating to the Company’s drug discovery and development initiatives. Under this agreement, the Company has been granted certain worldwide exclusive licenses to use the licensed compounds. The Company paid an upfront license payment of $25,000 in April 2016, which was recorded as research and development expense and issued 56,809 shares of common stock. The value of this equity was recorded, at fair value of $0.15 per share, as research and development expense of $8,000 during the year ended December 31, 2016. In March 2017, the Company paid a license fee of $10,000, which was recorded as research and development expense during the year ended December 31, 2017. The Company may also be required to make future payments of up to approximately $1.0 million to Stanford University upon achievement of specific intellectual property, clinical and regulatory milestone events, as well as pay royalties in the low single digits on future net sales, if any. In addition, the Company is obligated to pay Stanford University a percentage of non-royalty revenue received by the Company from its sublicensees, with the amount owed decreasing annually for three years based on when the applicable sublicense agreement is executed. In March 2018, the Company recorded $50,000 under the Stanford agreement in connection with the achievement of a development milestone. During the three months ended March 31, 2017 and March 31, 2018, the Company recognized $10,000 and $63,000, respectively, in connection with this agreement.

14. Commitments and contingencies

Lease arrangements

In September 2017, the Company entered into a one-year operating lease for laboratory facilities in San Francisco, California. In November 2017, the Company entered into an operating lease for a facility in San

 

F-51


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Francisco, California, which expires in November 2022. The Company has provided a security deposit of $158,000 as collateral for the lease, which is included in other assets on the balance sheet.

Future minimum lease payments as of March 31, 2018 are as follows (in thousands):

 

Year ending December 31:    Amount  

2018 (remaining 9 months)

   $ 258  

2019

     327  

2020

     337  

2021

     347  

2022

     327  
  

 

 

 

Total future minimum lease payments

   $ 1,596  

 

 

The Company’s rent expense was $5,400 and $101,000 for the three months ended March 31, 2017 and 2018, respectively, of which $5,400 and $8,400 was incurred pursuant to the service agreement with BridgeBio Services, Inc., an affiliate of BridgeBio Pharma LLC, for the three months ended March 31, 2017 and 2018, respectively (see Note 6). Rent expense is recognized on a straight-line basis over the terms of the Company’s leases and accordingly, the Company recorded the difference between rent expense and amount paid under the leases as deferred rent liability within other liabilities in the balance sheets. Incentives granted under the Company’s facility lease, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rent expense on a straight-line basis over the term of the lease.

Indemnification

In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s balance sheets, statements of operations, or statements of cash flows.

15. Subsequent events

The Company has reviewed and evaluated subsequent events through May 25, 2018 the date the unaudited condensed financial statements were available for issuance. In connection with the reissuance of the unaudited condensed financial statements to reflect the 1.196 for 1 stock split as described in Note 1, the Company has evaluated subsequent events through June 7, 2018, the date the unaudited condensed financial statements were available to be reissued.

In May 2018, the Company issued 4,430,162 shares of Series B redeemable convertible preferred stock at a purchase price of $10.8348 per share, for total proceeds of $48.0 million. The issuance of the shares is in connection with the additional shares related to the put option asset discussed in Note 7 pertaining to the

 

F-52


Table of Contents

Eidos Therapeutics, Inc.

Notes to unaudited condensed financial statements

 

Series B redeemable convertible preferred stock financing in March 2018. The tranche liability will be remeasured at the closing date of the additional shares to the then fair value and the tranche liability and put option asset balances will be reclassified to redeemable convertible preferred stock.

On May 22, 2018, the Board of Directors approved the amendment to the certificate of incorporation to increase the number of redeemable convertible preferred stock authorized and available for issuance by 369,180 shares.

On June 6, 2018, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a split of the Company’s issued and outstanding common stock at a 1.196 for 1 ratio. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect the stock split for all periods presented. The financial statements have also been retroactively adjusted to reflect a proportional adjustment to the conversion ratio for each series of preferred stock that will be effected in connection with the stock split.

On June 6, 2018 the board of directors increased the authorized number of shares of common stock to 32,292,000 with a par value of $0.001.

 

F-53


Table of Contents

 

 

6,250,000 shares

 

LOGO

Common stock

 

Prospectus

 

 

J.P. Morgan        BofA Merrill Lynch  
  Barclays               

                , 2018

 

 

 


Table of Contents

Part II

Information not required in prospectus

Item 13. Other expenses of issuance and distribution

The following table sets forth all expenses, other than the underwriting discounts and commissions, payable by Eidos Therapeutics, Inc., or the Company or the Registrant, in connection with the sale of the common stock being registered. All the amounts shown are estimates except the SEC registration fee and the FINRA filing fee.

 

      Amount paid
or to be paid
 

SEC registration fee

   $ 15,213  

FINRA filing fee

     18,829  

Nasdaq initial listing fee

     150,000  

Printing and engraving expenses

     450,000  

Legal fees and expenses

     1,250,000  

Accounting fees and expenses

     850,000  

Transfer agent and registrar fees

     5,000  

Miscellaneous

     60,958  
  

 

 

 

Total

   $ 2,800,000  

 

 

Item 14. Indemnification of directors and officers

As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

 

 

any breach of the director’s duty of loyalty to us or our stockholders;

 

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

 

any transaction from which the director derived an improper personal benefit.

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

Section 145 of the Delaware General Corporation Law permits a corporation to include in its charter documents, and in agreements between the corporation and its directors and officers, provisions expanding the scope of indemnification beyond that specifically provided by the current law.

Section 145(a) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of

 

II-1


Table of Contents

another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or other adjudicating court shall deem proper.

Section 145(g) of the Delaware General Corporation Law provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the Delaware General Corporation Law.

The Company’s amended and restated certificate of incorporation, which will become effective upon completion of the offering, provides for the indemnification of directors to the fullest extent permissible under Delaware law.

The Company’s amended and restated bylaws, which will become effective upon completion of the offering, provide for the indemnification of officers, directors and third parties acting on the Company’s behalf if such persons act in good faith and in a manner reasonably believed to be in and not opposed to the Company’s best interest, and, with respect to any criminal action or proceeding, such indemnified party had no reason to believe his or her conduct was unlawful.

The Company is entering into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provisions provided for in its charter documents, and the Company intends to enter into indemnification agreements with any new directors and executive officers in the future. These agreements will provide that we will indemnify each of our directors and executive officers, and such entities to the fullest extent permitted by law.

The underwriting agreement (to be filed as Exhibit 1.1 hereto) will provide for indemnification by the underwriters of the Company, and its executive officers and directors, and indemnification of the underwriters by the Company for certain liabilities, including liabilities arising under the Securities Act of 1933, as amended, in connection with matters specifically provided in writing by the underwriters for inclusion in the registration statement.

 

II-2


Table of Contents

The Company intends to purchase and maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits of the amount of coverage.

Item 15. Recent sales of unregistered securities

Since January 1, 2015, the Registrant has issued the following securities that were not registered under the Securities Act:

Issuances of capital stock

Issuances of common stock

From August 2016 to May 2018, the Registrant issued 529,124 shares of restricted common stock outside of the 2016 Plan to certain founders and a collaborator.

Sales of redeemable convertible preferred stock and convertible notes

In September 2015, the Registrant sold a convertible note in the principal amount of $25,000 to one accredited investor. In April 2016, the entire amount due, including accrued interest of $1,000, was converted into 24,202 shares of Series Seed redeemable convertible preferred stock.

In April 2016, the Registrant sold an aggregate of 779,033 shares of Series Seed redeemable convertible (including the conversion of the 224,202 shares in the preceding paragraph) preferred stock to two accredited investors for an aggregate purchase price of approximately $1.0 million and the cancellation of the amount outstanding under the convertible note.

In September 2016, the Registrant sold an aggregate of 2,264,492 shares of Series Seed redeemable convertible preferred stock to one accredited investor for an aggregate purchase price of approximately $3.0 million.

In March 2017, the Registrant sold an aggregate of 3,019,323 shares of Series Seed redeemable convertible preferred stock to one accredited investor for an aggregate purchase price of approximately $4.0 million.

In September 2017, the Registrant sold an aggregate of 6,793,477 shares of Series Seed redeemable convertible preferred stock to one accredited investor for an aggregate purchase price of approximately $9.0 million.

In February 2018, the Registrant sold a convertible promissory note in the principal amount of $10.0 million and issued a warrant to purchase shares of preferred stock in an aggregate amount of up to $4.0 million to one accredited investor. In March 2018, the note was converted into an aggregate of 1,324,823 shares of Series B redeemable convertible preferred stock.

In March 2018, the Registrant issued and sold an aggregate of 2,801,538 shares of Series B redeemable convertible preferred stock to 13 accredited investors for an aggregate purchase price of approximately $16.0 million and the cancellation of approximately $10.0 million of indebtedness.

In May 2018, the Registrant sold an aggregate of 4,430,162 shares of Series B redeemable convertible preferred stock to 10 accredited investors for an aggregate purchase price of approximately $48.0 million.

No underwriters were used in the foregoing transactions. We believe these transactions were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, Regulation D, or Regulation S promulgated thereunder, or Rule 701 promulgated under Section 3(b) of the Securities Act as

 

II-3


Table of Contents

transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about our company.

Grants of stock options and restricted stock under the 2016 equity incentive plan.

From August 1, 2016 to May 7, 2018, the Registrant granted stock options to purchase an aggregate of 1,637,583 shares of its common stock, with exercise prices ranging from $0.18 to $8.66 per share, to employees, directors and consultants pursuant to the 2016 Plan. From August 1, 2016 to May 7, 2018, the Registrant granted an aggregate of 621,888 shares of restricted stock under the 2016 Plan. The issuances of these securities were exempt either pursuant to Rule 701, as a transaction pursuant to a compensatory benefit plan, or pursuant to Section 4(a)(2), as a transaction by an issuer not involving a public offering.

Item 16. Exhibits and financial statement schedules

(a) Exhibits.

The exhibits to the registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by reference.

(b) Financial statement schedules.

None.

Item 17. Undertakings

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

The undersigned Registrant hereby undertakes that:

(a) The undersigned Registrant will provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

(b) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of

 

II-4


Table of Contents

prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(c) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-5


Table of Contents

Exhibit index

 

Exhibit No.    Description
  1.1    Form of Underwriting Agreement
  3.1    Amended and Restated Certificate of Incorporation, as amended, of the Registrant, as currently in effect
  3.2    Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon completion of the offering
  3.3*    Bylaws of the Registrant and the amendments thereto, as currently in effect
  3.4    Form of Amended and Restated Bylaws of the Registrant, to be in effect upon completion of the offering
  4.1    Specimen Common Stock Certificate
  4.2*    Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain of its stockholders dated March 29, 2018
  4.3*    Convertible Promissory Note, dated February 22, 2018
  4.4    Warrant to Purchase Shares of Capital Stock, dated February 22, 2018
  5.1    Opinion of Goodwin Procter LLP
10.1#    Amended and Restated 2016 Equity Incentive Plan and forms of award agreements thereunder
10.2#    2018 Stock Option and Incentive Plan and forms of award agreements thereunder
10.3#    2018 Employee Stock Purchase Plan
10.4#    Senior Executive Cash Incentive Bonus Plan
10.5*#    Employment Offer Letter Agreement, by and between the Registrant and Jonathan C. Fox, M.D., Ph.D., dated October 25, 2016
10.6*#    Non-Employee Director Compensation Policy
10.7*#   

Employment Offer Letter Agreement, by and between the Registrant and Christine Siu, dated December 12, 2017

10.8*#    Employment Offer Letter Agreement, by and between the Registrant and Uma Sinha, Ph.D., dated June 1, 2016, as amended on May 24, 2018
10.9*†    Exclusive (Equity) Agreement, by and between the Registrant and the Board of Trustees of the Leland Stanford Junior University, effective as of April 10, 2016, as amended by Amendment No. 1 effective September 25, 2017
10.10*    Form of Indemnification Agreement by and between the Registrant and each of its directors and officers
10.11*    Intercompany Services Agreement, by and between the Registrant and BridgeBio Services Inc., dated as of May 1, 2017
10.12*    Office Lease, by and between the Registrant and 101 Montgomery Street Co., dated as of November 14, 2017
10.13*    QB3@953 Sublease Agreement, by and between the Registrant and QB3 Incubator Partners, LP, dated as of August 17, 2017
10.14*#   

Bonus Agreement, by and between the Registrant and Neil Kumar, dated as of April 26, 2018.


Table of Contents
Exhibit No.    Description
21.1*    List of Subsidiaries
23.1    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
23.2    Consent of Goodwin Procter LLP (included in Exhibit 5.1)
24.1*    Power of Attorney (included on signature page)

 

*   Previously filed

 

  Application has been made to the Securities and Exchange Commission for confidential treatment of certain provisions. Omitted material for which confidential treatment has been requested has been filed separately with the Securities and Exchange Commission.

 

#   Represents management compensation plan, contract or arrangement.


Table of Contents

Signatures

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, California, on the 8th day of June, 2018.

 

EIDOS THERAPEUTICS, INC.

By:

 

/s/ Neil Kumar     

 

Neil Kumar

 

Chief Executive Officer

Power of attorney and signatures

Each person whose individual signature appears below hereby authorizes and appoints Neil Kumar and Christine Siu and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney in fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Registration Statement, including any and all post effective amendments and amendments thereto, and any registration statement relating to the same offering as this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys in fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys in fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement and power of attorney has been signed by the following persons in the capacities and on the dates indicated below

 

Signature    Title   Date

/s/ Neil Kumar

Neil Kumar

  

Chief Executive Officer and Director (Principal Executive Officer)

  June 8, 2018

*

Christine Siu

  

Chief Financial Officer (Principal Financial and Accounting Officer)

  June 8, 2018

*

Rajeev Shah

  

Director

  June 8, 2018

*

Eric Aguiar

  

Director

  June 8, 2018

*

Hoyoung Huh

  

Director

  June 8, 2018

/s/ Ali Satvat

Ali Satvat

  

Director

  June 8, 2018

*By:

  

/s/ Neil Kumar

  

Neil Kumar

Attorney-in-fact

EX-1.1 2 d544598dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

EIDOS THERAPEUTICS, INC.

Shares of Common Stock, par value $0.001 per share

Underwriting Agreement

[], 2018

J.P. Morgan Securities LLC

Merrill Lynch, Pierce, Fenner & Smith

                     Incorporated

As Representatives of the

    several Underwriters listed

    in Schedule 1 hereto

c/o J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

c/o Merrill Lynch, Pierce, Fenner & Smith

                            Incorporated

One Bryant Park

New York, New York 10036

Ladies and Gentlemen:

Eidos Therapeutics, Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of                shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional                shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis.

[•] (the “Directed Share Underwriter”) has agreed to reserve a portion of the Shares to be purchased by it under this Agreement, up to Shares, for sale to the Company’s directors, officers, and certain employees and other parties related to the Company (collectively, “Participants”), as set forth in the Prospectus (as hereinafter defined) under the heading “Underwriting” (the “Directed Share Program”). The Shares to be sold by the Directed Share Underwriter and its affiliates pursuant to the


Directed Share Program are referred to hereinafter as the “Directed Shares”. Any Directed Shares not orally confirmed for purchase by any Participant by [•] [A/P].M., New York City time on the business day on which this Agreement is executed will be offered to the public by the Underwriters as set forth in the Prospectus.

The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:

1. Registration Statement. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities Act”), a registration statement on Form S-1 (File No. 333-225235), including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (“Rule 430 Information”), is referred to herein as the “Registration Statement”; and as used herein, the term “Preliminary Prospectus” means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term “Prospectus” means the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term “Registration Statement” shall be deemed to include such Rule 462 Registration Statement. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.

At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated [•], 2018 and each “free-writing prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto.

“Applicable Time” means [•] [A/P].M., New York City time, on [•], 2018.

2. Purchase of the Shares by the Underwriters.

(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this underwriting agreement (this “Agreement”), and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $                (the “Purchase Price”) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter’s name in Schedule 1 hereto.

In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares.

 

2


If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section 10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their sole discretion shall make.

The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section 10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein.

(b) The Company understands that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter.

(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the Representatives in the case of the Underwritten Shares, at the offices of Cooley LLP, counsel for the Underwriters, at 101 California Street, 5th Floor, San Francisco, California 94111, at [•] A.M., New York City time, on [•], 2018, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives in the written notice of the Underwriters’ election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the “Closing Date”, and the time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the “Additional Closing Date”.

(d) Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.

(e) The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm’s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other Underwriters shall have any responsibility or

 

3


liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.

3. Representations and Warranties of the Company. The Company represents and warrants to each Underwriter that:

(a) Preliminary Prospectus. No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(b) Pricing Disclosure Package. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom.

(c) Issuer Free Writing Prospectus. Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any “written communication” (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i) below) an “Issuer Free Writing Prospectus”) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken

 

4


together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof. Each such Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Shares or until any earlier date that the Company notified or notifies the Representatives as described in Section 4(d), did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus.

(d) Emerging Growth Company. From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any Testing-the-Waters Communication) through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”). “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.

(e) Testing-the-Waters Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communications other than Testing-the-Waters Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications. The Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Testing-the-Waters Communications by virtue of a writing substantially in the form of Exhibit D hereto. The Company has not distributed or approved for distribution any Written Testing-the-Waters Communications other than those listed on Annex C hereto. “Written Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act. Any individual Written Testing-the-Waters Communication does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the applicable provisions of the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in each such Written Testing-the-Waters Communication in reliance upon and in conformity with written information furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Written Testing-the-Waters Communications.

 

5


(f) Registration Statement and Prospectus. The Registration Statement has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, as of the date of such amendment, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus complied and will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(g) Financial Statements. The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods covered thereby, except, in the case of unaudited, interim financial statements, normal year-end adjustments and the omission of certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included in the Registration Statement present fairly the information required to be stated therein; and the other financial information included in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects, the information shown thereby. To the extent applicable, all disclosures included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable.

(h) No Material Adverse Change. Since the date of the most recent financial statements of the Company included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt (outside the ordinary course of business) or long-term debt of the Company or

 

6


any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development that would be reasonably expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(i) Organization and Good Standing. The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, be reasonably expected to have a material adverse effect on the business, properties, management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a “Material Adverse Effect”). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Registration Statement.

(j) Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading “Capitalization” and “Description of Capital Stock”; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors’ qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.

 

7


(k) Stock Options. With respect to the stock options (the “Stock Options”) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the “Company Stock Plans”), (i) to the Company’s knowledge, each Stock Option intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) so qualifies, (ii) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any), to the Company’s knowledge, was duly executed and delivered by each party thereto, (iii) each such grant was made in all material respects in accordance with the terms of the Company Stock Plans, the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Exchange Act”) and all other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Global Market (“Nasdaq Market”) and any other exchange on which Company securities are traded, and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company. Each Company Stock Plan is accurately described in all material respects in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations.

(l) Due Authorization. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.

(m) Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(n) The Shares. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived.

(o) Listing. The Shares have been approved for listing on the Nasdaq Market, subject to notice of issuance.

(p) Description of the Underwriting Agreement. This Agreement conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(q) No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its

 

8


subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.

(r) No Conflicts. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares by the Company and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property right or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property, right or assets of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect.

(s) No Consents Required. No consent, filing, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters.

(t) Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the Company or any of its subsidiaries is or, to the knowledge of the Company, may be a party or to which any property of the Company or any of its subsidiaries is or, to the knowledge of the Company, may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

 

9


(u) Independent Accountants. PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company and its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.

(v) Title to Real and Personal Property. The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(w) Title to Intellectual Property. The Company and its subsidiaries own, or possess valid and enforceable licensed rights to use, all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights, Internet domain names, copyrights, works of authorship, licenses, proprietary information and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) material to, and reasonably necessary for the conduct of their respective businesses as currently conducted and as proposed to be conducted (collectively, “Intellectual Property”). To the Company’s knowledge, (i) the conduct of the business of the Company and its subsidiaries as currently conducted does not infringe, misappropriate or otherwise conflict in any material respect with any intellectual property rights of others; (ii) the commercialization of AG10 as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus will not infringe, misappropriate or otherwise conflict in any material respect with any intellectual property rights of others. To the Company’s knowledge, there is no pending or threatened action, suit, proceeding or claim by others (i) that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates, or would upon the commercialization of AG10 as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, infringe, misappropriate or otherwise violate, the intellectual property rights of another, or (ii) challenging the Company’s rights in or to any Intellectual Property disclosed in the Prospectus as being owned by or exclusively licensed to the Company, or (iii) challenging the validity, enforceability, scope or ownership of any Intellectual Property disclosed in the Prospectus as being owned by or licensed to the Company or its subsidiary or their rights therein. To the knowledge of the Company, there are no material defects in the any of the Intellectual Property owned by or licensed to the Company. To the knowledge of the Company, the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus as being owned by or exclusively licensed to the Company or its subsidiary have been complied with; and in all foreign patent offices having similar requirements, all such requirements have been complied with. To the knowledge of the Company, no third party has infringed, misappropriated or otherwise violated any Intellectual Property owned by or exclusively licensed to the Company or any of its subsidiaries in any material respect. To the Company’s knowledge, none of the Intellectual Property used by the Company or its subsidiaries in the conduct of its business has been obtained or is being used by the Company or its subsidiaries in material

 

10


violation of any contractual obligation binding on the Company or any of its subsidiaries. Except as set forth in the Prospectus, the Intellectual Property owned by the Company and its subsidiaries is all solely owned by the Company, and is owned free and clear of any liens or encumbrances. The Company is not aware of any specific facts or combination of facts that would cause the Company or any of its subsidiaries to reasonably conclude that any of the Intellectual Property owned by or licensed to the Company or any of its subsidiaries is invalid or unenforceable and, to the knowledge of the Company, all such issued or granted patents are valid and enforceable. The Company and its subsidiaries are not subject to any judgment, order, writ, injunction or decree of any court or any federal, state, local, foreign or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, or any arbitrator, nor have they entered into or are a party to any agreement made in settlement of any pending or threatened litigation, which materially restricts or impairs their respective use of any Intellectual Property. The Company and its subsidiaries have taken all commercially reasonable steps, in accordance with normal industry practice, necessary to maintain the confidentiality of all Intellectual Property the value of which to the Company and its subsidiaries is contingent upon maintaining the confidentiality thereof, and the Company is not aware of any material disclosure of such Intellectual Property other than to employees, representatives, independent contractors, collaborators, licensors, licensees, agents and advisors of the Company and its subsidiaries, all of whom are bound by written obligations to maintain the confidentiality thereof. All founders, key employees and any other employees and independent contractors involved in the development of Intellectual Property for the Company and its subsidiaries have signed confidentiality and invention assignment agreements or similar agreements for the transfer, assignment, and/or licensing of Intellectual Property with the Company pursuant to which the Company either (i) has obtained ownership of and is the exclusive owner of, or (ii) has obtained a valid and unrestricted right to exploit, sufficient for the conduct of its business, such Intellectual Property.

(x) Trade Secrets. The Company and its subsidiaries have taken reasonable and customary actions to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including confidential source code, ideas, research and development information, know-how, formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and, to the knowledge of the Company, there has been no unauthorized use or disclosure.

(y) IT Assets. Except as could not reasonably be expected to have a Material Adverse Effect (i) the computers, software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the Company or its subsidiaries (excluding any public networks) (collectively, the “IT Assets”) operate and perform as is necessary for the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be conducted as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and (ii) such IT Assets are not infected by viruses, disabling code or other harmful code.

(z) Data Privacy and Security Laws. The Company and its subsidiaries are, and have been, in compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended by the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) (collectively, the “Privacy Laws”) , except to the extent

 

11


that any non-compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take commercially appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the “Policies”). “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) Protected Health Information as defined by HIPAA; and (iv) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. The Company and its subsidiaries have at all times made all disclosures to users or customers as required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law, other than in the ordinary course; or (iii) is a party to any order, decree, or agreement with any Governmental Entity that imposes any obligation or liability under any Privacy Law.

(aa) No Complaints. To the Company’s knowledge, there is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently pending against the Company or its subsidiaries by the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (“HHS”), or any similar authority in any jurisdiction other than the United States or any other governmental entity, or by any person in respect of the collection, use or disclosure of Personal Data by the Company or its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened.

(bb) FDA Compliance. The Company: (A) is and at all times has been in material compliance with all statutes, rules or regulations of the FDA and other comparable Governmental Entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (“Applicable Laws”); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from the FDA or any governmental entity alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except in each case as would not, individually or in the aggregate, have a Material Adverse Effect; (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material violation of any

 

12


Applicable Laws or Authorizations and has no knowledge that the FDA or any governmental entity or third party is threatening any such claim, litigation, arbitration, action, suit, investigation or proceeding, except in each case as would not, individually or in the aggregate, have a Material Adverse Effect; (E) has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to limit, suspend, materially modify or revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is threatening such action, except in each case as would not, individually or in the aggregate, have a Material Adverse Effect; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and, to the knowledge of the Company, that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).

(cc) Tests and Preclinical and Clinical Trials. The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols designed and approved for such studies and trials and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company.

(dd) Compliance with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in compliance with all applicable Health Care Laws except to the extent that any non-compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, and local health care fraud and abuse laws, including, without limitation, , the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), and laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Physician Payment

 

13


Sunshine Act (42 U.S.C. § 1320a-7h); (v) licensure, quality, safety and accreditation requirements under applicable federal, state, or local laws or regulatory bodies; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the aggregate, have a Material Adverse Effect. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, suspension, or exclusion.

(ee) No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.

(ff) Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”).

(gg) Taxes. The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof, except where the failure to file would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets and which would reasonably be expected to have a Material Adverse Effect.

 

14


(hh) Licenses and Permits. The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or reasonably be expected to have in the aggregate, have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification or nonrenewal would not reasonably be expected to have a Material Adverse Effect. To the Company’s knowledge, no party granting any such licenses, certificates, permits and other authorizations has taken any action to limit, suspend or revoke the same in any material respect. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) as required for maintenance of their licenses, certificates, permits and other authorizations that are necessary for the conduct of their respective businesses.

(ii) No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining agreement to which it is a party.

(jj) Certain Environmental Matters. (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any applicable Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or potential liability under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) (x) there is no proceeding that is pending against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a Material Adverse Effect, and (z) none of the Company or its subsidiaries currently contemplates material capital expenditures relating to any Environmental Laws.

 

15


(kk) Hazardous Materials. There has been no storage, generation, transportation, use, handling, treatment, Release or, to the knowledge of the Company, threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or would reasonably be expected to be liable) at, on, under or from any property or facility now or, to the knowledge of the Company, previously owned, operated or leased by the Company or any of its subsidiaries, or, to the knowledge of the Company, at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that would reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. “Hazardous Materials” means any material, chemical, substance ,waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. “Release” means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure.

(ll) Compliance with ERISA. Except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Code) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan that is a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or “critical status” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; and (vii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA).

 

16


(mm) Disclosure Controls. The Company and its subsidiaries have established an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure.

(nn) Accounting Controls. The Company and its subsidiaries have established systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that are designed to comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. There are no material weaknesses in the Company’s internal controls. The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

(oo) Insurance. The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.

(pp) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, employee, agent, affiliate or other person while acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made, offered, promised, or authorized any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or

 

17


party official or candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption laws; or (iv) made, offered, promised, or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment. The Company has instituted procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.

(qq) Compliance with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(rr) No Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, directors or officers, nor, to the knowledge of the Company, any employee, agent, or affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked person”), the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, and the Crimea Region of the Ukraine (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity unlawfully (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any unlawful dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.

(ss) No Restrictions on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the Company.

 

18


(tt) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Shares.

(uu) No Registration Rights. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares except such rights as have been duly waived.

(vv) No Stabilization. Neither the Company nor any of its subsidiaries have taken, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.

(ww) Margin Rules. Neither the issuance, sale and delivery of the Shares nor the application of the proceeds thereof by the Company as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.

(xx) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

(yy) Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.

(zz) Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), including Section 402 related to loans and Sections 302 and 906 related to certifications.

(aaa) Status under the Securities Act. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date.

 

19


(bbb) No Ratings. There are (and prior to the Closing Date, will be) no debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a “nationally recognized statistical rating organization”, as such term is defined in Section 3(a)(62) of the Exchange Act.

(ccc) Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company’s or any of its subsidiaries’ information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology (collectively, “IT Systems and Data”) and (y) the Company and its subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to their IT Systems and Data; (ii) the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect; and (iii) the Company and its subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.

(ddd) No Rated Securities. Neither the Company nor its subsidiaries have any debt securities or preferred stock that are rated by any “nationally recognized statistical rating organization” (as defined in Section 3(a)(62) of the Exchange Act).

(eee) No Subsidiaries. The Company does not own or control, directly or indirectly, any corporation, association or other entity (e.g., the Company has no subsidiaries).

(fff) Directed Share Program. The Company represents and warrants that (i) the Registration Statement, the Pricing Disclosure Package and the Prospectus, any Preliminary Prospectus and any Issuer Free Writing Prospectuses comply in all material respects, and any further amendments or supplements thereto will comply in all material respects, with any applicable laws or regulations of foreign jurisdictions in which the Pricing Disclosure Package, the Prospectus, any Preliminary Prospectus and any Issuer Free Writing Prospectus, as amended or supplemented, if applicable, are distributed in connection with the Directed Share Program, and that (ii) no authorization, approval, consent, license, order, registration or qualification of or with any government, governmental instrumentality or court, other than such as have been obtained, is necessary under the securities laws and regulations of foreign jurisdictions in which the Directed Shares are offered outside the United States. The Company has not offered, or caused the underwriters to offer, Shares to any person pursuant to the Directed Share Program with the specific intent to unlawfully influence (i) a customer or supplier of the Company to alter the customer or supplier’s level or type of business with the Company, or (ii) a trade journalist or publication to write or publish favorable information about the Company or its products.

4. Further Agreements of the Company. The Company covenants and agrees with each Underwriter that:

(a) Required Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request.

 

20


(b) Delivery of Copies. The Company, upon request of the Representatives, will deliver, without charge, (i) to the Representatives, three signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term “Prospectus Delivery Period” means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer.

(c) Amendments or Supplements, Issuer Free Writing Prospectuses. Before preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object.

(d) Notice to the Representatives. The Company will advise the Representatives promptly, and confirm such advice in writing, (i) when the Registration Statement has become effective; (ii) when any amendment to the Registration Statement has been filed or becomes effective; (iii) when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication or any amendment to the Prospectus has been filed or distributed; (iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any Testing-the-Waters Communication; (v) of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written Testing-the-Waters Communication or the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer Free Writing Prospectus or Written Testing-the-Waters Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, or any such Issuer Free Writing Prospectus or Written Testing-the-Waters Communication is delivered to a purchaser, not misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its

 

21


reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written Testing-the-Waters Communication or suspending any such qualification of the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.

(e) Ongoing Compliance. (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact or necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company will, as soon as reasonably possible, notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2) if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.

(f) Blue Sky Compliance. The Company will use its reasonable best efforts, with the Underwriters’ cooperation, if necessary, to qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will use its reasonable best efforts, with the Underwriters’ cooperation, if necessary, to continue such qualifications in effect so long as required for distribution of the Shares; provided that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.

(g) Earnings Statement. The Company will make generally available to its securityholders and the Representatives as soon as practicable an earnings statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective date” (as defined in Rule 158) of the Registration Statement; provided that the Company will be deemed to have furnished such statements to its security holders and the Representatives to the extent they are filed on the Commission’s Electronic Data Gathering, Analysis and Retrieval system.

 

22


(h) Clear Market. For a period of 180 days after the date of the Prospectus, the Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with, or submit to, the Commission a registration statement under the Securities Act relating to, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition, submission or filing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives, other than (A) the Shares to be sold hereunder, (B) any shares of Common Stock of the Company issued upon the exercise of options granted under Company Stock Plans or warrants outstanding as of the date hereof, (C) any options and other awards granted under a Company Stock Plan or shares issued pursuant to an employee stock purchase plan, in each case, as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (D) the filing by the Company of any registration statement on Form S-8 or a successor form thereto relating to a Company Stock Plan or employee stock purchase plan described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (E) shares of Common Stock or other securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets or acquisition of not less than a majority or controlling portion of the equity of another entity, provided that (x) the aggregate number of shares issued pursuant to this clause (E) shall not exceed five percent (5%) of the total number of outstanding shares of Common Stock immediately following the issuance and sale of the Underwritten Shares pursuant hereto and (y) the recipient of any such shares of Common Stock and securities issued pursuant to clauses (B), (C) and (E) during the 180-day restricted period described above shall enter into an agreement substantially in the form of Exhibit D hereto.

(i) If the Representatives in their sole discretion, agree to release or waive the restrictions set forth in a lock-up letter described in Section 6(l) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver substantially in the form of Exhibit B hereto at least three business days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit C hereto through a major news service at least two business days before the effective date of the release or waiver.

(j) Use of Proceeds. The Company will apply the net proceeds from the sale of the Shares as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading “Use of Proceeds”.

(k) No Stabilization. The Company will not take, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Common Stock.

(l) Exchange Listing. The Company will use its best efforts to list, subject to notice of issuance, the Shares on the Nasdaq Market.

 

23


(m) Reports. For the period of two years from the date of this Agreement, the Company will furnish to the Representatives, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; provided the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on the Commission’s Electronic Data Gathering, Analysis, and Retrieval system.

(n) Record Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.

(o) Filings. The Company will file with the Commission such reports as may be required by Rule 463 under the Securities Act.

(p) Emerging Growth Company. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of Shares within the meaning of the Securities Act and (ii) completion of the 180-day restricted period referred to in Section 4(h) hereof.

(q) Directed Share Program. The Company will comply with all applicable securities and other laws, rules and regulations in each jurisdiction in which the Directed Shares are offered in connection with the Directed Share Program.

(r) Certification Regarding Beneficial Owners. The Company will deliver to the Representatives, on the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers in the form previously provided to the Company by the Representatives, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation as the Representatives may reasonably request in connection with the verification of the foregoing certification.

5. Certain Agreements of the Underwriters. Each Underwriter hereby represents and agrees that:

(a) It has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any “free writing prospectus”, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show), or (iii) any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing.

 

24


(b) It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; provided that Underwriters may use a term sheet substantially in the form of Annex D hereto without the consent of the Company; provided further that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to the first use of such term sheet.

(c) It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering contemplated by this Agreement (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).

6. Conditions of Underwriters’ Obligations. The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:

(a) Registration Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section 8A under the Securities Act shall be pending before or, to the knowledge of the Company, threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.

(b) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be.

(c) No Material Adverse Change. No event or condition of a type described in Section 3(h) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

(d) Officer’s Certificate. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives (i) confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(d) hereof are true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii) to the effect set forth in paragraphs (a) and (c) above.

 

25


(e) Comfort Letters. On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, PricewaterhouseCoopers LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a “cut-off” date no more than three business days prior to such Closing Date or such Additional Closing Date, as the case may be.

(f) Opinion and Negative Assurance Letter of Counsel for the Company. Goodwin Procter LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and negative assurance letter, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex B-1 hereto.

(g) Opinion of Intellectual Property Counsel for the Company. Mintz Levin Cohn Ferris Glovsky and Popeo PC, intellectual property counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex B-2 hereto.

(h) Opinion and Negative Assurance Letter of Counsel for the Underwriters. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and negative assurance letter of Cooley LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.

(i) No Legal Impediment to Issuance and Sale. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares.

(j) Good Standing. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions.

(k) Exchange Listing. The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance.

 

26


(l) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between the Representatives and substantially all of the securityholders, officers and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing Date, as the case may be.

(m) Additional Documents. On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.

All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.

7. Indemnification and Contribution.

(a) Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written Testing-the-Waters Communication, any road show as defined in Rule 433(h) under the Securities Act (a “road show”) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in subsection (b) below.

(b) Indemnification of the Company. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free

 

27


Writing Prospectus, any Written Testing-the-Waters Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the [                ] paragraph under the caption “Underwriting” and the information contained in the [                ] paragraph under the caption “Underwriting”.

(c) Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section 9, such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section 9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided, further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section 9. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened

 

28


proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.

(d) Contribution. If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

(e) Limitation on Liability. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph (d) above were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any reasonable and documented legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d) and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to paragraphs (d) and (e) are several in proportion to their respective purchase obligations hereunder and not joint.

(f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity.

 

29


(g) Directed Share Program Indemnification. The Company agrees to indemnify and hold harmless the Directed Share Underwriter, its affiliates, directors and officers and each person, if any, who controls the Directed Share Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act (each a “Directed Share Underwriter Entity”) from and against any and all losses, claims, damages and liabilities (including, without limitation, any reasonable and documented legal fees and other expenses incurred in connection with defending or investigating any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred) (i) caused by any untrue statement or alleged untrue statement of a material fact contained in any material prepared by or with the consent of the Company for distribution to Participants in connection with the Directed Share Program or caused by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; (ii) caused by the failure of any Participant to pay for and accept delivery of Directed Shares that the Participant agreed to purchase; or (iii) related to, arising out of, or in connection with the Directed Share Program, other than losses, claims, damages or liabilities (or expenses relating thereto) that are finally judicially determined to have resulted from the bad faith or gross negligence of the Directed Share Underwriter Entities.

(h) In case any proceeding (including any governmental investigation) shall be instituted involving any Directed Share Underwriter Entity in respect of which indemnity may be sought pursuant to paragraph (g) above, the Directed Share Underwriter Entity seeking indemnity shall promptly notify the Company in writing and the Company, upon request of the Directed Share Underwriter Entity, shall retain counsel reasonably satisfactory to the Directed Share Underwriter Entity to represent the Directed Share Underwriter Entity and any others the Company may designate in such proceeding and shall pay the reasonable fees and disbursements of such counsel related to such proceeding. In any such proceeding, any Directed Share Underwriter Entity shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Directed Share Underwriter Entity unless (i) the Company and such Directed Share Underwriter Entity shall have mutually agreed to the retention of such counsel, (ii) the Company has failed within a reasonable time to retain counsel reasonably satisfactory to such Directed Share Underwriter Entity, (iii) the Directed Share Underwriter Entity shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Company or (iv) the named parties to any such proceeding (including any impleaded parties) include both the Company and the Directed Share Underwriter Entity and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. The Company shall not, in respect of the legal expenses of the Directed Share Underwriter Entities in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Directed Share Underwriter Entities. The Company shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Company agrees to indemnify the Directed Share Underwriter Entities from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time any Directed Share Underwriter Entity shall have requested the Company to reimburse such Directed Share Underwriter Entity for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the Company agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Company of the aforesaid request and (ii) the Company shall not have reimbursed such Directed Share Underwriter Entity in accordance with such request prior to the date of such settlement. The Company shall not, without the prior written consent of the Directed Share Underwriter, effect any settlement of any pending or threatened proceeding in respect of which any Directed Share Underwriter Entity is or could have been a party and indemnity could have been sought hereunder by such Directed Share Underwriter Entity, unless (x) such settlement includes an unconditional release of the Directed Share Underwriter Entities from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of the Directed Share Underwriter Entity.

 

30


(i) To the extent the indemnification provided for in paragraph (g) above is unavailable to a Directed Share Underwriter Entity or insufficient in respect of any losses, claims, damages or liabilities referred to therein (other than as a result of the limitations imposed on indemnification described in paragraph (g) above), then the Company in lieu of indemnifying the Directed Share Underwriter Entity thereunder, shall contribute to the amount paid or payable by the Directed Share Underwriter Entity as a result of such losses, claims, damages or liabilities (1) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Directed Share Underwriter Entities on the other hand from the offering of the Directed Shares or (2) if the allocation provided by clause 7(i)(1) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 7(i)(1) above but also the relative fault of the Company on the one hand and of the Directed Share Underwriter Entities on the other hand in connection with any statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Directed Share Underwriter Entities on the other hand in connection with the offering of the Directed Shares shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Directed Shares (before deducting expenses) and the total underwriting discounts and commissions received by the Directed Share Underwriter Entities for the Directed Shares, bear to the aggregate public offering price of the Directed Shares. If the loss, claim, damage or liability is caused by an untrue or alleged untrue statement of material fact or the omission or alleged omission to state a material fact, the relative fault of the Company on the one hand and the Directed Share Underwriter Entities on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement or the omission or alleged omission relates to information supplied by the Company or by the Directed Share Underwriter Entities and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

(j) The Company and the Directed Share Underwriter Entities agree that it would be not just or equitable if contribution pursuant to paragraph (i) above were determined by pro rata allocation (even if the Directed Share Underwriter Entities were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (i) above. The amount paid or payable by the Directed Share Underwriter Entities as a result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by the Directed Share Underwriter Entities in connection with investigating or defending such any action or claim. Notwithstanding the provisions of paragraph (i) above, no Directed Share Underwriter Entity shall be required to contribute any amount in excess of the amount by which the total price at which the Directed Shares distributed to the public were offered to the public exceeds the amount of any damages that such Directed Share Underwriter Entity has otherwise been required to pay. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in paragraphs (g) through (j) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity.

 

31


(k) The indemnity and contribution provisions contained in paragraphs (g) through (j) shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Directed Share Underwriter Entity or the Company, its officers or directors or any person controlling the Company and (iii) acceptance of and payment for any of the Directed Shares.

8. Effectiveness of Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

9. Termination. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date: (i) trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

10. Defaulting Underwriter.

(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term “Underwriter” includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 10, purchases Shares that a defaulting Underwriter agreed but failed to purchase.

(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made.

 

32


(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section 11 hereof and except that the provisions of Section 7 hereof shall not terminate and shall remain in effect.

(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter for damages caused by its default.

11. Payment of Expenses.

(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the fees and expenses of the Company’s counsel and independent accountants; (iv) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum and any “Canadian wrapper” (including the related fees and expenses of counsel for the Underwriters in an amount not to exceed $10,000); (v) the cost of preparing stock certificates; (vi) the costs and charges of any transfer agent and any registrar; (vii) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA (including the related fees and expenses of counsel for the Underwriters in an amount not to exceed $40,000); (viii) all expenses incurred by the Company in connection with any “road show” presentation to potential investors or Testing the Waters Communications, it being understood and agreed that except as provided in this Section 11 or Section 7 hereof, the Underwriters will pay all of the travel, lodging and other expenses of the Underwriters or any of their employees incurred by them in connection with the “road show” (provided, however, that the Underwriters and the Company shall each pay 50% of the cost of chartering any aircraft or other chartered transportation to be used in connection with the road show by the Company and the Underwriters); (ix) all of the fees and disbursements of counsel incurred by the Underwriters in connection with the Directed Share Program and stamp duties, similar taxes or duties or other taxes, if any, incurred by the Underwriters in connection with the Directed Share Program; and (x) all expenses and application fees related to the listing of the Shares on the Nasdaq Market. Except to the extent otherwise provided in this Section 11 or Section 7, the Underwriters will pay all of their own costs and expenses, including the fees and expenses of their counsel, any stock transfer taxes on resale of any of the Shares held by them, and any advertising expenses connected with any offers they may make.

 

33


(b) If (i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters at the Closing Date or any Additional Closing Date, as applicable, in accordance with this Agreement or (iii) the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the reasonable and documented fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by an Underwriter that defaults on its obligations to purchase the Shares.

12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section 7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase.

13. Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section 7 hereof.

14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in New York City; (c) the term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act.

15. Compliance with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.

16. Miscellaneous.

(a) Authority of the Representatives. Any action by the Underwriters hereunder may be taken by the Representatives on behalf of the Underwriters, and any such action taken by the Representatives shall be binding upon the Underwriters.

(b) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358) and c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated, One Bryant Park, New York, New York 10036, Attention: Syndicate Department (fax: (646) 855-3073), with a copy to ECM Legal (fax: (212) 230-8730); Attention Equity Syndicate Desk. Notices to the Company shall be given to it at Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2250, San Francisco, CA 94104; Attention: Neil Kumar, Chief Executive Officer.

 

34


(c) Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state.

(d) Waiver of Jury Trial. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

(e) Counterparts. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument.

(f) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.

(g) Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.

(h) Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof.

[Signature Page Follows]

 

35


If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.

 

Very truly yours,
EIDOS THERAPEUTICS, INC.
By:  

 

  Name:
  Title:

Accepted: As of the date first written above

J.P. MORGAN SECURITIES LLC

MERRILL LYNCH, PIERCE, FENNER & SMITH

                               INCORPORATED

For themselves and on behalf of the

several Underwriters listed

in Schedule 1 hereto.

 

J.P. MORGAN SECURITIES LLC
By:  

 

  Authorized Signatory
MERRILL LYNCH, PIERCE, FENNER & SMITH
                              INCORPORATED
By:  

 

  Authorized Signatory

[Signature Page to Underwriting Agreement]


Schedule 1

 

Underwriter

   Number of Shares  

J.P. Morgan Securities LLC

  

Merrill Lynch, Pierce, Fenner & Smith

                       Incorporated

  

Barclays Capital Inc.

  
  

 

 

 

Total

  
  

 

 

 

 

2


Annex A

 

a. Pricing Disclosure Package

[list each Issuer Free Writing Prospectus to be included in the Pricing Disclosure Package]

 

b. Pricing Information Provided Orally by Underwriters

[set out key information included in script that will be used by Underwriters to confirm sales]

 

3


Annex B-1

Form of Opinion of Goodwin Procter LLP

[To come]

 

4


Annex B-2

Form of Opinion of IP Counsel for the Company

[To come]

 

5


Annex C

Written Testing-the-Waters Communications

[None]

 

6


Annex D

Eidos Therapeutics, Inc.

Pricing Term Sheet

[TO COME]

 

7


Exhibit A

FORM OF LOCK-UP AGREEMENT

__________, 2018

J. P. MORGAN SECURITIES LLC

MERRILL LYNCH, PIERCE, FENNER & SMITH

                               INCORPORATED

As Representatives of

the several Underwriters listed in

Schedule 1 to the Underwriting

Agreement referred to below

c/o J. P. Morgan Securities LLC

383 Madison Avenue

New York, NY 10179

c/o Merrill Lynch, Pierce, Fenner & Smith

                            Incorporated

One Bryant Park

New York, NY 10036

Re: Eidos Therapeutics, Inc. — Initial Public Offering

Ladies and Gentlemen:

The undersigned, understands that you, as representatives (the “Representatives”) of the several Underwriters, propose to enter into an underwriting agreement (the “Underwriting Agreement”) with Eidos Therapeutics, Inc., a Delaware corporation (the “Company”), providing for the initial public offering (the “Public Offering”) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the “Underwriters”), of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Securities”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.

In consideration of the Underwriters’ agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of J. P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated on behalf of the Underwriters, the undersigned will not, during the period beginning on the date of this letter agreement (this “Letter Agreement”) and ending 180 days (the “Lock-up Period”) after the date of the prospectus relating to the Public Offering (the “Prospectus”) (such period, the “Restricted Period”), (1) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission (the


“SEC”) and securities which may be issued upon exercise of a stock option or warrant), or publicly disclose the intention to make any offer, sale, pledge or disposition, (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock (and, for the avoidance of doubt, the undersigned hereby waives any and all notice requirements and rights with respect to the registration of any securities pursuant to any agreement, instrument, understanding or otherwise, including any stockholders or registration rights agreement or similar agreement, to which the undersigned is a party or under which the undersigned is entitled to any right or benefit), in each case other than (A) the Securities to be sold by the undersigned pursuant to the Underwriting Agreement, (B) transfers of shares of Common Stock as a bona fide gift or gifts or through will or intestacy, or to an immediate family member or trust or entity beneficially owned and controlled by the undersigned or for the benefit of the undersigned or any immediate family member of the undersigned for bona fide estate planning purposes in a transaction not involving a disposition for value, (C) if the undersigned is (i) a corporation, limited liability company, partnership or other entity, distribution of shares of Common Stock or any security directly or indirectly convertible into Common Stock to members, stockholders, limited partners, subsidiaries or affiliates (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or to any investment fund or other entity that controls or manages the undersigned in a transaction not involving a disposition for value or (ii) a trust, distributions of shares of Common Stock or any security directly or indirectly convertible into Common Stock to its beneficiaries in a transaction not involving a disposition for value, (D) transfers of the Securities following execution of the Underwriting Agreement, pursuant to a bona fide third-party tender offer, merger, consolidation, spin-off or other similar transaction that is approved by the board of directors of the Company and made to all holders of the Company’s capital stock involving a Change of Control of the Company, provided that in the event that such tender offer, merger, consolidation, spin-off or other such transaction is not completed, the Securities held by the undersigned shall remain subject to the provisions of this letter agreement (this “Letter Agreement”), and provided further that for purposes of this clause (D), “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation, spin-off or other such transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an Underwriter pursuant to the Public Offering), of the Company’s voting securities if, after such transfer, such person or group of affiliated persons would hold more than 75% of the outstanding voting securities of the Company (or the surviving entity), (E) the exercise of options granted or the vesting of any restricted Securities pursuant to any of the Company’s existing or future stock option, equity incentive or benefit plans or agreements described in the Prospectus (the “Incentive Arrangements”) and the delivery of Securities to the Company for cancellation (or the withholding and cancellation of Securities by the Company) as payment for (i) the exercise price of any options granted under the Incentive Arrangements or (ii) the withholding taxes due upon the exercise of any such option or the vesting of any restricted Securities granted under any Incentive Arrangements, with any Securities received as contemplated by any transaction described in this clause (E) remaining subject to the terms of this Letter Agreement; provided that, no filing by any party under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution unless such filing or report shall include a statement to the effect that such transfer is being made in connection with a “net” or “cashless” exercise or settlement of stock options, restricted stock units or other equity awards, (F) dispositions to the Company in exercise of the Company’s right to purchase or acquire the Securities pursuant to the Company’s equity incentive plans, restricted stock agreements and option agreements described in the Prospectus that grant the Company the right to purchase or acquire such securities, (G) transfers of any Securities acquired on the open market after the date of the Prospectus (other than any issuer-directed Securities purchased in the Public Offering by any officer or director of the Company), (H) the establishment of a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as

 

9


amended (the “Exchange Act”) for the transfer of Securities, provided that (i) such plan does not provide for the transfer of Securities during the Restricted Period and (ii) no public announcement or filing under the Exchange Act is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan, (I) pursuant to a domestic order or divorce settlement in a transaction not involving a disposition for value, provided that any filing made pursuant to the Exchange Act shall include a footnote noting the circumstances described in this clause (I), (J) the exercise (whether for cash, cashless or net exercise) of warrants to purchase shares of Common Stock (or any security convertible into or exercisable for Common Stock) outstanding as of the date hereof or described in the Prospectus and the registration statement relating to the Public Offering, excluding any manner of exercise that would involve a sale in the open market of any securities relating to such warrants, whether to cover the aggregate exercise price, withholding tax obligations or otherwise; provided, that the underlying shares shall continue to be subject to the restrictions on transfer set forth in this Letter Agreement or (K) the conversion of the outstanding preferred stock of the Company into shares of Common Stock, in each case as described in the Prospectus, provided, that the Common Stock received upon such conversion shall be subject to the restrictions on transfer set forth in this Letter Agreement; provided that in the case of any transfer or distribution pursuant to clause (B), (C) or (I), each donee or distributee shall execute and deliver to the Representative a lock-up letter in the form of this paragraph; and provided, further, that in the case of any transfer or distribution pursuant to clause (B), (C), (F), (G) and (J), no filing by any party (donor, donee, transferor or transferee) under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above). If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Securities the undersigned may purchase in the Public Offering.

If the undersigned is an officer or director of the Company, (i) J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated on behalf of the Underwriters agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated on behalf of the Underwriters will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted by J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated on behalf of the Underwriters hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of the transfer.

In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.

 

10


This Letter Agreement shall terminate automatically and the undersigned shall automatically be released from all obligations under this letter agreement upon the earliest to occur of the following: (i) the Underwriting Agreement does not become effective by December 31, 2018 (provided, however, that the Company may extend such date by up to three months with written notice to the undersigned prior thereto if the Company is still pursuing the Public Offering contemplated by the Underwriting Agreement); (ii) if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder; (iii) either the Company, on the one hand, or the Representatives, on the other hand, notifies the other in writing that it does not intend to proceed with the Public Offering; or (iv) the registration statement filed with the SEC in connection with the Public Offering is withdrawn. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement.

[Signature Page Follows]

 

11


This letter agreement and any claim, controversy or dispute arising under or related to this letter agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.

 

Very truly yours,

 

Name of Security Holder (Print exact name)

By:  

 

  Signature
If not signing in an individual capacity:

 

Name of Authorized Signatory (Print)

 

Title of Authorized Signatory (Print)

(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)


Exhibit B

Form of Waiver of Lock-up

J.P. MORGAN SECURITIES LLC

Eidos Therapeutics, Inc.

Public Offering of Common Stock

, 2018

[Name and Address of

Officer or Director

Requesting Waiver]

Dear Mr./Ms. [Name]:

This letter is being delivered to you in connection with the offering by Eidos Therapeutics, Inc. (the “Company”) of        shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company and the lock-up letter dated        , 2018 (the “Lock-up Letter”), executed by you in connection with such offering, and your request for a [waiver] [release] dated        , 2018, with respect to shares of Common Stock (the “Shares”).

J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated hereby agree to [waive] [release] the transfer restrictions set forth in the Lock-up Letter, but only with respect to the Shares, effective        , 2018; provided, however, that such [waiver] [release] is conditioned on the Company announcing the impending [waiver] [release] by press release through a major news service at least two business days before effectiveness of such [waiver] [release]. This letter will serve as notice to the Company of the impending [waiver] [release].

Except as expressly [waived] [released] hereby, the Lock-up Letter shall remain in full force and effect.

 

Yours very truly,
J.P. MORGAN SECURITIES LLC
By:  

 

Name:
Title:
MERRILL LYNCH, PIERCE, FENNER & SMITH
                               INCORPORATED
By:  

 

Name:
Title:

 

cc: Company

 

2


Exhibit C

Form of Press Release

Eidos Therapeutics, Inc.

[Date]

Eidos Therapeutics, Inc. (the “Company”) announced today that J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, the joint book-running managers in the Company’s recent public sale of        shares of common stock, is [waiving] [releasing] a lock-up restriction with respect to shares of the Company’s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on         , 20    , and the shares may be sold on or after such date.    

This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.

 

3


Exhibit D

[Company Letterhead]

[To come]

 

4

EX-3.1 3 d544598dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

EIDOS THERAPEUTICS, INC.

Eidos Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows:

1. The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by deleting the first paragraph of Article FOURTH and inserting the following in lieu thereof, so that, as amended, the opening paragraphs of Article FOURTH shall read in their entirety as follows:

“FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 32,292,000 shares of Common Stock, $0.001 par value per share (“Common Stock”), and (ii) 20,457,205 shares of Preferred Stock, par value $0.001 per share (“Preferred Stock”).

Effective immediately upon the filing of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Effective Time”), each one (1) share of Common Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the Effective Time shall automatically be split into 1.196 shares of Common Stock, without any further action by the holders of such shares (the “Stock Split”). No fractional shares shall be issued in connection with the Stock Split. In lieu of any fractional shares to which a holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation’s Board of Directors. Any stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock will, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent the number of shares of Common Stock as equals the applicable number of shares of Common Stock as adjusted to reflect the Stock Split.”

2. The foregoing amendment was duly adopted, in accordance with the provisions of Sections 141(f), 228 and 242 of the General Corporation Law of the State of Delaware by the directors and stockholders of the Corporation.


IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to the Amended and Restated Certificate of Incorporation to be signed by its duly authorized officer on this 7th day of June, 2018.

 

EIDOS THERAPEUTICS, INC.
By:    /s/ Neil Kumar
Name: Neil Kumar
Title:   Chief Executive Officer


CERTIFICATE OF AMENDMENT OF

THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF EIDOS THERAPEUTICS, INC.

Eidos Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”),

DOES HEREBY CERTIFY:

FIRST: That the name of this corporation is Eidos Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on August 6, 2013 under the name Eidos Therapeutics, Inc.

SECOND: That the Board of Directors of Eidos Therapeutics, Inc. (the “Corporation”) adopted resolutions setting forth a proposed amendment to the Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment is substantially as follows:

RESOLVED, that the Restated Certificate of Incorporation be amended as follows:

The first paragraph of Article FOURTH of the Restated Certificate of Incorporation of the Corporation shall be deleted and replaced in full with the following:

FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 27,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”) and (ii) 20,457,205 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).

The first paragraph of Article FOURTH, Part B of the Restated Certificate of Incorporation of the Corporation shall be deleted and replaced in full with the following:

“12,856,325 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series Seed Preferred Stock” with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. 7,600,880 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated “Series B Preferred Stock” with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to “sections” or “subsections” in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth.”


THIRD: That thereafter said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law by written consent of the stockholders holding the requisite number of shares required by statute given in accordance with and pursuant to Section 228 of the General Corporation Law of the State of Delaware.

[The remainder of this page is left blank.]

 

2


IN WITNESS WHEREOF, Eidos Therapeutics, Inc. has caused this Certificate of Amendment of the Restated Certificate of Incorporation to be signed by a duly authorized officer of this Corporation on this 29th day of May, 2018.

 

EIDOS THERAPEUTICS, INC.
By:    /s/ Neil Kumar
  Neil Kumar, Chief Executive Officer


EIDOS THERAPEUTICS, INC.

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION


AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

EIDOS THERAPEUTICS, INC.

(Pursuant to Sections 242 and 245 of the

General Corporation Law of the State of Delaware)

Eidos Therapeutics, Inc. a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”),

DOES HEREBY CERTIFY:

1. That the name of this corporation is Eidos Therapeutics, Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law on August 6, 2013.

2. That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:

RESOLVED, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:

FIRST: The name of this corporation is Eidos Therapeutics, Inc. (the “Corporation”).

SECOND: The address of the registered office of the corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Zip Code 19801, and the name of the registered agent of the Corporation in the State of Delaware at such address is the Corporation Trust Company.

THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.

FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 27,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”) and (ii) 20,088,025 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).


The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.

A. COMMON STOCK

1. General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.

2. Voting. The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings). The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law.

B. PREFERRED STOCK

12,856,325 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series Seed Preferred Stock” with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. 7,231,700 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated “Series B Preferred Stock” with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to “sections” or “subsections” in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth.

1. DIVIDENDS.

Holders of Series B Preferred Stock, in preference to both the holders of Series Seed Preferred Stock and the holders of Common Stock, shall be entitled to receive, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the Series B Original Issue Price (as defined below) per annum on each outstanding share of Series B Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board of Directors (the “Board”) and shall be non-cumulative. Holders of Series Seed Preferred Stock, in preference to the holders of Common Stock, shall be entitled to receive, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the Series Seed Original Issue Price (as defined below) per annum on each outstanding share of Series Seed Preferred Stock. Such dividends shall be payable only when, as and if declared by the Board and shall be non-cumulative. In the event dividends are paid on any share of Common Stock, the Company shall pay an additional dividend on all outstanding shares of Preferred Stock in a per share amount equal (on an as-if-converted to Common Stock basis) to the amount paid or set aside for each share of Common Stock. The “Original Issue Price” shall mean $1.3248 per share of Series Seed Preferred Stock, subject to appropriate adjustment in the event of any stock


dividend, stock split, combination or other similar recapitalization with respect to the Series Seed Preferred Stock and $10.8348 per share of Series B Preferred Stock, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock.

2. LIQUIDATION, DISSOLUTION OR WINDING UP; CERTAIN MERGERS, CONSOLIDATIONS AND ASSET SALES.

2.1 Preferential Payments to Holders of Series B Preferred Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Common Stock and Series Seed Preferred Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Series B Original Issue Price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Series B Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the “Series B Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock the full amount to which they shall be entitled under this Subsection 2.1, the holders of shares of Series B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

2.2 Preferential Payments to Holders of Series Seed Preferred Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after payment of all preferential amounts required to be paid to holders of Series B Preferred Stock pursuant to Subsection 2.1, the holders of shares of Series Seed Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Series Seed Original Issue Price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Series Seed Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the “Series Seed Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series Seed Preferred Stock the full amount to which they shall be entitled under this Subsection 2.2, the holders of shares of Series Seed Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.


2.3 Payments to Holders of Common Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.

2.4 Deemed Liquidation Events.

2.4.1 Definition. Each of the following events shall be considered a “Deemed Liquidation Event” unless the holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class and on an as-if-converted to Common Stock basis, elect otherwise by written notice sent to the Corporation prior to the effective date of any such event:

(a) a merger or consolidation in which

(i) the Corporation is a constituent party or

(ii) a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation,

except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or

(b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.

2.4.2 Effecting a Deemed Liquidation Event.

(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in Subsection 2.4.1(a)(i) unless the agreement or plan of merger or consolidation for such transaction (the “Merger Agreement”) provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the Corporation in accordance with Subsections 2.1, 2.2 and 2.3.


(b) In the event of a Deemed Liquidation Event referred to in Subsection 2.4.1(a)(ii) or 2.4.1(b), if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation Event, then (i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90th) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause; (ii) to require the redemption of such shares of Preferred Stock, and (iii) if the holders of at least majority of the then outstanding shares of Preferred Stock, voting together as a single class and on an as-if-converted to Common Stock basis, so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board), together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the “Available Proceeds”), on the one hundred fiftieth (150th) day after such Deemed Liquidation Event, to redeem all outstanding shares of Series B Preferred Stock at a price per share equal to the Series B Liquidation Amount and all outstanding shares of Series Seed Preferred Stock at a price per share equal to the Series Seed Liquidation Amount (an “Available Proceeds Redemption”). Notwithstanding the foregoing, in the event of an Available Proceeds Redemption, if the Available Proceeds are not sufficient to redeem all outstanding shares of Series B Preferred Stock, the Corporation shall ratably redeem each holder’s shares of Series B Preferred Stock to the fullest extent of such Available Proceeds, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. In the event of an Available Proceeds Redemption, if the remaining Available Proceeds following the redemption of all outstanding shares of Series B Preferred Stock pursuant to the preceding sentence are not sufficient to redeem all outstanding shares of Series Seed Preferred Stock, the Corporation shall ratably redeem each holder’s shares of Series Seed Preferred Stock to the fullest extent of such Available Proceeds, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption provided for in this Subsection 2.4.2(b), the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business.

2.4.3 Amount Deemed Paid or Distributed. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person, firm or other entity. The value of such property, rights or securities shall be determined in good faith by the Board.

2.4.4 Allocation of Escrow and Contingent Consideration. In the event of a Deemed Liquidation Event pursuant to Subsection 2.4.1(a)(i), if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the “Additional Consideration”), the Merger Agreement shall provide that (a) the portion of such consideration that is not Additional Consideration (such portion, the


Initial Consideration”) shall be allocated among the holders of capital stock of the Corporation in accordance with Subsections 2.1, 2.2 and 2.3 as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with Subsections 2.1, 2.2 and 2.3 after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this Subsection 2.4.4, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.

3. VOTING.

3.1 General. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class.

3.2 Election of Directors. The holders of record of the shares of Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3) directors of the Corporation (the “Preferred Directors”). Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders of shares of Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this Subsection 3.2, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. Except as otherwise provided in this Subsection 3.2, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this Subsection 3.2.


3.3 Preferred Stock Protective Provisions. At any time when at least 250,000 shares of Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class and on an as-if-converted to Common Stock basis, given in writing or by vote at a meeting, consenting or voting (as the case may be) together as a single class, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect.

3.3.1 liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing;

3.3.2 amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Corporation in a manner that affects the powers, preferences or rights of the Preferred Stock;

3.3.3 create or authorize the creation of any additional class or series of capital stock unless the same ranks junior to each series of Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption, or increase the authorized number of shares of each series of Preferred Stock or increase the authorized number of shares of any additional class or series of capital stock unless the same ranks junior to each series of Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of redemption;

3.3.4 (i) reclassify, alter or amend any existing security of the Corporation that is pari passu with any series of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to such series of Preferred Stock in respect of any such right, preference, or privilege or (ii) reclassify, alter or amend any existing security of the Corporation that is junior to any series of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with such series of Preferred Stock in respect of any such right, preference or privilege;

3.3.5 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i) redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (iii) repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof; or


3.3.6 increase or decrease the authorized number of directors constituting the Board.

3.4 Series B Preferred Stock Protective Provisions. At any time when at least 250,000 shares of Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock, given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect.

3.4.1 alter or change the powers, preferences or special rights of the shares of the Series B Preferred Stock in a manner that is adverse to the Series B Preferred Stock (a “Series B Diminution”); provided, that the creation or issuance of a new series of Preferred Stock that is senior to the Series B Preferred Stock in connection with a bona fide equity financing shall not, in and of itself, constitute a Series B Diminution;

3.4.2 purchase or redeem any shares of Series B Preferred Stock except as expressly contemplated under, and in accordance with the terms of, the Certificate of Incorporation;

3.4.3 purchase or redeem or pay or declare any dividend or make any distribution on, any shares of Common Stock and/or Series Seed Preferred Stock, other than (i) stock repurchased from former employees or consultants in connection with the cessation of their employment/services, at the lower of fair market value or cost, or (ii) payments of dividends as expressly contemplated under, and in accordance with the terms of, the Certificate of Incorporation; or

3.4.4 increase or decrease the authorized number of shares of Series B Preferred Stock.

3.5 Series Seed Preferred Stock Protective Provisions. At any time when at least 250,000 shares of Series Seed Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series Seed Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series Seed Preferred Stock, given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect.


3.5.1 alter or change the powers, preferences or special rights of the shares of the Series Seed Preferred Stock in a manner that is adverse to the Series Seed Preferred Stock (a “Series Seed Diminution”); provided, that the creation or issuance of a new series of Preferred Stock that is senior to, or pari passu with, the Series Seed Preferred Stock in connection with a bona fide equity financing shall not, in and of itself, constitute a Series Seed Diminution;

3.5.2 purchase or redeem any shares of Series Seed Preferred Stock except as expressly contemplated under, and in accordance with the terms of, the Certificate of Incorporation;

3.5.3 purchase or redeem or pay or declare any dividend or make any distribution on, any shares of Common Stock, other than (i) stock repurchased from former employees or consultants in connection with the cessation of their employment/services, at the lower of fair market value or cost, or (ii) payments of dividends as expressly contemplated under, and in accordance with the terms of, the Certificate of Incorporation; or

3.5.4 increase or decrease the authorized number of shares of Series Seed Preferred Stock.

4. OPTIONAL CONVERSION.

The holders of the Preferred Stock shall have conversion rights as follows (the “Conversion Rights”):

4.1 Right to Convert.

4.1.1 Conversion Ratio. Each share of Series B Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Series B Original Issue Price by the Series B Conversion Price (as defined below) in effect at the time of conversion. The “Series B Conversion Price” shall initially be equal to $10.8348 for Series B Preferred Stock. Such initial Series B Conversion Price, and the rate at which shares of Series B Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. Each share of Series Seed Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Series Seed Original Issue Price by the Series Seed Conversion Price (as defined below) in effect at the time of conversion. The “Series Seed Conversion Price” shall initially be equal to $1.3248 for Series Seed Preferred Stock. Such initial Series Seed Conversion Price, and the rate at which shares of Series Seed Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below.

4.1.2 Termination of Conversion Rights. In the event of a notice of redemption of any shares of Preferred Stock pursuant to Section 7, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for redemption, unless the redemption price is not fully paid on such


redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock.

4.2 Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.

4.3 Mechanics of Conversion.

4.3.1 Notice of Conversion. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall (a) provide written notice to the Corporation’s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder’s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder’s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder’s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the “Conversion Time”), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i) issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii) pay in cash such amount as provided in Subsection 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii) pay all declared but unpaid dividends on the shares of Preferred Stock converted.


4.3.2 Reservation of Shares. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which would cause an adjustment reducing either the Series B Conversion Price or the Series Seed Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock or the Series Seed Preferred Stock, respectively, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Series B Conversion Price or Series Seed Conversion Price.

4.3.3 Effect of Conversion. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in Subsection 4.2 and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

4.3.4 No Further Adjustment. Upon any such conversion, no adjustment to the Series B Conversion Price or Series Seed Conversion Price shall be made for any declared but unpaid dividends on the Series B Preferred Stock or Series Seed Preferred Stock, respectively, surrendered for conversion or on the Common Stock delivered upon conversion.

4.3.5 Taxes. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this Section 4. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.


4.4 Adjustments to Conversion Price for Diluting Issues.

4.4.1 Special Definitions. For purposes of this Article Fourth, the following definitions shall apply:

(a)Option” shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.

(b)Series B Original Issue Date” shall mean the date on which the first share of Series B Preferred Stock was issued.

(c)Convertible Securities” shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.

(d)Additional Shares of Common Stock” shall mean all shares of Common Stock issued (or, pursuant to Subsection 4.4.3 below, deemed to be issued) by the Corporation after the Series B Original Issue Date, other than (1) the following shares of Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and (2), collectively, “Exempted Securities”):

(i) shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred Stock;

(ii) shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by Subsection 4.5, 4.6, 4.7 or 4.8;

(iii) shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board;

(iv) shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;

(v) shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board;

(vi) shares of Common Stock, Options or Convertible Securities issued to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board;

(vii) shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided that such issuances are approved by the Board; or


(viii) shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board.

4.4.2 No Adjustment of Conversion Price. No adjustment in the Series B Conversion Price or Series Seed Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class and on an as-if-converted to Common Stock basis, agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.

4.4.3 Deemed Issue of Additional Shares of Common Stock.

(a) If the Corporation at any time or from time to time after the Series B Original Issue Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.

(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Series B Conversion Price or Series Seed Conversion Price pursuant to the terms of Subsection 4.4.4, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Series B Conversion Price or Series Seed Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Series B Conversion Price or Series Seed Conversion Price as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause (b) shall have the effect of increasing the Series B Conversion Price or Series Seed Conversion Price to an amount which exceeds the lower of (i) the Series B Conversion Price or Series Seed Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii) the Series B Conversion Price or Series Seed Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.


(c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Series B Conversion Price or Series Seed Conversion Price pursuant to the terms of Subsection 4.4.4 (either because the consideration per share (determined pursuant to Subsection 4.4.5) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Series B Conversion Price or Series Seed Conversion Price then in effect, or because such Option or Convertible Security was issued before the Series B Original Issue Date), are revised after the Series B Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in Subsection 4.4.3(a)) shall be deemed to have been issued effective upon such increase or decrease becoming effective.

(d) Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Series B Conversion Price or Series Seed Conversion Price pursuant to the terms of Subsection 4.4.4, the Series B Conversion Price or Series Seed Conversion Price shall be readjusted to such Series B Conversion Price or Series Seed Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.

(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the Series B Conversion Price or Series Seed Conversion Price provided for in this Subsection 4.4.3 shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b) and (c) of this Subsection 4.4.3). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Series B Conversion Price or Series Seed Conversion Price that would result under the terms of this Subsection 4.4.3 at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Series B Conversion Price or Series Seed Conversion Price that such issuance or amendment took place at the time such calculation can first be made.


4.4.4 Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock. In the event the Corporation shall at any time after the Series B Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Subsection 4.4.3), without consideration or for a consideration per share less than the Series B Conversion Price or Series Seed Conversion Price in effect immediately prior to such issue, then the Series B Conversion Price or Series Seed Conversion Price, respectively, shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:

CP2 = CP1* (A + B) ÷ (A + C).

For purposes of the foregoing formula, the following definitions shall apply:

(a) “CP2” shall mean the Series B Conversion Price or Series Seed Conversion Price in effect immediately after such issue of Additional Shares of Common Stock

(b) “CP1” shall mean the Series B Conversion Price or Series Seed Conversion Price in effect immediately prior to such issue of Additional Shares of Common Stock;

(c) “A” shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);

(d) “B” shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP1); and

(e) “C” shall mean the number of such Additional Shares of Common Stock issued in such transaction.

4.4.5 Determination of Consideration. For purposes of this Subsection 4.4, the consideration received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows:

(a) Cash and Property: Such consideration shall:

(i) insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;


(ii) insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board; and

(iii) in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i) and (ii) above, as determined in good faith by the Board.

(b) Options and Convertible Securities. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to Subsection 4.4.3, relating to Options and Convertible Securities, shall be determined by dividing:

(i) The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by

(ii) the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.

4.4.6 Multiple Closing Dates. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Series B Conversion Price or Series Seed Conversion Price pursuant to the terms of Subsection 4.4.4, and such issuance dates occur within a period of no more than ninety (90) days from the first such issuance to the final such issuance, then, upon the final such issuance, the Series B Conversion Price or Series Seed Conversion Price, respectively, shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).

4.5 Adjustment for Stock Splits and Combinations. If the Corporation shall at any time or from time to time after the Series B Original Issue Date effect a subdivision of the outstanding Common Stock, the Series B Conversion Price or Series Seed Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Series B Original


Issue Date combine the outstanding shares of Common Stock, the Series B Conversion Price or Series Seed Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective.

4.6 Adjustment for Certain Dividends and Distributions. In the event the Corporation at any time or from time to time after the Series B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Series B Conversion Price or Series Seed Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Series B Conversion Price or Series Seed Conversion Price, respectively then in effect by a fraction:

(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and

(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.

Notwithstanding the foregoing (a) if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Series B Conversion Price or Series Seed Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Series B Conversion Price or Series Seed Conversion Price, respectively, shall be adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions; and (b) that no such adjustment shall be made if the holders of Series B Preferred Stock or Series Seed Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of Series B Preferred Stock or Series Seed Preferred Stock had been converted into Common Stock on the date of such event.

4.7 Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after the Series B Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of Section 1 do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.


4.8 Adjustment for Merger or Reorganization, etc. Subject to the provisions of Subsection 2.4, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by Subsections 4.4, 4.6 or 4.7), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board) shall be made in the application of the provisions in this Section 4 with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this Section 4 (including provisions with respect to changes in and other adjustments of the Series B Conversion Price or Series Seed Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.

4.9 Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Series B Conversion Price or Series Seed Conversion Price pursuant to this Section 4, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than twenty (20) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than twenty (20) days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i) the Series B Conversion Price or Series Seed Conversion Price then in effect, and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of Preferred Stock.

4.10 Notice of Record Date. In the event:

(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any other security; or


(b) of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or

(c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,

then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least twenty (20) days prior to the record date or effective date for the event specified in such notice.

5. MANDATORY CONVERSION.

5.1 Trigger Events. Upon either (a) the closing of the sale of shares of Common Stock in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $75,000,000 of gross proceeds to the Corporation or (b) (x) with respect to the Series B Preferred Stock, the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock or (y) with respect to the Series Seed Preferred Stock, the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least a majority of the then outstanding shares of Series Seed Preferred Stock (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the “Mandatory Conversion Time”), then (i) in the case of (a) above, all outstanding shares of Series B Preferred Stock and Series Seed Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to Subsection 4.1.1., (ii) in the case of (b) above, all outstanding shares of Series B Preferred Stock or Series Seed Preferred Stock, as applicable, shall automatically be converted into shares of Common Stock at the then effective conversion rate as calculated pursuant to Subsection 4.1.1. and (iii) such shares may not be reissued by the Corporation.

5.2 Procedural Requirements. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this Section 5. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement


reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to Subsection 5.1, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Subsection 5.2. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)pay cash as provided in Subsection 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

6. SPECIAL MANDATORY CONVERSION.

6.1 Trigger Events. In the event that any holder of shares of Series B Preferred Stock is a Defaulting Purchaser with respect to the Call Option (as such capitalized terms are defined in the Series B Preferred Stock Purchase Agreement by and among the Corporation and the investors listed thereto, dated March 29, 2018 (the “Purchase Agreement”)), then each two (2) shares of the shares of Series B Preferred Stock held by such holder (or any transferee or assignee of shares of such holder) shall automatically, and without any further action on the part of such holder (or such transferee or assignee), be converted into one (1) share of Common Stock, (a) effective upon, subject to, and concurrently with, the consummation of the Additional Closing, or (b) if such Additional Closing does not occur as a result of such holder’s failure to purchase additional shares of Series B Preferred Stock, effective upon the date on which the holder became a Defaulting Purchaser pursuant to the terms of the Purchase Agreement. Such conversion is referred to as a “Special Mandatory Conversion.” If any Defaulting Purchaser (or a transferee or assignee of a Defaulting Purchaser) converted any shares of Series B Preferred Stock held by such holder (or such transferee or assignee) into shares of Common Stock at any time prior to such holder becoming either a Defaulting Purchaser, then such shares of Series B Preferred Stock that were so converted shall be deemed to have been converted pursuant to such Special Mandatory Conversion (and half of the number of shares of Common Stock issued upon such prior conversion of such shares of Series B Preferred Stock shall be forfeited by such Defaulting Purchaser (or such transferee or assignee) and cancelled immediately upon such Defaulting Purchaser becoming a Defaulting Purchaser, as applicable).


6.2 Procedural Requirements. Upon a Special Mandatory Conversion, each holder of shares of Series B Preferred Stock converted pursuant to Subsection 6.1 shall be sent written notice of such Special Mandatory Conversion and the place designated for mandatory conversion of all such shares of Series B Preferred Stock pursuant to this Section 6. Upon receipt of such notice, each holder of such shares of Series B Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that any such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series B Preferred Stock converted pursuant to Subsection 6.1, including the rights, if any, to receive notices, to vote (other than as a holder of Common Stock), or to designate a member of the Board, will terminate at the time of the Special Mandatory Conversion (notwithstanding the failure of the holder or holders thereof to surrender any certificates for such shares at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders therefor (or lost certificate affidavit and agreement), to receive the items provided for in the next sentence of this Subsection 6.2. As soon as practicable after the Special Mandatory Conversion and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Series B Preferred Stock so converted, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b) pay cash as provided in Subsection 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Series B Preferred Stock converted. Such converted Series B Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Series B Preferred Stock accordingly.

7. REDEEMED OR OTHERWISE ACQUIRED SHARES. Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption.

8. WAIVER. Any of the rights, powers, preferences and other terms of the Series B Preferred Stock set forth herein may be waived on behalf of all holders of Series B Preferred Stock by the affirmative written consent or vote of the holders of at least a majority of the shares of Series B Preferred Stock then outstanding. Any of the rights, powers, preferences and other terms of the Series Seed Preferred Stock set forth herein may be waived on behalf of all holders of Series Seed Preferred Stock by the affirmative written consent or vote of the holders of at least a majority of the shares of Series Seed Preferred Stock then outstanding. Subject to Section 3.4 and 3.5, any of the rights, powers, preferences and other terms of the Preferred Stock may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders of at least a majority of the shares of all series of Preferred Stock then outstanding voting together as a single class and on an as-if-converted to Common Stock basis.


9. NOTICES. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.

FIFTH: Subject to any additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.

SIXTH: Subject to any additional vote required by the Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation.

SEVENTH: Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

EIGHTH: Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.

NINTH: To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.

Any repeal or modification of the foregoing provisions of this Article Ninth by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

TENTH: To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law.


Any amendment, repeal or modification of the foregoing provisions of this Article Tenth shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.

ELEVENTH: The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, “Covered Persons”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Corporation.

*     *     *

3. That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law.

4. That this Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation’s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.


IN WITNESS WHEREOF, this AMENDED AND RESTATED CERTIFICATE OF INCORPORATION has been executed by a duly authorized officer of this corporation on this 29th day of March, 2018.

 

By:   /s/ Neil Kumar
  Neil Kumar
EX-3.2 4 d544598dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

OF

EIDOS THERAPEUTICS, INC.

Eidos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

1. The name of the Corporation is Eidos Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was August 6, 2013 (the “Original Certificate”).

2. This Amended and Restated Certificate of Incorporation (the “Certificate”) amends, restates and integrates the provisions of the Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on March 29, 2018 and subsequently amended on May 29, 2018 (the “Amended and Restated Certificate”), and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the “DGCL”).

3. The text of the Amended and Restated Certificate is hereby amended and restated in its entirety to provide as herein set forth in full.

ARTICLE I

The name of the Corporation is Eidos Therapeutics, Inc.

ARTICLE II

The address of the Corporation’s registered office in the State of Delaware is c/o The Corporation Trust Company, 1209 Orange Street in the City of Wilmington, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company.

ARTICLE III

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL.

 


ARTICLE IV

CAPITAL STOCK

The total number of shares of capital stock which the Corporation shall have authority to issue is One Hundred Fifty Five Million (155,000,000), of which (i) One Hundred Fifty Million (150,000,000) shares shall be a class designated as common stock, par value $0.001 per share (the “Common Stock”), and (ii) Five Million (5,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the “Undesignated Preferred Stock”).

Except as otherwise provided in any certificate of designations of any series of Undesignated Preferred Stock, the number of authorized shares of the class of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation irrespective of the provisions of Section 242(b)(2) of the DGCL.

The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance with, or as set forth below in, this Article IV.

A. COMMON STOCK

Subject to all the rights, powers and preferences of the Undesignated Preferred Stock and except as provided by law or in this Certificate (or in any certificate of designations of any series of Undesignated Preferred Stock):

(a) the holders of the Common Stock shall have the exclusive right to vote for the election of directors of the Corporation (the “Directors”) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate (or on any amendment to a certificate of designations of any series of Undesignated Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Undesignated Preferred Stock if the holders of such affected series of Undesignated Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (or pursuant to a certificate of designations of any series of Undesignated Preferred Stock) or pursuant to the DGCL;

(b) dividends may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee thereof; and

 

2


(c) upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the net assets of the Corporation shall be distributed pro rata to the holders of the Common Stock.

B. UNDESIGNATED PREFERRED STOCK

The Board of Directors or any authorized committee thereof is expressly authorized, to the fullest extent permitted by law, to provide by resolution or resolutions for, out of the unissued shares of Undesignated Preferred Stock, the issuance of the shares of Undesignated Preferred Stock in one or more series of such stock, and by filing a certificate of designations pursuant to applicable law of the State of Delaware, to establish or change from time to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof.

ARTICLE V

STOCKHOLDER ACTION

1. Action without Meeting. Any action required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by a written consent of stockholders in lieu thereof.

2. Special Meetings. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office, and special meetings of stockholders may not be called by any other person or persons. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation.

ARTICLE VI

DIRECTORS

1. General. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided herein or required by law.

2. Election of Directors. Election of Directors need not be by written ballot unless the Bylaws of the Corporation (the “Bylaws”) shall so provide.

 

3


3. Number of Directors; Term of Office. The number of Directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Undesignated Preferred Stock, shall be classified, with respect to the term for which they severally hold office, into three classes. The Board of Directors shall assign Directors into classes at the time the classification becomes effective. The initial Class I Directors shall serve for a term expiring at the first annual meeting of stockholders to be held after the filing of this Certificate, the initial Class II Directors shall serve for a term expiring at the second annual meeting of stockholders to be held after the filing of this Certificate, and the initial Class III Directors shall serve for a term expiring at the third annual meeting of stockholders to be held after the filing of this Certificate. At each annual meeting of stockholders, Directors elected to succeed those Directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal.

Notwithstanding the foregoing, whenever, pursuant to the provisions of Article IV of this Certificate, the holders of any one or more series of Undesignated Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect Directors at an annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of this Certificate and any certificate of designations applicable to such series.

4. Vacancies. Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors and to fill vacancies in the Board of Directors relating thereto, any and all vacancies in the Board of Directors, however occurring, including, without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation, disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining Directors then in office, even if less than a quorum of the Board of Directors, and not by the stockholders. Any Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director’s successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal. Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to Article VI.3 hereof, determine the class or classes to which the increased or decreased number of Directors shall be apportioned; provided, however, that no decrease in the number of Directors shall shorten the term of any incumbent Director. In the event of a vacancy in the Board of Directors, the remaining Directors, except as otherwise provided by law, shall exercise the powers of the full Board of Directors until the vacancy is filled.

 

4


5. Removal. Subject to the rights, if any, of any series of Undesignated Preferred Stock to elect Directors and to remove any Director whom the holders of any such series have the right to elect, any Director (including persons elected by Directors to fill vacancies in the Board of Directors) may be removed from office (i) only with cause and (ii) only by the affirmative vote of the holders of 75% or more of the outstanding shares of capital stock then entitled to vote at an election of Directors. At least forty-five (45) days prior to any annual or special meeting of stockholders at which it is proposed that any Director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent to the Director whose removal will be considered at the meeting.

ARTICLE VII

LIMITATION OF LIABILITY

A Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a Director, except for liability (a) for any breach of the Director’s duty of loyalty to the Corporation or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) under Section 174 of the DGCL or (d) for any transaction from which the Director derived an improper personal benefit. If the DGCL is amended after the effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

Any amendment, repeal or modification of this Article VII by either of (i) the stockholders of the Corporation or (ii) an amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a Director at the time of such amendment, repeal or modification.

ARTICLE VIII

AMENDMENT OF BYLAWS

1. Amendment by Directors. Except as otherwise provided by law, the By-laws of the Corporation may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the Directors then in office.

2. Amendment by Stockholders. The Bylaws of the Corporation may be amended or repealed at any annual meeting of stockholders, or special meeting of stockholders called for such purpose, by the affirmative vote of at least 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class.

 

5


ARTICLE IX

AMENDMENT OF CERTIFICATE OF INCORPORATION

The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter prescribed by statute and this Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation. Whenever any vote of the holders of capital stock of the Corporation is required to amend or repeal any provision of this Certificate, and in addition to any other vote of holders of capital stock that is required by this Certificate or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose; provided, however, that the affirmative vote of not less than 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of not less than 75% of the outstanding shares of each class entitled to vote thereon as a class, shall be required to amend or repeal any provision of Article V, Article VI, Article VII, Article VIII or Article IX of this Certificate.

[End of Text]

 

6


THIS AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this              day of                    , 2018.

 

EIDOS THERAPEUTICS, INC.

By:

 

 

Name:

  Neil Kumar

Title:

  Chief Executive Officer

[SIGNATURE PAGE TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION]

EX-3.4 5 d544598dex34.htm EX-3.4 EX-3.4

Exhibit 3.4

AMENDED AND RESTATED

BYLAWS

OF

EIDOS THERAPEUTICS, INC.

(the “Corporation”)

ARTICLE I

Stockholders

SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States, or if determined solely by the Board of Directors in its sole discretion, by remote communication, fixed by the Corporation’s Board of Directors (the “Board of Directors”), which time, date and place may subsequently be changed at any time by the Board of Directors.

SECTION 2. Notice of Stockholder Business and Nominations.

(a) Annual Meetings of Stockholders.

(1) Nominations of persons for election to the Board of Directors and the proposal of other business to be considered by the stockholders may be brought before an Annual Meeting (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice provided for in this Bylaw, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this Bylaw as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii) shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters properly brought under Rule 14a-8 (or any successor rule) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section 2(a)(2) and (3) of this Bylaw to bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this Bylaw, for any proposal of business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law.

(2) For nominations or other business to be properly brought before an Annual Meeting by a stockholder pursuant to clause (ii) of Article I, Section 2(a)(1) of this Bylaw, the stockholder must (i) have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation, (ii) have provided any updates or


supplements to such notice at the times and in the forms required by this Bylaw and (iii) together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this Bylaw. To be timely, a stockholder’s written notice shall be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the one-year anniversary of the preceding year’s Annual Meeting; provided, however, that in the event the Annual Meeting is first convened more than thirty (30) days before or more than sixty (60) days after such anniversary date, or if no Annual Meeting were held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than the close of business on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as “Timely Notice”). Notwithstanding anything to the contrary provided herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder’s notice shall be timely if received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such Annual Meeting is first made or sent by the Corporation. Such stockholder’s Timely Notice shall set forth:

(A) as to each person whom the stockholder proposes to nominate for election or reelection as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected);

(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest in such business of each Proposing Person (as defined below);

(C) (i) the name and address of the stockholder giving the notice, as they appear on the Corporation’s books, and the names and addresses of the other Proposing Persons (if any) and (ii) as to each Proposing Person, the following information: (a) the class or series and number of all shares of capital stock of the Corporation which are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its affiliates or associates (as such terms are defined in Rule 12b-2 promulgated under the Exchange Act), including any shares of any class or series of capital stock of the Corporation as to which such Proposing Person or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future, (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its affiliates or associates, directly or indirectly, holds an interest including a description of the

 

2


material terms of each such Synthetic Equity Interest, including without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (x) whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person, (y) whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares and (z) whether or not such Proposing Person and/or, to the extent known, the counterparty to such Synthetic Equity Interest has entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c) any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the Corporation, (d) any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation, and (e) any performance-related fees (other than an asset based fee) that such Proposing Person, directly or indirectly, is entitled to based on any increase or decrease in the value of shares of any class or series of capital stock of the Corporation or any Synthetic Equity Interests (the disclosures to be made pursuant to the foregoing clauses (a) through (e) are referred to, collectively, as “Material Ownership Interests”) and (iii) a description of the material terms of all agreements, arrangements or understandings (whether or not in writing) entered into by any Proposing Person or any of its affiliates or associates with any other person for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation;

(D) (i) a description of all agreements, arrangements or understandings by and among any of the Proposing Persons, or by and among any Proposing Persons and any other person (including with any proposed nominee(s)), pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (ii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support such nominations or other business proposal(s), and to the extent known the class and number of all shares of the Corporation’s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and

(E) a statement whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least the percentage of voting power of all of the shares of capital stock of the Corporation reasonably believed by such Proposing Person to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder (such statement, the “Solicitation Statement”).

 

3


For purposes of this Article I of these Bylaws, the term “Proposing Person” shall mean the following persons: (i) the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders’ meeting, and (ii) the beneficial owner(s), if different, on whose behalf the nominations or business proposed to be brought before a stockholders’ meeting is made. For purposes of this Section 2 of Article I of these Bylaws, the term “Synthetic Equity Interest” shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or so-called “stock borrowing” agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a) give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the Corporation, (b) mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, (c) otherwise provide in any manner the opportunity to profit or avoid a loss from any decrease in the value of any shares of any class or series of capital stock of the Corporation, or (d) increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation.

(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this Bylaw shall be true and correct as of the record date for the meeting and as of the date that is ten (10) business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the record date), and not later than the close of business on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting).

(4) Notwithstanding anything in the second sentence of Article I, Section 2(a)(2) of this Bylaw to the contrary, in the event that the number of directors to be elected to the Board of Directors of the Corporation is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section 2(a)(2), a stockholder’s notice required by this Bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation.

 

4


(b) General.

(1) Only such persons who are nominated in accordance with the provisions of this Bylaw shall be eligible for election and to serve as directors and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this Bylaw or in accordance with Rule 14a-8 under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this Bylaw. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this Bylaw, the presiding officer of the Annual Meeting shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of this Bylaw. If the Board of Directors or a designated committee thereof or the presiding officer, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this Bylaw, such proposal or nomination shall be disregarded and shall not be presented for action at the Annual Meeting.

(2) Except as otherwise required by law, nothing in this Article I, Section 2 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.

(3) Notwithstanding the foregoing provisions of this Article I, Section 2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I, Section 2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders.

(4) For purposes of this Bylaw, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

 

5


(5) Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Bylaw. Nothing in this Bylaw shall be deemed to affect any rights of (i) stockholders to have proposals included in the Corporation’s proxy statement pursuant to Rule 14a-8 (or any successor rule), as applicable, under the Exchange Act and, to the extent required by such rule, have such proposals considered and voted on at an Annual Meeting or (ii) the holders of any series of Preferred Stock to elect directors under specified circumstances.

SECTION 3. Special Meetings.

(a) Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by (i) the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office or (ii) the holders of at least 25% of the voting power of all outstanding shares of stock of the Corporation as provided in Section 3(b). The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation.

(b) A special meeting of stockholders shall be called by the Secretary upon written request (a “Special Meeting Request”) of one or more record holders of shares of stock of the Corporation representing not less than 25% of the voting power of all outstanding shares of stock of the Corporation (the “Requisite Percentage”) who have complied in full with the requirements set forth in these Bylaws. For purposes of this Section 3(b) and for determining the Requisite Percentage, a stockholder of record or a beneficial owner, as the case may be, shall be deemed to own the shares of stock of the Corporation that such stockholder or, if such stockholder is a nominee, custodian or other agent that is holding the shares on behalf of another person (the “beneficial owner”), that such beneficial owner would be deemed to own pursuant to Rule 200(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), excluding any shares as to which such stockholder or beneficial owner, as the case may be, does not have the right to vote or direct the vote at the special meeting or as to which such stockholder or beneficial owner, as the case may be, has entered into a derivative or other agreement, arrangement or understanding that hedges or transfers, in whole or in part, directly or indirectly, any of the economic consequences of ownership of such shares.

(i) A Special Meeting Request must be delivered by hand or by registered U.S. mail, postage prepaid, return receipt requested, or courier service, postage prepaid, to the attention of the Secretary at the principal executive offices of the Corporation. A Special Meeting Request shall be valid only if it is signed and dated by each stockholder of record submitting the Special Meeting Request and the beneficial owners, if any, on whose behalf the Special Meeting Request is being made, or such stockholder’s or beneficial owner’s duly authorized agent (each, a “Requesting Stockholder”) collectively representing the Requisite Percentage, and includes (A) a statement of the specific purpose(s) of the special meeting and the reasons for conducting such business at the special meeting; (B) as to any director nominations proposed to be presented at the

 

6


special meeting and any matter (other than a director nomination) proposed to be conducted at the special meeting and as to each Requesting Stockholder, the information, statements, representations, agreements and other documents that would be required to be set forth in or included with a stockholder’s notice of a nomination pursuant to Section 2(a)(2) of this Article I (including any nominee’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected and a completed and the additional information signed representation and agreement as required by Section 2(a)(2)(A) and (C)-(E) of this Article I) and/or a stockholder’s notice of business proposed to be brought before a meeting pursuant to Section 2(a)(2)(B)-(E) of this Article I, as applicable; (C) a representation that each Requesting Stockholder, or one or more representatives of each such stockholder, intends to appear in person or by proxy at the special meeting to present the nomination(s) or business to be brought before the special meeting; (D) an agreement by the Requesting Stockholders to notify the Corporation promptly in the event of any disposition prior to the record date for the special meeting of shares of the Corporation owned beneficially or of record and an acknowledgement that any such disposition shall be deemed to be a revocation of such Special Meeting Request with respect to such disposed shares; and (E) documentary evidence that the Requesting Stockholders own the Requisite Percentage as of the date on which the Special Meeting Request is delivered to the Secretary; provided, however, that if the Requesting Stockholders are not the beneficial owners of the shares representing the Requisite Percentage, then to be valid, the Special Meeting Request must also include documentary evidence (or, if not simultaneously provided with the Special Meeting Request, such documentary evidence must be delivered to the Secretary within 10 days after the date on which the Special Meeting Request is delivered to the Secretary) that the beneficial owners on whose behalf the Special Meeting Request is made beneficially own the Requisite Percentage as of the date on which such Special Meeting Request is delivered to the Secretary. In addition, the Requesting Stockholders and the beneficial owners, if any, on whose behalf the Special Meeting Request is being made shall (x) further update and supplement the information provided in the Special Meeting Request, if necessary, so that the information provided or required to be provided therein shall be true and correct as of the record date for the special meeting, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five business days following the later of the record date for the meeting or the date notice of the record date is first publicly disclosed and (y) promptly provide any other information reasonably requested by the Corporation.

(ii) A Special Meeting Request shall not be valid, and a special meeting requested by stockholders shall not be held, if (A) the Special Meeting Request does not comply with this section 3(b); (B) the Special Meeting Request relates to an item of business that is not a proper subject for stockholder action under applicable law (as determined in good faith by the Board of Directors); (C) the Special Meeting Request is delivered during the period commencing 120 days prior to the first anniversary of the date of the immediately preceding annual meeting of stockholders and ending on the earlier of (x) the date of the next annual meeting and (y) 30 days after the first anniversary of the date of the previous annual meeting; (D) an identical or substantially similar item (as determined in good faith by the Board of Directors, a “Similar Item”), other than the election of directors, was

 

7


presented at an annual or special meeting of stockholders held not more than 12 months before the Special Meeting Request is delivered; (E) a Similar Item was presented at an annual or special meeting of stockholders held not more than 120 days before the Special Meeting Request is delivered (and, for purposes of this clause (E), the election of directors shall be deemed to be a “Similar Item” with respect to all items of business involving the election or removal of directors, changing the size of the Board of Directors and the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number of directors); (F) a Similar Item is included in the Corporation’s notice of meeting as an item of business to be brought before an annual or special meeting of stockholders that has been called but not yet held or that is called for a date within 120 days of the receipt by the Corporation of a Special Meeting Request; or (G) the Special Meeting Request was made in a manner that involved a violation of Regulation 14A under the Exchange Act or other applicable law.

(iii) Special meetings of stockholders called pursuant to this Section 3(b) shall be held at such place, on such date, and at such time as the Board of Directors shall fix; provided, however, that the special meeting shall not be held more than 120 days after receipt by the Corporation of a valid Special Meeting Request.

(iv) The Requesting Stockholders may revoke a Special Meeting Request by written revocation delivered to the Secretary at the principal executive offices of the Corporation at any time prior to the special meeting. If, at any point after 60 days following the earliest dated Special Meeting Request, the unrevoked requests from Requesting Stockholders (whether by specific written revocation or deemed revocation pursuant to clause (D) of Section 3(b)(i)) represent in the aggregate less than the Requisite Percentage, the Board of Directors, in its discretion, may cancel the special meeting.

(v) In determining whether a special meeting of stockholders has been requested by the Requesting Stockholders representing in the aggregate at the least the Requisite Percentage, multiple Special Meeting Requests delivered to the Secretary of the Corporation will be considered together only if (A) each Special Meeting Request identifies substantially the same purpose or purposes of the special meeting and substantially the same matters proposed to be acted on at the special meeting, in each case as determined by the Board of Directors (which, if such purpose is the election or removal of directors, changing the size of the Board of Directors and/or the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number of directors, will mean that the exact same person or persons are proposed for election or removal in each relevant Stockholder Meeting Request), and (B) such Special Meeting Requests have been dated and delivered to the Secretary of the Corporation within 60 days of the earliest dated Special Meeting Request.

(vi) If none of the Requesting Stockholders appear or send a duly authorized agent to present the business to be presented for consideration specified in the Special Meeting Request, the Corporation need not present such business for a vote at the special meeting, notwithstanding that proxies in respect of such matter may have been received by the Corporation.

 

8


(vii) Business transacted at any special meeting called pursuant to this section 3(b) shall be limited to (A) the purpose(s) stated in the valid Special Meeting Request received from the Requisite Percentage of record holders and (B) any additional matters that the Board of Directors determines to include in the Corporation’s notice of the special meeting.

SECTION 4. Notice of Meetings; Adjournments.

(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given not less than ten (10) days nor more than sixty (60) days before the Annual Meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation’s stock transfer books. Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the Delaware General Corporation Law (“DGCL”).

(b) Notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice of all special meetings shall state the purpose or purposes for which the meeting has been called.

(c) Notice of an Annual Meeting or special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting, unless such attendance is for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened.

(d) The Board of Directors may postpone and reschedule any previously scheduled Annual Meeting or special meeting of stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section 2 of this Article I of these Bylaws or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder’s notice under this Article I of these Bylaws.

(e) When any meeting is convened, the presiding officer may adjourn the meeting if (i) no quorum is present for the transaction of business, (ii) the Board of Directors determines that adjournment is necessary or appropriate to enable the stockholders to consider fully information which the Board of Directors determines has not been made sufficiently or timely available to stockholders, or (iii) the Board of Directors determines that adjournment is otherwise in the best interests of the Corporation. When any Annual Meeting or special meeting of

 

9


stockholders is adjourned to another hour, date or place, notice need not be given of the adjourned meeting other than an announcement at the meeting at which the adjournment is taken of the hour, date and place, if any, to which the meeting is adjourned and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting; provided, however, that if the adjournment is for more than thirty (30) days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the “Certificate”) or these Bylaws, is entitled to such notice.

SECTION 5. Quorum. A majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at any meeting of stockholders. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section 4 of this Article I. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.

SECTION 6. Voting and Proxies. Stockholders shall have one vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i) in person, (ii) by written proxy or (iii) by a transmission permitted by Section 212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section 212(c) of the DGCL may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. Except as otherwise limited therein or as otherwise provided by law, proxies authorizing a person to vote at a specific meeting shall entitle the persons authorized thereby to vote at any adjournment of such meeting, but they shall not be valid after final adjournment of such meeting. A proxy with respect to stock held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them.

SECTION 7. Action at Meeting. When a quorum is present at any meeting of stockholders, any matter before any such meeting (other than an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except for any matter where a different or minimum vote is provided by law, by the Certificate

 

10


or by these Bylaws, or the rules of any stock exchange on which the Corporation’s securities are listed, in which case such different or minimum vote shall be the applicable vote on such matter. Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors.

SECTION 8. Stockholder Lists. The Corporation shall prepare and make, at least ten (10) days before every Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for a period of at least ten (10) days prior to the meeting in the manner provided by law. The list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law.

SECTION 9. Presiding Officer. The Board of Directors shall designate a representative to preside over all Annual Meetings or special meetings of stockholders, provided that if the Board of Directors does not so designate such a presiding officer, then the Chairman of the Board of Directors (the “Chairman of the Board”), if one is elected, shall preside over such meetings. If the Board of Directors does not so designate such a presiding officer and there is no Chairman of the Board or the Chairman of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is elected, shall preside over such meetings, provided further that if there is no Chief Executive Officer or the Chief Executive Officer is unable to so preside or is absent, then the President shall preside over such meetings. The presiding officer at any Annual Meeting or special meeting of stockholders shall have the power, among other things, to adjourn such meeting at any time and from time to time, subject to Sections 4 and 5 of this Article I. The order of business and all other matters of procedure at any meeting of the stockholders shall be determined by the presiding officer.

SECTION 10. Inspectors of Elections. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the presiding officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. The presiding officer may review all determinations made by the inspectors, and in so doing the presiding officer shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the presiding officer, shall be subject to further review by any court of competent jurisdiction.

 

11


SECTION 11. Action by Written Consent.

(a) Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the Secretary, request that the Board of Directors fix a record date. The Board of Directors shall promptly, but in all events within ten (10) days after the date on which such written notice is received, adopt a resolution fixing the record date (unless a record date has previously been fixed by the Board of Directors pursuant to Article IV, Section 4(c) prior to the receipt of such written notice). If no record date has been fixed by the Board of Directors pursuant to Article IV, Section 4(c) or otherwise within ten (10) days after the date on which such written notice is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be the date provided in such circumstance in Article IV, Section 4.

(b) In the event of the delivery, in the manner provided by this Section 11 and applicable law, to the Corporation of written consent or consents to take corporate action and/or any related revocation or revocations, the Corporation shall engage independent inspectors of elections for the purpose of performing promptly a ministerial review of the validity of the consents and revocations. For the purpose of permitting the inspectors to perform such review, no action by written consent and without a meeting shall be effective until such inspectors have completed their review, determined that the requisite number of valid and unrevoked consents delivered to the Corporation in accordance with this Section 11 and applicable law have been obtained to authorize or take the action specified in the consents, and certified such determination for entry in the records of the Corporation kept for the purpose of recording the proceedings of meetings of stockholders. Nothing contained in this Section 11(b) shall in any way be construed to suggest or imply that the Board of Directors or any stockholder shall not be entitled to contest the validity of any consent or revocation thereof, whether before or after such certification by the independent inspectors, or to take any other action (including, without limitation, the commencement, prosecution or defense of any litigation with respect thereto, and the seeking of injunctive relief in such litigation).

(c) No written consent shall be effective to take the corporate action referred to therein unless, within sixty (60) days after the date of the first delivery of a written consent to the Corporation in accordance with this Section 11, a valid written consent or valid written consents signed by a sufficient number of stockholders to take such action are delivered to the Corporation in the manner prescribed in this Section 11 and applicable law, and not revoked.

ARTICLE II

Directors

SECTION 1. Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided by the Certificate or required by law.

SECTION 2. Number and Terms. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The directors shall hold office in the manner provided in the Certificate.

 

12


SECTION 3. Qualification. No director need be a stockholder of the Corporation.

SECTION 4. Vacancies. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate.

SECTION 5. Removal. Directors may be removed from office as provided in the Certificate.

SECTION 6. Resignation. A director may resign at any time by giving written notice to the Chairman of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides.

SECTION 7. Regular Meetings. The regular annual meeting of the Board of Directors may be held, without notice other than this Section 7, on the same date and at the same place as the Annual Meeting following the close of such meeting of stockholders. Other regular meetings of the Board of Directors may be held at such hour, date and place as the Board of Directors may by resolution from time to time determine.

SECTION 8. Special Meetings. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a majority of the directors, the Chairman of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place thereof.

SECTION 9. Notice of Meetings. Notice of the hour, date and place of all special meetings of the Board of Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairman of the Board, if one is elected, or the President or such other officer designated by the Chairman of the Board, if one is elected, or the President. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of electronic communication, sent to his or her business or home address, at least twenty-four (24) hours in advance of the meeting, or by written notice mailed to his or her business or home address, at least forty-eight (48) hours in advance of the meeting. Such notice shall be deemed to be delivered when hand-delivered to such address, read to such director by telephone, deposited in the mail so addressed, with postage thereon prepaid if mailed, dispatched or transmitted if sent by facsimile transmission or by electronic mail or other form of electronic communications. A written waiver of notice signed before or after a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these Bylaws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting.

 

13


SECTION 10. Quorum. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business which might have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this section, the total number of directors includes any unfilled vacancies on the Board of Directors.

SECTION 11. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these Bylaws.

SECTION 12. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the records of the meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the Board of Directors for all purposes.

SECTION 13. Manner of Participation. Directors may participate in meetings of the Board of Directors by means of conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall constitute presence in person at such meeting for purposes of these Bylaws.

SECTION 14. Presiding Director. The Board of Directors shall designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is absent, then the Chairman of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chairman of the Board, if one is elected, are unable to preside or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors.

SECTION 15. Committees. The Board of Directors may designate one or more committees, including, without limitation, a Compensation Committee, a Nominating & Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers except those which by law, by the Certificate or by these Bylaws may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these Bylaws for the Board of Directors. Except as the Board of Directors may otherwise determine, all members of such committees shall hold such offices at the pleasure of the Board of Directors. Except as the Board of Directors may otherwise determine, the Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings and shall report its action to the Board of Directors.

 

14


SECTION 16. Compensation of Directors. Directors shall receive such compensation for their services as shall be determined by a majority of the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees and who receive compensation for their services as such, shall not receive any salary or other compensation for their services as directors of the Corporation.

ARTICLE III

Officers

SECTION 1. Enumeration. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other officers, including, without limitation, a Chairman of the Board of Directors, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine.

SECTION 2. Election. The Board of Directors shall elect, from time to time at a regular or special meeting, the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors at any other regular or special meeting.

SECTION 3. Qualification. No officer need be a stockholder or a director. Any person may occupy more than one office of the Corporation at any time.

SECTION 4. Tenure. Except as otherwise provided by the Certificate or by these Bylaws, each of the officers of the Corporation shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal.

SECTION 5. Resignation. Any officer may resign by delivering his or her written resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise provides.

SECTION 6. Removal. Except as otherwise provided by law, the Board of Directors may remove any officer with or without cause by the affirmative vote of a majority of the directors then in office.

SECTION 7. Absence or Disability. In the event of the absence or disability of any officer, the Board of Directors may designate another officer to act temporarily in place of such absent or disabled officer.

 

15


SECTION 8. Vacancies. Any vacancy in any office may be filled for the unexpired portion of the term by the Board of Directors.

SECTION 9. President. The President shall, subject to the direction of the Board of Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate.

SECTION 10. Chairman of the Board. The Chairman of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.

SECTION 11. Chief Executive Officer. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.

SECTION 12. Vice Presidents and Assistant Vice Presidents. Any Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.

SECTION 13. Treasurer and Assistant Treasurers. The Treasurer shall, subject to the direction of the Board of Directors and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all funds, securities, and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.

SECTION 14. Secretary and Assistant Secretaries. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.

 

16


SECTION 15. Other Powers and Duties. Subject to these Bylaws and to such limitations as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief Executive Officer.

ARTICLE IV

Capital Stock

SECTION 1. Certificates of Stock. Each stockholder shall be entitled to a certificate of the capital stock of the Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by the Chairman of the Board, the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary. The Corporation’s seal and the signatures by the Corporation’s officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these Bylaws, the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of these Bylaws the Board of Directors has determined that all classes or series of the Corporation’s stock may be uncertificated, whether upon original issuance, re-issuance, or subsequent transfer.

SECTION 2. Transfers. Subject to any restrictions on transfer and unless otherwise authorized by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the records of the Corporation by the surrender to the Corporation or its transfer agent of the certificate theretofore properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate may be transferred on the records of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its transfer agent may require, or in such other manner as is authorized by the Board of Directors.

SECTION 3. Record Holders. Except as may otherwise be required by law, by the Certificate or by these Bylaws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or other disposition of such stock, until the shares have been transferred on the records of the Corporation in accordance with the requirements of these Bylaws.

 

17


SECTION 4. Record Date. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a) in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting, (b) in the case of any other action, shall not be more than sixty (60) days prior to such other action, and (c) in the case of determination of stockholders entitled to express consent to corporate action in writing without a meeting shall not be more ten(10) days after the date upon such the resolution fixing the record date is adopted by the Board of Directors. If no record date is fixed: (i) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (ii) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto;. and (iii) the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting shall: (A) when no prior action of the Board of Directors is required by law, be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with applicable law, and (B) if prior action by the Board of Directors is required by law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

SECTION 5. Replacement of Certificates. In case of the alleged loss, destruction or mutilation of a certificate of stock of the Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe.

ARTICLE V

Indemnification

SECTION 1. Definitions. For purposes of this Article:

(a) “Corporate Status” describes the status of a person who is serving or has served (i) as a Director of the Corporation, (ii) as an Officer of the Corporation, (iii) as a Non-Officer Employee of the Corporation, or (iv) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the Corporation. For purposes of this Section 1(a), a Director,

 

18


Officer or Non-Officer Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, “Corporate Status” shall not include the status of a person who is serving or has served as a director, officer, employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person’s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders of the Corporation;

(b) “Director” means any person who serves or has served the Corporation as a director on the Board of Directors;

(c) “Disinterested Director” means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding;

(d) “Expenses” means all attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding;

(e) “Liabilities” means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement;

(f) “Non-Officer Employee” means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer;

(g) “Officer” means any person who serves or has served the Corporation as an officer of the Corporation appointed by the Board of Directors;

(h) “Proceeding” means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and

(i) “Subsidiary” shall mean any corporation, partnership, limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i) a general partner, managing member or other similar interest or (ii) (A) fifty percent (50%) or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B) fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity.

 

19


SECTION 2. Indemnification of Directors and Officers.

(a) Subject to the operation of Section 4 of this Article V of these Bylaws, each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section 2.

(1) Actions, Suits and Proceedings Other than By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful.

(2) Actions, Suits and Proceedings By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this Section 2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.

(3) Survival of Rights. The rights of indemnification provided by this Section 2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives.

(4) Actions by Directors or Officers. Notwithstanding the foregoing, the Corporation shall indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or

 

20


Officer) was authorized in advance by the Board of Directors of the Corporation, unless such Proceeding was brought to enforce such Officer’s or Director’s rights to indemnification or, in the case of Directors, advancement of Expenses under these Bylaws in accordance with the provisions set forth herein.

SECTION 3. Indemnification of Non-Officer Employees. Subject to the operation of Section 4 of this Article V of these Bylaws, each Non-Officer Employee may, in the discretion of the Board of Directors, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such Non-Officer Employee or on such Non-Officer Employee’s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such Non-Officer Employee’s Corporate Status, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section 3 shall exist as to a Non-Officer Employee after he or she has ceased to be a Non-Officer Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only if such Proceeding was authorized in advance by the Board of Directors.

SECTION 4. Determination. Unless ordered by a court, no indemnification shall be provided pursuant to this Article V to a Director, to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a) a majority vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b) a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d) by the stockholders of the Corporation.

SECTION 5. Advancement of Expenses to Directors Prior to Final Disposition.

(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such Director is involved by reason of such Director’s Corporate Status within thirty (30) days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all

 

21


Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i) authorized by the Board of Directors, or (ii) brought to enforce such Director’s rights to indemnification or advancement of Expenses under these Bylaws.

(b) If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30) days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be on the Corporation.

(c) In any suit brought by the Corporation to recover an advancement of Expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such Expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 6. Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition.

(a) The Corporation may, at the discretion of the Board of Directors, advance any or all Expenses incurred by or on behalf of any Officer or any Non-Officer Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or Non-Officer Employee upon the receipt by the Corporation of a statement or statements from such Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or Non-Officer Employee and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses.

(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 7. Contractual Nature of Rights.

(a) The provisions of this Article V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to the benefits hereof at any time while this Article V is in effect, in consideration of such person’s past or current and any future

 

22


performance of services for the Corporation. Neither amendment, repeal or modification of any provision of this Article V nor the adoption of any provision of the Certificate of Incorporation inconsistent with this Article V shall eliminate or reduce any right conferred by this Article V in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article V shall continue notwithstanding that the person has ceased to be a Director or Officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributes of such person.

(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60) days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation.

(c) In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 8. Non-Exclusivity of Rights. The rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right which any Director, Officer, or Non-Officer Employee may have or hereafter acquire under any statute, provision of the Certificate or these Bylaws, agreement, vote of stockholders or Disinterested Directors or otherwise.

SECTION 9. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any Director, Officer or Non-Officer Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or Non-Officer Employee, or arising out of any such person’s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article V.

SECTION 10. Other Indemnification. The Corporation’s obligation, if any, to indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or

 

23


agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the “Primary Indemnitor”). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies.

ARTICLE VI

Miscellaneous Provisions

SECTION 1. Fiscal Year. The fiscal year of the Corporation shall be determined by the Board of Directors.

SECTION 2. Seal. The Board of Directors shall have power to adopt and alter the seal of the Corporation.

SECTION 3. Execution of Instruments. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairman of the Board, if one is elected, the Chief Executive Officer, the President or the Treasurer or any other officer, employee or agent of the Corporation as the Board of Directors or a committee of the Board of Directors may authorize.

SECTION 4. Voting of Securities. Unless the Board of Directors otherwise provides, the Chairman of the Board, if one is elected, the Chief Executive Officer, the President or the Treasurer may waive notice of and act on behalf of the Corporation, or appoint another person or persons to act as proxy or attorney in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or shareholders of any other corporation or organization, any of whose securities are held by the Corporation.

SECTION 5. Resident Agent. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or proceeding against the Corporation.

SECTION 6. Corporate Records. The original or attested copies of the Certificate, Bylaws and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer records, which shall contain the names of all stockholders, their record addresses and the amount of stock held by each, may be kept in any form permitted by law, and may be kept at the principal office of the Corporation or at such other place or places as may be designated from time to time by the Board of Directors.

 

24


SECTION 7. Certificate. All references in these Bylaws to the Certificate shall be deemed to refer to the Amended and Restated Certificate of Incorporation of the Corporation, as amended and/or restated and in effect from time to time.

SECTION 8. Exclusive Jurisdiction of Delaware Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Certificate or Bylaws, or (iv) any action asserting a claim against the Corporation governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 8.

SECTION 9. Amendment of Bylaws.

(a) Amendment by Directors. Except as provided otherwise by law, these Bylaws may be amended, altered or repealed by the Board of Directors .

(b) Amendment by Stockholders. These Bylaws may be amended, altered or repealed at any Annual Meeting, or special meeting of stockholders called for such purpose in accordance with these Bylaws, by the affirmative vote of a majority of the outstanding shares entitled to vote on such amendment or repeal.

SECTION 10. Notices. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.

SECTION 11. Waivers. A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver.

Adopted ___________, 2018 and effective as of ___________, 2018.

 

25

EX-4.1 6 d544598dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

 

LOGO

DE L AWA RE _ SEAL EIDOS THERAPEUTICS, INC. CORPORATE AUGUST 6, 2013 This certifies that is the record holder of INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 28249H 10 4 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS COUNTERSIGNED AND REGISTERED: AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC (BROOKLYN, NY) TRANSFER AGENT AND REGISTRAR BY: AUTHORIZED SIGNATURE CHIEF EXECUTIVE OFFICER FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Eidos Therapeutics, Inc. transferable on the books of the corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers. Dated: SECRETARY SPECIMEN ET


LOGO

The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the Corporation’s Secretary at the principal office of the Corporation. KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN,OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: Additional abbreviations may also be used though not in the above list. TEN COM – as tenants in common TEN ENT – as tenants by the entireties JT TEN – as joint tenants with right of survivorship and not as tenants in common COM PROP – as community property UNIF GIFT MIN ACT Custodian (Cust) (Minor) under Uniform Gifts to Minors Act (State) UNIF TRF MIN ACT –Custodian (until age) (Cust) under Uniform Transfers (Minor) to Minors Act (State) FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s) unto PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE shares of the capital stock represented by within Certificate, and do hereby irrevocably constitute and appoint attorney-in-fact to transfer the said stock on the books of the within named Corporation with full power of the substitution in the premises. Dated NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER. By THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15. GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE. SIGNATURE GUARANTEES MUST NOT BE DATED. Signature(s) Guaranteed: (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) X X

EX-4.4 7 d544598dex44.htm EX-4.4 EX-4.4

Exhibit 4.4

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.

 

Date of Issuance    Void after
February 22, 2018    February 21, 2021

EIDOS THERAPEUTICS, INC.

WARRANT TO PURCHASE SHARES OF CAPITAL STOCK

For valued received, pursuant to the that certain Note and Warrant Purchase Agreement (the “Purchase Agreement”) dated as of February 22, 2018, by and among the Company and the purchasers listed on Exhibit A thereto, this Warrant is issued to BridgeBio Pharma LLC, or its assigns (the “Holder”) by Eidos Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms not defined herein shall have the meaning set forth in the Purchase Agreement.

1. Purchase of Shares.

(a) Number of Warrant Shares. Subject to the terms and conditions set forth herein and in the Purchase Agreement, the Holder is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the Holder in writing), to purchase from the Company up to a number of fully paid and nonassessable Warrant Shares equal to $4,000,000, divided by the applicable Exercise Price (as defined below), rounded down to the nearest whole share, subject to adjustment pursuant to Section 7 hereof. As used herein, “Warrant Shares” shall mean:

(i) if the Exercise Period commences upon a Qualified Financing as set forth in clause (a) of Section 2 below, shares of New Preferred Stock (as defined in the Notes); and

(ii) if the Exercise Period commences immediately prior to the consummation of a Deemed Liquidation Event (as defined in the Company’s Certificate of Incorporation) as set forth in clause (b) of Section 2 below, shares of the Company’s Series Seed Preferred Stock, par value $0.001 per share (the “Series Seed Preferred Stock”).


(b) Exercise Price. The purchase price for the Warrant Shares issuable pursuant to this Section 1 shall be:

(i) if the Warrant is exercisable for shares of New Preferred Stock in accordance with Section 1(a)(i), the lowest per share purchase price at which shares of the New Preferred Stock are or have been sold in the Qualified Financing at the time of conversion of the Notes; and

(ii) if the Warrant is exercisable for shares of Series Seed Preferred Stock in accordance with Section 1(a)(ii), $1.3248 per share.

Such purchase price, subject to adjustment pursuant to Section 7 hereof from time to time, is herein referred to as the “Exercise Price.”

2. Exercise Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the earlier to occur of: (a) the consummation of a Qualified Financing and (b) immediately prior to the consummation of a Deemed Liquidation Event (but subject to and contingent upon the consummation of such Deemed Liquidation Event) and ending on the earlier to occur of (x) three (3) years after the commencement of exercisability or (y) the consummation of a Deemed Liquidation Event or IPO, as set forth in Section 2(d) (the “Exercise Period”).

3. Method of Exercise.

(a) While this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by:

(i) the surrender of the Warrant, together with a duly executed copy of the Notice of Exercise attached hereto, to the Secretary of the Company at its principal office (or at such other place as the Company shall notify the Holder in writing); and

(ii) the payment to the Company of an amount equal to the aggregate Exercise Price for the number and type of Warrant Shares being purchased.

(b) Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this Warrant is surrendered to the Company as provided in Section 3(a) above. At such time, the person or persons in whose name or names any certificate for the Warrant Shares shall be issuable upon such exercise as provided in Section 3(c) below shall be deemed to have become the holder or holders of record of the Warrant Shares represented by such certificate.

(c) As soon as practicable after the exercise of this Warrant in whole or in part, the Company at its expense will cause to be issued in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct:

(i) a certificate or certificates for the number of Warrant Shares to which such Holder shall be entitled, and

 

2


(ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number of Warrant Shares equal to the number of such Warrant Shares called for on the face of this Warrant minus the number of Warrant Shares purchased by the Holder upon all exercises made in accordance with Section 3(a) above or Section 4 below.

(d) Notwithstanding the provisions of Section 2 and subject to the provisions of Section 5, if the Holder has not exercised this Warrant prior to the closing of a Deemed Liquidation Event or an IPO (as defined below), this Warrant shall automatically be deemed to be exercised in full in the manner set forth in Section 4, without any further action on behalf of the Holder, immediately prior to such closing (and in the case of a Deemed Liquidation Event, subject to and contingent upon such Deemed Liquidation Event), and thereafter, this Warrant shall be automatically cancelled on the books of the Company and shall be of no further force or effect, except as to the Holder’s right to receive Warrant Shares in accordance with the terms and conditions of Section 4. For purposes hereof, an “IPO” shall mean the first firm-commitment underwritten public offering of Common Stock pursuant to an effective registration statement under the Securities Act.

4. Net Exercise. In lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with notice of such election (a “Net Exercise”). A Holder who Net Exercises shall have the rights described in Sections 3(b) and 3(c) hereof, and the Company shall issue to such Holder a number of Warrant Shares computed using the following formula:

 

   X =    Y(A – B)   
     

A

  

Where

 

X    =    The number of Warrant Shares to be issued to the Holder.
Y    =    The number of Warrant Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being cancelled (at the date of such calculation).
A    =    The fair market value of one (1) Warrant Share (at the date of such calculation).
B    =    The Exercise Price (as adjusted to the date of such calculations).

For purposes of this Section 4, (a) in the event that this Warrant is exercised pursuant to this Section 4 in connection with and contingent upon the closing of an IPO, the fair market value per Warrant Share shall be (i) the per share offering price to the public of the Common Stock in the IPO if the Warrant is exercisable for Common Stock and (ii) the per share offering price to the public of the Common Stock in the IPO, multiplied by the number of shares of Common Stock into which each Warrant Share is then convertible, if the Warrant is exercisable for New Preferred Stock or Series Seed Preferred Stock, as applicable, and (b) in all other instances in which this Warrant is exercised pursuant to this Section 4, the fair market value per Warrant Share shall be the price per share of the class and series of such Warrant Share, as such price shall be determined in good faith by the Company’s Board of Directors.

 

3


5. [Reserved].

6. Covenants of the Company.

(a) Notices of Record Date, Deemed Liquidation Event or IPO. In the event of any (i) taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters or a stock dividend) or other distribution, (ii) Deemed Liquidation Event or (iii) IPO, the Company shall mail to the Holder, at least ten (10) days prior to such record date or the anticipated closing date of such Deemed Liquidation Event or IPO, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution or such anticipated closing date, as the case may be.

(b) Covenants as to Warrant Shares. The Company covenants and agrees that all Warrant Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance in accordance with the terms hereof, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period have authorized and reserved, free from preemptive rights, a sufficient number of shares of New Preferred Stock or Series Seed Preferred Stock, as applicable, to provide for the exercise of the rights represented by this Warrant and, if the Warrant is exercisable for New Preferred Stock, a sufficient number of shares of Series Seed Preferred Stock to provide for the conversion of the Warrant Shares. If at any time during the Exercise Period the number of authorized but unissued shares of New Preferred Stock or Series Seed Preferred Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may be necessary to increase its authorized but unissued shares of New Preferred Stock or Series Seed Preferred Stock to such number of shares as shall be sufficient for such purposes, together with any necessary increase in the number of shares of Common Stock reserved for the conversion of such shares of New Preferred Stock or Series Seed Preferred Stock, and the Holder shall cooperate with the Company in connection therewith, including by executing and delivering such consents and other agreements or documents in the Holder’s capacity as a stockholder of the Company as may be necessary for the Company to effect such actions.

7. Adjustment of Exercise Price and Number of Warrant Shares. The number of Warrant Shares purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

(a) Subdivisions, Combinations and Other Issuances. If the Company shall at any time after the issuance but prior to the expiration of this Warrant subdivide, by split-up or otherwise, or combine, the shares of the class or series of capital stock corresponding to the Warrant Shares, or issue additional shares of capital stock as a dividend with respect to any shares of the class or series of capital stock corresponding to the Warrant Shares, the number of Warrant Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price payable per

 

4


share, but the aggregate Exercise Price payable for the total number of Warrant Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 7(a) shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend.

(b) Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization or change in the capital stock of the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 7(a) above), then, as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities or property receivable in connection with such reclassification, reorganization or change by a holder of the same number and type of securities as were purchasable as Warrant Shares by the Holder immediately prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price per Warrant Share payable hereunder, provided the aggregate Exercise Price shall remain the same.

(c) Notice of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Warrant Shares or other securities or property thereafter purchasable upon exercise of this Warrant.

8. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect.

9. No Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder with respect to the Warrant Shares, including (without limitation) the right to vote such Warrant Shares, receive dividends or other distributions thereon, exercise preemptive rights or be notified of stockholder meetings, and except as otherwise provided in this Warrant or the Purchase Agreement, such Holder shall not be entitled to any stockholder notice or other communication concerning the business or affairs of the Company.

10. Governing Law. This Warrant shall be governed by and construed in accordance with the Delaware General Corporation Law as to matters within the scope thereof, and as to all other matters shall be governed by, and construed in accordance with, the internal laws of the State of California, without reference to principles of conflict of laws or choice of laws.

 

5


11. Successors and Assigns. The terms and provisions of this Warrant and the Purchase Agreement shall inure to the benefit of, and be binding upon, the Company and the holders hereof and their respective successors and assigns.

12. Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered in construing or interpreting this Warrant.

13. Notices. Any notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively given (a) upon personal delivery or delivery by courier, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the next business day after transmission if sent by confirmed electronic mail or facsimile transmission, (c) for domestic United States deliveries, four (4) business days after deposit in the United States mail, by registered or certified mail, postage prepaid, or (d) for international deliveries, four (4) business days after deposit with an internationally recognized overnight delivery service, specifying two-(2-) day delivery, postage prepaid, addressed (i) if to the Company, at the principal offices of the Company and (ii) if to the Holder, at the Holder’s address as set forth on Exhibit A to the Purchase Agreement, or at such other address as the Company or the Holder may designate by advance written notice to the other party hereto. For purposes of this Section 13, a “business day” means a weekday on which banks are open for general banking business in San Francisco, California.

14. Amendment. This Warrant may not be amended or modified, or any provision hereof waived, except by a written instrument signed in accordance with the amendment and waiver provisions set forth in Section 6.02 of the Purchase Agreement.

15. Severability. If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

 

6


IN WITNESS WHEREOF, the parties have executed this Warrant as of the date first written above.

 

THE COMPANY:     EIDOS THERAPEUTICS, INC.
      By:   /s/ Christine Siu
      Name: Christine Siu
      Title: Chief Financial Officer

Acknowledged and agreed by the Holder:

 

BRIDGEBIO PHARMA LLC
By:   /s/ Neil Kumar
Name:   Neil Kumar
Title:   Chief Executive Officer

[SIGNATURE PAGE TO WARRANT]


NOTICE OF EXERCISE

Attention: Corporate Secretary

The undersigned hereby elects to purchase, pursuant to the provisions of the Warrant, as follows:

 

                   shares of                      Stock pursuant to the terms of the attached Warrant, and tenders herewith payment in cash of the Exercise Price of such Warrant Shares in full, together with all applicable transfer taxes, if any.

 

  Net Exercise the attached Warrant with respect to                  Warrant Shares.

The undersigned hereby represents and warrants that the representations and warranties in Article 4 of the Purchase Agreement are true and correct as to the undersigned as of the date hereof.

 

      HOLDER:
Date:                                            By:    
    Address:     
Name in which shares should be registered:        
         


ASSIGNMENT FORM

(To assign the foregoing Warrant, execute

this form and supply required information.

Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name:    

 

  (Please Print)
Address:    
  (Please Print)
Dated:                                                        
Holder’s
Signature:
       
Holder’s
Address:
       

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant. Officers of corporations and those acting in a fiduciary or other representative capacity should provide proper evidence of authority to assign the foregoing Warrant.

EX-5.1 8 d544598dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

June 8, 2018                        

Eidos Therapeutics, Inc.

101 Montgomery Street, Suite 2550

San Francisco, CA 94104

 

  Re: Securities Registered under Registration Statement on Form S-1

Ladies and Gentlemen:

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-1 (File No. 333-225235) (as amended or supplemented, the “Registration Statement”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration of the offering by Eidos Therapeutics, Inc., a Delaware corporation (the “Company”) of up to 7,187,500 shares (the “Shares”) of the Company’s Common Stock, $0.001 par value per share, including Shares purchasable by the underwriters upon their exercise of an over-allotment option granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the “Underwriting Agreement”).

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and non-assessable.

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement and to the references to our firm under the caption “Legal Matters” in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

 

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP
EX-10.1 9 d544598dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

EIDOS THERAPEUTICS, INC.

AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN

ADOPTED BY THE BOARD OF DIRECTORS: March 31, 2016

APPROVED BY THE STOCKHOLDERS: March 31, 2016

AMENDED BY THE BOARD OF DIRECTORS: September 7, 2017

APPROVED BY THE STOCKHOLDERS: September 7, 2017

AMENDED BY THE BOARD OF DIRECTORS: December 22, 2017

APPROVED BY THE STOCKHOLDERS: December 22, 2017

AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: May 22, 2018

TERMINATION DATE: March 31, 2026

1. GENERAL.

(a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards.

(b) Available Stock Awards. The Plan provides for the grant of the following types of Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards and (vi) Other Stock Awards.

(c) Purpose. The Plan, through the grant of Stock Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.

(d) Amendment and Restatement. The Plan, as amended and restated by the Board on May 22, 2018 (the “Restatement Date”), shall apply to and govern all Stock Awards outstanding as of the Restatement Date.

2. ADMINISTRATION.

(a) Administration by the Board. The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).

(b) Powers of the Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i) To determine (A) who will be granted Stock Awards; (B) when and how each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E) the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award.

 

1.


(ii) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.

(iii) To settle all controversies regarding the Plan and Stock Awards granted under it.

(iv) To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).

(v) To suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not impair a Participant’s rights under the Participant’s then-outstanding Stock Award without the Participant’s written consent except as provided in subsection (viii) below.

(vi) To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or Stock Awards granted under the Plan into compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Stock Awards under the Plan, (C) materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Stock Awards available for issuance under the Plan. Except as otherwise provided in the Plan or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an outstanding Stock Award without the Participant’s written consent.

(vii) To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Section 422 of the Code regarding Incentive Stock Options.

(viii) To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that a Participant’s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant’s consent (A) to maintain the qualified status of the Stock Award as an Incentive Stock Option under

 

2.


Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Stock Award solely because it impairs the qualified status of the Stock Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws.

(ix) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards.

(x) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).

(xi) To effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted Stock Award, (3) Restricted Stock Unit Award, (4) Other Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of shares of Common Stock as the cancelled Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting principles.

(c) Delegation to Committee. The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.

(d) Delegation to an Officer. The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Stock Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(t) below.

 

3.


(e) Effect of Boards Decision. All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

3. SHARES SUBJECT TO THE PLAN.

(a) Share Reserve.

(i) Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 2,583,696 shares (the “Share Reserve”).

(ii) For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3.(a) does not limit the granting of Stock Awards except as provided in Section 7(a).

(b) Reversion of Shares to the Share Reserve. If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.

(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be a number of shares of Common Stock equal to three multiplied by the Share Reserve.

(d) Source of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.

4. ELIGIBILITY.

(a) Eligibility for Specific Stock Awards. Incentive Stock Options may be granted only to employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any “parent” of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section 409A of the Code.

 

4.


(b) Ten Percent Stockholders. A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.

(c) Consultants. A Consultant will not be eligible for the grant of a Stock Award if, at the time of grant, either the offer or sale of the Company’s securities to such Consultant is not exempt under Rule 701 because of the nature of the services that the Consultant is providing to the Company, because the Consultant is not a natural person, or because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with the securities laws of all other relevant jurisdictions.

5. PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.

Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Stock Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:

(a) Term. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Stock Award Agreement.

(b) Exercise Price. Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents.

(c) Purchase Price for Options. The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment. The permitted methods of payment are as follows:

 

5.


(i) by cash, check, bank draft or money order payable to the Company;

(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;

(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;

(iv) if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations;

(v) according to a deferred payment or similar arrangement with the Optionholder; provided, however, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or

(vi) in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Stock Award Agreement.

(d) Exercise and Payment of a SAR. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR.

(e) Transferability of Options and SARs. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:

(i) Restrictions on Transfer. An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.

 

6.


(ii) Domestic Relations Orders. Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

(iii) Beneficiary Designation. Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.

(f) Vesting Generally. The total number of shares of Common Stock subject to an Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.

(g) Termination of Continuous Service. Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Stock Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date three months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Stock Award Agreement, which period will not be less than 30 days if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate.

(h) Extension of Termination Date. If the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement. In addition, unless otherwise provided in a Participant’s

 

7.


Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of the period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, and (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.

(i) Disability of Participant. Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will terminate.

(j) Death of Participant. Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant’s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement, which period will not be less than six months if necessary to comply with applicable laws unless such termination is for Cause), and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.

(k) Termination for Cause. Except as explicitly provided otherwise in a Participant’s Stock Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous Service.

(l) Non-Exempt Employees. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued,

 

8.


or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Stock Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.

(m) Early Exercise of Options. An Option may, but need not, include a provision whereby the Optionholder may elect at any time before the Optionholder’s Continuous Service terminates to exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the Option. Subject to the “Repurchase Limitation” in Section 8(l), any unvested shares of Common Stock so purchased may be subject to a repurchase right in favor of the Company or to any other restriction the Board determines to be appropriate. Provided that the “Repurchase Limitation” in Section 8(l) is not violated, the Company will not be required to exercise its repurchase right until at least six months (or such longer or shorter period of time required to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following exercise of the Option unless the Board otherwise specifically provides in the Option Agreement.

(n) Right of Repurchase. Subject to the “Repurchase Limitation” in Section 8(l), the Option or SAR may include a provision whereby the Company may elect to repurchase all or any part of the vested shares of Common Stock acquired by the Participant pursuant to the exercise of the Option or SAR.

(o) Right of First Refusal. The Option or SAR may include a provision whereby the Company may elect to exercise a right of first refusal following receipt of notice from the Participant of the intent to transfer all or any part of the shares of Common Stock received upon the exercise of the Option or SAR. Such right of first refusal will be subject to the “Repurchase Limitation” in Section 8(l). Except as expressly provided in this Section 5(o) or in the Stock Award Agreement, such right of first refusal will otherwise comply with any applicable provisions of the bylaws of the Company.

6. PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.

(a) Restricted Stock Awards. Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:

 

9.


(i) Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii) Vesting. Subject to the “Repurchase Limitation” in Section 8(l), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.

(iii) Termination of Participant’s Continuous Service. If a Participant’s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.

(iv) Transferability. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.

(v) Dividends. A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.

(b) Restricted Stock Unit Awards. Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the will Board deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:

(i) Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

(ii) Vesting. At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.

(iii) Payment. A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.

(iv) Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.

 

10.


(v) Dividend Equivalents. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.

(vi) Termination of Participants Continuous Service. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.

(vii) Compliance with Section 409A of the Code.    Notwithstanding anything to the contrary set forth herein, any Restricted Stock Unit Award granted under the Plan that is not exempt from the requirements of Section 409A of the Code shall contain such provisions so that such Restricted Stock Unit Award will comply with the requirements of Section 409A of the Code. Such restrictions, if any, shall be determined by the Board and contained in the Restricted Stock Unit Award Agreement evidencing such Restricted Stock Unit Award. For example, such restrictions may include, without limitation, a requirement that any Common Stock that is to be issued in a year following the year in which the Restricted Stock Unit Award vests must be issued in accordance with a fixed pre-determined schedule.

(c) Other Stock Awards. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.

7. COVENANTS OF THE COMPANY.

(a) Availability of Shares. The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.

(b) Securities Law Compliance. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for

 

11.


failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law.

(c) No Obligation to Notify or Minimize Taxes. The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.

8. MISCELLANEOUS.

(a) Use of Proceeds from Sales of Common Stock. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards will constitute general funds of the Company.

(b) Corporate Action Constituting Grant of Stock Awards. Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the papering of the Stock Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Stock Award Agreement or related grant documents.

(c) Stockholder Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to the Stock Award has been entered into the books and records of the Company.

(d) No Employment or Other Service Rights. Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.

(e) Change in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole

 

12.


discretion to (x) make a corresponding reduction in the number of shares subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended.

(f) Incentive Stock Option Limitations. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).

(g) Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that the Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.

(h) Withholding Obligations. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock Award Agreement.

(i) Electronic Delivery. Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).

 

13.


(j) Deferrals. To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.

(k) Compliance with Section 409A of the Code. To the extent that the Board determines that any Stock Award granted hereunder is subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code. To the extent applicable, the Plan and Stock Award Agreements shall be interpreted in accordance with Section 409A of the Code. Notwithstanding anything to the contrary in the Plan (and unless the Stock Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding a Stock Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.

(l) Repurchase Limitation. The terms of any repurchase right will be specified in the Stock Award Agreement. The repurchase price for vested shares of Common Stock will be the Fair Market Value of the shares of Common Stock on the date of repurchase. The repurchase price for unvested shares of Common Stock will be the lower of (i) the Fair Market Value of the shares of Common Stock on the date of repurchase or (ii) their original purchase price. However, the Company will not exercise its repurchase right until at least six months (or such longer or shorter period of time necessary to avoid classification of the Stock Award as a liability for financial accounting purposes) have elapsed following delivery of shares of Common Stock subject to the Stock Award, unless otherwise specifically provided by the Board.

9. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

(a) Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive.

 

14.


(b) Dissolution or Liquidation. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.

(c) Corporate Transaction. In the case of and subject to the consummation of a Corporate Transaction, except as may be otherwise provided in the relevant Stock Award Agreement, all Options and Stock Appreciation Rights with time-based vesting, conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Corporate Transaction shall become fully vested and exercisable as of the effective time of the Corporate Transaction, all other Stock Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Corporate Transaction, and all Stock Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Corporate Transaction in the Board’s discretion or to the extent specified in the relevant Stock Award Agreement. In the event of such Corporate Transaction, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the value as determined by the Board of the consideration payable, or otherwise to be received by stockholders, per share of Common Stock pursuant to a Corporate Transaction (the “Sale Price”) multiplied by the number of shares of Common Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or less than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Corporate Transaction as determined by the Board, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee; (iii) the Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Stock Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Common Stock under such Stock Awards; or (iv) the parties to such Corporate Transaction may cause the assumption or continuation of Stock Awards theretofore granted by the successor entity or the substitution of such Stock Awards with new Stock Awards of the successor entity or parent thereof (taking into account the acceleration of such Stock Awards pursuant to this Section 9(c)), with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices.

The Board need not take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award.

(d) Change in Control. A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.

 

15.


10. PLAN TERM; EARLIER TERMINATION OR SUSPENSION OF THE PLAN.

(a) Plan Term. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan will automatically terminate on the day before the 10th anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

(b) No Impairment of Rights. Suspension or termination of the Plan will not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.

11. EFFECTIVE DATE OF PLAN.

This Plan will become effective on the Effective Date.

12. CHOICE OF LAW.

The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules.

13. DEFINITIONS. As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

(a) Affiliate” means, at the time of determination, any “parent” or “majority-owned subsidiary” of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or “majority-owned subsidiary” status is determined within the foregoing definition.

(b) Board” means the Board of Directors of the Company.

(c) Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.

(d) Cause will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a

 

16.


termination of the Participant’s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.

(e) Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (C) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur;

(ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; or

(iii) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or

(f) Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

(g) Committee” means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).

 

17.


(h) Common Stock” means the common stock of the Company.

(i) Company” means Eidos Therapeutics, Inc., a Delaware corporation.

(j) Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.

(k) Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.

(l) Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:

(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;

(ii) a sale or other disposition of at least 90% of the outstanding securities of the Company;

(iii) a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

(iv) a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

(m) Director” means a member of the Board.

 

18.


(n) Disability” means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve (12) months as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.

(o) Effective Date” means the effective date of this Plan, which is the earlier of (i) the date that this Plan is first approved by the Company’s stockholders, and (ii) the date this Plan is adopted by the Board.

(p) Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

(q) Entity” means a corporation, partnership, limited liability company or other entity.

(r) Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

(s) Exchange Act Person means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities.

(t) Fair Market Value” means, as of any date, the value of the Common Stock determined by the Board in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code.

(u) Incentive Stock Option” means an option granted pursuant to Section 5 of the Plan that is intended to be, and that qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code.

(v) Nonstatutory Stock Option” means an option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option.

(w) Officer” means any person designated by the Company as an officer.

(x) Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.

 

19.


(y) Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.

(z) Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

(aa) Other Stock Award” means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c).

(bb) Other Stock Award Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.

(cc) Own,” “Owned,” “Owner,” “Ownership A person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

(dd) Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.

(ee) Plan” means this 2016 Equity Incentive Plan.

(ff) Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).

(gg) Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.

(hh) Restricted Stock Unit Award means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).

(ii) Restricted Stock Unit Award Agreement means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.

(jj) Rule 405” means Rule 405 promulgated under the Securities Act.

(kk) Rule 701” means Rule 701 promulgated under the Securities Act.

(ll) Securities Act” means the Securities Act of 1933, as amended.

(mm) Stock Appreciation Right” or “SAR” means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.

 

20.


(nn) Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.

(oo) Stock Award” means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right or any Other Stock Award.

(pp) Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.

(qq) Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.

(rr) Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.

 

21.


EIDOS THERAPEUTICS, INC.

2016 EQUITY INCENTIVE PLAN

OPTION AGREEMENT

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, EIDOS THERAPEUTICS, INC. (the “Company”) has granted you an option under its 2016 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:

1. VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

2. NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.

3. EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans).

4. EXERCISE PRIOR TO VESTING (“EARLY EXERCISE”). If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided, however, that:

(a) a partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock;

(b) any shares of Common Stock so purchased from installments that have not vested as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement;

 

1.


(c) you will enter into the Company’s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and

(d) if your option is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock Options.

5. METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:

(a) Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.

(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock.

(c) If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

6. WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

7. SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).

 

2.


8. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:

(a) immediately upon the termination of your Continuous Service for Cause;

(b) three months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three month period your option is not exercisable solely because of the condition set forth in the section above relating to “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; provided further, that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven months after the Date of Grant, and (B) the date that is three months after the termination of your Continuous Service, and (y) the Expiration Date;

(c) 12 months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(d)) below;

(d) 18 months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;

(e) the Expiration Date indicated in your Grant Notice; or

(f) the day before the 10th anniversary of the Date of Grant.

If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an Affiliate terminates.

9. EXERCISE.

(a) You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.

 

3.


(b) By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon exercise of your option.

(d) By exercising your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto.

10. TRANSFERABILITY. Except as otherwise provided in this Section 10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.

(b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.

 

4.


(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.

11. RIGHT OF FIRST REFUSAL. Shares of Common Stock that you acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if there is no right of first refusal described in the Company’s bylaws at such time, the right of first refusal described below will apply. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or quotation system (the “Listing Date”).

(a) Prior to the Listing Date, you may not validly Transfer (as defined below) any shares of Common Stock acquired upon exercise of your option, or any interest in such shares, unless such Transfer is made in compliance with the following provisions:

(i) Before there can be a valid Transfer of any shares of Common Stock or any interest therein, the record holder of the shares of Common Stock to be transferred (the “Offered Shares”) will give written notice (by registered or certified mail) to the Company. Such notice will specify the identity of the proposed transferee, the cash price offered for the Offered Shares by the proposed transferee (or, if the proposed Transfer is one in which the holder will not receive cash, such as an involuntary transfer, gift, donation or pledge, the holder will state that no purchase price is being proposed), and the other terms and conditions of the proposed Transfer. The date such notice is mailed will be hereinafter referred to as the “Notice Date” and the record holder of the Offered Shares will be hereinafter referred to as the “Offeror.” If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding Common Stock which is subject to the provisions of your option, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares of Common Stock acquired upon exercise of your option will be immediately subject to the Company’s Right of First Refusal (as defined below) with the same force and effect as the shares subject to the Right of First Refusal immediately before such event.

(ii) For a period of 30 calendar days after the Notice Date, or such longer period as may be required to avoid the classification of your option as a liability for financial accounting purposes, the Company will have the option to purchase all (but not less than all) of the Offered Shares at the purchase price and on the terms set forth in Section 11(a)(iii) (the Company’s “Right of First Refusal”). In the event that the proposed Transfer is one involving no payment of a purchase price, the purchase price will be deemed to be the Fair Market Value of the Offered Shares as determined in good faith by the Board in its discretion. The Company may exercise its Right of First Refusal by mailing (by registered or certified mail) written notice of exercise of its Right of First Refusal to the Offeror prior to the end of said 30 days (including any extension required to avoid classification of the option as a liability for financial accounting purposes).

(iii) The price at which the Company may purchase the Offered Shares pursuant to the exercise of its Right of First Refusal will be the cash price offered for the Offered Shares by the proposed transferee (as set forth in the notice required under Section 11(a)(i)), or the Fair Market Value as determined by the Board in the event no purchase price is involved. To the extent consideration

 

5.


other than cash is offered by the proposed transferee, the Company will not be required to pay any additional amounts to the Offeror other than the cash price offered (or the Fair Market Value, if applicable). The Company’s notice of exercise of its Right of First Refusal will be accompanied by full payment for the Offered Shares and, upon such payment by the Company, the Company will acquire full right, title and interest to all of the Offered Shares.

(iv) If, and only if, the option given pursuant to Section 11(a)(ii) is not exercised, the Transfer proposed in the notice given pursuant to Section 11(a)(i) may take place; provided, however, that such Transfer must, in all respects, be exactly as proposed in said notice except that such Transfer may not take place either before the 10th calendar day after the expiration of the 30 day option exercise period or after the ninetieth 90th calendar day after the expiration of the 30 day option exercise period, and if such Transfer has not taken place prior to said 90th day, such Transfer may not take place without once again complying with this Section 11(a). The option exercise periods in this Section 11(a)(iv) will be adjusted to include any extension required to avoid the classification of your option as a liability for financial accounting purposes.

(b) As used in this Section 11, the term “Transfer” means any sale, encumbrance, pledge, gift or other form of disposition or transfer of shares of Common Stock or any legal or equitable interest therein; provided, however, that the term Transfer does not include a transfer of such shares or interests by will or intestacy to your Immediate Family (as defined below). In such case, the transferee or other recipient will receive and hold the shares of Common Stock so transferred subject to the provisions of this Section, and there will be no further transfer of such shares except in accordance with the terms of this Section 11. As used herein, the term “Immediate Family” will mean your spouse, the lineal descendant or antecedent, father, mother, brother or sister, child, adopted child, grandchild or adopted grandchild of you or your spouse, or the spouse of any child, adopted child, grandchild or adopted grandchild of you or your spouse.

(c) None of the shares of Common Stock purchased on exercise of your option will be transferred on the Company’s books nor will the Company recognize any such Transfer of any such shares or any interest therein unless and until all applicable provisions of this Section 11 have been complied with in all respects. The certificates of stock evidencing shares of Common Stock purchased on exercise of your option will bear an appropriate legend referring to the transfer restrictions imposed by this Section 11.

(d) To ensure that the shares subject to the Company’s Right of First Refusal will be available for repurchase by the Company, the Company may require you to deposit the certificates evidencing the shares that you purchase upon exercise of your option with an escrow agent designated by the Company under the terms and conditions of an escrow agreement approved by the Company. If the Company does not require such deposit as a condition of exercise of your option, the Company reserves the right at any time to require you to so deposit the certificates in escrow. As soon as practicable after the expiration of the Company’s Right of First Refusal, the agent will deliver to you the shares and any other property no longer subject to such restriction. In the event the shares and any other property held in escrow are subject to the Company’s exercise of its Right of First Refusal, the notices required to be given to you will be given to the escrow agent, and any payment required to be given to you will be given to the escrow agent. Within 30 days after payment by the Company for the Offered Shares, the escrow agent will deliver the Offered Shares that the Company has repurchased to the Company and will deliver the payment received from the Company to you.

12. OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to

 

6.


continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

13. WITHHOLDING OBLIGATIONS.

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.

(b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.

14. TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock is not traded on an established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the “fair market value” as subsequently determined by the Internal Revenue Service.

 

7.


15. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

16. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control.

17. WAIVER OF STATUTORY INFORMATION RIGHTS. You acknowledge and understand that, but for the waiver made herein, you would be entitled, upon written demand under oath stating the purpose thereof, to inspect for any proper purpose, and to make copies and extracts from, the Company’s stock ledger, a list of its stockholders, and its other books and records, and the books and records of subsidiaries of the Company, if any, under the circumstances and in the manner provided in Section 220 of the General Corporation Law of Delaware (any and all such rights, and any and all such other rights you may be provided for in Section 220, the “Inspection Rights”). In light of the foregoing, until the first sale of stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act, you hereby unconditionally and irrevocably waive the Inspection Rights, whether such Inspection Rights would be exercised or pursued directly or indirectly pursuant to Section 220 or otherwise, and covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. The foregoing waiver shall not affect any rights of a director, in his or her capacity as such, under Section 220. The foregoing waiver shall not apply to any of your contractual inspection rights under any other written agreement with the Company.

 

8.

EX-10.2 10 d544598dex102.htm EX-10.2 EX-10.2

Exhibit 10.2

EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Eidos Therapeutics, Inc. (the “Company”) and its Subsidiaries upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

The following terms shall be defined as set forth below:

“Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

“Administrator” means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.

“Award” or “Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights.

“Award Certificate” means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.

“Board” means the Board of Directors of the Company.

“Cash-Based Award” means an Award entitling the recipient to receive a cash-denominated payment.

“Code” means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.

“Consultant” means any natural person that provides bona fide services to the Company, and such services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.


“Dividend Equivalent Right” means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.

“Effective Date” means the date on which the Plan becomes effective as set forth in Section 19.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

“Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is admitted to quotation on The Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations; provided further, however, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the Company’s Initial Public Offering.

“Incentive Stock Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code.

“Initial Public Offering” means the first underwritten, firm commitment public offering pursuant to an effective registration statement under the Act covering the offer and sale by the Company of its equity securities, or such other event as a result of or following which the Stock shall be publicly held.

“Non-Employee Director” means a member of the Board who is not also an employee of the Company or any Subsidiary.

“Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option.

“Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5.

“Registration Date” means the date upon which the registration statement on Form S-1 that is filed by the Company with respect to the Initial Public Offering is declared effective by the Securities and Exchange Commission.

“Restricted Shares” means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company’s right of repurchase.

“Restricted Stock Award” means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.

 

2


“Restricted Stock Units” means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.

“Sale Event” shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.

Sale Price” means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.

“Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder.

“Service Relationship” means any relationship as a full-time employee, part-time employee, director or other key person (including Consultants) of the Company or any Subsidiary or any successor entity (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual’s status changes from full-time employee to part-time employee or Consultant).

“Stock” means the Common Stock, par value $0.001 per share, of the Company, subject to adjustments pursuant to Section 3.

“Stock Appreciation Right” means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.

“Subsidiary” means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.

“Ten Percent Owner” means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation.

“Unrestricted Stock Award” means an Award of shares of Stock free of any restrictions.

 

3


SECTION 2. ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS

(a) Administration of Plan. The Plan shall be administered by the Administrator.

(b) Powers of Administrator. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:

(i) to select the individuals to whom Awards may from time to time be granted;

(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;

(iii) to determine the number of shares of Stock to be covered by any Award;

(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;

(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award;

(vi) subject to the provisions of Section 5(c), to extend at any time the period in which Stock Options may be exercised; and

(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.

All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.

(c) Delegation of Authority to Grant Awards. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator’s authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section 16 of the Exchange Act and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator’s delegate or delegates that were consistent with the terms of the Plan.

 

4


(d) Award Certificate. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.

(e) Indemnification. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s certificate of incorporation or bylaws or any directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.

(f) Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.

 

SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION

(a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 598,000 shares, subject to adjustment as provided in Section 3(c). For purposes of this limitation, the shares of Stock underlying any Awards under the Plan or the shares of Stock underlying any Awards under the Company’s Amended and Restated 2016 Equity Incentive Plan, as amended, that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent permitted under Section 422 of the Code and the regulations promulgated thereunder, the shares

 

5


of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award; provided, however, that no more than 598,000 shares of the Stock may be issued in the form of Incentive Stock Options. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.

(b) Maximum Awards to Non-Employee Directors. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any Non-Employee Director in any calendar year shall not exceed $1,250,000. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions.

(c) Changes in Stock. Subject to Section 3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.

(d) Mergers and Other Transactions. In the case of and subject to the consummation of a Sale Event,    except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting, conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating

 

6


to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator’s discretion or to the extent specified in the relevant Award Certificate. In the event of such Sale Event, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or less than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee; (iii) the Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards; or (iv) the parties to the Sale Event may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof (taking into account the acceleration of such Awards pursuant to this Section 3(d)), with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices.

 

SECTION 4. ELIGIBILITY

Grantees under the Plan will be such full or part-time officers and other employees, Non-Employee Directors and Consultants of the Company and its Subsidiaries as are selected from time to time by the Administrator in its sole discretion.

 

SECTION 5. STOCK OPTIONS

(a) Award of Stock Options. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve.

Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.

Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee’s election, subject to such terms and conditions as the Administrator may establish.

 

7


(b) Exercise Price. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the option price of such Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the grant date. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code.

(c) Option Term. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant.

(d) Exercisability; Rights of a Stockholder. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.

(e) Method of Exercise. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Option Award Certificate:

(i) In cash, by certified or bank check or other instrument acceptable to the Administrator;

(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;

(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or

(iv) With respect to Stock Options that are not Incentive Stock Options, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.

Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a

 

8


purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Option Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.

(f) Annual Limit on Incentive Stock Options. To the extent required for “incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option.

 

SECTION 6. STOCK APPRECIATION RIGHTS

(a) Award of Stock Appreciation Rights. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.

(b) Exercise Price of Stock Appreciation Rights. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.

(c) Grant and Exercise of Stock Appreciation Rights. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan.

(d) Terms and Conditions of Stock Appreciation Rights. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.

 

9


SECTION 7. RESTRICTED STOCK AWARDS

(a) Nature of Restricted Stock Awards. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.

(b) Rights as a Stockholder. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.

(c) Restrictions. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, if a grantee’s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee’s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.

(d) Vesting of Restricted Shares. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company’s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed “vested.”

 

SECTION 8. RESTRICTED STOCK UNITS

(a) Nature of Restricted Stock Units. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established

 

10


performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.

(b) Election to Receive Restricted Stock Units in Lieu of Compensation. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate.

(c) Rights as a Stockholder. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.

(d) Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee’s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee’s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.

 

SECTION 9. UNRESTRICTED STOCK AWARDS

Grant or Sale of Unrestricted Stock. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.

 

11


SECTION 10. CASH-BASED AWARDS

Grant of Cash-Based Awards. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles the grantee to a payment in cash upon the attainment of specified performance goals. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash.

 

SECTION 11. DIVIDEND EQUIVALENT RIGHTS

(a) Dividend Equivalent Rights. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.

(b) Termination. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee’s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee’s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.

 

SECTION 12. TRANSFERABILITY OF AWARDS

(a) Transferability. Except as provided in Section 12(b) below, during a grantee’s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee’s legal representative or guardian in the event of the grantee’s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.

 

12


(b) Administrator Action. Notwithstanding Section 12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.

(c) Family Member. For purposes of Section 12(b), “family member” shall mean a grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee’s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.

(d) Designation of Beneficiary. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate.

 

SECTION 13. TAX WITHHOLDING

(a) Payment by Grantee. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company’s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.

(b) Payment in Stock. Subject to approval by the Administrator, a grantee may elect to have the Company’s required tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. The Administrator may also require Awards to be subject to mandatory share withholding up to the required withholding amount. For purposes of share

 

13


withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the Participants. The required tax withholding obligation may also be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.

 

SECTION 14. SECTION 409A AWARDS

To the extent that any Award is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A (a “409A Award”), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a “separation from service” (within the meaning of Section 409A) to a grantee who is then considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee’s separation from service, or (ii) the grantee’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section 409A.

 

SECTION 15. TERMINATION OF EMPLOYMENT, TRANSFER, LEAVE OF ABSENCE, ETC.

(a) Termination of Employment. If the grantee’s Service Relationship is with a Subsidiary and such Subsidiary ceases to be a Subsidiary, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.

(b) For purposes of the Plan, the following events shall not be deemed a termination of employment:

(i) a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another; or

(ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.

 

SECTION 16. AMENDMENTS AND TERMINATION

The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Award without the holder’s consent. The Administrator is specifically authorized to exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect the repricing of such Awards through cancellation and re-grants. To the extent required under the rules of any securities exchange or market system on which the

 

14


Stock is listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section 16 shall limit the Administrator’s authority to take any action permitted pursuant to Section 3(c) or 3(d).

 

SECTION 17. STATUS OF PLAN

With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company’s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.

 

SECTION 18. GENERAL PROVISIONS

(a) No Distribution. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.

(b) Issuance of Stock. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic “book entry” records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.

 

15


(c) Stockholder Rights. Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.

(d) Other Compensation Arrangements; No Employment Rights. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.

(e) Trading Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider trading policies and procedures, as in effect from time to time.

(f) Clawback Policy. Awards under the Plan shall be subject to the Company’s clawback policy, as in effect from time to time.

 

SECTION 19. EFFECTIVE DATE OF PLAN

This Plan shall become effective upon the date immediately preceding the Registration Date. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board.

 

SECTION 20. GOVERNING LAW

This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of California, applied without regard to conflict of law principles.

DATE APPROVED BY BOARD OF DIRECTORS: May 22, 2018

DATE APPROVED BY STOCKHOLDERS:

 

16


INCENTIVE STOCK OPTION AGREEMENT

UNDER THE EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

Name of Optionee:                                             
No. of Option Shares:                                             
Option Exercise Price per Share:    $                                       
Grant Date:                                             
Expiration Date:                                             

Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Eidos Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.

1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee remains an employee of the Company or a Subsidiary on such dates, except as may otherwise be provided by the Administrator:

 

Incremental Number of

Option Shares Exercisable*

   Exercisability Date

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

 

* Max. of $100,000 per yr.

Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.


2. Manner of Exercise.

(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.

Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection.

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.

(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.

 

2


(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.

(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.

3. Termination of Employment. Except as may otherwise be provided by the Administrator, if the Optionee’s employment by the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.

(a) Termination Due to Death. If the Optionee’s employment terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.

(b) Termination Due to Disability. If the Optionee’s employment terminates by reason of the Optionee’s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of employment, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect.

(c) Termination for Cause. If the Optionee’s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, “Cause” shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee’s duties to the Company.

(d) Other Termination. If the Optionee’s employment terminates for any reason other than the Optionee’s death, the Optionee’s disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.

 

3


The Administrator’s determination of the reason for termination of the Optionee’s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees.

4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee.

6. Status of the Stock Option. This Stock Option is intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements. To the extent any portion of this Stock Option does not so qualify as an “incentive stock option,” such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such disposition.

7. Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due.

8. No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time.

9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.

 

4


10. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

EIDOS THERAPEUTICS, INC.
By:  

             

  Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Optionee (including through an online acceptance process) is acceptable.

 

Dated:  

     

   

 

      Optionee’s Signature
      Optionee’s name and address:
     

 

     

 

     

 

 

5


NON-QUALIFIED STOCK OPTION AGREEMENT

FOR COMPANY EMPLOYEES

UNDER THE EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

Name of Optionee:                                                                                                        
No. of Option Shares:                                                   
Option Exercise Price per Share:    $                                             
Grant Date:                                                   
Expiration Date:                                                   

Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Eidos Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.

1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as Optionee remains an employee of the Company or a Subsidiary on such dates, except as may otherwise be provided by the Administrator:

 

Incremental Number of

Option Shares Exercisable

   Exercisability Date

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       


Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.

2. Manner of Exercise.

(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.

Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.

(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a

 

2


holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.

(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.

(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.

3. Termination of Employment. Except as may otherwise be provided by the Administrator, if the Optionee’s employment by the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.

(a) Termination Due to Death. If the Optionee’s employment terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.

(b) Termination Due to Disability. If the Optionee’s employment terminates by reason of the Optionee’s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of employment, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect.

(c) Termination for Cause. If the Optionee’s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, “Cause” shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee’s duties to the Company.

(d) Other Termination. If the Optionee’s employment terminates for any reason other than the Optionee’s death, the Optionee’s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may

 

3


be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.

The Administrator’s determination of the reason for termination of the Optionee’s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees.

4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee.

6. Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due.

7. No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time.

8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.

9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy

 

4


rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

EIDOS THERAPEUTICS, INC.
By:  

             

  Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Optionee (including through an online acceptance process) is acceptable.

 

Dated:

 

 

     

                      

            Optionee’s Signature
            Optionee’s name and address:
       

 

       

 

       

 

 

5


NON-QUALIFIED STOCK OPTION AGREEMENT

FOR NON-EMPLOYEE DIRECTORS

UNDER THE EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

Name of Optionee:                                                                                                        
No. of Option Shares:                                                   
Option Exercise Price per Share:    $                                             
Grant Date:                                                   
Expiration Date:                                                   

Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Eidos Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.

1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee remains in service as a member of the Board on such dates:

 

Incremental Number of

Option Shares Exercisable

   Exercisability Date

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       


Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.

2. Manner of Exercise.

(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.

Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.

(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a

 

2


holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.

(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.

(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.

3. Termination as Director. If the Optionee ceases to be a Director of the Company, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.

(a) Termination Due to Death. If the Optionee’s service as a Director terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.

(b) Other Termination. If the Optionee ceases to be a Director for any reason other than the Optionee’s death, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a Director, for a period of six months from the date the Optionee ceased to be a Director or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Director shall terminate immediately and be of no further force or effect.

4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee.

6. No Obligation to Continue as a Director. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance as a Director.

 

3


7. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.

8. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

 

4


9. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

EIDOS THERAPEUTICS, INC.
By:  

                     

  Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Optionee (including through an online acceptance process) is acceptable.

 

Dated:

 

 

     

                      

            Optionee’s Signature
            Optionee’s name and address:
       

 

       

 

       

 

 

5


RESTRICTED STOCK AWARD AGREEMENT

UNDER THE EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

Name of Grantee:

 

                                                                                          

No. of Shares:

 

                                                                                          

Grant Date:

 

                                                                                          

Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, Eidos Therapeutics, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.

1. Award. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company’s transfer agent in book entry form, and the Grantee’s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank.

2. Restrictions and Conditions.

(a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan.

(b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting.

(c) Except as may otherwise be provided by the Administrator, if the Grantee’s employment with the Company and its Subsidiaries is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company.

3. Vesting of Restricted Stock. Except as may otherwise be provided by the Administrator, the restrictions and conditions in Paragraph 2 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date.


Incremental Number

of Shares Vested

   Vesting Date  

                                     (        %)

                                            

                                     (        %)

                                            

                                     (        %)

                                            

                                     (        %)

                                            

                                     (        %)

                                            

Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3.

4. Dividends. Dividends on shares of Restricted Stock shall be paid currently to the Grantee.

5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.

7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due.

8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election.

 

2


9. No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.

10. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.

11. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

 

3


12. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

EIDOS THERAPEUTICS, INC.
By:  

                     

  Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.

 

   
Dated:  

 

   

 

Grantee’s Signature

      Grantee’s name and address:
     

 

     

 

     

 

 

4


RESTRICTED STOCK UNIT AWARD AGREEMENT

FOR COMPANY EMPLOYEES

UNDER THE EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

Name of Grantee:                                                                                          
No. of Restricted Stock Units:                                                 
Grant Date:                                                 

Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Eidos Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.001 per share (the “Stock”) of the Company.

1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.

2. Vesting of Restricted Stock Units. Except as may otherwise be provided by the Administrator, the restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.

 

Incremental Number of

Restricted Stock Units Vested

   Vesting Date

                                     (      %)

                       

                                     (      %)

                       

                                     (      %)

                       

                                     (      %)

                       

The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.

3. Termination of Employment. Except as may otherwise be provided by the Administrator, if the Grantee’s employment with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall


automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.

4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.

5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

6. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due.

7. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code.

8. No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.

9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.

10. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the

 

2


Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

EIDOS THERAPEUTICS, INC.
By:  

 

  Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.

 

Dated:

 

 

   
     

 

Grantee’s Signature

     

Grantee’s name and address:

     

 

     

 

     

 

 

3


RESTRICTED STOCK UNIT AWARD AGREEMENT

FOR NON-EMPLOYEE DIRECTORS

UNDER THE EIDOS THERAPEUTICS, INC.

2018 STOCK OPTION AND INCENTIVE PLAN

 

Name of Grantee:

 

                                                                  

No. of Restricted Stock Units:

 

                                             

Grant Date:

 

                                             

Pursuant to the Eidos Therapeutics, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Eidos Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.001 per share (the “Stock”) of the Company.

1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.

2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in service as a member of the Board on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.

 

Incremental Number of

Restricted Stock Units Vested

   Vesting Date  

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

_____________ (___%)

                       

The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.

3. Termination of Service. If the Grantee’s service with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.


4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.

5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

6. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code.

7. No Obligation to Continue as a Director. Neither the Plan nor this Award confers upon the Grantee any rights with respect to continuance as a Director.

8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.

9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

 

2


10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

 

EIDOS THERAPEUTICS, INC.

 

By:  

 

  Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.

 

Dated:                                                                  
   

 

Grantee’s Signature

    Grantee’s name and address:
   

 

   

 

   

 

 

3

EX-10.3 11 d544598dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

EIDOS THERAPEUTICS, INC.

2018 EMPLOYEE STOCK PURCHASE PLAN

The purpose of the Eidos Therapeutics, Inc. 2018 Employee Stock Purchase Plan (“the Plan”) is to provide eligible employees of Eidos Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). 143,520 shares of Common Stock in the aggregate have been approved and reserved for this purpose.

The Plan includes two components: a Code Section 423 Component (the “423 Component”) and a non-Code Section 423 Component (the “Non-423 Component”). It is intended for the 423 Component to constitute an “employee stock purchase plan” within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and the 423 Component shall be interpreted in accordance with that intent (although the Company makes no undertaking or representation to maintain such qualification). In addition, this Plan authorizes the grant of options under the Non-423 Component that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component.

1. Administration. The Plan will be administered by the person or persons (the “Administrator”) appointed by the Company’s Board of Directors (the “Board”) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such rules, subplans, guidelines and practices for the administration and operation of the Plan and for its own acts and proceedings as it shall deem advisable, including to accommodate the specific requirements of local laws, regulations and procedures for jurisdictions outside of the United


States; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan; (iv) decide all disputes arising in connection with the Plan; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder.

2. Offerings. The Company will make one or more offerings to eligible employees to purchase Common Stock under the Plan (“Offerings”). Unless otherwise determined by the Administrator, the initial Offering will begin on the date of the Company’s Initial Public Offering and will end on the following November 30th (the “Initial Offering”). Thereafter, unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each December 1st and June 1st and will end on the last business day occurring on or before the following May 31st and November 30th, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed 27 months in duration or overlap any other Offering.

3. Eligibility. All individuals classified as employees on the payroll records of the Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the “Offering Date”) they are customarily employed by the Company or a Designated Company for more than 20 hours a week, unless the exclusion of employees who do not meet this requirement is not permissible under applicable law. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated

 

2


Company for purposes of the Company’s or applicable Designated Company’s payroll system are not considered to be eligible employees of the Company or any Designated Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Company on the Company’s or Designated Company’s payroll system to become eligible to participate in a plan which is equivalent to this Plan is through the adoption of a subplan, which specifically renders such individuals eligible to participate therein.

4. Participation.

(a) Participants on Effective Date. Each eligible employee at the time of the Initial Public Offering shall be deemed to be a Participant at such time. If an eligible employee is deemed to be a Participant pursuant to this Section 4(a), such individual shall be deemed not to have authorized payroll deductions or contributions and shall not purchase any Common Stock hereunder unless he or she thereafter authorizes payroll deductions or contributions by submitting (either in electronic or written form, according to procedures established by the Company) an enrollment form (in the manner described in Section 4(c)) by the end of the Initial Offering or such earlier deadline as is specified by the Administrator. If such a Participant does not authorize payroll deductions or contributions by submitting (either in electronic or written form, according to procedures established by the Company) an enrollment form by the end of the Initial Offering (or such earlier deadline, as applicable), that Participant will be deemed to have withdrawn from the Plan.

 

3


(b) Participants in Subsequent Offerings. An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting (either in electronic or written form, according to procedures established by the Company) an enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering).

(c) Enrollment. The enrollment form will (a) state a whole percentage to be contributed from an eligible employee’s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued or transferred pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant submits (either in electronic or written form, according to procedures established by the Company) a new enrollment form or withdraws from the Plan, such Participant’s contributions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible.

(d) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code and any applicable law.

 

4


5. Employee Contributions. Each eligible employee may authorize payroll deductions at a minimum of 1 percent up to a maximum of 20 percent of such employee’s Compensation for each pay period; provided, however, that if payroll deductions are not permitted or problematic under applicable law or for administrative reasons, the Company, in its discretion, may allow eligible employees to contribute to the Plan by other means. The Company will maintain book accounts showing the amount of payroll deductions or other contributions made by each Participant for each Offering. No interest will accrue or be paid on payroll deductions or other contributions, unless required under applicable law.

6. Contribution Changes. Except in the event of a Participant increasing his or her contributions from 0 percent during the first Offering as specified in Section 4(a) or as may be determined by the Administrator in advance of an Offering, a Participant may not increase his or her contributions during an Offering and may only decrease his or her contributions once during an Offering. However, during an Offering, a Participant may increase or decrease his or her contributions with respect to the next Offering (subject to the limitations of Section 5) by submitting (either in electronic or written form, according to procedures established by the Company) a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her contributions during an Offering.

7. Withdrawal. A Participant may withdraw from participation in the Plan by submitting a notice of withdrawal to his or her appropriate payroll location (either in electronic or written form, according to procedures established by the Company). The Participant’s withdrawal will be effective as of the next business day. Following a Participant’s withdrawal, the Company will promptly refund such individual’s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4.

 

5


8. Grant of Options. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (“Option”) to purchase on the last day of such Offering (the “Exercise Date”), at the Option Price hereinafter provided for, the lowest of (a) a number of shares of Common Stock determined by dividing such Participant’s accumulated contributions on such Exercise Date by the lower of (i) 85 percent of the Fair Market Value of the Common Stock on the Offering Date, or (ii) 85 percent of the Fair Market Value of the Common Stock on the Exercise Date, (b) 2,000 shares; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant’s Option shall be exercisable only to the extent of such Participant’s accumulated payroll deductions and/or other contributions on the Exercise Date. The purchase price for each share purchased under each Option (the “Option Price”) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less.

Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was granted, would be treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section 11). For purposes of the preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other

 

6


employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the Option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted.

9. Exercise of Option and Purchase of Shares. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated contributions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan; provided that, with respect to the Initial Offering, the exercise of each Option shall be conditioned on the closing of the Company’s Initial Public Offering on or before the Exercise Date. Any amount remaining in a Participant’s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant’s account at the end of an Offering will be refunded to the Participant promptly.

If a Participant has more than one Option outstanding under the Plan, unless he or she otherwise indicates in agreements or notices delivered hereunder: (i) each agreement or notice delivered by that Participant shall be deemed to apply to all of his or her Options under the Plan; and (ii) an Option with a lower Option Price (or an earlier granted Option, if different Options have identical Option Prices) shall be exercised to the fullest possible extent before an Option with a higher Option Price (or a later granted Option if different Options have identical Option Prices) shall be exercised.

 

7


10. Issuance of Certificates. Certificates, or book entries for uncertificated shares, representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee or, if permitted by the Administrator, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose.

11. Definitions.

The term “Affiliate” means any entity that is directly or indirectly controlled by the Company which does not meet the definition of a Subsidiary below, as determined by the Administrator, whether new or hereafter existing.

The term “Compensation” means the amount of base pay, prior to salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code or comparable reductions under laws outside the United States, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise, vesting or settlement of Company equity incentive awards, and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside of the United States.

The term “Designated Company” means any present or future Affiliate or Subsidiary (as defined below) that has been designated by the Administrator to participate in the Plan. The Administrator may so designate any Affiliate or Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders and may further designate such companies as participating in the 423 Component or the Non-423 Component. For purposes of the 423 Component, only Subsidiaries may be Designated Companies. The current list of Designated Companies is attached hereto as Appendix A.

 

8


The term “Fair Market Value of the Common Stock” on any given date means the fair market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on The Nasdaq Global Market (“NASDAQ”) or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. Notwithstanding the foregoing, if the date for which Fair Market Value of the Common Stock is determined is the first day when trading prices for the Common Stock are reported on NASDAQ or another national securities exchange, the Fair Market Value of the Common Stock shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the Company’s Initial Public Offering.

The term “Initial Public Offering” means the first day when trading prices for the Common Stock are reported on NASDAQ or another national securities exchange, pursuant to an effective registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock.

The term “Parent” means a “parent corporation” with respect to the Company, as defined in Section 424(e) of the Code.

The term “Participant” means an individual who is eligible as determined in Section 3 and who has complied with the provisions of Section 4.

The term “Subsidiary” means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of the Code.

 

9


12. Rights on Termination of Employment. Unless otherwise required by applicable law, if a Participant’s employment terminates for any reason before the Exercise Date for any Offering, no contributions will be taken from any pay due and owing to the Participant and the balance in the Participant’s account will be paid to such Participant or, in the case of such Participant’s death, if permitted by the Administrator, to his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section 7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be an Affiliate or a Subsidiary, as applicable, or if the employee is transferred to any corporation other than the Company or a Designated Company. An employee will not be deemed to have terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing.

13. Special Rules. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees; provided that if such rules are inconsistent with the requirements of Section 423(b) of the Code, these employees will participate in the Non-423 Component. Any special rules established pursuant to this Section 13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan.

14. Optionees Not Stockholders. Neither the granting of an Option to a Participant nor the deductions from his or her pay or other contributions shall deem such Participant to be a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued or transferred to him or her.

 

10


15. Rights Not Transferable. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant’s lifetime only by the Participant.

16. Application of Funds. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose; unless otherwise required under applicable law.

17. Adjustment in Case of Changes Affecting Common Stock. In the event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section 8 shall be equitably or proportionately adjusted to give proper effect to such event.

18. Amendment of the Plan. The Board may at any time and from time to time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order for the 423 Component of the Plan, as amended, to qualify as an “employee stock purchase plan” under Section 423(b) of the Code.

19. Insufficient Shares. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date.

 

11


20. Termination of the Plan. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. The Plan shall automatically terminated on the ten year anniversary of the date of the Company’s Initial Public Offering.

21. Compliance with Law. The Company’s obligation to sell and deliver Common Stock under the Plan is subject to completion of any registration or qualification of the Common Stock under any U.S. or non-U.S. local, state or federal securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S. or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock.

22. Governing Law. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of California, applied without regard to conflict of law principles.

23. Issuance of Shares. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source.

 

12


24. Tax Withholding. Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by participating in the Plan, that the Company and its Affiliates and Subsidiaries shall have the right to deduct any Tax Liability from any payment of any kind otherwise due to the Participant, including shares of Common Stock issuable under the Plan. Where a Tax Liability arises in connection with the Plan, the Company and/or a Designated Company may require that, as a condition of exercise of an Option and purchase of shares of Common Stock, a Participant must either:

(a) make a payment to the Company, or otherwise as the Company directs, of an amount equal to the Company’s estimate of the amount of the Tax Liability; or

(b) enter into arrangements acceptable to the Company to secure that such payment is made (whether by surrender of shares of Common Stock, net share issuance, the sale of shares of Common Stock or otherwise).

For these purposes, “Tax Liability” shall mean any amount of U.S. or non-U.S. federal, state or local income tax, social security (or similar) contributions, payroll tax, fringe benefits tax, payment on account and/or other tax-related items related to the participation in the Plan and legally applicable to the Participant, which the Company and/or an Affiliate or Subsidiary become liable to pay on the Participant’s behalf to the relevant authorities in any jurisdiction.

25. Notification Upon Sale of Shares. Each Participant who is subject to tax in the United States with respect to his or her participation in the Plan agrees, by entering the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased.

 

13


26. Effective Date and Approval of Shareholders. The Plan shall take effect on the date immediately preceding the date of the Company’s Initial Public Offering, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders.

 

14


APPENDIX A

Designated Companies

 

15

EX-10.4 12 d544598dex104.htm EX-10.4 EX-10.4

Exhibit 10.4

EIDOS THERAPEUTICS, INC.

SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN

 

1. Purpose

This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Eidos Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those of the Company and its stockholders and to enable the Company to attract and retain highly qualified executives. The Incentive Plan is for the benefit of Covered Executives (as defined below).

 

2. Covered Executives

From time to time, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) may select certain key executives (the “Covered Executives”) to be eligible to receive bonuses hereunder. Participation in this Plan does not change the “at will” nature of a Covered Executive’s employment with the Company.

 

3. Administration

The Compensation Committee shall have the sole discretion and authority to administer and interpret the Incentive Plan.

 

4. Bonus Determinations

(a) Corporate Performance Goals. A Covered Executive may receive a bonus payment under the Incentive Plan based upon the attainment of one or more performance objectives that are established by the Compensation Committee and relate to financial and operational metrics with respect to the Company or any of its subsidiaries (the “Corporate Performance Goals”), including the following: achievement of specified research and development, publication, clinical and/or regulatory milestones, total shareholder return, earnings before interest, taxes, depreciation and amortization, net income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of the Company’s common stock, economic value-added, funds from operations or similar measure, sales or revenue, acquisitions or strategic transactions, operating income (loss), cash flow (including, but not limited to, operating cash flow and free cash flow), return on capital, assets, equity, or investment, return on sales, gross or net profit levels, productivity, expense, margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per share of the Company’s common stock; bookings, new bookings or renewals; sales or market shares; number of customers, number of new customers or customer references; operating income and/or net annual recurring revenue, any of which may be (A) measured in absolute terms or compared to any incremental increase, (B) measured in terms of growth, (C) compared to another company or companies or to results of a peer group, (D) measured against the market as a whole and/or as compared to applicable market indices and/or (E) measured on a pre-tax or post-tax basis (if applicable). Further, any Corporate Performance Goals may be used to measure the performance of the Company as a whole or a business unit or other segment of the Company, or one or more product lines or specific markets. The Corporate Performance Goals may differ from Covered Executive to Covered Executive.


(b) Calculation of Corporate Performance Goals. At the beginning of each applicable performance period, the Compensation Committee will determine whether any significant element(s) will be included in or excluded from the calculation of any Corporate Performance Goal with respect to any Covered Executive. In all other respects, Corporate Performance Goals will be calculated in accordance with the Company’s financial statements, generally accepted accounting principles, or under a methodology established by the Compensation Committee at the beginning of the performance period and which is consistently applied with respect to a Corporate Performance Goal in the relevant performance period.

(c) Target; Minimum; Maximum. Each Corporate Performance Goal shall have a “target” (100 percent attainment of the Corporate Performance Goal) and may also have a “minimum” hurdle and/or a “maximum” amount.

(d) Bonus Requirements; Individual Goals. Except as otherwise set forth in this Section 4(d): (i) any bonuses paid to Covered Executives under the Incentive Plan shall be based upon objectively determinable bonus formulas that tie such bonuses to one or more performance targets relating to the Corporate Performance Goals, (ii) bonus formulas for Covered Executives shall be adopted in each performance period by the Compensation Committee and communicated to each Covered Executive at the beginning of each performance period and (iii) no bonuses shall be paid to Covered Executives unless and until the Compensation Committee makes a determination with respect to the attainment of the performance targets relating to the Corporate Performance Goals. Notwithstanding the foregoing, the Compensation Committee may adjust bonuses payable under the Incentive Plan based on achievement of one or more individual performance objectives or pay bonuses (including, without limitation, discretionary bonuses) to Covered Executives under the Incentive Plan based on individual performance goals and/or upon such other terms and conditions as the Compensation Committee may in its discretion determine.

(e) Individual Target Bonuses. The Compensation Committee shall establish a target bonus opportunity for each Covered Executive for each performance period. For each Covered Executive, the Compensation Committee shall have the authority to apportion the target award so that a portion of the target award shall be tied to attainment of Corporate Performance Goals and a portion of the target award shall be tied to attainment of individual performance objectives.

(f) Employment Requirement. Subject to any additional terms contained in a written agreement between the Covered Executive and the Company, the payment of a bonus to a Covered Executive with respect to a performance period shall be conditioned upon the Covered Executive’s employment by the Company on the bonus payment date. If a Covered Executive was not employed for an entire performance period, the Compensation Committee may pro rate the bonus based on the number of days employed during such period.

 

2


5. Timing of Payment

(a) With respect to Corporate Performance Goals established and measured on a basis more frequently than annually (e.g., quarterly or semi-annually), the Corporate Performance Goals will be measured at the end of each performance period or such other appropriate time as the Compensation Committee may determine; provided, that if a Corporate Performance Goal is dependent on financial metrics as reported in the Company’s financial reports for any particular period, such Corporate Performance Goals shall be measured after the Company’s financial reports with respect to such period(s) have been published. If the Corporate Performance Goals and/or individual goals for such period are met, payments will be made as soon as practicable following the end of such period, but not later 74 days after the end of the fiscal year in which such performance period ends.

(b) With respect to Corporate Performance Goals established and measured on an annual or multi-year basis, Corporate Performance Goals will be measured as of the end of each such performance period (e.g., the end of each fiscal year) or such other appropriate time as the Compensation Committee may determine; provided, that if a Corporate Performance Goal is dependent on financial metrics as reported in the Company’s financial reports for any particular period, such Corporate Performance Goals shall be measured after the Company’s financial reports with respect to such period(s) have been published. If the Corporate Performance Goals and/or individual goals for any such period are met, bonus payments will be made as soon as practicable, but not later than 74 days after the end of the relevant fiscal year.

(c) For the avoidance of doubt, bonuses earned at any time in a fiscal year must be paid no later than 74 days after the last day of such fiscal year.

 

6. Amendment and Termination

The Company reserves the right to amend or terminate the Incentive Plan at any time in its sole discretion.

 

3

EX-23.1 13 d544598dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 of Eidos Therapeutics, Inc. of our report dated March 22, 2018, except for the effects of the stock split as discussed in Note 1 to the financial statements, as to which the date is June 7, 2018, relating to the financial statements of Eidos Therapeutics, Inc. which appears in such Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

San Jose, CA

June 8, 2018

GRAPHIC 14 g464287page105.jpg GRAPHIC begin 644 g464287page105.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@", -( P$1 (1 0,1 ?_$ .P $$ P$! 0 M $!0<( P8) @$* 0$! 0 " P$! 0 0(#! 4&!P@)"A M 00" 00" 0#!0((! (K P$"! 4&!P 1$A,((10Q(A4)02,646$R)!=Q@9&A ML=%",R48\,%38Y0FX?%28M)#-%34E7*"I#55M=4V)W76'B2 MHK+"LV5&5G9G.1$! (! @4!!04%!@,$! \ $" Q$$(3$2!09!46$3!PCP M<8$B%)&AL<$RT>%"(Q4)4C,6\6*"HG*R)'3" (O5/P5/\ ;P/O .!X M?W]$[/[?G\.G3^_@?4_A\?\ %TZ+_'\>GX\#UP#@' . < X!P#@' . < X!P M#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' \$=VL5>B+_M5 M$3_:Y55$1$X"(=A$=W-?+AH]J_*MDQUZ?P3N3R*J+_MX"1U_3B(X9;*")S>J M]KI0G.5$Z_FZHYWY5_XN D+EN/,:YS[FM:UJ_P"+SJY$_P!O1BI^' P-S;%W M(JI>UBHG3HK3JGX_W.$OX?[>!E;F6,.[$2\KNKE1$3S_ "JK^"?X4Z+P%:9! M4NY?E$22'JO^QJD5RI_L M3@+&O[E^/E.G7JB+T_C_ !_W<#WP#@' . < X!P#@' . < X!P#@' . < X! MP#@' . < X!P#@' . < X!P#@' . < X!P#@' \N7[$VR 1;3;N29=9P!#>6>P>M<$L;VLS?*?:+%)^.X#' MV;=PKR7^F%@8!*MHE#$R@HBY*IOTN7=3@Q&/1%5#$:BI\\!NE>R^G8=S%QZ; MG'LP#(#[ DZK?4NNE^PW8L+%W9G(PU0-R)6-R.+BR??('N1/K*CN[JO3@, O MTY,R-,5@;+]@77XO3@:YGWL9CT35E9LC$,OWID<7-755+J*A/FUIB$C;/UGMO-P:U+EY5\MIIS,:C+F@GT.9M"'LQBX<1M9=EH2G:^S M&E:&YOJ"_P!@>R]!=X[/PVAOZB\M)59/IKG8UO(QS J^=#G7H#AD9;=PC1H2 M=%0SV=45&]%4,$/VET38'#%KMD>Q\^<>9L>JBUD.]),L;&TTX,9]IQJV!%OR M2YY\+%)&DL(FN>USD:QKU7IP)4@[.TW^GTTW)]_Y_K:3?PH]C38[L[9*XKE< MVNE-9)CV!J)]A+FU$8K7-3I/2,]$=T5$X&GY=OW4N"6LZCS/.O9"CDP,0R'8 MGWEO2&QJ;K_%@1YF19E49("]=4W%#5QI8R&* SW"8[HK45%3@-W_ 'D]%,N' M4)]K;[AWCKS7V*1JZ5E;4ERUOFP$VUL;V7=RJ"5:8MF&/T7Z%C$8\N< M>=-E62>:U.P'4,=O5TCJB-3\Z DUI=^Y.;DK(5UM/%J>2 M>ULPG!#EY@DAT6*JOA-#%ES&37V1H[V*<*MZ"5W7KT3@2K,;NRDF!JLRWE<4 MN3U.-6.19OB5;C>77EM31/(1*H4.=$LEBO/+&QKWL_,X3'=WX=>!J8 ZY/ M6^UM55GR>MWKB!H.UWE](IJ0]%5905,ZE1LS_J*NRG&Q"H -\\ M>RQ"(>T1UX14*-AD;T5KR(B=>G3@5WS7/OPI/SE5O3IUX"^SM=K,+8LHO8BRMO/E8\,Q^ M0_',L@4[+E'##.3)+Z78-A1:X2N>@9+?RF5%5/\ "O UD/L=M''*P8K+:=A' MCT=W:T-I9269#:$R6]3.)>(4D"CI!?SZ.J\L(I?(0KU(UG5WPY.!Y)[;9J_[ M+![IL')#C&(V2S&[ER+)4SD/$.Q9S.PH')VHBI\)P-;;[E;"E$;*;M2]0?8) MHP H;)&R#M9'QR*K^J-147IP/3_#:.2*V'.431NQRP$20 M(B*5I .=8HYYFJO3H[HWHG SR?;O9"BDRV;7RIRQ&H\P6U1F]PU8G8U&?=[C M$\ZHU49^' P?][W/R#*1VS\O;%0*.[Y%;-C'"=YVL$%S637.[7BG :*+5[ M#S&4V2\,&MA J+:;:2[2<=@1 039O5\A.Y>H_P#H(BK\].!OT+V!S9-FQ-.W M6[[TN;.L8E;DI,6HKVTQK6,NT \U%'V/E2RPPJD\]4[58!IU8Y%1_143J$?W M_L7[>XKM;(-(5\V%F&PZ*5!CQ:RER*\."QC6#$DQ+-\XXF!BUIX14)]DJL&- MG7K^")P)%Q'V[GUF>-UEM?V&B3=@GL(]8ZBT_397G6/5-T4;5F5TO+GAAQ9O MTE1&G-':^.,B.3NX&X>P7L;MCUCL\6%G^1R;_&M@R)JX5?X9(O94:5%@H%TF M!=D.P?T+B.P[542=47Y^>O7@1%&_<X)D<[Y"65" $O\\_*K@>,(00F=T@8@V,_[L@@D^7,8'HG]O U^ MX]CK^.5M;%W!CMF<+'2Y0\?%FMY8 AHC>H1OC105Y98E1?GO[/[5X'M?9>3- MAN=6V.X+$XE&-9P9D7%XBGE?R1Q5'(DRR=Q'I^5[D1&JO5?PX&FV?L3L.NM" M&:6UA2*\3?+"RS<<^2I&N[58AJV!";$>9R_/5'_"=/G@,DOVSVJKH[I.?857 M,DFZ-%4P["]Y$1/'\)P-N@>W M&V!B<.5G^*3RH1L5\&QC3Z*SE>3JU>UP)#W17=/EKNGQP'NN]FB(T)8D.U@#&T(T:Y2L[G)UZ?/SP-GD^V-M]<*MM]HT,T$ M3R/-;5@LGJ"^1?Y1YIB (YQ?$,CU[G?JR>-.X:=/_ 'K@ M69U#O#/=KXS(V$79%]C&-#A3I=)C$"-+M,^RP54P;YLFMJSS1021Y:$0($<5 MI/*U?CM^>!%E?[99SL6TD8[IC;4N;F$)]@QVL=IU4_ \LN?IH1\V+C5^*=/H MY]_%$-W2%((%Y'-Z#ZKP,N@O8/>^T\ZR3%+C.(6'?T)1SK_/Y.2R+V"V9F%ODE#KC9F8Q,NP>K2^R+5 M^RLYJ?/ 8X_L/O@T6-:0\IS0 MXI<4B1!_I,%6.E(CFB&]C[M"(JJQ/*O3JQ.O 4RO9#?4/Z4NPOLOC!D=@U"R MGKR"D-8Q&RDC.2^17O89KNU4Z\!0OLMNI4$@,CRAA$:Q&#F4\#M\/5JJBO;? M.T^U0E*:9E^9E@,;WN[,9JV2/*I'L[6_P#IA3K%1W7JO^+\ MJ?' 99?N'LN,(C+'-\EB*Y'&!)3'*]4'Y9:L>%[F9%U4#!L[$54Z]?G@)IWN M%G#1"(S/\E$QBQTG%2GAI\N*UW8/ID+E;_*5/E$[G(G P3_;78SY<80-CY>9 MTN?UKFPL;!(=+CA:Y93);DOD:(@.K5;T^%;UZ_/ V3&]_;(V%48L8VP\OQ&L MMK67+=DTR#8/G2,8D8U5V=5%L,8J["2D.3'L9!7DE!*_MCJBO1$1>@3G9T6P M*P%Q,3V7/>PJ^@CY# %BH;*ZN,JKG!$\[\>J@7"2RD@+(:TK%1%<[JGPK53@ M1OFF1[2PQAB&V5LVWE"6$\$&'43HKRI8"::.&8L^^BA@2&@=W&\CD:%41J_F M^. S8+G6TX_=TT"M,6,V188Z:P)($.?*8 MHXH^Y'$VSK+8UY6R(M7:*]L;(1N+/+] MBG*(:E8Y/CQO:[_I)U#Q>QMPU'ZD\>V\\EP*>U!4LN75=K$J[_[$0$Z/88T= M]OX["N>PR_F54=T:O5/X<"%X&X-HS,@DT)LSV7!$D>3*BVSF$F#-]4G\Y)D* M%>EF53CB:XP1N:[RL8J=45>G GFH#L.8V!A)_5$>[BTEWDDV1<6--*A M8E&N[=F-%AB*<,K))/ZB)\)LJ,-KF,5KDZ.3N5.!!^8[2VOASV#%G&QL@G3@;G:UV;4ZQ[CW#2 HFQ9X)ER(, OW45B.,JM[,==2;5S61(E1:259!915\H*^NC'D*-4>_M;\\#0L,]LO7K.[W&:3'=NYY5%R4X8U47KMDE[.EZ?\S-G[#V!NS.R:'Q6Q.8CXN"5TS%X1K[8>SCM& MQLP\%JT^/L)VN,4JJQH*M;>R.N,AUM+S7)LUVSA,K$\@DX'LO'LGW%FUA;8# ML $1;$]:R325D@-K@%_5_P">QN\?V-F0WJ-W:83FH&^.W]I2/)?#+M+:"2PV M4>D-#;FVXB2Q7LR"VPA4;X_]/]_ZO-K7)(!&_P"M*!R/:BHO ;&>S?K^8(YD M?<6PUA.J37GW9F>;>CPUQ^/.?62+UDA:!HG5(K5CHKY'7QM,U1]4/Y MX"&![-:-N3QH=/LG;MPJ<#IEP#@' .!QM]@4D.]-\T^L0S)*8WOWZY8L9),H) MTVM$498L17-;*EBS\RU; M-E>PD&%BF=+KBL+>&)WE'B]G.QP.,"\4<]=&&]_8\;"N1"_@"V'ZO:[R"X M[JFMY=])TNND:[+1XO#IH<*JJ0Y"6$3!J^U%<4%%/N>WH%WJ'U#UM:3Y5C)T..KM9MI;3+[8.3XG]S?$K>[\H3WA&-4V>YO#L-<:29'$J(&M+S,R#1MA=1HQY[NY']RN:G0'/8NE+77M!?"P2BQ3Z8I4E^1@8>% MG>QK2Q220)[?-;>Y%-MKMTERL688Q51J._PIP(ZTGAU!L:76Z)SB-676E-S0 M3BH:W*0.L,7UAO&DK9.1C+40O*C*#"-Q5E)-I[['A/;#-($TZ,A9>4X6RL/VQKF75MRTKATDZVAZ4NI#Q29:.<9Q7"& M0@D8U5(1$:OX]>!%=ZZOO)>19GC4:K#K*L_2+5OU,I6IRC([[&"!#E[UQ(I& MNR*BL982!8IW=$"GYFKT3@5>V/[.U6/VN18P&^/0XWE$B!L&M@Y'53,DE8@: MO>P%5'8%H8R5,6["](X5^$ Y6_E>YJ+P-TP7=E1N3^NZZ_'<&)LVTQ3%22_* MZEJL<-2U@KIUQ.@?:&7'WV H# M:P*-4]?:9'BP<2QMSXF081(GS8XY,.UAQH#U%)(]Z=W1!M1J]>!FS*#2M5F, MX*W7]EXK0]S.Y[&L[7?V(%>] MC[6KM,Q0.K36<')-<9-,LK.['=FMJ/)QWIWDJ\;/*8.0:[;!AE(*)W/4GA5% M5JIT1 B3$O:6NO;VDQ"-9%LJQ^QHF3O2EHY&)2&6H8\ZPEX]72Y)X[;"R$%I M(Q(YC(UZ*I4;U>Y$"TV+7=#73:G;42'03JW+KK*]A7^OYY@W._%J\"I[/C8$:NN(!JZHR?8%Z(@L9R.KR,8P(:BN"]/M,:SL1CD M5557*O T/)Z<60SS4^.AQN$/&\;E8YLVSK7[,<.!B5S)=_$KHW M5/KO!6G9'LG38M:N%6GEXKC&XK#7%77#QY'*[,*ZA M /;!C60GE)^?HJ.?T(J*K>!"]YDY<[QS&LR'(LC,O[O'C1;-@?TJ/(%$VS>1 M$.2(Y4<%AA1D,%58KG-7H[IUZ\!KEU6I-?:BM[')[G&TS[/&9UD^,Q75[;&U M<>B/.^F%]89CX=K&E31BBR%>>.OE+T:UW;P*W8)<[DV4^LB8UKS7TGO"(LJW MDZ\KQ54"Z1@"EI4G,,63,>)2?SFA81 L_'HJ=.!,1-3^RM5",<#_ %X?=@23 M+LL>@X_CL[('%8$CC5\&ND'=;.10N:X3GQQHJ?XNU.J\#3-/8[ M5:OI28-7/-D5TNYM@9_K;(X,A+*9AV(X364\.XP^/9M/(99Y,R'V3 MQ%Q:L/(^RY!(UKN!"WL7BU+IG%K;VC]=K>;59;E>?2 [2QC)IJ76/ M2;V\LBBBS T,YO\ F1RS#9*C 5$>/RJG7ITX&':E_F&A-!QW9+D$DF_O9(=; M-VYL $:/6V,>LMZQDV#AE7X'L?08_08WV1Q1X[T[2F>K_E45 KIJ?%-U5ME7 MWVIL+OF5L2FF4DG),A;"P;%4QN\ H;5BY1>%@.?&.%5(AXK"G8_JK>J_/ LI ML2599M%PS&\SW>V'%PL3R5.O=,XD;<1C7,I1-M[7(=@Y\2FIHDHC!,:CHT0R M(Q7+_9U!?76>'UU(:L;JO7Q(K6O;^O;3LXN27+CM:C'$#CD"+5US&HY/(UO: MY.OPB<#:8F:;'R5C(E189YDS9@5"*#KC%WX-2*QC7,&C;2 &NB1XHFM9VK]C MJB(G7KTX$AXQZV;1RBR9)3$ZFKG2XT60*5E=W:Y/>5)Q,[2M=].+9#**4O3R M.63U7@6,QOTBV/:?6#<99<4R1QOCE'38_5T\41WN4B/C3Y5C-ESX+R*BJY1C M5B?@U5^.!.>+^B&,L0,G++.TL;834$8)-%_3(PW.<_JYO1 MW]R\"7ZWTXU-! \3\?QY2N1K1RA8U ?,"S_I!6;,?)D'&KO\*O57)P))I]": M^IQ.:VK">0K1#24R+!@D8(7Y1C8V)%8C?&W^*?*\#<4UGA2L$,E(([0KU&I" MEZ_@BHKE&]G5%5. \1<.QF&QPH]-$8-R]5:YKR)^'3\OE(_HG]R?\O 5NQJA M>C4?3USVL^&(Z()RM3^Y57\/C@?&XQCS>JMI:YJ_QZ11)U_X$X'Q<7Q[KU_1 M:S^'S],:K_P_CP$Y,0QDK>A*2OU>@5'\/=U1KOS+UZHY[GKTZ_A_9P-%R'URUQ?@((E:T#S$:\AGQ8$YS^U M/^FDN,Y>BI\+\]>!$5YZ,:?MVJ%*''1QW-57M9CH(4I55%14;.K3Q)#&N=\] M.J?/ A/(OV[:R&Y#8%DMY222@2*0HLHM!Q A0BD[!55DVRBG1'=$:CE;TZ?C MP*_Y?Z2[EA?7CQ,F)DKBE(I2Y+A5=*J6,;VH\AIU/9/E#\J?"?Y9ZK^/QP*Z M7FD-T8D<[XV S!ACJ0,Z;K7+Y>.R8;V=568.KL1TI&N*WIVHBN_L^>!'%OG& M4PHYZW.[&5-JFH&,2AWAKP-K$[P+U&P=U*BL/(8=[D[R".]5Z]?G@8,F+BN3 M1(A/]/6X>=J-@EN])V&/S8T9A7/"^7_0V3PRQ9P&-6"%.R*,I9E]-F4E) QZDJU+X06RR31U(P$ M@JD>T;6>5J-17-Z?/ ?[/7?L]/DUH8FS=0WT]X9)(E'5X]0W9R" -I2NEGKY MO@-(]K2-$02(J]J].G N:*+JNX9C^2ZKN29%4P+VVQZYL7)T2'D M3JP9#@!/)$@/?%B$&Y7]0N'W/_*[@2MA66KC>)ZRG20UD\1,3QR(>/%O 4H; MJ+8X' 9)K?U&8R(*--EU\$ZJ-BJAVKV*OSP)OQ/,L8SAV35NOYE?K?(B2L5H M],5=%'B3LAA,B!AR[G'J+*(XVQK))XH*HI.Y5=)(Y2-15^0F&'CLW9#[YM]A M-Q<;'MD8=84ZSI6'_P VT:HKNC7/3JB)P,TS M'#:V)')'Q_*JW-,>V2RCQN!4CC7>2V.'69EBEVE5U$1BQ3P(H1N0$:4K4[FJ MK7*OQP(BRG/*O /IV>QK.HS[-GR+F!N/'@U1&"8[@3M6$.^70DR*QRB_P!&VV1Y'FE->V=O'9B6 M)5<6((V*1*"!YEL )76+'AD^1JC&U6JYORB<#;8>G!UAL:OA-*/ E9)"DU\,1GO)V.84G5J=W B$? ML'KXMI"DY+B.#'L\?\L7-#&MZJB#9YM!"*!B>7#QY1O;:GA08 NK7HYH#"5O MY0D+"5R@.CGN>SY1K53@-]L++*8;ZG52Y1B^19%K:/89+.HH@LAC8/D-5* MCUY\*RF6J)'KPQ8'G.74]YX#X?>RH M];C,V@V2&,C+B2N1FE'>-EK]N0QTSN$X+T:]K5(Q.@%!M77^93K"%!)CV$44 M/#&T.-LJ8\*T6LVC9R9 $R*KO(H6JRWD&EO(='$$Y$;V=%;\\"88%7DMN?(, M=SO'[R\V""IQ["=?AS[)8$2?L1\F*.PR*OF2AEDB!XRB(>O:\?D\71%5O5.H M/UA!LL-EY#CN&6L?'+2A]7=T#I;:*(( TLS^K:H12PYL0BA*>I*X@_*U['N* MSN_Q?@'!?#?334V34%)B--@>Y[FNM];R=28[KRIW#FUO!'JS,\RKLOSK$[6S M@3X\B!0Y-?!^W(!G]ALT=DFT#VM)96]OB&I(V9>O6@G7MW M+RJ-1U>MBMPNZSUAYQ'OLMG[;S2'*0EJ0;IX*^#' PO8KNH2IA>&DBRPX%LO M:&N9N2Y1X@W6GN"8U@&WZ2SS+$]8Y+$S[5..9_:9([.=3Y55Q)P*:7B6T*.VKLMM(4&.*_P 0GHU$3@5\N/9S <3UQ7:]U)00, P"KCV%6F&8-56.)D? O9IK M:_J,EV'-G6NP#XI8V,SSRHP9 X\A[WN5/^MX'6?U)Q&+$]-TDD;G.QO W/8GJ?BV$9-(DW^/9Y87AMA8CN"FRK&MI;:R?%,HSRGQJ/C."91$L:9 MYID.PGZVCQ8L*:Q),4457/5/)U7@5AO]!:9AX14XNNK,S9+D8AE&JH>,7^UM MEADU^K[W,)&92L<)6%EL::I!DDI]IT1J>4S$>KD1SEX$ETVL=2&R4]XV/LV' MDM/D-5M>3E<#;F>%NO\ 5.'BD775=FL8 9DH-1L6P/6W+[S3%K*R:-Z\/N+F%L+V ;"U5EUY-RW(\036,2?]FYC9 M#?R3SG2O_M60OG;U[51 _3!H/JW2WK^Y##EJ_,=6.=*%'=%')>3.\_(24R([ MJZ*IGD5WB7\P^O:ORG ZH< X!P#@<=MY-:_T^S%'B:1JXG[ *]CC/BB<-=K" M0[B2!JA !:-%<5S?S>-%[?GIP. &AK6FJ,$V?48)DVL_\Q[ ;6BT4/55WDV6 M:_/)E6K''7%;K8@P9#9V,:4UZV+3HX+):]HNUO1JA8S]>L*;&J;;._)A)^*8 MS9'Q32.JZ"V=59'M/.: ,N198S4VX&RBX?K7!H\]Q\EN7C\45CT8-''(QJ!4 M;.?;+967G3$)F3SHD2.]AX&M=.1;[!-:#8LQ01T^ACA1Y;F4Z,Y?$:PMY\B1 M.(Q2*,;7HU L!JO64#.I):'9F![3KL=D!AO=$G97LN%A.82X[FN$#**(][(K M;VI69XWB!(8C'?/GX<"XE]L!];ZH4=!6_]O9'BEN[*LHJK6E_5H=S@>3$ MDQ)[I$1KA.5YA"0K2=JJ%RL?U3\>!S*G:PUSEJ69)3[FPVY# F-F MV=E2"L&@CJ:%/!>(RLRBLM0-,J28UG >TXS,5S%5._\ '@6#V]ZZ8KHW7U_D MUWMI^H^*HFOX'5O+C)?9'#R&%A@\\/ V9@5W0QX[7S:X$NOT%>D'E< M8[#I"M:(8E^U%.CD 5CDR4>7CUDYL1YHXT.= IX^]B]_ A_]MS3NC-OYEM'_ %Q@560Y M QDWQZ0(("G4_C:%_8]CE7KP(;VAB> MM]?>X6?XMJ+(HQL#;87JVL^LR>SRB_=E<:G!8V>-Y &<*+&KX%;D3FQ8CPN, MP$;L"U7*Y.@=+%8Q9-[E.7QJ^M%-CV>7UQY$8L:1(*-! ,]K$7O M1$!)Z\BGBUSDU]''+FD3%Z-EKF8&A=LZI#=0X4K+#8732U>/N%&4RM+ M_&HNUK^!9K+9.2U>LHN565?6XN>7B^-P(^[+W&VVF3U^.-/+DTA!0OU4@CD97:XW7A MQVPI09915V-8V*\GV.%SZ.SC2"%N)]O,%#G':<$41/ Y&M5[GJ3L1_5 ZNXN M#*+C(-C5B88[-H$>QQMU[A&15L(^#5((4X#,4CZPL0/C$DBE5 WJ,K'*K.B* MHS=JOX$+9A+DY5AFSKZXH:S-Y&*Y,>:ZR'&7$1ZQ-+USG=!N[UX%2/3C6^E]L>T^68AMYP+O%UA9128E]W)HU70["B3X0S PR M?0W"+;VS:J*CY<10E YKQJ]>J?' ECV;QS',9RFZQ/"JN/7XU5YWB]34-I?K MMKZ6D9LN4*,"'XO/Y8I2*X1.CV.15Z\"E^?6^*/)K&DO:RZR*M)-S$8RXI:B MH+J&EAEK\>)CY[4D2P#^DW3^CB-5B.$=ZD:Y'_"!=3/;HNI,&)H[3^%Y-696 MBR,'DWT653S\@QZ7^@QLLL[FK;9R:R8_%JJIE'AQR-=YB%8^0Y>O14"ER8_B M*3Z&HAAQ&TN[2-.L06^.F;EX#QH3H[I=?/V$-\2UAY_%BR$.\9D0;N]6C.7M M7@6FU?>XQE.%[KU720,FCS\UJ\,M,/R;*SQ(5QLYN&38L'8N+4P:\WF_5(L> M)WJU7J:Q8QW8U?G@42SG86P]<;1AY]DU;$J#AH0\0TE,)ZRC37L(5[FC[5"1:;6% MALS*&5V>8/E.CM&81DF)[0S&GVYE-==Y5*LHD.7*HH%7=5PH,2FPER.5[4.T MDHZJQ7$54Z<"SVVTL\RVO2VT6QPNEN+)*RTQO(<@QN%F<+%:6SHX I$/$HMA M^9+9ZQ0B+->%[6(B]JIU55"$DU?L[:F0ED6&.Y!EEA3V9*1^5;0N%B8W"L(4 MEL*935=4!TE9'C*WJQ(L+Q^-?RK\<"XF">A6QLA:,V;W6"ROK!L=$1HR@BQF$:GX<"Y6M_1;56#EC6!ZJ >^"9DQUR& LZV5S M/\ 2W%\^S*;L^?D0P*O7_"G M%2:OPJG$\0J1DEBO[T2T(:Q0;D_Q>!DM5&% MK_Q[6,:U.!OP(L>*-@8H QQ#:@V#")HF-8B=$8C6(U.U$3XX&3QM3_HK\?"( MKE7X_P!Z_' ]=J)\(BHB_P!B_"?[OP^>![X'E6(J]?G@>N < X!P#@>7*J)U M1%5?[DZK_P ' ^HO5$54Z<#[P#@8%[NY>G5/C^+>O5%_M3^[IP!!IU7JWX_! M.B*Q.G\>Y$7\57\%3YX":;6P+$!8T^%&F@*G:44H S,(GPJ(Y'L57=%3@1E? M:5P#(4(DFE2+Y!/ K(:HD)J/9VJ3]*D,DU1'HG_2>)R]>!2G9G[<.MKJ]_S_B^/C@47V#Z/;QQ@!'" ME!OZ)&R7GB9Y2@M10(,=JD(K,KQH,D(&$Z?D>>!'_,O553\>!6V@C;LP>XJL M3BIF&K*FZ?;MD2[-(&?ZN+75\0DJ=:#H9)Y5%* 4':U1%<$[NJ]K$GRDF%U& 9)01=>9,<4$6(X_\ 8S'()+ENZ+&:Q#Q:Z+,L7A;^8CU: MDA_^'ITX%3LDPG+==8WE.*RM]6>T%D*M*W:&I96S[!^*NQ2;G.,!JI M6T\6KX"?2APLSQ:QC +G>'Q&,8^-85IP2TCJ@R,=V*]0TN^]J=)82H&)8 *796IKV;;=))919G8L4,9CQKT547@6A]A]CXKE.5+AEX77N9G=CE M1#G'+FXJL[ODJ;Q])S4[&]S?C@5EQ.GJK1E16:^RO&Z'+&Y59TM%20I*X;GN M0R:FQAPBVVOD-7#K6T\63,%'4MA+ALE#QJ:2!:@Q'(\?NY=-$%'/E-5;G'/K9[&.&%[G!['L7X"O.C M\@2?@(ZR-0%Q*LI20H@J\;OA&M M^.!=/1GKEC'L=(PO6>=6]M&QMF*:QRH[<>-%%9H:EPV(V-4LE3!3@!AG&-S' MO&U'JU5_,G7@5ZR3#IKW5B1JJ7+J9F'7EO=Q;X5$0+%^Z_I MCA'I_BF%;8U#D>P0S(^49 :96QVT=C?FO+H,BP6_DV#D@%?B5,P:@?7B$1BM MD,5STZ=W >=/.D6.M\QL;M0S;ZCPZO; O):N#J/"ZS.A!DD)91(;C/G#C.,0 MAU)W#85B*BE^6M"PV36- S7QS-Q9]CEF1X_AM/(#:7TVL5Q8IH$38]I6V+9#XU.";$^V-^-!-$^PTWYGN\J=J$1 MJ<#I5C7]/2,KV) N:\OZ/7Y/CDX,77DBPA["UC,Q%8L> ?-Y9D:(]A>C&CB( MK2>9CUZ/;\"X$8Y+DP(N,9WE<)E_B$Z)E4ZZI@8%<'LA6T#,#=A+/,GBKDEP M;H4?JD@4A1L_F*X@AM3NX%1?6/0,;W%W]G>&[(RNWCX=@&.Y9CIJJKK@-ER: MXEFV"(^)Y0&$>DA78ISWNG(5L@QF$ZC1J(JH"CV)TO\ ]UGV.@:TU[DEP_%] MF5V+(Q;Z+3I@^-U8N^-%HLM?&.ZPG9+$EUX[ +2!U+ MW]HW$]B>OF"7.:7SZ2QH(X<;_KRF#%R,F/$.]I8L+/H8?YZU:]BN"A&>0+'J MB*K?G@T3;\M\?1),; <0">NIII%DK*JHEUD,\238-4R:@ M_ML U2*)$8J=CEZAU0SF;Q:/9OH:2MC M K/Q3@4E@X)F-EFN$9[02W?8VU7Q'9,-'M1Y&=K_+T5>W@;)LR79:DK*S$<'S+VFIL6H(3!5V*XON/8 MD3"\19Y"FFMQ.'3M%'KJGR%(X &R2AC]RM;V,3H@0D?VJSFQ;#J<@R5-X8/2 M3VNF:M]D9<;,;N4HV-7Q8GN&'5@SW7>1R!(YL.1*)-A*YJ,.!PG*[@39BHJF MJ).VGI^.S*-7[;B6V-6-+EKZU^P]-9Q#C1SY#J_.FB!-!6Y=C=:QIZ>PB*@9 MT;J@?J(T.Q$TOH!J-4*.S/53U&\_V2,4N=Y\7^?([6 M)+>Y7?\ 6HB(1?S)\+P.IW . < X''W=OV&^H65NC)(=(;C>^/K?2:,LUQW[ M;CH-L,15:(DM7]$$QRHUS^B+\=>!P9QR%.L(.T(6=UNT[?(4]B=LRQGVS689 MAFQ@!C/CR(TB_P ;PTZ4%735PT3P3PE85S"A<]KGN56AN?M-0UE!L+,*FH\1 M,5T[18_ZZXY!13,% CQ,1JCNHV<9WDMJQ4N"S6VLB9'@_0,Y"%L3246"*(9A.]&O M&U41$3ITX'Z!)6(MWMI[",V:ZA:6FFRG;E%3S8;&)'C1F^?)T#$?V'*&M:]& MM5$1"+^7@4XCWN26!<-/*KVHYW M1.YK_E/G@5CA8-KN9?U\IYI46.TK/M0&UWVW1P.,XYCL^/%\=5LF^ M^K)JJ"6[)&R/TJ%+*C&M(QR]$=T0*G;O]B_8FRV3>4V=V$',H#YKI-AC67U5 M;;TDJI1HI(H8'+'8^()$^(Q@E:C40Q$=+HY 5>YI2=WD_.U?RIP.O7K['A,]7?76_M;+(X M]#@.29!D>/FQNVY$?'$!&M[')T#[F6 M-PAL%#S\&5WR P*1EF)7LH=7C^-8Q%RN_8M$?):19!WK>5,R0-)/8U>AU<1> MY?C@43VAZPVA X[;9<7-Y.)0+G&V1Y[WNX%X\)I*R&/(%89/'&FXGB^1U>+V>RLAP37N.T>O46$2RJ96(Y>:0AID6N'):(XU)%5GY4X%,O8+2%-EL [:"CK MH] 7,8&#X]C=V8,_,\:SB)%21>C:D:,L"G:K M'^+@7QQ76]-C]Q2Z^JZ.AOL[9>DPO(ME8[DOZ"W'YE[4GO!W"XPW[Z2&QZJ; MV)/8T;&-5J+^5/@)^+14[J*3!C2-@4>QUD[(-@28)<5RBNQ M>L&[*ZK'XX72Y)(1(K&R'->C'&5%5'-[4ZA0*#ZO9-;#JI&'DR.FBW60Y!;8 M-74=)^KXK;WC(DF!8#GY#+E@F'(^L&C8II(3*-R*!&KW? 69TKIG#,:Q>DM# MU6$VE=(;9:_IL-6Z/C.01<] )^06UED66O,!\:SEA&YG1K.THVHU&)^9O N; M@F*U-E6XN[,:[)1KR/*G5M<6Q1L(DRPRHT=K B\?C ML1EFW/6RI)&7 M#(@V>=A'-4QV#:WNZ)P*);.]=[J\RZ@LZDL>1D9\$D96;*M>PTM\G?@]DDJ, M$_TRK7"6R;0*]OV@*(HF*UKNJ+U4-9/CX<&P#4V/@GSR?IF6U,&)<6T5E983 M:I-HVLP;K6N#+)X;+H=BJ)SB$26U7*O3@:#LJ@VV&XH[;5D&O_IR/B=K/D,E M1ZN5(+D#+ UY8C^I,C'>Z248#O\ L=6,&5JHB]R<"S-5O73'LE489EUO2CK] M@+B$.DV#54N0?H60VDR%7@A!-,19$4%E238"JXI5+WHO<-[7CZIP*Z9+^FX? MG939/:Q$1A8\2*O=WN>O-7L%F&/55N$!<3F0LKFF1 MLBJ* " 5W5.JHO >+X.8V=='AW&:AO:=AT>&-E5'5Y+-M)P^JEE3[)$#+L9+ MQN4O?(0SOE7=Z.;P(YD8_=T<*19T5A5!&:*JO!KK%:N'91(TET8KE',@@/;- M20Y'.(UBL:G?\KP-6K]>9?GKOI83B&2W=K;SVJZSKHE@UQU4J.8R^MY@D:U# M'(BE>5SE'\\#J=HSTTLY)C8%LR_CY]+:?&[;:44EK9VF,8M#KR.GUF TQ"D4 M%M-FR6JLY2M1&M8G1514ZA8397HO#M/W:*:9%B$BA>B1^U!_/:B_/5 NSB&L\)P"(L'"\6HL8[ ME<5YY1$?)D%,]55SG/Z_PX&ZJCT:OK.BKU7M7M:O3K_ 5/]_ 5 M=4^%Z_"_A_?UX'W@' . < X!P#@' . < X!P#@' \N>C5Z+U_M^$Z\#RA$5> MG1?G^U/_ !<#)P#@' Q/8YRHJ.Z=.!B1KG?"+_;W_#?G\4Z*B]6JU>GRO15X M$,[-T3KS9558AM\6J/UT@32*F^ !:ZSK[U@"#K+8<^&UIDD0C/:K7.:3HB?A M_#@5EP?]OW6L/',XK]G#@YY-SFMET_URUXV4V*U#;$QSH4..9_B:N M>L85J6 )C)0GM\:2VO8]4/*RZR_!,XH\BH9,B/$G&JK.):/,( MQ(\FU;91W]K8@1*J(UCG>82=J-5%Z<"3,/M,TGSRBL Q[AH4$JODB10J]J] M> Z;I]HL/Q;%G:0]<(5%8;(SC.<;=D&3QO-E59!QZJFI)J<9GW&029),FNIE MB ;C='N"U&+W(KD3@:-AE)N6E((VX;%EU:9YF$:TK)5C.8QM\MM8MPV M97XC$L'QPY'0?ZB64S$ MM26%Q@68D^-DF+VF55@XV%46)5DA)395='C(-4Z-[.U4>WHJJG 7[*/: MXO:W&1V67X5,RC$L&B:[V'MFFH9!LMQK++*2CX !4\6N*0C+ZL,G>4*-(O7M M;VIP*+>PGKYW"L\QPU;N2EW84<2LV .TGXX3(CV$P\K(L>R;PR?U> U9 &/< M4#%-&3N_*B.7@1%/IMS;NRK$8&XLUL=DXS79#<2J&-2Y/+D%J&2ZJLIY^K(, MT]5&C4#94&'W2'E;(-)8]B]4Z]5"]V%8.;#,?K-=0K3.XN>Y=^L8(7 8D1EY MK>1?DA+^AU>574=V6:Z=3LS3&,MJ[%^, MZSQG7&8TIJZJ=M;7K@%R&IQZ:^O(YM8:*Y/&7IVE>Q45'-_$*Q[-P2-O@=F, MTH^P+^BR=E'&UY&JI-!5XIC5?'KHU_ H)KQUT$I*CQ*]"!8HQN1'=55.U HO M"7V&QBGO<$PW9%D+#[J;E-UB##%8A?)&9W+WHY.O O!K*PMI2OFU6?W&+V&T&4F;X3:7N,2/UG*L, MU[%(W+)6P2R&3GCD3(D4S1=[B*1RL:YJK^;@1UD8*F6\F,ORJ@PO!]IY9DV5 MUMCA5382Q[)QYE;)05L<;>Y>G<[H@4$S'56P=+9K39 M-KJ1::YR 4.[N R79-,INS:.VL6=]RP=5E171907C*Q'%155$3@ M8\$T_LC:>?7.4[!GVV>[XTKO?HC6N1 KQ1X'D>J,)V-88W5QY6< MMLJBB3((0?O%IJ2T$;R6](Z+"CO*MFY>J27*BM?V*]RHJ.V6-D)'L\))*D M8C5ZHH,6#QLA#B5Y818)+W"\EJ"1LQQD\A@["RJ8@7)#E &7SECVU:1SG".K M5(S_ ]'(J] @K%\#TKA=Y*R6MJKS+KP$J+9P:&R@0*"J:9BN=%^W/C2YOW& MCD=$.- ]2C_*G;W*G LKF.57[!Q8]@-Q>Q=!=7)+C8^9XW9AGB>"L1A%KW@> M-&#C,KB0W1#PG%>B/&-%'U7X3^/ K8+)/^\'09G"GU,&O]@XB^#KW(Q7*U?P4)H]2\A-)9D6$UTJ5CDW;VN/6&VM79A($9A&ML(%90V^.2"-;UF56:8D[UA4EI&#"N9EC(U)&9$.>NL(3P?3DB;X(I'N* M-5;'5$#]5VC0>'46B!HYCV?U7I]C58SPHJ#S;/7-Z 5[OJ,['(B!5.H^G;_# M@=2N < X!P.0NXG 7U+R=LEXFQW8SO\ <93*1@>QNTQJ[SJ)%,D;HOYU9^=& M=5;\].!Q(]7<(Q3*,,W9FL6STUAFBPV4[@RRHBGK*'8NU[+--?4>453 MJC([G%)6)XGCX[6UJ)+DE4D3+;*DD2X44S?.D4@U*G.YCY+Y,@/\H;E[!C7IT7@;=AT2_@B/"% M++4@N(QJ^3"K99(3K"OF#_F M9M *7V'@/GH]I(S&(XB$C@5$<)%5'=>!'F1:OSJXR1V"5]6S)YMX)LZ5$O(X MB1(;"->R5(M7RW/AQ:\49.KWD[?_ %U$Z<#8<^U7Z[8"&LF9;DA;^CQ7'*O' M+*56.9)7),M9&::11X_/(0C) ZM7-:^2GDCE ^MH:"O"QS MI'5%$P7?T547J&F5.<1;"IDQ IK+1IST<7+EWYE4^'07<@S+'UWR$ M%%>@E^1U%KW),F>P?>1O>Y/A$Z-X$>[1V'D!A'E87ZY;H#9NQD52 M2@Q/5>356-0Y-:]DTH\?4J*.3(MRC1K#KV.17.8_N1$Z PZUV3FLMM<_.-+^ MU,.H!;O))J)NG[ZL&>$D'L?7S:.#+E1B072GHB%5RN*K5?T:O1.!+<6^Q0ZU M$Z'J_>NL*\N1VDJ;@D#UYR7,HT"_3J.JV!'M9TX;X4GJUI5>J(YZ=45>J)P& M^/>Y$.MM8^0RO8"QBP*(V/VB0-#Y;E4O9F1RYTB179^Z%<%'^DV%&$JHY1][ M^WHG=T7@.^4Y+2U>.3ZBIT]M_*Y) 4$B)G\+3>3UN=9#90P,D7,7)3B>K:^& M<[$02,4G16>->K7=.!6F#M#;P\XG(OK_ .T574FG$(^=6ZKN6U,^#(KB%&T5 MRD@5K 9'+U V.@^Q"='*O1?@+ UF64L^-0Q96F]]8QF=5CMM(C;ELM*Y'>7] M/?D"@'5Z5#WAC73K2*KFN,[HXB-:UZK\< -:W)05 \1=O;'ZR?1AHZN-_H3F M6.EU=E [$5E:9Q$JX<@T:0TL:QN M_J&LQS/O7C(L9QMH 1SMN1%:)41&L5Z?/17)P*[YYL+.8L[I MB/KY[/6U8[(K286;6:IO32AQ+0+C!DBIIQ!#+%K9 4$Z/Y5Z.>US%:B*G D+ M&-B6$BHLC[$]=_8_-Y),8% !BN2:ZR4L QOS+,84HW/'7F-$D-:J!7\R,4;E M5$Z\#<;.R"!+>'C?^OF,2TH*5N/R >M^1!%1XM%\$NQU='R>-+?9+'L !=&< M5G51L)V(U43@5@]A+T$FUPB_=23,<\,B/;3:>Z@6,";2#%MV8S_M6'("V5$+ M]=4[G':][T5BK\KP*XMR*^@TUMY/;%R/)*.PGU-@Z0\E-.;$@ MF22,XE=WM"K&N$JHYO B\-!J(9!-A8/C4<[@LBU@06.>IV#6,2.,;Y8(0B.4 M8VJC6HJ(O3YX 7"L.<:3:2L-PV>RRA0FB),R+,0%<<8T 9Z.-$60*:R.Q/&B M*BM[47^_@3<^;;;'!41[:QPQF=X:"SA:WK5=9/K\RQJ7%&V1CEC:VPV!BY75 M2(PC E&16R4[OAKN!,=;@+[#&,7R/&Z_+KI]B"T#L#$;"7#K(GV(XE$]K7*SJJ+UX$NZ_T%AL6PI+FIW9N#6Y?"KK&GR'$*J?"E M2B@\HZM(CCR9%G(>5K4$QJ*X:I\K_'@=$-6:XS.QC3GX_:Y/2TU]# &=G^60 M(%58FBC_ .M9A6OXS$CTO\.! MEX'AS$=^/_J/C^[@>^G . < X!P#@' . < X!P#@' . <#RK47Y7KP/G8G5% M3^"_Q_\ %P/?^[I\_P#@O . < X&$?PY47\?G_C7K_R< )^*?[O^)>J\#PXG MPK>B?Q3XZ_P_#\>!$^T=44&S:N V5-L<;RBB,LS$,VQ\B1(LZ/':UH2IU8QW7HOX<#=K/74K&,,-)E2:P><7LFWR&;" M%:F!0830R+=TR.H9XHWFR0]'6HH9D3QM"9ZH@>J_' K#:5^%VIFTT9:>?@-B MMK(L&S8604DK,LAM71?U&X9 APFDK:FN!$ ")$(U"E4?<]47XX&B7F':5JDC M)-Q#$#PT>./&'%7/>]OB?X>__*UKR?:8-ZJ]J?D7@+8V):E,"#%AX?A<2(G> M8+V-SN+*0D(O>*4,S(*284UKWM>BL^HE3R@(Z;E ME]?F<6.&)#C,L[:(X@HD5HVJT2-\A'?F<[^' LQI[(:YF%8B;-9%!3!M\/P^ MONYF3C&UE( 6*W!WEKX,]O;978#Q1= /1BE[W?P3@64=D&(7423;Y?;^6TO=\]$#0,[]D]3872 MR'8MM 0Z:9CF/7UO46Y5R7) S&MAB">[EB"R/.NH]<-$X+6=[5Z_' -= M^T&NLZD#H[C:V-UU'<9B ^6^?RR)-Q'JTC$-*)E4J%&D+<5"E:H)/;W 7M:Q M%Z+T"0ZC,M;Y '')F.['PJ]QDF[3S]*_+W[,"1@W5\Z&P)6EQV:D3 MN0I$\?B>UBK\JO 969K1WE?EV[$2#>FEJ-B,J[>54/%)8-J_]8CW)^=RH@-O]:Q,>C8+"Q.U MTQ;P@MCRM;V*9)6VK)EU++/DY/%R>78?6G0JR/#*HHS7]S.Y!HBJTCDX#FZS MT?$825:Y7BTS'*K8\=V.T&M=AO;.J,EMHKAY/?74V8#JN/QPI]=8[6#:6.SI M^*HJ!!N;>W6O,8+7PZO;<*=C4*VR&FH3$-8QPQXH(SE!7Q)\$$N10Q8T5#H- MZL1DE$0:_+NO D*D]A=-Y?C,HV9;D)48U0X,^!30\-:''[ZI=D+XX["#!7P] MTN/85,@Q7C?W)\(1WY_C@;U+R:I%(GSJ?,M)7UK PW%L?&MKGD>7*LM3(R%V MW4FFF";"3*OTN*].SR-()".5/S.1. V4F18O?FQ$\W*M.XO+19N,WMZ[);R95UYI*4S)T]J#'^FCD(XT6'^9&A*C%1>G7@;5@N28[GN&8W ML1D&ASNDL_5;9]Q'9;P>VDR"')V/&JKB!;0IHT442WAR#1#1WC1C/A6I^5O MYIXMMC(_7_/L[U3%OY&4T^D=D99JBO)=.DR/ZEP" &),QJDR1YGF9-7'*6>. MO>=_4JJ!I.O7XX%RJG)-#9EK^5,6IDX#/SJ8L+&,F$S]3AXIF%:1A)%)?()! M(>/81WJ@I?Y7,8Y$5>J+P(NQK%Q1+Z;8D6,3P1)4F@DO\ '$D%&@Q4L>L Z?%(!$&P09I((%\^XL[4-8"''K.MS,G6-0 :L$P7>0KFC@0P? ^B(U6+V_PX&@G M)$SN$[6V=2VV%=)AR)..V\A\@EIC5XP95A"':$+VOI3RB-4L=[U1'+U:J+P* MS:"]?&.T?Y"3$5/OJK?E9+NBF_QJGYN!U/X!P#@' X=;AW-!I-/4.!XQA4G<6P\H MN=\U=-JP4TU)766,U^P+!CG+P-6P^C@8P>?8YSL@^9Y4B(]:+6KR31I)K2M<^-.RPY7QWE5ZN:X MHFJY%5$1?C@==-$[XK,ICXY VIJB'5ZMIT!!J,ISL[ 9'COA$_ZZ.NI4<)+# MP,\BL&)CD(HTE0/*0E7(:CNXSF M@:14:JI_#KP(KRB-:2,DME8Z:*+62#I'JQ*0+YB1%8^78$1B-,60!1J[N14: MC4_!>!ML_*JTVNY.2R,H@7UYB=.V+)C?JXW3;?&KXSJY\J ][6(;ZIBH-7,[ MNTB?/RG3@(L&RNF$@)-4DD-!&EB4UT2&KYT2\@L::!$%&*J"/%@J[N/(>O\ M,6<4FNP$RQG:B]8,UJ8=C'HG4MQ06IH,LTR#%SB);V,ZR4XW=&BMY=8K?R MO_F$5G_K*<"V'H5L.LQO87UY<=QP[*U7G^JZ8RO0DE,VIDK=C8W11@OZ"/.R M^%0V (:HJ/)(C=J(JMZ<#M[!QRDSS967XM:SKZO83+M9D;88G H1HUS6+VO:O15Z=>!-J^K>&*G1O5-GY O5?[? M\7 $]7,-7JBYMN?Y7K^;:%_^/]O5'?'3@>D]6\,Z]/ZWW-T1%_'9U^J+\_@G M5_XKP//_ '6\+_\ [VW/U_M_U/R'K_\ Q.!]_P"ZWAB_'];[GZ=.GSM#($^/ MP_\ 6_[%7@?%]7,-5?G-MSM_M[=GW_3\$^$_-_?P/7_=G_P T M_(.G^Q/S_P 53@?/^ZWA?3I_6VY^G3I_]\[(/C^WY[^O5>!]_P"ZWAB_'];; MF[>G1>NS[]$7^Y4[_G\.!J-OZ.:0N[%ES9KGTRX;$)"=:ES>U)8%CFEMGD88 MQ$=Y%),&TBJJ=>]$7^' :9?H'H6::.OX=5X"8O[?^ MBS2B3#S-G22ND!G(A]@6)!-F@3L'(&-8ZM:96IT5>GX<#XWT T8YSG%E;,*W MS*9 'V%8E"I$=U:J,6/\-157HG7HG V?77I!Z^ZTN/UVDQFYL;!OV$ N2Y/; MWD:+]I&>=\:$9CE"%A0JYW>\@ MGO:]PWOBIP-RZ=5^4^>BIU5$5$1?GIU7KU^>!\VIT1$7_P^>!]X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . M!\_BOQ_9U7I^/_/TX!^/5.G_ #+P/O \N_A^7N^?X_P5/E%_X43@?%ZIU7HJ MNZ?'3X_'HG1%7\/PZ\#7)^)8[9N,^PHJ:6XZ/\SBUT?RE4C%&]2G8QI"JYJ] M%ZK\)P*L6/H=ZY6-I*LQ8C;TIYDT]@05%E=W A@FR2_:/)A@^P58KRR%[E:- M6L1?P1. E3T*T+YR'?'STA'RV35>3/[MW?)8BHDA?SHJ%[W=Z_VN3KP% O1# M0H4B]L7.7+#.Z3'5^>WJN:5[2(KWKY$ZN;YW=$X#<7T"]?Y'5"1-A.5)[[%" M+L3(6/64].CWJK3_ /5]%Z(W\/[N XIZ(Z$4$82P,U18Y"%8YV=WCS=Y45%< M\SBJYZI^*)_!>!G@^C^EJ8P)%#_7--8">%R6\/,))K%XHT7Z@8YBV<.P&H6 MKLHJ^K5^?S(Y<[^K*[JGXHB_\ RN]%Z_V?PX OJ=AKOAB]^:;4>JIT7ORFL=U:GPH^JXXJ]KD^/CX5.! M]7U*PE4Z+FVU5Z(J)URFK7\41%__ *<5$5WQU^/GIP/O_=+PQ$1&YOM?M:J] MK/ZLK$:W\/EK?Z=[4ZKP/?\ W3L,^>N;[65&K^1%RJL%*U47-]K+U5.O7*JSN5>[NZJJX[\I_#^*=O ^?]TG!^J_^G/:G1W;W MHN45?:O3KT3I_3ORC53X_P!W ^_]TO"D^?ZVVLGX]>W*JQ%T]3\/:BHF<;8;U_'MRVN3X_'HB)CO:J(J?AP//_=-PSN5?ZWVOUZJJK_5 ME=^/XHOSCWSW?Q_LX'C_ +H^#JJ.7-=JJJ*OXY15]>O7NZ]?ZK4A$&'CTD"=J/MX\5B2'14_G1D(:-\DB0]WB'U5'$?V]>K>!'^.6%Y+R" MOJTGRB@.TL-@7C5P8YT<5PASWHC9#()GL;W,0WTV21HK0HA(T&IL//4W<4 !M4K$_*1'JO:BKP-$P^' MDDQV;JRBV1AN/97%R6N]>MRU1IT+'L@A%%)!<^ON5Y!%E/UODH)2>:-42 M&3,?FR&L:C0JJN0.MGK=MK7^P,#UK%Q"SGO_ $7&X3GP[6#VGBN5CE1 [%\ X!P#@<6,MU7D#<+P7 M:NFL@J<,W=B^2;SE89D>5!'88A.K;;8EE_66K]BP)1QH76^QS,CL85JH2HMF M DL<@T>U0JO-_+VBN$HWLUR+P-NL?8WU6?34]J;3%3C. 9U,.[%=T:SIH\\@C0V M-E3JF51STE/J+V,4R(^$3M>5J(\:JBIP-3S;%<+_ %^EL[S/+/*\'R<338SE MU*Q;%)0!*CGULVM1[6T=G"$1K9,1S>X:L56+V]> JL&XU@E["L<#L*:3]A6% M!/M9TZ!(D*\2-(^/)^L\;.M-??H]_)R^TC5>0WM7*6! M.IVRIM2)ZCZ_7L7US5:!9[4Z$?U3X_'@0;$JJC-<5I!51L9BQ18_?A:C)I(" M?9JY8S- T'58Q(\P"KTDZ M3#^RCB?7,QB&%*CL3\A%;W+V_P!G W'"/3#"KZGR6C@;&Q@FG,WLX\N9J795 MW#Q/+J>X 418&18C8N*YL*SAN7HU4:ULAC%1Z?*\#2)7[:NU<$FV<3 KJMR. MJ!(J,@PW86*9362,BP?+LUS3/QQ&(*E<^=,2=3C!9, M@"8]PPJ5S7D>K&JY&]B*BN;^9>! NR8^M[6'42&8]56^07-[%BRHT5J(K^G1>!J>6V6/5;CT!$QT583(!UM581JFPLGU5= M%%'1\Q[FO4LV8LHSE&T?( M2U"7L$LB%'2,QOG/V=6*C4(Q/P7@;S'H<(RFN?>WM]$I&QWM8Z\C%-("^0X2 M%(^'6R&L/,[7N5.JHYKU^/QX&OX7+JJF3=#%L:1CN&U<=Y[^?;UK!UT\9'D? M&!6U%B]XI=K8/:C? WM7HK?GYX%B<G@JXB/E2%08E7@3AHW5V51[ M:#N;9UUB=EMC9_L-I._S,&OHOBUW1U>&5N3X/KO7^$6#W.E9- P>N/-#89#( MZFO+%SG#:..T36AV@X!P#@' Y*[-8POJ=E0%1ZD/CGL''8V.T;IKT+LMXV?4 M<54']MA'HHD=T9YD:J_"<#B7[*0XF?ZQA;"M,!V#BV:2H-G2YQ1;)ATX,M/F M^E[L."KFF0MQHYZ);+-,ZC5[D1_5>!"WJQ.R*WP[V.U]/C?8H8 M>(Q,[I5FQ4-6T>2UA7M9.KXH6(L:3/3L&1[41ST>K'IT^.!9S20FD326K0(-&)]DM>5_>K&HU41K5^4X$V)A=S!I4I[.4 M6#:RF E"J3$64:JKS25$PWYU\L60?M3L%T15X&HYWA<=M9&JK@LH>.J\0L@9 MT=^MV%B%'?1@BC,4?T&,8_JY57J3JJ?PX'NIUG0Q-9U>)FJ16=_3_JMZ&?&, M>-(OUO5SVKV_'7@1_CBSC9!5LA@?#@5\F$4:#BEA MLJXT(IC(..!_3Q$8YZJ-KE5>J=W7@2KD><55AD<%N25[[" :10I>-#*?%GCJ M)$]XGB"7\XQ3#PWN:UR]41_3\.!NB;^LK;"QT-D6'8_@DBJ9.L9U2P1,O MQ[S0 O\ #DECTDSY)7!(UKVC!R$S3),6P"W05C"RC;N92E:<$F1 M)/CV',D0FJUB&)Y"6X.K8T5%=U1$=UZKT3\>OSU55^7+_P ' R\ X!P#@' . < X!P#@ M' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < M X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . UORYA6.5JI_8O Y3>V/[<-/LR9;[)T785VL= MPW+(8\EM3U9+7#=H5=7&0590;9QB.>/*ME@#$T4#(*YX+VN9^5RR0JK$#D!3 MMV;JW8K,%SN/;ZLV;+K;"568K;W<:_QC8$* 4OW[#6.; 8#',^B,:+MD17B! M:1D5$D1FJO50M1JS7M?M^_A4F1XL"&!(TH(LQHI"U@X]@%R2RONJ@K5C,CUZ M/52*BHCT_!$;^ 27GN<^O.OM89]A.-I.W1FD;Z- +)KL$>104IIGGBHY4X%.<6O)-W3W]-*LR EVS(P8DIL5(Y88/&1H03'B> MB$C(5.UZ(BJC>O5?G@,>.X+D]K=1JIM!,L8UG) $U6*']R*<,%S3,LP2TPL3HK"!4Q!TE?#J==SI5%8K C.@3)V431-)-#:6*D M+YA=RJK'N=W-^.J\!PJM>6UY4)7LBS;4E;4LFU#HT8TR5440^L<);J)'OCLPQHXCHU/9AJQ1F&:48I#[*PK3CKC.[ ME>]BH-6IT5BIP-.W_:6L/,%PID,1<0US$B0<=J(YN]2D\0?U;(/L+([GV4^0 MXCD*YR'<+JGE[/C@(<1O+C7^$Y'L["<+V58Y-3;/U7ZM8-:Z^PV'G>8XME&[ M@1/Q/!X\UST?C='1K6@,'Q]KAM3L$J*UJJB=5#I]P#@' .!RAS7'+7,/6 MRQQ6DKFV%SD51[ U-762)+8<:PEDV2:2X,F:1XV1(/UXQ"2"(Y%#&8\G5.W@ MIJV)Y&*C'-X%BM-R/5G3U=,P>/9P\PJS%_4\TM8@$B#R\U0+[8P MME*A9<+#H12-:YB.52MZE=?- GDD3%I+&0J= M+"PJHA'?E1%3@/-G7@0]E^7VHXT246JA117(W)#G.BRFDFF>08GST>U& F.CD557QJK&HG M1>!&$&,V7(LK^VD/%CE2>+;9/:*=1QHH(2A6!BEG5:XV)D^\M=Z;;DD>+#L[;":+-;RQ@95F5!6SD=#DWOU< M?4,,1F. .5):547M1%#OAZW^F>G="8W&B8GCE>'[HX\ZRE%0EG>Y/8?]:6^S MS+)Y"W>:7S?O'[ M$8]['W&B_7K!*>\D8+7Q[&XA6%'-R#(,P(RAA9/;LJZ\%G6F'65M5-:C61&F MFF5A"-7M1&I^7OF!\W_.-CYYE\.\'V>+-DV=(ODK;';)DS_Y=O/[B=9LR7,H-LZQRC4-K2(X609?/!)_ MTQII 1^0K,GR*\C4Y,&,1%3L%8(YJ]43RJJHB^T^ _.W'Y1N;=L[]VS==NWV M/ADR]-K;6DQ&L_%R7K2=O/LC)&G_ 'GHWS5^E7>^&X,?=/">\[+OVRW&DX-K M2:_ZAEK,Z1.WP8K98WD1QZK8-)C29^'$1.E>?9/][SUZUA8OPW0M':^R6=DE MNK1%QTTFDP(4_N4301,C?66%EE.=JR?HO M'Z7[GOYGICHF:XM?9%^F9R3KZ8ZVB?\ B?4/E)_MW_-3S+:QW_YF;C!XCXS% M/B3&>*Y=[-.WN+2VGTJV\5XS"M(T:1("-Y@N:UJ- M?ZYX_P#-;S>OEFR[1Y7L<6':=RO6,=.BV/)CK>TTI>(M:UIKU1I,7K69B)FN MFFD_5?F;]&?T^9/DMW_S?Y+^1;O?][\3P9;;K/.?%N]IN : MK%)$8]"-[NTK>ICRWF\1,ZQ,N2U8TX/U?][O[?\ B3_FYW7&.]W]O_$G_-P# MO=_;_P 2?\W .]W]O_$G_-P/J.X9*JW!&$TA6K76'YRM< M[^8-'=%3@6BC4V3U-L4=@)'-8YJ-8Y51O MX*[I_#@-&)OL;BD(76]K8Q2.]ZL+)IRC"JE 12L^> MO1.!LA5JJ0Q,W@A="OIU825E6*B>Z17L$YJNM20Q-Z<&QB33#(HPO5 MAQM559\+P)*VKJ/36VI,IFK[>-/S3&8%?6!A3D$&5F=#$0J@/@.C3'?GF0WQ',<$SOSE&K7.^57@=1> < X!P.*'L_<2\ M8]*LRR6!-GQ[*DQ/V.41ZQ)))T:DN]B/HLOL(@(C72"DJL3L)3W*U%48E>]5 M1$54#CW0[!JJS,\@PNREU^,X]D>KTUKB-W$>]L7%J<<.$+'9S&Q^[P5]E7A& MU3"^&#>ORJ.5>!I&OM/>Q=+F%2UF!2\OCQSQA1K#&VMR;'K>#,:6,*75E@DD M"G0)0F=I!._*K7*UR)_ .FU#A>%>N6/6V0I+=;[CNCUN/Y1K"YM/US$-.5=^ MPS"Y#CGFC/-%R2I*(;'PSRCAAM(Y$1JHG C+!2YE*FVU3CLDISRT_5;LZ"=( MAT]85.XN12)KW^(+$&Y>HW.;UK?/">)ZO:]57L5.COPX%T,0*+O T_!HY=)AN][;-B"H)T>EN@Z[Q M1\9M;997F$\3HJ7:4I^I1Q*X!FD&=S6=")VHO5.!,GIAB]OL_=F@J"XDDFR< MOV(;9SFA"LFXEMD]]DMJ-5([Q2,HM(-6)KNB.>;HU7$ZH@?LWIAD%65 MXB^-'B@Q1/07P/O8)K7]B+\H/N3HU/[$X#GT1%ZHG]WQP/G>W_UI/[?_ !?\ M/7@'>W^W_E_#^WYX CVK\]?A/^+X1?G^SX7^/ .]OQ\_C_9\_P"W\/PZ)P#O M;_ZTGXJG^U4_%$_MZ< [V]>WJG7XZHJHB_/X?"KU^>!\1[%Z*CD7K\)T^>J_ MW=.O7I_=P/OU?P7KT_'I_#XZ_/\ %/C@'>WJJ=?E M.G7^'PJ=>O\ [ST_C_=P#R,_#JG7^S^[IUZ_W_E^?]G ](J+^'RG]J=%3@?> M < X!P#@' XC_N!Q9F@O;3UZ]JZR&KZJ9+K*3)E$Q4^Q.QLYHLZ,5P^CG2[K M!;TP0(O57+!Z)U[>G/R1\[,67POYE]C^9&WIKMKVICRZ>ML4S%HG3UR;?):M M?;\/W/Z(?2]FV_S/^1_E?R3WF33?4QY,VWUG^FF>L6I:-?\ #AWF&E[SRCXW M'374V>QG[6>Y?<3V6RK.]S>T-DSUJF3:NWU_K;'!6AKRCA)45L-CNJ-^@^1_*OO7FGDN7N'>>ZV_Z7M:M\.&D6ZJQTUC MIZ+1\.D\)_S-+VG7C$>G)\I_K-\ ^0WRCV7C?R_\-PS\W:8\F+>]PSSCC#FM M.7):,LYL4SN\U>F:UC;=>#%2:STVM'&9?P/]M-WKKG^O+/U8O\"P7%*N]I)N M?7^6XF[*=U9'55YP%M:PF?6J6X3UUV$91+"K8^/11>9%D&J->*8YKG(BJG7UKPRE_.?G!W#RC-$SV_MLVKCUCA%JZX<,:3RG2,F68 MYQ;B_27SXW&#Z=_H<\8^3^PO6GD_E>/'FW73:)FV/)T;_>WBT<+4Z[[39UMQ MBV*)B)F(?I4Y^G'\D1P#@' .!B. ,D)HTD(I$>0(@)$&YK9"F1UO(264PU9&L>GWXN M.QK2?.A8Q&FIU:1E>.,UPU4?3Q_EYBN.E9ZJQQ769X2M#S:#@' .!]3\4_VI M_P O _(-B?\ _P!JB_\ YY&:?_7N0\Z$?\__ ,3EG^C\'Z^.=]Q#@' . < X M!P#@' ^I^*?[4_Y>!GX!P#@' . <#XJHB=5^$3I\K_?P/G>W^"]>G_B7HJ?W M*G %>U/X_CTZ?V+U_#HJ_' .]OX=455^41%3JO\ ;_P)^/ ^(1B_*.147^/5 M.G_ATX'WN3_PZ?/]Z?/X< 5R)^*].J]$_O\ ]G3KP!'M551%153\43Y5/_#K MP/OOX=.!Y\C>O3KT7^Q?CK\=?C^'X<#SYA*BJCVJB(BKT7KTZ MKT3X3Y_%.![1[5_!>O\ L5.G7X^/Q^%ZKP/GD8GSW?Q5%_N5/CHO]_7X_OX' MWN1?_5?P_M_NX'Q"C=TZ/:O7KTZ.1?PZHO147HO14X A&*O1'(O5.OPO7X_' MK\?W<#ZCFK^"]4_\$_Y> =S?PZ_V_P#%^/S^'QP#X=\].O3_ &+T_N_V\"FG MO3IJUWQZT[3UE22(]?=9?AESC=-:RC?6B55_+)"ML2LY\KKU#5QJV,F*SI>4+-LL8V5A%[Y(-C4Y76O=C6P,$O(XPM M#'F5THR()RM:V0-6/9WL)W*'A-%5V=_;M]#9_7S(=AVRBX%,E0*'-\3,CWFL M*>WCS3 %=5]48J-'*9_+5$1/E5Z<#I%Z5:9S/7%J/(=D9E PC!ZZ2&1-"6]B M75C9!JRB/]*OKX)Y8X+;)SE\_E0?5JIV]>B\"?\ >>^;3;.;;$P&[DQXYV18 MEWJZM 4;H@&4#E/(KXZ*A%"&ZI2*I45K7*YG3KUX$-[0R&Q MV/I,K>J<#-G>;9>*'+78YA$EA$989LG<&GIC53NP]O!GW!1"(P:(UX7JJJB)\!.MSH MV%DD!^W< AR\CW8"OK)>TL$@Y 6ZPO660R*CMNDU7C8Q^(M*RS,X9/,^2:(8 M;E8Y$^>!6W%L+VK3Y57Y9G_VL%PVF-'OKO(K6'CS9YC^- M&*]Z]J*[Y_BG TS*MK0LOS$V0UYF09&/;1PK8NOI7:A&U4LN;5V/AHV!5B.- M5Y]%L)%1. CG.DQISAJBM^.!WYK\=J<0@8)B^/@?&I*'FE_P"KLEU558CE.?0-8:!;C>54"5U5FQ7325 M%"C(-[ED,;VECS)%BJI8!Q?\Z]45XW%ZKVMX'/Y(YQ&CL@S85V'J:5'K/&\L16/56O!%GL)O.!DMC*#KCV M@U?&R2I@=+['+'*<*-:XE?ED#CNKY,ZZ X2%:0+B=@C*\+E5'(C_ (X%%*[% MY&]<^)0"/<;^V'(:ZK6LUR61D+!63NATG6NQ),<6O-;X['1>X\N9)16)U5@R M+VM4/T<_MV>A;- UQ]E9^E/;[GS&N%"R6PJ#29.)XKBU?8OL,?U9KE)+1&)B MU39*ME:6;V-/=7!7O1WUV":@=;AL5G7KT^?[/P5?CY_N^$_#^'3@9%ZKT_L_ MC_LZ+_?P*P^Y&2YCAOK7MS)]>WYL6S>JQN.['LC"ZM&ZHF2KNLB/FH^Y82I% MXXIB=22$4;$7N7\.!P#W'MW]P+$<@M-=:]]H]N9GES,1'LC'<@PW#\'V;BEO M6V%;$)&QBPDXI@TY:;ZEM/=';+>KFR'QORJJ*O @R#[1?NO"-@XYA/>"=#!2 MWXLT$1IUEDA0M?4O@F3#&@A44$JJK2=GF>S_ !-5>!)NL=L_N=3Y5;3; M W][34LR8R1-MKB1ZX5,N@Q]S+.O2!3!FU&O?L6R$B-/]HZC8YC%56HJIP+3 MY=L[VBJ16]36[X]K+VTF??'"R7$=2MD55-T(L'>8=6_HB+-:9B-1/EGTSD1RI\(G 50-U M^USHURR3MSVRAS[:PH1U4:YU$$:T3%>\4\-62)KZ.65#EC5(,EH]:[T]E,DNL4CR25>61-&TUEC&RD/-"@AUB)K<1*&PJ M*M7.=',,;C&1%5RL=P(T_P"\[^[)^M0/KF]VI./-PQ*T3IVD<+KK"9G#I#E2 MYO'CPR0VNK&#)\,"-6N8U.J(J\":-3;+_<9M[:IHMB>RWM11&@#J#Y!DMOZV MP(6.2K29824L\?AK3Z\E%DU%57M&C[%@AD!/MQMGVFANCP![G]NI M4EIPR9MU0ZE!+JWOKIS%)7@%8ZK$]:VV@*K2/:U#)T56.8Y$7@:GL/NC.D5^/V:M4PS2FG.+N1$5 M43@5 L/8C]V['I>Q( LR]OTG1(LR589*V7@4*4.?4 MG0D<0&(2.1%[GHJ\!SU'[H^]%YMO3'XC%W5J75&9Z]V!A^L8F09U MF%OF5#29ICD^E!C4*[QNI8&P*ULF.]>JIT_*J<#]?3$1K51/A$_7^)B=OMS:&:56128&58?29I M''7-OH6,876QZ^]C38M?(R;*)#+W?=9ZY.G+BIEB(B\4Q1%;Q,5F^29_/$1:L4F:S$SJ_H/]$_R'\.\[[! MY=\TOF?DWV#P7LW;\F"+[;=9=I: M1GF&U>CF]R.1/?=O\P?$-QY)?P^-]A_ZEQ3%;8=+1K?IBTUI:U8K>U8G6:UM M-H]8UB=/R+OOD_\ ,39^%X_F1_I6Y_Z%S]5L>YUQVTQ] MU*TM,?EG28UTC-?>KU)U[L_&=-91O/"H^R,JR&'BT'&ZR5)ORUU]8R60J^MR M:;0QK&MQ.1.L"CCC;8FC*IB-1>B=53FWWGOB';NZ8NR[K?X([GER1CBE9F\Q M>9TBMYI%HQS,Z1'7->,O8/'_ *.=PMXELMK?TX*Y-*UF?+?J1::V?6VX;&54PHDO*99Z277S(\V>Z1-*#RN>56]$;\D^5GGG>=[Y M]WWPSRBNVQ]QIN,F3%\+%3%K&.\UO69K$3EUI;'DK>_5>:]4S:8TT^R_4%\L M.Q;3Y1>(?,OPK/W'<]CML<.VS?J=SFW'P_BXXR8II7):U=M6N:N?%?#ABF*M M^B*TB=9GJCS]$OQ:XS^Y7[Q&KM!7-]K?3-'&V_LZ@G&JKZTF32UVL\5LHR]D MJ%*MH:NGY3:P9"*(\6#X@#(CF/E-(US.=?)GK2=*\9:BLSSY.=\7W$_>:VU' M;EF!8-L.+C4WK(KOZ,]>ZT5"^,7^8)8$W+*&VL+*/V*G:3[!D>GRBKUYQ?$W M%N,1.GW-:4CF^8Y^[5[Y^O68P\?]G-> R6*]['S<CR5TP2K\*J?BB,^6L_G.FL\G?WU2]R-+^X.''R;5UM)C7-,D8>8 M8%D#8\/,,1ER4<@OU""$\@,RJEO&](L^,\L60C53N:1KQL[5,EU'=%1>BJWYYM'#7]O?]SC>GMA['&U!L+$= M7TN.#PC,'N543HJ?/7K8LUKW MZ9TTT;M72-7='G98<_?3I)Z8_N_ZI]A[F@UMMNFCZ?VG>'' IIK+!)N MM,NM"D[(U?4W4QXYV/V\][VLCPIR/88GY!22$M?'KJ6.5Z)!U1J&3GS8 VKT:"TRS)H%_"++; M\=ZM9$ZK^ VI\YKIK'-XLO=[]X72 FY1M'#)TM&>M$K%^7K+$B)\]?CCXF>O/7]AI6>3HIZ@_O):EWC:T6 MO]V4@-,[#O)@:VHO V"V.K<@G2.K8P&WDQ0SL3FS3JT00SD+&<1S6I+5SD;S MEQ[BMN%N$I-)CER=GOP^%YV&%0O<3W0U7Z8X) RK/AV-]D63'G0,%P.A4+;K M*;"!':>61\F2J1:>CKO,%):Q$SR M)#DYQK6YD"DSZH,HB ':_ MW>NH1VFM19( ;;C#Z0E@<&3V==[@H&M-[K%H"X2E;3&L])8/62S9TAW^6\R.8'"SQX% M:!CT[0B&]'M:G5.O G34.S?W$+:^IJ;8GLE[4TD>(E4F09%?>ML.!02[*4ZQ M=;5\ M)KP\E]/5!:!B3&C:\Q7]4:B)P)ONMN^U$ L:)&W%[Z7"JISD&0)):'>G7I_;P*?67L)^[ MGC1MCU8L_P#;3.);X3(&J[Z'H;%Z>FDR)$4+SV=Y%L,'A36VD.1W-'&&-XOE M.[JO VRLWW^Z9-JHC4_B%O:7._;^KQ,-WD?LW[(91+4MFB54;3B8K>Q9K9/961[ M"-(U>M9-K'B17M\)VG>CFHK?A> 1=L>UMI71Z-^\O:K'KBTOIR&O+73X?MT= M/:-0<:0V#$UV6.^KQD+'2&]\8DF7U_QN;T3@5"V-OC]U($9'8'LWVG-(QN]@ MT=S"B:5QR[D991O))D3,NQF>3 !P13'!8(38,M@"-<1WQ^1>@-YU=&M8=)"P2WL-*XC%KZ22,79;6N3F7"IJD.\Z*18XQN8\?PU6JOP$ M^ZFV/^X-D%D^+FOLO[-4 :L#X8Y.4^N3*FMR^6R@>^;8I)HM=SY%#&!D3&AB M]$=YQ]7.:B+TX$O/W)[00*3=J#4K)=;D@_I%CRX3D=K2%/ MC4S+$K3!)&4$IXAM153JY%",L\W%[WUD:):8QN#VHLA7@YE3(K:K3$>3-Q$C M[6'#@9H^%::W0LVJ."S(]8R&*0;8/547OX%/+HJ* MB+P.X:.1G\_[:I=JY$3<>G9=+0[1 6GE74/)X?T&]B,>RL4C(_7O,2O"9\:T M?K++M:9;320/D)((:NM9.08O;PAD1.K1R(HT3\5'W(O FC9QX^ 8])U2S6FS M-/9>'$3YZM3LY:.1)V#AE,J1+6[P?*,*NKG'K=^.OD-277O(V?&85I'L[5[N M!'NEQ2=A9EHS8E9/-9V@,I@ZKR2*AE^Q(4TT4BCLI,!Q>B_+4 M5>O1.!.OO]3X!K?:K+/9]?*O\!PZ _#=.:6%<2PREC*%%6167<8R]7G>Y%>SM>Q>BIP*O>INYO=UYE9"UM MB.U,NQN!:X@/5V+)E<^VK(E,?)\TR6M6$.38TY3-"@BC0;>Y$Z<"L^=0HWJU M^B[*WE>8**\B;&P6BUOA55_4&8:?P/9^93W0L#V'O'95)6*W++7%)DQ"4V/8 MZ$D")9#9)E]Z)W-#N=H_[BZ7]?"3YJV,\^;JK,IQ7>L#/+?V"RB^8'=V!4\+: M#<.!X)=+DPJ_ *1<./4RW>-M;*A"F(6*J>1!O554).WO;6$O-09PV'+3"O9& MXQ5U+E;Q3*_'ZWV#P_'XN%;1UEG(U$M'[#V.^/2K34$<%@(OZM<6KPPI4%H( G1/(Y>Y$ M3M1[NB<#YDL'86_&QL^IZML+$KF /^FM@[BR.TUQ4[ HH#!#BR=88-%Q[(LP MD8HSM5&6,V'7QI#'(X+7M7KP(+S;5>68+7KFF4X\2BP69(^B;-\8L![*U5'9 MW(.0F17U#$K[O70_YO\ U]O6Q8K%" M3IE=GNTY=F0-V%1JW6&MJ5(8\XV:V$%SWNF5$"0VKH$16.E74D;!]/&Y4#]$ MV!>G6DL;P?&\1=K[%P0,?K(5= JF8]0&APHD1C5 .2.372$LK8JN\TZ;(\LB M7-(4KGKU3H$X4.H]?XV$,>JQNJB"#(24P$6#$A1'G8G1A"U\($>"9PT^$[AK M_P 2<"1F":Q4[4:U&M[6M:G:U$^.C4:GQVM1/A/P3^' ^.O3I^'] MO_)P,O\ 9U_'_P!1P*1_N,X\?+_2W?F)1#0 24/V'1VD<@6$^6H[JJAU^21*;U5KWIW*YSN@)2]7 M+U^.G5>G1?Q3@'V9O7N0CF?*KVLBG8WY;V=7-3X[NGS_ '\#XA9#?P5_5%ZM MY/\3>Y>K4 M3\$3I\IP.364>C_LY/\ 9&^VQANZ853K3/\ VSC[AV-K&XN\MM8A<$H]:7V( M89;X&Q2M@X=G$.ZM?^V*QO=67$5HBJU) &N4- E>C7MALS$*7#=A9##U+_16 MEM(:AJLKP';F1Y%D-K>ZJVF+/)FT81@5]>ZG0H84=CX,E2'L.\DB%UQ8EQ^FS2IRNFP_'Z MS,_&>#C[1N9%B,[Q%0ZJ[@/VJ_0K?&O]S7>:9?0X7LH%WH/#-98KF9]B&!-U M-EM!KB_Q2PR6BK\BQZ7ELETBTLQ)WQK 82C:XJ#1S6= L%Z ^G^WO56UV,_9 M&8TN:$RG"=8XQC$_$ZZ/CM5 K\-!:DMJV^Q2NCC%:YF"WM".)E+G/);1'@81 MC' 57!TC;*E,5.USU5CN]'.CRC=7)TZ+_-4J*OROS_A_NX'U)4SKU1[OS.[G MJ2(9WBI^9&?X?X?V?W<# MRYQWN[^KVN[^[N;&.CV+^5>YBHB-5&JG5$Z?CP% C3G%%VO*YW>Q43PRU5R* M[H[KWNYWC^!8WC5CH['84I:FJR( M <%EUV/R17V]U[EO,].[Y[U^+DP3.\KDS5G#6^.>K+L<6WQXK7M7'..TZVUBT-KI-2?N M<_N*Y-<9\E'C?IMJG.5679WE912-=6V5P710Q!K/?7,!N/8JS(8&HK["3 J# MHWN:C4Z)SEVOCOS'^8>_S=XQ[?;]CV.ZG6^6F/X&3+&D1^:U8C?,#S;MOY<>')FC?8MM?JFT]$9)MVO8]-K3PP M8\^YI,Z3,\92L7]MN]]&)N,;)U;H^E]JLU_-,4V=.CHC6-8RQ;<7CG'1+TS']6G;/J0V^]\2\U\CW'A/:-WCR8,6PV< M5P5S8KQT5C<]WRQEG-K6=+;:,>PP6UFDQEJ7Z\W#?>POO_IC:VO=;WN#Y6>7 M0P=LU4>02TK4B5D.PI^< M?.OM7DG8]AFV?FDUI."8K,7C7JK$:S,PX_*O NU_ M*OZ7O(?"?*N[[;N79*US7[9DFL8\G5DO3+ML,5Z\D7R5W<6O$XK37HO:9BM8 MG2Y'[OGMK:^O6B*_76!V\RFV;O ]C30+JJF?3M,6P>F^D3,+R)($Y)42=8LG M!K(I6=CQK**4;VO"G/W1GO-*Z1SE_)ZD:SQ0#^T_^W7A-+K_ !CVAW305F7Y MCG=:"]UEB>05@;"FP;&9)%/5Y1*@6(2AFYED 6-E ,YBI7Q",\?\]Y'-Q@Q1 MIUVYSR6UIUTAWNZK_:O.TPC7:^G]9[QP^QP/:^&4>;XO9A,(D"ZA#.6&4PU' M]^HGHC9]+:@1>HI44@3BREN,7L;:[P4 M*1*!O]O:U.J_*_/.[$1$:1R<9 M^,H^O MEPQ,=5.%FZVTX3R<+_1/(+O*_?OUTR7)+*;1CD1Z>2816O8>'1"$:RD,5%0@(;F?"N1>=[)?HIKZN.(UG M1P#_ &R?18WN+F>2^ROL5.L_L5D-E.QJC M?+$LIB+_ )V0YL9.@1%8[K8T$&MKPQX<42*O^%C$3KSNQ$1&DBM>PC'(K7L>U5145%14X' O\ =1_;7P*SU_E/LOHC&ZS# MI/=;)P+&Z@4/'LWQF(]"6F15E16A'%J_JYL,: M==>;=;3KI*4OV;?<&TW9JRYT1G]K+M]@Z7@PI5#>V4XTZQRG6=C))%K'2Y$E MQ9$F?AT[M@$(YZ]T0L3KU=WJNMODFT=$\X+QI.LCQS*04]SD-I%:Y4&%YI>22"O(G3N\+.Y>C$Z<&?CETG MEP:K_2_6%K_7>$:HQ&FP+76,4^'XCC\04.KHZ.$&#$",0V#<$;8PZ\P#8^,U.88?D<,D&WHKJ*.7$D M"(U488?>GDB3HK^A(\@3F'CE:T@WM>U%1-8M&EN1R4 ],/VP]5>GN>W^SZ_, MLMSO-YW]0TF-RK [J6FQK";:>TD:F-45TES,DN/H1@-E39SR">8?D!' Y$7G M%CPQCGJ]6IM,NG7.9D< X!P#@' \$^6.3^U/[>G_ !_PX'$+]RW5/^M>^M38 M,VGQZS/$Q"DS*L+E\Z1"Q45M1Y=?OBUF2#BSH$PM/;@$43GLG_6+_ !7@8W&EN^7$Y4;%D=J? M"(K&M7X1BJU%1/P1>!Y4AW.8Y5?U:Y7)_EI2(WY1W3IU1BM[DZ_AP/*^=7J3 MN5 26.3QN5S$3\W8WJ]?QZ(J(GRO Y=>W/JIO_ &S[#83N'4+,?\%+ M2:WI"V.9Y?#D8W5#Q#8\S*KY]GK2WQBRM)$@L$KFAFU%C%F2F]HB+VL1.!H6 M+>D7N)KW)Z?8F.>S5SDMY2V7M]-Q[6^8WK3:OP.VWG6Y'"U9=U+H5'&RFZ3& MI5P*3-CS)AVQFM5H4:[HJ!%L7]M?W5%I#'-(R=XZ?G$P+9>P]B:^SN5CV6Y5 MCR-V'K5:^9C.4X)L2TR*RO @V,LJQ:=\M71 3E=%:Q1-%P-Z]:_0_ M>9IBU/G5)::RQC#\6R6XVC56=[K"[J]3LPV[OJ?_ -*2Y0Z9:Y&V0P*PI@(T M:OF,)X%,)R.";_03U@WCZZ9'L3_4=:2NPNUPG!Z;%X29#4YOFQCD5>J=/X?CUZ_CP/OV)3FH MQ?RM1W>G2&9G1>G1?E&]R_"_'7X3@"%D]$;UM-46>04>7X^2BLHN2@+,<&,-4"/JK%Z!V^>U7*O\%O7@6 MDNV-Z-(AXYG?(NJ!R2_;U_IZ9MZCDUM#-AXG>Y 9F1T-UYEOM=[0PJ<[[U'< MQWM4U=;8Y+"Z.=%5J(!PG_F1R+P-$]C\2*6T@&3,QP<^1G M6F:&>^(\T.KCXOMW+75[BEA@3WH MC71S':J+P*<;X?GMG?XV3/FT.M-78K-^Y%I<>@)&QRIDF9*>A854#K,R2_F6 MIX[610?9E$>5@Q-^47@7G]=M=66N,3EY9F%=DE3GVPKZCS>XQ:SKV4 8Y#02K-HG,:8*J@-GMGCV1Y=A&MJW4^&[J MM;T7L!J+()--HS$H,+9\&KJ+O]0R/)XY=A5#,3H:P-:U[[%+-@.^(I',;Y.C MN!U2T[&6#J71,-9))BQ\[U>Y9!W-?(.7^M\\[WRNS^6^8CEZ%<->SR=>GQTX M'33@' . <#C?MW/*/"]*:OJ<@IZ(V;CS[/*;RW!=E+:!/ M" ($BJ:+R&&\;7O3^W@,.'7VU\H/15(?8;?>)EOC+28X*W+J>4V:6NB-(5K9 M#,$ELALBQ@HY2G(P*]W7N_'H#7EV&7F007FW#M/+-C8W>NF8[D6LLSN](W^, MYSA-;+:^SL,HK\=QX0C8O&E_S8]@ X)D,J*X)!JOR$7)Z<^N. 7&;9C2:(Q/ M[F)Q:V=@UC'VK<;H+7UUB01(&0X)KK8%[EN+1Q0$()PS2:XK(BKU9TZ+P'C, M-H;-T507DF7M/VMLAXY_/?75,31UI/LNYJ$+*9:6V+!B/C1F]S'>4C&A:/HB M(G1.!:I= >Q.R,:IK&QW1N6=3WM157 X-@N@W#DU]M'#-)56P!XHT4N'(BG\ M!3B^]<]W>I<[-1ZGT# V!J?;[+NAM=&XSFU%06FK;&::-2I)7&M>X$Z8$4L6!X6R2][9"M&6TM32)CT[?#P.ES& MJBK\?Q_'X15^/[$^/CKP/+AKUZ]57^[JO7\?[N!]8WHOX+^'\57^[^W@#F*Y MR.ZI\?\ -TX&7@55]U9#8?K'MF4ZK->>.II$'3 40Y-N9V548P5H#2$4 3S3 M/:-I'(OC5WV,5Y'$47QTZ)P.MGW9"I\SW=5_'YE+_=\]7?QX!]R1_[? M+_O20O\ P=7?' /NG3\9W3_WT_\ [%P#[IU_^KU_W)(Z+U^%14[NG7I^"_CP M!9AW(G=.5?CHJ*DEW]WY5>]5:O3^*?/\. ?_P#( MJ)_%.!]^[(^>L[YZ=$5&R4Z-5>JM14(B]/[E54X LPW\)O3X3XZ251>WKT3Y M?T;UZ]55/E%_#@>?MGZ]?N_@O5/B2BJOPJ=5[_X+\]?QZ_[>!]^Y(_\ ;]_X M_P 5DJO^]>_Y7@??N'^.L]?[U5LA?_WNJ\#S]L__ +?+_P $G_V+@??N2/X3 MW?\ P3_[%P,@YLCRA5+!W_6#1R*DCJJ->B]J=7_@J)\\#\_LPZEW#F5"#)\G MN)]6(QK _ M3"WY147I_B?_ (?X='*GSU_Z7 ]\ X!P#@' . @E0H9M2E])O$3,3K&L:Z3[8M8B]NE<=[6MCI_3$S,Q77V1/"/P?D:_>PRB7 M>>Z@:"P13U.%:EP.MAP_(X;'@N9U_D5JB/1'>)\UTY!N>B*J(-J_/:G.IN)_ MS/NA:M\?_ $_G9/\ M^3UKC_\ &'D'_P @>/U,^PZ/>H#[Q>_5I[O_ .G)\EUMB>OYVN6Y2&-.HLDG M79[>%D[:5Q84O]0@0?KA@GI6D'V*Y7.*[KTYQY,OQ--8TT6*Z/U@^E=K)N_2 MGUPLI94,Y38!1RH,\K& MJ2EJ:Q7M1>CE S*I*IU_!7?'.37G*R.!]3 MX5%_L7@?D1QW!H&N/WI:[$:H8PU<3VEEV]?'$UK!Q8F6U$W+QQ!L8C6,%$6] M4341$1&L3G0TTW&G_> M]O7M58L6;*1JJGQYE_MYR;F>4)3VNM7[>&"UVO?2CUQI*X0V+8ZVI0BRKES$5?E&,:GX(G.?%&F.(]S%OZES^(P2.:Y%^%1>!^2?]K^*[5G[GD_7, M COTX)]_ZS='#^7-IZ<8CX]FF!FDQH)LWQ^H=+D5-ECTJ6H8JY74LE/ L8Y M1CFQ48T;FE$UI>7-BFWYJ\V:VTX3R[_I[#B:JV_AQ/.>(,H]1)7[U1,*/RMKKZGDL!; M4-D@_E8\L(2]/E$5/GG/6U;1K6=6)C3FF#F@< X!P#@' \O_ ,*_[O\ EX'& MKW^SRFPOV-P4%G@TC94K(-'Y!7U.$5ED*MN[VBJBM.J=45%^ M4141R=41?E. )-D]>JSU7_:DIW^]?YC>OQ^'X=.!]6;)7K_V@J=>O5.DI47N MZ]Z_]9U17*O ^?=D_P ;!W_P5_R=Z_PX!]R1_P"W[O\ X*_]CX!]R0OXSW?_ M 3_ .Q\#Y]PZ?/WU3_=(5'?^NJG=U7K_=P*3?N*1(^0^G6X,>M,M-B]=UPAF\"KYNXO>]0[, M(B?CT^?[?]W_ )_NX'K@' %_N_'@-DZ "PAG@RXPY,66,@),Q ML(D>56P-MX]70)E>^DWS5U16QS'GN)0VR1XI)0U(-ZJ&WZR]-[Z![!X_C>0&QO>5G0746>.PQW9-WK:SK)M8EC*BVU1E>-'PV3!N !0 M#S1T0;C*!6J-R*O D*DPC3^/EI,HP_2^J<1!:U%UD<#9HG7@/WKOLV!L''*_'J MW",DP0&L]S:2P](V3V=;=6-XR1+R2Y9< GUB"%XC29).JO$)55%_+TZ<#KEP M#@' .!QYV%CQ+[#/6YK:_(+@%;N+>EE,K<9 LFQ/$2ZR,#W'1>UPZP)"M<=Z M?+43@-5W.MZJQO\ #<RZ;CV<."UM1+HF 6 M,0 B-,Y'N;\IVKP(7E9_JJIARJ:)C-%92*];G'::_P YC55 W#$C4X#UF6,KLK7F>_?QS+I^PKF M9DC,UH[FRBUEAB%-6UAGU6?SJ.5*&)M3:>=SC1(PGKU7J1$5$1 Z^ZV&C=?: M_;W-QR MN0B,*UZ([KT_V=$Z=.!E:%&=B(YZM8G1$5RJJ_CV]7?BJ-3^' S_ /@O_J. M< X!P#@4_P#?6J9=>H^[*DE7,NVVF/U,$M-72Y$*=9AD930B?"A3(R./"DG8 MJHTS$[AK^;XZ=>!S5] ;W&9WLALP. 8W=8?AM/J*17U%!LO:?U"U;$W3[$ZBU;L[57M%E6<.]7 M]$U.[-F7V4:XG:5#@JDQQ^D]UW,+'*\.76GW9$>M"%KRB0QF=1]3=8UK,\-> M'-MZ6.PL_P#4G8NR]8>Y7O%1VNLZS=&8P\JVUH;4^HMB9#9XIKH5S5XID&$; M-]5L74^O*JQK6R(J+Y&_P!_ M_9H$Z_/]GUN!\_4IR?\ LQ/_ '6 7_[%X!^IS?\ RB?^ZL'_ +B\ 6PFNZ-0 MZ,<[_"Y:T"(U5^FU(,F#DP8UM[S:XP^+E4> MDC5M-86-AOC%) ,.;++#^W;UXH_?)D2@O003/1CG*OP@?LB:B]%_P]>Y_3^S MHKU_'^_HG ]\ X!P#@' .!A?_B7_ '?\B<#SP#@' _)_^^#@EMB'M?A&SX\9 MSZ[/=841*^20?=%)D>N[N?%L*]WHH%A6D=+<1I>+>V')3EI MZOT@Z?!IS<&J]=[2Q_ \!DU&?X;CV51'CQ&@Z,_6*R/+D1GM=7(YAH4HCPD: MORUXU3^'.U6*VK%M(XL3K$I'_P!,=:__ (.\%_\ N1Q__P"1W+TU]D(/],=: M_P#X.\%_^Y''_P#Y'<=-?9 /],-:_P#X.\%Z?_XAC_\ \CN7IK[(&R/A0ZZE M- KXD6!!B5D@$2%"CBBQ(H!QB-&&/& P80"8GPC6M1$X]!^2?]EC_P"CCE?_ M #I]G?\ QYQ;G2V__,_"?Y.6_)T0_?AUQ9WFE=,;0@1G'A:[V#;X_?$&BJZ) M7[ J8HX,LR)UZ1TNL;C@[OP0DEB?Q3G+N8UK%O9+-.:X'[4FU:39WI'J6%7R MQDN=80I>KLJ@HYOGK[+&9+UK'$'U[T%98U,A21NZ=KO*J)\M7IR8;1;''N2T M<71SG*R. EG3X57"F6=G+CP*VMB29]A.EF9'B0H,,+Y$N7*.1S1@CQHXW/>] MRHUK6JJ_' _'/IC:43=G[M^&[6K3+(I\W]FK&TQ\ZL>/S8R"+;5>,E\9$1[% M+C]?&>/BW5GZO3JG1\2SP8J5T%KTZ]?\YCCH,EJ_P 6G3G+AM%L<>[@EN;H M-SE9' U+/LXQW6>$9;L/+IXJS&,)QVWRB]G%W9$,BBI,P'H]$1Z.AVD:5'8YZ;P_:=]-=QP;0U5 MKP6H,NF!,L/*M7&)01XDYS?Y$F5AR$?A]B!A4ZD']01"-540C'*CTX[8<=O3 M2?G5JI_ M;\?\? XM_N'ZJP#._8/7N69[K.[V>'7>JWV,.!39):XNN.Q9&46LRQR4UE4* MPC$B K%$3SN^K]J_CP+#_J ?J4[_ ,HG_NL"G_V+P#]2 MG?/\Q/\ W6!_Y/J_' /U*=_Y1/\ W6 3_EC<#[^I3D_$B)_=^F1^O_%&7@?/ MU.;_ .5:G^VL G_+&X'U+&,D=7L:KDZN3I_'@4,_9'L; M*UVY[:R;F';K9PXN"TTK)+C#W8*7*#U![>OE2XF-D#'-&A5LF,Z.USV]2.:K MFJK7)P/T5)_'\.O7YZ?^-/X+P/O . <#YT_\/^7_ (>!C\?XKW?/553HG1$Z M_A\?QZ+_ ,/ ^HSI\_W=.B].B)U3\/A%Z(B"]Z>-R(B)V]7=6KTX&3*I7.+NZM MHF0AR?4^/PA,QU$E E$+CX*RK PC'=6*IU&A/S,=P)ZK)MQ;EQVKV#?97;ZM MM[O*;R11SK"-:2HK.[*(@9?ZE#,! M3;;U]IIC*Z+([VVN94';\^QR6I+=I:555U(H\9"H7,3O*O:A51ZIVIP. MQ.KT1-<:Y:BN[68'B2(UW17=$H*Y&J_IU8CD3\>B_/ D#@' . < X!P#@4\] M]G'3U&WDZ+8"IS,QBL*&UE%DAB12#R:D/$D'OV5]5]C;DW/HS?NH?8^Q]1XWN>7KV9D,>PI\ MTLZV) DP3ZYB> PD>Y4*1%Z)^)JLQ$3$QK$I&Q+4FX#Z9VEJS?/L,7>M[LBB MS+%HFPP:8Q+4LO%,:S##S8L^MC8MA]A-I[HU;)F'G,DR",*5Q4"[HQB.X29C M76(T;[H76,/0^C-,Z.KK0^2UVFM4Z^U5 R.QJ_H6&00]?XG4XI&NI\&*0T6% M,M U2'*(;WC&]ZM:Y41%X)G6=4L?8_\ ,B_]#2.$'V/_ #(O_0TC@'V/_,B_ M]#2. ?8_\R+_ -#2. ?8_P#,B_\ 0TC@'G7_ ,@/_=$DK_R)P#["_P#MNS_T M')_YN ?8_P#,"_WQ9"?\2\ ^Q_YD7_H:1P#['_F1?^AI' $D+W,3PC3J0:(K MHLCQHKW(U.Y%3HK5^>!^1_V$S0F<_N&ZYP]M%G5!9Z_]X->18AJF:6\P/*Z1 MGL(&YD7-U11Q.#BD^*:Q0+I)E:LAHF_/Y4X'[/V=>B]/_6W_ (ITZ_F7X3@9 M. < X!P#@' PO_Q+_N_Y$X'G@' .!0K]Q3U!_P"^%H&;BN/,K ;4PJ>F7:ML M[,OU8RVXAH"WQJ7.1C_JU^6U'=&(']4:T I86N;W(R=62YT:SKCM3_$.0$9&K\*U%3G;B])C6)AC24-[U_< M+]2?7^JER\JV[C>2WP0.+#P?75C S?+[(R.[61F0::66%5J]R?\ 6V$B(!J) MU5_X=Z/O1ATWUME2,)QVE0L2#KNXD%L]=TFLEF0R M95D>X1PO&"UG6WA&J%"K909"1XU>]'HI"=:,F3)D_)R^W-O2*QQ?J-G=WZ=, M[U:K_H2>]6(K6*_ZS^Y6-Y:L7KTSR<4<)U?E"U/M#?\ ^T5[/Y/A MF<8_(R'$;KP1,KQX)I-?CVSL2C27_H6Q< GRFI$9>5XB$:)Q&N\*D/"E(Q>C MV=*LVP7TGE_%RS$6A^DW1W[@'J9O^GC3\/W!BU'<$")\W"\_LX.$9A6')^,4 MM5>2HPK)S'?'E@&EQW?]$B\[=:F]*\Y@TE^?3W@_7JY,LY/R8]=/XMQ73C*D?J/KRXU)^Y5IG5V0GA2K_7V^78E=GKG/? ? M;4T&VBV"0B$:QY8PY;'L8]43O:WNZ)UZ-=7Z]O8;2.*^QFF M<_TUF V)59K12(,:P4*'/07H.DO'LUEQQ.DZORJZ-W5OS]I7V3R76^S\?F7.&6SP+F^&U\I&5.;4K4("AV=K>QG M-%%6P$)JM;W^-"C0D*7XBC:\/2K:V"^D\G),1:/>_2CI+WU]3]^4T2RPO:F]*\Y@TE^<3WY_%:QP\YW)>)-: M^IHH-%&+(E5N)BE!'(0!5;)E$8U\AH!"5CNIES3D_)2.'\6ZUTXR[5?MN>F# M?3W27TLJ#7FW'L23'R+9MA!*V8&NUK6R8&+P9#_*]B>,T^1((Q MSAJ->=C#CZ*\?ZIYLVG6?8*)<,:J_!ZX\N. MY/P?UZHG8KEI:.$\6)K,'G??O3ZP>NV,SK[-=J8Q;6H0.?5X-A=S4Y3G%_)^ M/#$KZ.MG$?&:9SDZR9;XT0;>JO*U$Y;9*4C69(B9?FV]2Z+,_??]RI=R+6DH M::KV3&WUF:A.L@6+8WBEA _HG&/O*)&2;*RE5E? 3\K5*QD@S6HP:].I2)RY M>KWZN2?RUT?L,YWG$. < X!P#@>7KT:J_P!GS\?[>!QD_<.KY1=O2[=F?AP> MM)ZQVN,6->PEBZVSH-UF=O)?C$*'7@)W1R1H1.XLAS(K3/$PO5CU5 L_Z5L! M7>H/K+70XD@,2%I7 XD<4^*UD\<>-2A:-LX,%Q80936_#V#>X;%14:JIUX%F M_L?^9%_Z&D<#YY__ #(__0\G_GX'W['_ )D7_H:1P#['_F1?^AI' /L?^9%_ MZ&D< ^Q_YD7_ *&D< ^Q_P"9%_Z&D< ^QU^?"+_T-(_NX!]C_P R+_T-(X!Y M_P#S(O\ T-(X!]C_ ,R+_P!#2. ?8_\ ,B_]#2. ?8^%3PC_ -J19"]%_A\) M\K\\"N/MCLK&=2:6L-F9H8]?B EK6_R.=55LNPN(<$>;4D=ZPJT*J6819, MAB=K>BHU57^' IU^W/M:%NCWA_<'SF!CV08G')*U;51:2\NA6X"5L&OG1:>^ MJ(P$1N/1LC@QVRBP41'"*15?^=5X';1O3Y5.G3_C^/QZ_P >O7@>N < X!P# M@' U_*>JXWD2)T54H;A4ZI__ "Z0B)U^/X_C\IP.(>LK($G"=:E%DF:U#(NF MJ;$DW("4)\@MU4'M!+7M[Z9IZ14.O\ 96#9W8V5>6^R.MNW$Q%+*SF7=N"WMQ0+ $1BTPL"#2#= M"2,YGB(J*O FC4MT2RP>SC90TME9P<7#2X[A-I,+$U)15N>!9>1I>1V MC"/0"#FRBD*H^U(RM\3E[$8BA;#5LV'99-9RH$"=7O%LKU:K+499Q["M?.I: M[**]S\3DS7>0F//&%%"[HB.1RJW@=6N < X!P.7H6$+1Z'CJ7&8]2N8^R_\ M4)\M>"+6-II$[)(:A#-,K6PYTF><8V%:YKF]57K_ 4*UY-AQ;[!0Z[LY5/@ MHL Q9;6-K%D]+#,,DN)DQK(\T]XR(I[:-+K".>%_D3HOP-JKUX%'\5E>PWK] MDN3P='Y7E..-EX]7T[:C+KBHJ8F.JIH]O*AP<9M'2ZF^R8HQ*,$Y_P#,2,1! MO17*BP][&@UMC)J\ M+A2XT&Z23^CR)0:+ M7YLHQSU_P2AR^XU1"FP<5L)<"Z@1JR-4EEUP%1@82?S8[?(HCL>JOZ=.!V,4 MD15_ZNV_O1QWIT_!57K]3JJ='?W_ #\)P/BDB_\ 1#;*G]YW]4^/Q7I%7JWK MU3JG7@"/BKTZ"MOGIT_GOZ+^'X*D5?[?Q_!?[>!\4D9/_9-KTZ].JR'?"_V* MB157_>G5.!][XG\16R=%Z?)W)_QK'[?E$7I\]. >2+_Y&W_AT_G/^?P_LC+\ M_/\ LX KXJ=>HK7\%=\2'N141>B+U;%5$1>O\>G ^>2-\_R;?HG7_P!GDZ]4 M^.WI]7_&Y?P3^/\ ;P/?EC(B(@[9?]AW.;\_/7JD5>G;\]>O ^>:/_Y.U_!% M^#O^$7\.O^4^%_N_'I\_AP!21>OR*VZJOS_/O3^' ]M+ M%ZMZ#MT1RJWJZ0Y4ZN3X142*O141/A5Z)U_CP/S0V^D[^E]I,RV'+KI>/56; M^\^(9-47]/TN;[+:^HWO05%A3W\LCQ="G:Y456-:Y'.#]7C?P M=_B_Q/\ Q_'\5_P_W?V<#VGX)^/^_P#'_?\ W\ X!P#@' .!A?\ XE_W?\B< M#SP#@' .!3KV?]$?7'VTC,/L[#W0,QC#\5=LC#C Q_.8@VC\8XTJT9%DQKZO M'T16QK$$L+.GY$8OSSCOCID_JYK$S#DU=_L 4AI1"4'LU/'$<1ZA#D.IZZQF MB"KE\8RS:[,JP,@K6_"O0 D_,SRNG M"]'R:'$<0I<%68B?/B)<2[3+9(0O7X=XA#)T_P +VK\I8VT?XI3K=E=(>OFG M/7+$0X1IK!*;"Z1O8^:6&,DJZO);>O6PR+()SY-S>SG.J=41WQS0YK>JG[7VG_4 MG;A-Q83L'9N2WI,;R#&5J\K-BI*A(F12J^7*.C:?'*N;]D#ZYB#_ )O;TW]1H+J&2-;T5BU$3^=%.)ZI^5RJU51(U!7N)'HG^(CE^5X)VU9G6): MB\^K4\?_ & L?I)Z\>I=:\>J,,9_4\P"1[G8F3E'>Y[*)$7HBJ-7)W<[%,=:?TLS,R@"M_:XT]6>U;O;<.PMG$S9VT;7:RX MV4V*KB?ZU;%FF/6]C,;;;HB=7K\]LZZZKU3IHZ9\Y MF4,;O]>M->QV)&PO(VOMDZW6?UE]&?7'U.B/? MJS"VGRN2/QV.QO=&K@Q([^O5S'+\\YJ8Z4Y M\Y$0AO?UQTO[+8E_1FY\$JLPJPO*>JF&\T'(,=FE&HUGXYD, D:W MII?3IW>$K1E1J-*U[?R\S:M;QI:%B9CDXTYO^P9KRQLI4C /87+L>IR/<^)3 M9CA%)F9XB*JJT:W-;;8BL@;$Z(BNC=_QU5RKSKSMHUX3P:ZR/#/V",)@6D21 MG7L7DES3#.U\^HP[7]1BB?7W4?K;A$/7VG<.K\3H0J,LXPNZ5=Y#8-;VON,FO)*DLKRT-U7J4Y'(QJ M]@T8-&L3L5I6D:59F9GFF[FD' . < X!P/#_ / [_9_'_P!1\\#AO^Z!F>=X M+NK6%K@E=KBWD6N&TN/7\#:D_P"PXVK\4*\^/F5*$[WUHW$-3HR*O2J(_JX#4Z=& M.1$3I^(3^KXJ=$\5KU5>G3SO^%1/EKE^KVHY%_AUX'SRQ?\ R5K_ '?Y@G]O M1.O^4ZMZ_P!_3@??)%Z*OAMU1.G^$[E7Y_L3ZWRJ?Q_L7@"/C+U_DVR]$ZKT M._\ VKV]8J=R)_=P#OB_'\JU_%6K_/(B(Y/Q3YB_\W7@?%)%1>GBM?[$_GDZ M_P#!]3\/[_P_AP#R1?C^5;?F_#J=Z?[E_P KTZ_[.OQP#R1?X"MNJI^"'O7\/P_%/]P'?%3_ M -E6WSUZ?SWJGPG7KU2*J)U_AUZ< 0D1?CQ6O7X_&0_IT5.OX_4Z+\?V*J< M5\9%5%!;_']AW*O\/E6_71W1%7^'7@"%B+_[*M^G1?P._K\*G7\KHGST_P"? M@46_/3X?S=H@M.=\<#6L*K2*K4#N\G\?Q_'^/3_Q?^KX'W@' . < X!P&#)VN=CN M0HQ.KUHK9&I_:Y8$E&IT7X5.O]O]O XMXD:WQ[!--1Y_CLZ37UE\&PG??L*Z%D?4;\;L89E4B*(75HG.[E17=O U'-;;V.]B ML@PVGW1EME/JZ^1=S*6!BMI2V]TRQR%BUM4UF41,@QU"# M:P<@D2R15\J*O&8PL*U9Z^6EE&B'K++<>[\?LXU MA*$*',AS+K)2#B2!G(C9GFDC8J!9_,-LE"O6XT:!%_L-LZOUWK?;U?794C,>M,6#==F8T )M@R2^N9$L[K+3-@2#);A* M5PFM8YGURL3M7M7Y#M?JYR/USKEZ.1S5P+$G(Y/^DCJ"NO]W^_@2! MP#@' . < X'Q?_#^'7^[@5.]WD OK#ME\@\( @5N-2R$M57]*1L'-<=FJDY5 MU7A&9'V-0[0H-)[FMJV9C%K2:,C88W![# M7=?8$RBJAY"LFLL1V^6S)3B'')B$4Y7E:)RM:KE0*BVG[CWL#)NY5A3>U.:5 MV%R-DP\.J\=LL)PH^XZNAKFU\FYR>TQZ-CR4IJ.TA.E#!)=(UR9**SIJWW1RJLR^:>I'B\G*I^NX&*P8$I9%C-L+63#QA\J5:1J@*![' MC8!TE>YJ=51O AC8?N=M/':3*#$\ER[W/D QXUJ]F:WM-:X(:7!B- MJOL1ZRKHWX^LB1,GS"L&T[6$8Q6*CW?*J@0!L[WOV%#)BU'JWVYS]+W,\DA1 M*W,-UQC%0Y#FGQ]@6=;CTHU5)ZQOKH2,,J#85A>BN=T8"+2?O[GF58] M;VFRO;'9M=8Q,MF0/%64NN:VLC8S%='KHTC&B6F.(3(V'L8GSP-XOO;F?CE95);>X&S)66P8TRRS#&L2@ZVNAA$2 MR;"@8_CLF31C6UR(0U[T5"/C%5$[G-15X%.L=_<5WM,R7 YM[[99@/7NP;O* M)2U5!C&'66RM?8YC)!@2ASD!L1%6U%A<(JF%,5'_ ,ASC)U:SP\"[>+^TD_. M([**@]V;^CS*/=#+=V69V&NXF,PL7@A4$TE&.!BQR6=K8SP.1J27,4?>G9^7 MX0($R#W9VY&R L;&_B!86'[&Y-45M/DN;^YEVW R4F0R)MUC=O@4K(I%O$ \-1##4NQUW@ M(68]I7/(WQ*+\O=U1>!5_9/OCM&-D&)8EK?V[RN!+L?U>[M,NV12X$'7TFBJ MJX5C$HDMZ[')CA9/:D<@$\ T$R4U@FD[GO>T(LT#M'#,DJ\%MKS:>T,EV3M' MVCU7DUG0Y+)K:ZKC9)E6Y,-OYC\0Q*)%B>*FL8<%/NR4[B/".SC&Q?(N)PY< MM8TM'3:MK5O6=-:Z3$O;/(/#=QV/MV'O.VWFR[CV?-FMA^-MOCQ6F:E8O..T M;G!M[SK2>NEZ5MCO772^L3$1'&V3;8[O#=M%$Q'8FPG1X>K[$%3B@ZLT''Z\ M^,V/VI"R,IR'':**>RD@>K8L8SY8G2E+3>TQKTZ<7O6?Q+8=T^77COOY6Z-W[C%O<4.,XU09S?VN2 M8W_4ZOJJ:#";C%&._GXK=3LD)D5E5)5S\6O*\H9<)1FE^5O:()E1Z-\O'FG; MMUNL/;]AAWF?<[C;_%_)CK7X6.,EL.2V7XMZ=%L.2LUO32;ZQI6M])B/7+?+ M+O.R[?N>[]VW/;=MLMIN_P!/IDS7O^HS3@IN<5,$8,>3XE-QAR5OBR]5<73. MM\F.)K-L57N: .MQFLQK']C[7LUPK%LJNI53!Q1EQ5TF15Z2J6TRU9UQBE,V M_OHX#&; K6%,[QO*)M.DS%(B:Z[W?@&[MN]YN^[[GM/9-I_J.YVV&N6^YG%DRX+ M].;'MNC%N5M3.R"3FMQCD&A QL!8<6))DCE.=&>((5:$G9X'Q7RVD=EQ8 ML.'>]P[EES[S+&/'$?$IA_7;FE+9)SWQ5QQ^7HI2]XO,UFM::4MI[9Y]\OVX)S9;6^#DW7^E[+)DI@KM,6>^:9ZXRY,N/';'$9*WR M9(G)7JD>-[!XY;1(#<;Q+/^6OZ>*4IFK&"\8\UK_ M !I9OE?W;8Y\D]WWO;-IVC'CV]_P!9;+DR[>\[ MO'.7;TQ3M\.;+EODQ5MDF*8IC'2LSEFD\$'7>^WLWQAMOB>+;,SZ->Z0SR S M7&,18@K6!EN-;/QRJR!,E@WEY3XQ1V.+GC2(1Y,B5_C=XX[S-*WN].WGFDU\ MSVN[[9M^X;W'F[/N*QM<,5B]=G[9FVWD>SO._W%K3COMMQV[/EP?I[X<.7<9L>YK:F:F. MF/\ ICKRUQS2>E]=[(Z\R'+M<9(;,MDX'"IX>\X^6AN_O>-6J[NSY[V/>]TV&_MN]_L\6*G<(W&VO MCQUI2^TQ4OGKO(GJR5MAK:+XIPVM6_5KK-9C7QD?*7ROM?8N[=IIV_M'EL6X_4TI?%->GIK>)TD'"O9*FRO M)L9QRXUWM#7(\_'*+K:]SVBJJ^GSI(=86[+%@NJ[RWG45L6DCDF!AVP(,@T< M3U:WO8YB><[1Y[M.Y;_;['=;'N&PKO8F=KDW..E:;CII.2:UZ,E[8[SCB;UI MFKCM:L3I&L3#U;R+Y2]P['VC=]UV'=>S=VMVR:QO\.RS9+Y=GUY(PQ:_Q,.* MF;%&:U<5LNVOFQUO:NMNFU;3ON6[2B8W?)BE1B68; R<-0#(;2CPN+2ED4=# M*D3(L&RMIN1WN.5 '6DFNDCAQ6R'S)3HY%8)6,?Z;M=MNM[W M&,49;X\$8YG'CF;5K>]LN3%2.N:VBE(M-[S6VE=(F8]9['X;G[MVW_6M_O=A MVOLUL\X,>;=VRQ7-FK6MKX\5,&'/EM\.N3';+DG'&+'%Z1:\6M6LM-KNB%%L MY5118%L3-9]+7U=EE\?&*BG4V&#N8 ;2!770+V_I)$O(25IVG=6US9TU@E:K MAHI H3K;GRO%CW%MKLMEOMWFQ4I?-&*E-<$7K%ZUR1DR8YMEFLQ;X6*,F2(T MF:QU5ZN[LO -QGV=-_W+N7:NW;7<9O1K!C>]"-'P9O-^VSFQ[?M>#=[_-FV=-U2-O2LQ. M"]K5B_5DOBK$Q-9_):8O,S$5K,]41V]O\KN^5VF?>]^W7;^T;;;=RR;#).\R M9(FN[Q4I>R]M;7NM9<: #]6+DE9)6M"8X$LH$)LD49;#N^ M;!^GV^[IL=W2UMOGO2M<6?HKUS%8ZYRTGIBUJ_%QXXO%;369TC7B[]\M>[>/ M;?=_J]WV[)W;M^6E-YM,66]\^U^)?X5;7GX<8,E?B36E_P!/FS3CM>D7BLS. MC91^Q>.W-=CN3&PG9%!@&4DI05&Q,AHJN#C3I60EBQ:9D^(&^E9350;&PG!B MBG2:XUJTKDMBC'-IC\^DQ,]SN/RJ[MV_=;KM%.X=IW7D^RC+.78X,V2^XZ<$6MEF MEIPUVV6^.E+Y+8<>>V>*UG_+ZXM6-GM]N1:#*H>/7.%9O755AD-9BL/-I,7' MTQB1>W)H\.J *,W(G98^!.LI0XC)J5GU$D/1KB-;U>GD-UY/BV7&V/A&?N?9W]P[= MEWN+:Y-S?:5MG_45PXHM;):;3@C;1>F.MLLXOU'Q9I$S%9M^4QA]@,>/;2(J M8CG@L=@9](UE:9Y(JZ8.)UV9BR1<2CUQ5=?_ -0R8<[(%%&9-CP#1!DD"0I! MKY/'TJ^;;"^YMC_3;R-A3>SM+[B:4C#7/&7X,5G_ #/BS6V72D9*X[4B;5BU MJ_FZ?)9/EAW;'L:YYWW;)[KD[97N&/91DRSNO8_\ 6+$OT^HFC%<2)=QL@^JHU%'A@->"S"#:6$&TC2HK9G@! M"J8-3)LY!O*K6U@E.U'=6M=WY\I[;\#%FK&6V3+OYV<8XK$Y(SUO:MXF.K2* MTK2^6UM=(Q5ZXUUB)\5'@??/U>;;7G!3#@[37N5LUKS&&=K?'2^.U;=.LWRW MRX]O2G3K.XM&.=-)F)=Y[(]+' . < X!P/#_ /"[I^*)_>G^_KP.2?N@>KK? M:365E9MQLCW:GD KX&8"EKC=^L3(,BD6%%+.U?TU/O,E!&K9/5BH]%_AUX%, M:K?(=0:ZQ;#L<]C-R5@<%Q@D>5@^O\.Q.YH<=B1;7]+J<.PU)F,!FVDREA/: M@VN(Z*K!M_FO:G7@5NQ3WP]H2WVO)^;>P^T@X/GQ\JMYE7BNM*.RV!A-91RG M08-%G0CX3'J:)EB9&]%0:!=K%M_9?G$<%/3^WFP:#)ZR],;* M;',X.(U= '%*V.9#)BS08<9UQ/NYH>C/L*THVN3M;T3Y"O=U[=>PP;Y(]#[4 M6-'HXY#-8!XT3H]5ZH@5 MJV#[E[Y)D]#B&K/9?:D"P2JR#)+_ "_8^"XY#UU,KZ"'73X.*UEC48=-DKE. M0AFD"X3%:B20L"-R*]2M#;-)>[&9Y'BF'76U/9'V'K)E@<3\PAKKW$,=F5@S MF))#'K:^1B2E-4BK>C#355TASD_EL[FJKPW_ &7O_69)V2NL+" MC;$BU-W!QVEEV#(]"VW=&P8\I9:1&J>0PJ-(WO[43JG 9-8>R/L%E[[@-I[, M6C;&!56)*NI\=#51+B3&AQ@,F#LY^+ 43C6$YI0!(YG>(!&JGRG0''-_;^SQ M6K?85/LU[&Y?,I\Y92]4541%Z<"NDKV[]B7Y"^!6>TU],I94B, M,19..5<6THXH317R;(BKA$6-,9,BAD#[.Y[A$(U6L5$ZH%B3>P>7X_ )8YC[ M9;'9 G8G3V>,_P!"5N(7]O<9#./%))\T6;B"1:J!3QI/BE"D^(JE[G,1R-=T M"B7L#[2[7V(3),!=MK8.9:XH,(M0P04=#KRQQW&X]S M5OQU3\/G\/C_A_M^?[^!ZX M!P#@' . [M;TX&Z7$>/ALR[R*[R2^H]EQ;BORC(X=S%69B-;E=Q7%1:K!Y#1&DR M9QJP;(YWL:\(9"$*UR(Y> Q^N^8"S7--LS 3*R02L]D_7RL/&IXCX*PG.@Y" M=H+%7@C$/8&CF88A$&T3_(BMZ_BH=FN < X!P.)6\L,'GF >K%6L"1.D5F^= MW9#!.,WA6JDUUEEP%MGN(GA>*-%E$:C'M,U$",&PH,SR&;#;%I@9M8!G4&];7.+/&U6% MF.NJF$R?DM==U-+4Q<>-(WI)> ^/9%?0[2,QUGB(_*Y%^5\:#>G1[NO >)^9 MW9K#/29D6#?#"3$<+VT355:>JV'>Y3.425%WB^1M=$>>AENBL7L85D8K!O>K M>U$50A?V.UDS9.!;0R!F+!#C4UENVO-?7#O/?3:^$I+6LGU;7(KKX(Q@5PQ$ M>V2K%<1/PZAVYUBB-UWKMJ?]'!,3:UO;V*U$H:]/S,Z?D_#\/CIP-_X!P#@' M . <#XO_ ()_;P$,Z!%L1%BSHD29".)X9,:8$GX=>!Y?KG 2HYI<&PTC7*JJA,8I']7*J* MO7O@JB]R_P!J+P/:8!@S$1/Z*Q!GPY.C,;J$3I_8B-A?'PB?[>G ^?Z>8"3Y M=A&'*J(J(O\ 3%,O3K_CD1?\ !C=.O8YW:J]JK"14Z=J?[>G QLUO@ R. M,/!<+85Z='E;B](TKT_!$<]L!'=$3XZ=>!E)KW!2]R%PG#W=S>WN7&Z9[OX) MT_-"7XZ-3_@X'Q=?8*C>G]$X>WMZJB_TW3].KDZ=41(75/P^?[>!Y9K_ O\ MW7#[K!1'.&JKT_LZKTZ?/4/!=;:_,SQDP/"BC3MZ, M-BU&1OY'][/RN@.:G83\R=/^E\\#-_I_@W;VKA6'N:WMZ-7'*;HWM57-7HL% M4^%7K_MX'C_3K OE?Z(Q!/E%^,9I%[NG14O3@?%U[@SOA<*PY MR=.C4?C-,O5J*KE8J?1^&H3H[I_;\\#,S!\-"8$B/B6* D1R(8!A8]5A,$S7 M(]I@'9$:4!6$:CFN:J.1R(O7@;8-BM&UG]C>GXN7^S^*KW+T_#Y7KP,G . < M X!P#@87_P")?]W_ ")P// . < X!P#@' .!JNZX>Q=_P!EWK<;;'O,&TW6/+;! MD_HRQCO%II;A,:6B--9K:(]:VCA,*:DTC;X'FTS-+$>KZ1DG!XV%-QC5V%2< M7JT6%=_JPKR=/FVJD>_U+QGQ'<]F[O;NV>.WX8M MLXP?"VF"<5/RY.N,EK6O:U[3QC28_+&FDS/5,_0_./F)LO)?'^[SO78]WM8Q[RN&ML.?#>U:SBI-?B5OCR4MU3KQK/Y;5B(B:S'5/2V MGE7A6_\ %.W>,>4]NW\YNVWW-J;K:;G'3)DC<9*Y/@WQYL&3'%(TUKDC\];6 MM,Q>LQ6JS"--2L/R+^H)&4K?2I.OI^*V\@]4. >TR2[SB_SN_P F04:22-!B M3K;(3(*$Q'?7&B-0CD3G+VCQ3)VO?_KK[F##L\&SP;?6U8M> MU,6"G5FF8Z[:ST5U,%/J+86OUKI.M,KP\4N?A."XCF0LQQVYL8,FPP.D2@J\ MNQ]M1?ULB)*+6KXI$ [R!.T(5:4+FD<7I[7QCOG9)I?L&YVL9+[3;X<\9\62 MU9MM\?PZ9L?1DK,3-.%L=IFMNFFEJ3%IMY+?^=>,>41EQ>7[+?SAQ=QWFZVL M[7/BI>M-YF^/DVN:L_HI\'RX8MW7%B[QEQ9OBYMUMKSMMS6VYS[BNML=\=<>XQ6SY-*5R_GI>?\ MN8Z9I[O_ *G'S3P;FN1-C.B;'8%!2;*DOQ'-68CEV6LM MZ^Y'C*.AVN%R1GK6GJ59Y'K52$%):1[VE'Q=O\-S][V6'OV2=KN^X3FW6D[[ M:S\/-AS9NNN2,7Y;X)B:1;#IK/P;=-XM,Q:.QW?YE;7Q?N>X\2PQO^W=FC;] MOZH[5OHC-MMUM=M.*^*=Q^;'NZS&2:;G7IK&YI-\,TK6:7W GKOLW'+_ K- M-79[K7#,CQ7!2$QH"AE$F%*-" M2"%4A4=Y2?!?(-AO=IW;QW>[#:;[;;/-AMBC9Z;7+\;/7-;_ "\>6EL=:S6( MK-;S>9B+9+6ZK1/@:?-3Q'NW:^X>.^9]L[OW#M.][GM]UCSSW+JW^WC;;6^V MI_G9MOEIFM>+S-ZWQUQ5K;IQ5IT4F-=B^EK)YXL_-<^)DMMDK-[2]N642C92 M.RFWW?B5!AQ78O%'.E1\7K,1J,?"*&(GW"$1C7$>KUVKC^'\:^_PX\$_!B+3&&F&F*L4B>N9TUM.NKRN;Z@[[7%?:^/=KKM M-CM)[-7MF.V:CMLR, MKUS9[?VSC^;XYIR1)L,&K,G1K1IYKMOA_DM^Y;#<>4=SP;S8=JM:VWIBV\X;YVE,5<=)O;JGE%7K7>_F-X1B[+W7:>"=CW7;>[=_I6F\R9]Y&YQX,,9Z M;F^VV5(P8K5IES8\^-- 1J+X7B:1?/=Q[-WC M'W:_>_'<^WQ[K/@IBS4STO?':,4WMBR5G'>EZWI\2\376:Y*S&O3:L6>I]F\ ME\F.N* M<^&M,E=.NE*:X1?N<00PC8PB.5O1JHUO/V/Q/#V'>TS M;7+-MMC[;BVL5M'YYG'DRY+9;6C2-;SDG6L5B(G73A,1'5\I^8.Y\L[9EVV_ MP5IOLW>\_<)M2=,=:YL.##7!2DQ-HKBKAB*VM>TS72)UF)M/S'-4R,8Q'3-" M2Z#.?J&N."3(9 *%M_\ ^D2]Q+J 2RB.K^I+9#]%<9>UBL_%>Y)L?&K]N[9V MK9VS1>>UXYB9Z9CXG_L^3#PC6>G^OJ]>6GKJUW7S?%WCOG?^Y5VUL5>_9:S6 MO7$_ _\ ;,.ZXSTQU\,71PBO&>KTTF&M:ZRVEF>F]58?F6:8X76KL9U]<6,: M/B-A6["M*RJ#47L#";2:2Y?1P8L>7$%'E3P0V2Y,02L083/U]VW>">P?I]M>\1AM7]OB?#K$6K6M\E:1>]*Z=-+3-WOGE M_E_AO8//N]]^\?[?NZ^6_K-]BQVG.D8HS7M:MK7QX;Y9QX M\EHM-\F.L8SK)];L@E9M)O3W>OY,)VV:C:@LIL<'DVNUCAKY.[VWE\VRMBGN=-Y&:VWF^\F*9JY M8V_QK9)BF*D5^'2<=:S&.*UZ8_-:W1P_-KMF#QZG;<6W[I3<1V3+VZ=M3>5Q M]MB?OXKDOVG+VR,\1;) MW7]9U=/*/UM=W\/3JXSI'P^K7G^;3T>IX_/L6/R';]\_2VFN#L'^FS3XD<9_ MTN_;OC=73PC6WQ>C372.CJU_,T/ :.NR;V.V'F>,SUG:_P LTVU,>/)IPB][1_5UO9?)>X[KM/RI[5V#O&+X?E.[ MO;2W5_F?Z-CO^HVN+-3_ UR[[+GS89G\TXL5)T^'\.9MSSZ6^)#@' . < X M'E[55KD:O:YS51'*GJ=43@5<]EM\TFC*S6]4/7UCN/:NY\^B:PT_ MJG'28_!M\OR?]!NLNOYTJWR0X*G&<.PW#<9L;>XM)"O%$BQD8UA9!@!*6(U^ MXAJ-X1HVT-!:5V!IP^";+WAJW<>RB4X+7%,JI<%#I>ZU;47&.V5_5($=Q+N$ MVI#+$+#"H&LCE:3L=VHHTX3,US"]DS:>7L;)ZB//LZBJ"U5EUM-8F:5/J/8IKIXSK/ M)OWL5[59CI'$/7O*X?IWD&:/WMDNM]?/QFTSO5>$Y)K?:6UI=;78K@N51K*1 M;5TLP;*66/83:Z3*B171G*UQF.:[A(K$Z\>1+[ >XF2:/R#):"J]4[C8X=8> MME?[/;HE4^PM:X\_!,.E3L\@V-)30\@?'3.H9'TYC. M]G<[L=U3JOX\,\E2_;#V2SGU8Q_.MF.]5)>Q]%ZRP8N?Y]L:AV5K>@MJVEIA MS)V4#J\!R)D6UO)]#51U,(?V0MF/?XAN:[JO#58B>&O$AWE[D8UI3V-TCH4^ MF+G+8NX)^O*RSV-6V>(5];@DK;.495B."MFX_:&'?9&.;<8=,=,=":J0@H-[ MN]7=J"*ZQJ>]Y^P.:Z R=MA;>K);O1:9AJW$[7<])L/7$:;$D[3S#%, C62: MTG!B9'-CTF5Y='#):T[2E ,AAM=T:QPB(GUXEQ?;/30=KYWJ+(<1MX%OAGL7 MJWUHA63Z"KM:K)-@[9T=2[YH9D1(I22:NBB8W;OB29$IC%9, O1JL>QRCIG3 M7W*?-_=?U5_WC?\ 0-FI,85!^V__ '/ONIO+1Z[/9F:9&F++F7_=_2U_U-;K M]+;H7[GB\GZ?TE>/Q_'"]$Z:^[5:.%[IZUGT>!W;=<9$V/L'W;V#Z0P@E#CB MEA9MK_,MK87/SB:J2U&_%+&9J>48+1JZ:@Y84<-'(]&DZ?X:KN.H*5ZM5]36 M/5CNYBOKXCE8O7JJM50JJ.55^5_MX956T5OPFVMP>Q6DO4W7AS% MF9#B&85>98QM*+EMAA^251\>9WTYI$#$BOD0I3&GCN,Q.KOE>%F-(B?24%:! M]XQ;?V'HS%\A]7[K5^*>T>$;*V%HS/I>8:WRMF2TVM X[:6+/)TA6JK!,KON3J?V4%KZ-B%#DF*Y-LCUQP3VD#C5U40F-JM?[#R;)<2 MIPV%Y5'D54S(F7F+2VFCC5R,$C"(Y4?PU:LU_:NDB=.O]Z]5_P##^'#+[P#@ M' . < X##D_SCF1-Z*JK1VR)T7Y7K7R/RHB*CNO^SYX'Y_?4?6U'@^IM03I] M#;0L;L8=BTLN*;[4^N=8VUM)@_I5;WM<6W-:O>\0^Y2.=T[T\?QP++QLF%IA5WLB(&/4HRS]B- 7+I=0=9P+131K\3K M!TYY56;)_*UBHWHT;6]$143@=GN < X!P.4-G15^2X[Z[5%KC,O)H)-B>QT\ MPF6Q:@-0:LFY5.@W=E,$072K!-"QAF*[HHW]/P^.!!V196ZHH[[/L@@Y+99G ME42-;)L&HL06. @N:I\V/CC*JA<]H[:5CXV,1TL2#(T#_P _1W;P*!@S+%J#$;#9DJ!_2S,A':T<@TDK+V3+)&V:Y$G @0H,68 B1B(\DAC$>BC1' MKU#>-'[]M:V]E8KG"7S!IDME)R''Y5,>C#G$"ID0ZRO)2R"JE["L8'0K!PG+ MXD:WJQ>U4X%X612PZV\QPV,XO%E7.N]A;37FO7O[$(7!L5(5K?S(A'4%8 W7 5RO"X6>08^0$9A6VS>X_LGZ]:@KL^K$N2)_0^RJ#2 M<>N_4PF!]+,9( E1(UD%(AR=,?;[DE1OCV3UQ=V^N\>-A^TK/ LCSAN2[/U)I"9GX\IQK&M'XOMUT6GU9,]B<* M' R'$3Y$D:\9#R:W*^(:"2/&8:4448L5K/$X4GO#[@6%ML/+:S5.%[$U[J:@ MI+C/X6OZ)TO"F0#>EVOO8:XLL+W\[;$QV87,C9><1ZRLJH>%RF3*.4$Z2D=W M'0=->7K_ 'G':_N+[,:VM\=UQCN0:KWEE.69#JB7$SS26H9>10X=+L+%=^WU MK@])KZW]C*N#DV617:9%-JY1+!@W[BVQ\PE>NU+ M.B833"SS \?)N38U+KO8N:83@>?[XOLCPSUMK9=EC][,PS7%^&YI84K+\8R/ M(?M12WD6MB3WE8LH@Z8XGZV]DO;JDK-70791KC*K_8F1^R0#R\/T?05[Z>GT M/GU1KJ$%:;:?N/K:FD.O)4TDZ5)'=ED >HXXX3Q^64P:5^W_ &-XUE[9[@NM MQT5%D&0:@R?$\Q]I]T>MD77&+XQ:T^TR0= M]*BTM'Z[1=F.U7D.64U/DL?(H%;=2*+'WW$G\@Y,>T:L1H5DQN18I$SQ]D$N M.^^6[=K;/L-75%AIWUVN\8V;F&N,\3;.,6V,D& ^^'L3L'_6?-!U&&TF&ZPUI_ M5=?41L.QNVJ+"\)Z=8'OZ/&GYE;>QV+[*("=F>:*V,R%KXX"5#8['RV$)(DQ MQTQ]OO65]5MW^P^\J_V%Q',9&.8-G>M;/#*'%[3*=3#Q7):RSRC$ Y1)LZ6!&#)7D(4S:(C315&%^X1[,8QI6BSN\P+%] MPY%E/H#L;W"21K/$ZS"Z+ [ZB;2NH*_*J[/=[LG6V 5J33+--5R9-M+:S^6 M*HU"1KIC73WZ+;^K^_MT[DVOLB'E[Z.#KW',JVKC&/1:K#@Y",&%TJLVB(= 53KT^5^/[/X_P"WAE]X M!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' M . < X!P#@' .!3OVGT%L'9&1Z!W/I"ZQ"CWIZW9_ M;A&U]893.QZ%;VU%$R>EDQ9\*TCP)QJ^XIH1/ 4/F&\U68C6)Y2C[:6G?:G) M=I^L7LGB-=Z^KMK4>M-\:WS[6N2YWL>'KN:'=5CJ2U;KUC8Y+(-CDC4 M@1J"=C4=LL=@1>\+@-\HB8TF..BO%WZ'^P]9Z2:,]0,?FZ#S^+A&O[$&597D M.0[0U%FF![R@9%!S+6.[?7S8^)8WL.QQFXU=D99SX@YE0V1+?]8CY+ I*@RB M]4=4VXI:]D="^Y^U=6^H>,T=MZ\9CL32^P=!;JW)FN<9%GVOJO-]GZ7EU%O; M1<.Q[$-;YJ.LQS.[H-67K;@6G9.OZ;-MEU%8[(*O-MD95G KL./6^(U.=8'=P-QICU%]DM?YWBVD:#$*'V1R MC/8]UJM=;CRM,L#C5!$U'LO%#UN73L@#->QI8GFD14\[7?E )UA9N( M10&5QN$ZORZ1,MEWK^W)KK97L1J_V:PNTRS$-D4OLGJ7>.UAIMO<$'",\@ZI MU[9X!5M;J^HRMNMWY>VHCU$1LXU8QY:^*4)2N85["4BTQ&D\M$D^T/J5 W/= MZ&R;!<=U7C66:[]JM*[TSC-+?' 1LLML2UC<2;VYJ:6YIZ219SLCOBAC1&)+ MD C)'>1Q"+V-$0D6TU^Y5"A_:MHJ++M=[5C0-1AW/C'[B^UO;[)=GQL>L1Y5 M?:HSW.=TY%5ZX;<+&^Z[(:^CV)5Q#>14@*M>]&N5OC52]?IZ::.Q7##EEK_U MC]P87OSF?LME>3:9Q/36:6F,DO\ #M>Y[LRYR[*:76VJML:VP.IR>KMM>XIB M\P,RSV/&OI+'RSLK9U4Q@/LJY#L-S->G3U,'K=Z:^S6!;#]-#[5L=$1]>^F& MK-T:YQ^QU[DVP;_,MFEV95X9C]5:W-#DF!XM282ROK\363)$"SN%4YD$-W8W MRJ)M&DZMU- M-]8L3T3C^N,HVMMW8QL8M*3:65YS-)0QM@Y5DE-C^%CJK6%'KJ^$HAP3-E*$ M0FR2J4W-IM&D\]72[^WY_P!B?V<,#@' . < X!P&')U[<)@N+;8DZZQO+I$3/O]079%91$R M5UD]ZGCU1JV.TS6,5K6C=^=O;\\"IWL!["3SV;L-QLN11(-MDE%&P['K"&DF M/@I+R8*#,R.WE59229$JRR)SF (-JHXJIW=$ZN0-"L+K?FD8S?R\AWK*M98JJ7D$EZ1_ M AO%;!M:11QI(QC3R'9T5>WHJA8 MC!!PH^3*.LH*"@Q]^>>J]C2!Q0SR5,U+J%D]C;6S0.:UT%9%J1Z(SI_+&B-_ M!.!U(X!P#@' Y+9!$B6>+>OM3-O+7&R3LV]FQU\ZO891GL!RUS.SJCD3KP*M[ .1KW#X% L*1=TL>YN[+$L/[X^E,:QJS&ZAD@ MD%ZF,D1\PP7%:/JGGZ?+DZ] BSTE]M:CTDI\SUWMK$,R/ ,"HR&!9!LZJ7;R MK6>Z%"K:3%Z"66$TF)R81B3?U!\SQ-Z>-6H[KT"(VVN8;]]E=E[CQK [.+&S M:?E^,N96W#KV%+@?5@QA7&)Q)\M9,:T'CU4BV;8K6#!(_*$BHJKP+YV]=6R* M:Z%,7.:FLC:?S>UM,$MZ81\ZNIV+U3ZA;6KDM\L^#1S%.L@\=Z=5^%>TB]7( M'8C5Z]==:Z7IV_\ I"Q!>UW3JG6@KT3HB-1.J?A_#Y3@2#P#@' . < X!P#@ M' 85Q7%W F1EQNA6-8-5L^.M/7J"SR"ZCXCC +G+(PX656P:"J%9Y+#$%T<43()[(C95S&''KE%#U5O2 MKN]@:4FNS:B$7:,V/<44Z#8;;QZOP"P?KNTR_$YRY-#D!7*3)$@$#,^M8^"* M4O3K//BF3>NU9%-ZJMWWDGK1HS;/],3K"ZG8),V :7CE?3VUX>I/?8KE.6Z! M%,FWMG82 NEQCT-8B^4JK)*HV^8D1QTUEH%][G:MTM;['-9Z#QG'MSXOMC%] M-YE7X.0)_P!V-)UW$R?',@D$MO7N;FD60S$X!($X-]0X]>UY(H6!B2J\T:8\NG MOGDTVZ]X-89/)W=GFM?6S2>R\]TKM?$-;7\R\V5A=1E=_A.?9LSU^Q/8];=T MFL]@W$*KG[%K;VF)56B09@J.J;,3O'-CQE'3/#696HTK[-Y'M#>6QM;GU1K[ M$5UQE$G6F7W\?9N1W673+3&,%QS-%;340](5%!:8I"M<[?$BDDY'$DH/RR?I MC>18_"3&D+A-Q7%VQDAMQN@;$2D+C216T]5W?V-Z]>B<+K+UL9T?;,]93+3'"XM%@$.C'XP"8-7(5S58C?XK^"A0^X=G M6B=R8CO1,5M)\?7)*FH)71[YE$2_DGN+$X8VR+4U?+C AS8DYQ'$:-K&D"UO MY>[@3G[Q^X&*^Y]%A6I]883>2_TW*[Y9MD:]6DM(E['QT,<%K3+7V+8<["0O MMCAF29BC7JUK1,57=.!)6G:^94X/96=S1WV+FFXG4+49>VN%*UICA<.IX\!Y M[.G\2UUE$M7)'7M&C7D&Y'N:5.G M[K>#"K,NNQ@=9R"3]A^IUQ.L[0#HPK: M9W$2/8Q:H\Z[R$A3NKY;2BEH6.)X^U45SD?T^/A> P6L:69, MI_TIAYK?ZTGLQO%KS%J>BKHU#53/MN=G=];.E-_4:JEBH%9$9T5QFC>BM1O< MO7@5^R/3.LK&TR@E+:8U&989,^IU?32@P,Y7)L5K(9R7LN,P@;2;&?!BC(4K MG#&T#W]K4ZM>G ?L3P?%,*,2+K.)2;#M[N!'M-&WM;=M?>R)UC."*\CS8A8; M&T+8394@+Y17C:(G1%'VN3H&X['NK'7NN=U1+?)=@56>1*^1.%DMN^)D5YC^ M,7$)_BP6-9N6*0T"6<_85(H^\37(WN>W\ [ :S=W:]U^O16J[!\5?V_*-3OH MH#E3^'547^U%X&^\ X!P#@' . < X!P#@' K%@?I[H;7-O5VV/8]D\L>/R\K MG8MC^6[+V3G6&8A+S>7*F9,?$<(S/++W$\:)9%G':BPX8O (Y!B[!O98-J7)\NQO"*S/JN0;MR_,M+XIFMU?X]:UGK[C-U:([AFOS?;[E^+3+-/^P;;;U^S:@R!\C+, 7. M;K!2U;4F0625[RJ6(M'+F5XA>^E5=KRDTG&O=D9]K?V%3!-5TN*[#R_=^U:T MU9E^JZO-\9K(,K.[W(I^OZ$.#Y53_9F!+ #"L+2K"4K)QHK>%GJUU]8:[6T'/B>N65W,//N^<8-C<(&G)6-T6+X[CVO:>KNDLJ2Z7 M&L RS"\UQ>/92ZV]D3KX=7E>"5LP$J;)DRGE"9'O5),IIB:S#?L;]==;X?LO M)-K8R78--D689'89?E%-#VSL]->7F3VF/U^,3KR?JXF6OUV6P/4U49.]*Q.T MP&'3H9/)PFLSP3IP@X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < M X!P#@' . < X!P#@' . < X!P#@' . < X!P#@5/]Q]6WVV]5U>-T&*V6:% MA9M47D['ZRWP*&63"BU-_"'(D4.TJBUUUG,*!96,P]*_9651[V@6F$ M"OLM;;AH:"6[#\1KAZPN)$C+\NK)+& ")T3M22BME"5W" M:Z3JB[#_ %$WJVQRB=D^-V$/91];:ZE83MI,PU[=PL?VGK?4>GF4;;'+)4,F M];>N-M77<@%B(\D];95\HSC#>V0Y.#JC\".1ZE^P\_8]GL#)<)A6>6Y_H48Y MMI19A@L_&];;WS!N_;S-H]9;YG ?LRGQ[&[S9E1"K9^,OB.F1*T;RA8@T&@U MC31I /0;?^#U\/'H$&-L6!76=/=87,BY)A6,XSB>82]:ZNHK&WOM66%5&HXL M&!E.&3R%RK%9U5G,3[:GA?9)+DN87JA/NJ_6/<>-X/[FXY:8D^KV'N&C]BX> M&;%=?:W2!HK\2Q#$ZC9HYNIQXQK_ #)/V%#_J+:^M]T5)[J)7 M55/)H-@Y'LFWO\!RBPGT(!3\QEBIKUQ?M3VFDU7UUCQW]AGMX)F)0/F'J3LJ M^35)A=8]O%FN_V^=IV\#?4BP+CU\;63J3"I$D0+">ASXLX2Q8+DCR"HL.J$@S_47V2I\ZV5D. M(Y3AL+ =@9)J>JH-74468P WCJ=4>O-87U-TKN?35[D])L3(&9/@-1J'0^#ZKM)N66V396 M!F++LFSS+'7-=SAD< X!P M#@' . < X#'DJ-_I^^5R=4_1;7JGQ\_Y Z*GS\=5:O\ '@<4=2YE29KI?6UK M%O'QMC2(E)C&LY>+T=48]#25TR0VWQ&38/"L&?:27#(<7V4\0WE;U_#@8,^Q M&#FDB$W84"=BF9RLULHF7R3^J<"-(>F,"K3NNZNZPN_/CI8[H51/!_1-?>ZADN4PLF!*96-#=166 58XG0 MY!B0)1YA5:/K,M98XSCE-;,=B^6XQ.C/ "/-Q\2AD+ M]6?&4CO,C0^%&/:QPUZ(&W:FR$^0YIGG?D5ED8*C?/KU4QG64.(!E%"BCR1@ MZ*N?">L1T2J5OA;X>B=6KU3NZ\#K1P#@' .!PE]I(%_9ZE]6@8\:OCO7V$W& MEJ>8$*2EIW6F6BE!JW2A%"&=(*\:=ZHB^-'=$ZJG EC5\3)H])53\FGY:?#* M;,UR#*[?'\AB@@XM55T:0=U/D#"MD_K-)9%E(PD/X,]_PG :Y.=:D)1U[JO$ M(=K>-3)]L8W94N 2,/'A^MH8GAMJVK19Z2C7S&-!F56/_H,>1&F29L['@ BM09YD$"*Z;.#%KR! M8KO'(8[K\<#OUJY%;KC7357N5,#Q%%=\HY5;C]>B]6JB=.[@2!P#@' . < X M!P#@' . < X%;MP>O!-E93$SG$]H9GI[,3898:RRG(,,K<,MY.4ZXL[']6=0 M2 9MC>20ZJUIK0ASU=E%&,T,DR0CVG81&L+$Z,.B_4K2GKW>YODVO\0I8V1Y MK:03.R25143\II,8J<'P# :? *W*Q5HLDD8=5U&N8!!1I58YCLK(I6IJB\Q74TZBUN[+-QXWN?(72:(V"/@ M;'):6N+1Z@C8#[#9+K>\J-<9) MJJ8;7^H]&XO23,2O/XI=T]W92",EP #620GDD,*1.Y2=7N M8)'[;FA(_P#2P,5L,\PZLQS*-&Y7+K*O)"6891)^3[0MG7:9V;!)ALK_;!T1DE' MG((=A:8WF6TZS;55M3/ZG&=>$N=GQ]L;>=N\J9]76&(RZ7)6X?G2-2J:<*M2 ML<6%(\X#.:A8O*W^A]0BTA@3,$CV]1<1 7-I:Q246NL!U=61!VCQ&)#!BVMJ M/'L;8[[32%?(2/\ 8.\JJ1SNB=#,SK.J9N$' . < X!P#@' . < X!P#@' . M < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X!P#@' . < X% M>O:?$XUC]Y>76U\7-]R@Q>P@JZQKH^4J 3$KP^8$(#CFM8T+ ^F?M M%385IW%*/<5S77 LB/B=>#6OH>\ET%[*RLYR4\ M,.23+BSSVDMM*;8B[AE0<LGN.3'H.+0[K,,]Q_$:;!78(^-M_S6]C/-3[+DVF-[ M;J\BR3 )>75^NLKR"&&)?UV55E[^G K)@EG3X!PFA%H3?NO3ON;FN=81E>&9 M3C>/XQ@NDI>#VF%0M@9P*3FF;;(P[+,?V%;Q[-)5; FAP^W=C4VDL;L)+,9* MN6\*@?,)Y*1-?7VH,L?6GV\KKJJJ[V/G&X<)Q&@CXCA,R-[%3\3RDTE-6I"Q M;/E$O,#S"P-6S)XELK&R9"#;>&1*,1C"ZU]."Q6Q,#]JHT?+\:J 9 M!L"9G7I+4:>9L*CSRAQ:IQOV"J*O:0[?/I-#;WU!;P'9+8Y'5/%8U42L-WTZ DO60-8;?A?K?[.$N-D!GW>88 M-D4[?6<[&Q+:#,HKIE8N."V9M;,=<4\X%?M*^N_R5C/U8+F"M%>Z2!L-XUC\%XO33!=I:[UC>8[M"I-3F; MF]A+Q&)86ZS[]<4-0XX'SY'5P-@;.Q'&+:1D<>Q>L2AMWU9A.9,2-#DRI,41 M+3$SP6WX9' . < X!P#@' . Q9-_\KN0?*)_V';=.Y.J=?H'^5_V?[^!^=3T M=QW8::^U,V990)LR4:REQJZNG1!Q+.VB7%J2""K@!&)X)@JU!^,CVJX%! / 'W MM=V>)ZQ1=J.?\)P-,AY/JRIJ,DK)>,MQ[(Z$V.1K5Y<,-FT&!JB]&*TJ<7Q$ M#+)\-GD!*:LV/WB=V/=W(K6KT!^VM%O5A7F54C8.#466Y)1T-'XLF>UEOAPZ M<%75QX=!&WIT#((EGM-KWJC>K>G [E\ X!P#@98_45V0#BY#DU57]ZY+'GX6YXEMJFZ+$4@)'RJ]&JJ=41%"M>; M^T\3#Y]SBI+Z37P/ZGBYW4!RNMD9+8U9[9@FQ\,G&CQA+6@NX41J!1W1B^+H MYJJ]5X&_8#MJJWB#)JC(QV)$V9LBGGLF3W&KL6J+'%! 5:V4YCDL,<=;&.QQ M(B-&GC1K4-:.8_7NO7#ZJ-V#8JYGQUZ#=0P%9U=\* MB]O_ \#?. < X!P#@' . < X&K93EM9B0(QJJG=UX&J W!AAU1$G&%T8QY?LQ21U"BR7PY;7C?T+Y* M:6U!SF].Z+W->Y%&J.X"DFU,6$KD<6:KF!E%26(#DD M(-J]2Q>I1]S47@8'[>Q%JN:P\DSFD(-?$#JPCFL::,V.17(TRVD5WFA]/B2Q MKD8O>G;P,X]K8D8PABDG*(Y([!R1A[HSAS@O-72O-W-:V).<-P6D7HT0"U,MB"G-5%?$5[7/3L7N MX'@VX\1CL1Y76+6IU:5$AN*4!A$\, VC\GF/.B+]B(C%5LH"*HUWL/(434E2F *L9WVRPC" ,,KJ)LDJD1 M%&"-8)].2KD18LKHTJ-1R.X&5NV,3>A7--+1H?&I>L5W<)6G^O9",/KY!R:- M50DT717AC.0R(X:H[@?#;8Q80E?UL"D_S;4CA@E*9YH3AN+%&C>K2R3P2?;C MM:O^9BHKQJY4Z<##_J]BCG*P1C&=W.:Q L1Z&BM''9,18IW.Z?5E]!E1J MJB\#R;;.(1P?8D2S@8T:$,PT0K#QFLDLB3TD@7\X24AGHLUG17@$OEZ*/J[@ M)_\ 5[%6M,XGZ@UX6R%6.D-Q9!"17(\H A"XBGD%@K]N.UBJDJ)U()7=JIP% MK-J8D1BO%,(1J/*-O8+Y(Y +)A.%W.:UXK@#5^F_KV'(G8BH_P#+P$[MN8BQ M&N(>4T;_ *RL-]9?$HI@U='.YRO:H0-DI]8SGHB1Y2H,O:JIP/C-O8>]!O=) ME $X;2E+*BO V,QIG G(=KOYC2TQ^ULYG3NC-(U[D5B]W ]&VUBP6E5WZBYX M?MHX(X3B&4D%ZI* QC'N4LAL;_,C8WJIXR^0?]%;P,R;9Q1R-5A9)$>\#6.8!5&K M)8G/B27$5R-%$,=CH[B.Z-#)3QD[5Z1TB 8*1A$5PY M)I/7KXFU,EJ"FM7\\57M>]$8O=P,C-NXNK'/=]]%&)Q2A9%4LAK@$[9H$ -S MG.E0A=#O$BJ]\5[3#1[.O RDVUB0W^/S3'D53(U@X17J]6B21$:+M2;;Q82#4BSVM=W^3K">A6.!(44T7@1SB./7Q^DLK/\2P5\[.]G7@ M'^KF(^=8_FL/(J%:)$KRN229C4-'CQWMHV-C6CF>".]5[72E0+NU_P <#"NWL0:U MA'FFB"Y@'O.>$4(@,D*@E-(5WPGZDI&$E MQT8."\SS2XKU^3) [PD.81XI!EBCB M&0%F.6SY44RG9J@'$\IW2 .17PF#& M]RDE'AK]J,C>J2XS7/$KNU4X&==K8DCE8V4KPEJ7]KI;.B MO )[2*BL7NX'@VV\4 ]XU?/(5OV&^*/"?(>X\4C4/':T3E5YTC$;*&UO53Q/ MY@^Y$5$#PFWL1(B>*2O3P2/R$1J\!,/< M>&D:CW2)<5O:-Q$F0S1G 8YSA2B&8]O>W]).B-FMZ=T5JH1R>-4=P,PMMXF8 M32L-)ZJR0[Z_UWNEJ6&J.G0DC#[R/L(T14D^)O5Q8J^4?EVWASE&H9_E&56*, MW1!!4)F=8DIQ#*Q!Q9[M1DYJ@?VOZ=0^NVUB+>U5//&UXQ%[SUT@(Q MM<98LI#*]J.$ZIDHC9J*G=&1R/1CHY%26 M%K$-OYW0E\XT>U%X'L.V\1,JHR3*Y$9 L M#M^L(J_E27_*)V.7@>?]6L1[HR./,$TZ (XAHCQ( )7."]$:O=P/8]KX@\92/ER J$1#% 2*1)+/K2&QK *@3N(LFK\C2G8GYD MCKY6]S$5> E)MW%Q.*URS7*)T@;%#&\Z2Y /Y@XT11/C@M@2F>&6CD1T4CF^1$:J+P&\>Y< M-(BJLJ4)K/(AW&B.$^.L8WALAG$YW>.34(K2R!?+TC/0K.]B]> L'MC%B.,- M'SED"68WZZ1>XABPFH=\>+VO5LDTR$OGA]J])8NJC55140!=LXGY"#%(D'1I M/$)X@HK9+RQ_L05CN4C!D!:=%#&)W(Q\IK@JK7ITX&-FWL1(CE8>2J(H58]8 MZM$0$A4&V6A%=T;&C2U^O)5>BQCIVD1J*BJ&5VVL.8C7$ER1,\:$.XD0S/J( MPZ@G#DHJ=PS52]"26=.Y@'(5.K/G@8/]7\41Q6O6>WQLDN[6PW%*Y\7^86.T M8E=WRGPNDH(VJYTB*OD'W?*(&=-L8FJ_$B2Y'*O@\<=7MDH4"2*XD=Z.[2!N MA_EB/3\IC=1=4(G;P,1-N8H-K7]TU6/43FD^JYHT#(#W!DF!X%N#$2=%>>3&;_ "%>Z5%,!0->Y!R_L,>WN82G.Y&S6?*Q MV*A%ZC7NX&]J':Z..$\DC[,8C4-!:-CU4LU8:K,&-O530T4H M^Y$X#U29S39%)D1*EQ9!HK6D,JC\3/ 5!OARQN(J*:!8A)W ,Q'-NJ<>35=[=S MH5AY,CE">^!D]F=7B.\3ORJWM54_'@:[GFS6>OX*ME,.[%>ZQMY8+NSFV3;G M',QCYF<\L..G<1LMV22GUE@L<1>]S.U&*K/RIP(PQ#VG@Y%?8/C\.?+N*F)L M"5FK T]&>AMFR(LPQEMIOU(9Y-,%JQ6Q<.OH2^*,+L(X*]$_PJJA+^ MN(#*K++:,3(J;([63LWUHM;ZPI:]]3!NS2H>+:#L(N,-RJ94YC[.6(@2A)(%4.9*R9C<@.!7-84< M!"_+7=Z.;^7IU5.!4[:8P.UIB>228<*XB6JVE'+W:.N)CL&8*'6R9U;*@X\> M0RTAB%8(^,8<=5>O>WR?E5%0-6_;+TMH;R<6UK=,N=;1 MWYL.BN*[*9V0SLQR.JEU+34&62Y (38-A!R!Y8WD$G?XA,8-SNWKP.D]P3*( M$*/C]=C(:LC-(Y9$B8C3QH5EK*=CDFC=/R>7DUC(593)(B#148G_8$#X;U5WY?_ %E.O7IP-_X!P#@' . < M X!P#@09NQC5C8^[L$YZRI@!]0D^T7[,=!$B1#O=^G2'R1JO? .WK.$CFBXH^[ANM8MZZ-6Q;]T33-%NK+?7_V@K+ME0H.%;*(,'ZR#QQ'=O"=$\-..L+#Q-PZMG:T#N=FPL)G: M2&16CR$ MV2WE9(1]*Y]>YUO6.>$S'M1LCA>BVNFDZL&8>\WIOKBFUIE&7>S.DL;Q[FN<&2TD5SE8(I:> M4*TXA^[_ .K^;X5B>QL1E2IVK+S!?:#++^YGY9B-!D.$Q/6>-!OK3'[/69K. M1D=R[.:VU@3P!JY$AN/+90I9"#9(>$9KX=N4\^!1ZG?NHZM]H,5M\US+%\2] M?,"I=%2?8V[RG,=[:SS@5+@%AFDW I;-@TV/!I;2AL6RZLCK=DEHH,Z6%8T9 MWZ@+J\EJ3$Z1QG59'_OT^GS-31-]I[*:R/J2TRP^&P,]K,DD6K96>1(DE\[% M(=>M8;(['+!4U<21X25PUGU07@GC%V-DJ3IMKIIQ;9M[V[T3IGU:R'W&R/-: M_(]&4>#P,]H,RUV\>2 SFDD3(\?"X^O; 09L:!93X\F*5C">%\U7X=M-5CY?N'ZL5VX;[UYNM_ MZMA[EQFMN;G(=:3K/[>4T<*JQ63G>:MLX,$:5LJSI\0C+<7%5&D)+D5J)9Q1 M"*BM6L]-M-=.#[ZD>V6E/>'3=9NK1M^:WQRPOK2@DPICD!E]7DM=/E4XH%[& M,0E?%R:^H1QY<9#/<&XIY88DCQSD5>"U9K.DK#/"@G#7M:PL8(S"D1T,X;AP M)[8<25#(0B&B+&(3Z<20?O)5&5:^>U\9["(0H;(:Y\D*I"&C%LV$"_[T$#4@ MF')>UL$;G'@BJ9+E61'8Y34K>!GDQO+W%6&YSUDG8]),04N059E M?]R0,T"(48)$DXV_:G11JC;*,B6,!S#-5B@WIWM,![&M<(ZULI&#)T))^]%= M%$<+R*@9\BTCM5 E*C 7L)/KF0KJZ>UZ.0G :YP4BM5K!@##:PW1\J/*K1PFU\M#*.6 MQA'R(U;53'IY C7S8_+5"C4L1SFH"QBODR#C)%:IWND1RC* $P:L.'[QXL@4 M=S>I2/8DB;$!T0[4;/@N3M<-0^=/(UAE:0CB%B]_5\>1/(ZSCO"JN.G^3L#V M8&=6]4;'R&(U47QRAHJ@@88PNQX?YR!C@.Q(LYCU>D8I($.1$DSF](R/[_! MGG1RC1'5T]JN5A. X/-$\355@1, R6QAG&/6LC"II+7,_*@WR:F)32W_ )E_ M-(QR2_HJ&C$^ \2PHACHC7/&_P"_'D0BE\_1"B9,EC?6QQL>1L=Z)(EPPKW- M54GP'(BO9P,D:0)Y!HYR$65)AJA3?YN1,-:0W-+',R.QL:SL;6./JK&](N1Q MFHX?BE#3NDXW*7H9 M#0BM[0H MG.8@>)40Y9(_*SR'._M43HI)[;(5E&:T[GM Y@[J7/CL0A6C5@+Z.U'!04P: M]0Q0I!&M,5JHXQH9I9HQI'AR',8":%KJR:C)#4 M+P%GU4^DYS2 9X!N,0C/,V..)3S7"#*BS7/^S60ZJ4Y6QG$1TC'IG<"2A8CD M5 1.&0#GC<^,-S&S(0U5YRC:-DH"312B6,!\B8$T2"[Q2I\V,W[$H3'(&[C=)T/Q2&J/ M@>'QED.&>"H7*[Z4OL#8^0QSRT^D%J',UL21,LH:>.',(U(]E$:L"4UDGM)P M$7=V=5&0;V!8XQ6.>2,%R55@D4,H+G.=*KFUT@RQH9R]QJ:0[Z,Q"QRL(@." MI&*(HD;$8WMM(A0$'+AB8R*8 MX?D;\L&.(5""EH(;&0);XL*9#E&1YP!8XCP0ILA'/KB*Z#.:\;VO0$)1-B-> MTS8[1,'+9_-!(@C:"%);)<(PV*^17Q*@[^Z0 ?<>CE*V0!7Q'N8@.S59)!\43T>B-@6$^> :HQ_:V->QVJ!Z"DC1RAX!*,BA\;^]1 M B&C%C6HF-CG.='A39/>L9_= GM60^MCEC2IC4&20 M9O6-!ED_*8*.K)R(5&D4,I8I/"A6-%XAB,\,Q!$#&"E'+ B/$&!C'M*8*QC.4,*: M9K!RQ=8$Y$-V$X'EDGZXPA7N04:.]8AGG2+'"R#8, (K3JI9D&-7G$5F2T"Q#2!QU:*^BH MV3&\4D3VJ"F"9CFL1S2-5[85"0@J*RE,;'FOL ,<*/*>U V8&? M4DM9(&CU#P97N$LD'>IV"CJO@E-:"0.ND.# E@ER1J2 6&1?#&ER$<2H-UC2 MT>%[7("6.Y@ LC$CQQ1AK*"-'1),% /@%=,<*9$&XLFO'5&(I9(6.<6DD.2: M!212.8T'/J^68@BB0SC*1#1C/ASVE_4XOV)8GQ8J##)-($/S3H@5:.U"C9D% MPS,(W@(GJ<3F2$[G^=\:0Y'C;*E$E3QNKF/\K%;$L#6T<:# 5R,!=Q&K"/XY M8VOX"V+8-<$I%3N2,,!V.%9-CQU6"?ZD*;%D2XY'0!@,YP(0_=')':V*521ITF*@V1BK7Q"?6*U35TV60$N7#DE<5$J)CWD0AQ#1\6P<])4?L0CFH%C M@_\ 5I_N7KT5.J]/E51>O1>J?AP,O . < X!P#@' . P90G7&\B3^"T-NB]$ MZ_\ VOD=>O\ M1>!Q(UK )<8;KO#)N$1I$2/IFM"'4S@K73V5L<-A=LS^7DI M']C8$FP>J.B$559"Q7)/8S7&.9Y;2<YG8U^0PZ"/K* M5%R*6PLHUG;+)II[)@X@(\AH6?DC'3QJBKU0+E?N:Z$T#I_"-77^FX&,4F8& ME9(>GQ@.73*VOG4B"F95>YU6U\44EL_* 6LZ/W27%8YT8WB8U>[X!\T4MU!U MWG5S""::4V/4II6P8Q(S]H"K,GHX4K(FXG3G*:'(+5$:;JP;5>1BL:51N3O< M%M]=+?'R:1(OZ@%9,?GGJHL"0[L6[N:4<;*X]9=9&(31^"^EUS4<0:L;XV_" M*Y$[N!U1X!P#@' Y36$ZKJ\9T!>6T_(HK,?SSV2FA%C"#D6MF4]EDE>* T'E M&R<,9):&>#N3O:/IT_'@1/EN"BA2+?$\]B9'<9'2XMC ,0RU25%?A5/-S&:R M71RCX\YRI'M"%"Z,X8QJT;7KW-2NDTV+9Y)P&J M;;43[V.0<@+Y$F1-AG@QYEJ ;CQAN^F3\ST:G;TX$JZ?T748#*S"[V/"PTUU MB-A+R+:%;_I^5R?*<#K MQK)K&Z\UXQBJK68+BC45557JU*& C%2, (SE>^O1.VTA!>QKS(!63(K M6_9"J^%S7!S1]P/7S*/8R/ZS1\8MZ*KE:>]R]%^PN0/R:*EC^NXUKW^HYU[0 M4GZ5"-"GYC=0K02UZE6-7W<<'>\@I8NCS59B-=?6%!O;S]MK9/L!DW[DMYCV M6:KKS^Y.D_4+66J39::\DEP>RT7E3;>^E9/:LQH\N'0WK ,%2RXYI;DE#2'9 MH(B#?PU%XC3W3+0]E_MD;GO,IWAG5+)TG'66 MA,3TO(=BNY=3")?:KSVMR"C>6R:6GR*J6$5D60P0B([A8O'"./+1;BS]*=L9 MW^V1<>DFV=W5N2;JN]27>$W6Y64CX5 ')8>2MSFI@VF+5M743;?"ZLL:%7WL M18P["T@A=: :KCG&IGJB+]41P5UVAZ8^\V]8&([7SFX]5\0WUJWV(P?;>!:S MTJ?9&O<*RF@I],Y-J?(0YI[(8EC=?N"?G63T^0/ML?G!J9$6%#C?1B*=7'ZE MBU(X<=)C[<$N>JO[?N1Z.W'ZK[2R FG),#47K;O_ %]D=5A4[85JD;;GL?[# M4>X&WVLI^TYN369<7%#C6$%EI:2P$L)Q7@-$BL(@ADM?6)B/657]6?MC>SV+ MTNDJ3-LO]W5><&NLJR1MCB]6S%Y6)Y;TM<8[,A_ML^IWJ/6 MRX4W/_THNY?4KF9>O>3:PF[6F54RLQ5^59DZS#C,PSJJ' D3JRNA?6IQWWU GR,< M5XYT44[HB&>J(OU1RU5ZV%^WIO\ W=@ONA*S:VT/C>RO:WU=]+-04/\ 3MIE MU_@^"Y3ZW9/=2LF(MUD6%0LJB8+;2C165LWP/GUUJ)P[ (Z!?PO56)C372) MG]Y=-]"/:F=[Q8%[!9GG.G\JU3J3V_SO?., EW6U,8RLFK\DU-?:^D:YB:6Q MZB@ZEQG+=62[O[5AD;CV617;$'+)+#"&H2#JK%=(YS"W/[>VA]N^L7K1C/K[ MN&9KFQ)K;(R-+F'B(HHAW M=8M]$:L*2ULUBO4R;&^0:(5AV,,Z.*:&1'GQH0RB'8)40SP9D[J6#%A&>H@% M.CCUAU=6SD)'>,B J0CT ]LE0@(-LSR(<):T'CJI2-,B#1'2J^) DKY#L:KI M-#,5#A5\%_3@>C1_*=B_:1>XLX14*:(CG=X2N,V0L1[2L("Q*5]Q"<6/,!(5C8H&S!M*X9A,@"KI34?$*L<;Y-9"C3"(4H7*25C\M M$(Q7PWN1 ^CD,*J-K$WM(LMKFGFQ0.[3,1MA7 M.:C2,4%)48YZ=CS&:<@F,5ZQ[4_VK*,XZ2&?61L>QE3XK>T;G=(F0Q?RJK)H M^J@V^98_:<$AC6O2*=OAM%$(K#O?6UYXUA8B(CB1G-<*#,.W^4[K7V:._E/X M#P.2YSWE5[? -AU:LDGT@@%5/\+!E&-GZG7Q*T[U5S7+]C'Y2IW*2&5$0$1Q M+$[O&UJA$0[94HW11 MJ:,]IR(!D>ND-@@/%EF9]VK#4SB]S?,TAL>E.5I4+7E1$!S88*O-"EM"B1VS MF(QX9\5X_P!,8.;8]T2(1SFM4CVFL*^(ODAJK;* OBQS!I\0DF=D0Z M!CI&A2EKXQWC:28U%/#?7 M-0=,Y)<^/(A02J81!F7[$P 5\T R)8P>Z,KA4J2X;UB/)['("1[?I2.BO'V!22U7FB*&/X:HR/ M=&D!C-<6N@03$\TJ,WK+H9#DD@5\0CF(#H,P7,,$C'=40X)$,C1]PWN;]V<( ME7'W@(I,9'^)[OLO245J]6I'M'G/:1WM9)C M&:-(]E928C%8$Q$2+D($\!&MEB1W ^!DL:UQ1R2#0PF3(YPV7T!N4KB5T0@K M&>%43Z'C0,*<7JZ,9?TZQ[A^-R@K,T)0JK^CQL%)\D=[7QHW2G(J."<;!K90 M8E?**ARA:OV\$][>^6C MO++@1NOG;TLJ]4>KV!7HAHUA*:6QC^5[^U6AA6O14<%J1_L$.!@5[0BHY[8;%'U)]RMC52A'-)8PHS^Q&JVT M@*C5CGM"GDF,6-$)%F'5L=3J)CH]=,D)V3!HM;/;Y^TBA MG* 7C&<;U4(8ZR8LA7.A1PPX,I(0NJ&=]VMBU0? SQY M#".I1#5L6]B)]J-V2AKU# 4/Y M_.U_D$JP%"1I8Y&1762$C12#MSM[9(2@8HJV69JQYX>Z#8(DA!$X&&/)(%SB M$(T(0M\X2AFOB-$&-+2OBD+)GL*2NC5YD5D8SU^S1R'_ $YODC%8[@9Y ?\ M+E$8JC9'6U809$9828[Q"&V#;ELHS44HD:(-V :28BCE,>C@6Q)3I" MJQ"/\A#0G#*U12I(UN!N'%D1SM8V+8+($+QPI!D\%P)%B2T;)&CE!++#W]KQ M_5$]D>/*(.-.FU[&LC271(IH\B0,IZX-65[OJ2WHCZJ3W1)Z$C/:J!Y8<<8R MB.5&! P[AK(B/A*QM,1IYD67%C)]FNCP3E0\J,+_ #=(5R3(CGQ"N&T%JHQ! M$$1W>9SB@-'*QS'2'%%^HS&EKP/5ASRXC&OEQ0J@K2/VS8*,D->G 2$&5CAE M Z2K)+V.:1CQSSM);@\(7A(]1@LI$@ E" Q42/>QD^H=!S!M>H. 9[C1QO ] MC7-9]SH*;+KX_P D_2XTF/.L0*YGU'M4<6:_\U>?K76"/%VOX&:2!7HL@;F* M0#"]%7R@B(.E,YWU#$:KIL./$/\ SC":BRL>F_YH/?"T9W M0Y(7(81Q*D5;:>YT(+GQSOFHY3SZ^/\ DL!)^J5ZM?W,X#B/QSFHB*6422^* M[_+R1W2R?UD'5"J0G9#G3;&)\!(C61K^*WP$1DUO7@,J^(3&E\C!1I$:.5AA M2)"?7=]Q*:"1LZ6Y6MC@OEKY:ND59GJP+WQGC5 LN)55O5W^+^*=$3HO\ M?A.OS_O7@9. < X!P#@' . B<""=]Z&Q_,8L<^.8]1PJVXRV-08K6(5MSF]'E./!2QRD#84< MCZN2"-'>EC+V93@K:*NV/ M.C1FQYH@,F.2?5@K(PW"1'B KFN&]BN:JH%^L6P6LHI-/K2FQB$S/675K@5I MM/'\F2N!BYGPX=O*G?TB4EBT925S5>AFH@6>1.BHQ4=P)NP T8N<9.L6GN:F M3!VSZNTEP7(9+9DG(Y=169'"9E$9 $4<8-LP?D:-KNUR+W]J*O3@=4> < X! MP.%GLEF!\0UAZL3ZR38PK>VW_NS'*UU=%CJ4Y@8(GLCN53*J_ MAT3JJIP)"P!F.Y[!C5UK@P\QN[S9$4-5)RO+V1S4#'NF$9E>),?)B$G.Q\GC M>D!7/=Y51>C>O >SX-D<6L%?EV6>77AV%?T66U#$V9=NB&CX];F4!"3 MR1\=E$;V*5I $>SO5_YN!ZGX%;T8;*=L?,X.8VNJ\.BQLKD9KC#J776>9+,+ M%-C=->Y,O5U\*BBO8)%=YW3>J=&IVIP*@^W6RHF+X3M6QA8J\,IV(PH=C48Y M(?%$R4"*$0J+$X30RU0$TQGE89412@56NZ.3N0.^.KG*_7.N7=%3NP+$7=%1 M>J=KE5JIUZ?/\ LX$@\ X!P#@' . < X!P('WIW?IM(UKWC8DLQ#.4 MS%B"&-8ZL/*CL1;"(@)"L4=E'Z_IQNTADTHG-ZH89X\R*_S- M,V4LJS0]; 1>VTKE:-"#X#KU+)>]C7O(Y[3,$3SQK-#EEL M1PQ/:QK0V4B="Z]S6]L:_BHKV(R6-5X#2\9 H/HT8VHYC8\D1"159W"4%@9PE>UZM1GB9T#\,D)6ACBCM\:D IQK-J(E M5/)V">7NDX_*=XS(2(5%0/,B.XH.UPFL>1K!N1]:8(QJ%_DM(\N+#(CG"CN[ M33H '(4)52PKWH/O;P$XI$AJ/8KI,AQ%)WL4X+0RFD=#$*YO8R+9R+*$WO(( M/;#R$#?)'0:M'$L"/;&,_ND8^9 M5#,\L0K.T,GFC &T,D01!8P@$8>KECCM $C2VT65!KR*:#7PY!&DDPVJZ34E M@1 M#PU%*8[J#?W/_P ;!J]YE X2L0,YRDDL(VNE"F(C8]BZPCM<,$DB(*TCM6OF M(V2UA. MBR&E$UBJ +$2*Z'-;.? &U.]P8+V3)#B2@P66'44$TA%-32>L2=W MQW-7@>)0"C<]"#1C8[7NE,-!0(6 CF0L_OBQ"$F0P5\Y&E+# JR:>0Y+**Y8 M;W#X";^8-4&@7$['';WL6"TXC.("1.BDC#3P272H;FRYT<'0-M'1)\!62FO9 MP''QDLD4"B*Z2^0KPD\U--*=[@-6NF1Y*0,\6=^G@('J^)7F!)G#*^(R+-[H\8I^[].*JU]@CP.&] M5!D-.3L*B=@ C\R.431 AB(YTE2^,?VH$2NLE3OCC196/2>AA*Z"]4X'HC1I MYND,BR7+("=I4CM,0J#)+M?+71&M:>:<+6&G08SD9:#[;&O5IFN:H(_*5BM* MSRR%<5Y&+]V!;G?(DC:R.>+*8 4*7*LX/=XRO1!7L5K@'1D]B*H.+"!*-SO* MC%ZA03V32UZG Y',J#PYIT>U$87N!$F'17QNJP)[51R.X#5*"./':H_RQVJ$ MC4>0@&5[(AE^VQ\5@OU.N@5$\G:]&JLC'I+^]G?"(YO R"+U(@SQ/$7Q%$6- M(B(UID:1#VP2Q:_\D]41[3380?RE166-U6"?%LCI M(DB10MJ MDALI3". Y7,>"',D(J)T=7V*.Z#?P'.-* L9KPN*D=B!1"M,L8$,,=/&=R-, MJ2:@53.ZHUS^Z1C\ARJ_OB$3@)31W <0SPO;'5KON125R]/Y3UDVC"QH+E56 MB:YDB9$!T(-W2QKG(Q7LX"F+,,YC&*0\DSU<,122H=F4TZ2WS)&E!$K(=K/E MUO1RM:K8>2Q.BA[)@W+P,Q8[Y"/Z*1R*UI0.1T8YQN.JQZD[)SU2*=Q.CA1) M9$\;A*M;8,5R,>@-S7O&\85&P:LZ>,D(ZP0H.(_QADA^SY"TK:^;U8)7*Z3C M\ERMD>6"5B(#B.2QH5B3 M:Q$=T617N48D8576#6P(9W2(T>,1R&GU_5#Q#* MEI"=X7=O \D 7S,&\#22D4C?$](\A]@Z0)9,EA8J*D6PEV-]KW.& CXZF \3AMAR'B.>,J5LF+/*-.*WZ\X+5K)K M4EHTB@J5GV %)VQQM(V.=% YU1%^J-Z,C2HLN5Y#P00IGY([WHLF@E=8\KOB MN^ ;B#5C'AEQE?'6.\?4T, 8[(\>4,T]I61'/FPPU\Y&G/%#UD09#DL83EA* M\? SQI)_*,!&N;)*&3%>B"@%?*>Z2,EC#D"\?U)9Y4!/L3(P.@;R.U)\%1G8 M]B@JE!D2'L?6L,A5,X8"")5S32#N8]M<4".\#IK"$KG5TSJ".4R.+1F584SR1RC>@ M+%_S4=5>HR@:G0JR4%XF@$J+91Y46*J38D:)-5KBQA?YBGEJDF,KHCW)P&V2 M HR.889'D,LIA0D"PAAF5K9DX9X,)$C3)C31E15 M:@1A8-[GM1\**.-$,KI8'A>UUC5Q8,HC5*)'?8I)+D.%SHA'-0'$3R/ U"@8 MCG>4$@!ZY6E:5'-/8,)'@E\,Y'QW,),B1U1DMJ-FP%1Z/3@8)48K5,\+'R5D M)WJR.^/./)/)"Y@$:^8WZ4NTL(;5&CU:D3(8C4 _LF#[E#"(W3PO9XW,O:1%3L40AM$0C!,+ M%& .K3+XS.=*IXM3.7KV]5DT$EWG1SX3T:@-PV'C&1#L>QK?(QS)=6^0JJW M_-6<25#K'JCWH)R2)8 ]$7JEG7*CN]B@[L*TS7*Q7F>I'1WB?(C6$C[LQJ.8 M(75J1+:;,K6HJHO^2R.'^5OCG#5>!@.'X9T"YSE[2!-WB?U1SWQZ1P+ BN&Q MKRK]>%-.U4:U5JK)%Z->@(@D$%Q7+''$&KT\PW'?6L#%AR_ K@(YSY-2&NM% M[1-[EDX_*=VD4D B= B*-S#,&-6E>O M2$Y40&\B&80G=%$=6.6-+C/BQBB3P24-:B>&$UAF!A%YDEJ*9(IS,/(M?/;]A!OX M&!AQ!*.9_0%S'18 L4;W"KCAL98R&C) FJX,24=%+4&>L2DV/W0WJQ T[) MR5QB.D$>[RV#" B/\4TY8BL++C!5&V(D;-@N:9KV\!"01D(UPUE&57KT5)@9 M\ELLXT;$59$E%@SY5A!9XVN1&Q+Z*GU"HV1Q)E/"KY[DQH1LEPI3Y))'S%1 MKY'^6M9P^H7=DYB+P),TX-H+VW:,HFM+!80 QF[2$BMEM'' < X M!P#@' . U%[:6U7Y_#XKSK\I^/1?PZIP/SJ>FNS/ZRUIJ").D M9'9T,*59%"(QQ5U5/IHUW:5LJMN*@#BI^CK,"1@B.*U1*GD*B(K>!>BMUJ6X MD8*N+)'U1 RR3E]_C6(U5+'SS',5NX#9"IGZYN"0^+&&?ZC7E'Y6'4SNB+\= M. QUN%9P7&[&ZEYS97,&R)#P\C*7'I6:V64;2 :0V3L@=59M,'&V@A%(G8QJ M/+XE17='+P&O/I>,8777F+I5XYD9Z2UJHA-6OCDDK'<)&HUI!.Z*O [@\ X!P#@<9MO0(5IKSUL%;3(==7,W3NLDN0 M:#*LFN7]=R,,>+&!&"WHSJORGQP/$J?.Q')7:UA1,)LKNJR:OK M).4F5(^0Z\K]6K^5[5X$7V\_ H+#5.2VN6& MR'&AW&M7Q VS8[DV'2&O=9'R2B,@9$O(*(3&E< *=ZG[1]W:S@- M&T::#M#5N<982XG61<@M)1X[1R01Z*PK89'/ECECBMD5>)VR2$49)2IW M?#&*B)U4.R>MF*+7^ #_ "IX\(Q5CD:J*U.VC@L5&]/E>G3_ &=.!O? . < MX!P#@' . ?\ A_R<"#MTN1(U$A ^4+)1R*]0C:@"M^NP#AVGUPR/(QLF;%C_ .-.V?7* MC?(W@+5&P@T52$(9Q5>P@_\ ,'F&>!0%8Q"](-H:UC)U_!L>ZCM[VHR6/KP& MI44)D["&=XVQG1R-<*1_U'<&*\@9([F"8 MUGD"-!*P)&_YR(&,*&4C^YSC/4]5#K)"]B.7K*H93D&521'IT#+)CM.U$4+W M+W.8J.@#5PVRG/-)#)C0R-,%S'(AIL$'YP+VS:]4;WMX"8I1 M/"V1(=]L7A(K(@5;764FU8/O($2I'NH[$*#LEC=U!P80C>Q6$D/>QPU"(H$:YA1"&)_1!=WZ7V?1> M$D24$Q'/E0X]257,%(,KCTDI7 E^2$YJ("D1W=KQ>-C!J*6)/(P:":&04=1D<8<81WMEC[909<4 M/;&G.FL1'O$!& NHG0\;LELX!F3#J\T&#"/ MW!CRR]QJ>2JQ)J/C.:O P'C]&G9^7N3["2@-5C!-:0WV_%]3L<:/]60QIY4< M2J6ID*D^(JQ'.9P,**TO1+M(:=D8ID^O

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®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end GRAPHIC 15 g464287page106.jpg GRAPHIC begin 644 g464287page106.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@#2 *$ P$1 (1 0,1 ?_$ +$ 0 " P # 0$ M &!P0%" $" PD* 0$! 0$ 0(#$ !@(! @(' M PH#!04%! L! @,$!08 !P@1$A,4(146%U>7"3$BU4%1T2/4E5:6&%@RUM=A M<5*2DY%",R2T@:$F)SCP)35U=[%B0X,T5#9V-QD1 0 " 00" @(# $#!0 M !$2$Q80(205%Q(H&1\*&Q0L'A\=$R4F(#_]H # ,! (1 Q$ /P#^_C 8 M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8 M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8 M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8 M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8 M# 8# 8# 8# IG=?('4O'>NM;;N&UI4ZMNWGD23+MA).V""_AF5#SJ[!HZ(Q1 M$"] 46[""<0* ]1 ,+$3.C9:[W7K':H)%HUK8S#I:M5VXEC3$<,)8E9M@ROL MY,+1;]%L_09S 0KHR!CIAWE1$0]'0<$Q,:K/3616%0$54U115,BL"9RG%)8H M%,9)3M$>Q0I3@(E'H( (811(\G]"!MHNC1V=6/><=X:*)7/.AU-82LADS5,) M'IZL&X!%%%V,3XWK#RH"KX78 FPM35^%Y^;:@FLJ+E#PVZADG"GBI]B"I.WO M35-W=J9R]P=0'H(=<(]O,(#XO19(? *!U_UA?U)3$\0IE/3]PID_O (_D]. M\PA^J_7)?^8*)T/UA/UQ"D!03I>G[Y0(/=U#J'3TX$6G[]3JPF0\U88QHHM& M/IEJT!RFO(/HJ+69-Y)^PCT!4>/FL>M)(%6.D0Y4Q5+W=.H8$F;O&KHH&073 M4_4H.!*!@!0B+D@J(**)CT.F54@"(=P!UZ#^; ^Y#D4(51,Q3D. &*<@@8IB MC]@E,'4! <#0O+576$O"0+R88H2]D+,&@V*C@@+205\B*DUY4.O108TK@GBA MUZE[O3@?&V7*KT:!FK-;9R.@H*NQIIB;D9!PFBA&19#BF9\[$P]4FP*%$O>( M=!$!#\F!K*_LRA6FNS-M@;5#25:KK^P1DY-(/$O5T6^JCMTQL3=ZY,8J:!XA MTR5(OW" $$@]?LP4^VOM@T_:=,KNPJ%--[%3K;&MYBN3K0JI6*TD&0 MK$3.LT=HB"B2@!VJ)F Q1$! <&F)2SS3;T=%TC"(K%*!5"F$QF_7QRE !$1, MET^\'VA^7 C#F^5)G4W%X>S;-E5V<"O9WTU,QU>AY.>EG -8J(8.I-^Y[%%?!9LT#N'"H)(E455$B*8B!2%,8WV C M@1"/VSK66EVO@M6R8G./_ '2AU' U MU>M]9M=;C+A7IN.E:Q,M4GL9-M7*9X]XU64\))9%P)@3$IU?NAZ?\7H^W WJ MCAND(@JNBF)45' @=0A1!!+M!580,(=$D^\O<;[ ZAU^W \BNB!DB"JF!W & M% @G+W+ 0O><4@Z]5 *3TCTZ] ].!I'MKK,;8(6J2%@AV5GL;63?0%?)*I+IE514362-U[5$SE M.0W:82FZ&*(E'M,40'_:&!\C/69$EECNFY$6QQ2<*F63*F@H E 4UCB8"IG M3E] B ^D/SX&#-ST/7(J3FYN1:QL7#1,E/2;QRJ5-)I#P[?SJABD$0#H&!L3.FI"+*G<(%3;&$CA0RI (@<"D,)5C";M3,!3E'H M/0>@A^? K^1V]K:):;$?R5PAF;/4SQI'[&<+NBD2J+U_"Q%B9MI@P^AJJXA) MYFY* ^D4G!!_[P86I3AC*QLE'L91B];.8Z22;KL'B2Q#(.DW12F;F14Z]#BL M!@[0#TB/HPB%2.VM<1,'>+))6^%9P6MGB["\R:[LA&M9>-D&KE=M**#Z&ZJ: M+U(P@/IZ*!^?"U*<,Y%A())+,G;=R19JV>IBDJ0PBT>)@LU<=H#W DNF/4HB M'00PC(3615(11)5-1-4.J9TSE.10/SD,41 P?[L"-35WJ==GZG5IN>CHRP7E M>7;5*+=N"(NIY>!C33$PE'D.(>.=A&D%90 ^P@=<+4ZI-XR/C"W\5/QP3!84 M>\OB@B)A("HI]>X$Q.40 >G3J'3"/!ET2JD0,LF5=4ICIHB MXQ2=?2(!T# ]DU4U0,9)0B@%.HD82&*<"J)'%-5,PE$>ATSE$#!]H"'0<#YF M]/Q $Q.\O7J7O*41#K]H!@#K))=OB*II]ZA$2=YRE[E5!Z$2+U$.JAQ^P/ MM' TE@M5:JD0:Q[-JXF'S>,B47#ARJFDBI)2+I)! M#" JJJ%*7J(@&!NDUD51,5)5-0Q (8P$.4PE*J7O3$P (B *$](?G# NB98 M[!82,I-RD?$QL1 M%OYN4?2+M!FUCH>+1%Q)2CQ=P0*)UECB!$RAU,(!@81+;5E((MG)8H M4]MWK.3C% 2$D@P<-U%$G3(P+DZ*$$2??#T^D,#9% M$1=$RH^)T3*H0QQ\'PO%Z% 1-^J\QL$%)24M#1TQ&OI:!.V3FXUH];KOHE M1XCYAH21:I*&69GEWJ@ M^!'D76;-VY5BI@=45G"[U$B9 *)SF4* /4,$1>(8T]M'7U5C(:6L]MA*XUL M4>O)P:N%F3)P119,J8G2*8.\ PM3.B1P]B@[!! M1=GAI1E(0$U&L)>+E6ZY#LGD;*-T7<>[16Z]HI.F[@AB#^4#!A&X.JH%3' MN'MZ] ].!].XO0![B]#= */4.AN[_#T'[!Z_DP/D5TU.F58CA R)E11*J55, MR9EBJF0,D4X&$HJ%6*)!#KU P"'VX'NDLDL!C(JIJE(HHB/UBMV;<# MG'TJKK& "@&"(O$)$+IL +F%P@!6I>]T(JD &Q12!<#+]3?J2^"('ZFZ?=]/ MV8& E.1:TC(Q1'10>Q)&:C](Y3IE0*_+WM!%4Y2I&\8/LZ&'T^C V0K(@H5$ M54P6.0RA$A.7Q#D*( 8Y2=>XQ2B/I$ Z8$9G;Q3JQZM"PV>"ACS,JI!0Z4A* M,VJTM.)-UW2D-&(JK%4?RI6[90_ET@,KVD$>WT#@IL82P1%BC(Z7B'A'+*69 M!(,#F*=!5=GW%(*_EURIN"$*L]WM#:6"\+(M&R,1:[++,) M\S6Q62<);I>"F6J3&*GEVT^1L8Z!S',5(Q3 !"IB-.7+M3VH'&;D3K%W.ZRJ M4UJ)/54ULN][&)MJ49RDEN:,;7=A*]8AI$+1/J<;9#SLB0[>7%_T+'(@ET _ MW<)<3\J2J'TY+JM<:Z_MS35E9UQ#[.U9:+=J^J3-QF8+:Q];1VZ1>[1M?K-@ MR_\ F';9O8D4X6;=!:&-%]53F%-+O+//Y4_I'@/NJ;TM->L*CKW74I,S=Q4L M%2F9R\ION0T$TWQ>+1#53?)_5P.(. ]G5FX,3QPNE107*F/1$"]"SRA=<+]/ M;;456+*\&>U@]NPZ$L6MM7Q,P>U3--U9)VS;UDOLG6(=-P@FY=TIC4Y9M$MU MCE\T8S8I1*5(A3#$[1_:#ZT^FCN&F:N85*5F]6RMR;*;Q85NWE=VH'&LJIM9 MYIJ;C:Y5 49J&28QTK194'+E(C:U7?3^ MO&SN[U^V0L_M=M-6T;MNYE;[Y7K3&PNSVA8U)&)BM;UV&/#1P,UEA.V$G0"] MRN5.T.[-'<>;AIE/IQ\F9 MS8=YM5HV%JIP2SZ6LNL'DLS"SIRUM?3FNJ%5(N6MYCLSEF%(>:J[MT=11,A^ MC@#)@8XF "]N/BW>FM.+\O5^.^Y=)VUY5K"IM"S[MEB=B3\\",7M"Q3TO',9 M9)5!!TH=LUE2$= 0H@)BF[1,'0<,3.CDFI\"=^4I6@T:NV76$5JZLQ6II1XX MCI6X,9>-L.NN.5)T<_K%>@4(P8H:S+S%45EP75535 KGH)/$ <-=HU\LVI_3 M3E:G.ZD?IX[S-LF%M,5=*$#-;C*]TAIE *J;MRKVBJW=C<0^)Q>+[/8]88#76]"MC+5WJ M&IUY25&.B9:MZUBJOL&250D$R$26N-J:+R!S)"(K>+WJ 4XB&&>4W\N(8+Z9 MF]8>6VNLYW17I6 O&M=H4NLP;R1MZJ=6EHNG3&J>-,NAXC(4R>R6LY$@3QB] M3K2A/%1!4 V&N\5#>2OTPWMCC-M0$U$ZE%"S7/>>QJE.HGLI9%Q>=LZSL=6 MK=FGDB-"^2FJ'/RJ1DW#PM;6BD5G4]BCBL",$-=:^DYQJ]:JH+*+B#!,Q2%5$P"QX M.T?A;.J^).VH_:U+W7M>/U++7"'W/:[J1I#2]LE?8.GV#5=@HA6U2DYF.:'7 MFW,D_15=I*$*V% QQ(<3@4!$\L5&C;[KXC[ V!R)L>UF#'65LC+)0F55J=@O M&41"G:)G&(8VK/I^[UNCOB MOM.4L3W7T%3*I3"EUDO:+C6YG2ZE6V+:;A(,JD1-HHZD6>P(63:,'S:2*DN5 MJB""I2 )NT3RB+]V[QY>\1[5O_8%!OE+EJM6IRKZLW!K(]GDC2R%FAFNR7M" ME1/!.8Y!4A8V61I*\1)@(@L5C+**(@8Y ##,345X;CBYQKONG=1;GI$V"9B M9?GU ?2_Y!0&C-FZT/>Z-8YZ_P!CJ)99Q:I^X6"NSC6 8[(:RNQDXAXU1)7[ M_/N[TV7<*(F'O+'@7I^K1[C4\[FUFT#Z>N[JLR:15PD]3[.GW&B7>JF6X++/ MWH;GJOR];N=9;P-#8#$*-9&L2R=H2<**.CIK@(+E.013;"9_A/._VZ]X:\4) M#BK$7FK,WE>;4RP1^KAK]9K"TP2.AYVK:FJ5'NDJ"4BF -E;-8:\H][D1'O* M<#&*4XB4#/*;^7'VL?IV[ MY0U^SG-7R-ANHTCD;8*=+7Z2G=O[@?+1!GL5?+L%R;&=(-DW+;Q8\""842I! M@[QN^2_TQ]LN+IN:\%OE&91>W-:JZOB].)/K6^UQJ5FKKS653"VT)V\CR2BE MIKN$:QY>X%$SE"4=ZBHAOK1]-V[,()*J4=#54SK2+NS^7K.E[ M/+7"+H4 A.Z8U%0_;-LK'Q[]ZE<:=?Z3,3[!,A1145ESJ=Z:QC 6G?SY:'<_ MTTMR;#U_['N[AK?:KEW$/X1VXVD]ML8V0M$C2:+6#;U+[.QKQ1[LA%[555A1 M5*9N!#D$IA.)@ D=_SBNU&AD]GT38%6BI]:U6N-5EV%[9 M,F4;3[;7(QHJP4KE$9L_+,%$C JD3M4( G,< ?"]XQC#O[D;Q]M5KT UUEQL MDZEJ>XU!U7W.LY&3;2*=9K*,.Y3(X8"WB$'3PC5Q$BHB4I"' !$HCZ PS$U- MRX(@/I/R;6BU*@WJZ5_:T91K%M]"KNKJ[LKYZPH :=3TSQLCCK>$"Q['0H*( MCG4LX _:L^*JJF941#JAJ><:PN37O"S;M,$8 U&0>)>(DN=;QA0 JG8"_<7"3RB8IM-^<--L;(Y=U M3?M!N$'4(UG17U/DIV1E)V9GZ^*[)1J22IE9612@J[.IG5[TWJ*BBBQB]%0( M ]<$X7U4@.'B2)3)_>ZG,*G7"SYY9W6MJLI]BV6E"WF@0RYFK<@IE21((BCW& %34?IV[>LNTN25E!]JJR4+; MS2A2:%:OKZUV&8L]EI&S=:;";H3,ZJT!6 KSE*@*H'8MB&12X=#\6^)VT-'0>U9B5I?NZVZGZQ8PC)]8+'<$;(LX@%$C'L4XW;&9 M5>*81[ELC%ID!%N8Y#)&, F$"[3Z@8\JY"Y:]8:]:REY;& M@:Z%@86>S4^TUMLR@HZS$%N,5*2==G(\BQS*&*F!#E%(QC%,&#M'6O+4\F.! MNT=TN$)?6>Q*,S:0<(5L$95>DO=&SMP MX:BJ+QLU4!7M4*B4T(Y1$;J9F?IH[MM%[U%*>L-+4:DZ\UH]WA=[0AO_$3*42]XNX=T\5^ M-EBT1+V]]/I4Y_+VW7>FH2:OT*O++6BRV77M37J#X)\DD@DFX81S1FV.P7Z^ M,H590JH ) ZO.S/*;^'&]?\ IJWIVYV7'; >:PGH2TH3R4P^7=6B8>;RF9/; M@;+J=RVS%OV"#&.F]61"RD5$^4.X$P&,!A!$J70UW]?^'5?,WBA+\AY+2,S6 M(^A.7VJWU_:IA%-/4C5>J;35:Q5*M.4F?L.N6,K9H&K7F8A]/4'7$G.OI%DW4? MLYB*L%5=2K 2E[%C.NY7M5Z@*&HYYMT'R_T5L*2X<:XPAA.,_:U*MOIW;7 M2DZ7Y]SJ^::-DWB,/+N9^ZH2W%R+=;.N]Z3KNA$21YD9J,C*Y:T(-H>1,V4% M%BF"G:D4.H[0CL']-/DZWN=R7EN3$>77LG"6Z'I$+&.+2$S2U::T]F.+LJV. MNT(T4?4>GQS+UZ/B#YM\*QDQ4 0,+X7O'I*]!_38$Q0)/*)T]+? MX.<;MV<0J_+T>=8U*W0MTV2W=>=@YV6D)6KU:-JS.+/-6.RV1%O*W:6DY)EW M%4532<"B8O>0#]P .4QR>G,#A?>.06VZM=8=EK"=C&*% 28S&P)2U-+#J9Y2 M+VAGG:OTP+>ZU=+T?3 MKR@5@[A]IBR1<6YG+DUJY+_2Z#?*A=K?9(5!NLC;TK#+6UN]4:.3I$<$:>*; MHX32(:59'/.7ZQ:Q6OR#!S7;Q"1K0:LQKL/&V*)7*#"W*-XA-*7DVD4/Z^': MIODNU-(__=-Z/0&5B:\+0PA@,!@,!@,!@,!@?A94OJ$-8UIFN7EW-$*V**?;&B*9CH LHF=.L M?AZ;"YC\QK/=N8^EX2)JNOBZ\U3O6'I=G:-GKO8D/,Z\H1Y6O[G9UMLFX=K0 M%]E'!DHLJJ:38BY""W5<'*9/)DCCQQ+%IG-OE32KCLC52E"K\G7],Z0N)XDM MF?RSW95JFZ'IE&]P^X)!H@V6EGM5V';5O5X%.W2;@<#E0646 $A+UXSG=,6_ M.3EQ!\BJAIV>HE"DX1MJVMSUADEDY&&FM@R=DU5;]C/KC18=%-R^3@*I,5YM M#N$!3.D0[@WF%47!VR*E3KQZWY?:X\R^4NO%G5.ODSJ^L-Y9UJFRFY .:1<# MT/6-9V;5MKV)*K6&"\CW24NV?:S;QZ3PYTDSK2W8;HN+5)81QXSHSHCGCR4E MN2FP=$,3K$1NZ4X4@/;FQL9:Y".5:].+UNNL+ M.5Q2#Q1Y1*TQ"B$D#9%1FHLN==$Z"I$WB:R"=3EQJ:AP7J/ZA',#3'&?7CJ;9Z\BW>V]7-+%K6)K=M]J]DU**,S56(H5W$E%02G-VX*B(F70_+#DWR"TYY5G3_ M !DJ&TVM;5C)A6UD;<^H M3R>A(S=*-*U'"12VFMM0/'NXVZWM9.,K=?ND];;0_1V0B]ERQT1)ZY;ZA/6Y M-1X=PFR1?2JK=58AD@ 81QCSZ?ICQOW!);3UG07]Z"N0^U)FAQ-QLE4@I$7B M249(OG\4PLD>18B3@T#/N8M51LJ!3(F])2'.!>X:Q,5\/S7:_4.VB@^Y/2[N M2I%A8:DD>1]?0H%0J5KD+9K7W/72?K5%MUV>'CRM96/V G')@8B1BMFYP$05 M'H<"QKKB$=USS,YC[TT^;U0C5*#=(:%Y1%L%J;5"0L1;$;5?7U) MZ\W;>:M;K!6;4]<\9.Z[K>47D)8Z!5M64) T$F]K M$A:H%@FL@HZ0*#4ZH% !(7KD(X\9A7&W.?O*JPW3D]KJA/XFA5RCP:ULJ&RA MJ"LK)T).D[?;U6V5ZT1C)60$325306C=K5_7 M$#1[5-RC5O"3R\L,X'Z]%3J=T!02*=,>_%I/&*N%R\XN1-[T-7Z8ZILQ4Z6S MGE;.\?W^[P1]7KJ]/H]XK.O-SQ4-JZ-K5DF-G:KF:YI&XWRK;2GG*S D?* M-E;5!-(U%@EW@*\@D0XE<=B)S76(J]'JXYO;WI6O7+-GY?Q@35 Q$04]6N B=1W;8['>K>Q)L/57L3[25="!,V0,J!57(@H< MC@[9):D<8F+7K*;PW72>#;3>LY&P=MVVZJM2GI!K"P4ZSKL AX"%$3E:,U$\J\/SDV7RHY6W&%@7E9V>P8P;K M7FZ:[6[51ZC+L8?=]KJ6WN(K>H[7J#@6:SV+BC1%_L# S!/Q@7;L) R8G+W" MF:B(]+ VQSLY?ZM0UW2D*9KN>LS?9]ZIUUVC,-I2L4BX&I:>GWL/6(".>)-U MXZPWIKM)V1HF@#APH,$H9NDH'F 1'6)N8?I+H"^[:O33:ULV"2#C8EC:#P]& MJ,?#2Z$E!,XBNQKZ5]?/UVI7LTZ>2TB9,GEVX]B: 4#*&,0IGE$0_,&N_4< MWC*Z[OXW"9UAK.VPO(=KK]OL5_6;+,ZLAJ7-,MANX*/:':-E9*0N(JT5-N\9 MR2;!^R4>%%9 @+,Q<&ND7M3>5+ZA7+2Q[KJM5=Z0KL) 'H3267I&F83QXUJ^L9SPV,I1Z-LB7 ME(W83UNPV?/6Y/7E*V)&1VMI).DZWF(_6U@CG=?!M:[!2IJU.&C]5-4 ;@V$ MSGP#E7*F^"..4FXA\J]\\AMA<>W.P!/$I,+1RGI=P3J)$_8N]LZY1-+VJC6: M14B7$M75#LE+<[;LU&;YPU5.FH8BACBZ6U]T@2'CI+7N MK-WZQUG2*C$QTRQLMG5F=40.QIJS2EB4;>17C"R=C%@1NCWH=&AO$4*H/9A* MBMZ<8:UYD\H^1:3R#JE\HT/<*M?=(RAY>NU"W$AH!KL:AMKI:]87R!EHUHM* MNZBO(#&@Z3$$SJ(]ZHIK=R96K77C$Y8#CG'RRBZ=O7:9YNF,Y9:G\1[+3M6V M:$I8V33E;,+U%B25=,FR3PID3J%4+V8.L76\OT:V M;R0M+'B5K?=]<49T&1V1'ZM6E;-L&L3B<;JR-OJ+!27MEKJYFR4DV;UHKH3* MHN@022'_ ,8Z90$<,1'VKPYNXF[-WWO?EBQOFP[,];ZSB.,\B2IU*$B+!!4B MVV-ON*?IQ=S-4)I@R762V)5X=.1CVZY2*M&#I,I2F+]\8URB(XU&MH1??J"< MAZ-O#DE 26OZTVUMJVN[4"#B44WDSL>*&B0\@YJ.R)& AR/))>F[">-TCIJ/ M463-)LJ!DW"INH"S^#K%1*/:_P#J#;[G*EK!Q?9"AZZ3?7W9,5.;(DJ;9+1 M[$+2;*_8UW7--C: VM#4;?=*^DF\178KO$G!! &7F%#E(:G6/"^>&>Y^0TAN M6T:\VE('M>O[?+V$PJ,W"J$@J?JVKU.W+[:9,(U\B^0 MVPO;&$2ZA&54M3%N8$?,'1;>&842K&='(B=<'&-%72GU&^19]K\FJ)3ZU5#5 MJAZVL,SKBQ7F(E((E?MU/O\ 4Z2_C+HLF"IF19:+FW,BB>:+%)E% %3G!@5= MRF.L82G6/U#-ZW/9/#^(DJY"-:5MFL@RV*AZB7;7>0O"KUO$GFJW'++ECY?6 MZ#EP"Q).N+3:":0"HZ.@@4ZA2SPBI]NB^67+/;6F=XT6@5&(@&\(]B:[.L8Z M^7.R[_:%KSLJ%V]R#G*H-JCK$SKL5%UJ);NJ34FT/$QDA--JG#+) M>"IZO;NE%"^*=(%#" 8LY5<>J<3UOG;RNFX72&U'#N%=G1J?)F+N^MX2M'D: MQL^[4P*,[JKRJ66KJ6!)RQJ-?DY28419*+O7;*+6NO&+M<<;SJ MVX:-ULUD-B:L"J3-OFD'G(]"@7MW0K\O".*8=OIZJ5F+B'LBUO,^A:'B:+D M.F%FW#JCCKPP&G[$DX=XZN>N:YMVQ2D4[GI6T5^0T;L20F4G M[Q1'S$2^F+LR8J%=JE)V.Q3(/0Q@*)(J9ER&AS,YG:>T"[:S,1 W^UGB]/3L M3LVQL).&CM<5C:MKW[#OGFSUYM"-CW_L8GJ*/26=*+-RF6G$P5$H CXQ:XWL M[SLFX-OV_@*7;KEF[I&RIJHQK^QK:Z2EII_ Q/M8A%V&RTQ(8T)-TLI5$E9! ML2C9%\<%%BN52H9&JN3*97L:':KK$ZQ2$;'^H/R>UU6]12CF(JDK9K[9KM M;7E:0J4G'1JNLH+9;_7<14(^3F%6#^7MZK>*/).BQ:+V1227(?RWEC)K'+'' MC>S/91U%M&[D)V;0V%(TZ]VPD5MT67/74]=R-5UG3IZ\S-[2I] MN]6L5>CWM0A$)BOZ_385]H\73GMF/E!CV:BG:? MQ/0W*LK]P"<8B=4EXJ[IW1NBS[BD]D5EC0:Y51UW%5BA'BI(EDBIB=U]!VZU MA89EX@W2?+1TO+G8D3;$,4O@")Q _4@"8I^><[]1[D[%U_DLT9T2GR]KH^Z: MQ3ZC88YF_0USKO6=FO!*8I:=@2TSZN>1]@KJ)_.OF,XG$F23**_3R71P,:Z1 MA;_]4/)FYZNJE]F(&L0C!.BZCE+36:LA9EGEDM%[NT1%A,URRC&%.SK32,<^ M8,B5,YE0ZE,()")\J=8N5/0'U#^7L_0N3-D=Z_U=3)BC-81S382S/I,7^MY. M0V%%TQY3]DE:-U6<=,$@W:LD@ZFE8AF"I0,X.DP [HC_ !>O'#KR[\A-L7SZ M=D1R"U[*.M:;*F:C2K(_E9RF/%?41/7L46X.3UQ5,Z@QQXDKHR:Y/$1*B8%2 MG,4.N&:KE3EN+Y:\M=3L]_21X8FZX=9WR/M.J8YU&S32;K9:#L>N5Z.+*2JK M)./>TM"%FG,FFF0_FX@XE>><3GB.3,G+X#"B)6QE0[NV7^UGC$2J MR)^HORF/K-"7M"&I*\<)VVK1VV&+"8ME+MLC6JW*V:)T<@C6$I6'CMA6MXT3 MC$EB/50*?J0I1>G2;J4Z1N[PX=3VX+?NKEY:-IS\ZO&.;/J]GKNC2#5TRB]; MUP*>\?OH"/(J@DU?OEY-Z*CQVD8QEC 0#@4Q.F&>55%/T(PR8# 8# 8# 8# M8'YW0/+WA]J@NV*;7:[*T]OK!_&/9Z(BM83Z+JT/['L.N4!![ 13>)4FK"X5 MV'=(YF4YD>]15T51+N2(8Y34\>4TU.SOJ*:+IVM(7:E6IMOND[<5H^$7@4Z! M/Q\]7$37ZJ:_DFVSE%H4[RFMXJ8MS8OAR!2%.)P, >&!U"B.,W4IGR.YA5CC M[+.T76HK):)&/4KLB@%%(JAR4ZS,U"UM["G[22$C)((F#7LMI8MT%ER@4IEA4#HFFJB%ZN;93$[R28GK=X?-GD;2YA]-/XC7MBKE5L$>T;M8M60732GK:Q133Z M>$8JIE?0DFHH05.BF:[SXTU.UZIV2@1Y/=S8HR2.,BZC7\.M#V:.N\+3I.G. MZXRBG+LDR=].E$IRD%L9- DAF]AE*K(%=%C#"#@ITSIJ$*J4283K-6MC MCQO/4?)G7K78NK&CI>JI/W46Q/,U9U *!W-V;]-9@A(,T"JLI".>-U@,B)@* M)_"5[%TU$R$F)B$L3@D:_M#VUQE7U[K>Y/ M)=I Q$.^4>N -?6[,&Q^Y8XI%%,#AU I:G%:HW&<^>/,FRN%DK4-9X23J%>D MF;^2NNLKK2V1PHUG?UZRTA"3<5DSAQ*4^636%9D@FH1(5 ,7T&$<'6=$/J7- MSBYKJBL;-8]:SNFXK8VZ-T5"63=T%XJW/+PFWK?6K)<[7),&*Z"D?;[6S-=)2LG%BV14\RH8X$!,0#KA)X3=-Z_YY<6&YJ%#OFMC,%K M*1\\9CJVQN&FM%XN].]6O/>3VPBC6CNZ]?(M>+6\WX9D5$!,412[3B.LK U+ MN#CGOG;FR'].KY7VR=)KR>NYNW3%0>,S-6;&P+N99E"3CQH#8J*5D;***D[D MG1E"^)VBF(&$DQ,1G25;J\^>+2+*??%CK6LYD)JK1D'&(:JLAI;;C+84^RJE M4M%%:^I2J72JV&>DT6WGR=R"0J 9<4R?>R6O7DN/9_*'1VF[2QIVP'#V">*Z MKM6Y9EZ-3E',#4M:TXY#34]:9AG'K1\00),Q&Z#8YQ1N<>_\ 7BXVEMX#\4VC9TR* M_(+<#E5[ 62*?MZ@V7KRGXA8Q_J":BD8.SI6NBVV'FH"Q\A6<7 V"G3$K'J0 M7&XKE6P[%E'L;$RB$+55CMR^ L)3N1.8")IG4$I1)UF)_GE&[7S7XYZ<@]SW MC76G[E=I:'EXR0ODYKW64\K W6[6>R5RM66&:7]U#HQ,O.PJTNDJY;J+E Y$ MA!(#' 2@7K.%F2/-SCO A#PUJ9NDU'=KFF*\;"4.QS[.BQ]7EJ[!.[=?A;UT M&U0BXFP6QBU5>*AX"1W'BD4,@FLJF3K+Z3/U N,L&XV4VFG-J8-M>PUK;O)FMZDINM)AQ"RW']?;C_:%A@9.%6CBN+.WKB> MO%&3^&*Z9S35T"YG[5XJV,GV)B0BI5 -A9XS$7NF&O\ FAH+9\I*UFLR,TN+ M'9[+3) ?5*:9Q56D+;;$C!J1-'<6)]K:4 M30\P*92BW(*G;X[?Q1UE)-&,PU%5^H!Q_ME=BI^!1V("L M_:ZE7H^N2&LKA!VEPVO<+(6.M79:"EHAB];424@X9ZY"95*1D!&:H&4 Y>T1 MUESYL;Z@7&FPUX'FHZ"RW?9*YO6@5)I!^SSEG&-W5^DK;7$=NMUTH:0,_KS# MV0F2'=I-U7!/+>(SK8]3A]26YU8=?,H&;>U>7G+_ 4- M!.7E-@@E8A1$CEP0B;@J0F3[R$,)1UG\(7(_4AX@JQ>WU_:ES,--8N"-; 5A M77[Q.S$<3,M2SO:X[20\I),TK! OF!W!U4B$\OW]P(J(J*#IR26ISW%+BSQ[ M4W/J[61Z;KB\.(JV.8VI4B61L4Q+3;4B;5U*Q;Y$D@U<-FB'8=5T9)N@FGT MX%$O5C4J9FIU8=>YU<5+_8:768(\K/--@U:CSR%D-K>>&EQ,1>&82M%86NQ/ M(8D5#O)10YBHM%S@H@L41.4@"!A'7DAE=Y_U';,WL*K:WU?8[5 UUGI\EIE::QK44TUE;6LML"N7J=1K5&L^MHYQ#-E[11IR:6!%!^V 6:7 M^-0Q"=#83K*2;UY3:>TC89&OV&'>NKPZT]8ML2RB=,FW\5%ZYK:AV#F2O%CB M823"-BS2)!;$;F!9=0X"":)NF"(F5*;E^H7Q^U8TOD)"U.9M\]K%O/3;!@RH MLXVJ%@=4!\:/OK:D6HL O!RMDI3INLBLT:F,\.LGT1(Z+[:[@_HTTQ'72FF'SAI;*W:(O=\TB+VU2HU88VQHKL0=3E?/%3)B1[DR*S)P+MN51XS M27)U34246:JAT,F

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end GRAPHIC 16 g544598g02u25.jpg GRAPHIC begin 644 g544598g02u25.jpg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ȏ\+#O[1VV2HK")=59U'AZ0Y@VK MN%"AM0384V6<.D(O;U1Q_>. YD']9=.E&,C&.8Y9D75=O-XK.13(F>&&@O6L MNPN#4J0J"XXOFF[X]4=NF15[%V1F6$98IQ9L DQ7!>,KC#T="9ALA?+FT7"$)>(! Q MT,_Q]CQ,(>S*!Q972Q)7*$ MVI9*0>866)L=6SUX]0:+/5G&S-IE$)?HQ?+)=)89(9*S3TW;[*,G)3)YFZT0 M<2!XH@XVDB1<@DD]=G\;NU1Y!@^PV" !C)XR%#\LE@XV-YV,9JY51CTL71:+ M*)Y:J.XF[<.&<=881;:MG.9$P66.2E(KOEPH1$M009Z.0RF9=,'3M\'*VE*+ M975$F&D0S=5]NS0VW$*E6ZVN\D9QD8[R\CFYMFU;F'!!D4:IOEVCY@!4<%9 MS"H"R^!X506;"FTM' 8N,+(*-D'J:PQ^U?);LW2CE%J[TW:JJZ[-G*K-XD@O MC.4EE&CG1/;;9!7&H53@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X'F M^_M0?WHQ3^0=0_TDO#J_!V)\T_$.ZIX-OW6/0_\ #?7O]NSPYZ^W5YJOF6R[ MA)P' E^QJ BB[ @)8^G9UOV14DCKB&G M1DO0M^LX[$I7%P$BE0&O2TS92&'1:33=64=R/"IJ3H^4-P>45O!(EU^N"#QZWX6Y>S\ M58]JKF5ZN2CMN-#S\]6!"SS).3P\^W911N@= ;[&Q,?QV135-6^\3;+9?3;; M5>7BX]/[4$^''J+3.L9Q]\4@Z@$C7WBATD7 M;&=E2 3PA8P@>CFK4WIHSR[O&.:0@^L[LGFW*\!P' 'M"P,\#(-"P8R*((:.F!,448+.&1 >];*)N&CQHNLW<(* M:*HJ;Z;:[9"J\#AD![ LP>BBK%F3%DFCA@1&D&R+U@_8NTMV[MD]9N=%&[IH MZ0441<-UTU$5DM]TU--M-LXR&(\BYQ79O9T W/61#IC.RAN6MI7+VNI*H0#P M#C?S*T&(1!4E*XUK)&.7;B(')1DH";GWVL,=.! H+!T0OZ$3>(V1% M7""87 M5P' Z?-MO2-"*C5+!-BM@>7$Z.1Y+375^P=I#) = M8(.V;A!RW:&2B""J:;]UJJ%)VBSEIJY]A28^*RLU<))MW;A*1#DG610,0/>8 M1/IOB*.!3<'APBQ'%1P]^1+'"IIL3)D/6T@_OA29-5,ZJ-HZ:1V>XSJX0<$( M^NBP>2=33">[%=*0I.' "'+(*K/-2;?63R%@XPB-B[ DBF,#C8FC1JW;N#X> M0QC"C1NY=Y+#<.V8C;<$6D+]$R;CK@['AR89D%>MRA9OS A M!Z%QL28TGAQD<09/_5%]&SOU-T@YRU<[M&K_ $;.<([[Y;N-F+YD\U15\Q7+ M5VV<8U]$NEON'.X#@. X#@. X#@. X#@. X#@. X#@. X#@>;[^U!_>C%/Y! MU#_22\.K\'8GS3\0[JG@V_=8]#_PWU[_ &[/#GK[=7FJ^9;+N$G S$RSB;,L_'$V(EPT,;/7J"+MB4:O5B6X'@. X# M@. X#@0].T/,JB,E;!ZG.0@3VL0=G)SURDSMP+IBQB+U?=V6-Q!VR9D7%&V8 M5H+XAMP>V@[)L;AECP[U1*PZ@GC- MN$LF!.7OIM6:AD.@\?L2D>*[MG?T;G<3)R* 2Y)HZ<164&46SG=$,U\!P,/3 MB'RX>1/655;O8:VC0^ 32;R413LBPQDZ4AT=$A8YA(DHC+5&CF1A6T^C MD=ZMG;),CZOHD319OW(=X0:($T,)/T&I!U'@*S]NBXT2?;AA>76BO MJ#;"0<1...&B^Z@Z22%LW5>(O%6#MVB<;^=N?*GBJ:+DZV(EFZ);)7<3AJD3 MP/!!& D;%V0-L/3TV#AY"7BPQ MSH@2!"$EO:XY-^*9;$2$B'H"&!1XP+E$TBKQD.68A"[ED%9'E!A9#UD418$V MV%7*.7 ]VW>H869O'(YVEZ5LHHGZ5J09/&+E/SO/0>-'+97&JR"NF@<_@. X M#@. X#@. X#@. X#@. X#@>;[^U!_>C%/Y!U#_22\.K\'8GS3\0[JG@V_=8] M#_PWU[_;L\.>OMU>:KYELNX2 M1$E)1*#)&4D!"(((2VO M.3<+LB'>MJUY<$#=M@MDP)R]]#L]3#&'#-^Q*QXKNV:9DD#E@R10"7)-&K>5 M1KZ-!(27-'KPDXH MVS"KE1%FTC,H+D81+B3ABUK^?&) 35@X()@\!P++ED$"R]]$S#]0JU-04YO( MXN0%'I"%U0)*#W8M=J:: BPE&41U^R>K(E(P?]>"/MM6KO=HF2'C'[(+5@DV MDZ9()6EHLD,VIB$+2TM(81$YFWJ(^V8R->.NE([(C:#]H#.^8H!-$J[-2,B> M"MI&@B*+S06+(27@9>X#@. X#@. X#@. X#@.!174= O7^I5R('JE-,CLX)9 M:I:D,^R-RJ@G3=[IKJY43&*G3:H]+=79-FL7)*M]$U'KC90*+B+$AS'=M')8 M<9JH-%$1FDA5S,6"2Z,::@!.2RAA7$I,-&3MDC('V,2U@:.F%B*Q(\IJ_4QH M'-4=2UHMIC84',,U7JNNRS BN,?LVCF0C6C'RCG[9RS?:CHXY)EC3[4VR76> M"46 D&YR6QN.")UH]]:.ISLMUKZI6$N:C5L]G4Y&K#1Y-LUT'!TP[ M;[^U!_>C%/Y!U#_22\.K\'8GS3\0[JG@V_=8]#_PWU[_ &[/#GK[=7FJ^9;+ MN$G QF%63%VMQV7")'0 MPGM!-#]C:",%2X-&RKG;+/AS^.C&Q6,S!N[#QYI*Y5HVADH+H 7 0 M9DDJ;AF\QMO;QG='M^XWJGXNQ,>:\*/O$8$/6I(46ZLV$3&$62R;EF_'OXYL MZ9/6CA+;9)=JZ;*I+H+)[;)JI*:;Z;9UVQG@H[=/FCYA:GA2M7#H)W%ESU<, M[=2+M@S%MG0)1\JRR&@75GK+!QS)=0CHFX]L#' 4DRD2:>,L&\A2*MQ>Z@U) MJKN2VO\ [$G )P>T+!C(H@ANU? MC"HM^BX9$![ULHHW=LW:"S=P@INDLGOIMMKD(>_0FVNK7_-T\T/W9U_;?Q/Z M((E\/[5JL=K_ -ZU"2R1/DL3.)CT\9W3I6?&$R MEY[6L)RQ&BH]53X)+5E: MD N.*MYG7$C:R,$J[=C'>VB#P<6!'!JF$"\8E4>+-F$@B4M!.LY92"*288*D M0)]KNR+#&;K39+ 9!X&,;IKX;:M36%7I40T-H2F*EA[1@\5W:Z8-Z-MG<=?M MGZ*B#D23$2!N,+AS;)PU(@RS%D7'.VCYDW<)!UI?!=Z+^,9U#M:Y9?VQDZ5C M!)/ 8Y'X@$MGM/*; :$$ID/('W+#87BQW4=-Z 45_4".T<6;.MO.'N5D4U_ M2IGI^2JBJV&,-KWRB+WMNW?V[(Q.SY''/I(XDE06#J*$RP4 !DX>F%GRLG"E MO2:XES:/QTFK*AHT.KIHE(&1 %H09^L(.!R)=GH\H$W"[YMZ-RKNKL$@N X#@. X#@. X#@ M. X#@.!YOO[4']Z,4_D'4/\ 22\.K\'8GS3\0[JG@V_=8]#_ ,-]>_V[/#GK M[=7FJ^9;+N$G /))2>>CFMZ-B-M':-D\BH] M,&?5D4*@-JQVM;5*P0],C^(R$,2<;%]C8V$N)2G&B B1.Q9H:53AB?Y1?++Q MWS%XOE?*[7?9'A\=G&(:Y0W7FHNMM;QCM_X?<*Z-V#6RMRR_>+]5G$)1M>*" M)E7QAO2B#NYXFA +<)^E"O@5<2!Y+HZP7=.5VD@)/QAL51E>_P#&J:HG;-[: MZVG+6\[==M-\7_H17Z/AX7E8?[W^S XIUXZ3_N]CL/B=[SR'T]*Q]7QMX@+? MSVHPQ).'RI^8PXV2D*A1JXV+,4& ]UNHW8-\:FT56JIBU.=49S$7SF-)V=R8 MGA :NW_4R03%ZUV9KSOLWVE,:H[//7]L-HW=DMK-CY7>%%=%<:,8$W1UU1WR MV0U3U;-<:-D4M-3S;2N X#@. X#@. X#@. X$:;-Z\X-2I>WZS!B*P8A]ECAB>4QT7O& Z/1+2Q0+1+RMA!I$D L>&MU%T8/.8\R?&!Y8/E9 M]AE(R6C9\JR%-I^':(XRZ,1UV-C M]E0YMLFXF4'#"W@8N8"2_ ')D-.-&5KUT EL?B,2T]+J:@\1;5L^I8[C5YKLCN'DLWD<\*AETM]G MZ;[^U!_>C%/Y!U#_22\.K\'8GS3\0[J MG@V_=8]#_P -]>_V[/#GK[=7FJ^9;+N$G S\K M1EIG,I\[5JVSENCC;":.BDK!.\:OH_*XV2%2( 03 M2?AR;)XDFMJ$:/IG;?5G_E;;=2*\.OC;^%E> \3DG;E4#M/+YB5ZQ2.L4\SZ M'CD\8TWN:!B$S@ACA)S9T']GC));+H,F4-VZZQ]H7,T9]>+SK:XG-=D6XR9H MP*2L3VP-=[LZT'N5O5=\X[%]H*.L1/CL<4%&7A9B@X<-$G; ME\JILRGR/CY 6Z".F[7$=?"ANKD8[ \<7V%R76:#:IL1-W/6>H)CJ1 ME53.H_6#OTWKRI1ZLSMYM,YV"W]6T01:MH" DZ.SESLK%5446#D/CRX-07M9 M285A<$78M)^T@0-^UA.UFZR_4CA;V=-A0VD"-HGX] 7&R.='0^0E8A*%X3*Q8:1B")*-3%LDHX6BQY@U=JN MQ!_5JBH[U$OT4'RC/7+Q-#=MY%H9WWTPNT>( M[MW*.=TMM%=,*(J;Z9W3WTWU\[RZ;:[8QG :9NFO@4]/.F)^SY'$9%>,Q(V& MX:-AS@O:DE@[V$QD>[=OFH ,5J!W7A]KHWKC_MU]O4M-O-Q_Z>=:M'6 HIY,?^2VZF^?\ 7.V<_;P' M[C;_ !_VA^Z]L$]L?;KB?U1UL.)Y_P#LIK!*AJ[?;7/^^$U4MO\ TVQ_KP'T M$[I,_P" ;V5Z_D$K9S]GG8T_V!]9.P MFO\ $1SC'^VOJ.%,_[)YSG'E!];Z%, M_LD-2]KH]O\ [I_5-[ 3+S<__3Z6L(#.V^W_ /+1;;3_ '\_R?;P'UU^O*'V MF3EBP_&/^[-A4!V"K?"?_P!ULSVKHYA#&/\ RRMYF-?_ "\G MF4]L?#WL!H M/"6)V!ZF'VPXT,D N/V;855X5'R,.ME8.;9 )P21!6@Y3K?*LOU:H[+#QCV06$ULHJ[KN_PLM3*&=<*ZOQ2(:3&IU&A< M3D.CC?)J-1T()&.G/HR;=)J621?Z!E505=+%-^[CD]@TR1)V&V,,FDOBSH1H M$K)WA;VI$AIN(%,ZDC@Y11!>.R4H$7U5:-]QIMD^0TQ M(7[;-C(1,&O74EC4OW<0LAZ;(^RY$RD#F!/P8YIMHW:R:.B&TL.!WKO106G( MPK=X;;AJ5[4^/QU*ZE=L6W3^<51V>D-@K%XB#5D4>K8$&ACX%BHFO8\ MT@DC*!TG>GK*4G!QLI&#HS=$G%#!]BLDON5%%Z9JO3%KY3.>47RBS>7PDX#@ M. X#@. X#@. X#@.!YOO[4']Z,4_D'4/])+PZOP=B?-/Q#NJ>#;]UCT/_#?7 MO]NSPYZ^W5YJOF6R[A)P' .76&)/&5O:H@/A3]B3YR<"AH6_J:*P:H7Z^C[*$$X2: M*;IO#H$22)--GVK1OJ@S5PNLBIYFFQD93'=/PFYTNLNKK;ZJ4--:9E0Z:5PI M7(", 9")T=IL7+B (9@1]DEH^;-'.J@:1QHN%<^>AKIER/6RCLJAE-77R_[\#%*O1;I8HILNCU,ZXCG>^V=MB 2F*] %/.SG MR^=@H$CX\CKMY?MQMJZQMC.B&Q,.T MSLY5&X#L-[?LC=E1'K"TB5[0KUJI5 M*J^M/:Y_=CM%T=6OF:8TEWG[;;_2?R^3R'IE@Q88OBP_Y;KW[6OLXM4]\IC3 MT0/B*1I@"=EMX^-AVKZ8,QUL7G:12/H27#6?%AUCKR<;,LO&,^Z>Y^J4\<=C;O:*MZ[;L^N6U3W'VGL?JI#8. M N5T7[@Q-W#FTP0BEWV14^1*0D55]AR&$NA;=DBY0(1MI)HJ16-'-GNK)R)H MFU\^S%6F6=LHF^LS,_GDDNH&;I3>\[F M(R 6K%EFI]%ZVD6ADTVQ;<,VG+OMEZKRBGB-RR11+I9)%:SCK97M1X=]Q]V3 M35,Z243B4AK""4#+V<$%J;,]=B(4JO+/V8IE/B0]DH1UMZV]B[&@_5:I87V^.5,K7<]FUGV:K4]!02Q*0D]N M)G>R\RQ7X1,>;/E \?@,39 =1T40D\O1:FIKZL)2?G3(IO,Q%YF(G9K,3&41 M?QGPC1EL_:LZAGUZSBV6+:,V'%,2= >@YD\5G@A$UN]0BL?<,A$95=UI[];6]XV[/%M?X2\WW] MJ#^]&*?R#J'^DEX=7X.Q/FGXAW5/!M^ZQZ'_ (;Z]_MV>'/7VZO-5\RV7<). M X#@. X#@:G>W70"W[DLSL-,:/MJNZ^"=S.JPOJ+V-9S^$R*5EPD1#.K#9L+ M(JE<')P3/>::0^UYE&U $H3U [NV\;.:OT]V1 >2*BJULKX:L49^%X\,HW;= MZ/GBG^"M4?R([/TK5T2@-,2QW('+;Z5Q.LHY)QD.J:6[E'^L4&1 MQ^6D6IDG)F@-"0)/!Z"29#4>JNTV,B=DZ7OW]\]^3D=<_P!GJ\.>N*6@#'5O]HZ'N(O";^#V,?,6Z?\ )/!C MJW^T=#W$7A-_![&/F+=/^2>#'5O]HZ+4G?@-^& Z@\R;0SJ)%FLP<160H11U MO8]Q)Z-I*L(>)@G&V[JQE6VFJ)39JIMNX240UQKG*NFZ>-MQN$W\'L8^8MT_P"2>#'5O]HZ'N(O";^# MV,?,6Z?\D\&.K?[1T1/Z7> )TTC=(8&=MNKD0DMP?O-N=[DHUM"S7J7[O"5K M2Y_4K'T\=G8X;Z096CB+CU4O5O745&^R1%9R^T774-JKF9O&49;(W1?W2P]Q M%X3?P>QCYBW3_DGAF.K?[1T/<1>$W\'L8^8MT_Y)X,=6_P!HZ'N(O";^#V,? M,6Z?\D\&.K?[1T/<1>$W\'L8^8MT_P"2>#'5O]HZ(G]9/ $Z:!93VM7[#=7( M@;C9WLS)C76ENA:%FNM@'7I:#5^UCX1QJ&G;-=HNC,FDW=9:G%'QG31WINL\ MW;*-4DC9KG*V5HSRC.;SG\)8>XB\)OX/8Q\Q;I_R3PS'5O\ :.A[B+PF_@]C M'S%NG_)/!CJW^T=#W$7A-_![&/F+=/\ DG@QU;_:.A[B+PF_@]C'S%NG_)/! MCJW^T=$4*N\ 3IFQ[9=K3UC=7(@^ZRG8KUU0ZTQ].T+-5< )('!3Y*^'#AHR MG:!UIJ9,NX2JCN&8ZM_M'0]Q%X3?P>QCYBW3_DG@QU;_:.A[B+PF_@]C'S%NG_)/!CJ MW^T=#W$7A-_![&/F+=/^2>#'5O\ :.B)[CP!.FF>\PB3H=7(AKTX3ZHR$"4B MV;0LWUM3LNM;T9( C^&.9WF2Y;HU&8ZM_M'0]Q%X3?P>QCYBW3_DG@QU;_:.A M[B+PF_@]C'S%NG_)/!CJW^T=#W$7A-_![&/F+=/^2>#'5O\ :.BQ(KX3M5]7 M.\W3:]^D53#:;KB+L>Q\?[5[B+-G:JTPB\OJYJPJ<&^CTJEIQ.3C&-DM6IW= M@@CJ@.)#A1YSINY%C5FKX_Y_LQ7B8GNMDW6<).!$/3J'&].^CCOGB7G,R]QU M(;]2-H%EDP^C>L<;W$M<6LNP1_\ FGMO8FMD/EEG_D/4<87Q_P QY>%8OXX= MF+%[61D">%37H1W#':5JS)?:&>);8OB6-=% X375[.K%1EB+ZM%\ZY\J<3'8 MECG+4JG_ -85RT0]-CR;J<$U7V?XQ3^IB;^QIX5%>Z#Q@_%K3/.@SQ4W_BII MJ>QPGG*V"_/%SV]5;X\ODQ#4UBZK?4QK_P!;RFCIMG'G;;<$5S%[6SIP>G5= M/7GP^Y;U?M4D^J3M/-!/6(C:ECW!CJV1JFHR[-C([1=&CLCCPVXGL?4L8? F MLQ..94# LEFY=@X0;C5I,]&;OF[T3-XTSM$7[HTR\,L[],X6QUZE9KM1UP[3 MUD4C@^25N!L>EK>"21R28-YWU]M3>.R1^V#OQ@HUNE-H#98 ")D+N79%F)D3E,;[3'=,=8GX8EKOPY*_@$?Z81O,ZD4A&=-)E?TN!H%! M(C5*P<=@87;\)D >3I)9SHS8"1]P%5F61_E4=J"V:3K'HUW'#<4_RT_E:_I: MO2.TJFX-/4Y M99Z+U.IBXR3*+EF!Z0NDS;<35>^^J;S_K=W^UHR4:H_"^S7C.H MQ4L[*3JR0_7_ *OW!T_ID8\@< BR4:IJU 5;1Q+)UT!9:D)9.(Z*JV,M=I&Z M=L1A?1OZ3$:%NU7[H@,6N6M,_A76"C^M]*7BE M:8K>O: MI6ELNJB+6FTGL/@=?-8#JSDD/+DPK-NL638LS:RHHLUT1?-_4U4GPM9RS6,O M%YF8[[78$HKP]-Z9LOJ4CI*VAJD.CU)6%&Z79NU/CP M6)1>/QR#Z$(Y74;BB[YOC2RI>W$O-]_ M:@_O1BG\@ZA_I)>'5^#L3YI^(=U3P;?NL>A_X;Z]_MV>'/7VZO-5\RV7<). MX#@. X#@.!"'N)V3L.G9%UGIJE <(+7=VNMPW6D&)6=N?S74,$PFL9I;<[F, MF8199G()!NPCD+W$A(T,*@U"9DVS7<&V3-@YT<%1%[SLBTSZS$?VKG2#LN<[ M14X=E,SC(:(V965S77UYM@'&'[XK$=+(HBQCU=R,I#B!1NU*KQ:1;!VLC#(E M$-2(UJ6U$O5WSAAN0=&3%I](F/"8OG^TPN&' <##M_W9$^NM/SBXYFF0>B8< M+259@ J'K4"0V)C-?)L0D)L:T\[3"N=]38B\ MV^^,]T:S.R$?/#W[+6AVHHF0SVY87$*_LB'WO?E)2B,P8B3+1MH2I.T9%7#A M9B2+*JNWN7*X!595S_PD%]]O2MT$$M]4]15%IM&<6B?W$3_:,IO]WMIW"3@.!$#OQV$G_5'J!??8ZM(3$;!DU-5^;GN(Q-Y08B8)T*C[7=\ M8<;/@<=BJ M3NSI\&"@*%FM==H[6JNK6U6LG<\SV4R-E@M0E:-O@=&ZZD3TK^DF&4Y)+='H M-\VUCB>,DI6!(DQK=0V(B8G.8F(OW=T>OV&T?A)P' C_ -K+5FE%]:KTNFO8 MI&9O+:FJZ96.-BLPDQ.'QXNA"PKJ0ET7Q\/&I:1;J(A1Y%V/9MPF^#))NS"K MDX^V(+2 6;&SJU"FRZ)>8RYO(QHJ43LS$J\K^,QDE*IQ(G*CD"#.&X;WMOF(TSF M-=9C9,;)O,Q$-S#5TU?-6SYDY0>,GC=%TT=M5DW#9TU<)ZK-W+9=+;=)=!=+ M?15%9+?9-1/;7?3;;7;&H!I:J;Q->S5V,Z7J:$07 MK[M>=V]B.V]7P2YUE[&?]79[3W4:/@S,EOBO1+)^G-Y&%FIV4AZ_C ]K,5Q/ MM<=)9&E*2@H>U'/2YIB+YS:+7BV<7V??TV6]'>R[CMWUCKR]248:PN1'GD]B M4SBK DL8%A9Y5-C2VJ)RV"E7#1BY(1]:5PHN]CSIVS;O%0CH?L\2T=96UP35 M&&;>'O%_[2SX8<"FFLF-0Y;:.IC59!J-?Y!I&EG3<.J8PU5R,3+.&*#IZ@-W M>^@U?K,VSATDURKNW055UT3V#3W6_B/6V&8]WA-TP^IK)DW6&<5%4M3R+K0[ MEFD&[!]@+E%.&PSK7'-9J[-ND;1@T\<16+6 [9F7X^/-9V'RNRNJ[Q77&NB>NB>IDVB#;]UCT/_ WU M[_;L\.>OMU>:KYELNX2/R1!5PP0D0%154*91U06053("UEE%F3C13&[= M;;"R><*::;:B]M&'NG/2NF^CT'GI1^2?87>K&S,S-YW1'ZBR7?##@.!A7L;0 M\*[043:_7JQESK6#W#"#D$DKR,$4Q4B8CCC79ON_"OUVK]H@28J>C=M,/QY$ M:LJCJ@3'$&"KEFN;$VF)W,+]:.FH_K_:%V7G([:G-UW1?8BKHS.)M+0-(BUHB]O5 M-+A)P' CAVWZY#^V_7FS>N1R>R^N8O;4<>PZ7GX,UB;J1KQ0NBHT.AF>TRCL MH$LM2[)7=JJ01&8)L]<^E'/&CC&%<&Q-IB=TW_2.46\/\_$>Q8CLJ,[=W@K, M4X14-92P83@?68R-F-<5/Y5E8*D3,480E5=1NPB;DJ=GK&I)! ]RIXG[6;+, MGHH$L+%\K6BV<[ZE/:)?5B69%15.Z-<4:Y3EGKGIM]-M]K( &+C (+&@;35 M@$CPD<##L=-U5-&0L2S18#VFJBVZBRFK=HW11UW5445VQIC93?;;.=LDJMP' M P!VEH ;VFH"S.OIJ;3*O0=I!&T<.RF K!T9.W!^V!I R);?2 2<"N!LH&,7 M46D; D)>M24;,EA^Z6OK.%-#8FTWU\48"GA]%2<;HY?/:NWVMT=:9/,2=%7F M-KGK+'RT$A,]@K.NY/4&E8Q*D(W3!6MW4>9-E631W ,2$88'A'S21:(!6;'C MU^_?NC<6N46G6,]8TG6]^LI5=:>O<$ZK4? J%K=4X\BD#9E=4B\G?-R4GDAV M2R M+YA+9*^9LAK%S(9?,#YV3&E!XT:-P2*N=!PY@QU;LT29F^?WP]-C.G < M"U)Y&%IM!YG#&\C/0]Q+HI(HPA+8JY09RB++'Q#P4E(XV\";N]28= MRX:N4$"+5NJJW63UV3V" -1>&)3D,I6.]=KDE!GM'3%=D(F7IR"6M *1BHRI M#,7#R@(N?C;FD:QJPL>DLG:2LBM)I//2$MD)$BH[*>TTR!H\Y)E35?/2=LQ, MY^\^UF>^F'3RJ.C%',:%I[!9:+M9=.IL\*'U6:QLN#;]UCT/\ PWU[_;L\.>OMU>:KYELNX2QM\1F.!&:0\-'X_;U@A@@A@WU\U!B,%#I"V8,&:.O\ "DV:()(I MZ_9IIKCAZ8:9SFFF9\(5CZY';SXJ>R'SQL[]4<&"CAIY8Z'UR.WGQ4]D/GC9 MWZHX,%'#3RQT/KD=O/BI[(?/&SOU1P8*.&GECH?7([>?%3V0^>-G?JC@P4<- M/+'0^N1V\^*GLA\\;._5'!@HX:>6.A]R'SQL[]4<&"CAIY8Z'UR.WGQ4]D/GC9WZHX,%'#3RQT/KD=O/BI[(?/& MSOU1P8*.&GECH?7([>?%3V0^>-G?JC@P4<-/+'0^N1V\^*GLA\\;._5'!@HX M:>6.A]R'SQL[]4<&"CAIY8Z'UR. MWGQ4]D/GC9WZHX,%'#3RQT/KD=O/BI[(?/&SOU1P8*.&GECH?7([>?%3V0^> M-G?JC@P4<-/+'0^N1V\^*GLA\\;._5'!@HX:>6.A]R'SQL[]4<&"CAIY8Z'UR.WGQ4]D/GC9WZHX,%'#3RQT/KD M=O/BI[(?/&SOU1P8*.&GECH?7([>?%3V0^>-G?JC@P4<-/+'0^N1V\^*GLA\ M\;._5'!@HX:>6.A]R'SQL[]4<&" MCAIY8Z'UR.WGQ4]D/GC9WZHX,%'#3RQT/KD=O/BI[(?/&SOU1P8*.&GECH?7 M([>?%3V0^>-G?JC@P4<-/+'0^N1V\^*GLA\\;._5'!@HX:>6.A]R'SQL[]4<&"CAIY8Z'UR.WGQ4]D/GC9WZHX, M%'#3RQT/KD=O/BI[(?/&SOU1P8*.&GECH?7([>?%3V0^>-G?JC@P4<-/+'0^ MN1V\^*GLA\\;._5'!@HX:>6.A]R M'SQL[]4<&"CAIY8Z'UR.WGQ4]D/GC9WZHX,%'#3RQT/KD=O/BI[(?/&SOU1P M8*.&GECH?7([>?%3V0^>-G?JC@P4<-/+'0^N1V\^*GLA\\;._5'!@HX:>6.A M]R'SQL[]4<&"CAIY8Z'UR.WGQ4] MD/GC9WZHX,%'#3RQT/KD=O/BI[(?/&SOU1P8*.&GECH?7([>?%3V0^>-G?JC M@P4<-/+'0^N1V\^*GLA\\;._5'!@HX:>6.A]R'SQL[]4<&"CAIY8Z'UR.WGQ4]D/GC9WZHX,%'#3RQT/KD=O/BI M[(?/&SOU1P8*.&GECH?7([>?%3V0^>-G?JC@P4<-/+'0^N1V\^*GLA\\;._5 M'!@HX:>6.BT"M@SVS'RTFL>;R^P))MA)AM()O)3,K-[,6B6GJK+)8\]?O\M& :WI5?5V^7'H4?2;^CTU\_;RFQ$1I$1X19_]D! end GRAPHIC 17 g544598g09o87.jpg GRAPHIC begin 644 g544598g09o87.jpg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end GRAPHIC 18 g544598g14a87.jpg GRAPHIC begin 644 g544598g14a87.jpg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end GRAPHIC 19 g544598g26d26.jpg GRAPHIC begin 644 g544598g26d26.jpg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g544598g26i65.jpg GRAPHIC begin 644 g544598g26i65.jpg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g544598g27s63.jpg GRAPHIC begin 644 g544598g27s63.jpg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g544598g37r77.jpg GRAPHIC begin 644 g544598g37r77.jpg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g544598g40m37.jpg GRAPHIC begin 644 g544598g40m37.jpg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end GRAPHIC 24 g544598g43o89.jpg GRAPHIC begin 644 g544598g43o89.jpg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end GRAPHIC 25 g544598g47c03.jpg GRAPHIC begin 644 g544598g47c03.jpg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end GRAPHIC 26 g544598g50d92.jpg GRAPHIC begin 644 g544598g50d92.jpg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end GRAPHIC 27 g544598g51t31.jpg GRAPHIC begin 644 g544598g51t31.jpg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g544598g52l98.jpg GRAPHIC begin 644 g544598g52l98.jpg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g544598g53l99.jpg GRAPHIC begin 644 g544598g53l99.jpg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end GRAPHIC 30 g544598g59e05.jpg GRAPHIC begin 644 g544598g59e05.jpg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g544598g60d29.jpg GRAPHIC begin 644 g544598g60d29.jpg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�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end GRAPHIC 32 g544598g63x56.jpg GRAPHIC begin 644 g544598g63x56.jpg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

HD,V'E5NW-!I>L:>P5V0GO+ R&^42>N.NL_YFG , M�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end GRAPHIC 33 g544598g67t70.jpg GRAPHIC begin 644 g544598g67t70.jpg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end GRAPHIC 34 g544598g74w05.jpg GRAPHIC begin 644 g544598g74w05.jpg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g544598g79k21.jpg GRAPHIC begin 644 g544598g79k21.jpg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g544598g79m02.jpg GRAPHIC begin 644 g544598g79m02.jpg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

/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V MQM;F]C='5V=WAY>GM\?7Y_<1 (" 0($! ,$!08'!P8%-0$ A$#(3$2!$%1 M87$B$P4R@9$4H;%"(\%2T? S)&+A7U5F9VAI:FML;6YO8G M-T=79W>'EZ>WQ__: P# 0 "$0,1 #\ ]522224I))))2DDDDE*22224I0MM M94POL,-'S))T:UK1[G.=^:U-=?717OL.G U))^BQC?SG.0Z:;'O&1D#](/Y MNKD5@_\ 57._/L_ZW7_PJ4Y/[?ZK=]N?@],;D5X%KZ7L.0&W.?6QEKFLI;1= M7N?ZOZ+]86/TG_&/9U?-KP<;IK:[K@XU>MD!K7%HW^F',HM_2;-WTFJ?U5ZF M6_73ZR=)>?;9<,JD=I:RJC)_SMV,N9^O?1K>A=>9U#!_159;_M.,X<5Y+"++ M6=_:Y^W(;_QEU?\ @TRH?7C(ZAT_(Q!@/QW75N8V^K)VV,<1[+:BRM MGOJ=[_IKJ>G]2JZW]7F9]5 O;ET.W8I( <^'5W8KG6>W^=:^CW+SRS#R,*ST M,JE^-9KMK?/'_!V&?6:S]]KWJ#F333?^EK=5U"PPQYR;6ULWT?F-S*Z?ZF)5_(]*M?1U[& M?A]-SCF.NL?9C4YCLTL%EECZ\MMOZNQEFREC;:*O49_VHMK]GI,J70?4C+-O M3;<1QDXMI#1_(L'JM_Z?JJ62W]I?6_&IYHZ-2[(LTT]:\>G0S^S5^F4LD'.Q7_ *-KF^S_ -*?I;+WVSZR?^5>/_[&'_WC6LDI6L\W7]9^K6764CIE M0LJ>ZMP.7'N8=KO^TRI=6^OV9T;J573^H=((?<*W,MJR&O8YECA5N8YU53G> MD_\ G&;?^K8FZZ'=/Z_ZHTKRVMN:>VYL57-_"I__ %Q7?K3T[!ZG]7?M%[)N MP-M^-:-',>QS=)_T=S6[+J__ $9Z;U3PY\IYG)AG5 <>.A7IC+U\7^/C7$#A M!?_0]56=UNIC\6NVWW4X]S+;J3);8S6MU;V?X3;ZGKU5_GWTU+16-]9>JU8. M/10&&_*R[ZJ\;'!#2]PLK>6^H[V5_P!9R9D($"3V_'HR88REDB(BS?X?I:K" M["Z-U2ZJVUN)A9-#;:6.<&U-MK=8W+V-<=M/J5W8?Z)GZ.S9;9_.>LK-'6L. MW$S,]MK+L3%<[WTGU#LK:'6.=Z9=^=ZO_6UBCKGUAMZLS#=TW';G8]?KNH&4 M-QIL)J_<_-M8SU/^L+,ZST7,N];ZQ9&(<%SZG4=6KI?^DMQG#8_,I8W?^FQ* MQ^DIN=^LX[+?SU'QFZ -:T.$_P#29CAC5RE&S5RXX2_YGS_X3WK7->T/80YK M@"UP,@@\$%!R\MF(VMSV/>++&U#9&CG^UF\OYOJ>EZ=7[_J:+NL])RJLNIQ-K<> M6Y+=IV@$;O=;_,[-OY_J?HO\)L3CF@!1D(R,3.K]7!^\P2APR(&M&NS9/4\1 MKA6YQ9:8FIPVO /M]3TW>]U6[V^K7^C3/ZG4+/38USWQ.P^QQ)^@UM=FVQWJ M?FOV^E[/YQ<]@LK<1G8]-XI>_P!V7D.=9EY.T;ZFXCMWJ8V$QWT_3K_2U_X+ MTO4O5NQ]>0'5,ZFRG.M 'I.():U\-ST;?ZB@/,3].Q$M=_;GZ M=^'W?G5PAV,:IUCAE7P;2/T;!JVL'\UG[SG?GV_^BU:5' NS*V-Q^I"L7B0R MRF16]H^B6M=]!W\A7E8QY!,&CZHGAF#I*,O&*TBGQ_-ZG^R/\8M_4G';75G; M;S_P-C*Z+W?V&O\ 4_ZTO1/KIT@=6^KN52ULWT-^T8WCZE0+PUO_ !K/4H_Z MZO,OKE6'=:SWG4?:K:W?#;6]O_56+T'ZJ_6#;T3$9UJVG&N92S;8^^J7MC;6 M^QGJN>RQ]>RQV_\ ZM")N4XD;DL\QPQQY 0"(QZN+_BGZIN9G=*<[1I;EXX[ M[7_HLC_->VE__7EW>9A8N=0['RZFW5.Y:[L?WFN^DQ_\MB\P^JF#E=%^L[,M MUF,, ^O2YS,FE[C4_P!V-^AILLMV>K7C?F?HOIV*Z/\ ' _TVV.Z;CM:YH=) MSI(D,=#F,PWOW?I=CO[:= >BI#PU6YB!DXH'^M<3L7=Z!4WHOUDS>D6.+J[Z M67XUK]"YC"[VNCZ3V^H]N[_@5H?56LVT9?57C])U+(?:#W])A]&AG]G8Y8/U MBZB;*?J[]9FU>DW+K]*Y@,PW*I]1M?J0S=M;ZVQ^Q=ET_&&)@X^*/\#6UACQ M AQ_SE'CCPS,0*C"S'_JG\ILN?)QXQD)N>7A$S_L/1+_ !OU4VPDO,;/\7_U MS][CGT%TN=ZCLW,&A<][7/K]+T_:QS&?];6YTGK]'U:Z'C]/ZQ;9D9&++,C* MK;==5OL<^^JC[3:QOZ7T+*OT+W>LRO\ ,4X!.S4='Z[8H?TIF:![\*QKR>^Q MY]&UO_399_UI ??ZWU1RSR?1!_(S_JJTS_K/C=;Z?=3BX&;E8V2Q])MJH&WW M#8Z'6W5MW,W+)Z;G,/U>ZEANG8U^[>S=]-ZI\Q'V M^9PY#I9]F?\ U3TQ_P#'?:71U!'U?__1[H]2OL9DVY&6WIIP]QNQS5N>U@+A M5:Y]A=]HJR&L_1/QJ_I_H/YZJQ46?5R[KG3C?U/+R*;^GU=GJ^JNDLQL:VVNZVIEEM,FJQS07,GZ7IN/N9]'\U%3. $ZZ MULR^Z0/3Z;WT&W[KY]G_ %?R.E]7QLW.KLS:\AAQWYF)D/IO=D';Z-K_ +5= M^C?DTM=BLQ_MOV>Z[TF5^E;912MEN1T;"Z)EY.+?;FOJ98\TYUEK]E@'I>AE M47?T;W_H]EM3'K7^L5]='1F+0*W%M=USJ#_.LHJ<^]]?_!KD M[>F88Z+U?-Q\OULAM60TUN(/D5-_G:?0M_GO3L6EDXO5+,.FKURK^;_FTW3ZS7]=,BK'M:S&Q6UO:QP)LL^U544V-8&CW4;<&O(]? MZ%=M/IK9S?L73G8&&+!16VZMF)5#B22YS[?>[=^C;2Q]?_!_]=J4<\1E<@+Z M<(\/TOZT8>O(NGDXH@6=_P#H^CU-#!ZKU-VS[-BU7_J[G9&7=8YK6D./J>G6 MVNSF'(?5Z>3>_=DO.Z76 -:[=ZON_0N_5]G\W^B1.*4I1XYV/U@X8G@D(] M(\/_ '?K^3_608;WT:.1T'J^%@96/B9;LO#K9ZV RXG[31;6-[*:DO*/RHM\KZUTZSJ'4_K$*^<-UV8?^M-H]G]MCK%6^I%F*R[( M-XJ:RBRK(]2UH< T[VVM^B]_Z1M7M7??5RO$OR?K%0ZMIL=U"RO(/YSZW54F MK?\ R-MEC&?]<7FWU>Z5]JS.I]$M'Z9U!KI'?[11D5,J/_GWU/\ @?4466-: M@ZFS]1ZFWR^0$41I&H_X,AP%I4ON/5C=BL!OOO=Z5;8(<;GD,I/IRUS7>IL] MB]2^JEK,C&OP,WI[69O3'^A;^C;!;J:?TCPSU';/^W/T>1_AUS/^+SZOF_J= MG5,IFVCII+*P[@Y$>X^[_N+6[_MVRO\ T:[0,ZMDN.5T[)J9CVOW'=#PX,M: M#LAGTMM:RAKC?0QSMNN,UUKG,])V[:RMOT?^%]-:.'U&G.K-N+^EK;8^IS M@1HZMWI6#G]X?YB6'1D##IJZ@YF3D5B'VAL!Q$M;;L=NV/>SZ:?*JR&T1@!E M=OJ5N=/M:6!S/7:899]/':ZKZ"F^C6\++E_6@]9NP:L/IM46YMHILMWAOIM( MWN<[Z+MGM=ZGI_I/3_XQBV6,Z7T' QN,X,N(ACG< _<[_ *A_]19>!UBFC(R>G99MK.-8&UY%X)8X M6AMU=3LOWT^M7ZOI>G99ZFST_P"<6RL7J5#L3*NS'4_:NG9; W/I W.:6#8S M(:S\]FSVV_\ ;BCR$QJ0Z:'R[K,A(J0Z;_W4'UDZSCLHOQL<.RS$?37F,L8TW4VL_F',]3 M^5Z7Z7V>HRO^:I6HS%P/TMO2>JUTTWM:'MO#;F.DNJ;3_VTT!N,_:YGN?5]%]_[BAL3)E+2OW")L0) M),B3$57H-B0XN+]']YR']:JQ.M=4ZH["N^T.95A5-W8Y>PUM==:'_K3O9ZCV M?S/^$K]/^=6;U'K%QH9A96/DMZAT?U;79%SZC99C[?U\U6^LW=DXE;V9&RGU M]_V:O_2+:Z=TC.?9U#!R-K[&48]-ECVSZC'5N]6BB^*_3W;?TEVR[]-_PBAU M[ZLX>%]5\^S(OMMLJK^T5DF6MOJ9Z>.ZEC_5_2]/ N@9'4BAZOS:W3?J_UI^.[[-D54Y#QN;EL?-C2]U=P^V4 M[+:LVG;5^K>G=Z5?KW>^SV7*STSKF;T3,9TGJ^)E!EH<:'5A^8T/:=]K<*RE MK\[)P?2>RW]:H^TX/\QOOH]+T*W3NJ8AQ+\3J'5!2<>I[\++P(:V[$>7;;*= MOJVM?BOWT68-7I_8?3_XN]9%KOJG99C9S^K=3<=[F67.LLLLJ#&O?4W'R*Z2 MZO?;^Z_?L>K,<(,I&4;-5Q0AZI5']7<_^X9#+Q^TOH3NN]&9BC+?FT-H)+ \ MO:/>T;WT[2=WKL;]*C^>7,=%ZIU#J8RLW%?G6]0??NKJW[9];]+17_ILOI70J>M=4ROV4RQG1[G5C*S\EKCD.8&N^UX=&3D.= ME?Y1>_\ 6W?Z#Z?^"HM]*39".*Q7%*5'7]#^K(*&KP'1>K' ^NOUBQQ6Z]^9 M8UU%+?I/LK#6;9^BQNR_?8]WYE:S>CNMZ;_C'SWWM!1 MY;%%C/6_QC96*;K,=F7D74V65$-?'I-O:UKGML^G90S\U"^M-_4NC_61G3*L M_)=@[:K-EEADM=N]7WMV?G5NV;52GIE-RG4LJJ;7?7E4S+F?K_ /3GNM8^W(;] M)OL71?47&^MN.W-_YRFR7>E]F%MM=VH:_P"T.9Z!=Z;7/V>UR?" B!72(C]( MJRYIY 8DCA,Y9>$?OS_Z3L]2Z;EY.PX67]B+6V!Q%;7@FP;66;7;??1N?95[ MMGJ?31<'#OIJH][; S80USO496YNY_\ ,_S;/^#96BYF;AX-/KYE MS,>F0WU+'!K9<=K6[G+/^MG3.H]6^K^7T_IEPQLR_P!/TKG/=6&[;*[7_I*6 MOL;NK8]OM:I-=]6&AV"#ZRXAIJIZM3<F]CO:_;[&JSRL#$9,D8@V/4"?FX?W/F_=5EF2,<" M=(7P4-N+=!];Z68OUDLMI8I9CD7 =K6GT[F_]N-]O\A<]]<>EUX_U79U7I.1>W%M+#E476&S M=5=#?HV>ILMIN]/?L=_I5R_2^I9M>.<:G(>RFQP%M(=^C?N+6/W5.]FYU?Y_ MTT\@YL&HJ6+3OZ0M^6?]Y__3]522224\Y?T_'RLMQ)1^U$[C^WS6>U'MO_+5I=-HNH#ZWU,IJ;M;0UKM\- _FFNV M5N]&MW\SN4.O=*;U?IEV$7N87M<60XL:7[7"KUMGN=4VQS;-G\A:"2DA<*H[ M;+@-*>5ZM]4>EX=!ZMTYHZ?E8%#GCTVBQCS6W?79959]+*J=7^CRF;+[?YO) M^T4_H5<.+;BY5.1DXV)5]I>*#=B-++F/?K7;ZKOYQMES?3?5Z?\ QC[:O46\ M@9F'CYM/HWM);(B"U^)#,AQ?23#+SRWP9D?\ ?;_^W?\ AF2J]-5/ MEN9=Z'^,!]Y,"KJE9)_DN]&JS_H6+T7-^JW1>H=7KZOG4G(R:65LI:\_HV^D M]]S+!6W;OLWV_P"%WKRSZV.>WZP]6=68>W)W_JE''4R'BQXB1+)1_2*9)))/9'D/\85%O4&],Z13_.9%UM\>+<>F MU[F_V_46S]5LXY_0,*]YFUM8JMUD[ZOT+W._K[/46;;FXS_K7EYV00W%Z'BM MK=9S^ER#(#1^_LWU;5E] Z]C=#R,C'R&O9TO*M-F/9$FDQM:R]C-[MCJ65LW M5[]EE?\ POZ.>4H\$<-@9*$XQ_2GQ]/\7@8SDA&8!D 9: />+Q+(QG='ZWE= M/=+?L=[FUGOZ9_24._M8]C%[31?1D5-NQ[&W5/U996X.:1_)>WVN7 ?XT>BN M8_'^L..W1NW&S8' )_5;W0/WW?9['_\ "8Z?RF3@R&)VGZ?\+HNF+&G35LX; MG=:^I>=TM@%F9BDO;5J2]N_[4S:/^&_2XZ\[PSZ.8VF9;ZC T^+2YIK=_FKK M_J5B=)ZM:['RKK\?-K:74^C::Q;5_A*_:WU-]7Y[66^^K_KBG]>?J;B]+LP^ ML=+:YE'VBFG+HDN:T.>WTLAKGR]OZ7]'9N?].YBE,XXY3@;'%9VT]44 <0!? M_]3U5)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ4;?YM_T?HGZ7T>/S_Y M*^5TDE/J/7?V-^V,WUOL/J>I[_\ E3G;7S]D_5O^V/8NJZ5^S/V7A[/VIL]" MO;]F_:'H1M;_ $7U?TOV?_0>I[_27@B2 W.WTW0-S\O^#O\ X3]"_P"3O_-U M_P"SR7^3O_-U_P"SR^>DD4OL&1^Q_1ZC.[;]M;._]IQN_P#-AM]_VW_1[/U9 M#S/V/]E,[8TGUOVGLY_D>Y>1I(3_ )R.VX_G/Y[_ /ZW[C%/YO\ET^?YWV+ MZL?L7U[]OK;I$?LK]J_^S6_]%_GK8ZQ^S?V3F3^T8]"S=]M^W_9HVNW?:]OO M]#_2>G^D_P!&O!4E)/YOT_\ JG\XRC;I]'T_H7[#_:>+L]"=_M^P_M;[1.U_ M\QZWMW_O^I_@?574=;_9O[,MW?;XW5S^T/M_V;^$)(Y- MQ_.?]6^;_!4.NWT?_]D .$))300A !5 0$ / $$ 9 !O &( M90 @ % : !O '0 ;P!S &@ ;P!P $P!! &0 ;P!B &4 ( !0 &@ ;P!T M &\ FMC.60B/SX\>#IX;7!M971A('AM M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R M92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @ M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO M&UP M.DUE=&%D871A1&%T93XR,#$X+3 S+3(R5#$Q.C(U.C0W+3 W.C P/"]X;7 Z M365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%C&UP.D-R96%T;W)4 M;V]L/@H@(" @(" \+W)D9CI$97-C&UL;G,Z9&,](FAT M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL.FQA;F<](G@M9&5F875L="(^4&]W97)0;VEN="!0&UL;G,Z&%P+S$N M,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C8X M,48X-D$Q130R1$4X,3$Y,CDY0T(T,$1%,34T0C$U/"]X;7!-33I$;V-U;65N M=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D$U0D0R M1C&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3 M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS M=$5V=#IA8W1I;VX^&UP+FEI9#HV.#%&.#9!,44T,D1% M.#$Q.3(Y.4-"-#!$13$U-$(Q-3PO7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS M=$5V=#IA8W1I;VX^&UP+FEI9#I!-4)$,D8W,49%,D1% M.#$Q.3(Y.4-"-#!$13$U-$(Q-3PO&UP34TZ M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU M=6ED.F0P-60X-64Q+39C.3,M-#=D,"UB,30Y+30Y-6(S,S8Y8V-B,#PO>&UP M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E M9$9R;VT@&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO#IX;7!M971A/@H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^ M_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$!_\ $0@ Z ' P$1 (1 0,1 ?_$ !\ (" P$! 0$! ) M" H&!PL%! ," ?_$ &80 & @$# @,$ P@+!PH7 $" P0%!@<( D1$A,A M%!4Q"A8B02,R41<866%Q@9'7&20W0GF7F*&QM_ E)C,V4K/6&BA76'>4LL'1 MX2$0 " @$# @,%! <#!P<( A,! @,$!0 &$1(A!Q,Q M%")!46$(,G&!%2-"D:&Q\%)BT18D,W*"P>$7-$-3DJ+Q"24U8W-TH[*S9).T M&"8V=7:#A-/4U5159I6DP]+_V@ , P$ A$#$0 _ +_'&FCC31QIHXTT<::. M--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--' M&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC34)]_YC9BG:U9"R?J] MEG&^*+AA^I7K*MA6R9AU_F.)N=6HE!L]A6I4?&L,E8T4J\I+RC&,,2V*/9]) M@V0-7U,>9;M]JS9?[I*7ITS@+5$I4R K<1#S4S,QHND8F M-D&N>.Y^''/\-2\S'U)-ZZ9U!-J=:JIJQ#N*;B3IMY_VEUOI;N5;VS)6SN3\ M89!K=.J$VW+39-=Q4J5;Y9_,UJ#QT=FXODT#%M.&=1;F;CX5FU\_U_7]?P[Z M1A=?M(G4)KNMV8AA(;#-HV#H.3-,6T#9#:YY@QW!K1NS>-FC"5EH>.=MNSTG!/I_7/8GMK["CG@_T>KC^NWSTQ M70S[0'*;9=2C8&C7:Y81Q/T\:'JTDWAXP7)Y!!0CKG^OZ_/7!'N@_'X_NY_EJ0^P.UV_SO M?+3;!>K>Z^H%CU^Z@,;LC=\/9%CM9%LML,=T[ ])C;@T9EN%8V:C8',_WF.\ M6BOO-#JTII'JMSN CY 0,V(UQR/E^??^OZ^.M92^UO5BH^\FR6I]AVJU9L\/ MJ_I4UW8G+3'Z8V&O.LB0Z/4]&\J/K,FV.X*8:DN" M/95IVX';YCX_#CZ_76KND[U@]VMQ]J]9<1V&QXWSU3,G:\3N8MJ8ZKZH94UT MEM/GCFIM)O&9VU_NV0K'6LV5R_61XUJ\1/5F#:QLVT=)ST,I\$051:Y([<^G M?@#_ '_[NVK9O&OG1QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXT MT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<: M:.--'&FCC31QII3FX?5AHFL+NDP%!P?D_9JYY'S70L"T.O8WDZ;7&%POM]3N M231C7;5=YF)@9!*-F*>K OWPN$(RP VB CIC*6O+].6@ROW$6J]8R4! M>):*7%L^:JH/&A'POF?DV5=MD47C-1?%Y#-8S%M&M^R*YE!,?5%.X8 \'AHX MG7D?$$\CD$C@CF3;?V=N/=*SM@<<Q9_E>.I!ZW?:*;9MW:IVD:Y]+O9O)MMK4$%GF:_'9EUIAI)K ? M'MHP\JFA:,@P?QS1!^]9-79V NA9JO68.@1!T@*GOHYK%Y.1XJ-M+$D:=;($ ME0A.0O4/,1.0"0#T\\#Q,O^R0[[?P(FX/\ CXT__K@YE-1[1_9(=]OX$3<'_'QI M_P#UP<::@OD3[2;+XFR+:\2Y(Z7NU-.R-2'J$?:*G-9,P$A(Q:[MDVDF2GD6 MY*-7C*0CGC5_'24>X=QT@S<).63I=$X'Y'O;;LPY M!#1UW1@1\58CZZL7:_A-X@;TH_I+;&WSEJ76T9FAR>&A*R+]Y'BM9&":-A\G MC4\=QVUCZ?VG=DK_ ,'TU]F3_P F5-?_ /0-R[^WY_LYB6\2-DI][/0#_P#1 M;_\ ^R:E@^S=XV, 5V);(/H1EMO?_O?7U%^TU%.'K/)7E9(KN1KRO#YL3B*P MB-!80"6O)+$RNV*4_.SS:_0S'&HV/NB]NU?-5<0+8HJ56"#VBUDQLS-R&4F4ZH\8NH6OO)$'S)$9ABL0YO-L]*H:587.XC<5(9'"W8K](RR M0^?$LB 2Q\=<;),D7KK6.KRIXIZLUBM-&Y21"T4SA9(Y(GZ9(W59#Y&R-G?+&=9_8:^="3=R9O M]IU6N^F=@3)L_JO&0$E@?(EG);;9 GC8K-#)=K,R$H42)61@^:2[%H%VU!':S=WV&O,_E),U:U.AD ZN@M M5KS=#$9M=JS3(F M/RU6HZM9"9'J<7;T(B3*6'*P^%3*FD6'7=)N2D [HGG'X?$W8]B%[$.;#P1L M$>88[+")7(!"&0T O600>CGJX[\<:EUGP+\5*=B.I:VJ8;4R&2*LV:V\9WC! MX,BQ+EC)Y8;W3)T] ;W>KGMJ3%.V(NVQ^1\F[Q4+HK;L76:V?UN?ZJ6JW0^S M>J[2N3.(HN>EVDA'1, \RJT4A9]I-IR;-:8%!)\4Z(E],2%(8TPQ^0IY6G!? MH3K8IV5+PS*KH'4,R$],BI(I#*RD,JL"/35;YC$9+ 9*UB,O5>ED:3B.S6=X MI#$[(DBCKA>2)PT;HP:.1U((X.OEQY7,BXHONI&4,>="??6J7_2_#*FO.)[1 M%[8:JHOYW"QXXT>ECS*B8Y?,SR/ ,CJN92,2G6IEXR==*S+!=O($;KH>S6-Y M[HUA668P99A[FW5)VV+*28+? -50B\IOED?BA;J)IK+))M_6]-$50661(IB M 2"1S]QQO*P2->I MCZ#D#G]Y&M51W7LRW+%*:.Z3^TCH#@ E$F:=8"]P'MV'])D@@^_?E57?M%># M&/+"YOBI 5YZ@<5GVXX]?]'B7U[%QE]_NUV/^W'_ +WUF[+K2;)2)/48]'[: M]P0 ?(F;=50#L/T'\64"CR&W/ME_9GQ\ABN>*F-KR+V*O@]U\_]W D'T^!. MO?#MG.6.\-!G^/\ IZH/'X-.#_#6T([J>;QR\0WGHOHG;@/XIVT%ZV=-B2-'!48::&6O-+!,ACFA=H MY$/'*.A*LIX)!X((Y!(/P)&E=+_:X<2-5UFSG0'91NY;K*-W""]_PZDL@NB< MR:J*R2DZ4Z2J2A3$43.4IR'*)3 @(<[/TUC/_XI?_LD1S ="LB,2S1A!PTB#I M+=1YY (!(X,;J.2.WXC_ !_K]VK0?/?KXT<::.--'&FCC31QIHXTT<::.--' M&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::_P1 H"8 MP@4I0$3&$0 [B(B/L 'N(C[ '&FHC24Y-[.23^JT>3D(' 4:Z7C;KD:* M649R65G394[>1I6.9)$2JMJ>FH51E:;XQ4*K(J)N8*L+>'QLJFTU7]^T(9'A MM3[7T^LK5Z"8LZY@?;+46Z-ZW'-4V[(("E6#.1 M5E06-YG[B;SVIC7K33COY4;2<>O/3W(_,=M>S'UO;+M:KSQ[1*L(/R,G*@_D M2#]?35JZ,DF$S&Q\Q%.D7T9*L6DE'/FQP4;O&#Y!-TS=(*%_"HBX;JIK)'#V M,0Y3![#SO!# ,#R" 01\0>X/YC7D92I*L"&4E6!]00>"#]0>VE+]9W0?]_/J M5-(TR)(\SUA49'(^&SHD(#Z>1D+["MP;1R!E$D M\;57;E9- MJU<>> W+AUS.,EA4#VF$&:JWQ$JCNGH>TJCH(_M=)Y[:F_A]NR79^XZF1ZF] MCF*ULA&/1ZSL.7X^<+<2#X\!@/O:YPSHGF3R$AR'*(@=-0ADU4SE'Q4253.! M3IJ)F 2J)G*!BG 2F ! 0Y0G#1NT;@JP)5@?4,.Q!//J#VX^>M[7D@N5XK5= MU>&S$LL;J005=>1P5_'GXC4CM)]J;7I1M'B78VJ Y=$H]A22M\"V5],+;CZ8 M#Y9=JNJ F!$RDG KNC1BC@#I,9QO%R?@95BGVR^&R,F*R->XG<1OQ*G/'F0M M[LJ?BR$]//8/TMP>-5OO3;\6>Q%W&R@*TL9,$A'/DVH_?@E'QZ5< /QP60LO M/#=NII0;U5,GT>GY(HDRTL5+OM9A+A5)Y@?U&*5%DC<>C(ZAE8?B"#K2BQ!-5GFK6$:*>O M+)#-&W9DEB8HZ'ZJP(UEO.S73I(W6.Z:IMNK ??C!7N0-4^*JL62;%4!-9%4JBJ#ELY14;.V;I!0R+MF[:K%(NU M=-7!%&[ELN1-=NNDHBJ0JA#%YI[EH)J,\L$Z-')$Q1D<=+*P)Y4\]^01W&OV M$VW?HY['4*>&>)@Z2(Z*RL&';NI[CX'W3WY VS'L I0$OU]O? M\_\ S_[?3Z1&Q/W8]7]?[A^[ZGY3*&H)& Z?=' _+_Q[_#]VLV9M *0H=NW8 M #V H>_P#)]?S'W_+ZC[\CUBSRS=^>2?CZ_#\_P[<#Y#6;AJ*JA>GW0 . M.W X[#]X)Y[\^O.G.]&W8%7'&=I;!\V^,E5,TL5%81%0W]K,LBUMFN]8G()A M B/S^O(2D:N8.ZCI^R@6P 8WCVOW[/N[31SEK;5F0BKF8S+45N $R-9"PXY] M/:*PD1N_O/' H';6CWVW/#1-6E.;D:_*O1QIK3.=-?L2;)TI''V9JDWN%6;3\/9VK)1[(Q MCEG-0BQU&CQE*1#MC*,3JMUGD:]^$>("\BI!_'KB9L[5(;&Y;#X[.TI,=E:J M6ZLT.JP%/;5F^W MAZ]'M(QHR@CUB.+.>#=LD0RAG,A\A5=NE#F6<.2%6)(HU1(/UI5$4 GEHR['WF)Y8DGG6P'@/D,WGMW;FS^6R%S M)6EQD,ER]=FDGEDEELD0JTCL>%"),(XQQ&B@JBJH U.;H=!(FZ>6-W#_ -7T M7=VRNXB_5[]OE_W]F43>D(@'=(9%&0$.PF#R$P=P$!*69^'T30[5QZ$$ -9* M<_V#8D]/ISSJL?&&PEK?V8F7NS1T/-/;DR>Q0\\\?'I*?EQ^.FZ\FNJQT<:: M.--'&FCC344]X,6.,R:H9OH\>U%Y.JTI[9*PV*7R5<6JDK(7*N-$1 !,11_+ M036.$Q.QO3=J%[@!AY&-Z8<9_:N/D>Q_'U]-59\4W(JS&/X? M3MW#^4/R,WG@N9;"M'W5G4@C@\@DX!XXX[#Z>O//;M^/Q&F M.8?M9'ATFAE $%"@0 [_ )CV)V'^0WCV[_E_2.DOBSM=JZF]''P49@YZ>/=/ MO#]Y4'X^GR.I=A;?3.BL> W /R[]AV_,?A\].=UBG32F.#1:@]U:W.2,<4!, M G,U>^E-(*B'?N!/6DG39/N >S40#OX]^?LM_P"3YWM_E;]G# 8V6427=CYC M-;2L MRXKQ6%S&,Y'J$3'9>O6C^'%8@?=.H'O6I[+G[#@<);CBM+V[5^*D9M@NFB3P9 MP-^.B[LT&L;LBC-GL,.4K9!&'2<;1YS'&K8-B-?\WL,6[>DCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHX MTT<::.--'&FCC31QIHXTT<::.--'&FOS55202477431113.JLLJ8_+'IQE]OE5F/_<.LUMP=6>Q"_VLA6'[Y5&G9=#? M8L-DNF?KE./9'YC:<80#C!-R$Z@JN4)7%*A*_!B\4,(F4=R-#"GS:RAOXCSJPM@6<;7;GEHU\EOCWB]U>_P >4Z#S\>==VZ*7L.M[2*9YH<-\)A/:.1E;(*;-N5 M*-I^:2^H_OE;*"102;-;>4XWR$3.)?5=O;8R9HILH-,H4]OG"^QW%R==>(+; M$2A1VCL =5]'2783%_E ._O_)V[\@X/Q'X]OZ_W<]M6_D(>0W;X'X?'@^O] M#U^&KMOV9O> 4<]SY4C>O]F10.RZ MU.\6MO>PY./-UTXKY B&UP#PMV-/=<]@!Y\*?#]N%R?>;O:7Y/-5!HXTU5$Z MU&EU!Q1E2L[.8PDH* ?9OL+R/RIBT%B-7$G9V[!=^XR_6611\"DD/1:Q%^:) ME12=SS^$L#HJJKV'?T_Q[:R:K6F;H5IJ]ZK#HS*QTNP0UI@G91$/1EH M&0;RC!0X>_DE\2U3!9,P"51(3IF 2F$!R&#R=G#Y;'9.JY2Q1N06H6'PDAE6 M0 ]Q[I*\,/B.WQ.HWNK 4=T;=S6WLE&):&:Q=W&6XR >8+M>2O(5[=G59"R' MU5@&'! .KV^-+["Y2QW1LDUPXG@KY4X"VQ7D8AE$V4_&-I-%NN)!$I7+8KGX M=R0![IN$E4S=C%$.?IYC+\&5QU')UCU07ZE>Y$>>?B]A,I>Q5M>"!Y]&S)6D9>H E':,NAX]Y&5AV.LWY[ MM8?1QIJH%UZ,REO6?X?&,*HH^0Q35F5M7"( !P[#K?XBY$YK?5/#P'S(<'419E7DCVZZ5GD7MQW$/LJ$=R&Z MQVX.MUO!K#KMCPIR.Y+86*SNK(2O69CTD8O&AZ<3GGN.JR,A(".QC*-SQJS% MIEA$VN.J^"L+.")DE:-CV$:63T0 $CV^33/.W%5/L >2:MHE)-'X]#(1U2D?0R,Q'XZU!W!DVS.;R>3)/%RY-)'R22 M(0W1 O?TZ85C''H.-2;YD-8?1QIHXTT<::.-- @ @("'19YFC ^!Z5<*>/CS\M2>C-UPH M2>X 5OKQV/IW^?\ 78;XQ!W\PAV_H_DYIQXD[96 M]BKJB/DF-SZ=P5!X/?D_G_XZD%*?HD0@^A'Q//J._/TXY]/4:?3J-80--V&' M\P%&:@6,V@7O[ I&.2MU?'\NZB_4Z9#$AP.1Q"I^')[M_P /G08G(J/O*]=SQ_:4 M3(.?ER)>/S^>I09HPWC?8/%MVPSEVL,;ACK(4&YK]G@'_F4CEFX\3I.&KE(Q M',?*1KM-O)1$JS51?1G=6YE*2M>$+CNEC=WAK+0,Q!E8(HAIQ M8:S8U4$RM(N_5]N)"3,6 II2#<$IR)*:/=&2:1K&8^7'Y66-^6C:NYAEX[.O MG0=CVX$B^CK\^X]TC7H+AXS\QZC\CZ?370\Y*M>;1QIHXTT<::.--'&FCC31 MQIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FOF>/&D> MT=/W[INQ8L6ZSMZ]>+IMFC1HV3,LX1F(O4*!DP[MY"\BGW."%> M.!7[34N&C1JP:MF+%LW9LF:"+5HT:HIMVK5LW3*D@W;H)%(D@@BD0J:229"I MIIE*0A0* !QIKZ.--4X_M9P>6,L#A^W,&$ _I0V(YB\V>,1DCZ<4Y_\ Y#K/ M[6'.Y,(/GDZG_P!,NL ^RB;&C'7'9G4N6> 5"P1$-GBE-5% * 2<"NPHU^30 M(8?QK/(^3HRX$3 1]&'CO6D/\ =?F6+\@RR_FX';5UODVU5.H9;_Z?U?>;57)^OE@%DQF) M^+^HQ$E29790>!+$3Q+$W MS#H2!SZ-TMZ@:Y>=VJ5GH=IL]&NT(\K5TI%BFZ?;Z[(I^D_@K-6I)Q$3<4Z) M[AZS&1:.6QCD$R:@D\TC&3.4PZ]V*TM.Q-5G4I+!(R,IY[%3P?R^(_$'Y:WT MHY&MG<54RM-P\%N!)E*]P"R@E2/@02>?D1\];PTBVFL.E6V&&]C8'XQ=I1K2 MV+J\8GD5%59_7';XT8"X'1;3:$8_\!49IB7)83(-C,A7 MM+R1$X\Q0?OPO[LJ=SW)0GIY_;Z3J [QP<>;Q-['/P&EC+0.1_HK$?ZR"0GX M!74!N..8RR@@,==4NK6> NU9KMRJDHTG*O;8*)LU"G6#>4B)-FL M'LJU?L'3=TW4#V.DJ0WY\O\ 1UD1)$8,DBJZ,.X96 96!^1!!'TUII+%)#+) M#*C1RQ2/%(C#ADDC8HZ,/@RL""/F->X0"0.2 >!V')^7)[#GZ]M? ) )Z02 6X)X'/<\# MN>/7@=]4H^H!.;0VS/D[>-I,873%!7\@I 8_BIUL5Y2(RN-%US1$!5KO#K2% M,L+PR)U'\@,7,*R#M\Y>/'3%F*OPR6COBKBM\RYJ[F\_C; BD)BJ/6Z[5"E2 MC9C#5@FC7@*@)DE=T1IIV>9PO4%7]I/LQ[C\%:&R<7M'P_W'1L9&)!;S$605 M<;GLIEYD07,C9I6&$A#%%AK10O8BJU(X*RS2&,R/$5%,I2AV[=O;^?V^O\G* M,=B22?K^7]?UVUM:W [#T !Y^?;UY^7&OK('<>_Y!_IYYV/)^GPUYV/)^GPU M_2GZAOY.<+V8$?,?SU\$<@@_$<:M9='/*"M]U :55XJ*DAB&]VBB?I#^:QXA MX9I=(50WYE101M*\2V*/L",2!2]BE _0'P0RYR>PZ,+MU2XJQ8QYY/+>5U" MU 3] ECRU'H%C 'IP/Q;^V!MA=N^-&7MQ($K[FQ^/SJA1PHG*/C;?'PZGGQ[ M6'/Q:YYTUGEO:U!I=;FK1+J@( 8&$''N)%R5(! M_6643;F203#N918Y$R@)C ^3(78,;1N9"RW37HU9[<[?**O$TK\?,E4(4?$ M\ =SK(X?%VLWEL;AJ*>9BAY 7;T506) !.JJ2U=L96P2.P)E+QQ@']GS'C"KZ"-. .%UNKX[ M92IL_9V/VCBF\N&CC:>!IA> Q"0"&:5^.YD->*9Y']3+*&/=N=71N;-ZT9T< M::.--'&FCC31QIHXTU6KZW.*E:AES#6PLV*J. M%Q[]CN9: D9]F!Q#R!M6$2"/B4@!K5]H';?M-?'9V*/EE5J%@@?V>N: GMZD M-*O?X(H&LIC9>EFC)]?> ^?H#\?A\.WQ]=+AQY9_!RT5*IV,0Z9OK]1*(>_U M_F'^7^/VT6W+BEEKSQE>0R..>#\01Z?3X?RU(87*L./3^OX'^OCI]6I]T]&> MQA+E6'T7<@E6WP=P$5B3J2L,T3,/_)+)/8U?Z@/D@7Z]NPT#]E+,OX??;'V] M2=_)J;K_ $UMFP/02C,XZ6W20\\>N8HT54=^6 []]2C-)[?M&5_5Z4LQ/T(V(B61#$3]9T[ M<&*0HJ+*)-VZ)?)=TY51;-DU7"R:9O)>O5,;5FNWITK58%#2S2<]*\L$50%! M9W=V5(XT5I))&6.-6=E4Y3#87*[AR=3#82A8R63O.R5J=5.N60I&\LKGDA(X M8(8Y)[$\K)!7KQR3SR1PQNZPKC.I5KW/PZUHK%7V,M=*(F+EI?:UK7F.7H\J MP#W"3B[,VJAHQQ'&)W5([.LB0Z8"''?L!ZGBVOO6Q67NMN+;TJQ2)Z M^9'#//#=*<>]WJ*Q'HI/;5@MX2Y2*>.I8W?X:5KKD)+5EWY@F:K*>WE6+,$\ MU%7!]UC';E13SU. "1(K!&SV ]F81_.X-RC5\@MX=8K:>81+T4I^N.SB8H-+ M'6WZ;2=@UQ4352($E'MR+*(K%;G5](XA)L3G,;FHFDQ\[.T? GKSPSU+E=B/ MNV*EJ.&Q">>0"\85B#T,P'.HING96Y=FV((,_CO9H[:M)1OU;5/)XG(Q*>#) MC\OC+%O&W57E2XKV7>+J43)&S :WSS+:BNCC31QIHXTT<::.--'&FCC31QIH MXTT<::.--'&FCC31QIHXTU\$I*QD'&OYF9D&<5$Q3-Q(24G(N46;!@Q:)&7= M/'CIP=-!NV;HD.JLLJ.K=.WU^>6I#]\RZK?] M+[94FH>_^MF:)!^:.J;*_LZAD);S$KN^S7*\I/"B0*__ +*0=#$\=B%5BP^JC5X[QQGM^)NP*O,O MEEXOGYL)\R,?[;)T<_V6/ UU6 'O[A[@/N A^?+@UK7HXTU1\^TK:2)8NS73 M]T*1%@VIV?%6](RJ1JD<&\=F&NPYU("=5 I/20^_5)B%&RP%$A3RM,>/%?-Y M,G,I5^_,2$>++0KP).(+7']H ^7(?@.H#I/SZ1V^.MC_ /W4>;.U[Q/4./@W'H-5;GJ?8$L\D1U>]5IQ*HLB++"=\]Q/9@= MR^/W:A3CY"G"NDK'34") *36+KT*0PE,L4!NC9V1]KQGLSGF6BPC')[M _+1 M-W[]CUQ_0(OSUJ9XF87]&YXW(D*P91#,>W"K:BZ4L*./[0,4IY[EY'^6K$G) M=JN->3.0,'9XE_ 66&BK#!2C<[23A9R.:2T3(M50[*-GT<_1<,W;=0/8Z+A% M1,P?K%'GRZ)(C1R(LB,.&1U#(P^3*P((^A&NR&::O+'/7ED@FB8/%-"[12QN MIY5XY$*NC ]PRD$'T.E"['=&S!F0TG]@P$_4P/<3E<.$X!NDYG,52KHP>9$5 MJRNY!_42*'*5%):G/V<3'D44<&JLHJ!4QIS>'@EM/%OVP?$S8+5L?GI_\ +C;L?1&U3+RD96O" M. ?8\N%>9F5?NQWEM(> H:,=Q7OSWKKF76"UI5#---<5M9\LLE7+,R5/*T:Y M$0+ZBJU4M!$&[=\H1/\ 3+P[]O%65@@)%I*#9I*HG4U$WGX:[GV3.1DJAGHL MQ$&3JAI*"W'5$_'H_$?SU<6GI M="2Z*IV_9/'2B@B@[A_?NH1]#%.8 [=DTP$?H'- MQOLY7&-+/T"?=5Z=I!\B1-"YX^O$?IQZ?'X?F%]O7$JN3V-FU'O/%F,7*W'J M$:G;@'/IV+V#Q_>Y^)U8[YLSK\]-*BZP&81QYK %'9.BHRN6+$UB'!"G\5PJ MM;\+'.K)@!@-Z:L@VK\4X[@*9VLJNF?L!N5#XSYAJ&U4Q<+<6,_=AI< \-[) M"19M,.#SP>B&%_FLQ'QXUL7]F;;B97?TN>LIS3VEB[.3ZF',9R%E32HQL>" MP66U9C^(>LK#TU''H.8.-7\-Y3V-FF()S.:;JK7ZRZ43'U!H= 478BNW.8 $ MJ,E;G<^@N4H>*@P+13N( 7ME?###KC=OI.5XDM$*IX[F*$=///K[TQEY^?2I MU@/'7<;9O=\E59"T-!2SCGM[19X?]Z5U@ ^74P]>=/KY9.J3T<::.--'&FCC M31QIHXTU WJ6X(5V!TVR[5XJ/&0N-2B290H221#'=FM6/_4G"L6!2@(B]L,& MG-U9$O;L;YZ8/81 P1;>F&7.[:RE#HZY37:>N..2)ZX\Q.G^\X#1C_7UVP/T M2HWPYX/X'M_#U_+5/K&5I!VBP7*KW*H5,PB!OR, #Y?Q]P'O_&/\_/SJW'C/ M+:>,KQP6[<>A]"/R]/H.?PU)XGY ^!'RY_C_ %Z'3M-9K0[=4%]\ ?REH!=* M6B@ W<22#$J;Z..7Z]A)(-FYP_"("(!WYH#XCVI?#_QE\/=\UQT'$;BP>5+# MD<_HK+U[4H)Y'WH0R'DCL3WXU.,1_GN*RE$]_,JR](^IC900!_>X]-6-8R0: MR\;'RK%4JS&38M)!FL40$JK5Z@FY;JE$!$!*HBJ0P" B @/L//Z-X)H[$,-B M(]44\4OY'^1TYKG.N-'&FCC31QII6G5M@#.< X?R!+Q 6;&>#MN=IJ1[AO%*J/2';HG*,9W44AI4[\RA MZV+RE*];#+U@549X9I.G@\^4L_F'MV52WH#JSO"FO/D\[E]N4I6ARFZMK9O! M8=D?RVERDD<-^I3$@(*'(/CS13@@R26$B])""T)FY:/&;5VP7;N6#IL@Y9.6 MBB:K5PT72*JV7;*I"9)1NJB8BB*B8BF=,Q3$$2B \DJL& 92&5@&5E((8$<@ M@CL01W!'8C59NCQNT;JR.C,CHP*LCJ2&5E/!5E((((Y!'!TF7JFX^@<)2& ] MY<+,"43:&N[-:YXA7LM>0^6QV8L=9GRK7,;VW&.9D6GIM;!5%XB>5E(V:DT7 M$S69:)CE85\T%0Q1P^2K0++6OH!%J)G4NC MYF=1;1QIK7=-RK1[_8\BU6IS!I68Q58FE3NZ:;%^DSB[ \B6LT2,1DEVRE'N7*D81R+$EU(89Y8( MY64),T*S(DWE,PBF#Q/PZ,!GLQMG,8"G@+V5K+5AW-B?TWB%,\#SSXLW+5&* MW+7CD::K'8FISM6]H2,V(0L\0:-@VMBL#HXTT<::.--'&FCC31QIHXTT< M::.--'&FCC37D3T_"U:%D['8Y1C"04*R7D9:6DG";1BP9-B"HNY.O M&2(]4I%FM735*1[4Z([#R?>+>E3Y]7';X_/M^_Y?CV.NI)TC=H_P!]YT^M= M5C):+GD]XSIDG,CK":B%OGJO";HZEYIUUEQ:MW]XJCA2ES#M,IR5S(L HG/4 M&P=^PJ$0CK3'QHR)43$4=1"DBQ\P3=* /BR-*/(4K%.0>[/&5!/[+CNC?[+@ M'65PF4FPN5HY.!BLE2PDAX/'4G/$B?[2%AKE@3T/,0$G,5ZPQKJ&L->E)* L M$,_2,@^B)V$>KQDQ%/43!Y(NXZ0;.&CE(P>2:R)R#[EYKS/"]>>6&0<20R,C M<_ J>/KV/ .MY$N0Y7&U,A P:.S7BEY'H>I1S^?/_AIMO03VB5UIZC>+XF3? M UI&PZ+C EL(JKZ;8LC;G+1UCU^!3"5+XI'(,=7HHJZ@AZ$=.2OB/=42FF&T M+QJ96%&/ZNV#6Y.J<-=*;/MQ;RD%-M M0264@%I*_/'#'WT]'Y'OG]0_L\_:VAW6:>S_$26"GN/A8*&:X6&GFB M J3("$JY!NY,:@03D%H0CGR1F71.M<7%;DV6(+ @S>7HRL$DDQIZ8V/# M.\-B%F"CCN50NQ^2\G6/^W50>WLG:V6KHTU>IN("6:,=211W*%M$9W!X57F2 M- >XZV0<@D VQ.;<:_+S557K390>WO/".-Z\*\@>AUZ"I$;'-P%0SJY7-9&9 MD$VA2^0*+N6\C6XLQ0 #@Y8'1$/(O;FL/B3<.>\1L=A829(L+5AC9%/(]MN% M;,O8'U\IZL9X[]2E0.=;U^">-7:7@OF=SV0L,^Z+]J9)6[$8W&JU*OR2!P!8 M3(3 \\=$JG\+'VM^'X_ .!<28:C1(=+'=%@*Z[H[-V]N;)8^HE&C4IH %K011=OB44!F_%FY8_4ZTER^0DRV4OY*7[] MVU-8X/[*NY,:?@D?2@^BC6[.>S6.T<::.--'&FCC31QIHXTU_@@!@$I@ Q3 M(&*( (" AV$! ?80$/80'V$.--40=F,3AK-MWG'##5N9E7H&[NIBDHB4P)$H MUQ30MM1;-SF_X=.*B)AM!JK![&=QCLH]C%. :.^*FW1B\_DH$7B)I38@[H['X_'U&F#Z36CUY%_%&. @[C1.!._U M.V.4_P!/S$2G'W 1]N_/S0^U-@N<+2R2)[U2^JLX'<1V$93^74J<_P"&IYM: M?IN^63VD1EX_ $C_ X_H61=:I89;!V/?-45E(2*0_MC]G[<_^67@EX7;C9_,ER.R\'[0Q8,WM52G'2LAR M.W6)ZTG7V!ZN>0#VU6V7K^RY._7XX\JU,HX]..LDOY'^1TYKG.N-'&FCC31QIK';=4Z]?*K9*3;8QO-5>W M04K6K%$.RB9M)PLVQ7C9-BL "!@3/OW,5?I9/'V)*E_'6Z]ZE:A/3+6MU)4G MKSQM\'BEC1U/P91J&NB=A>0M4R1K1,3JUIF=3;NEB9M9%S)*KS-)6AFD:R^UW[2JU\9'XH[;@WIR6/GR=(\>6T5PB']2B#64;]Z]S&T&H^9<051PF MQO\ )0>)A;LG;E3P/V\1E M67IO?QUJM$W1,T8>!N> L\+++#R>#PID10QX/"DZK7:N4K8;<&+R%V(ST(K MCOP@6X0"Q=@.H LA5P.&&FYL!/MS+6*#N+%1O\YQ>0C'-? M*8ND[1Z<@T M,^*A&,EGJX"U*L*X#Z2(_4@?4.+&3I0+8_SJN\]>"6=JRSQ&?IB1G(\H,9.X M''W=>6CAMUJD5EJTPK]=F984/FE!&1U-_:^!U%3I]-B/=8*= MD9PBF$[F^7MF:;&]*(&6DGE\L#YY".':H>ZSIG36]8AU%C?B4+&$.< .)@Y% M_#BF]39F$DG ]MR<#YK)/\9/$%84Y(BAEM5K-I8E/"-88#GUUO#8?+Q\ X/RAFL* M39,BH8OJ$I=9"G5 &QK)+P\$F#V;&*3=G(BLO'1";V5.W#S7<(,54&B2SI1% M$\JR=JQ2HV;56F;\\"!TJ+,MCCLADX\-4N3>3)DI:\EN.LS(_DEH(GC=Q+,(X.>M%C\SS)&6-&(RK%N2Z;F M;&]%RSCR62G:-D>J0=SJDLD'A\;!V&.0DF"BJ0B)FSHJ#@J3QFKV79NTUFJY M2+(J%#T5YXK4$-F%NN*>-)8V].5X/(/<:\E^C9QMVWC[D?E6J M5B6M/'Z],L+E'X/HRDCE&'9U(9>01K/.=VO)HXTT<::P3*4[;:OC+(UFH%:3 MNE[KM$MT[2J>LY.R1MEMB*_(2% MGJ'5QV/3SWX/?@\>G;4+=<]B=C\PX(QMGJ.H^,,GUS(%2C;(M!T*V/*[6 M72$D[4B1ERCXRLKNJO,HOX)X]=W)HJZ79&62C0 Y2#0]&QX]U,3!E\/EO#WQ M)20SR3XG+X_(^'^25XI&63'U$^<)M6U@CTU?T)92(5=1ZZ@"5NX5YD\5XZ8.*W%B/$7;^XO" M7-R2)!$N\Z]?_)F_.[="+B=\8N>]M>P)GZ4K5\A?Q64L,ZJN,5ST#JDQ4A!D MHSPY&(#G_-BPL*/_ %E254GY [L8EFC7N?,X[ZSC.&0Y?%6*+CD6 K1;C(56 M/:RA*^,@,85\R^9L4)-8'Q&KT4_E\6N\DRE!N<' LP0\T@5]4EB;WS]C;.T, MYN6DM69L-0;*N+0D>LU&JT<]]SY$L3LRX];$D)$BIYJQER8^KGQ5HEFGCB?J MXD;H]P@-U$$)P2&'W^GGMZ<\=^^O[L.<L99,QBF#\!TP, _A$._MR'Y'QY\&\782E/XC;7MY)^GC$87()N+- M LH8!\-@%R>40])'(>HO'H>#KUIA\FZ]8I3)'_ULZBM"?J)K!BB/KV][OK&* M]L/BG*(SU7Q#E/'TWD5*#D',)#OI SCTWQFB_P JD9"%;N6$O(017@)*OOEB MJ:RK(BY4'**G94F3P'BIL_=MN?"X7)7Z&=,,QI4MT;7W/MB:VRHQ6QCZVY<9 MA'S4$1XEF7%RS,L2L7>$P%[^CM7DE\OGT!< $^ MG.M-0LKE5&'OKS-6Q<96VF, 8IVNX8WH\%4:VL_=-U)!ZRCV5Q4R(];A$E78 M1"3=5[)2DP[43710:+OFT!Y'R=SV6G2QC1T*PL6ZT MEF8S-8E8(+,L<#A6G\M1-%&'*^7P00RD*X&M=0U.R==)F@7?*MFMUAQ>^R97 MRT'$63(VO(6*2:+D.DTOM\956'K,>W'E;";DS>YK&]_%';FVLE1W78CRTW^3UG'9J7-28EJL- X]L;7@7, M363'9#-0BKR=$$\@;SUEBOI=::&&$5,?/.CUU\H><)(5B$GW@_6S>4%[??+< M\J"&3,Z6J9)%]&-67L>>ENJ2$GX 0?$A;:V]B^7;E-;WH^RY;VA5X2Y&)>WIY@]V3\2Q'4 M>/GW^NU/A!F#D-LRXV1^J7&RO$H)Y/DL T8'R4*W0/ET'\T=M):4KLS%V""? M+QDW R;":AI)L<2.8Z7BW:3Z-?MS_4CAF\01<(G#W*HD0W?N'(U5D,;QR*Q5 MD(8$?!E(*G\0R^O&I;E84FBDCD4,DBLKJ>X9&!4@CY$'@^FNM'JOG"(V6UMP M;GV$%,K++6,*==E6R9RG^6RLS"M5YV&5,0 +\3!SGS&'=% \'+%8G8!+V#8 M&G86W5KV5])X8Y./[)9067\5;E3]1K3?)TVQV0NT7]:MF:#G^TL;D(WX.G2P M^AUOWGIUX='&FCC37@VJL0=VK%CIMGCT)>MVR"EJU8(IT4#MI*$G&#B,E&"Y M1_61=L72Z"@?\E0>?$D:2QO%(H:.1&C=3Z,CJ593]"I(.NV":6M-#8@=HIH) M8YH9%/#1RQ.'C=3\&1U# _ C5"VA3]ET8VMB33JKI2;U2V 4A+(LEW(YG:1 M3Z\%85FP?WR-RQJ]?+LQ,40,WF4%.W?Q$-,J\HN0O'KSVU4^U[@Y#:CJ48VFY=J+MD3(EIV&M*"Y?5*PCZN MZF7QYJKX7B3=6_,MN*92R2W[>0][OY M$X&LC0?CJ7X^H^H/'(Y^'''?Y\ZASI M=;RM;] %.MXINE0;'[B'80<$$G8?S]S 7V[^X]N?FC]HK F]L7.JD?4\%12USX6N9]K/=;DMD-P;HNER26E\[/7PLK$DDET13W)(' ^&KM\?IXFW MU0H0$>SX38GA[A88UX$<*T=H8@21QJ. JF:260@ 7J MQNTKE,3S5C;JV*PLUW\NQ7,\3Q>? X[I-%U^9$X^ZZJ?AJHL1?7%9;&91J=7 M(KC;2O+3LQ6#3N1]_,JV1'Y-A/VXG=?CI).LG3GU=N<9D2CY"KN M5*EL!0;$ZBLKS%3V*S?'C<%)E9\XB+T1@-Y/#K,K*W3=+-B.8-NFNW32DB1$ M2PF&L6A2VQ]I[;R-/)X'/X:L=S[:LKB\S9AFM0ME(I(O-Q^90QSJWEY2FPDD M#?=LK8' '2-;5>)WB_XC8G(8;<^U-USMLC=M:3+[:H6\1@[4."GCD1.-L/:=(T\EF2*-TK"Q9DJR3O[=IZ$&M4L+I:K9UVHHCESZ@B$5>*!+LQ. MN0PB?F?D\&MAR?=QLT7OAP$M2,%I;TC;S9L)7#Y;D/&N$A[DZ>R<#&5)ZR^-QW*L(8D:C8 M:Q3,B02:MFI%CKDP6+4*A)5EY%(R\2=DZQ>/P^YMOW+,>.W+.8*481'>/6SFI9) M+&]=M7#@LW7M=*BW7N004Y<5D,A%:8SV+65JVWL4[$1BCB?]:+.==ZN&&+7K MSF"UW2'0QCF2@:\VS-;'$]MDX^3@LLU1I0)2W5ZSX"S%D(5H92O2DMK5:025[\*Q,ZV,;881^TP2%2 M#&R1V(FZDEB'26-09;PJNUYL=D]O7'W#M+(9>'%-EHJS5[^!O/82*3&;HQJ2 M6#BP_5E^980/CT,WF)\>EG'HHXDGC-LM*"4=U4E)CL>1C\L 6;BS'!TT[;<\ M\>=##Y$Q[*9(X6[R3.39ELVPF$Z?=JUC:Q9,JL??;?*,H:O5(L@#V=?2,D[2 M8,4%&$>1TLP*Z>KHM$G$D#1L9PJFEZWF#8V>+29BZLK D#D\#4+MX>KEIVOC> M[XN84J4S/:Y)O+P$ PDJO$.X&*MO@ZC8N::JR#ETZ6D8N1$CR*4AV@OCN$T? MAUT#'\RUKD/&N/?>'GQVV-B9&:OEJHCBR&]H\93QPK75Z8KL6'JSYJ]==8G% MB.AD8<.9"4BFEA?S$3V+CQ7<--97J1CS'7#LW4G)*M(PB5>XX+)YGQX!UC.L M^OV\5'UYI=TVXEL@9)I;B$F?F6%:W>+O$Y1Q33Y-!HO6YRRMH26:!?Y2 *#Y M[,59D8+5 LETV3L;D\.]CJW ]W^!.0Q^WX\K!AY-[;;IU+$N1\),CFKL&-J1 M>3,5S.T:=N['M^KFJ/FR65VYE8!MVVRA(SB+;/<'LK94-,8S,:LC%56_&@:0 MGD/2I%755.LZW<+2PN[<;?BH8/='Z>Q<'LEB2SM:O$F;EOY<5_TG6AJ8^=[T-E9Z:S0N MKGZR.(REK*6%J5;-J&>9Y:TL?7-7,$C=2@623&%CY\MR\@*,I5^&!UJG/=VU MSS"LS2S752LJ73C.9:#R0V?3\!DJJ3R9>S!_3+#2W3.T5]=XY]-K\#&OUC3! MU&[=\T5((LS4YMW[<&S_ !F\;L)X65-A6I_#_)19.&//Y"C>O;EGS%6NUFCD M*^.Q!G3;V%A\B62YD+D\S5*C#)9&?"P5+*KE[.SK.,P\N0DN*+J&-C C(D"Q M,P5T,DA4S2GD="(!U-^KC65F4Z^W 56H%RF59K&&'K?9G4Q: M'$^8_B&5,O2<^]I8R.4M7)ILC9YEAH+5C!\VRXGM/Z?JT/%> ?W0>J9^?5V3M[@.I-P7O2.NY+460Q]8]GM<*[10:)=UE MUHYF]5?))MRGU. 6*0&-A(_ [GH4E MO=][MV[\:SFVHRJ(JHF%-0/8Y/$P>P\ MU_B(60@,K#D]+ ]2L!W#*5/!##N".001QSSK<^XOGU(Y.EE8+TLCJ5=".Y5U M/=77GAE/<$$$#CMOW0O9=WISN9K[L6FHX+#X_P @1A[H@V\_5>X]L!%JQD%D M1,H&!5=:G3,P+,AR'*5^FU5\1.F4>2K"733N03<^ZD@ZASZQM[KCMWY*,>!P M1RW[JSW1BQE,3P:WZ]9]9LBGEL89 M>?8^E79"_I$ZKE.M/7PF<& HB*+>RT6"00\Q B:TJH #Y+=C03?M428V"R![ M\%@(3_3\ "@_,CZ:N#P:R!K;BLTBW$=RF6Z3Z,\,BJ !\^F4GY\)V&J M,S\O8QNP?M[_ -';E5P'T_'D_EW_ #]1K8&^. XX^?[AR/\ =\?]^K_GV9+. MRV3.G[+XIDWH.)77C+]KJ;%N8_DLC3+NFUR) JG[B(@D:>GKDP;!W[%1C 3* M %3 N79]GSL2(B>6K321@?$(_$B\_[3.!] !K5WQ(HBKN#VA5X6_5BG)^!E MBY@DX^H2.)F^K\GUU8OY*M0#1QIHXTT<::IO]=#$B..-S&F0&33T(/8C%<;, MOU0(8$7-YH!@I<^ #W\/+[K$H:JA"@ G5645, F.8W-:/&G$>3F<;EXEX]IA M42,/C-6;H)_$1&'X? _G^A7V0]U>T[5SVU;$O4A+A?IK# M>CEC(KR\[$9Q=) 8K$*[AVNK>/Z@IIHW&W%(8>X!Y_$4TOX!]Q2.!OH',3X! MXOR-OW,HRD-;L&&,GXHI$C\?0DQ_QUG/M<[@]LW=C<$C.3\C_ _QUST'YC]__#7]A]KJZ40D%4(G:P4P]A4# M#5=$@#W .PG_ '2_$/<0#Z_40_;QS]#_ _QTZ#\Q^__ (:L(ZQ;$X_VUP!B MC9/%2<^ECK,E18W6GDM,:A#V$L+(G6(V^;1C9])H,G8^@AA/$G M_P %Y#^6N^LW3,GR/NG\_3^/'\]53M:[H,;9(-V542BW=M50'O\ 0"J)F[C^ M?T#\A]A'^7GYZ>).#7(8?(U&3J$]:>%A\"7C8 T^M"?[H3M(BX? W_'[-ZB'Y;R)JTIX MY)0=1X UG-]0^?7Q640 K)$()& ]'X+]_P ^I?RXUHOJZ_W1.D#_ (7#7[_5 M1GCGZ_GT_,?S&JX'K^1_D=.:YSKC1QIHXTT<::P?)MR:8ZQQ?K^_4*FRI-,L M]L)2_4YA H (B ;R28?#9;+2=TQF-O7V']H M4ZTMCI'/J6\OI ^)( [G6>VK@YMS;GV[MRLI:?/YS$X:$+SSYF3OP4U/(] # M-R6]% )/8:3/KQU-=1MB9G(MFA*37G4AQJY'%8>"##XZY6I0K=R7DVJ5&&U'+)2BCECD$D)9&76P M(_KHZ,R"PHE7RRW.'8 %Q2(L0.<1 (0&UJ<&$P_4.Y0*/;];OV 9&?&;:J MM+2S\2@<]34*S#_X=^0CCU/( ^.HVWV,_%?TCRFQ)VYXZ8L]?Y'U_682,<< M]NQ)Y/IK35*ZH&K\5MIG;)4[)VZ.@9&F8[I$)&LZJ1Q*+S<:W6D+.:PIH2(( MMG\*D%?C ;BNX9I M'Q^,AF!N6O+E*1R6+4]@0)U,S58X)#[KIS,LE]FKQ(R_A]M#:6*?;=BU@,MN M.[E;5C-&"J9\C-7%6OC7EJ!IZX@B>:28*D,S3121,_4X3?\ =>K[@QHM2E\: MQDW;'V(:)C?]?4DD#P23I-T?J).!(O*^9%SYBX M;;_V+?$"RN;32N92+$:]44@#> M7,!Y3Z.ZC6NVM'4@P#)9BQCD;&]8S33J/)PB+Z\R[* @[[0'IADY?!^96YW2 M3M*OR$F5*6J-F9*'E<>7QM&VRIR;9PFZ46G*[WV5NK#C.8S0JS.)#%*_$8:'S4,H5ZLLC!2:FI[)W[L'*WW2?R- M 4F.S-@]6RY+UORUE*Q2T!.0V&Y1TS>7/$+9G!5N6>7!FXEI$\^UCQ<-VD:U M>R5CB%3Q\$P(XQD]>YNVICZ-*+'UBTDMWVZ[):2YC9O+BF:K0K1U^+$=X2"V M#9GB05V=Q%*ZKY5BX_*T?"/-Y?+Y"QE\QC;=2#%3X;'05#C=T8J66Q5AR.5M M3VPV-O85X)<7**E::>/)0)6:Q'#+-[3HW%VO^2M'NJE5\)7_ .81UCQO?X1T MO%T&:G%W.1J+;8IJ\/5Z39(J1J,[Z]]I<\]K4=(F7BWS5^Y.E),DG3=RQ+$, MG7M;=L4ZN7I3963VNC4MU\5,T+7%MR1Q PR-+2*0V'>))NN:!(8I9/-9HXW5 M[)Q&0Q'B'B=QS;9R$.#Q_P"B\OE<5+N:NMD8U<?H>@JM-V! M#XA2\9BG6ASI7&^/I&7.U04-7Z\_+& [7D+5VGM$TI_T[EZ=&KE&22+&XF@L M9QVVZ$G3S4JLD<:VLC.%5LIE63S;,GZF$I4CC0ZM[^\0([](;2VUDP,;Q M39K<&3\R/+;TRL'45NVH7DD;'8*D[NF!V_&XAJQ_YY;1\C,[1,)Y8.JAT<:: M.--:FSG%UFPXHN]5MK9V_A;; OJPM'1RS1"4D%)E [1%M%K/F[QH@_ Y_7;N M5VCE-H9$71T5"HB4:S\7L]@L#L/+MGT]J@R[5,!2Q:9086;-93,68ZE'%1Y+ MJ#4X[$C%[UI YJ8R*[;:-XX'4^_&5YK-M%BY7RU>:23RS+Y442EGD\O]M@!Q M&O(ZY"B @L#J)&&>GEHOK,I#6"#QC6276!DF-F;W*_V)[<[7ABGEBL6O+#2>3'%4YED6.1(//2+I1Q9"X2((+$ZM[G,<+E>"?0E M057ZDMV[\GCG49,^[SWC.&0G^MV JS?\:XK^.<5K/.WEOQ1-%K5/QJHM(:9MZ+.#9E=EE%VBS J"[FO,IXAQ>*.,LPXALE4\-+4D MF,SN:Q%&[F,[F*,\Q=RL?*FE:,;@:*R%>' R1NTGJ6HU"1? M,"FZH#QI*5CBB<$%3S*46613W'/ZGD=O.!!$C;'6-)8?'[>C( MAO/TB393-CL[>+;HL(R,LT$FHL^R).R2Q$4"NGJ9KDZ>KK RGF1WKTZT>\1O M"?[-WC[A*>S[LN*QV7PN-,>W\AAE7;^Z?1R%66 MDD<8?HA=$E3UX_)9S#3-;A,CI(_,Z2$3UYV=AV?I9O>=CPKHP1$NP=]/?K>,OBE4L5:OB%=Q@J9"UB M=KTL981JF(V/[96Q2Y6MB[N0R&X[T\CY=X<77KTDSK[OCN">Y:C*7J@C.*I\ M%Z,4H=!+9<\]TV.*=;<@P%RQID&LU"$DK% M*IIC-X^M1XV+:+/'(1T._&T03IP1)']&BXN+ RYS%21 R@% _LRGV!MM;%QN M0S6.W+%?Q^+JV+ULYBHT-@5JL332MU5S821PB$*BJI8@*@][I&/&Z+-R15D0 MAY&"@HW/))''J!]/X_/4 *GNGMUIW9(6&O5+N>/8">=C*-ZSD.M+EJ5B-)G^ M->N8F1 H1[QPZ.J9P^?5N8^)%H% XBFLBD+HVP'A%]I39OB7F)]D9"2';7B-2A::7;=J<&++UX@S27=N MVI GMR(B-+8Q[A"[A[-6+VM%::F6 \Y1_HR?03 ?!R&(74I.;(:Q&CC31QIHXTU4\^TJF\)S34P_0-FM;!__ #FP/(OO4<[1 MW(!__)[_ /\ 0/J=>&!X\1-EG_\ J3$__;<>JD6RE;+ 9:M8(D C.Q>C:&78 M![":2 Q)'ZA^L,L@^4$ _5*W*!Q,I>C69OO1CRV/;N%[J?3^P0/RUN; MF856_D(E^[(19C 'H6]V0#OQSU]1_ _$:BR^1[@8.WN'O[>X_P"WU#Z_GR2U MY"I4\\ O/\_W=OPU?(Z*/5/?VS5_$V/< MXO$Y..QPW0PVM> (!96LIU%JQ95+[RIIE#YM#'J"T 5>;]/YHW<$=KOCRA2K MK-Y%B]_OC"K \$$$<$'N#V.E, M=="C(WOI:[3MC-RKNJQ!TN]QYA*!CMEZ=D>HS3MPD(@(D,$.WDTC&+V$45E4 MQ$"G-R/[JB\W 9 <9--"?KYM694!_ M_.='X$ _#7-(D _$(_M$.4?">/S/'S_LZVSOGEG^O)_C_P =6AOLJ66%H/9O M9/"B[LY&&0\,PV06;0QOT1YC&=O90QS)D$>WKJ1>17)S>/XC),^YO(I $MD[ M'GZ9[=;DD20I-Q\ T;\'M\.1,?QX&J#\5*@:GCKH ZH;4E=FX[]-B(R#O\@T M'''UY[>AM7;*]3S033O(+3%6SFT6-<-9#?UF.N3.J6]Q,(R;FKR[Z5C(V:2* MQB7J!F;M_!RS5(WK>?JL%P,0H 436/R/K^XG_=JE.#_XD#^>H]_V>GH]_P#; M^8+_ ._K'_T>XY'U_GH]_\ ;^8+_P"_K'_T>XY'U_HMI'NK8;14]5MCL?9NL5+A6EBM433%Y59S"0KY\$:TD7O MQ\6Q2*@X?#\,GX*'.*G?\'B F!R/Z!'\]."/Z!_EI:OVAS&QIK5;%^7V33U7 MN(0@) 3F[=P25M+*E)"'?\ 7.0?VCRL_%7'>V[;6=5Z MGI7(WY^44RM$_P _VS%].VM@?LW[@.%WZU5I"D67QL]?CG@-/7=+$?YB(6 # M\.=*=Z:.:FM@UXS1@R<>&+%XJM]WV 8$6.4J2SVV8[C,>5J-;B)^YQ2M!WLL M=$"CXF6]7ZF]M<=RYC_[S\?@)9"D45_(98'CL\D5*.E5K@\]V\^X\I'P"%N3 MK:E\+(GB1)N/'H'M9]]K;4;I!+PTWR\^GL.0UFGI MGT)*CZ?XX>&0]*1R,YL>49-02B4787&9=.(!R(#^VG-JTB4?H)$2]NX?B':3 MPYQOZ*V7@*Q7ID>C%:E!]2]D>;R?KT,@_+6D_C7G#N#Q/W?>#]<465FHP=^0 M(J)]GX'T\U)&_P!K4]^3?56:P3*7]S+(O_S$MW_\?D.<'T/X'^6N1ZC\1_/7 M()Z8&;\+8G/?:UGAY$L,>9+MV&&EBLE;R);\/[ 8GC*PZN#I?.&'[O"P5EJ5 MR88Y2F%WETU^OD!86>8UW53;P-;E9>N@YB_M@IC0%NDB5GZU4.\15 JEHF!2 MQ%*)71H_OJ5ZEX4R,OV.0>H#J/EJG0Q*JX9U8],B^]"ZE%;K^Z1V/)"J9>:> M;(X%Q]/]'5_:]S-F;7F)]9ABFLO4L(W"QX8>4ZD&"[?X!9)-61C2ONOIY\OJ"JS8">M(%)*K=9LD8XPW?OQ-5"OR>! MQU'W&Z?H\#S0O6R_I6*9"1PS5D%0%N/0 B*7J7MR>K@'K'4MV)VJRO5--AA(>>_EB&(JD7!/"B26RTW"KVEK%B06][M4A M'L,O ZT*#CMU&60,\G(')9(X1$>H]TGX (4]/4*Z)>0*)6.D;T_6EDNE3K[H MNN5/.9M-6*(BW!2*+/O YD7KM!0I3^9? PE #>0=A'N'.P>GYG^9UYG^\?Z^ M TS-7/6%41\393HBAO\ DM[+%NC#[%'\(-G"PF]C /X0'V_D'MSKYU\G[X+$ M!N_H7%)[]/\ U-AK%*>7?MV\?ET0Z\_K]"]^WOW^@]FF@<\X_.7R9I7N3]NX M!'8LR6X$?81_#_O4(4?I[=A]_P"<.-/Z]-8M=<@5?(-/M=%EL89BG:Y=*U.U M6<;)XXF&1'<-8HMW$R3?_=KY8(>NR=K)=S% ]0!'L &\>N:))X98)!U1S1R M12#YI(I1A^:DC0'@@CU!!'8^HX_K_P #JE=>-.-B=-BU"8S16T82&M$Y(P=< MD"//44?K1:*;H3N6OI$.S469J$<@D8ZOB8%$Q-^C QM-?$K8N0PM43V_9W@N M26(X/)E+M^J4/RZ%%"AT;W0&;]H'IX4MG*MA7;@<@CNP(_M>OQ()Y Y]/AQZ M=GH:=97*-7H-O*ZRZ]?D)=NU3-V*+H[; MN >(=OS'PFXSX!?:LVAOB5FK;>R^22EG''4(_P!%Y@?HW)LW;O[.DD-W@\CF MOU?#G5@+#^F=LVZ/WK%0&>N.W5S'RX _'WUX''/6./AK>/5O527O_1]704(L MBMU;->U454CE.FJDIB;.YTU$SE$2G(<@@8ARB)3%$! 1 >?T!JZ2(DD;*\;A M'1T(971N&5E8N-'&FCC37QR$@QB6 M#V4DW;=A'1S1P^?OG2I$&K-FT2.NY=.%E! B2""*9U55#B!2$*8PB !SIL6( M*E>>U:FCKUJT,EBQ/,ZQPP00H9)9I9&(5(XXU9W=B%5022 -=U:M8N6(*E2& M2Q:M315Z]>%#)+//,ZQQ11(H+/))(RHB@$LQ 'K;GX1K6=\NYONE:H%A=ST/3J%BEE"1<]\NILY(5%R^LMMM$996:9WDG"OO MAX>'K@"@P(U='GC.':S!C/\ P]\+\5M%) M''''%'.D?7))*9&5FZ%''/F=4OI=:G=/W54N,QPR\H&;JGCF10O!4@])J'8'C[XQ[AS#X M>#)Q>QS5[$]^Q3Q&/,]!!$T,=P6K,$]B%4EECBZ*L]:24R 1R(WO"5^IW2,Z MRM28R=_"V.#EDW+.5(# MQV@X6#X]B]?1[QH^<]]?PRV/FJT5Z)+TD4Z]7!LH&1E]UHG40GI:(CH*\E1T MCHY7I)P65^T)XQ;8R%C#7I\3%9I2=)XH3,DJ-[Z6(I#:4RQV%82B4@2.6)EX MDZP-BY,Z)H5^2IS+7')-D=1\@M,A>I3-MCA'[.O,4 BQA35N.I>/X>4E9-V9 M64!9!ZZ29"FU2!5\P.H516"[L^SSC,E-CO\ )NV<8/-G.4L7Y#:X@Z4\E*E> M*&/KD+F0MYDJ(%"^]SV-D^'WVS,YAZ^<;?6/&=D->JN I8BNE%6M%YS:?(W+ M%J7RH%C$"H8:T\K,[?JR!R)U:R],/!& W)+1;C*YPR(!4Q2G[S%,0K$ J0R: M@J5*B&/(QD8Y]9(BJQ=E>$VU-E*)J];])Y0CW\I MD8XI)E/8_P";0])BJCD<\H#+\&E8=M4GXH_:'\0?%"1JURX,#@0Q\K X66:" MNZD,O^?V0RSWVZ6(99/+K'[PK*W?4!^NOIT_:XZB.I?K(A(4+;G3E]%WB5N5 M*$[&:N.%HT%&%WCY=LW3.TE7-/@WAK$1Y(H+E5IT18JU(IOXMXU:-9;G\<9J ML]NHQKWXT5H[,9Z7#P\F%S\#Y3,0>KL87E1NI6Z=038^X5H93'T,M"F3P#V7 M%K%6O?KRPV_*2] O[H"783JD=+_:2TUMO M4LH_-*+@C+TC'M?@ZM;8BV3KJ K60F#1K>RY*K-7J7?=Z8IDF=HTM1J>ZAXYF+#NH"JRDJ0%V M(W=X:U-H[8W%'M[*?IC:.X*.1R>!D+B2W4FH11VI\999 %D>M8J1JDON2$F6 M.>))HG:2^]RZM:=ZU/D?+]9QRF"#P3R4VJGZB$,S4(54I3 (IJO%C>16B)^W MX1$BJQP_$1$Q.YPU=^T+]K'PW^SY6]CR\DNXMYV:XL4-GXF:);8CD5C#9RUM MQ)%B:A8-P"F_:/?:=P98WF6XQTU9^B2-++UHCE5:,>(LB>@5H\2.H J*/&J1"&4 M[$,FH05&WI' 1#\\MC>-?BUXV^,T7BG@GD\.KL>/I8>'$8BUD+N S>,QEBS8 M2/0 M!6]GD1>N)0$5@.IE+L8T/,U@F5"$:OZK$XQMLBD MVFO#](S2M;:,/5%8\RH""

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end GRAPHIC 37 g544598g85y30.jpg GRAPHIC begin 644 g544598g85y30.jpg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end GRAPHIC 39 g544598g90l53.jpg GRAPHIC begin 644 g544598g90l53.jpg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end GRAPHIC 40 g544598g90s62.jpg GRAPHIC begin 644 g544598g90s62.jpg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g544598g91s26.jpg GRAPHIC begin 644 g544598g91s26.jpg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°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end GRAPHIC 42 g544598g92g83.jpg GRAPHIC begin 644 g544598g92g83.jpg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

    O\ 6$2$'KVG5^H1GP>:A"1K=FH\.F': M5>1=E(+R3= 7T%U(.'+DP>AE1S4V3S&4S,_K.5OVK\W/A=9E=((P3N6PQD]W M"S?_ -.)C&#P:MPXK"XG!U_5<1CJF/@Y<3:T+(S(6]'32 =Y._F?RDSWO\W+ M.,ZU=HF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$ M3")A%ULA#Q$L0$Y6*C9-, Z 208M7I ?F %T<5.O7S!J< )^O MW]XQ_=U]1^OURT^BL83N<=0W\_4Z^_W]WNNV&K-4AO"-2Z@#?U1FPKS8:S1->-K%&QT%- \=OI\E3@F,Y.M M?8(GV2'%[)1[*/;JMR<_N_=S4,4J\<']B3K^)J%9UC*6"2L".IU6RNEW$4_L MRA86R2#%G%FF*.P/;=>N8'65I6B;E$GE-;OV%(DR1M@<)PIRHE7GX[_CU^2K M55RBTFGHM6]2IU5JR#%JZ8LD*Y7HB$19L7S[WF]9M4XQHU(W:O)+_P"(.FZ) M2(N'W\;6(=?]9A46581,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,( MF$3")A%CH!^(!_:K MRMDHCU[PB. M[KU$1^?S$1SCWWX[KO[M+[KH>YUV!'D#5K:],]GW&OVE92$T81"/1 MFG$V=1V>*2AY0JCE]Q_'DJ5[L\-%U/SEFMNB+0AJZ>?+RD16FXW_ &HW;P$% M9];;5B9*:8S#>0EI.%<4W<6P:1MZ@:SKZ##7T,\T?76-:4HLE?K1/19 >>Y& M_P!WG\/QZK;:D4Q$DR'4,L

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͹IF1VI+3T1M\C.7)7;F,1RPNV[.Q6]GFM,=^6UJVPAY#\QG&0WXPD_I_P#EWJ&_#")AP+'J MN?@K^W8F=1-8"K'3&RT*'J0Y3+,_7JSF9A12@5N?%'7"N8&P5X45CMT.2:D# M!3K2SW\9AUN"\W[<\]G-4W"[8V&0_1<8A;-O0<(N0VY2=LS':)0; M9NHC+K1*=%-SR&XJ76_1JCB"DH::BN0]=V4ON9N'#="&VJQ#J%,*PP+\J'!B ML:NN9KR -N!Q/8W$K/RAB]P?BW7A???V+5CR%D)EK*$A3R1ZG8NW1)9!#0^Y M;4VC6FC;74PPW<)@"Z;.923+*8#P*^]:'@;48!#=C-KD1HY5HNM3+_>V ?LY M!+WS'R=I(^<-I]5RZ?HU?FD>E&^U]Z"61-(YZD&6(,1PF-+/N3ME;,?'(B+@ M.1"25SL.QE1_#.(S+9?0E/>,O^1<_:'^[W!4?,[#ZUS' JF"-+VO=*D;V7"G M4KHKU 6H<\!<]@BWWKY7(._"/9G=T49EVN:!/0&(#=1'@Y<= ME-V[+XSL&Y9 N./S82+]S]X5H%K#9I%I/(V%8;T%U(YU"2XUJ*C3EM -"P_P M:]9E*L)4=K\J&8K-!FWZ4:D$'!,X8'?M"V1Y.1G!:?&F08;VN#8_*+]=WO^]OV1=WJOB,FWQ=B-VNLSMK3-,#M8:F_.*8-.'8&Y3>OANY>H1H;,!G MHD9!Q\ *9EB;(<=6N/L<[JUB"Z\0P?+$'9UX/>V#.P['Y.IM<.0UYVLY_GLN M&(5G8A6M)@AL%BS;+D&(W5Z%J(J+FX7!VJMZM,V"OB"0ING8)9JDRONP"Q*< M@I*#R9,1_$>1$)QV!L)N,NN%WS=V(!./8K?BY^>W6'9LOY*K*,>VY+,PU$KM M9QNR7T[=_.<"$2-IW0^-BQZY''B1LH MU'LQ64JD#LN; /@]^/7EMV*!R<\;I2)#CEIGL' ]E;L#L/:.I3!J$PTWLM%0O)F-6@DH<8FM"7&B2"\VB M[%PS ;-AP+;%'+&_+:2.H[0<]FS%=7=.M^BNU$8#/.E8A$K>+F I[Y&U6K80 MFV1@L)-ADSZ5=K2"$V$G4F(:R#(=5IP[.:\TD1T,L9A08!Z5;+:'>H1C8 84\?C!KA*LA'/H: MZR&+6""9CAD&F;;F5'"5-$,FRT.'22Q!2$8==[MN;'M[;LE(MKEKOD^OFV*T MJI!&!>+>NXD[A6M3G=\P9.P+$#)6>N.R%M=)NE$5/!NU5I^">%U.;9HQ".3) MQ24*#)/PA88K.RQ+D0Y+8,VNV_M%[NI1\'-QQV?L@A1^%)%R[GK4OMFS[2%: M[BUCJ>%TBWK-['K=@*U#.S]7*UVW:[4!>@7%:9X:!*DU=X]-8(6I RNRYJRI M:6SB?6Q 8GY+X7&]VV>%_8?!W;Y3&_"YGV^-RA^P;KM-[7ZV#LW8P;9P#I[" MFZV\3O&RZJ=,6=YBW3!1&I:VUP"AQ[E>$-0@6-C/WLW)&@)GAXO Y;*[,WXWAMK8OR"[ATAB<]8>I$C,8?1DQM.L$8[SL=;+ M4T[J5FOP]DO1=D;#.G MMD1;]4]_=/8,.'&VZW1ZA "F@O3BQL,;#IL(EBK&0)*1:[PT47-&$HT9:9,J M(["EQ'I/,Y9-%L#_ +37]B7L27)! ;ALW]2UT.R3XMZU8V:MNV(.XC'4;< E M_K;QK83%+72T,;-E5D<@$^ZC7K%54!&U*?5)8B.B:<2V_.>D$9OI&XS2+BS, MUV#['WY]7!4&\.[O?BVUMV77Q59@W;6- .7.44V:G9)OHSZ5#[A%1[8,LN7? MK=UM,G:KJ8:9[S,PN*!9&2S,),992/DX5FLQTR[6??*N#:T0XB[W\ ILN=S# M";GZBKDMVQ2%OM]W)B+1>?S)9O&C(5JL%>DW /$AT5^N;!799]7*C<0B0\'+ MNK%-%76QU1Z-F.*P6S.)1X\*6_',P%PUK[CFX;E@CN3>6<9X,7WB]5T/FG1$ M&]N:V.;'X2,,0^GFK.U,BX4).>>#K$,W'_P#P:>)2)TR; MX6"1AD)DMQ,QV];.T.7]X@_JE^Q\8O\ A<=>[/%3JQ.6?6(XNN"7W*='63IW MJ=@LJE7ZW3B;5VEWJN@"5CA'S<6Y.Z_0T(L!&=;GJ<#:6(K(V23!@V)X<Q&1NB&S/F@ MQW.-I.PC$YJT>JTR="7"(0@V6PH9A:\?EB*2/M.S-=23A]DP1=5*UQ::-&.U M^U;*<::@#T4.\U&P#G8Z@ZV6VAQD^EV0^O%@0V]\.M(L1?V7\FV[+\U")H*3 M+VGLD!$)[0JTV^]3VI25GA#+E?!)&1KLWT\A'2*6YP\PF,.&R;5 -UR81KTF M(\-4(AA8$V!&KE<8&79L^:6N&(/OCGUH<=H)BA>_81_/W98-HL]B'[7'LUTG M?8$VM=0FKJ2_!.[+VM8+"]KU=BI]6-3I>OX@R'KT=K4R%F394>ZV^=:#)V=+ M\[3SZ;))AM#S7;,"<<7&0P1[VOQ&TX7#J8[_ %A;:KB;K?>_C6RU;=8C M#--;5.0FQ5ZOM76NW0MTWV#7"6 B-Q;:6]]R[GU22,&=7:V,6%;[I\K0:<2..2FNXDN&)U M>'2B2Y#'8;[E]XVZ MMB[17(\B?*8!6H37S8P=8A;3Q0IC$8M&E85&)$8#BECY\N*]02/Y!1@>W&\A M^"M-MMMEMMEEM#332$MM--I2AMMM"<)0VVA.,)0A"<82E*<82E.,8QC&,=0LBK M2YZ4U_?RLHM981QYPH+A ["/&V^V@@-L"CGYDB$)MU?"&AX6RP&5D9[2F"\& M4F5!F21W1()M9" :.640,G6^V$JJ L5E220> M.U^GSS4FL!BA-!DPER4/%,+C)+EL0?"X)S\2*Y]V488^]_OS5L\BJ<(G")PB M<(G")PB<(G")PB<(G")PB<(G")PB<(G"*M]H?J"'],1_L1#FX,>SUA8CP[?4 M5+ZY^SP+Z&%_86.9.)ZSWK0P'4.Y;GD53A$X1.$3A$X1.$3A$X1.$3A$X1.$ M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3 MA$X1.$3A$X1.$3A$X1.$3A%6^T/U!#^F(_V(AS<&/9ZPL1X=OJ*W%>L(! & MA9P.E:0XU*DJ)0DJ2I,)G"DJ3E[&<*QG&<9QG'EQGY,\A!]>AO:D'W_(QR/ JN,QQ">D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D' MW_#'(\"CC,<0GI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0 MGI'7O7H;VI!]_P ,D=>]>AO:D'W_#'(\"CC,<0GI'7O7H;VI!] M_P ,D=>]>AO:D'W_#'(\"CC,<0J\V6<"/@HB&# MY>"S"LI:(1 H'%83B'/QE64H>SG"<9SC'E\GD\N<8_Z<#AX+$9!%Q&/BO_V0$! end GRAPHIC 38 g544598g86b78.jpg GRAPHIC begin 644 g544598g86b78.jpg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

2HXK?3.WG1=W.G$RNV'8%4KS]1Q:]\%0EC+DW$UNMUW,W/Y$1/8E M<0ADK+&U^E#D,92!&%2Z"\1S[S:6G+&*O2JJ"3T@+RQ[D#@>^J M7._6[N5"];,_2HX5>HD]*\?LKSPH]@!SK7EHOA-Q)XTACBZ-X\ZJUZ0.G"?O MT54XTNX%^/CUR=WEVI&WRSO_ /%DYLMS^&%8Q\=9:QU:+QX^,?&.C1HZ-&CH MT:_FZTV^TXR\VAUEYM;3K3B<*0XVXG*%MK3GSA2%ISE*DYQG&<9SC/QU\(!! M!'((((/H0>Q!_?HUCOD*^1I#-6SEQ>Y\_C@A\N"[8\CM^:O(QD@;OSZQ.I M]^.3P3IY8^2&5G MX?CI4)V/-85X^?2Z,4ZWG^[.?']G7FMXEU;>U-TXK/4"T%JA>J9"K*IX,=S' M61:K.IX_,DL<;@^H(]_>0<%(MF.Q6D[I+ Z,/JK+T,#^]6([\_WZAOA3M:>N M^NK%IV_G9'WAQOL#^JKYZEXP1+,PS:,4Z\CMK3A1,/DP2V?BJQ M3H*U+4)C4-#VQV]>?(XYJID*9#&,8.KGYF6,E(V8$GD$+Y;A@1RHZOS:OWQC MVFWKW>RH>97F-BMHL!5N:&6K" 6+>$ZO%5GF,KS\,R>2"J^0G&?=25)1V7\K M8&;>ZMY]@'Q27:.>;8=^\9=L;M9(L+9FD4&CF@2U6C;'95FE)EJ+(H"V'G@8 M=)C:)&=NVH;!:WY?18B_IT (!'H[H..>DD=7!)*D$?J7!]>R.H_T=&C2G.XC M_6N[.'^/>[_\$?*OHT:;'T:-'1HT=&C1T:-5DY260B.O7B4=4]A^1&I4*DDKQQ.[MH[3?=-JY MY^5H8##8FI\?F\[D_-:KCZGF+%&D5>NDEF_D+8M6)!2R^/\ NG*=+,(5L"W3LHOJ]*YY4!FZ1\SQ2012 MH.>%=59PW]S[3Q>/@^^-I[BCW5MUG1'LO0DQ&9QDLG'1#FL,\]Q:O6QZ(;56 M]=J3-T@RQ2.D)OUTOZ8NCHT:.C1J,MI[AU]I>*K%LY\#S5E:=)P+'"FC5M<8QC M&,8QC&,8\8QCXQC&/VQC'\,8Z-&O]Z-&CHT:1GW3?Z\W90_QO3_^XS9?1HTY M[8%)@=ET.ZZYM(J3JQ?JE8Z78@EXPI)<':81MN M364_J'8>T-/6QA3-HU7?K909YE2%(\2M2G3J_(*2E>,9]ITF.4XUG.,)6TXA M>/TJQU +(]+(-$_9XI)(9!P?SQ.58=_U! '^/;FXD4L64P:3Q<-%+%#:B(/? MR;,2LI]^/E(/[S[:]-CM'\C%\I.W=Q?VC(2*9.TC:\"UY>R%.866Y==7O/4* M<-D$^M:FC)U<"S9ENM[6K(Y3]8*<(QC*QHV:2^;4["ZA+BTUVP2JFFU$( M8RG'+XZ/*X^Q3D YD0F)O>.9>\;C]S=C_LDZSVSG;&V\W1R]8#/0LS7I:8KMBBCX*Q5^4DX"P0(D M0W<)=%/C9$8D(P9Q*5LD,.-*QA2<]5^GADKS203+T2Q.R2*?V60\,-7D2Y7R MN/K9"JZR06X$FB93R"'0'V[=OI_#3Z?PX?+QS0W-DC0ECDW1]?\ *>%Q516' MGO0"#M>L-F3-#D,X<7AM#LR%FQ4]"6D^\;)3L&VK*DC-X2]]D9$UL@:CM^%> M41@$]EGCY:)O7@]8\R/MW)=>>PU!_BQA/C<0F2B0&QBY/,) [M4EX2=?3GY# MY4WJ0JQO]=>@9U+NJVZ3+ST[31'+#8"_VG\_X3XVKMJ7 8K,[7ALS MV&A@1<;EEFMR^98LF[&KQW9V 1%:["\GDQ05Q82""%(\[V^>)'(7BK(Y$W7K M>2@X5PE D?L"%4NQ:VF'WE90.R#< F4#!%EJ2OZ2(L8U?GWTI4XF'PWC*L5: MWCX;;IVOURVJ;6J(/:_2#35NGV\TA0T!/TE5?3L3ZZ],/"W[1/AEXHQPU,/F M$QV<=0&V_F3%1R?4 .H5D:1H+RCGLU.68@#J=4/80HRI&4>4J3G&?V\9_A_# M_P"O45,&!(8$'WY'&I[#(1R".#_K^/\ #]VH:V39;%19>OVJNF?0M2[CM1G' ML#,D+2V2A\Z&?Q[[;K+*6R&Y 3+JD>K+T@*A"TJ\8S?#["LFVLUO//[%W1 U MH7\2V>P%=[4L%>3(XR2),C79(7BDGEFQTBV5C$G08\=,7C<=U\S_ /TBVS[I MVIM7Q+PZ]%C"WSMG.2I"LDGW7DQ+:QD[LR,$BJY*.>OUL.SY1 ."0#JR["7( MPC9W&.V:2LDM]=;-"W8Y$6DE_P!P\K7&P7BK1 E.9<7EUY,?:';E"(RA.&0X MT*&%QZ<9;QFX?C3M*IMW/TKF+IQ4L5EJ*=$%:(15H+M+BO8CC1%")YD/PMDC MU>669^YY.O+O:^2>_2DCGE:6Q7E8,TAY=HW^9&)]3PW6@_15_=IM?)#;X6AM M'['VL7AEQ^J5PI^&%?4E+9]D.RB-K<>O*OGVBYPP!HC*4K4V+E]W"%8;SCJO M6ZL[%MK;V5S4O232JN\",0!+;DXBJ0]_7S;,D2'CDA23P>-2OL#:LV]MX[?V MQ#UJN4R$4=J5 2U?'Q V,A8' ]8*44\B\\ N%7GYAK#2TDF;B]R[\LYZR9 R MR1>HZ7)D&^B5(N%M?>N>T;<-G"O=*^T:]AI6N2[^,YP,7M*&?RILEP96=7V/ MMC',[FEW+DZXN1X^O\56I5VGBI!5@_F].&"NW0*^-QX"QQQ@$%8RT(C!4_*(0.1R-."_#Y4^T;* MO_*[E;=)62G?HBH#05,/EG7#24O(0'L+8?ID"5.$NXS]9KP;PIQ>,?3N)SG& M<>.K*>-V.V]B,OB*&'Q=.A<-![63DJ)Y*RF:7BLK01D5U8*DCEUC61NL=3, M-5(VK+RK./*O*J6_:6V\%S-++H@"Y*@L/7U]R?;V]]?YQ?L7U):@E+\X<87C'G/SG*4>K&/\ 9G'^O.>O)K[0 MN$Z,>EU4X,,RDD#L%)X8G/\ $?3TX^NH M@Y_5:RAN/;=1 M\)&[L"[?#VQ0DHVEZN3$WHLK#AJ_'RX'=.0:/DQI=G\R/G@25YG\PIW']5@R M=NS<'VU=Z0'K6VZ;"W2G2H\G'S<4)-UZ=BWL*08$4RD@0D=YI7JPXG"L><>K M#C:TJ:5A+K?IQX^;?S&X/"_=EO"YBO9QU[$9)Z>0I2EHYJENI,!U(000RLJR M03(>&C*21-P4ZI(R%2#*U$NU2KK)&'! YZU(]2!S\R]U<=^."#W!TUGBYN_^ M5FDMQEB(;;V13V6(VVB+]#3LFAO&&0K2*SCQZA)AM.%%Y;0E DK@L;"$L9$6 M]^AW[./C9B_&38U*V;D+[GQ->&KGJO7&)IRJA(+H1 M##UPME<<^/LLO2?*3WU9[JPVDO2G.XC_ %KNSA_C MWN__ 1\J^C1IL?1HT=&C1T:-'1HTK?N414K09GB!S,CX\F:A^'V^GY_9<6* MRHLAC3^X:C*:DV!9P048RLR3J8\_&RHS6,MI;&P<4\\RP.ZXEL[DD-!&=%=R6,[L42+%>W;C4BP+2,$ MCEW'BI&O8JB[L0J#)?SFA&Q!/Q%B!0/F.F=QLE'S,"WGI5TW]'1HU!.[> M1>MM"IJ MQ?G)6S; L0-6HU#I<(5:KU;)4QS^>^R5J.\FE!Q8B"9.6-S[8X4 M<&4^M:E->VIOYC&U]D9K=<&8OTVH8_#X"E)=R^=S-KX#$4@%/P]1K)CE>;(7 MY>FO1HUH9[,\SJ?+6%9)4C_G;K'.W.)&\ZBPVMH<7J9 M0@@AA9KQ])!!Y]QZZO*?JKSKRJ6*3;1X\#S1\,(N<#SA/PE04Q M@X1:,X2I"V%)4E"L93A4P&33-8/$9>,\KDL;3N]B#PUBO'(Z\K\IZ79EY'8\ M=NVFMOG;DFS]Y[KVM+R6V]N'+X@,W/,D5"]/7AE[^HFA2.53[JX(['4Q=*^F MKHZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:ZK-WJEUIS+-@ME=A7L>,Y8DYF/#?Q MC.,YQG+#Y"'<8SC&^Z]Q[[VEAQ.NR''WK">9!3LRQ_]8D,AC[>OX@7H[>_?MKK MLAN75,77Y:T&["J2(*$#<.DCVYL$A# [?C'Z&AWG7R'W7,H9&%&:=)*(=9&& M:=?>:;7NPGB/L#>VLKDIUD>#&T\S1ER$Z1(TDKPT1,+4J1QH\DC1 MQ,J1JSL0H)U\EH78$,DU2Q'&.QD:)Q&I) 9^.D$D@ $@D]M0[7*E9=]SD7L M;:\.97]<0QK,MJ_3;LH?XWI_\ W&;+Z-&GF=&C7G5?B(N/ MG\B_%V1&0VXE)SS)4 M-B@P)!)"_P XKMQZA1%*L*\\\^40--'_ I7(]#]?Y,\198O/U$)+Q6^Z2.X MYC*EQTRQ&4:^M,(SGRAD$Z-HQ/H3^G+TP2[X\J5GIW;-N>97FJD\E>F9/UYX M23^\1G^/H-1QXG8WR;E7(*O D#59?]Y2TD7[^1YH/^Z-;#NGKJ+-8-_Q('"- M.C>3,)RJI$/@/6_)S+S=RR*C*0X?>D$'E9$.?7RW/('LK*!K./6+A9-<76I;"ITD]"VVB6:!N-7EALY2 M_%V&M2HLS"GLYQ_^L#D0AB$XS\9RCTJQG&%>Y*\?M-[] MJN$MPFW-=56\CAX7AQ<43.10Y4I!D*QE6/K(&54;#&I]2O08 ^C.GK4$J?U4\J?U!U2_(TI,=?N4)>\E2Q+ 3_7$;E5<>GRR M* Z]AV8=M3?UT:X]<=+P\18(L^$GHN.FX64%>!DXB7!&DHN1"(1EM\0\ QIX M0P5]O.4/#D-.-.(SE*T*QG..L71)%9)%5T=2KHZAE92."K*00RD=B"""/76R M*66"2.:&22&:)UDBEB=HY(W4\J\;H0R.I *LI!!'(/.D0S'7+ W+;!XA$ M!4>Q(:>-+TM+D.)HD^_A>7G6J9,$NNOT60>3E:!(@KZRGJ<2( &W40?>+3!F M^/!+#YP37]OK'BLD59S5 Z:%E_7Y1W^%=OJ@,/)Y*)W8W3\&OMC;JV@:F"\0 M#8W3MY62%,JQZ\]C8 .D=;GI&5A3LS"=UN\ D69B%BUF&W36;O% 7"BRNN;. M]L&H20OY@UF3!'_G$8FO2 4U)#)@6VE'$%BQ@JY<1 J'D20;;3X"BQRF%NM+ M[-="39GVB-BG<%7)5O@KV629:L4\D\+3[?RU:&=XX%+R48Y9HYKBRV0DBK1*++1IJ+J9RWW'R&W7%D\5-"VJQW*N4EB.EZ%QBHEKC2!ZK"1 MC,([*3$7KY]$SY?E5QQ2SGWI6LVF ML+8NF.^ZRS.\P$8MIT]* F**.-.(H2>D@ \^&=? Y.5 +'DEG[D$MR.\;GWCS6I"OR_O#C%R%KBB(\2;^S;+B]BM^Y'N/DL G MJ M$\\C+>2!RFAG%M>K#K+Z6_&4+\1_DO%;P(Q]J+%Y/.8F*Y,J6(:,V.QGG MR)ULLN-@C]''4AX/(T^L'X9>*>1HS[@P&/SDV.K2RTK&7Q\N0$$4 MWE1O-6:W$4 D\F>(R1=1)25>I>&[_B[;$YD<3*V;+;5X<;&T]6-QU26I4;-6 M_3N)*/.%EW8\R1'B9$T&79JEI,9"%]E_W(NP/@)<6)[C+:G6G91WAX;9)H8Z MV3FK?!68K\:1K\$DLL:.L?F+5DC6>-0YYBG!BYXY7E1PS[> SC.7LRK:D8&) MFGDDGD Z@2%:=6(/4H^>-NK@D#Y78'5%^'CA=D1/"*V';(B/RJ_<-[VVZ56F MG#)C[+!5.4JE'C!"[)%K:8/C2K!*PDQ+ CR;2"W(UT8SQAHEM"(&\92J9"7 M'7'KW5JV$L?!V61)#7DZ&;H90>X)[.)$/#HZ*^/J)=.O1T:-'1HT=&C1T:-) ME[UNO5RV@M<;7"%]PW5>S@@Y0I*<^H6J7\%Z#,RM>,X\-*M(E.1^KSA*E^<> M/.?,*>.V&&2V<+BIU28RY'(2!W6&PIAD]CZR^0.XX[Z[\=)T3\<]F']X^GT[ M<]_TTJ/BW9L-6N%PIS]#[C36?. LJ?_ ##_ ,OW=_;MH!U1KBB?%20ZFC(V7"8D0G&B1 MF74WQ_\ 1\9B/<7V9,)C)V$OW!G]SX*5.?FC0Y$Y: >@Z&$>31T([CA7!Y]$ M/>L1@W#98#@2QUY@?J3$JMV_WD(_76:7CY/;$[8/*FP=N7DO,$G:RG)!^P<7 M=N2J?I8NPU28->1#,*)<5@83ZM;3L;-QJ'5MP%N%-$:4N-*%-)@#[='V89MP M5K/BAL['F3/4G]A^P;Z=F^NG3QI<[2;7%["I+Z!+%#K5[C"_7]#-1 MSV-U2>%DGACD1Y9W PY"!^E1PP)^7U5N M#TNA_?\ P_@3IL&KMGUW:U8'L,$M3#Z,I&FH4E:/N,#*)1C+P)K:<_*<_+@A M2<89-&R@AKQZE(1^C'PG\5MI^,6T*&[MJ7$F@G1(\ACVD1KN(O\ 0&EHW$4] MF'=H)@!'9A*RQ\H/;Z$KD[B/]:[LX?X M][O_ ,$?*OJ3-,I<:<4G/QGK"2-)HWBE19(Y$:.1&'*N MC@JRL#V*LI((]P=;JUFQ3L06ZDTE>U5FBL5K$+F.6">!UDAFB=2&22.15=&4 M@JR@@\C5#>#,R_2YW?W$A@^3L]8XLVJL0M$N!KZS\*IE\B#+%#48V3RRVDF> MH.!GXJ2;];BAF'PF&VPP6P16V!L)K%-]R[;,QN8[;.9^!Q%PMUNM&S4@OKBY MG_;FP[6#3Z^>3"(4;AXVU-WC7'!EX]A>(TL4-#/^).VI\WN;%10"LOWMC\K; MPLFX8H58K'6W/\$V2155.J?XB?\ $,QD:2N=/&V1Y3<<;=KFJ3#%7VG"2-=V M;H^YOJ6WBF[HUK+C6K7LYDEI#KP@KDP F&ERF&GGVH.7E,LLNN92VIY92D.N1M7NP<^G4\$C&,GLLJHWMJN^D>ZUQQM6J6)K>]C3H?<]0P36MPZCL\/8 M'9>N; KJU1UG%JJHZ-DF;E67Y08A^O3=?(DF"HUT;!2V#$D,-L\^)FT*L+C* M9JC3O5V:&W260V95L1DK(L2U1-YJEU/25)(Y ?I;MJ64^SGXK9:U#+M79^9S M6"R2);'V )*\ELY&6J*DRQ,OFK(1&S O7>:)HY&^J)[N?$:='? MD8I&Z3H5AU:/O@^E+V]&NLH5A*C6W&HU;^ \*5C'NNL-+\YQCVO*D^4Q?%S; MDK?@4,Y9AY'\YK5\=.I0\?B"M'E&R!0!$D[_A-=FH1XXN.D\NEQX>Q/F\ \1CP+Y+Z"Y/[IW3O>8VI0SMM M2EXL>KM,:YEK$ %<*/I&ME", JCZM)O#FBV#8+'U+<@@M5-OUF\O%8^G'/T=7F1@WK:5NLF[9 MG,GS+PJMXP[#W?M' [?VGB]O963:.V<51O;FS>.K/=QE_>UZJLV;N9&W2$RP M0XN24X?%_>!B KUY)Z_,5P,SA2!V"QWQ26D/C$LNCD,N8]3;S#R%-NM+3_%# MC:E(5C^.,YQU+#*&!5@"K JP/H01P0?T([:K.K,C*Z,4=&#(RGAE93RK ^Q! M (/U&EU=L.;6-H.YZ7/?]V=XS[ZW'H^7PMU+CRTPMM*L<:3A/PXD-T"SM# K M6A.'6@E>W^A.,88OAU$U';IPDG(?;^4RN' )Y)@KWII*C ^I4U)H0I/'('H- M3E]H9XLGOZMO"L%%7?\ M':&\$"C@):R&!IUCD\]R=7S M+NM3!M\-0#+!%BW2Q0DU9(*M/DH;E9:#KA42%.R0 RO"B!XHF=B6C,MYRMKZ MYE>4^CUJ2]3/"L\=9I%$\L@I*2E)9<4+G'U'MN9]"L-YPO\ M1ZNL7'4K*&Z&=656'Y@2#W7ZE?7^&L@">6"EE3@N>"0 6"CJ(] 6(4$\ MI&D[=O&6WAN34EEC[9R4NP/)32=^L.M]LA3XE:N%/L9X3WU,!?L53\MTN>$@ M;E%NMR-:5%VM,0;'L_6LY):*^G8KAB_">";[YAVWOWQ(V-NRAD)SG)MK=\=C%S-!:EM;,REB7"YR.&4&.S?V[GZ*M) M%/'3PDDJ&'6$]7&R]/E/)C;$D<8;<&UHS'C=U;5QNW,O/NW!R6 MW,ISMJ!:YM43B(EB.2PV4JX]H\;):R"SS2"I$<*V*EGZZ[(L,YY>&>2Q$L$@ M4<>4O+<-YAYZ)$+\N%3@?,=2RWR2EY_+>-?'0ZA:58RG.<>?"_'XK>(&[OC<& MU-F4)87[QS]-+([JS"1NI615DPTP(K7@/AVS6:G2U5V&?38W&,J?G)^K M5>7-GG86/1C+TM(08DLS%AH>/.4R(RXZGNK[M\9,=:BL[I\,ML?R>(YNS[1W M[=SNX,<"#^*,+DMG8&ID8HSP9A6S$8EN9D;UXYC8$\ D>H@:@F<086YSNV]<6B%NNMB*<;=;U<)>[3^X(I,O M:YA"JW"5]VWS%L,A)B6><);BJ=7?H,O*$7'C1&"VW&E1;L[ ;7G^TCQ7]V;'H,=3Y)3HL;HK54=&@0]EC9:6DQ,P]IOQT8VP1)7V3)]ET6KNE MDP%38R@=Y!D\\4:._?M&\1>%FY,5A(6CWKO2O'L79AEUW!NB:.A5FJ9 M"H8K=>''*TF6OLLJPFE0G6P'B8QOS83C[P@EE/-6HWQEH. \9AK_ #E61N5) ME/3"@(YZY%X[Z8J&V^T(*T4[A\IL9ALE].,X2\^AI*7G<8S\XPXYA2\8S\XQ MGQGJ=ZLFOIZWZ^:.C1HZ-&CHT:S>=^C>49QJWCVD-XS4=B5B-?66X]B57(.9P,]E:!5-X3C*\*PFYB]+C,7?R$%;XR:G5EL1 MU?,\DV'C7J$(DZ).AI..E3T-\Q'(XUV8Z*E8R%"OD;AQU"S>I5KF0$(L? UK M-J*O+<:$RP^8E9)#,Z>:A*(P!YXU>V#[GL1]Z;7K,/+F,(S MG&,J3'2$5#,D>,>5>,23*LXQX2E6<]0?C?'FG8E1[90$K6R&*DHQ2<#G@6:]R\Z-Z IY,2R$:7VHY0[BX.TMB9K]6VG$J=;:LD>\E!D: MD2V5: #$24UAEYZ?4Z&\\T]AQ;TW'>QFXL+4S&*LQVHXI3#(5Y$D*SIU=$\1 M >)E>- X')?E2RL&U'>Q\9G-E;IO;=S].6A// MJ$/PT-DU)>AI*DRDQ3QO M#-(S-&Q(\KI<(ZD+G;[._([_ "5^Y5QQNYTG]LJ%WM?\C-\=<=]H)=8VKA%7 M8(D7/4E*8^"M!=9LY"U^4-8@D/*QGV_E,VG=\B[7+-PKMY3]^Q67\/OW]%;I M<\^G3_:X?$7%"WC+R*O5)$OQ,/\ O0\RDQ01BKRJO.7;4A+Z,>X!M6DMNS=0PP_G&5")GGV2*A)DMXRM M,'8Y1O"58/R<;% M17L)YW'[5=R%F4CW^0E@/ZRCTUY;9Z5YQ_.M.,N8]27F'D*;>9=1G*7&76UX M2MMUIS"D.-KQA2%IRE6/.,]0"B-'*\;CAD8JP].ZD_\ $#]^KD3RQVJ\=B(A MHYXEE4^Q5U!'?Z=_\?W:WE_A@^1+VRN%-ZT/,'X(FN.>T9!F%%6XE3P^O=GM MO6^'3Z,JR[EMNY(OZ$J5CT-M9'81G"480F8=F6S/C&KL>6J3,%'TBFYD7]_S M^;P?IQJL'B9CA5SD=Q%X3(5U9CQZSUN(9/XF+R"?3OR=.+W%R/VSJSE#QCTY M':'#NFHN0<[::9+;5BMB^U==>VBO:]NFQJ5XV'2!#)*C<@\^48P_6.W0K-*D<;#K+2GI94!1GC MMEXB$BGJ/FI&Z^G'F!^GI/[3 1N[KV C'4K,0ZK"E4[D4+-4%Y= MI9(8U4*>6:>N\Z&/U\Q5\MX9.!RLXZ!SWXDCM]\JO\J[5&Q[#*E33-UU9R!W M!I6\UNTUV.JEGJY]#L>45K[O"1CBQA6;G0)"I;*A&O62['P-TCH,J7L1L.58 MY;8@8P5G8?.\;"4>K+/'+)%/$X "K)%(A1@ORD!7'9QKY/T"Q.J#I17#1@-U M*89$62)T8]VC=&#*S=_4'@@@4"YZJ+VZ[N[?.A==5B9LO'+3%IR7LA0&/N=F MBHEU,U+!#G"L.*G&HH0"4D:E%O94DM$?*NLFL!3.&ENZ_638>VYED,DD=)!6WL![ MX#7>M]Z,D/H\F7F."WS!266F$2,G*"/Q]4OJ"R\)2^:X^V;3Y)MM:W%)<:EB M?C+CJLU@\'MQ7KYS6+REN:W;^*FR8FL2M)+))/(OQCD#DECQWU MZ8_:UV+A\1_(W.O3JUZ,!?$0PQ1 1I'#52>M&H_+' M#$GHHUPUVCLYE4*X0VN9HA&SESI]-M9)0RZG'I6S&VU<*((YA M.4YP=:UJ\^MS'3,P$G\N?%S+Y-CYV/Q]HUZOJT?P6-_"B(_V+3Q-+[#JM'CG MGNY=X0GPK^SKMK!+_-LOEZ"W;RCY9?O3-DV9E?ZRT8YE@!] M(#N%X.I7*4J MQZ5)2I/Q\9QC./C]OC/Q\?P_LZM)JA&EV;""+XI;N$VQ C/?R1[--Q&7J(#: M]3$/*D+=*>?$&;]*&U)7AZ&) I#==^D."3_P H48_+CDBX[GS#WCR&U/#:,M/'&IZAV='WCQID-C94D084 U9-ER>\!IBF6&R1DXV%JZ[*B-7QL$GM_"KG%6^1'*_G9H5JSBR9NEKA1; M!K1 MHAK&#;--V6"=@W[I%8B2BF8M+#J3P>\Q_N.LA_'6V^U*U\S#OC"7Q7O.<^G/ MCU(RK]OG^[QG/_TZ\I?$["BWBLM49.1+7L1GMV[HP']Q]>/;GO[/&G)TR1N/ M8@]OT//?@^WOK4KPZGD.6._PN/GT+4@JQQTDO'\,K2V["I5G' MG/IRCU>,83Y>?_HP,V3LSQ3VE*P\W#[PI96.,GYEBR>-6FYXY[#S<5_5XZB1 MR>W'3OZ/JMXVV/2Q04$_5D*(8]-,KC(< MI5>"55ZNEA&S#E?F'2R2#]J*1?E=3S[,!U*-,1'*-R/XC_7N/8Z1%P=Y,[.K M=TL?!?F-&$4KE#IMQ4*([+N8P/L6N!MI^US,-(K]#$X@R.PT;%2P67!YV*4T M6TKZA+J%>$_VT?LMV/#_ "]_Q(V9CI!M;(66EW#BJ\3,,!?G?4?+Z\?@3NN#.X"TUC'3-'%FL#9D;[NS5'KZI*]A/2*<#EJMR,"6O*>M20 MTR3+6=V]6RL#\(%EXY1E ZD;O\R?O_:3T8?PXZMS&V?6]H M]T9FH,I2,2<*8KA%RM_F26TY_G!W8Y\.C( MZ[VED':3Q"W2(V_K1P68JJG]>!#T\_IQ[:G#QJLQ3UO!R./M\-X*[/@D3DDK M*+V>:3D'\I=V9^./1AQR.-7R<0EU"VUX]2'$*0O'G./*5XRE6/* M<9QG'[XSC/4BD @@CD$$$?4'L1J$ 2I# \%2"#]"#R#_ &Z4AH+B7QEINS=B M<9=K\:]#WZ1 ^X;.US>[IIO6]CL-PHTK(,C$_?IN4K94C)S<*;)- N2!Q*BB M3$6 6.%CJW#PC"HDV5CJ>WLME?#Z[4J68*$7WYMJS8KP2S3;?NV71J<[O&7E MFQ5TO5$LA9Y*[P\]E'-B?$G'6@&W'_/N+B]= M04&OY\_]&J$&C\L^/5G*?9RCTY\93XSC&<2(VWL"Y);#8LD\\GX&L/7]T8U$ MT/B)OZ *(=Z;JC"_E"Y[*=O[;1^@UC+[PW;>VGPDW%=[5HJ8G:_I3;DLQ9M) M993B1A0)<#ZJ=G>/OYBD1RYVI7J.(8-F]5/B3 R+[5!L5-1!EGC7E/1YF=F; M?K9)+%O'J*%DAQ.YKSYO'0Q?>=21EM9'*8RI)YL=ZA:L+-=CF@ZF7)PT)J\LT 6PQ9 M%E4,"X =V?D1KWBQ1.0)ZIGDSQMCIX?56Z:A89=Q_;W&O9C:670V +L4R:?8 M]8W*+)$E==EWI1KC1#K^M9"RASD -8;EM.5RFTH!9439; 0NM>W5E=GMXJ1N M\4U:S)UR/CK"%1''89UKR_S=)%7@GJI;4VIXR7&Q4CT=H>(MB&3(8G*U*\5? M";QK1@_%U,GBJWD5JFXJ#J[SV<3#7^\*G5D+%*>P9"52]O[O-W_C!SUVOM[; M(ECD]7\C-A7>2W516<)8D(XVU6B8LM>LL+'R9((8\Q4)664(VDA]EAZL2$R# MA7O.@OCZ\3?DQV2LYE9A9QN5D>Q<\C\4<2,6%B-8R59X2>DA.[1]2 %@O'#N MW'RYS;>+V5D*1Q^?VA"N/PYNH:D\7E*L#F'2*3KZRP4K4;)BSQ<61%BB5 MF5%E!")0=F?D&)*0BH>-%AC<3:N.U66(FW--/CL3, MY:[EE9)XX52S.MF8=75,L(@#@L2O,:NZ@A>%)! 8CJZ5YXU&^9M8JYD);&&Q4N% MH.D/1CI;0Z:0B^_&DJ7\ =4_,*]42NZQ?)2G-23-<_-<>F;CHY,OAC!Z_L9Z MGH0M]S S6&B3HXH@3'NX#=8P0_AWB>M7DFALO#&\\ <0RLH+Q"0=,G0Q[KUK MV/'?@D>A/*I6S>8IXO(X6KDKM?$9=ZLF4QT-B2.GD'I.9*AMP*P2?X>0^9$) M P20*X'4JD+MWQQ M.I+_)\E=%V&Y/0/V4.M;9TU49D:HR\UJ>)=,F>1QSI5MG[K/*&VURP:0XDZWDMA%1*C8@Z]QU,DK): MR1[%-JAAIB8$&;5"P)TY+RK 0CQ@@V')$L<0 1MY0XC=:]IY_P 7]P;?K4'^ MZ=D8B=9;-O$;(Q%B6['+GKLUFW5GSF7R&?97MWLA(JRX6#&RPS3!:%N!(XB% MBPM&.=V >RX;I6:W*I'$0 0^5&L(/3&@!642 \'K4\ZN;QC[7-FXI\>V=BF; M&B!N0S\=9[7M.OW$YA_1;U=LT2TBP:N]7TKRJC]%'C>DK9E=1@M^<68^<%,P M(T&+%RMNGPGQ-':-S.-FZFV-P8["VX+V[(TZQB)IHVD4K&GRR!P>5EA< F.13PP('3P.) M R\ZO3Q?YEZ]M^KJ\NU2$E79PF%;F:I79J"D@)NPT;# ;4=.P2UX>B[;!N$. M.L@6RL''U4V.5&NBRS_K<>5#GAW]H+&^!?A+B\1X_1Y_;E[;U:.EMBS6VEN6 MWBMQ;9$8_DQ2P^9:.U'9RM?&QI6M5=POM[*5?(Z+E$)7DR%A7M8>3-9)Y,/Y M,HL,7G1K,"203^MAY(N5(B+DLK0">-@>0P+>6I?N7K\)(!3BVOLE*BY(59<> MA#)D_9&E/X0F*;QZ7?360?;R\6/%GQFV=@?"C M:K8K8>/S]3*9[%RMC6SN:*#'LH^,S= MV%Q"7/\ R+QN,Q5J;)61)<>!HX9!YGDPV9%Z84KP1D2VI6D(5%8$R<_+$A[B M,]:7[3^;G_*'M*MQFMP@IPJ=USK"!KT0)3Z?(R",((V!;VH%#6+)MB4;SG!$ MR3'/CUH=6!8=;IF2)1RU6+^WQX!6=T9';4*;JBK4[[5%W32VZM[;.2D0*DUV MF]"S)FWI>;U)!:LX.!K4*I92,0R(=-2?:64A@CF=ZO6Z=1K&8B>/DGI1^4\D M/QW91,0K$J22-3UI?8KW(W=.S;AE#0VL-+3S5&U6 0OT'W2P.P?_ (:VCX_V])N7_P#9MO\ [,?_ #KI,S)Z<5>)]H1_ M^5CU6;ASO$[>6A*[.S3S)%HK#;=-M!#.,(<)DH<9MH.1-:3YPP3.1S23_<\- MM&DMR2AD8^D(0U3/>.UC@KIN5>6QUVRZ*/\ ZI8;\85V([F-XV+UW;@L(YD/ M4T)=_2S[/?B5'OS8N,K79!]_8O%I7N%FZVO)2_F+W1U$LLYDCCDN1 L(S;K2 MKTQV4CC_ -Y*P,U=M%;DH<084S^<*44,]',N*^FF38 L.V5\,T?PMI]+=C@8 ML@9:DY='(;0Z.MI?E72GMO(STR521EBGZ([$8/R21K(K ,I]2K*'4\=2D=CQ MVTK[TPM7)*)9($>S3::>G-T_B02F.6+E&'! >.0QR*>S*>"#P!K*C(+>0V(> M,\ZP2QEIUDAA:FWF7V%XRV\TXG]3;K;B4N(7C.%)4G&?0\C]=>KWV_N1S?+;AAQR MY!J>9=E]A:R@B+=AA6%M#WZ"0Y6-@"(SC&,X;&ND+.,LX4E*LLI;5G'ZNIUH M6/BZ=>Q[R1KU_I(ORR#^#JW'Z:J3F*)QV3NTN_3!.PCY]3$_$D)/ZF)T)_75 MP^NO2;KS"^\;Q\8XU]Q;DY0XJ.1&56RW).W:6,PU[ :*]MH-FZ$"QS.$I0W' MPUGDK%7Q6FL>TRW$>RCX;].(1W33%/.6>A>E)^)EX';\7@GC]W/''U!&K6^' MV3;);2I];=2=<]P*QZED#5,Q/( M+3EG@@!,N>EDFYZ])&OD(ZM&7D)*Y M/RV(&4#GUDC D!_@JN/X]O?3-\4*7GXB*VJ\M2N(S$#TBG!B?OZ\&1HB?0=N M_MK:OM_AAK+=NV8G<=NO'(&(L<-1)77(D)KKD#M75U*(($C Q$=(\EQ(GR@\MUJYZ^0>I6Z%5E/RL@Z2."W/UR'#73995EEX5>ERDAD5&3CH\D%B/("B%E)5D8$\X*Q M0(JD@1J5C[GE"R!&D5N>H2D*")>>M6 *LO2O%++IIS6.E-V[;IG$J!)JVT^6 M3M)_EMB:V8+$:\BT4^M-5N!.B:;"A!0-1LCE.8RW:YV*"&/D*XE@B;5*'?9R M8Q^[3P]>M5FW%E_DQM.9[56)QU?$6OEC\Q%<'F,.D<<42L%FLJ&;DI(7@3Q7 MWCD;^0J^&FT.)MP9J)*>5LQ,5&.Q\P:5H))(^6BFDKM+9N3LI>IC6_#'5/#Y M3*-9:>J>M- MA@/"EI:]2FKFLK/G+T]RU^63F.*#GJCAKCGHA4'L0 27/'SNS.1RVI2V7M2A MLC!TL-C/S0<3VKG3T37<@P3SKDG!)4LR*L*=1$$$<4*L1&"<)^OY>Y\!NX"? M2X$@C[QJO;>P='Q[CSRFLR-7V '-T6G3!WJQC*Q\QMGJMQPA2?"GA&5M^?2A M?5.;*MEHJJ#D&0RU9OA&[@=7#-#+Q[]( //<>JWG8KQ3\)= MJS9V5%JK/@;V2F90?)3'78'R@!/Y>J&*Y!U>@60L>W(UHQ[4.HT-[IY$[6*; MPXW2H^'TK7G\XRK'U)9F+/;LH5G&$X7AB-I_RG]7H(7C/C"\XRZOL_8KRL5E M\LZ_-/<-.-B.Y6$*9.#[@L$[\\_PU"/VLMSMD/T"R7@YK@ MCGL5CDD'IQQP/;3U^K$:I_KI]^I$'L>H3M+L;&7HJ="6,ZI&$^^(^E27@Y 1 M2L*2@R/+;9,%6I*D8>91AQ*V\K0KMQU^QC+M>]5;IFKOU 'GI=2"LD3@$$QR MH61P"#TL>"#P0B[BP-#<^%OX/)Q]=3(0&)BO'F0R AX+,)8$+/6F6.>$D%>M M &5E+*595;06G-LWNO<>>7-,>NUFT7*2TWHTXFZW^N0S@,ED(T]AB(K=H@8J MPH+" '.CVYX*8S]D^[U]Y+0(;X#SSW3CZV0AK;PQ2\I81(\@G9FKS]:_.Z?, MB]4JI%9Y #R)!(>OS 1#/A3N#([=R60\)MT2\7,7)+-M^RQ*1Y"CTM+\/ [\ M/(J0.]NBO4S15WMUOPS3Z-7%A>"'$FN/0Y%?TK7X1Z!>'+BG(F4M,>H>3CYO M8UF@YU>1)YKZNR56Q;;V-.4JS&?43](EK4>?4I*%*:"=%CT(H3RP.$"A H[! M0M;X,%/ZCFK_ #=I%XD:(!&8J !8,R.6+$\LS%F) /43.+1# CAE^( F"-RB MR&E8?FF5!*>/S!&9D[>@*LS M$%0#\S GACSB>IE1>Y6-G9/?AG"ASSZGJ"KSU$CY1[@<<+_]H5[-/_CMUO\ M_A+;7_Y>]&C@_0_V'1_]H5[-/_CMUO\ _A+;7_Y>]&C@_0_V'5I^*'*F ^!R^:H] Z8K5J-!P>#'UOY1'Z&,J1]/3U M&G-3DZD1N_<*>>1S^H_Q[^^M'G"BV-.W/6L@X_\ HMVO[%54IQG&?=E&68FS MC^K/[^6@:E,^/.?C+N<>G.5^4P#]@3*_R7^T;XK;'E?RX\_@;%^I$3TAYL1D MX;*]*DCD_"9"=NP)X4\'I!TX]UI\3M_$7!RQKRO [>O9U/'/K_4_3^'/&FV= M>R^HVTH_NN]MQOFUKJ&V-J$L6C\PM')=G=); 9?3%*G4"N*/)UE:I-"/5FOS M9&%/0II&U]V;8Q^Z<3;QN0J07(;5>6M/6L1I)#;K2JR M2UI5<%2K!B4+#Y7_ -EGYW03/!(KHQ4J0P(/!5AZ,#Z@C]/^ TLO@MS)+WW% MSFI]P0Q>N^3NI2RJSL^@6 1:>]]"OKQD-^AM>?J&,Y M%<3Z/SV_:K^S/DO!7<4V9P=:Q8V%EK3_ 1_.$ [./0>8!^8#\P'4/?B2]Q,-8YR=I5 M_",8>SS.O#65XQXRI&>'')M7A7Q\^,IQZ_P#T7EB8^+6_ZQ=C M#_ZN9)>CJ/3UIN; (K%>>DE5DGMI+\0XHQC:DP4"0WU0M]0:]@_ MXJ/WZTL]>W^HBT=&C1T:-'1HUT^^WZH:QJ47H=.,96M&/7E"<8SG"?GU8ZKR\EMJ M)0.0 Y'\G964 D#NQ[MZ^G,<7GO8;F8V/K/;,N%IZ$V8/3+/%?:0X261&Q=+ MFS1,U]Z9CI"WFGIGI4M%@D11R#VV18-$/(9CE)FF2%,T;XWKDLY+NBK'B3>H MX]]O5Y8,?9>FT4ED7+Q57N2&66*:."'S/-,2/YL0CZTE.G=%]GWP9QN-N;'L MY+=R;=LWJ&XYQD,UC8LK)E8J\U6%(Y8L'6B3'M3E#<)4,TEB.4-95(E0\O9> M[AR*WR919H*Y5JIS&MY$Z8 /UNP=#OFN2K PCP]C&(G9B-EXY30WIQ'% )"= M]U]+S#Z5>E+0WGXE>)-AL6]FU'B)\9:DL4;N(KSTY996C$;QVDEL3U[4#+W: MM)"T+^DB,"%U(.P?LT^!>-K;DKXN"WN6GG\?!2R%'<5ZADXZD<,QGBGQ\M:C M3M4+2NQZ;4=@3KP/+=&'4634/GA!=P#4E[XK;9XF6OD18)ZL-@V6+US]M JS MON.-_:;'/V>:.C([4LP#),M2\)8DRZ'Q9@)LRO,LE#-#HF38?B=NS>6)GQN3 MV.^8N"#RCD:=F#'8FT3PH?(?& MCW_;=Z0NDN"U>I$ J"GWBY]G[:WA!N*CG ML1XL8W;U W/B:N-O0W,CN:@$9GZ<=7QT.OM72%#*CY"8M,0HF&:0,.]_N%DBQL6ZHA)7JF*69:N1N_=[(4*+%;9/@A?CQ ML[]2BY7,35V\_P KS$/3'')))')+=PL$ MGWJ3U'L*=1KBP5 MR5/5-M0IP\.NTULB(N##R9"2B+/% VAYI)RR307QLY"ER(Y\ "*T97;E/:U& M5\%)-%4ON9$B>068J]DUU'G022B0LEE4$C1OYB=:,Z?+(5"CB_$W,^*66M%8K"M,T$L<O04$T.' M7X<1#$?'AX=+>^KESY65/?\ @<%CL)7F^!1FFR$WQMZY,[36;MAT55DEE;OY M<42I#6A7IAKP(D4,:(H&H+WEO+-[NN51E3#6IX6NV-P^&I0BKC<1465Y)(J] M92>JQ8G9[%Z[.\UV]9=IK=B5^"(3W[R^#N4'C6>A)78\(7>)DBMF2KP.9'HRRO##894;RDF>,%S )O+>:)>DSQ*\(DC\SS%9$Z/+$\<=P M.W=TX['SYG"X3<64CRIVKCQE_@LQDJLKQV,[\!2GL1R6V2Q.K3K1CF->"55/ MEQ.5,D;AW;D<]MB#&'(YS)0W?N*SO&#(T<0,8V2VGCY]N;0>C/2@%OR,?MHQ MTW-QXVL6B\TR6)4CL:O53=D;JU*X2]O"5UQLC0) K)]$Y!ZZ1-QTE%0A.5$! M,[;JQ1=EB6(L2+4UEK:4!;GX.50S]1-1$ 66-]'4^VT[C%4?M9^,>'\-]B?R<>,Y'<6^.<=2Q4$@6=,2LL8RE^50LC")T(Q] M9>@F>U:'2KQU[ 5R[:Q4M^Y\1SY=>G^(\I';S"I\M!SP.0?G;N.%7CD%E.OD M=W7QHTMK-B?A)C65'K!,3B6A8.,*JU/#DW\CX^F&:QA<=%H)>6VAC)+[F$83 MC#V75-82O+JN_:+\*L7LY,[ALA'E[&@6>0*D"<.LF1KP:,$JB?P^W1>\8K8K;R\2-IQ;YJS#,X3PZ&'OT M,9B/(=)!-#MS,6,-N#=/PD2^5)G+EF0UW>2QC:N(,C]?;=K#'J6JT9_@OZ*6 M[YJ2M*3R 'G@\VO!U'YA G / 5VF*@A@FX[#8Z3K-G^7/46E)FGPKL='UZ*H M]XL0DXY+-LY"A(S7,,91X>1C;&H=*QHH:OS0Y(0>"$I/:CVBGD35N[#;UR^W M:,"&62>=+E#HM:)#-Y_G\UO+\U)4*! M@FUI*T4\/ES2=9[ *$,#$D]N.?FYXU M*XIW?8\34MS$G"H8 ML3B)6NZUL!)0TEK^DS;^'!C0K*F-R'-WK[&ZE;A,I6PD82ML4>:PE#[\A7'< MWV*-K6=FU\+X+9./8FW=RY[&YW?F*N)D[=W?>WX;E2S#MB?W:L$< M]BCA4K_#6KL\=S*K)9@@>!<@W9;%@RY-/C988)(*DG*H*W;GZ:4E>^-/<5XQHA=K1M?E+1!_;09Y=MTA+2TZ?7F"@VSW6IR 9#C;<#] M$TM:9(IB&D()E+:_=EE-^<](5SP#S>W8:F:P:3K+%!%:K7L)8GKY2BTD0?Y6 MKF&W$Z ]#O79E[$<]/;68R22EHY"."2K+( 48 \>C%9]"I(1MAI.<)R8,G^>,ZXMJ_ M:\I[(W?0\//&BY'4@R+BOB-]2I'6AJS%UCAK;JC18X(*[E@B9R)$BA;I.4B6 M,SY%-[[?DNPR6<:A=XU+R51RS,H'),'J2PX)\H\DC\AYX0M>2I*TI6A25H6G M"DJ3G"DJ2K'E*DJQYPI*L9QG&<9SC.,^<=7X1TE1)8G62.15>.1&#HZ. R.C MJ2K*RD,K*2&!!!(.FN002".".Q![$$>H(U^NLM&CHT:.C1K(?^+-QZM:\$D^ M//JY%6#'_P#C.U9_O_LZ3__ -NC_P#+ M23^TW;2\[NM&E/3[[6TZG./00V7,X]%QJL8398-P9GSE+LE+*AETD/UX4EMF MXG+1C#F4JQ#N25OT0URF4X]'D*35?8]%AQQZC4G?9 MMWP=NY=/,G\NO2R%2]..>SXK*/!AH-QTG '?@^XY^H'K^[_7G< M\^O/(Y!'\3SVY';ZZRJ<@J&G76W=H49MI3(D%<)-44UE.4Y1!2JONL'C&,_P M^TFA9^//S^V?VZE6E,9(ZL_//7"JL1WY>/Y#_:P].Y^FH&R=;R6R%4\CX>TS MQC^K#,!(H'U !(!]/TUL)_"I\EOS+I#?W%*:DG'935=R#VM2@WW/4INF["'; MBK$$ G*O4D.(M\$B3(0E'H09TK8DJRUB>3&PE3_ ')!PP'Z M*R@GVY?MVU6GQ'QQ@OUKRCA;"-!(?_>1$NA/ZM&Y [GM']!K.!IONA=^?>NJ MMQ;RJ7/>_,Z[TU>8>H7DB)U!K>[F4$.?CYR:$ONQHNH:2 MFGNX)KG46W MQZJUPZM6E;>7):6L6[?SY%1DM,3X>DIRLV9@&DU>SS5BCJ:W M;#1@GTQ2PU'+F"5R.E'E5F/ MEGKUE=W1G\E6GKWS+Z$>Q&F](O1(Z-AHZY3REQ=-A09JF$HD=9ELG@-8DB4B1ZU0.KR!1^+*T M%8%6G5AU?C)I(S7<(==;NMR1VK?5*E+-(&K]\R,8-=P8F%]_RK&2$.GY2,C+HT>*XKKW5G4R<\=&@!%B,>!#4CC!5)2@Z//Z?7IZ1T0!NXCY8\/ M(XTD^%>PYMLT;&KU;SO$O\*E<>C=&JJ3=\G,JRC/YSI9I]'->9\8QA+XT1 M6ZB2I2%85[K^'%>%+]2H#\3./VN@1?O\ []7( M\!L^MK8V5V_98.M2]8C2-CR/AKB)-T]/]5I7L<\]N.WL.-+G:08:D^%M,V9E M/^?[KLMNV=)KRGTN.$ER6*NQE?Q_ "JA^$X_2GSGXPK*L=/?PJQ9Q.R<778? MB227IY3[LS79T5B??F.-#S]-0UX]9I,WXF9F:$_S:I4PU"L@](HH,348QC_< MFEE!]^>0>^F9]2+J'-'1HU43E?J.3M7(2/*U#7B_LVWF,?5W5M_S(=U;587:.WF)P8Y0..'4D#I*DN_P_WG4WQMRKF(?+CMK_-LK40D_"9"-5,JJ"2WD3*R MV*S$GJ@D4,?,215PB_B:54=KO;\+C=EZ]'VOKZ)XITZ?N6NB+17Z>NV5VN[- MY$3TI%QLW;&WZKF>R+'.$5N$LXY5=M5@8C*K."%10[QMQ(D9!$C*$X/5P7R.>CY2 0ZM\Q*JP5E9HV<=T6108VD'!0,7 MY'3R%$6W0/&T1[G>NKMU#:$/&]MRL;AT_*V;2]:T;M_5&V)?DQJ^,>I6R-54 MJ2(U_5M_P6L3;XJ6$I8^1)K6[45=PHR+PJ3P)HD+"O;].M+V,1)(V)5XG-5[ M!C!Y9%"EEL)U-Y;^?E>K>+HX *R*+"0AR/E=N51H7X4NC1 M$*6 <\)+%ZCT%OW@S( :(XXNT2Z=O[16S.1L5L74-+V4&^=2Q=A[-WVF(A]B MC6"&B-TW2!J3%9&D3@G+<')R-;KL>_%!R:@C-K,8Y;WR]:Q_#2Q1^TC_ '54 M80!^Q1)KTDD4C*1T2EN3S&PUK1!)'5!SM#5574$,7C M4!02X):;^#;D5S'/CE[+NB1H#LKQB-DG (<$>+B G#]T4 I8D5&"(:$C8T93 MN60(\5IL8(5#0P[:&6D)Q\1>A$0LSE%5>MSRS=( ZF/NS<>E>?V5YX'Z ::_W?:+_)9SYDK2.U[$9N>@TV^)<3C*&53,2P]0 MIIE'_54ZE%3BY(CT^,YVJ_+D*<,W/';S8U-=AZ>I M\H,>_P"UWTI8^3Y.GW1C[\=CP?\ (?\ #5S>$.RF&*K3+"Z_X5KZY14J:XG/ ME8\"\\@>PN(3_'.*X=-LI1\>K*_3YQY^/,W&Y@>$GVNO#+>4SFMBJ9*K)7M5IT5DG1E(# GCHL1]C%*"""J@LI6-X^NIM^3 G('EKVJ(^QP,C0=T:[YQ7VK;=UC/B/1=AJ-JC.'?)T. M18,BRL)+&:R6A:4X=1CT*SA&%.-Y:>=H+]D7P#SG@9]H_P 1R1M3AB)J46OV&G1!!QV? M0HJ1DI$IF/BHH%#BVT.'2<@2,$*A;C;7O/)4\ZTREQU"7F6!W2/99HEN/<^;\3MQY" MS==DQ6&F>+&8V(L:=;HF6,R2#00S[BW=%YJY"T(_BX*$L+30PUQU,L)Z%26R(BP5G\@R2H@DDGGLI<%N(/ M(C25PVWN;4@.XKO3=L2U #?V/+NV2G)CPJM3[.RZ%K=IH&JLK4Y9U-D.6<*V M2CQ3#QHLJ(&6W&"6:\+<#A[N%DR-O$UFO?&S0LTG5,GEHD31@1R?)V5@IY4\ M]/(Z1\HJ;]JW?>]<%O2IM;%[PR:8(X"C?2&HJX^3SY[%V"?S;5>1K%CJ>J9> MH21(#(5,3,GG/?/NF\6N!.N."&[K-8M64#13M8K!QFM;9HVKUO55]:VH\&0) M0X:!+IPU=%"+:>X]Q1Y.WS%+O8J&M7IU*ST$2&2M%!#'&!Q\LT4:*%5)2&) Z9.H>G!/WQ9Q&YL)NBU> MRF5RN0CS4LMNO?NWKEJRQY DIV;$\CR235%,:*[.QEK^2_(;K1&-;RX#<9^1 M%BH4YLBDY6%K]FP-!UBJ%_D>$GUV!R&=6Y9B*FS$6&03&JA6_MPHTZ 'X,.2 M<.:AY"&^K-;.V]N&>C-E\?';&.,[5X"3' 7G\KJ>9(N@RE?)4(&;H +=2-SV M3-F^+.^]@4\Y3VGFY,6VX%II?N"**S=6*E\5Y<52:TLRU0YMR&62*,3DK&8Y M8^D]5D==:NUQJ&M"T[5M&JNOJN'GU,P=1@X^"C\O90E"RB&8]AC!9SV$)R2> M7E\TI?EPA]US.597ZM2K1@2M3KPU:\8"I#7B2*-0.W9$"K^\\:=WD/'L.KA1V '&J<=T;C!2N7W!W>F ME;A,5VL'2-9J>Y*D,(8@A4+R,HZI.\8527;J*J&)X/?MI< MF^:HC$5;ER[YR>77HPR3V6'4O+)'&K-S&>F0-P%5E4EAZZPC7?E%NVT=M^.X MY;0D1+[K/-N@+%K]1I)!UET9MG6UG,K%OH!!#[>7HX4VM2\X>U67W"HUJ.G( MF5K!XJ';%"M0@V0N5(;&!>=[N-!CMT97AL#X0L6,4*SO$(GCDK.955))$0/' MR8Y&>-KL38G;N[GI[YI4A@]Z01K3W+226K'!G:Y"0S985ED$HMU\E#'!8811 M6"ZS>;'/!'!;&S;M_P"H6>4/!_C#L7XY[ZIEO?'MB]W;BJ%&C5,M=DB4JRCR9YWGAZ0>.4\N1 M0I'*L!R"?75J]M6NMZTV3$!04?6C!8?2\K2FJ8(L8 >F S MM@Z%(2R5_O++78PKV +$;+'C*,BV90K-/9HQO!),;C7;IFD' M2TS-P&Z(TY^4=/BAR" A[GERR%@JG%5U$ZU+&:ZJ#=2&')2$3AVO9% M#CTQLN,VPD>3^K0 WDS[DP^LM+A/J1EAYYKJD>Q'=U55("&? MKVNKY&6G7$70K-58@TB* &&CK'<8VPQC$)].]"H#^TNBM 1K+ [BU(RWGTLQ MF2\;\-C*V*@VO@]XLD"Q4]P9W:-MK_% MR9N5@LJJ5J.W["$BI5>JN-S08/2S2'Q;QGB=NOQGQNU-TR[=\1H*<>-W+N#$!LM5\.]AVIZ]FE1P M&/JTKD&X;^::K!5S%J"YFH$R29#SYL;C8;->[&Z6 MUVZH;K>:25XS#'"&+1JR0=2,G2LLG2R"'^,?;_V#R-Y!4K9/,FK#0\<>*%>X MC1#C#[10%6$,48(1M?!JG9E]X]M@$0BOS\A)6,S[_$$70S&7'X3J4-K;;RV% M\8=C^%&$K5X?-Q4GB1XE9+X>O$<9MJI,:.(P5+&5((<5AIMR9:&O5-:G7KK4 MPZWYZD$5^5KL:9-*DV.MY&2%0TD!6 [#:8N2@KDT\)!:XEM5M#Q6VSK"M&6X6LTK ;"DS^5+0AU-: MGPI>G(;&3(3<7]''_4#W,WQX:[)\1<=%CMVX&KD15E2SCM,T98%77LT6T'8-?3.UZM!\BI>>KQ 417HFUQT%<*.)"BJE+% #QDL+7=? MS*L4JW@NMP>0H5:'B86\2-O^)=#'[1V+M?.8S>5*Q'>G^"\ M07N#,;DN;?%C*5*6=W1BVAALX>&6?%&;'O@FRF:J8>6#([A$EVU:=2ISTVDG MM3PO7?E5+T^A8X4FXC=H8'!"2L X#^8(HC+S'" BJ.YV_N.EZPCD%7"@Q##@ M:&F92NI..,R0R"/SZR2< >9% M&P9 L7MO8V&-)(+MCYT5P)#7F(ZU#@$Q="D]+#GIH1:AQ1I\%9('H?(2AG#LDB-^%95E'C'C-E-U M^+N#WUX:[WVWD,9F-L9G.;/W#C*BSUVR>/.0N8FS#3CAOX]'FX:R\8\RW0I( M.Y)].46M2>O=JRAXYHH[,+OP0C>6LBE^5?M^7GL&8Z9;K2VU^[T:LV&M3L18 M8TR&C?\ 2$+(AR862$!L)(9^I!=>8]UEWU(<;]>%(5CPI./VZG_8FX:VZ=G[ M;SE>6-VOX3%6+<*L/-IW9J%>6U2M1<]=:W5F=X;%:4)+#(C)(BL"-)MJ(P6) MXO4)+(JL/RNJN0KJ?1E8<%2.Q!!&JR[BXO5ULN?V5JROB0]HD(HU]PG#6PEG MEZ4WR2<#EX">.)4^JC]M/=>2O?UZYH;>CD.Y'56RG))K!?H8AY5U?E<,XZK^ M:9?>5G]44M:O1_._JCE9\^K J5-LTT^QI]K[->&N:H^"'C)8M1;5%YL)@,UF M1)#D-BY06/ATP>9DL]$B[<^*ZZZO:_$V].RHSKAU*8YW;JVS!D(6S.)Z&G*> M=/%"04N1]/49H@O/XX7YF X$P!/'F_GOQU[9ZB;1T:-'1HUD5_%B8QG7G W& M?X\C+#C_ &_R8VOQ_P"_]O2;EQSC;@_]U_\ G+IK;UE\C:V8E_J5XS_;9A'_ M !UG!X"W5G6?.[B/?1AIE2E><8^6!0<+P K6>+ M, X]$CE5/I\OH#KV%V/G?Y4[&VWF7;S+$^+AKW6)#$W:'52ML1VX,DT#2]_ M:13[CG-/W.**F!W+6;D,/AH6^TM(Q;J$>,/3E4+4(^M:L?"G,PQD(UCS^KT, M>/X=.+!3==1DY^:"96'?D]$HZ>WOQU*3V^I]=-/<]?R\D)./EN5'C8^@,L#= M0//U,3@#GGGI'';4H=@SD$_Q_P"Y]I,,@WZ2L[T9GM"65"W,H;?5>1FBZ8CT M?*%OKV1!TX=K*O3E+91'I5^O*52KM2WY5Z%23TR]4#<\?])P4'?_ -X(_P"_ MCGG4 ^(6/^)PUB0#EZI6RI[=O))$I/O_ $+2GMVY /UUS_'CL/=]GBK:_P [ MZ(ANF2*2%^X(:.5.AP5)*<])/0_3U(3U*00.(#$ M@5XW ^:*5)D/'+XZC)CU5(GD!@6*2&0@H'99.BX_S,2"2"%^7C2_M M_;68W )SB8HYON^S#;E:6:"#IDE;S(A^(ZAT+5/RJ.0%()^;21CZ#M![6L9J MEG%)CJI%WRR;$5@(J=S)RDS/P5:K@@TP6^,0T='56+KK[=892*R2 ]9[6\24 M:J63@9.7=F$D*'XB8E595!KR@?B%3(W'3P#)Y<8;T'$2@ 'J)66\/]T1!U-. MN 64MQ_5J0U,*K/DKA68='2)(Z2N&F:-GCF1)IEYCB9XI GXCA>M%U+WV<_#[9 M6=W#?W/XJS0T]BX'S\45[$XU;?M$[_#7([G.S[]+<>0%*I9R+Q1WI*)F MN2_A1M)2=ZRPR.IBZ.J>6(]2!HE=074PW]LS;W@V_O>WC=JUI\ MA@J>9./P,-F.[:ABW#2IY>6]!3Z[/6L..J6T6&7HMO7+K$\>A NRWUFP14:+ MK5PR",3%YD['BWP+"8A1?H^Y)S$NI^N/^T^I?G(WC!WH_P V\>K'2LE7'FM- M*V4"6$\WRJOP5AC-T<^4?.'XFHCFRFX4R-.M%M=IZ$PJ?%Y, M9G'QBD9BOQ0--Q\18^#!))B_YQT_A>HU_)FS[ 67:67=8.,#1(DH]6C,W* < MQ;2A"/:C0TL(3[L%]W8_SG!$EY:!Q_,D^7.OIJ8X)4894,TSQ+:3X*R/@T=> M97+'M8\EOEZ8N#)ZKVU@F5W&TV61]J,D5.&V^+F^^\9:^2OST2\MK-7^(>H47>-:\8-L;:=1HHRN;!OVNV37AG]D9EA+178*RQ@ MRORN33CCFF5#%VJ4'F]4TZ],3L;7&F6(3 M<5YBL26:Q+8S,J4JOHC9]8F,X(5D_('_ -[9'J_%]](?B/EMR_RYD*[2=H,I'A[N3G^_<;_R M-8O5JYOTRG!;(?=GS?CU/PK84+7]M-#9M5TS)V4(K64JR#$A3!D!+#V.L%#V MI8#B41L<.,H\4@FVK<2O3@NSX^Y'D\3+%EV MKL%JUHXC9BGIV;Z\O&+<:5X .+%E&/&NIP6WY2S04[)0.NY66FJW;B*C,5:. MMM ,DP# A\N2#QA8]D,B>AIU2-GP./-D1+FZC0>4 MS-;%:]Y2S*X4UBGP_G>9TD2<]'0%(!;J(!U??F?&.:V^RLPESXJ.),4V1P'Q M,M5X3)]X)/\ >?P7PXD'D>6U@6&?YEB,8+:[,7[A1WUG-FLU&^+6/:.4G6]!6EO.E_!JN(EG? MHGK6A)DD:Q)47\25Z LQ2+V@>5N%UG[[@G.VQ]L?D/&1&L:''@/[T%E;"P-L ME;A&NY.-B)H04I-2$JM@C3/O"Y1\HGQ*2(#M:BYID-$"2Q)"$B-CQ+W]GZ>+ MVWC\9C\?F+"HSV;T\=XSQ'K\B.@>#60RLG099%DG23RXG_.7U9#[&'V7/![> M^Y?%G7%HRS;W H\9KF(G*1MG=QM5'K,=+SEB%B60 M=86VD'>6IBRSISA)=1E7V&R.3S\G /8.XX8QKN>';57.Y*OL_)9C+;.NG@_4_P!W^6D#GT[_ +O_ TLW<78(T99,; B-8]N M?C3QRKQWO :_O^V^;'(^6OM?%:/9RBT2]==VM(4EV3-C&W_:KI ,I'Q!A:,O MR2!A',YS'@& MA*ATH%D,,'FCN)NZLELZ_P#"+M3;5O ")IC:DM9:UD&MJXC\I?)L23K 82KG MJCF/7YI5E/0IUG0AR4(E.1R"7BQ7RPE6.N(>.>OYH^#)U)UY MV[2X) 6RAT3"JT:\E0=A"4'Z',X^<>E7CSG'GSXM?:KV=-22,'S4BZN)"A # M#RR4?D=P4Y]NTC;8N+%<6.0\Q6%,+\\<'J''S?IW]._;]^M7FAKAFVZO@"#" MO?E8!C-8GGG58]U9\$VV.V<5G.?2EZ6B\Q\VYC&?2C[CZ?CTY3CU?^S7XH0^ M+_@OL;>8F2;)S8J'%;@1&#-#N'$*M')K(H)Z&L2Q+>C4\(CG_9('OW!')XU 6V.Y+P>TN49'7;D50G)B/6MHR# MJ!1E_EQB&\J2X*4'21)[(12%IRAQ@Y0SC:_AS"/GQ:C%>'>],RJ24MOWA%)P M4FMJE")E/HZO=>#K0CN&0,#[-5G3W MQ^WRI_+*;Y?LHQ^Q.-67%3*OC_JH2!DK]_./D?'SC.?V\9RY3X*;^"@FC0!_ MJG*4PP_>3($_L8ZX_P"4>*YX\Z3_ .'F_P#T.?[M+AW?L[@=R0[J/:EY%<;K M8LW>#*=.=A)5 MN*D5&!Q<+B-8FX/#O-[5M1YC,8I:CV$;'+;CLT["3%BM@1EJTTK!NFN6!8+U M*H#8R%!YA4QRQE1R%) D1.1RP!XY[_ ,=:F.D'75HZ-&CH MT:4_RVW'<);FCQHX^T,%1R?M\;*.3.1",1B$9K1XQ7,YN#?.Q-B8!#*T%ZMN7()UE(#\/+*(FN.%?R MZ]2"*:5W*/\ -:BZ$DE\I&MSX3;1P&)\!/%3Q)W'.M27.31[%P4Y023QP1O0 MR&4>G"SQ_$36YY*D4:>;$'?'/7::))Y'5<_=9U3QAGMS#KT#&[T9+0JG<>=NSP0V+M MC'UYI+-E?AX(JM:*O5A3!VANZ3NS2=;V%QITU3XJYW#:MO8O5.:>KMDN=A5+ MCUL:'L -E#EQ$%&2F/>9.:8$BY A\1QAM2D\8-RMN/Q2W5=VU3 MPF(AAC$>0HXVED(8[DCF*YD;5:R\)C>V D5<12S*[],Z&,!IQ[@3/3FHM68,N!K$_J16NJ=6W%-9#(LA+6(6M_5_11[ZQ6BC!I$@$<@U*"4 M?6$)RF*GBGD*DUK>%:X\$!-D>9'2J5ZL:IQPM:K%$"W<\R/YDG#=/H#U2'C9 M/LM[7RM/%>%>8P:YC*K'BW->UFLO=R;D??K5>>#M>W%*S$3# UW9!.HGR17TUZS%/&18$N^,8'X:>DZXJ M2#;4I6,N1+J<*;PM7KWXVIN3)U[:X";(5YD$22V,=:>M+'RQ=4>2.2-BDG0P M(/;D \?*-?-Y9'PLVSD<-)XB5L#>JS-9EK8_.XL9*M854$,\T"-6GCCL56L1 M.'/2Y5F0'<;])Z2FPL4.3[2>3V]2![]N--2[='&[NV@1=^L?(ODE9=2 MHF\PL76JGLD>,Y#V%L$1)91LS#H+V(] 4M];A X"DG-2QQJ6%*>CA&AVEF2/ MMG:6\ZL$IL[KRN-:7H0I/)'GK!1>?FA.5ENU:; ]CTUY6<'AN H!K!O[Q'\, MJ8O(91.!U*)+D"0GDH6,C=+7JAQ, MJPDP';-NWB_\B;D _@N/D-L24>358,O"L.(?KFM*]&PE C'1W4H>!.+@I29 M?3AX26:<_5T\:.S\;7MQY'(6,AN#)Q=X;V1RT\MK.9.,CLT5[)SP' MM^%V'&>CO4ZX/X@P?**>KM9>DN,W<8C*IBZQT<.ET;4G,_7,]!6>%V .+E"6 M8^'W51:H;&V)0>4$OV^$(FC5NI,RP\F[R1J="_(B,U;)1Q1S!0.(;<,R30V# MSV"S(CQ2$#DMY9[\ :>_@Y)%EMR;?JS21ID,%2K M)+%=+=X;;=Y+]OFGB'9R7HRR(A-I@3 Y&-L@$DU(. Q(E.U@Y:.<>QEJ-+ M*Q#B_A;1AFB>-GC*V*TJ24+CKT=8ANUYEDBX$.K8& M;>.SK#++C=P5 :^4JSQ0V89H[=.2#)5X>+*U%O59P]&PI$]::":(2:'MIZ^N M'(VATC?&L>4&NKB_?D15>K>ZJKJ^)I/T; 41)WB3^V%'RQILF$4 MS#DU2=BW77(P4YWUXKW]IW8$6XL_X3;PW5FZ6[_#O(9"WLC+6LI5..H;7S^> MEI2[1W)DCAGK"&O]Y4GV_D,A:3R\5#EY#)5F@MV*\E5Z:[:JB29:EBLY)/EKD%>5993CY%L,F/).G6" MK1YC49+D0LN0AI][ZCD^SCX>IXB-7SA_DY2@FR&*7+X^7;T.0NU[*I2H5X\> M):H>W#0Q+SQ35?-\^".-YHY&XGG [N\%]\Y'>.(O;2V;6VGA=O[F.QX*V-O4 M]Y0P0'&8ZI8N9BX_PV9R%WX^SD,7'K=L >E.H!)BM9V>VD(S;H"C$!OK;E:W/71B:NT 0]&PKX@]JP J$ M#.;>4U$^4^V-F_%JY1V7X+KDL-]\U,??W5N_(TX1=VRMNE6-K;>TJ[QR1SW1 M()/B-PWHI$IF::/&UI;*PY&M4O(;1Q^WLAE)3E_O['FV9,)UU_A&-,PQ>7\? M""3%/&P83U$EF061,%M3UA&TM:^(>DOR9N.7YC\]B,L6VJ@GWL&#ON<$LZ]C MWJ@BQPM@F(\[&<)NV42@.82(<0IZLFY9\,MVC.,1"9M[Q$@\(?M#;3\+,CCG MI8>EMC+[JW':MHR6"MW<-2K26Y9;5S*7,A-7EEFGF.1OYB8+8L100 M3O8TG'G(X.WD_,ZY_B8:\*@]$,$(E42.W2 BIR%51T)&IZ59BH5LFG]E8@J M5*6]](#6HDF M)C9USUU99I=[?"K9MC%R;GW[N&)/Y;>).1@S&9X;SEQ&(IUQ4VUM6G.4C:2E M@L8%5Y?+A^.R-B_D6@@:WY$36O61)Y-6$GX6FK1Q<]C([MU36'7D@23/[ GH MC2./J;HZC8;6FJYW\Q+V]N$D"&\%$1H#BR*IJFO%YPM=5IB7TH^H/>3A M.+-<7F&I2P$84.W])"M# XE_MZGV]_T]_P##2?J3KE6OOS$;)!2C<)-UHQV5 MAIET1)XPJU"O"FLG!_4"*)CRA'5X(:;,%7ZVF'/>RAI;+K2W;@(,[2I7%RCX M7(;?N_?>)SD*Q3#'6(*UBO9:Q#*5AM4+%&Q:JWZLCHLD$C$21RQQR)TUIC"[ M*8Q*DR^5)"W(ZPQ!7@CYE=7"LC#N& [$$@KTLO'K0/*.AL)MUW ZZ0>%7C-M#Q$ M\2=S[?\ $^5IK>8NU*?AUF,E3I8>A-3JK+$M%12CB?'YG+3R&Y#'=N7!:#PX MI9WL5*XNNW*X.S2H5YZ2CB)'>]'&SR.K/\Q<%B?,BB4&-NE5Z0AFZ>EW*+GY M!]A<>+B[);- <@)(-F-"D9=BF;9@&I5M38S3I:A&[U5/MI(@[+:,MLJ)I4N3 MZ$XR^2ZOU.9L'OKPUP6VMN;BW76L7/A-NX7*YZS0Z(IY9:V*ISY"Q%7F>2!1 M*T,#K$)2%9^D/(H);3=J3R6)Z]8A0T\T<*MR0H:5P@+#AN%!8%BHYX'8.=/; V!FV8'LM3A!BQ$'6*)R7;=(70-YW"&09LMMO$,K!V<*9%#GAX*TB* MS[P+,>5[+^(8\.-ZX7<$\^2\/-R1RWZ,4,F1J0$+;@KRDK",ICVZEFJ.Y9$= MA/6,P(AF$R JJ7L?8J<1W8.E6+>6_K&Y7CJ\MP2>H @\?*W'L =:F^W=W2-+ M<\X#$&(Z'1MXPL?]59=;%GH>;DQV$HP58*.:ZI#LU"XRI*RPW$)EH3*_:-;) M$2Q*EVYVKO&+.A:5Z):&91.IZX)^'MA0>N6B[DL> "\E9R9H1R0TT:F8M^: MQ_,IZD)['W7]&["HK?M*RO^3^XV86!V'!M(7EJN6^ M720]&VP3./4V-%6E\=8$VSX9:;LS@!K6'RK&Z4K[A^&3RQ=G*%8,G(L?2/B'1!!8E/>1A"[=3LY+@PFWIV &F,\2=I?RQ: U_=G'O?,(CR(H]S*LK6HJ%,?CDK<7G.< MK=>%8&?<7G.5*6[E2LY5G/5G?L]Y?)9;PCVBN9M37VH8VG? M%FG7?GD,@![^W'O[\\=OWG6^J&U1=NXUIOBIRHH!58"?VEHFJM;5D)B06*-' M[!K"W(2TJ0."&88>\F>8FXE&&1\);:@QD/.,X6WGKCW=LB_NV]B,OC7JQ&2@ MM?(R6)&0!X';H<*B222%O,D3@+^6- 2O.O1CP4\9<3M795S'YU+UEVM+=QT- M*%)F>2:$0WH2\DL,,$:6:PE!9NYG=E1B&&D%][#C-.ZBJZX>6<3*'ZLN=;EV M9U@1T,:7IUWC%1BY(-AU;ZVQUSCT;'$(R\XELV,+:]S.6L>IE2X2QMC.38FQ M(+ FJ+)!85#&LPZ1)U!&9^.ETDC/+$]2G@^O$X5=TTM\;6J;CIP-5>MDG@MU M'E6:2K\Q@*M(J1@]<GI67E>DCJ[*0.KI/J.1P0>.(E\1:N0FQ$T6-2>24VX1*E?K\QJ MQ$G6.$X8H6*=8[@IR&^4G6PR![I-^/@(2UX[>W/5%:L<1'3\%/5J3Y4F04S! MS +$A%R\42-"RD?(1Y\>:P8"6PMYAYA]I]A><92KJ7%97574AE90RL""&4@$ M$'W!!Y!';C5;W1HW>.1622-F1T8%61E)5E8>H92""/4$'51^6W<%[=&]3*5 M\ZN*O(H65K DP928_:]SV%5Y>+!G7A&9HN(&LD+7CGQC'XD1A\A7OMIK7$T3O"K%!(S0S*"BRL0O([/U$$<'5.?NGXV"XS4M>1K)"D-?2YL-N*R.ZZJ6G ME/.J$N-J22PR\%9HH17C<-RQ@4EA'\W/4%/)!]>YY)!UST-VYNCC[>,2;S<= M8O/E)JC@B%BAQ^TSIWC010..FHJ2FN M5W5>@H" KD@F4(=<)QE3REJ< MJPRQX"-EF J+E7C6KY2\^>*:,9_/YZSRA"&+CIY^?GJ.HNFO5;/B%966F6R\ MFU(;+Y3XJ7I-%LQ/&E 4./(41SJTRV0?,Z2(..A1JV?27IT:.C1JC_/_ ((Z MR[A.BD:2V5.V*I)BK9%7JHW"KX#=E:Y:(D*4BVB5 R#;@4K'%Q,U*QY\<_EC M+K9*'QRA2QAWT<=VE%>A\F7D<-U*P]5;@K[]B"I((_7L00#I2Q>4L8JS\17X M)9>AT8D!UZ@P[CN"KJK _4<$$$C2T=U\9>0_#/6? ?C%Q H.W]C:&UKRLXUW M/;%XJEGA6K9U:!%8584N<]BP=YJ&0+2.J\GJCF,+0J1TLY"(&G,!39D,C-E9+ERP4- MN=8 .X3RTAL4D2.,N>#YD0D65N>I4!8E8O-!Z=M"T\J[CW#-"]1VC7=S@MEPD0!IGEC+3MCK\; 0$WFN0\!,3]>J.Z^.DZ61=-K;$, MU)Z#B#@.J]5K.W;-Y%46W9K>X):F.2(S"H^1 M%PL,KS+*@8131*%1B"\1@'DJD@!/27A2-NWREQ(1W;NY/HUKU3S=G%KCCRCN MEKJ>_J/1=PPR]=U0)VB6VLJ.+JRL3]N(!M\#:$K:.K4U(?4F@!FULV)L ;<> M\\@_#)"$I5)RTF!JUIJ?-?[TN3QVF="LDAK4D>%8N.L&$(DAEZND^:% !4DM MK&L*6_5BR2 M*%4_:>QY=M%75S:';EY1V73LTEHD8/6FYRIJZ5**&D&LB&-U;9$5AW84"R@1 M;J<-6$+8!967'&U&)O1 KKI\)8K =*JLMCM4>K L8'7ULY815ER.#PY"]'CX5F=2W7(L87KZ>Y#'D<@@4M:"6P\LLY2O"LX<1ZR,%.94G.,XSG/C/GS\>>I_QOV>=L=,8R>=S4]C\ MLR4_@*L2R \,JF2M;D['MSU^O?TTBSYVPO48:T(7U4NTC,PX'!(!3U]N./\ MAIE':CU;J_DWS&TWJWDN1=]ET;8S5WB2(DK8EPJC29^+H\_:H0E1E(F*P=G& M3:_]N^ER7D@ MAU*L 6X#<,.5)'/?3]1NEU8]P&!(XY'KW[>FLI7&^^R-6L$/8\C@_Q[#@.:I,4=67D$$.O'/KV/J/J/?]_?VTXCEQ M26AM>UKB;9IYPF^W"$@[SKJ,M U3AK4S,L9BQ)2R2JWP/=C:Z8I/W2))/Q&F MA'8+) ,+AHU*&K_Z,'QJPO@-XY;Z\#_$&K'-B=Y12Y?85RRGF? ;OQ49D>I6 M\T/'#_*3!HZ"Q&C3B[AZ-6'CXV0E2W[BI<_A*.7J2.LE0BOD4C/!EKMR$=R. M"1'*1SR0I$IYY" C\:4_#72/>=FE88:A3HPCLKV(Q8E8?5E<>G^_I!7QOWZK FWCV'//2<;7X(^GI_;QP?76XX M/'$<& ?O!/UY_P!?Z&JBRW:=J?;_ .X5VJ-CTK?>R]FP=RYJX* MB7%\1.1\\B9:L58$@F2W$)AE@Y#1=W>).9WGC*N.RU7' MH:EP7%M5(GAE=A!-!Y;IUM'T$3%OE /4H[\:W4\96HR/)7#+YB=#*6)''4&Y M[^_R@?N_CI]^TN6MC;W'.\:^.&K2MS;LJD#!V&_%24NQ5-5:F M++Y-7SL6X M.I)-8/G!6%' 0%>B9JPEQV5' Q9C Q^0X)RV>S3Y.3![8Q,-RY72)\CEXK\Q:E[";)P<.WJ6[][[A;#X?)SVH M<-AL173([ISB4937M6ZU:5X:./QT=I):JWFFVD(PM:7,):=:4WA&$LN-9]*T]0V;$H/&X M]X=1#=LX[DUM;D;N[9_/'F-L:M4O<,WI6@72 N55IQNS1=?B M@"6^8EIG\KV8V7K ,\ZBI1#,3(13#4A6)QE]#GTXV&FCMO9^"S[93.7(+5GS MKUK'8_+/E]\1YKUK5B&26FD4GE&HM60'J8A9$WKXO;UVDN MW=MXJSAL=\)B*F9R6WZ^TML0X7;^=S*OK-!%D99(S.]Q[4 M3\*O=P>F>V-P_P!+F?>!M=N;*L2'TD#S^XCT; ("<2E/I0U'&&O@J=B/DGIN5\)!0CN ](% MI90% 4 :IIRZ[ O#/D??2=WZJD+[Q Y!KFD6L?96@I-N(B'K@P_]8-9I&@$ MXQ"BRJ9#"9(F1HY=$F9"2]?!TE#%/\ B*8R.&B;K#+)&Z\JTKN5NL=L09\B'0X^RQ8U M>&"M%((K9&,$>%8*2:/A3%V[DWV?9MQ MY#%W^BXL!G2"-9)*ACZCU2(6160>=TEE<#T*]0*C4\^(N$@\;:>*^X-U;:BN M;?FR<52;)W):E3/16I*Z+]WRK#,Z3-\&9E@EB#!6*R%&C=G'+FQ"V M23T;=A9R0IY0K%FK9;;\=88D:2P\N(E'XF09$/Q&2:1BFF"U"H;P:$:)G.DS;6Y:NY*LL\4,E2>O/+!/4G*EP$=A%8B9>!+7LQA98GZ59>6BE1)8W05 M3WQL#<&PET#MRI2125<:N$XZVR MC+CKB&D8_=;BTH1C_6I6<8Q_MSTXV95'+$*!ZEB /[3VTRE5G(5%9F/HJ@L3 M^X#DG76[?.N0%.M%D P*21"5N0?W'0596*LK!AZJ00P[<]P>X[=_W:S86JC=T7N, M]JL/:^P=_<(2:7R*XG5KD"SJ:.X9;9_,\/)RM!C]L5BO5^]N\OWQA[-"3;4< M'%6E=3?%^N806572@G2(I[@RU:*WC;T$T;31O6E)C5A&[LBET"2%) C]:J5< MQN%;@]#<<%4[B2$31 M&1"R"1">H*I[7EYY8]QGCO9>V?-[^XAT^LZYJ#MGUY%;#XD7NYW"4K[ME.DB M[-3[C7>4NOT1=LH$]817159KQA)4+*IS($S,;F<%<9> L8C.XR;;4]25(88# MY4=B:.65HBY;S(I4KU^F6!W5E(C)X8$EE##4S;ZBW=LG==/Q-QV7K37[UT/- M;Q]*>G5CLK"L7PUFI-?R!DJWJ\+QS1M8Z"RO&%0F,ZZ.14NY'V[MK;=XWU3E M'HY^""L59,L @>F++/U&Y,1KT-;:Q+F0A.\%/UJ:+CTQX-C!&>"EVAEFP3\C M(Q7TAA-;O%1]FX^GNGPUR]'/Y/"9N"&MEZM/<>.CBE7F&[6E59MNVS3OUY4@ MG#H?-CDC16>1.5:VFTO#S=/V@=G8'?.5N;+H69*N3KXVQ>V%G$R-!W^)QUF2 MI=AWQ!%?J1S^;-0FL5)Z@L1BP*:3+)'IF%!B^XI,0$[]MY8<2V-?ZZJ]$DZ: M[-<2-N$P@<%L^*.M,B57VC.8BF8I8OV)EF8+=,D7TJ** '>C@\$BD1)X_P#B M_LK=_P!F';U//;>WKN.OE-\5=A93;V(W?0Q^ZWS6T+!5/O3-MM/*5LA9N"/% MY2W7AP-8SV+T)0QB/EZ)5]O93;>\,SC[+5J-[#?&QV#-5E>O#(LK0V8DB-F) ME$>\<5G[-68*'A>/'UMJ[;L N"56:02+&PC=(.1YD;:SF1>RSI\9 M#-P_'$%=X01[\DSS#]?7GVY]A'.T]:]POEWS?D>*@(I5BP;J,?9UO;C MM-WW0SR#V1OI^KVO>6F^2VY>*+EOJD-(5RG?E[2QT+!/F:_I,I,6)V@Q-LEU MGSID/F?L$JE#XD?*V:>R V8Y<\#CTX'MV''8>@_AIN:ISWB.7&P*C6!M:ZTN M,E1(B1E_M5EM4&\ZQ*+;82[F0P.0*^*3[(V6GDH'8,$R4X-G"B6D.X=:\Z=] M^+\GBUXO[L\/\5.]G8GADWW=RT-7>&\H6Z;[9:6'J^*P^&L,N,J8^9+% M)LA#:REBM:EBQPK.^+'G&8ZK9<=%S(()ED(Y>O5?GRUB!XZ9)5!E=U(?H9(U M*CS.M=W!_1O>QB69#:6J+-8)?14]%R)6-<Q\B)9Y6J M3$JRM.:S,6 .%JY3[XQ!QTA#+<*7,,?@UEL[M#*5L&\WAOD\SAK5"2YMRR]: MA>BNUVCEKY3;\BI0RU6Q$[U_BK$-7*5X)II,3D<98D$Z\"Y189XVE NK%*D@ M6PO64*$%6CE_/&RD!N%)C8CB1)%^74S&]P;:=:I=YJF\];1NQRN5KVL32MQ96A3J8K=.VCEK5"WCI MOA<)EJ[2X1LS13'Y>2W5=;W7DK.%?HDFKFQ3EIS,IECC=9) T3.\D$PA$BNH M=XF"R")C+%TM+VC>]-N?D=67-8:\[>W(384^] "UERW5F1^OC7DN ,QY,Y9I M64I%7J==>D6LNEKR=/!QJ'B,>V[["<)SZ ;RDWYO7PYW/L3"8JC3R>XMK9#; M*9RS:M3P4$RE%L99MS5H\;$LTRU)IWC(FKQ&QY;>6(P8RRZAK5+U:W,S2106 M([#1+PK/Y;B0*&ZCP"P /8GCGO[Z2UI8C:W M=D,Q;N%N2(%D5%KE:L>@M:FV]FQ(UB2Y# SVKMBR@>".-X8(ZB$3S-.PC5=S; MAAS7PB5H988Z_F.S2E>II'Z1\H4D!55.03PQ+'D#CND7D%V#K]2>0\7R*[:^ MX*QH&0&L UG8UW=#K(+7*;.86^\>109V @[%(1]<+5E#7Y(F(F7BT,&R,>.> M)7\"0#%A,ML[+VL^TN-@Q=#$1UH;-7))EKJ9B++B63S(DQB88U8J21"*2*V, MU).TIEA:BD05V04L1"$!S(\O404\M?*\KI'!\SS>HN2.Z^2 >LGTNGMJM= MP[9_$CDMI_E#I/5-WL4O5W2]=6O0FP0'H;#]*O<=2)UV:%NL"F6 M4/%P;;3\<8Q&@)64*I1;3RV+\8J]2U@KL6"\0<'E_C;&2SN0RM7:N5V[&L\< ME2CB,!B=JVJFEMK*)+*P2PK#T(^,?B0":G-&$6.*.-K$4YZ M2'DEFELAX6+<=HXW0*1PO4I+?9VI>0E%@^'FN@;H7,5ILZ6GGQ+7,P$L)1CG M39/#+4>-(>#\/L%=Q6Y\5N?$8E M,_E9?Y6_<-K(;2C:3X)-^;#^3_ --8S5/'45!#K;9&#:VV*4MR16KR M5Y)/+0?#F98YSQSW19>A9.3V"QN[GTZ=.1#-#D1F38\L8X,A&'&"A'FR!WD9 M_933S2EMK3_>E6?[.K,8G,8G/8ZKE\'D\?F,5>C$U/)8NY7OT+41])*]NK)+ M!,G/(ZHY&'((/<'2/)%)"[131O%(AX>.161U/T96 (/[QKZNE'6&LC?XKP=X MF@\#&6&UNNYY%65:6VTJ6M26=66YY?I2G&5*5AMM6<8QCSGQTGY;_P!G6_\ ML_IS^TO^'J?TTUM[UY[.TMP1UT,DJXV>P$'JR5 +